text_modified,group_label_id,fake_example
"Low [ENTITY_A] expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with [ENTITY_B].",1,0
Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the [ENTITY_A] inhibitors [ENTITY_B] (quizartinib) and sorafenib.,1,0
[ENTITY_A] affects aromatic amino acid biosynthesis by inhibiting [ENTITY_B] (EPSPS).,1,0
"Furthermore, they suggest that [ENTITY_A] works in concert with ZnT4 to regulate [ENTITY_B] translocation between the cytoplasm and lysosomes.",4,0
"This effect was prevented by [ENTITY_A], an inhibitor of the [ENTITY_B] (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).",1,0
The alpha class [ENTITY_A] enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward [ENTITY_B] conjugation.,4,0
Phosphorylation of ER-stress marker [ENTITY_A] was also increased but only at 30 min of [ENTITY_B] exposure.,0,0
"INTRODUCTION: The principal aim of this study was to assess the efficacy of [ENTITY_A] in suppressing [ENTITY_B] in vitro and in modulating the rate dependence of the QT interval in the ""SQT1"" form of the short QT syndrome.",1,0
"Patients stable on warfarin therapy and concurrently taking a [ENTITY_A] (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, [ENTITY_B], or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.",1,0
"The competitive inhibitor of [ENTITY_A], [ENTITY_B], also displayed competitive inhibition of hCOX-2.",1,0
Add-on therapy with the [ENTITY_A] inhibitor [ENTITY_B] improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.,1,0
"Moreover, wogonin repressed [ENTITY_A]-induced phosphorylation of [ENTITY_B], cav-1 and vascular permeability.",0,0
"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified [ENTITY_A]-mediated reductions in [ENTITY_B] and IRF4 expression and increases in p21(WAF-1) expression.",1,0
[ENTITY_A] increased the number and area of [ENTITY_B] (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.,0,0
Human serum butyrylcholinesterase ([ENTITY_A]) is currently the most suitable bioscavenger for the prophylaxis of highly toxic [ENTITY_B] (OP) nerve agents.,4,0
Compound 6 stimulated OATP1B3-mediated [ENTITY_A] uptake by increasing the apparent affinity of [ENTITY_B] for its substrate.,4,0
"An angiotensin II AT1 receptor antagonist, [ENTITY_A] augments glucose uptake and [ENTITY_B] protein expression in 3T3-L1 adipocytes.",0,0
Our purpose was to test the impact of single and/or combined treatment with the [ENTITY_A]-receptor blocker [ENTITY_B] and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.,1,0
Synthesis and antagonistic activity at [ENTITY_A] subtypes of some 2-carbonyl derivatives of [ENTITY_B].,3,0
"All three [ENTITY_A] proteins showed similar K(m) and V(max) for [ENTITY_B] and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.",4,0
"These data support the conclusion that renal ecto-[ENTITY_A] activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of [ENTITY_B].",1,0
Our work shows that [ENTITY_A] and glinides additionally bind to PPARgamma and exhibit [ENTITY_B] agonistic activity.,2,0
"[ENTITY_A] (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ([ENTITY_B]), markedly increasing brain GABA levels.",1,0
"Cellular release of [ENTITY_A] by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists [ENTITY_B] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.",0,0
"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse [ENTITY_A] selectivities ([ENTITY_B], indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.",1,0
"This is distinct from [ENTITY_A] inhibitors based on non-[ENTITY_B] derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.",1,0
"In combination with [ENTITY_A], the ability of resveratrol to reduce the contents of [ENTITY_B] and its target gene products was also evident in a time- and dose-dependent experiment.",1,0
The [ENTITY_A] activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of [ENTITY_B] and menadione.,4,0
"Interference with [ENTITY_A] enzymes, rather than a [ENTITY_B]-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.",1,0
Agonistic activity of [ENTITY_A] on activation of GSK 3β/[ENTITY_B] pathway in the rat uterus during the estrous cycle.,0,0
"However, some experimental findings raise the question whether these effects resulting from the [ENTITY_A]-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting [ENTITY_B] polymerization.",1,0
This work resulted in the discovery of the [ENTITY_A] system as the foundation of a new compound class of potential [ENTITY_B] inhibitors having improved potency toward PI3K.,1,0
Monoclonal antibody 25B1 generated against [ENTITY_A] inhibited fetal [ENTITY_B] has been extensively characterized with respect to its anticholinesterase properties.,1,0
"The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the [ENTITY_A] antagonist [ENTITY_B], by indomethacin, or by glibenclamide.",3,0
"In agreement with these data, the exogenous treatment of [ENTITY_A] or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on [ENTITY_B], the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.",1,0
[ENTITY_A] is a [ENTITY_B] secretagogue that also enhances tissue viability in different organs.,0,0
These data directly demonstrate that [ENTITY_A] is the major [ENTITY_B] uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.,4,0
[ENTITY_A] expression was increased in all BPA males and BPA 0.5 females and reduced in [ENTITY_B] 200 females.,1,0
"It has been known for decades that lithium chloride (LiCl) leads to [ENTITY_A] accumulation on GPCR activation by inhibiting [ENTITY_B], the final enzyme of the IP3 metabolic cascade.",4,0
[ENTITY_A] inhibitors: [ENTITY_B] incorporating adamantyl moieties with strong anticonvulsant activity.,1,0
The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited [ENTITY_A] chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of [ENTITY_B] (IC(50): 10.9 ± 0.63 μM).,1,0
"In the present study, we identified [ENTITY_A], a widely used HIV PI, as a potent [ENTITY_B]-selective agonist.",2,0
"Unexpectedly, both the [ENTITY_A]specific agonist, [ENTITY_B], and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.",2,0
"In conclusion, the renin inhibitor [ENTITY_A] dose-dependently decreases [ENTITY_B] levels in humans following oral administration.",1,0
"In alpha2B-receptor-expressing HEK293 cells, [ENTITY_A] rapidly increased phosphorylation of the [ENTITY_B] ERK1/2.",0,0
"The accumulation of the post-[ENTITY_A] products of 22:5n-3, 24:6n-3 and [ENTITY_B], in cell phospholipids was saturated at concentrations of >18 microM ALA.",4,0
"[ENTITY_A] (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ([ENTITY_B]), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.",4,0
"[ENTITY_A] reduced the expression of pro-inflammatory mediates, such as [ENTITY_B] (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE).",1,0
We sought to assess the effects of the [ENTITY_A] blocker [ENTITY_B] on HRV and BRG.,1,0
"[ENTITY_A] activation of [ENTITY_B]/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.",0,0
[ENTITY_A] was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as [ENTITY_B]-selective antagonists.,3,0
"In this study, focus was given to evaluate the ability of [ENTITY_A], an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric [ENTITY_B] (Aβ42).",1,0
"Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist [ENTITY_A], whereas the triple cysteine mutant [ENTITY_B] retained its full response.",2,0
"We also observed that [ENTITY_A] efficiently suppressed the phosphorylation of [ENTITY_B], S6K1 and mTORC1 in adipose tissue.",1,0
"Therefore, decreases of [ENTITY_A] and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with [ENTITY_B] (GABA) function.",1,0
"Treatment of A549 and H1299 cells with [ENTITY_A] caused a dose-dependent increase in ERK1/2 and [ENTITY_B] activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.",0,0
"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by [ENTITY_A] resulted in the inhibition of downstream phospho-[ENTITY_B], phospho-AKT, and cyclin D steady-state protein levels.",1,0
"This study was designed to determine the gastroprotective properties of [ENTITY_A] (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and [ENTITY_B] antagonist, on mucosal injury produced by 50% (v/v) ethanol.",3,0
[ENTITY_A] usually catalyzes the conversion of [ENTITY_B] to o-diphenols and oxidation of diphenols to the corresponding quinones.,4,0
"MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two [ENTITY_A] inhibitors, [ENTITY_B] and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.",1,0
"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive [ENTITY_A] inhibitor [ENTITY_B] (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",1,0
"Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using [ENTITY_A] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to [ENTITY_B], respectively.",4,0
"Several members of a new family of non-sugar-type [ENTITY_A] inhibitors, bearing a [ENTITY_B] moiety and various substituent at the N2 position, were synthesized and their activities were investigated.",1,0
Here we show that [ENTITY_A] rapidly increases the levels of both [ENTITY_B] and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.,0,0
The reciprocal inhibition of [ENTITY_A] and ABCA1 by BLT-4 and [ENTITY_B] raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.,1,0
"[ENTITY_A] antagonists, [ENTITY_B] and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.",3,0
"However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan[ENTITY_A] inhibitor [ENTITY_B].",1,0
"Collectively, these initial findings suggest that design and systematic modification of [ENTITY_A] such as 3 may lead to development of novel cannabinoid ligands with dual [ENTITY_B] antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.",3,0
[ENTITY_A] depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of [ENTITY_B] pathway.,1,0
"In contrast, the selective [ENTITY_A] antagonists ICI-118,551 and [ENTITY_B] inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",3,0
[ENTITY_A] (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of [ENTITY_B] that are known to be involved in tumor cell proliferation and tumor angiogenesis.,1,0
"Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a [ENTITY_A] Moiety as Potent [ENTITY_B] Inhibitors.",1,0
"The mRNA level for [ENTITY_A] (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-[ENTITY_B], but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.",0,0
[ENTITY_A]-induced [ENTITY_B] activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.,0,0
"[ENTITY_A] (IMQ), an activator of [ENTITY_B] (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.",0,0
The positive correlation between [ENTITY_A] and [ENTITY_B] concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis.,0,0
"These results suggested that Captopril can protect the vascular endothelium against the damages induced by [ENTITY_A] in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in [ENTITY_B] activity and NO levels.",1,0
Recommended management may include use of [ENTITY_A] inhibitors (e.g. [ENTITY_B]) and wound care on a case-by-case basis.,1,0
The structure-activity relationship of a series of [ENTITY_A] [ENTITY_B] inhibitors is described.,1,0
In vivo [ENTITY_A] antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. [ENTITY_B] or ceruletide (caerulein).,3,0
Neurochemical effects of the [ENTITY_A] inhibitor [ENTITY_B] on brain GABA and alanine: A comparison with vigabatrin.,1,0
"Similarly, [ENTITY_A] (3 mM) reduced [ENTITY_B] Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4).",1,0
"[ENTITY_A] catalyse the last step in [ENTITY_B] biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.",4,0
"Concentration-dependent inhibitory effects of baicalin on the metabolism of [ENTITY_A], a dual probe of [ENTITY_B] and CYP3A, in rats.",4,0
[ENTITY_A] inhibited [ENTITY_B] activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression.,1,0
[ENTITY_A] catalyzes an unusual oxidative decarboxylation of [ENTITY_B].,4,0
[ENTITY_A] inhibits [ENTITY_B] and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations.,1,0
"Aqueous [ENTITY_A] (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting [ENTITY_B] (IC(50), 55 μg/ml), with moderate COX-1 (IC(50), 66 μg/ml) and COX-2 (IC(50), 119 μg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.",1,0
Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for [ENTITY_A] antagonism in the broad growth-inhibitory properties of [ENTITY_B].,1,0
"In vitro studies with blood-derived T cells, however, show inhibition of all three [ENTITY_A] by [ENTITY_B].",1,0
"[ENTITY_A] exposure (20 mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased [ENTITY_B]-Thr-34 phosphorylation.",1,0
Gonadotropin-releasing hormone functionally antagonizes [ENTITY_A] activation of the [ENTITY_B] in prostate cells through focal adhesion complexes involving Hic-5.,0,0
"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of [ENTITY_A] on [ENTITY_B]-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.",1,0
"The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel [ENTITY_A] antagonists, such as [ENTITY_B] (UK-427,857).",3,0
[ENTITY_A] prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and [ENTITY_B] production.,1,0
"We examined the N-demethylation of individual [ENTITY_A] enantiomers using human liver microsomes (HLMs) genotyped for the [ENTITY_B] allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant.",4,0
"In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for [ENTITY_A] but no difference for milrinone from the recombinant [ENTITY_B].",1,0
"The carboxylation of glutamic acid residues to [ENTITY_A] (Gla) by the [ENTITY_B] (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.",4,0
[ENTITY_A] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate [ENTITY_B] (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.,0,0
Coadministration of reboxetine and the [ENTITY_A] blocker [ENTITY_B] also increased spontaneous locomotor activity.,1,0
[ENTITY_A] was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the [ENTITY_B].,2,0
"In addition to affecting [ENTITY_A] function, MDMA rapidly decreased vesicular [ENTITY_B] transport as assessed in striatal vesicles prepared from treated rats.",4,0
"Additionally, the expression of hepatic fibrosis-related factors such as [ENTITY_A] and transforming growth factor-β1 (TGF-β1), were reduced in rats treated with [ENTITY_B].",1,0
"Felodipine and nicardipine have similar affinities for 60-kDa [ENTITY_A] isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by [ENTITY_B] Ca2+-channel blockers.",1,0
Phorbol esters and [ENTITY_A] destabilize [ENTITY_B] mRNA in vascular smooth muscle cells.,1,0
"In most instances, C6-substituted [ENTITY_A] exhibit [ENTITY_B] specific inhibition.",1,0
"[ENTITY_A] and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ([ENTITY_B], EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.",1,0
The studies with dThyd rescue from [ENTITY_A]-cdk2 protein overexpression and growth inhibition by [ENTITY_B] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.,0,0
"In TPC1, BCPAP, FRO, WRO cell lines [ENTITY_A] induced a strong increase in [ENTITY_B] mRNA levels.",0,0
"[ENTITY_A] are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to [ENTITY_B], but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",4,0
"(3)H-CGP 12177A saturation binding, in the presence of [ENTITY_A], increased approximately 5-fold following overexpression of [ENTITY_B].",0,0
"On study day 10, the acute effects of [ENTITY_A] were similar to those on day 1 (i.e., [ENTITY_B] was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased).",0,0
[ENTITY_A] (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of [ENTITY_B] inhibition.,1,0
"However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P. Within the class of [ENTITY_A] blockers, [ENTITY_B] differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action.",1,0
"Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of [ENTITY_A] in peritoneal macrophages were detected in [ENTITY_B]-2-treated mice.",1,0
Moderate inhibitory effect of [ENTITY_A]-C oxidation by [ENTITY_B] was observed.,1,0
"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the [ENTITY_A] moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating [ENTITY_B] family proteins.",0,0
Transmembrane isoforms of [ENTITY_A] (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate [ENTITY_B] production in response to calcium entry.,4,0
"Furthermore, inhibition of [ENTITY_A] with [ENTITY_B] (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.",1,0
"In H2O2-treated cells, [ENTITY_A] also suppressed [ENTITY_B] release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.",1,0
[ENTITY_A]-stimulated (100mM) [ENTITY_B] upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.,0,0
"In addition, another drug that is both a substrate of uptake1 and a [ENTITY_A] inhibitor, [ENTITY_B], was investigated in the study.",1,0
"To explore the molecular basis for CPT hypersensitivity in Top2β-deficient cells, we found that upon [ENTITY_A] exposure, the [ENTITY_B] (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells.",1,0
"[ENTITY_A] uptake in PC12 cells, which express the [ENTITY_B] endogenously, was 20- to 28-fold lower than in transduced cells.",4,0
[ENTITY_A] increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to [ENTITY_B].,0,0
"[ENTITY_A], a specific inhibitor of [ENTITY_B], reduces the activity of CA I and CA II from red cells.",1,0
"INTERVENTIONS: In the 8-week run-in period, all participants received the [ENTITY_A] inhibitor [ENTITY_B] (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.",1,0
OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting [ENTITY_A] (AR) agonist ([ENTITY_B]).,2,0
"The mitochondrial [ENTITY_A] is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of [ENTITY_B] oxidation.",4,0
"[ENTITY_A], a Toll-like receptor-7 agonist, induces [ENTITY_B] in cytotoxic T lymphocytes in vitro.",0,0
"Effect of [ENTITY_A] (TAK-375), a selective [ENTITY_B] agonist, on motor performance in mice.",2,0
"Finally, we found that [ENTITY_A] worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of [ENTITY_B]-producing cells in draining lymph nodes.",0,0
Our optimized [ENTITY_A] production assay to measure [ENTITY_B] activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption.,4,0
The ability of [ENTITY_A] to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner [ENTITY_B].,0,0
Addition of [ENTITY_A] restored the induction of apoptosis as indicated by an increase in the number of detached cells and [ENTITY_B] activity.,0,0
"[ENTITY_A] inhibition by [ENTITY_B] or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.",1,0
"[ENTITY_A] is a reversible, competitive [ENTITY_B] (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.",1,0
"Acute intoxication with [ENTITY_A] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase ([ENTITY_B])).",1,0
"[ENTITY_A] (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different [ENTITY_B] (S1PR) subtypes.",0,0
"[ENTITY_A] (NS-398), a selective [ENTITY_B] inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.",1,0
These results indicate that [ENTITY_A] treatment induces [ENTITY_B] to elicit a male-specific and growth-suppressing signal.,0,0
"Clinical studies in cancer patients treated with the new [ENTITY_A] analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of [ENTITY_B] (TS).",1,0
"Here, we compared the effects of a dimeric [ENTITY_A] inhibitor, [ENTITY_B], and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.",1,0
"The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of [ENTITY_A] that breaks down [ENTITY_B], the key pathway for the production of erectile function in humans.",4,0
"In contrast, the [ENTITY_A] catabolising enzymes [ENTITY_B] and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.",4,0
"In conclusion, of the seven NSAIDs investigated, [ENTITY_A] was the most potent inhibitor of recombinant [ENTITY_B] via 4-MUG in a competitive manner.",1,0
Overexpression of [ENTITY_A] induces [ENTITY_B]-dependent and mitochondria-mediated apoptosis.,4,0
These results suggest that fluoxetine inhibited the activity of [ENTITY_A] by a mechanism different from that of [ENTITY_B] and did not directly interact with the active site of VMAT2.,1,0
Analysis of tumour-conditioned medium indicated that [ENTITY_A] decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of [ENTITY_B].,0,0
"Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with [ENTITY_A], a [ENTITY_B] inhibitor.",1,0
"In this paper a series of new [ENTITY_A] derivatives has been designed, synthesized and evaluated as the [ENTITY_B] inhibitors.",1,0
"By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the [ENTITY_A] (MR) by [ENTITY_B].",0,0
"Our data showed that chronic [ENTITY_A] over-activated [ENTITY_B] but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).",0,0
"[ENTITY_A], an inhibitor of [ENTITY_B] (DAT and NET, respectively), is a standard treatment for ADHD.",1,0
"Furthermore, [ENTITY_A] caused mechanism-based inactivation of [ENTITY_B]-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.",1,0
"Previously, we have found that [ENTITY_A], a nicotinamide derivative, inhibits vascular endothelial growth factor ([ENTITY_B])-mediated angiogenesis signaling in human endothelial cells.",1,0
"[ENTITY_A]-induced inhibition of [ENTITY_B] mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status.",1,0
"Of the rat CYP isoforms studied, [ENTITY_A] isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to [ENTITY_B], but they were less effective than the human isoform CYP2D6.",4,0
"Preincubation with 1 microM of the [ENTITY_A] (PKC) activator phorbol 12-myristate 13-acetate ([ENTITY_B]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.",0,0
[ENTITY_A] is an uncompetitive (channel blocking) [ENTITY_B] antagonist.,3,0
"[ENTITY_A] (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of [ENTITY_B] (mammalian target of rapamycin) to reach the oncology clinic.",1,0
"However, [ENTITY_A], which is transported by the plasma membrane [ENTITY_B] at a rate equivalent to PS, is incapable of activating Atp8a1 activity.",4,0
These data suggested that ambenonium had a dual effect on tissue responses to [ENTITY_A]-producing potentiation by blockade of [ENTITY_B] and concomitant antagonism by blockade of muscarinic receptors.,2,0
"There was also an increase in [ENTITY_A], Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the [ENTITY_B]-treated cells.",0,0
"In summary, activation of [ENTITY_A] and oxidative stress were observed after [ENTITY_B]/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.",0,0
"[ENTITY_A] (PB), a typical [ENTITY_B] activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.",0,0
"Thirty-week administration of [ENTITY_A] with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of [ENTITY_B] inhibition and the decrease of thymidine kinase activity in the tumor cells.",1,0
"The order of effect was [ENTITY_A] greater than ROAc greater than 13cisRA, with increases in [ENTITY_B] times correlating with increases in hemorrhagic deaths.",0,0
"Blockade of [ENTITY_A] by [ENTITY_B] could theoretically confer disease-modifying activity in AD by inhibiting the ""weak"" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia.",1,0
"[ENTITY_A] failed to activate the channels made of cbv1 + β2, β3, β4, or β1T169A, indicating that this drug selectively targets [ENTITY_B] via the BK β1 steroid-sensing site.",0,0
These findings demonstrate that [ENTITY_A] increased [ENTITY_B] activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells.,0,0
These results may have implications in the development of novel [ENTITY_A] inhibitors based on the use of [ENTITY_B] as a lead compound for the treatment of type 2 diabetes.,1,0
"A comparison of bosutinib with [ENTITY_A] across the whole [ENTITY_B] panel revealed overlapping, but distinct, inhibition profiles.",1,0
"Furthermore, [ENTITY_A] abolished the LPS-induced increase in [ENTITY_B] expression and [Ca2+]i elevation in KCs.",1,0
"In this study, the activity of the [ENTITY_A] subtype-selective agonist, [ENTITY_B], was investigated in a guinea pig model of citric acid-induced cough.",2,0
"In the high-dose [ENTITY_A] group, there was a twofold increase in [ENTITY_B] times but only after prolonged dosing.",0,0
"CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of [ENTITY_A], the inherent rise in [ENTITY_B] concentration inhibits its enzymatic activity.",1,0
"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of [ENTITY_A], an important neurotransmitter associated with memory, by blocking the enzyme [ENTITY_B].",4,0
"Further, compared with [ENTITY_A], another [ENTITY_B](V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose.",1,0
"Inhibition of platelet aggregation by AZD6140, a reversible oral [ENTITY_A] receptor antagonist, compared with [ENTITY_B] in patients with acute coronary syndromes.",3,0
"The pretreatment with 20 mg L(-1) [ENTITY_A] could alleviate the effects of UV-B radiation on the activities of [ENTITY_B], glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",1,0
"Removing medium Ca2+, blocking [ENTITY_A] with 50 mumol/l [ENTITY_B], or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.",1,0
"Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, [ENTITY_A] activation is responsible for the enhanced hippocampal CA3 network activity initiated by [ENTITY_B].",2,0
[ENTITY_A] induced dose-dependent reduction of the protein levels of [ENTITY_B] (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).,1,0
"mRNA levels of [ENTITY_A] (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with [ENTITY_B]-RANTES.",1,0
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [ENTITY_A] (10 micromol/L) cis-inhibited [ENTITY_B] (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",1,0
"In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, [ENTITY_A], at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the [ENTITY_B] and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.",0,0
"[ENTITY_A] (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield [ENTITY_B] and ammonia.",4,0
"OBJECTIVES: The aim of the current study was to assess the activity of [ENTITY_A], a nonsubtype-selective [ENTITY_B] inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use PDE4B wild-type and knockout mice to begin to understand the subtypes involved in the activity of rolipram.",1,0
These results strongly suggest that [ENTITY_A] is substantially involved in hepatic [ENTITY_B] secretion.,4,0
"The presence of [ENTITY_A] inhibits the stimulation of [ENTITY_B] activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.",1,0
"[ENTITY_A] and angiotensinogen genes were downregulated in dTGR and were increased by [ENTITY_B] and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.",0,0
"We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by [ENTITY_A] in the rat dentate gyrus, increasing [ENTITY_B] phosphorylation.",0,0
"Recent studies indicate that [ENTITY_A] initially acts as an antagonist, but later functions as an [ENTITY_B] agonist, promoting tumor growth.",3,0
"[ENTITY_A] (CYC202, Seliciclib) is a relatively selective inhibitor of [ENTITY_B] (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.",1,0
"[ENTITY_A] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of [ENTITY_B], cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",1,0
Activation of an apoptotic signal transduction pathway involved in the upregulation of [ENTITY_A] and apoptosis-inducing factor in [ENTITY_B]-induced primary cultured cardiomyocytes.,0,0
"However, after 12h [ENTITY_A] treatment, cell viability diminished in 50%, accompanied by a drastic decrease of [ENTITY_B] production, and an increase in p53 activation and the pro-apoptotic protein Bax.",1,0
The estrogenic agent [ENTITY_A] and estradiol at a dose of 1.0 mg also inhibited the [ENTITY_B] gene expression induced by P4.,1,0
"Several effects of [ENTITY_A] are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, [ENTITY_B] activators, calorie-restriction mimetics or epigenetic regulators.",0,0
"[ENTITY_A] enhanced the ratio [ENTITY_B]/IL-4 (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M DEX, 55.0 +/- 27.5, P<0.005).",0,0
Chromatographic analysis of the metabolism of [ENTITY_A] in this system revealed that PB-dependent inactivation of [ENTITY_B] is markedly increased in the presence of 100 microM H2O2.,4,0
INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of [ENTITY_A] for the treatment of myeloid malignancies expressing activated forms of [ENTITY_B] and FLT3.,1,0
"[ENTITY_A], as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of [ENTITY_B].",1,0
We previously reported that [ENTITY_A] antidepressants act as agonists at distinct [ENTITY_B].,2,0
[ENTITY_A]-alkylation of the pyridazinone ring markedly enhances potency against [ENTITY_B] but suppresses PDE3 inhibition.,1,0
"In hearts treated with [ENTITY_A], [AMP] was increased at 50 min and [ENTITY_B] activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.",0,0
"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to [ENTITY_A] NPs, the messenger RNA level of apoptotic genes ([ENTITY_B] and caspase-9) were upregulated in a dose-dependent manner.",0,0
[ENTITY_A] activity was found to be strongly increased in the [ENTITY_B]-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line.,0,0
"Ex vivo, lumiracoxib inhibited [ENTITY_A]-derived [ENTITY_B] (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",4,0
"[ENTITY_A] increased the amount of [ENTITY_B] at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization.",0,0
"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel [ENTITY_A] (COX-2) selective inhibitor [ENTITY_B] (Prexige), so that dose recommendations for clinical use can be provided.",1,0
Our findings confirmed that [ENTITY_A] protected EA.hy926 cells against radiation-induced injury through the [ENTITY_B]/HO-1 pathway.,0,0
Binding of [ENTITY_A] to alpha1-acid glycoprotein may be involved in its inhibition of [ENTITY_B] production.,1,0
"Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that [ENTITY_A] acted as an agonist of the m-[ENTITY_B].",2,0
"Effects of [ENTITY_A], other [ENTITY_B] antagonists and omeprazole on gastric acid secretory states in rats and dogs.",3,0
"However, the role of [ENTITY_A] in metabolic activation of [ENTITY_B] has been disputed.",4,0
"Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective [ENTITY_A] agonist [ENTITY_B] (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.",2,0
"Furthermore, [ENTITY_A] was able to not only decrease the paclitaxel-induced p38 MAPK-mediated [ENTITY_B] expression, but also augment the cytotoxic effect induced by paclitaxel.",1,0
"In addition, [ENTITY_A] inhibits [ENTITY_B]-dependent inflammatory responses by modulating IκB kinase (IKK)-inhibitor κBα (IκBα)-NF-κB signaling.",1,0
We describe here the isolation and biochemical characterization of the marine natural [ENTITY_A] palinurin as a [ENTITY_B] inhibitor.,1,0
"Although treatment with [ENTITY_A] reduced [ENTITY_B] levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG.",1,0
"LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of [ENTITY_A] by driving MRTF-dependent [ENTITY_B] expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A.",0,0
Coagulation-induced [ENTITY_A] and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of [ENTITY_B] and COX-2 activity.,4,0
These data demonstrate that [ENTITY_A] are a unique class of [ENTITY_B] inhibitors with high potency.,1,0
"Consistent with these data, only [ENTITY_A]-expressing RIN or AtT-20ins cells transported [ENTITY_B] efficiently.",4,0
"[ENTITY_A] (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [ENTITY_B], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",1,0
[ENTITY_A] type dual inhibitors of [ENTITY_B]/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.,1,0
"In contrast to [ENTITY_A], GnRH-induced nuclear translocation did not transcriptionally activate the [ENTITY_B].",0,0
Measurement of Transport Activities of [ENTITY_A] in [ENTITY_B] and Multidrug Resistance-Associated Proteins Using LC-MS/MS.,4,0
"In vitro, [ENTITY_A], but not doxycycline, inhibits [ENTITY_B], at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway.",1,0
"This leads to decreased expression of [ENTITY_A], which in turn reduces [ENTITY_B] transport.",4,0
"[ENTITY_A] inhibited both [ENTITY_B] and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2.",1,0
Liver [ENTITY_A] activity was reduced by 45% with [ENTITY_B] and 61% with hydralazine and 81% in AOX-deficient mice relative to controls.,1,0
"[ENTITY_A] did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an [ENTITY_B] reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus.",1,0
The identification of [ENTITY_A] as a potent [ENTITY_B] agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.,2,0
"In order to examine the site of action of an [ENTITY_A] subtype-selective NMDA antagonist [ENTITY_B], we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",3,0
Increased [ENTITY_A] activity in the serum was inhibited by both [ENTITY_B] and MCI-826 by over 90%.,1,0
"The nonselective [ENTITY_A] antagonist, [ENTITY_B] (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",3,0
[ENTITY_A] also induces the rapid phosphorylation of [ENTITY_B] (PKD1).,0,0
We hypothesized that [ENTITY_A] is activated by a distinct signaling pathway in response to pulsatile [ENTITY_B] in a frequency-dependent manner to dictate the FSHβ transcriptional response.,0,0
"RESULT(S): [ENTITY_A], a [ENTITY_B] agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.",2,0
"[ENTITY_A], phorbol esters, and bradykinin each decreased [ENTITY_B] mRNA levels by 70-80%.",1,0
"[ENTITY_A], an opiate agonist of high specificity for mu-receptors, was recently reported to suppress [ENTITY_B] and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.",1,0
"Contrary to the hypothesis, orlistat at 1 nM inhibited [ENTITY_A] activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of [ENTITY_B].",1,0
"In vitro, [ENTITY_A] elicited a 4.4-fold selectivity toward [ENTITY_B] inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for COX-2).",1,0
"In addition, cells pre-treated with [ENTITY_A] (PAG, 3 mM), a [ENTITY_B] inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.",1,0
"[ENTITY_A] showed more potent inhibition on [ENTITY_B] mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg/kg/day.",1,0
"The contractions to 5-HT were inhibited by [ENTITY_A] and alosetron indicating involvement of [ENTITY_B] and 5-HT(3) receptors, respectively.",1,0
"Patch-clamp analysis using inside-out recording configuration showed that [ENTITY_A] inhibits the [ENTITY_B]/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM).",1,0
"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the [ENTITY_A] inhibitor [ENTITY_B]; and the 5-LOX activating protein (FLAP) inhibitor MK-886.",1,0
"Porcine TLR8 and [ENTITY_A] are both activated by a selective TLR7 ligand, [ENTITY_B].",0,0
"Importantly, pre-treatment with buthionine sulfoximine ([ENTITY_A]), an inhibitor of [ENTITY_B], prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.",1,0
Withdrawal from free-choice [ENTITY_A] consumption results in increased packing density of [ENTITY_B]-immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.,0,0
"[ENTITY_A] (intravenous, 1 mg/kg), whose serotonergic actions include [ENTITY_B] and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).",3,0
"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, [ENTITY_A] (C7) and pentylparaben (C5) showed the most potent [ENTITY_B] and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.",2,0
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that [ENTITY_A] uptake by rat astrocytes is mediated by H(+)-coupled [ENTITY_B].",4,0
Most [ENTITY_A] showing estrogenic activity exhibited [ENTITY_B]-agonistic activity at lower concentrations than those inducing ERα-agonistic activity.,2,0
"These results indicate that [ENTITY_A] prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through [ENTITY_B]/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.",0,0
"In preliminary studies, in vitro incubation of rat cerebral cortex with [ENTITY_A] produced a wash and temperature resistant inhibition of [ENTITY_B] binding densities (Bmax).",1,0
"Although generally highly specific for [ENTITY_A], some ARBs, particularly [ENTITY_B], are partial agonists at peroxisome proliferator-activated receptor-γ.",3,0
"Moreover, [ENTITY_A] inhibited [ENTITY_B] and 5-LOX protein expression in vascular lesions.",1,0
"In [(35)S]GTPgammaS binding protocols, [ENTITY_A] exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at [ENTITY_B] sites.",2,0
Induction of [ENTITY_A] (HSPs) by [ENTITY_B] in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.,0,0
[ENTITY_A] also suppressed the activation of mammalian target of rapamycin (mTOR) and [ENTITY_B] (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.,1,0
Transport by [ENTITY_A] and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several [ENTITY_B] derivatives.,4,0
"Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the [ENTITY_A] antagonist [ENTITY_B].",3,0
"The selective [ENTITY_A] receptor antagonist, [ENTITY_B], slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.",3,0
[ENTITY_A] are classical antagonists for [ENTITY_B] for many of their pharmacological actions may be due to blockade of adenosine receptors.,3,0
"When further examined for its anticancer mechanism, [ENTITY_A] effectively suppressed the [ENTITY_B]/mTOR pathway both in vitro and in vivo.",1,0
"[ENTITY_A]-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of [ENTITY_B], and high MGMT staining.",1,0
A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the [ENTITY_A] tyrosine kinase inhibitors sunitinib and/or [ENTITY_B].,1,0
"Differentiating the roles of mGlu2 and mGlu3 receptors using [ENTITY_A], an [ENTITY_B] agonist/mGlu3 antagonist.",2,0
"Under [ENTITY_A] and sorbitol stresses, [ENTITY_B] (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.",0,0
"However, other [ENTITY_A] antagonists ([ENTITY_B], WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.",3,0
Insertion of ERα was blocked by the [ENTITY_A] antagonist [ENTITY_B] or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).,3,0
KIEs were measured on the arsenolysis of [ENTITY_A] (MTA) catalyzed by [ENTITY_B] and were corrected for the forward commitment to catalysis.,4,0
"In vivo, agonist actions of [ENTITY_A] at [ENTITY_B] sites are revealed by WAY100,635-reversible induction of hypothermia in the rat.",2,0
"Rats received a concomitant treatment with the selective [ENTITY_A] antagonist, [ENTITY_B] (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.",3,0
"On the other hand, treatment with [ENTITY_A] significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of [ENTITY_B], GLUT-4 and adiponectin.",0,0
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of [ENTITY_A] (a GABAergic enhancer and [ENTITY_B] inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.",1,0
"Pretreatment with [ENTITY_A] (1.5 ng/mouse, intracerebroventricularly), a [ENTITY_B] antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.",3,0
"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the [ENTITY_A]-selective agonist [ENTITY_B] or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.",2,0
"Both the non-specific [ENTITY_A] inhibitor, [ENTITY_B], and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective.",1,0
"We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific [ENTITY_A] inhibitor ([ENTITY_B]) on acid lung injury in rats.",1,0
[ENTITY_A] has a direct inhibitory effect on the [ENTITY_B].,1,0
"cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile [ENTITY_A] regulates [ENTITY_B] activation remain poorly understood.",0,0
[ENTITY_A] is a nonpeptide dual [ENTITY_B] antagonist.,3,0
"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the [ENTITY_A] inhibition of [ENTITY_B]/SUR1, but had no effect on homomeric K(IR)6.2 channels.",1,0
"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, [ENTITY_A] blocked basal and ligand dependent [ENTITY_B]-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation.",1,0
"Here we report the re-engineering of [ENTITY_A] to create a highly potent, orally bioavailable and [ENTITY_B]-selective inhibitor, ABT-199.",1,0
"Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of [ENTITY_A] activity by [ENTITY_B] (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",1,0
"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord [ENTITY_A] (cyclooxygenase-2), with a subsequent increase in central [ENTITY_B] (PGE2) levels associated with the development of hyperalgesia.",4,0
[ENTITY_A] inhibits nitric oxide production and [ENTITY_B] via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.,1,0
Inhibition of angiogenesis and invasion by [ENTITY_A] is mediated by downregulation of [ENTITY_B] and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.,1,0
"[ENTITY_A] secretion by MSCs was directly related to their [ENTITY_B] expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.",4,0
"[ENTITY_A] prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic [ENTITY_B] and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).",0,0
Inhibition of testicular [ENTITY_A] from laboratory animals and man by [ENTITY_B] and its isomers.,1,0
"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with [ENTITY_A], to [ENTITY_B], which is converted back to arginine via ASS.",4,0
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the [ENTITY_A] (CDCA)-induced expression of [ENTITY_B] and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).",0,0
"KEY RESULTS: [ENTITY_A], AICAR and metformin increased [ENTITY_B] activity and decreased I(amiloride).",0,0
"In contrast, in the same system, [ENTITY_A]-type currents, formed from transiently transfected alpha(1B)/alpha(2)delta-1/beta(3), showed strong [ENTITY_B]-mediated inhibition.",1,0
[ENTITY_A] inhibition of cholangiocyte growth was associated with decreased cAMP levels and [ENTITY_B]/ERK1/2/Elk-1 phosphorylation.,1,0
"Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant [ENTITY_A] hydrase activity of enamel [ENTITY_B], which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.",4,0
"The [ENTITY_A][ENTITY_B] kinase inhibitor ZD1839 (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",4,0
"Exhibiting unique properties over other MMPIs (e.g., [ENTITY_A]), these newly reported compounds are capable of modulating activities of several [ENTITY_B] in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).",1,0
"In cell culture experiments, it was found that triclosan inhibited [ENTITY_A] induced [ENTITY_B] production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.",4,0
"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the [ENTITY_A] inhibitors cyanine 863, [ENTITY_B] and corticosterone.",1,0
A high throughput assay for the glucuronidation of [ENTITY_A] by recombinant [ENTITY_B] and liver microsomes.,4,0
[ENTITY_A] was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric [ENTITY_B] agonist and mGlu3 antagonist.,2,0
"5-Fluorouracil ([ENTITY_A]), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [ENTITY_B] (TS).",1,0
"As with GABA, the metabolism of [ENTITY_A] involves a [ENTITY_B].",4,0
"Pretreatment with the dopamine D1 receptor antagonist, [ENTITY_A], and the NMDA receptor antagonist, MK-801, blocked amantadine induction of [ENTITY_B] in the striatum.",1,0
[ENTITY_A] inhibits [ENTITY_B] activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.,1,0
"The following alpha(2)-adrenoceptor antagonists were applied: [ENTITY_A] ([ENTITY_B]-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).",3,0
"Although the IC50 value of [ENTITY_A] for inhibition of [ENTITY_B] was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.",1,0
"In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the [ENTITY_A], was significantly inhibited by [ENTITY_B].In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells.",1,0
"Favorable enzyme profiles (high [ENTITY_A] and low DPD) generate high intratumor levels of [ENTITY_B] that are effective against many tumors, especially those with low TS.",4,0
"[ENTITY_A] blocks the action of estrogen by binding to the ER, and possesses both [ENTITY_B]-agonist and antagonist properties.",3,0
CONCLUSION: [ENTITY_A] is a well tolerated [ENTITY_B] inhibitor.,1,0
"With exposure to [ENTITY_A], a selective [ENTITY_B] inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.",1,0
"Although acetylcholinesterase ([ENTITY_A]) is primarily a hydrolytic enzyme, metabolising the neurotransmitter [ENTITY_B] in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.",4,0
[ENTITY_A] levels were low in virgin control mice and increased after [ENTITY_B] treatment in both strains.,0,0
Discovery and optimization of [ENTITY_A] as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of [ENTITY_B] binding.,1,0
[ENTITY_A] represses [ENTITY_B] microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.,1,0
"In vivo, A431[ENTITY_A] tumors demonstrated a 33-fold higher [ENTITY_B] uptake than parental tumors.",4,0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of [ENTITY_A] analogues required for inhibition of clot lysis induced by exogenous [ENTITY_B].,1,0
Chelation of calcium ions by BAPTA-AM or blockade of [ENTITY_A] activation by [ENTITY_B] also prevented the NMDA effects.,1,0
"This group of drugs contains secondary or primary amines, and these results suggest that [ENTITY_A] preferably conjugates [ENTITY_B].",4,0
Apple [ENTITY_A] suppress antigen presentation of [ENTITY_B] by THP-1-derived dendritic cells.,1,0
"The immune response modifiers, [ENTITY_A] and resiquimod, are [ENTITY_B] agonists that induce type I interferon in numerous species, including humans.",2,0
"Substantial evidence shows that [ENTITY_A] is involved in aging by inhibiting free-radical reactions, activating [ENTITY_B], and probably interacting with the age-related gene Klotho.",0,0
"At nonconvulsant doses, the [ENTITY_A] blockers [ENTITY_B], dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.",1,0
"Pharmacological inhibition of MTORC1 with [ENTITY_A] abrogated the [ENTITY_B]-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.",1,0
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists ([ENTITY_A], alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [ENTITY_B] in an identical cellular background.",3,0
"These results suggested that [ENTITY_A] could inhibit invasion and angiogenesis by downregulation of [ENTITY_B]and MMP-9, resulting from the inhibition of Akt pathway.",1,0
"If the effectors were added after 5 min of aging they increased the activity of [ENTITY_A]-inhibited [ENTITY_B], but to a considerably smaller extent than HI 6.",1,0
"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective [ENTITY_A]/COX-2 inhibitor, [ENTITY_B], resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.",1,0
The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist [ENTITY_A] was a pure antagonist at both rat brain and human [ENTITY_B] receptors.,3,0
"The effects of histamine H1-receptor antagonists, [ENTITY_A] and homochlorcyclizine, both of which are inhibitors of [ENTITY_B], on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.",1,0
"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both [ENTITY_A] and BuChE, [ENTITY_B], indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.",1,0
Treatment of C57 BL/6 mice with [ENTITY_A] increased fibroblast viability and collagen production and significantly downregulated [ENTITY_B].,1,0
"It has been claimed that [ENTITY_A], the human high affinity copper transporter, is the major entry pathway for [ENTITY_B] and related drugs via a mechanism that mimics copper.",4,0
"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, [ENTITY_A] (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of [ENTITY_B].",1,0
"In the CCl4 hepatotoxicity model, pre-treatment with PSM or [ENTITY_A] resulted in significantly increased activities of [ENTITY_B] and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group.",0,0
"Cytosolic [AMP] reported metabolically active [ENTITY_A], which triggered increased [ENTITY_B] activity, but measures of total AMP did not.",0,0
"Inhibition of the NF-kappaB pathway was responsible for this effect since the [ENTITY_A] inhibited RANKL-induced [ENTITY_B] activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.",1,0
"Additionally, [ENTITY_A] and Ad-Nrf2 repressed [ENTITY_B]-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.",1,0
"We now demonstrate that [ENTITY_A], a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced [ENTITY_B] production at concentrations readily achieved in vivo.",1,0
"db/db mice treated with [ENTITY_A] showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes [ENTITY_B] and carnitine acetyltransferase, respectively.",0,0
"[ENTITY_A] served as inhibitor of an interfering [ENTITY_B] present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.",1,0
"[ENTITY_A], FMO2, FMO3, and FMO5 metabolized [ENTITY_B], and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.",4,0
"Given these findings, a unified PK model including the inhibition of [ENTITY_A]- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood [ENTITY_B], 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",1,0
"[ENTITY_A], isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of [ENTITY_B] expression in human prostate cancer LNCaP cells.",1,0
"Alprenolol and BAAM also caused surmountable antagonism of [ENTITY_A] responses, and this [ENTITY_B] antagonism was slowly reversible.",2,0
"In PC3 cells, [ENTITY_A] inhibited [ENTITY_B] and resulted in increased sensitivity to UV irradiation.",1,0
"Compared with the untreated colitis group, the [ENTITY_A]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of [ENTITY_B] mRNA, IL-27 mRNA, TLR4 protein, NF-κB p65 protein, and IL-27 p28 protein (p < 0.05).",1,0
The atypical antidepressant [ENTITY_A] exhibits agonist activity at [ENTITY_B].,2,0
"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective [ENTITY_A] inhibitor ([ENTITY_B]) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac).",1,0
"The protein exhibited modest [ENTITY_A]-dependent [ENTITY_B] activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).",0,0
The acetylation of [ENTITY_A] is increased in [ENTITY_B]-overexpressing mice compared with wild-type mice.,4,0
"The results demonstrated that intracerebral infusions of [ENTITY_A] (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of [ENTITY_B] and Aβ1-42 in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of amyloid precursor protein (APP).",0,0
"[ENTITY_A] is an [ENTITY_B] blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.",1,0
"In conclusion, this study provides the first evidence implicating that [ENTITY_A] inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced [ENTITY_B]-ARE signaling.",0,0
This inhibition was blocked when mice were pretreated with the selective [ENTITY_A] agonist [ENTITY_B] (10 mg/kg).,2,0
"Effects of the [ENTITY_A]/HER2 kinase inhibitor [ENTITY_B] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.",1,0
"Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on [ENTITY_A]-induced disruption of [ENTITY_B] system and cAMP response element binding protein (CREB) phosphorylation.",1,0
[ENTITY_A]-induced [ENTITY_B] activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.,0,0
Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor [ENTITY_A] for the inhibition of [ENTITY_B] messenger RNA expression and antitumor efficacy in xenografted tumor model mice.,1,0
"[ENTITY_A]-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), [ENTITY_B] (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).",1,0
"It was reported previously that [ENTITY_A] gene (F7) expression was up-regulated by [ENTITY_B] treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.",0,0
"Furthermore, RT-PCR analyses revealed that [ENTITY_A] treatment increased expression of interleukin-10 mRNA but decreased [ENTITY_B] expression.",1,0
"[ENTITY_A] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of [ENTITY_B](WAF1/CIP1) and p53.",0,0
"[ENTITY_A], an Inhibitor of [ENTITY_B] Isolated from the Culture Broth of Streptomyces sp.",1,0
"[ENTITY_A], in particular, act by stimulating the catabolism of [ENTITY_B] and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.",1,0
"The antidepressant [ENTITY_A] has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter ([ENTITY_B]) in vivo and in vitro, on both an acute and a chronic basis.",1,0
Other [ENTITY_A] antagonists also produced such a shift in the following antagonistic-potency order: [ENTITY_B]> ondansetron=AS-8112>>metoclopramide.,3,0
"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of [ENTITY_A] decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [ENTITY_B].",1,0
"The acetylcholinesterase ([ENTITY_A]) and butyrylcholinesterase (BuChE) inhibitory activities of a series of [ENTITY_B] (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",1,0
"[ENTITY_A], a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from [ENTITY_B] antagonism.",3,0
"CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike [ENTITY_A], also inhibited [ENTITY_B] and ALA-T (and increased brain ALA levels).",1,0
Differential [ENTITY_A]/lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal [ENTITY_B] deficiency.,4,0
"Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or [ENTITY_A]-induced [ENTITY_B] expression.",0,0
We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether [ENTITY_A] inhibition of [ENTITY_B] plays a role in their effects on bone metabolism.,1,0
[ENTITY_A]: a selective [ENTITY_B] antagonist for the treatment of heart failure.,3,0
"Inhibition of binding of both [ENTITY_A] and plasmin to gp330 by [ENTITY_B] was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.",1,0
"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, [ENTITY_A] as well as [ENTITY_B] activator, forskolin.",4,0
"CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect [ENTITY_A]-dependent [ENTITY_B] efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.",4,0
"This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with [ENTITY_A] activator [ENTITY_B] (EtOH).",0,0
"1. This work investigated the drug interaction potential of [ENTITY_A], a novel [ENTITY_B] agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin.",2,0
"The vasopressor response to the [ENTITY_A] activator, [ENTITY_B], which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",0,0
[ENTITY_A] (100μM) induced [ENTITY_B] and depleted heme pool when incubated to human hepatocytes.,0,0
"[ENTITY_A] activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of [ENTITY_B] and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",1,0
"Furthermore, we validated the inhibition of [ENTITY_A]/NF-κB signaling following [ENTITY_B] treatment.",1,0
"The antagonistic property of [ENTITY_A] at [ENTITY_B] indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.",3,0
These findings support that PPARgamma plays an essential role in mediating the [ENTITY_A]-inhibiting effect of [ENTITY_B].,1,0
"Furthermore, the enzymatic activity of [ENTITY_A] (ALT), which converts the critical gluconeogenic amino acid alanine into [ENTITY_B], is decreased (approximately 50%) in KLF15-/- hepatocytes.",4,0
[ENTITY_A] antagonist [ENTITY_B] and the defence reaction in the anaesthetised rat.,3,0
CONCLUSIONS: These findings indicate that increased synthesis of [ENTITY_A] through up-regulation of [ENTITY_B] gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.,4,0
"Moreover, [ENTITY_A] and S3226, both specific inhibitors of [ENTITY_B] only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.",1,0
"[ENTITY_A], in doses administrated in our experiments, inhibited [ENTITY_B]B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.",1,0
"Furthermore, the [ENTITY_A] activator [ENTITY_B] (AICAR) significantly inhibited ghrelin secretion.",0,0
[ENTITY_A] carrier status had no influence on midazolam oral clearance or its inhibition by [ENTITY_B].,1,0
"However, amantadine induction of Fos in the striatum was unaffected by the [ENTITY_A] antagonist, [ENTITY_B].",3,0
"Similarly, [ENTITY_A] and the p-chloro analogue inhibited [ENTITY_B] activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate.",1,0
"Overall, higher alcohol production was reduced by [ENTITY_A] supplementation, and this can be correlated with a general downregulation of genes encoding [ENTITY_B] and dehydrogenases of the Ehrlich pathway.",1,0
"Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of [ENTITY_A] from [ENTITY_B] to lower-density lipoproteins.",4,0
[ENTITY_A] which also inhibits [ENTITY_B] secretion was less efficient (inhibition by 20%).,1,0
"CONCLUSIONS: Our results show that [ENTITY_A], a known cyclooxygenase (COX) inhibitor, is also an activator of [ENTITY_B].",0,0
[ENTITY_A]-induced reversal of [ENTITY_B] suppression by TGFβ was associated with a significant inhibition of TGFβ-stimulated protein synthesis and hypertrophy.,0,0
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the [ENTITY_A] inhibitor [ENTITY_B] (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.",1,0
"[ENTITY_A] also inhibited other channels including [ENTITY_B], Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.",1,0
"Although highly homologous to other class III RTKs, Flt3 is resistant to the [ENTITY_A] STI571 (Gleevec, Imatinib), a potent inhibitor of other [ENTITY_B] in the family, such as the PDGFbeta-receptor or c-Kit.",1,0
The agonist activity was antagonized by the selective [ENTITY_A] blocker [ENTITY_B] (nor-BNI).,1,0
"Blocking [ENTITY_A] formation by a targeted knock down of [ENTITY_B] results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.",4,0
The results suggest that most of the [ENTITY_A] in plasma is derived from deamination of DA by [ENTITY_B] in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.,4,0
"[ENTITY_A]/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, [ENTITY_B], and MK-499, at submicromolar concentrations.",1,0
"RESULTS: In the [ENTITY_A]-injured brain, the [ENTITY_B] mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes.",0,0
"[ENTITY_A] activators [ENTITY_B] and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C.",0,0
The increase in [ENTITY_A] activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after [ENTITY_B] treatment.,0,0
"Inhibition by [ENTITY_A] of oxygen consumption via [ENTITY_B] respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts.",1,0
"Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of [ENTITY_A] as the first potent and selective [ENTITY_B] agonist.",2,0
"Consequently, [ENTITY_A] inhibitors including [ENTITY_B] and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.",1,0
"Finally, SA-induced [ENTITY_A] expression was found to be prevented both by NAC and specific JNK inhibitor, [ENTITY_B], strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.",1,0
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate [ENTITY_A] to [ENTITY_B], ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.",4,0
"By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, [ENTITY_A]-induced [ENTITY_B] activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus.",0,0
"The [ENTITY_A] treatment also partially improved the [ENTITY_B] sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats.",0,0
"Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with [ENTITY_A] decreased the frequencies of SCE and the malondialdehyde level and increased amount of [ENTITY_B], glutathione and glutathione peroxidase which were decreased by aflatoxin.",0,0
"Novel mechanism of action for [ENTITY_A]: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of [ENTITY_B].",1,0
"Additionally, [ENTITY_A] significantly down-regulated [ENTITY_B] expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.",1,0
"[ENTITY_A] also down-regulated the expression of [ENTITY_B] target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",1,0
"ZD1839 (""Iressa""), a [ENTITY_A][ENTITY_B] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",4,0
"The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of [ENTITY_A] by [ENTITY_B] increases the density of these receptors in the PVN.",1,0
"The [ENTITY_A] block caused by [ENTITY_B] and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells.",1,0
"Upon [ENTITY_A] pre-exposure, brain acetylcholinesterase increased, while [ENTITY_B] (MAO) decreased.",1,0
[ENTITY_A] treatment also inhibited LPS-induced NO production and [ENTITY_B] expression via its inactivation of NF-kappaB.,1,0
"In this setting, [ENTITY_A] (10 μm) effectively blocked the [ENTITY_B]-mediated regeneration of oxidized Prx1.",1,0
"Based on the results from those studies, we concluded that [ENTITY_A] PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited [ENTITY_B].",1,0
"Ginsenosides Rb2, Rd and Rg1 significantly decreased [ENTITY_A] and/or epinephrine-induced increase of [ENTITY_B] level in macrophage cell line (RAW 264.7).",0,0
"RESULTS: Following administration of the highest of the [ENTITY_A] doses used (2.5; 5; 10 mg/kg i.m.), [ENTITY_B] activity decreased mainly in the frontal cortex, hippocampus and hypophysis.",1,0
"In addition, pretreatment with [ENTITY_A] (Z-VAD-fmk), a broad spectrum of [ENTITY_B] inhibitor, could not rescue apoptotic cells from ClpP toxicity.",1,0
"In conclusion, we find that [ENTITY_A] exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress [ENTITY_B] and its ability to attenuate activation of hepatic stellate cells.",1,0
[ENTITY_A] showed partial protection in the cortical neurons via down-regulation of NR2B containing [ENTITY_B] and up-regulation of Bcl-2 family.,1,0
"In concert with these results, we highlighted that the secretion of pro-inflammatory [ENTITY_A] and NF-κB activation induced by [ENTITY_B] can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.",0,0
"Additionally, [ENTITY_A] significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in [ENTITY_B] expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.",0,0
"Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or [ENTITY_A] ([ENTITY_B] inhibitor), decreased apoptosis in U937 cells.",1,0
The selective [ENTITY_A] inhibitor [ENTITY_B] (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).,1,0
"Serotonin-induced or neurotensin-induced reversal was blocked by β-ARK1 inhibitor, dynasore, or [ENTITY_A] antagonist [ENTITY_B] (Gö6976).",3,0
Here we report that [ENTITY_A] treatment resulted in decreased transcription and protein levels of [ENTITY_B] by 3LL cells.,1,0
CONCLUSION: Our data provides a novel insight into an effect of telmisartan: [ENTITY_A] inhibits AT1R gene expression through [ENTITY_B] activation.,0,0
"Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports [ENTITY_A] exocytosis in the presence of [ENTITY_B], and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.",4,0
"In guinea pigs, antagonist actions of [ENTITY_A] at [ENTITY_B] receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.",3,0
UNLABELLED: [ENTITY_A] (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to [ENTITY_B] and glycine.,4,0
These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of [ENTITY_A] uptake through an effect on the [ENTITY_B].,4,0
"These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of [ENTITY_A] may be related to attenuating the decrease in [ENTITY_B] activity and NO levels.",0,0
"Moreover, [ENTITY_A] decreases the amount and phosphorylation of [ENTITY_B] and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.",1,0
"However, despite activation of L-arginine uptake, the inhibition of [ENTITY_A] activity by [ENTITY_B] was still significant.",1,0
"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the [ENTITY_A] inhibitor, [ENTITY_B] (FAD).",1,0
"Unlike the nonselective [ENTITY_A] inhibitors, [ENTITY_B] does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.",1,0
"[ENTITY_A], a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased [ENTITY_B]-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.",1,0
"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by [ENTITY_A]-inhibiting ADs such as [ENTITY_B], desipramine, and imipramine.",1,0
"Collectively, our data indicate that [ENTITY_A] contributes to the production of proteolyzed [ENTITY_B] via GPR30 with augmented migration in MCF-7 cells.",0,0
"Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-[ENTITY_A] rats showed higher [ENTITY_B] and depleted xanthine oxidase activities.",0,0
"Previous studies by this research team proved that vasodilating [ENTITY_A] (PGs) E1, E2 and I2 inhibit [ENTITY_B] (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.",1,0
"Based on these suggestions, the rational redesign of [ENTITY_A] 24 (clog P=7.41; [ENTITY_B] IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of quinazoline 67 (clog P=5.28; Aurora A IC(50) =25 nM; HCT-116 IC(50) =23 nM).",1,0
The results in vivo show [ENTITY_A]-induced significantly broke Treg/Th17 balance; [ENTITY_B] treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.,1,0
"[ENTITY_A] is a novel, orally active inhibitor of [ENTITY_B] EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP).",1,0
[ENTITY_A] release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) [ENTITY_B].,0,0
"Tyrosine kinase inhibitors are [ENTITY_A]-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of [ENTITY_B] signaling.",1,0
"The mRNA levels of [ENTITY_A], CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined [ENTITY_B]+NaAsO2 treatment group.",0,0
"Because clinical studies investigating interactions between garlic and [ENTITY_A] inhibitors [ENTITY_B] and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes.",1,0
"Like conventional ACE inhibitors, [ENTITY_A] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of [ENTITY_B] and bradykinin.",0,0
"CONCLUSIONS: This study shows that [ENTITY_A] acts as a non-competitive inhibitor of [ENTITY_B], and that inhibition is substrate-selective.",1,0
Inhibition of the [ENTITY_A] by [ENTITY_B]: affinity for open and inactivated states.,1,0
[ENTITY_A] and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the [ENTITY_B] of rat left atria.,3,0
It is possible that variations in [ENTITY_A] enzyme-mediated metabolism of [ENTITY_B] may contribute to this phenomenon.,4,0
"These results indicate transcription of [ENTITY_A] is regulated by the NR5A family and cAMP signaling, and participates in [ENTITY_B] hormone production in ovarian granulosa cells.",4,0
"The potentiation of heteromeric [ENTITY_A] by mGlu1 activation was attenuated by GDPβS, blocked by an inhibitor of phospholipase C or the calcium chelator [ENTITY_B] (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.",1,0
[ENTITY_A] is a selective [ENTITY_B] blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia.,1,0
"In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular [ENTITY_A] is reduced when [ENTITY_B] is inhibited.",4,0
"In addition to the effect on ROS, [ENTITY_A] ameliorated MPTP-reduced lysosome-associated membrane protein type 2A ([ENTITY_B]) expression.",1,0
[ENTITY_A] is a novel ER antagonist that destroys the [ENTITY_B] and its signaling pathway and is not associated with tamoxifen-like agonist effects.,1,0
"Indoleamine 2,3-dioxygenase ([ENTITY_A]), a [ENTITY_B] catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.",4,0
"4.  At a substrate concentration of 20 µM, the most active [ENTITY_A] glucuronidation catalysts were [ENTITY_B] followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",4,0
"The recent identification of [ENTITY_A] permeability of the lysosomal ion channel [ENTITY_B] (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.",4,0
"Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. [ENTITY_A] inhibits the [ENTITY_B] and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.",1,0
"[ENTITY_A], a lipid-lowering drug, inhibits the induction of [ENTITY_B] in human astrocytes.",1,0
These studies show that [ENTITY_A] and CYP3A5 metabolize [ENTITY_B] to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.,4,0
"Both the 5 alpha-reductase inhibitor finasteride and [ENTITY_A] antagonists (e.g. [ENTITY_B], doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",3,0
"At a low pH (pH 7.4), but not pH 7.9, [ENTITY_A] reduces the mean open time of [ENTITY_B]/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.",1,0
Gelatin zymography showed that [ENTITY_A] inhibited secretion and activity of [ENTITY_B].,1,0
"We demonstrate that two [ENTITY_A] family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to [ENTITY_B].",4,0
"Our study shows that human TRPA1 is a target for [ENTITY_A], suggesting that an activation of [ENTITY_B] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.",0,0
Concentration-response curves for the inhibition of monocyte [ENTITY_A] and platelet COX-1 were obtained in vitro after the incubation of [ENTITY_B] with whole blood samples.,1,0
The results demonstrated that [ENTITY_A] is a competitive inhibitor of [ENTITY_B] (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).,1,0
"This manuscript presents the preclinical profile of [ENTITY_A], a novel [ENTITY_B] (COX-2) selective inhibitor.",1,0
Cellular responses to DNA damage induced by [ENTITY_A] or doxorubicin include down-regulation of endogenous [ENTITY_B] coincident with increases in p53.,1,0
"Chronic treatment with [ENTITY_A] reduced the levels of [ENTITY_B] and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats.",1,0
"In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that [ENTITY_A] may be the main enzyme involved in [ENTITY_B] formation in mouse acinar cells.",4,0
"The [ENTITY_A] secretory responses to isoproterenol, furthermore, were inhibited by [ENTITY_B], a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.",1,0
All these results demonstrate that [ENTITY_A] prevents CS(E)-induced [ENTITY_B] activation and thus it could be used for the prevention of CS-induced inflammatory diseases.,1,0
"[ENTITY_A] encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate [ENTITY_B] [PI(4,5)P2].",4,0
The [ENTITY_A] antagonist [ENTITY_B] prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.,3,0
"In addition, derivatives of [ENTITY_A] and sinapic acid efficiently inhibited [ENTITY_B] activity and reduced melanin content in melanocytes Mel-Ab cell.",1,0
"We investigated the efficacy of [ENTITY_A] at inhibiting mutants of the [ENTITY_B] PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.",1,0
[ENTITY_A] also reduced the [ENTITY_B] activation and platelet aggregation stimulated by PDBu.,1,0
"Whereas, the levels of both the basal and [ENTITY_A]-inducible expression of [ENTITY_B] were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells.",0,0
The growth of the [ENTITY_A]-independent RS4-11 cell line was only weakly inhibited by [ENTITY_B].,1,0
"[ENTITY_A]-Containing [ENTITY_B] Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.",1,0
"The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous [ENTITY_A] may modulate VT through alterations in autonomic tone by activation of arterial [ENTITY_B], and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.",0,0
Our recent study has demonstrated that coadministration of [ENTITY_A] (MAO-A) inhibitor [ENTITY_B] (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.,1,0
"Diet, physical exercise and [ENTITY_A] administration increase serum [ENTITY_B] (AMH) levels in women with polycystic ovary syndrome (PCOS).",0,0
"The molecular mechanism studies suggested that [ENTITY_A] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of [ENTITY_B] (NF-κB) p65 and p50 subunits.",1,0
"[ENTITY_A] 28 showed dose responsive target engagement and provides a useful tool to explore a [ENTITY_B] inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD).",1,0
"At the same time, mean plasma active [ENTITY_A] was increased 16- and 34-fold at the highest dose of [ENTITY_B].",0,0
"PURPOSE: To compare [ENTITY_A] (PLZ), an antidepressant drug with anxiolytic properties which inhibits [ENTITY_B] (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",1,0
"[ENTITY_A] (10 microM), another [ENTITY_B] antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.",3,0
"The nonselective and irreversible [ENTITY_A] inhibitors, [ENTITY_B] (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.",1,0
"The uptake of [ENTITY_A] by both cultured rat DRG neurons and HEK/[ENTITY_B] cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1.",4,0
"We investigated the effect of [ENTITY_A], an [ENTITY_B] inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy.",1,0
"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with [ENTITY_A], a [ENTITY_B] agonist, inhibited the stimulatory effect of insulin.",2,0
"The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and [ENTITY_A], a selective [ENTITY_B] inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST.",1,0
"Discovery of a series of novel [ENTITY_A], as potent [ENTITY_B] kinase inhibitors.",1,0
Ex vivo IC(50) values ([ENTITY_A]: 105.2 micromol/L; COX-2: 26.3 micromol/L) of [ENTITY_B] compared favorably with its in vitro IC(50) values.,1,0
"A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor [ENTITY_A] provided strong evidence that [ENTITY_B], potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.",1,0
"Together, our findings suggest the critical role of 'Rac and subsequent activation of [ENTITY_A]' in [ENTITY_B]-signalling to nucleus.",0,0
[ENTITY_A] was also shown to induce the expression of cleaved-[ENTITY_B] and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner.,0,0
"Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the [ENTITY_A] antagonist, [ENTITY_B].",3,0
"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that [ENTITY_A] is the low-affinity transporter of [ENTITY_B], glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.",4,0
"[ENTITY_A] (XL184), a novel [ENTITY_B] and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.",1,0
"[ENTITY_A] stimulation of [ENTITY_B] phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.",0,0
"[ENTITY_A] is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated [ENTITY_B] agonists.",2,0
"In support of this observation, elongation can be reversed by the [ENTITY_A] inhibitor [ENTITY_B], mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.",1,0
In subjects with dysmenorrhea the increase in pain following the administration of [ENTITY_A] was significantly lower during [ENTITY_B] than during placebo infusion.,1,0
[ENTITY_A] and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced [ENTITY_B] and phosphoenolpyruvate carboxykinase mRNAs.,1,0
Both outward currents were significantly reduced by the [ENTITY_A] antagonist [ENTITY_B] and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.,3,0
"Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the [ENTITY_A] antagonist, [ENTITY_B], on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.",3,0
"On the other hand, peptides modified with [ENTITY_A], apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to [ENTITY_B].",3,0
"Collectively, we have elucidated a basal mechanism for [ENTITY_A]-induced [ENTITY_B] mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo.",0,0
"The [ENTITY_A] inhibitor [ENTITY_B] (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",1,0
ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the [ENTITY_A] (PI3Kγ) inhibitor [ENTITY_B].,1,0
In this study we investigated the effects of combination chemotherapy with melarsoprol and a [ENTITY_A] antagonist [ENTITY_B] (EMEND) in this mouse model.,3,0
"[ENTITY_A], a competitive inhibitor of both [ENTITY_B] and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.",1,0
"Known [ENTITY_A] antagonists ([ENTITY_B], thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",3,0
"Using whole-cell voltage clamp, we examined [ENTITY_A] block of four [ENTITY_B] isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).",1,0
"Plasma [ENTITY_A] activity was significantly lower after [ENTITY_B] than after placebo, but this was not clinically relevant.",1,0
"Given the anti-inflammatory properties of EPA, we suggest that induction of [ENTITY_A] in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of [ENTITY_B] or n-6.",0,0
"Furthermore, we found that [ENTITY_A] activates the [ENTITY_B] and consequently induces Pirh2 expression.",0,0
"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of [ENTITY_A] that inhibit the [ENTITY_B]/CXCL12 interaction.",1,0
"A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with [ENTITY_A] inhibitors, [ENTITY_B] and mitoxantrone, and an alkylating agent, cyclophosphamide.",1,0
Local LC citalopram effect was abolished by LC presence of the [ENTITY_A] receptor antagonist [ENTITY_B] (1 μM) but not the 5-HT1/2 receptor antagonist methiothepin (1 μM).,3,0
"Although [ENTITY_A] exerts local antioxidant activity with beneficial effects on lung tissue, this [ENTITY_B] inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.",1,0
"In conclusion, the production of [ENTITY_A] and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by [ENTITY_B] than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma.",1,0
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by [ENTITY_A], which has been reported to preferentially inhibit [ENTITY_B] (COX-2).",1,0
"Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate [ENTITY_A] downregulation by [ENTITY_B] and paclitaxel as well as cell viability and DNA repair capacity.",1,0
"These results indicate that the [ENTITY_A] activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties ([ENTITY_B] selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.",0,0
Our studies shed light on the possible in vivo potency of the [ENTITY_A] and provide a foundation for future studies aimed at creating more potent [ENTITY_B] inhibitors and at understanding the physiological significance of QR2.,1,0
"Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly [ENTITY_A], are partial agonists at [ENTITY_B].",2,0
"This study shows ability of [ENTITY_A] to raise plasma bile acid concentrations, mainly through [ENTITY_B] upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow.",0,0
The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing [ENTITY_A] formation from [ENTITY_B].,4,0
We find that FP causes a decrease in stimulated eosinophil secretion of [ENTITY_A] that is regulated by [ENTITY_B] (PLA2).,4,0
"Western blot analysis of cells incubated with [ENTITY_A] demonstrated activation of [ENTITY_B] and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2.",0,0
"In [(35)S]GTPgammaS binding protocols, [ENTITY_A] exerts antagonist actions at [ENTITY_B], h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",3,0
"In addition, [ENTITY_A] (CoPP), a specific [ENTITY_B] inducer, predominantly suppressed LPS-induced NO production.",0,0
"One major route involves the tetrahydrofolate (THF)-dependent activities of the [ENTITY_A] (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with [ENTITY_B] (Gly) as one-carbon (1-C) source.",4,0
[ENTITY_A] are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of [ENTITY_B].,1,0
"In cell culture experiments, it was found that [ENTITY_A] inhibited [ENTITY_B] induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.",1,0
"The activity of the human nasal mucosa microsomes was inhibited by [ENTITY_A], a known [ENTITY_B] inhibitor.",1,0
"3. In vitro, [ENTITY_A] demonstrated little/weak inhibition (IC50 values >30 μM) towards [ENTITY_B] (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.",1,0
The potency of the selective [ENTITY_A] antagonist [ENTITY_B] against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.,3,0
Discovery of a novel series of [ENTITY_A] [ENTITY_B] agonists.,2,0
The primary aim of these studies was to test the hypothesis that [ENTITY_A]-derived [ENTITY_B] has a biological role in endometrial function and conceptus development during early pregnancy in sheep.,4,0
"Additionally, [ENTITY_A] leads to growth inhibition of a [ENTITY_B]D816V-harboring human masto-cytosis cell line.",1,0
[ENTITY_A] and omapatrilat reduced the production of [ENTITY_B] and BrBK1-7 with more effect being observed with omapatrilat.,1,0
"Targeted disruption of the gene encoding the [ENTITY_A], prlH, abolished [ENTITY_B] production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.",4,0
"Inhibitory effect of synthetic [ENTITY_A], 4-MA and cyanoketone on [ENTITY_B] activity.",1,0
"[ENTITY_A] administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and [ENTITY_B]/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.",0,0
Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the [ENTITY_A] and isomerase substrate [ENTITY_B] bind at different sites on the same protein.,4,0
The test procedure was verified with respect to intestinal [ENTITY_A] hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal [ENTITY_B] activity by in vitro assay (R2 = 0.95) in a further group of subjects.,4,0
"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to [ENTITY_A] (DHP) [ENTITY_B] antagonists.",3,0
[ENTITY_A] (CE) induced surface erosion of poly(ethylene carbonate) ([ENTITY_B]) and drug release from PEC under mild physiological environment was investigated.,4,0
"In conclusion, the results suggest that the enhancement in the reduction of [ENTITY_A] activity by the combined [ENTITY_B]/VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs.",1,0
"The present results indicated that [ENTITY_A]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of [ENTITY_B] and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.",0,0
"Furthermore, proteosomal inhibitor MG132 suppressed [ENTITY_A] activation, GSK3β phosphorylation, cleaved PARP and deceased AEG-1 induced by [ENTITY_B] in HepG2 cells.",0,0
Comparison of [ENTITY_A] inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and [ENTITY_B].,1,0
"Furthermore, a mixture of [ENTITY_A] parent compounds, and a mixture of isoflavonoid metabolites were found to have [ENTITY_B] activating abilities.",0,0
"[ENTITY_A], piroxicam, and sulindac sulfide were found to preferentially inhibit [ENTITY_B].",1,0
"Formation of [ENTITY_A] by [ENTITY_B] is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.",4,0
"The activity of [ENTITY_A] containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of [ENTITY_B] eight to 14 times higher than those required to inhibit wild-type polymerases.",1,0
"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM [ENTITY_A] was reduced by 83% in [ENTITY_B](-/-) mice as compared with PEPT2(+/+) mice (p < 0.001).",4,0
"We observed a significant reduction in CSE induced luciferase expression, NF-κB DNA binding, [ENTITY_A] degradation and c-Rel nuclear translocation in cells pretreated with [ENTITY_B].",1,0
"CONCLUSION: Intake of high [ENTITY_A] and MUFAs appears to increase expression of PBMC [ENTITY_B] and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.",0,0
Rats were fed experimental diets containing SPI or [ENTITY_A] as a [ENTITY_B] source.,4,0
"We also shortly discuss the ongoing debate on whether [ENTITY_A] is the actual reaction product of [ENTITY_B] catalysis, as well as the phenomenon of NO-mediated autoinhibition.",4,0
"A review of the structural and functional features of [ENTITY_A], an [ENTITY_B] blocker.",1,0
The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of [ENTITY_A]-induced [ENTITY_B] secretion.,0,0
This work showed that appropriate structural modification of [ENTITY_A] can lead to [ENTITY_B]-selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.,3,0
"Here, we show that oral administration of [ENTITY_A], which leads to activation of an [ENTITY_B], suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.",0,0
[ENTITY_A] inhibitors [ENTITY_B] and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.,0,0
"All GCs including the antagonistic compound [ENTITY_A] efficiently reduced [ENTITY_B]-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression.",1,0
"During repetitive stimulation of skeletal muscle, extracellular [ENTITY_A] levels raise, activating [ENTITY_B], increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation.",0,0
To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of [ENTITY_A] derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against [ENTITY_B].,1,0
"Of the compounds active in the present assay system, the most potent compound 7, [ENTITY_A], significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and [ENTITY_B] (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.",1,0
"In vivo, agonist actions of yohimbine at [ENTITY_A] sites are revealed by [ENTITY_B]-reversible induction of hypothermia in the rat.",3,0
"Design, Synthesis, and Pharmacological Characterization of Novel [ENTITY_A] Analogues as Extremely Potent [ENTITY_B] Agonists.",2,0
"Pretreatment of rats with the [ENTITY_A] inhibitor [ENTITY_B] prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA.",1,0
Pre-treatment with arsenite increased [ENTITY_A] (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after [ENTITY_B].,0,0
We find that [ENTITY_A] causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by [ENTITY_B] (PLA2).,1,0
"Conversely, opioid antagonists such as naloxone and [ENTITY_A] (which bind to non-selectively [ENTITY_B]) have been shown to decrease alcohol consumption under various experimental conditions.",0,0
Extrinsic apoptotic pathway markers such as Fas levels and [ENTITY_A] activity increased as a result of [ENTITY_B]-QD exposure.,0,0
"To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using [ENTITY_A] (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a [ENTITY_B] probe substrate.",4,0
"Western blots showed a decrease in nuclear [ENTITY_A] protein expression after exposure to different concentrations of [ENTITY_B], while the phosphorylation of GSK-3β was simultaneously increased.",1,0
Block of [ENTITY_A] [ENTITY_B] channels by novel alpha-hydroxyphenylamide analogues of phenytoin.,4,0
"[ENTITY_A] inhibited [ENTITY_B] activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine.",1,0
The potent [ENTITY_A] antagonist [ENTITY_B] (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.,3,0
"These results suggest that [ENTITY_A] increases Aβ peptide burden via activation of [ENTITY_B], which further affects APP levels and activity of β- and γ-secretases via the NF-κB pathway.",0,0
Physiologic levels of [ENTITY_A] ions decrease [ENTITY_B] activity in part by increasing NADH binding affinity to the enzyme.,1,0
"Pretreatment with a combination of [ENTITY_A] (CGP20712A, a selective [ENTITY_B] antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",3,0
"The non-selective [ENTITY_A] antagonist ([ENTITY_B]), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.",3,0
[ENTITY_A] irreversibly inhibits [ENTITY_B] (BChE) in human plasma by forming adducts on the active site serine (Ser-198).,1,0
"Fourteen of 17 [ENTITY_A] exhibited [ENTITY_B] and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.",2,0
"[ENTITY_A], a potent and selective [ENTITY_B] inhibitor, achieves antitumor activity while sparing platelets.",1,0
"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to [ENTITY_A] by ecto-[ENTITY_B], and metabolism of AMP to adenosine by ecto-5'-nucleotidase.",4,0
The binding domain of barusiban differs from the binding domain of the agonists and the nonselective [ENTITY_A] antagonist [ENTITY_B] that has been used in previous studies.,3,0
"[ENTITY_A] inhibited [ENTITY_B] with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.",1,0
"The affinity labeling [ENTITY_A] analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the [ENTITY_B] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).",1,0
"As further support, [ENTITY_A], an inhibitor of [ENTITY_B] (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.",1,0
"With the pentapeptide linked through the C7alpha position of [ENTITY_A], the resulting PROTAC shows the most effective [ENTITY_B] degradation and highest affinity for the estrogen receptor.",1,0
"Unlike the sedative hypnotics that target GABA(A) receptor complexes, [ENTITY_A] is a chronohypnotic that acts on the melatonin [ENTITY_B] and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's ""master clock."" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades.",2,0
[ENTITY_A] (AR) catalyzes the reduction of toxic lipid aldehydes to their [ENTITY_B] products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).,4,0
CONCLUSIONS: [ENTITY_A] produced after antigen provocation sequentially induced IL-5 production from some immune component cells via [ENTITY_B] receptor activation.,0,0
[ENTITY_A] are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of [ENTITY_B]-responsive genes involved in glucose and lipid metabolism.,0,0
"In many countries, a [ENTITY_A] antagonist [ENTITY_B] has been used in the treatment of alcohol dependence.",3,0
"We have previously reported a nanomolar inhibitor of antiapoptotic [ENTITY_A] protein, [ENTITY_B] (S1).",1,0
These findings indicate that human pulmonary [ENTITY_A]-metabolizing activities differ significantly with respect to genetic polymorphism at both the [ENTITY_B] and the ALDH2 loci.,4,0
[ENTITY_A] interferes with DNA synthesis by blocking [ENTITY_B] (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).,1,0
"While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and [ENTITY_A] or n-propyl gallate efficiently inhibited the activity of all three [ENTITY_B], demonstrating different functions of these antioxidants.",1,0
"In summary, [ENTITY_A] attenuated renal fibrosis via the Nrf2-mediated inhibition of [ENTITY_B]/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.",1,0
"RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of [ENTITY_A], an [ENTITY_B] antagonist.",3,0
[ENTITY_A] metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit [ENTITY_B] phosphorylation in human colon cancer cells.,1,0
We concluded that [ENTITY_A] could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of [ENTITY_B].,0,0
Induction of heparin-binding EGF-like growth factor and activation of [ENTITY_A] in [ENTITY_B]-treated squamous carcinoma cells.,0,0
"There was significantly less [ENTITY_A] activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of [ENTITY_B] used was able to selectively inhibit one of these enzyme systems.",1,0
"Furthermore, [ENTITY_A] treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of [ENTITY_B] (AREs).",0,0
"Thus, the biological activity of [ENTITY_A] appears to exceed its previously known functions, inasmuch as it boosts up significantly the [ENTITY_B]-granule system.",0,0
"Some of these derivatives showed good inhibitory potency against two [ENTITY_A] isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [ENTITY_B].",1,0
"Of note, [ENTITY_A] which is a close structural analogue of SB225002 with a potent [ENTITY_B] antagonistic activity did not exhibit a similar antimitotic activity.",3,0
[ENTITY_A]-mediated [ENTITY_B] activation stimulated the expression of several key intestinal genes involved in lipid homeostasis.,0,0
[ENTITY_A] agonist [ENTITY_B] enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.,2,0
"New series of [ENTITY_A], 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine [ENTITY_B] inhibitors (MMPIs) were designed, synthesized, and evaluated.",1,0
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by [ENTITY_A] and kilobase DNA fragmentation may correlate with the reduction of [ENTITY_B] expression and the increase in cyclin E and cdk2 kinase activities.,1,0
This report reviews published and unpublished data that suggest that [ENTITY_A] acts as a selective partial agonist at the [ENTITY_B] and does not affect 5-HT receptors at therapeutic doses.,2,0
"These data suggest that [ENTITY_A] represents a novel, negative regulator of basal GSIS that acts by hydrolyzing [ENTITY_B], thereby reducing glycolytic flux.",4,0
"[ENTITY_A] effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on [ENTITY_B].",1,0
"[ENTITY_A] (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced [ENTITY_B] expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity.",1,0
"In addition, inhibiting the binding of the fast inactivation lid ([ENTITY_A] ICM + MTSET) did not alter [ENTITY_B] block, confirming that the drug does not preferentially interact with the fast-inactivated state.",1,0
"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the [ENTITY_A] release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core [ENTITY_B] and more than 45% with HMW core PLGA.",0,0
"On the basis of these findings, we conclude that [ENTITY_A] and HCB have additive and synergistic effects on the development of [ENTITY_B]-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.",0,0
An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement [ENTITY_A] and this can be accomplished by breeding with CAG-[ENTITY_B] mice that express SpmS from a ubiquitous promoter.,4,0
"[ENTITY_A] secretion stimulated by both 200 μM [ENTITY_B] and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.",0,0
"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity [ENTITY_A]-dependent amino acid transporter, with functional features of [ENTITY_B] transport.",0,0
[ENTITY_A] was also shown to induce the expression of cleaved-caspase-3 and inhibit [ENTITY_B] expression in SGC-7901 cells in a dose-dependent manner.,1,0
"Agonist and antagonist actions of [ENTITY_A] as compared to fluparoxan at alpha(2)-adrenergic receptors [ENTITY_B], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",3,0
"Ovarian AR was not influenced by either treatment, and oviduct [ENTITY_A] was reduced after [ENTITY_B]-melatonin combination.",1,0
"However, mutating putative [ENTITY_A] did not substantially reduce induction of ras-dva promoter activity by [ENTITY_B], suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.",0,0
"The current study examined the bioactivation potential of [ENTITY_A] inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and [ENTITY_B] (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure.",2,0
"In further studies, the diuretic effects of the [ENTITY_A] agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with [ENTITY_B], but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",3,0
"In contrast, [ENTITY_A], which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both [ENTITY_B] and dopamine-beta-hydroxylase.",1,0
"In DU-PM cells with acquired resistance to [ENTITY_A], [ENTITY_B] expression was decreased, while Bcl2 was increased.",1,0
"In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the [ENTITY_A] (MR) antagonist [ENTITY_B]; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.",3,0
"This selectivity could, in part, account for the more favorable clinical profile of [ENTITY_A] in comparison with [ENTITY_B] antagonists that do not show subunit selectivity.",3,0
"In addition, treatment with [ENTITY_A] and hyperoside resulted in inhibition of TNF-α-induced production of [ENTITY_B], and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.",1,0
"As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both [ENTITY_A] (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and [ENTITY_B] levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay.",1,0
"In overexpressing cell lines, [ENTITY_A]- and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin [ENTITY_B] investigated.",1,0
"[ENTITY_A] decreased [ENTITY_B] expression, but not ERbeta.",1,0
"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) [ENTITY_A] enhances [ENTITY_B] and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.",0,0
"The obtained results showed that [ENTITY_A] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, [ENTITY_B], acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3β-hydroxysteroid dehydrogenase (HSD), 17β-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",1,0
"This is described in a case study of the expedited review and approval of [ENTITY_A], a novel [ENTITY_B] inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009.",1,0
"Administration of [ENTITY_A], a [ENTITY_B] inhibitor, isolated a single response to ω-agatoxin, which was characterized by a reduction in network activity.",1,0
"Other [ENTITY_A] inhibitors, including [ENTITY_B], with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced.",1,0
"At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas [ENTITY_A] and its monodemethylated metabolite manifested slight [ENTITY_B] agonist activity.",2,0
"[ENTITY_A] treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in [ENTITY_B] activity and glutathione levels in gastric mucosa.",1,0
"To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the [ENTITY_A] inhibitor [ENTITY_B] (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.",1,0
CONCLUSIONS: [ENTITY_A] is a dual inhibitor of the [ENTITY_B] and HER2 tyrosine kinases.,1,0
The Ca(2+) response of [ENTITY_A]-transfected HEK293 cells to the endogenous VR1 agonist [ENTITY_B] was potentiated by low pH.,0,0
"[ENTITY_A] were activated by [ENTITY_B] as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.",0,0
"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of [ENTITY_A] (DXM), a dual probe substrate of [ENTITY_B] and CYP3A, in rats.",4,0
"Pretreatment with the [ENTITY_A] antagonist, [ENTITY_B], and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.",3,0
"Additional pharmacological effects evoked by [ENTITY_A] and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of [ENTITY_B] in cell systems where Na+K+ATPase is an important component.",0,0
"Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective [ENTITY_A] antagonists, [ENTITY_B] (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).",3,0
"[ENTITY_A] antagonist (OTA), [ENTITY_B], was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.",3,0
These observations suggest that uptake of [ENTITY_A] into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of [ENTITY_B] respiration.,1,0
"[ENTITY_A] inhibitors such as [ENTITY_B], potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.",1,0
"[ENTITY_A] is a [ENTITY_B] antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels.",3,0
Inhibition of this [ENTITY_A] probably presents a major source for altered therapeutic activity of these medicines if co-administered with [ENTITY_B].,1,0
An amphiphile with branched [ENTITY_A] architecture also activated the [ENTITY_B] pathway but only through L-ficolin recognition.,0,0
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the [ENTITY_A] blocker with high affinity for 5-HT1A and 5-HT1B binding sites [ENTITY_B] (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",1,0
"Phenytoin (diphenylhydantoin, DPH) is an established [ENTITY_A][ENTITY_B] channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.",4,0
"Moreover, [ENTITY_A] treatment inhibited the phosphorylations of [ENTITY_B] and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively.",1,0
"These data provided a novel insight to the mechanisms of [ENTITY_A]protective effects on [ENTITY_B]-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.",1,0
"The [ENTITY_A] inhibition of these three [ENTITY_B] and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor.",1,0
"This approach is validated by the clinical efficacy and safety of [ENTITY_A], the pioneering drug for selective [ENTITY_B] inhibitor therapy for ED.",1,0
A novel class of [ENTITY_A] that inhibits [ENTITY_B] kinase was discovered using a combination of medicinal and combinatorial chemistry approaches.,1,0
"A dose of 25 microg kg(-1) day(-1) of [ENTITY_A] elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar [ENTITY_B] downregulation.",1,0
"[ENTITY_A] (DGK) catalyzes the conversion of diacylglycerol to [ENTITY_B], making it an attractive candidate for a signal transduction component.",4,0
"ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors ([ENTITY_A]), which are also activated by oxysterols and some derivatives of plant [ENTITY_B].",0,0
"FCEO significantly inhibited [ENTITY_A] (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of [ENTITY_B] (iNOS) and cyclooxygenase (COX)-2, respectively.",1,0
"Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while [ENTITY_A] activity was the highest only in the [ENTITY_B] group.",0,0
Thus our data suggest that the [ENTITY_A] preference of [ENTITY_B] observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed.,1,0
Neither ryanodine nor EGTA inhibited down-regulation of [ENTITY_A] mRNA by [ENTITY_B].,1,0
"The inhibitory effect of [ENTITY_A] on [ENTITY_B]-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist.",1,0
"In addition, [ENTITY_A] supplementation significantly reduced hepatic mRNA abundance of [ENTITY_B], ATPCL and G6Pase compared to the control group.",1,0
Most reducing cofactors for the peroxidase protect [ENTITY_A] and prostacyclin synthase from inactivation by [ENTITY_B].,1,0
"In conclusion, [ENTITY_A] is a potent dopamine D2, D3 and [ENTITY_B] antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.",3,0
Contribution of the [ENTITY_A] NKCC1 to [ENTITY_B] secretion in rat OMCD.,4,0
"Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the [ENTITY_A] inhibitor [ENTITY_B] on several properties of thyroid cancer cell lines was investigated.",1,0
[ENTITY_A] inhibited the phosphorylation and activation of AKT and STAT3 through [ENTITY_B] signaling blockade.,1,0
"This same dose of [ENTITY_A] also inhibited, but to a lesser degree, the [ENTITY_B] mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.",1,0
"Our results demonstrated that [ENTITY_A] suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of [ENTITY_B], a pro-inflammatory enzyme.",1,0
"[ENTITY_A] derivatives were not oxidized to products serving as substrates for [ENTITY_B] and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",4,0
[ENTITY_A] antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated [ENTITY_B].,3,0
"Interestingly, both isomers of [ENTITY_A] were full agonists at [ENTITY_B] and h-rChTAAR1, whereas both were partial agonists at rTAAR1.",2,0
Late INa induced by the [ENTITY_A] long QT mutant R1623Q was reduced by [ENTITY_B] and quercetin.,1,0
Western blot analysis revealed that [ENTITY_A] decreased the expression of [ENTITY_B] and repaired the balance of pro- and anti-apoptotic proteins.,1,0
[ENTITY_A] activates cortisone to [ENTITY_B] to facilitate glucocorticoid receptor (GR)-mediated action.,4,0
The effect of [ENTITY_A] antagonism with [ENTITY_B] on concentration-related AMP-induced bronchoconstriction in asthma.,3,0
"In this study, we demonstrate significant inhibitory activity of [ENTITY_A] against both wild-type [ENTITY_B] and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.",1,0
Prolonged use of [ENTITY_A] leads to increased endogenous levels of AVP and perhaps over-stimulation of [ENTITY_B].,0,0
"Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of AMPA receptors. Neuron, 21 (1998) 907-918) further confirms that [ENTITY_A] enhances [ENTITY_B] responses by reducing desensitization, since lithium's effects are reversed in this mutant.",0,0
"The efficacy of [ENTITY_A], a new, long acting, oral [ENTITY_B] antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.",3,0
"Aspirin and [ENTITY_A] (an activator of [ENTITY_B]) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.",0,0
"RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive [ENTITY_A] significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as [ENTITY_B] (IL-1β), and apoptosis (Bax and caspase 3 expression).",1,0
The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous [ENTITY_A] agonist [ENTITY_B] was potentiated by low pH.,2,0
"We tested the new orally active nonpeptidic [ENTITY_A] inhibitor [ENTITY_B] (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.",1,0
"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of [ENTITY_A] (hPheOH), cocrystallized with various potent and well-known [ENTITY_B] inhibitors and refined at a resolution of 2.0 A.",1,0
"(2) Exposure histories vary in secondary 11q23 leukemia, as the only [ENTITY_A] inhibitor was [ENTITY_B] in one case, and, in another case, no topoisomerase II inhibitor was administered.",1,0
Zolmitriptan (Zomig; formerly [ENTITY_A]) is a novel [ENTITY_B] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.,2,0
"[ENTITY_A] have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of [ENTITY_B], an intermediate in the pathway of arsenic biotransformation.",4,0
CONCLUSIONS: The chemotactic responses toward [ENTITY_A] were inhibited by [ENTITY_B] at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L).,1,0
"In mechanistic studies, [ENTITY_A] decreased the protein level of [ENTITY_B], which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells.",1,0
"In mice, [ENTITY_A] (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the [ENTITY_B] agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).",1,0
Small molecules bearing hydroxamic acid as the [ENTITY_A] binding group (ZBG) have been the most effective [ENTITY_B] inhibitors (HDACi) to date.,1,0
Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to [ENTITY_A] due to the potential inhibition of [ENTITY_B].,1,0
"Further, [ENTITY_A] metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of [ENTITY_B] (SREBP-1c) that bound to the regulatory regions of these genes.",0,0
"[ENTITY_A] regulates gene expression via the activation of the [ENTITY_B] in human DCs, and RARalpha acutely regulates CD1d expression.",0,0
The development of specific [ENTITY_A] inhibitors and further experience with the dual enzyme inhibitor [ENTITY_B] will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.,1,0
"Mass spectral analysis of [ENTITY_A]-inhibited [ENTITY_B] digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.",1,0
"Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide ([ENTITY_A]) significantly inhibited [ENTITY_B] secretion.",1,0
"[ENTITY_A] 7-hydroxylation, catalyzed by [ENTITY_B], was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.",4,0
Reductive detoxification of [ENTITY_A] carcinogens by human NADH cytochrome b5 reductase and [ENTITY_B].,4,0
"The inhibition of UG synthesis and [ENTITY_A] down-regulation by [ENTITY_B] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.",0,0
Inhibition > 90% of [ENTITY_A] secretion was observed at 1 microM [ENTITY_B] and 10 microM AACOCF3 compared to the respective vehicle control.,1,0
"In particular, we showed that [ENTITY_A] significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and [ENTITY_B] (SOD) in EA.hy926 cells.",0,0
[ENTITY_A] are [ENTITY_B] inhibitors broadly used for the control of hypercholesterolemia.,1,0
"In conclusion, the [ENTITY_A] substitution does not significantly modulate CDA activity toward [ENTITY_B], and therefore would not contribute to interindividual variability in response to gemcitabine.",4,0
Dietary [ENTITY_A]/DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving [ENTITY_B] sensitivity.,0,0
"Notably, the antioxidant Trolox™ reversed the [ENTITY_A] (20 mg/kg)-dependent augmentation in [ENTITY_B](MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.",0,0
"[ENTITY_A] was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for [ENTITY_B].",1,0
"Exposure to [ENTITY_A] (a [ENTITY_B] antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.",3,0
"TCDD had no effect on AR activity in PC-3 cells, whereas the shortest [ENTITY_A] variant was induced by [ENTITY_B] in PNT1A cells.",0,0
Differential activation of [ENTITY_A] in discrete nucleus accumbens subregions during early and late [ENTITY_B] sensitization.,0,0
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of [ENTITY_A] on [ENTITY_B] expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S.",1,0
"The treatment of U937 cells with [ENTITY_A] inducers including [ENTITY_B] effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3.",0,0
"Down-regulation of [ENTITY_A] by [ENTITY_B] was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.",1,0
"In the present study, we investigated the molecular mechanism of [ENTITY_A]-induced up-regulation of [ENTITY_B] expression in HepG2 (human hepatoma cell line).",0,0
"On the basis of data obtained in rabbits, the imidazoline receptor ligand [ENTITY_A] has been suggested to decrease blood pressure in humans by activating central [ENTITY_B].",0,0
Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in [ENTITY_A] activity lead to specific blocks in [ENTITY_B] production and impaired LXR-dependent gene activation.,4,0
CONCLUSION: Oral [ENTITY_A] is effective in suppressing the gain of function in [ENTITY_B] responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia/ventricular fibrillation noninducible.,1,0
"The anti-inflammatory drugs [ENTITY_A] and aspirin inhibited the activation of [ENTITY_B], which further explains the mechanism of action of these drugs.",1,0
"In addition, the disease activity index, histopathologic scores and [ENTITY_A] activity were also significantly reduced by [ENTITY_B] treatment.",1,0
"A [ENTITY_A] derivative showed promising inhibition of [ENTITY_B] in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.",1,0
This is the first study to establish the in vivo relevance of [ENTITY_A] in [ENTITY_B] metabolism in mammals and one of the first for xenobiotics in general.,4,0
"[ENTITY_A], a [ENTITY_B] agonist, induces perforin in cytotoxic T lymphocytes in vitro.",2,0
"Down-regulation of [ENTITY_A] (PSA) expression, an AR-target gene, by [ENTITY_B] and bicalutamide was accompanied by the blockade of the mutated androgen receptor.",1,0
"After [ENTITY_A] administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an [ENTITY_B] increase; the pattern of ACTH response to CRH was slightly delayed.",0,0
"Fragment-based design, synthesis, and biological evaluation of [ENTITY_A] derivatives as novel [ENTITY_B] inhibitors.",1,0
"However, the precise mechanism by which [ENTITY_A] counteracts [ENTITY_B]-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.",1,0
"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not [ENTITY_A], an [ENTITY_B] blocker, prevented GRIP1 degradation.",1,0
"Pharmacokinetic Interactions between [ENTITY_A] Inhibitor [ENTITY_B] and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status.",1,0
"[ENTITY_A] increased expression of [ENTITY_B], the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.",0,0
This prompted the design of variants of [ENTITY_A] which exhibit significantly improved catalytic activity against [ENTITY_B].,4,0
[ENTITY_A] caused [ENTITY_B] mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.,1,0
"The activities of [ENTITY_A] and other ATP binding cassette superfamily members are inhibited by the drug [ENTITY_B], and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs.",1,0
"Agents that have only begun to undergo clinical evaluation include [ENTITY_A], an irreversible pan-[ENTITY_B] tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).",1,0
"[ENTITY_A] antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of [ENTITY_B] in disease, through an evaluation of their influence on disease expression.",2,0
"[ENTITY_A] and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented [ENTITY_B] degradation.",0,0
We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to [ENTITY_A] by the [ENTITY_B] reaction is the primary and preferred fate of the organic acid in Arabidopsis.,4,0
"Brain tissue analyses revealed that neonatal [ENTITY_A] treatment produced a significant decrease in hippocampal [ENTITY_B], BDNF and ChAT that was eliminated by olanzapine treatment.",1,0
"Furthermore, [ENTITY_A] (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the [ENTITY_B]/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.",0,0
"Reciprocally, [ENTITY_A] blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of [ENTITY_B] (IC(50) approximately 275-300 microM).",1,0
This trial investigated the possibility of pharmacokinetic interactions between the [ENTITY_A] antagonist [ENTITY_B] and the thiazide diuretic hydrochlorothiazide in healthy subjects.,3,0
"[ENTITY_A] and COX-2 inhibition in horse blood by [ENTITY_B], flunixin, carprofen and meloxicam: an in vitro analysis.",1,0
Cell culture studies demonstrated that [ENTITY_A] is capable of delivering anti-TNF (tumor necrosis factor)-α siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of [ENTITY_B].,1,0
"Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of [ENTITY_A], while the phosphorylation of [ENTITY_B] was simultaneously increased.",0,0
The vascular protective effects of [ENTITY_A] were speculated to be attributed to oxidative stress inhibition and the reduction of [ENTITY_B] (NF-κB) mRNA expression levels in high glucose conditions.,1,0
"Next, [ENTITY_A] significantly decreased the levels of [ENTITY_B] and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.",1,0
The [ENTITY_A] immunopositivity was increased in degenerating neurons of the [ENTITY_B] group.,0,0
[ENTITY_A] blocked [ENTITY_B] channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher.,1,0
"Adenosine and N(6)-cyclopentyl-adenosine ([ENTITY_A], [ENTITY_B] agonist) constricted MVs but not MAs.",2,0
[ENTITY_A] is expected to be an effective [ENTITY_B] antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.,3,0
Methionine synthase reductase ([ENTITY_A]) is an enzyme involved in the conversion of Hcy to [ENTITY_B].,4,0
"In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the [ENTITY_A] agonist, [ENTITY_B].",2,0
"An angiotensin II AT1 receptor antagonist, telmisartan augments [ENTITY_A] uptake and [ENTITY_B] protein expression in 3T3-L1 adipocytes.",4,0
The toxic effects of [ENTITY_A] significantly attenuated with [ENTITY_B] pre-exposure.,1,0
It is suggested that all the additional actions of [ENTITY_A] can be attributed to a partial agonist action on [ENTITY_B].,2,0
"Olopatadine hydrochloride ([ENTITY_A], 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/[ENTITY_B] antagonistic drug that was synthesized and evaluated in our laboratories.",3,0
"Administration of [ENTITY_A], an [ENTITY_B] agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.",2,0
"[ENTITY_A] induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing [ENTITY_B] with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines.",1,0
Rasagiline [[ENTITY_A]] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain [ENTITY_B] and is specifically designed for the treatment of Parkinson's disease (PD).,1,0
"The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [ENTITY_A] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a [ENTITY_B] (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.",1,0
"[ENTITY_A] activity in plasma increased slightly (compared to control, [ENTITY_B] or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.",0,0
"Racemization of [ENTITY_A] is catalyzed by [ENTITY_B], a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver.",4,0
In [ENTITY_A] transfected cells the rank order of agonist potency was [ENTITY_B] (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).,2,0
"These results suggest that [ENTITY_A] inhibits the induction of [ENTITY_B] probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.",1,0
[ENTITY_A] inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via [ENTITY_B] suppression and Nrf-2-dependent heme oxygenase-1 induction.,1,0
"Treatment with [ENTITY_A] or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of [ENTITY_B] at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.",0,0
[ENTITY_A] or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of [ENTITY_B].,1,0
"However, after 12h [ENTITY_A] treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in [ENTITY_B] activation and the pro-apoptotic protein Bax.",0,0
"Extracellular application of meclofenamate (EC(50) = 25 microM) and [ENTITY_A] (EC(50) = 2.6 microM) resulted in the activation of [ENTITY_B] K(+) currents, heterologously expressed in Chinese hamster ovary cells.",0,0
"Taken together, the results of this study demonstrate that [ENTITY_A] inhibits LPS-stimulated inflammation by blocking the [ENTITY_B] and MAPK pathways in macrophages.",1,0
"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of [ENTITY_A] to inhibit downstream ERK and Akt activation, despite inhibition of [ENTITY_B] phosphorylation.",1,0
"Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with [ENTITY_A], trichloromethiazide, and furosemide being efficient inhibitors against [ENTITY_B] (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).",1,0
"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by [ENTITY_A] (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial [ENTITY_B] pump.",1,0
"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a [ENTITY_A] agonist [ENTITY_B] (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition.",2,0
"However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of [ENTITY_A] activity by [ENTITY_B] in the tissue lysates.",1,0
"A low tyramine diet is recommended if [ENTITY_A] is used together with nonselective [ENTITY_B] inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.",1,0
"After inflammation was established mice were dosed with the [ENTITY_A] antagonist, [ENTITY_B], or anti-IL-13 antibody for comparison.",3,0
Preferential block of late sodium current in the [ENTITY_A] by the class I(C) antiarrhythmic [ENTITY_B].,1,0
"Inhibition was still marked and significant after repeated dosing with maximal decreases in [ENTITY_A] levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of [ENTITY_B] was compared with placebo.",1,0
"Regarding [ENTITY_A] inhibition, [ENTITY_B] was the most potent fraction (IC50: 97 µg/mL).",1,0
"These findings suggest that the anti-allodynia effect of [ENTITY_A] is ascribable to blockade of [ENTITY_B] receptors at the brain, but not at the spinal cord.",1,0
"This observation suggests that [ENTITY_A]-induced reductions in [ENTITY_B] density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.",1,0
Reactive Metabolite Trapping Studies on [ENTITY_A]-based Inverse Agonists of the [ENTITY_B].,2,0
In vitro and in vivo studies have shown that [ENTITY_A] has advantages over heparin for the inhibition of clot-bound [ENTITY_B] and for the enhancement of thrombolysis with TPA.,1,0
"Previously, we showed that the [ENTITY_A] (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged [ENTITY_B] treatment.",1,0
"Intriguingly, the inhibitory potency of [ENTITY_A] [ENTITY_B] inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation.",1,0
UGT1A6 exhibited a significantly higher Vmax and Km values toward both [ENTITY_A] and UDP-glucuronic acid than the other [ENTITY_B].,4,0
Only FFAs that increased [ENTITY_A] caused impairment of [ENTITY_B] and PTP1B phosphorylation at Ser 50.,1,0
"In the present study, we have evaluated possible participation of [ENTITY_A] (MCTs) responsible for the bidirectional membrane transport of [ENTITY_B] in the cytoprotective property in osteoblasts.",4,0
Phenelzine is a more potent [ENTITY_A] inhibitor than is [ENTITY_B].,1,0
"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the [ENTITY_A] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal [ENTITY_B] transport.",4,0
The inhibitory effects of [ENTITY_A] on [ENTITY_B] secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.,1,0
Inhibition of human iNOS promoter-driven luciferase activity by [ENTITY_A] in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of [ENTITY_B].,1,0
"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide ([ENTITY_A], TAK-375), a selective [ENTITY_B] agonist, on motor coordination was studied using rota-rod performance in mice.",2,0
Functional and biochemical studies indicated that [ENTITY_A] signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the [ENTITY_B] and culminated in enhanced production of cGMP and microvascular vasodilation.,0,0
"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that [ENTITY_A] produces a large potentiation of the [ENTITY_B] splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function. J. Neurophysiol., 81 (1999) 1506-1512).",0,0
MicroPET imaging in nonhuman primates with [[ENTITY_A]]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the [ENTITY_B]-rich brain regions and peak uptake being achieved in about 55 min postinjection.,4,0
Treatment with [ENTITY_A] is associated with a reversal of abnormal regulation of [ENTITY_B] and VEGF in the failing ventricular myocardium.,1,0
The procedure was to reduce liver [ENTITY_A] activity by providing [ENTITY_B] or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.,1,0
[ENTITY_A] is both a substrate and inhibitor (IC50 = 1.9 µM) of [ENTITY_B].,4,0
"A series of phenolic acids and phenol natural products, such as [ENTITY_A], p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [ENTITY_B] carbonic anhydrase (CA, EC 4.2.1.1).",1,0
"Additionally, [ENTITY_A] suppressed the production of inflammatory [ENTITY_B], including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6.",1,0
CONCLUSION: Our data provides a novel insight into an effect of telmisartan: [ENTITY_A] inhibits [ENTITY_B] gene expression through PPARgamma activation.,1,0
"The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean [ENTITY_A] level after 1 week of treatment with [ENTITY_B] (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05).",0,0
"Expressions of [ENTITY_A] and PC3, but not PC2, are coordinately regulated by [ENTITY_B], consistent with the important role of PC3 in regulating proinsulin processing.",0,0
"[ENTITY_A] targets and activates the [ENTITY_B]; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).",0,0
"Catecholamines ([ENTITY_A], noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ([ENTITY_B], EC 1.14.16.1).",1,0
"In the [ENTITY_A] group, [ENTITY_B] activity was decreased with statistically high significance compared to group I.",1,0
"[ENTITY_A], known as the [ENTITY_B] antagonist of reference, was chosen as the template for the elaboration of probes.",3,0
Univariate regression analyses showed that only the use of [ENTITY_A] was correlated with the decrease in [ENTITY_B] concentration (p <0.03).,1,0
"We found compounds that inhibited [ENTITY_A] currents with a rank order of potency: [ENTITY_B] > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.",1,0
"EC50 values for [ENTITY_A] were 0.89, 0.92, and 4.44 microM for [ENTITY_B], mTAAR1, and h-rChTAAR1, respectively.",0,0
"[ENTITY_A] activated [ENTITY_B] (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",0,0
"Our findings reveal that [ENTITY_A]-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein [ENTITY_B], leading to apoptosis via both extrinsic and intrinsic pathways.",0,0
[ENTITY_A] required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate [ENTITY_B]-tRNA([Ser]Sec).,4,0
"Safety and tolerability of [ENTITY_A] inhalation solution, a novel [ENTITY_B] agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.",2,0
However the [ENTITY_A] antagonist [ENTITY_B] was unable to reverse these anxiety-like effects seen with PNU-282987.,3,0
[ENTITY_A] binding and activation of [ENTITY_B] in GH4ZR7 cells.,0,0
"The purpose of the present study was to test our hypothesis that [ENTITY_A], a specific [ENTITY_B] inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing.",1,0
A molecular mechanism of action of [ENTITY_A]: Induction of [ENTITY_B] activity to decrease inflammatory gene expression.,0,0
[ENTITY_A] and netupitant are other [ENTITY_B] antagonists that are currently in phase III clinical trials.,3,0
"In contrast, inhibition of [ENTITY_A] only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with [ENTITY_B].",1,0
"[ENTITY_A], a second-generation [ENTITY_B] receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.",3,0
"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several [ENTITY_A] including ergovaline, may be due to [ENTITY_B] activation.",0,0
"In perifusion studies, FSHβ mRNA levels and [ENTITY_A]LUC activities were increased by pulsatile [ENTITY_B], with significantly greater increases at low compared with high pulse frequencies.",0,0
CONCLUSIONS A diet that partially replaces [ENTITY_A] with unsaturated fat may improve [ENTITY_B] sensitivity in a population at risk for cardiovascular disease.,0,0
"Moreover, [ENTITY_A] treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [ENTITY_B] and activating protein-1, which were increased in fructose-fed rats.",1,0
"Thus, [ENTITY_A] acts as a TrkA and [ENTITY_B] agonist and possesses marked neurotrophic activity.",2,0
"However, combined treatment with [ENTITY_A] and SB216367 resulted in a significant reduction in [ENTITY_B] and an increase in cleaved-PARP in U2OS cells.",1,0
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, [ENTITY_A] (atRA), which regulates the expression of a battery of target genes through several families of [ENTITY_B] (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.",0,0
"Moreover, [ENTITY_A] repressed anisomycin-induced phosphorylation of [ENTITY_B], cav-1 and vascular permeability.",1,0
"Synthesis, biological evaluation, and molecular modeling of [ENTITY_A] derivatives as potent [ENTITY_B] inhibitors with anti-heart-failure activity in vivo.",1,0
"Caution is necessary only when it is coadministered with drugs metabolised by [ENTITY_A], such as [ENTITY_B], or administered to the elderly or patients with severe hepatic or renal impairment.",4,0
The [ENTITY_A] allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in [ENTITY_B] metabolism.,4,0
Block of human NaV1.5 [ENTITY_A][ENTITY_B] channels by novel alpha-hydroxyphenylamide analogues of phenytoin.,4,0
CONCLUSIONS AND IMPLICATIONS: [ENTITY_A] analogues constitute a novel class of [ENTITY_B]-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine.,1,0
"Interestingly, [ENTITY_A] increased proteins' levels of [ENTITY_B] (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.",0,0
"Phosphorylation of [ENTITY_A], which was shown to be activated by AhR ligands, was also increased by [ENTITY_B] and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",0,0
"[ENTITY_A] (1) is a potent [ENTITY_B] agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.",2,0
RESULTS: The density of [ENTITY_A] in liver tissue in [ENTITY_B] group was higher than that in control group (P < 0.05).,0,0
"[ENTITY_A] locks the [ENTITY_B] in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.",1,0
"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as [ENTITY_A] ([ENTITY_B] agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.",2,0
"Disruption of contact inhibition, which was induced by toxic AhR ligands [ENTITY_A] (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced [ENTITY_B] protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.",1,0
It is currently not known how much this [ENTITY_A] antagonism of [ENTITY_B] contributes to the therapeutic or adverse side effects of clozapine.,3,0
"The [ENTITY_A] catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous [ENTITY_B] and bile acids.",4,0
These results suggest that the pro-inflammatory effect of [ENTITY_A] may be mediated by [ENTITY_B]-NK-1R related pathway in mouse pancreatic acinar cells.,4,0
The agonist activity was antagonized by the selective [ENTITY_A] blocker [ENTITY_B] (nor-BNI).,3,0
"The cardiovascular effects of three different [ENTITY_A] inhibitors: [ENTITY_B], tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats.",1,0
The production of [ENTITY_A] was reduced with [ENTITY_B] while no significant change was observed with omapatrilat after 4 h of incubation.,1,0
"Furthermore, the activities of the two [ENTITY_A] were enhanced 4.3- and 7.6-fold by [ENTITY_B], 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.",0,0
"[ENTITY_A] inhibits mTOR signaling, activates [ENTITY_B], and induces autophagy in colorectal cancer cells.",0,0
"We concluded that in overweight and obese women with PCOS [ENTITY_A] administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum [ENTITY_B] levels.",0,0
Subsequent analysis revealed that [ENTITY_A] strongly activates [ENTITY_B] and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.,0,0
It appears likely that the [ENTITY_A] blocked by [ENTITY_B] obviated the pulmonary vasodilator effect of tolazoline therapy.,1,0
Terbutaline (Bricanyl) and its prodrug [ENTITY_A] (Bambec) are highly potent [ENTITY_B] agonists often used in asthma patients.,2,0
These results indicate that membrane [ENTITY_A] levels in N-38 neurons are dynamically autoregulated by [ENTITY_B].,0,0
High [ENTITY_A] increases L-arginine transport and eNOS expression following [ENTITY_B] activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.,0,0
This pretreament had no effect on the inhibition of [ENTITY_A] or the elevation of brain GABA levels produced by [ENTITY_B].,1,0
These findings suggest that [ENTITY_A] inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of [ENTITY_B] activity.,1,0
"In HEK-293 cells stably transfected with this receptor, [ENTITY_A] elicits a potent stimulation of [ENTITY_B] activity, which is blocked by antipsychotic and antidepressant drugs.",0,0
"DRG neurons display substantial capacity for accumulating [ENTITY_A] via a transport process mediated by [ENTITY_B], but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin.",4,0
"Oxysterol-dependent NOX1 activation, as well as [ENTITY_A] synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular [ENTITY_B] and flavonoids.",1,0
The ensemble of results suggests that the ability of [ENTITY_A] pretreatment to enhance hepatocellular [ENTITY_B] activity may at least in part be attributed to the protection against menadione hepatotoxicity.,0,0
"In the presence of this inhibitor, the selective [ENTITY_A] agonist [ENTITY_B] reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4 nM.",2,0
"[ENTITY_A] activates [ENTITY_B] and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.",0,0
OBJECTIVES: The hypothesis of the present study was that differences among [ENTITY_A] (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as [ENTITY_B] uptake inhibitors.,4,0
Activation of [ENTITY_A] (eNOS) results in the production of [ENTITY_B] (NO) that mediates the vasorelaxing properties of endothelial cells.,4,0
"[ENTITY_A] pre-treatment also attenuated the KA-induced increases in [ENTITY_B]/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",1,0
"These results suggest that [ENTITY_A], although identified as a 5-HT antagonist, acts as a [ENTITY_B] agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.",2,0
"These results indicate that [ENTITY_A]-induced down-regulation of the [ENTITY_B] involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation.",1,0
"Absorbable drugs ([ENTITY_A], nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce [ENTITY_B] (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.",1,0
[ENTITY_A] treatment showed reduced production of pro-inflammatory cytokines and NO and increased [ENTITY_B] activity.,0,0
Addition of a [ENTITY_A] extension to the N-alkyl group facilitates both enhancement of [ENTITY_B]-inhibitory activity and restoration of potent PDE3 inhibition.,1,0
We tested the hypothesis that [ENTITY_A] blocks [ENTITY_B].,1,0
"The inhibitory effects of [ENTITY_A] and T0070907 ([ENTITY_B] antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.",3,0
Reversal of inhibition by [ENTITY_A] agonist [ENTITY_B] was produced by serotonin (50 µM) and by neurotensin (5-10 nM).,2,0
Weekly subcutaneous [ENTITY_A] produces cumulative increases in [ENTITY_B] and total hemoglobin through a noncytotoxic mechanism of action.,0,0
"Resulting from this study, a structurally novel class of submicromolar fibrinogen [ENTITY_A] binding inhibitor bearing [ENTITY_B] moiety is also described.",1,0
"[ENTITY_A] completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the [ENTITY_B] mRNA, during both the infantile and the juvenile periods.",1,0
RATIONALE: The selective [ENTITY_A] antagonist [ENTITY_B] has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure.,3,0
"The hydrolysis of fluorescein [ENTITY_A] by [ENTITY_B] and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",4,0
Comparison of all the [ENTITY_A] antagonists tested revealed a potency order of [ENTITY_B]>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.,3,0
Characterization of substituted [ENTITY_A] as highly selective agonists at the [ENTITY_B].,2,0
"Moreover, the effects of the [ENTITY_A] agonist [ENTITY_B] (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.",2,0
"The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of [ENTITY_A]-inhibited, solubilized [ENTITY_B] from human erythrocytes was investigated in vitro.",1,0
Inhibition studies demonstrated that the [ENTITY_A] group on the phenylacetic acid ring is required for [ENTITY_B] selectivity.,1,0
Binding domains of the oxytocin receptor for the selective [ENTITY_A] antagonist [ENTITY_B] in comparison to the agonists oxytocin and carbetocin.,3,0
We show that both [ENTITY_A] and a novel class of structurally distinct carbamate inhibitors inactivate [ENTITY_B] in mouse tissues and human cell lines with high selectivity.,1,0
We identified a series of [ENTITY_A] derivatives as novel [ENTITY_B] inhibitors with high potency and substantial cell permeability using fragment-based drug design.,1,0
[ENTITY_A] inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and [ENTITY_B]-dependent heme oxygenase-1 induction.,0,0
"Unlike mouse RetSat (mRetSat), [ENTITY_A] had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either [ENTITY_B] or all-trans-7,8-dihydroretinol, respectively.",4,0
"Among them, [ENTITY_A] markedly inhibited [ENTITY_B]-induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations.",1,0
[ENTITY_A] are thought to be activated predominantly by [ENTITY_B] generated enzymatically from cholesterol in different cell organelles.,0,0
"The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the [ENTITY_A], enzyme that converts riboflavin to [ENTITY_B]) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.",4,0
"[ENTITY_A] also partially depressed predominantly [ENTITY_B]-mediated EPSCs, but with lower efficacy.",1,0
"This study provided the evidence that the [ENTITY_A] inhibit stimulated cerebral [ENTITY_B] at multiple levels and are effective at very low doses, offering great potential for therapeutic use.",1,0
Inhibition corresponded to increased cAMP production caused by rolipram alone or [ENTITY_A] plus salmeterol and blocked proportionately the phosphorylation and activation of [ENTITY_B] in FMLP/B-activated eosinophils.,1,0
"Neither the superoxide radical scavenger, tiron, nor the inhibitor of the [ENTITY_A], [ENTITY_B], prevented the metabolites' toxicity.",1,0
"The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of [ENTITY_A] analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low [ENTITY_B] inhibition.",1,0
"The [ENTITY_A] pathway generates inflammatory [ENTITY_B], while the 5-LOX pathway generates inflammatory leukotrienes.",4,0
"Compared pharmacological characteristics in humans of racemic [ENTITY_A] and levocetirizine, two [ENTITY_B] antagonists.",3,0
"Synthesis and evaluation of [ENTITY_A] linked prodrugs of BMS-582949, a clinical [ENTITY_B] inhibitor.",1,0
"In conclusion, [ENTITY_A] has adverse effects on phosphorylation of Akt, [ENTITY_B] translocation and (14)C-glucose oxidation.",1,0
The catalytic competence of [ENTITY_A] in the synthesis of [ENTITY_B] from 5-methoxytryptamine in the brain: an in vitro study.,4,0
"Using standard assays, [ENTITY_A] was found to be a poor inhibitor of purified [ENTITY_B] and a relatively weak inhibitor of purified human COX-2.",1,0
[ENTITY_A] and debrisoquine are substrates of uptake1 and potent inhibitors of [ENTITY_B] in perfused lungs of rats.,1,0
"[ENTITY_A] is a potent and specific inhibitor of [ENTITY_B], which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain.",1,0
This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to [ENTITY_A] ([ENTITY_B] and apixaban) and IIa (dabigatran).,1,0
[ENTITY_A] catalyzes specific elimination of L-serine to [ENTITY_B].,4,0
"Mitiglinide ([ENTITY_A]), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the [ENTITY_B] in pancreatic beta-cells.",1,0
The beta subunit has been cloned and shown to lower the K(m) of [ENTITY_A] (the MAT2A product) for methionine and to render the enzyme more susceptible to [ENTITY_B] inhibition.,1,0
"Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with [ENTITY_A][ENTITY_B] 3-kinase, and down-regulation of Akt activity.",4,0
The introduction of the [ENTITY_A] group resulted in not only improved water solubility but also enhanced [ENTITY_B] agonistic activity.,2,0
"Accordingly, docking of different [ENTITY_A] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, [ENTITY_B], indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",1,0
Sixteen of 34 [ENTITY_A] inhibited [ENTITY_B]-mediated E217βG uptake by >50% (IC50's 0.7-7.6 μM).,1,0
"The treatment also prevented the high [ENTITY_A] diet-induced increase in serum [ENTITY_B], total and isoforms, markers of neurological, cardiac and muscular damage.",0,0
The persistent membrane retention of [ENTITY_A] causes lasting inhibition of [ENTITY_B] function.,1,0
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of [ENTITY_A] for [ENTITY_B].",4,0
"This is significant because [ENTITY_A] production underlies the role of [ENTITY_B] in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.",4,0
"The inhibitory effect of [ENTITY_A] on theses pro-inflammatory [ENTITY_B] was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.",1,0
"Arsenite triggered strong induction of [ENTITY_A], which was prevented by 1 micro g/mL [ENTITY_B] (CXH).",1,0
"Methods: The stability of six [ENTITY_A] in the presence of [ENTITY_B], hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37°C) were investigated.",4,0
"Furthermore, because S-(+)-isomers of [ENTITY_A] and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of [ENTITY_B].",0,0
The mechanism revealed that wogonin inhibited [ENTITY_A]-induced phosphorylation of [ENTITY_B] (cav-1) associating with the suppression of stabilization of VE-cadherin and β-catenin.,0,0
[ENTITY_A]: a unique class of [ENTITY_B] inhibitors.,1,0
"The holo activity of combined peroxisomal and mitochondrial [ENTITY_A] with a low Km for [ENTITY_B] rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).",4,0
"The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and [ENTITY_A] administration down-regulated the [ENTITY_B] protein level.",1,0
Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of [ENTITY_A]-induced changes in cell morphology and growth similar to changes associated with [ENTITY_B] (EGFR) activation.,0,0
Using the [ENTITY_A] inhibitor [ENTITY_B] we found that TGFβ-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.,1,0
"The reversible binding of [ENTITY_A] may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent [ENTITY_B] inhibitors, e.g. hirudin.",1,0
"To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing [ENTITY_A] exhibit an [ENTITY_B]-dependent apoptotic response.",4,0
[ENTITY_A] has been shown to produce dose-related suppression of plasma [ENTITY_B] activity (PRA) and angiotensin II when administered intravenously.,1,0
"Second, C427A mutant human TOP2alpha, which exhibits reduced [ENTITY_A] activity, was shown to exhibit cross-resistance to all ATP-sensitive but not [ENTITY_B]-insensitive TOP2 poisons.",1,0
"Consistent with these results, the translocation of cPLA2 protein as well as the release of [ENTITY_A], a principal product of [ENTITY_B], was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner.",4,0
Correlation between activation of [ENTITY_A] and resistin downregulation in a mouse adipocyte cell line by a series of [ENTITY_B].,0,0
"[ENTITY_A] decreased expression of pro-inflammatory [ENTITY_B], such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and IL-8.",1,0
Sodium-dependent [ENTITY_A]-induced currents in [ENTITY_B]-transfected HEK-293 cells blocked by cocaine and antidepressants.,0,0
Exogenous [ENTITY_A] activates [ENTITY_B] via Rac-dependent signalling pathway.,0,0
"Statins are inhibitors of the enzyme [ENTITY_A], the rate-limiting step in [ENTITY_B] biosynthesis.",4,0
"The expression of key genes important in [ENTITY_A] metabolism, such as [ENTITY_B], betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.",4,0
"In muscle and liver, [ENTITY_A] (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of [ENTITY_B].",1,0
"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent [ENTITY_A] inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or [ENTITY_B], and therefore their coadministration is contraindicated.",1,0
"This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory [ENTITY_A], IL-6 and IL-8, caused by a mixture of [ENTITY_B] representative of a high cholesterol diet.",0,0
"Considerable attention has focused on the investigation of theories to explain the better tolerability of [ENTITY_A] over other [ENTITY_B] antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801).",3,0
The Bcl2/Bax ratio increased and [ENTITY_A] expression decreased in MIN6 cells after [ENTITY_B] stimulation.,1,0
"To extend structure-activity analyses of binding sites within [ENTITY_A] and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the [ENTITY_B] compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles.",1,0
"Conversely, AMPK inhibitor [ENTITY_A] or GSK3β inhibitor SB216763 blocked the cleavages of PARP and [ENTITY_B] induced by ursolic acid in HepG2 cells.",1,0
"For the [ENTITY_A] antagonist [ENTITY_B], none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.",3,0
Reversible inhibition of [ENTITY_A] by [ENTITY_B].,1,0
"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM [ENTITY_A] (TCDD), the most potent activator of [ENTITY_B].",0,0
The discovery that [ENTITY_A] and AMPH activate the [ENTITY_B] motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).,0,0
"A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with [ENTITY_A] inhibitors, [ENTITY_B] and mitoxantrone, and the alkylating agent, cyclophosphamide.",1,0
"BDZs and other positive GABA(A)R modulators, including [ENTITY_A], ethanol, and neurosteroids, can also inhibit [ENTITY_B] (L-VGCCs), which could contribute to reduced neuronal excitability.",1,0
[ENTITY_A] (10 and 20 mg/kg) increased [ENTITY_B] activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).,0,0
[ENTITY_A] was easier reactivated after [ENTITY_B] treatment.,0,0
"The effect was counteracted by the [ENTITY_A] antagonist [ENTITY_B], pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA.",3,0
In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that [ENTITY_A] is an avid substrate for both [ENTITY_B] and BCRP.,4,0
The glutamate-aspartate transporter [ENTITY_A] mediates [ENTITY_B] uptake at inner hair cell afferent synapses in the mammalian cochlea.,4,0
Cross-inhibition of [ENTITY_A]- and ABCA1-mediated [ENTITY_B] transport by the small molecules BLT-4 and glyburide.,4,0
The dextromethorphan analog [ENTITY_A] attenuates kainate-induced seizures via [ENTITY_B] activation: comparison with the effects of dextromethorphan.,0,0
[ENTITY_A] pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and [ENTITY_B].,0,0
"In contrast, aspirin-like nonselective NSAIDs such as sulindac and [ENTITY_A] inhibit not only the enzymatic action of the highly inducible, proinflammatory [ENTITY_B] but the constitutively expressed, cytoprotective COX-1 as well.",1,0
"The most potent compound 5 ([ENTITY_A]) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved [ENTITY_B], inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.",0,0
The [ENTITY_A]-induced elevated expression of [ENTITY_B] is coupled to enhanced iNKT cell activation.,0,0
Previously we have proposed that regulation of asymmetric [ENTITY_A] concentration by [ENTITY_B] may provide a novel mechanism for the regulation of NOS activity in vivo.,4,0
"Finally, [ENTITY_A] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and [ENTITY_B], fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.",1,0
"Our previous work, built on the early pioneering multikinase inhibitor [ENTITY_A], resulted in the only [ENTITY_B] vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.",1,0
"Nicotinic-receptor potentiator drugs, huprine X and [ENTITY_A], increase ACh release by blocking [ENTITY_B] activity but not acting on nicotinic receptors.",1,0
"Upon activation by [ENTITY_A], [ENTITY_B] CAR binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter.",0,0
"The results when considered with previous reports in the literature show that [ENTITY_A] is about 1000 times more potent and debrisoquine is about 20 times more potent for [ENTITY_B] inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.",1,0
[ENTITY_A] is responsible for pyruvate conversion to [ENTITY_B] through glycolysis.,4,0
"[ENTITY_A] (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, [ENTITY_B] (DFMO).",1,0
"Notably, the antioxidant [ENTITY_A]™ reversed the Mn (20 mg/kg)-dependent augmentation in [ENTITY_B](MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.",1,0
"BACKGROUND: This study examines the effects of [ENTITY_A], a [ENTITY_B] opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).",0,0
"Activity of [ENTITY_A] (Cabozantinib), an oral [ENTITY_B] inhibitor, in patients with medullary thyroid cancer.",1,0
Improper function of these proteins can be induced by selective disruption of their complexes with [ENTITY_A] using the [ENTITY_B] geldanamycin.,1,0
"These results demonstrated for the first time that [ENTITY_A] induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating [ENTITY_B] and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.",0,0
"Second, [ENTITY_A], a [ENTITY_B] catalytic inhibitor known to deplete Top2β, specifically sensitized MEFs to CPT.",1,0
"The [ENTITY_A] group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial [ENTITY_B] compared with the placebo group.",0,0
"Our results imply that [ENTITY_A] has the potential to be inhibited by [ENTITY_B]/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.",1,0
"RATIONALE: [ENTITY_A] antagonists, such as [ENTITY_B], have been shown to possess cognitive-enhancing and wakefulness-promoting effects.",3,0
[ENTITY_A] reduced fasting plasma glucose and [ENTITY_B] levels after 4 weeks and Hb(A1c) levels after 8 weeks.,1,0
"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by [ENTITY_A] formed from [ENTITY_B]-generated superoxide and NO.",4,0
[ENTITY_A] only diminished [ENTITY_B] protein expression and MCP-1 gene expression in vascular atheroma.,1,0
"Reduced synthesis of [ENTITY_A] (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of [ENTITY_B] (NOS) and cytosolic arginase I and mitochondrial arginase II.",4,0
Both types of granules contain [ENTITY_A] that catalyzes oxidative cross-linking of [ENTITY_B].,4,0
[ENTITY_A] 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as [ENTITY_B] or ALK5) inhibitor.,1,0
"Moreover, [ENTITY_A] resulted in activation of astrocytes, up-regulation of [ENTITY_B] in cortex and down-regulation of ADAM-10 in hippocampus and cortex.",0,0
Both [ENTITY_A] and captopril also prevented substrate degradation by [ENTITY_B] released in conditioned medium by cultured cells.,1,0
"Therefore, the objective of the present study was to investigate the effects of [ENTITY_A] inhibitors [ENTITY_B] (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.",1,0
The results also show that the binding modes of representative [ENTITY_A] are reversible and competitive at both [ENTITY_B] isoforms.,1,0
"METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, [ENTITY_A] (0.1 microM), an inhibitor of [ENTITY_B] inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3.",1,0
"Moreover, kinetic analysis revealed that inhibition by reserpine, a typical [ENTITY_A] inhibitor, was uncompetitive, decreasing maximum velocity and affinity for [ENTITY_B].",4,0
"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, [ENTITY_A] serves to broaden the spectrum of ceftazidime versus [ENTITY_B]-producing Gram-negative bacilli.",1,0
Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual [ENTITY_A]-Sulfatase Inhibitor [ENTITY_B].,1,0
"In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable [ENTITY_A] prostanoid TXB2 was significantly reduced by [ENTITY_B] (P<0.05), but not etodolac.",1,0
"Whole-cell voltage-clamp of [ENTITY_A]-293 cells reveals [ENTITY_B]-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.",0,0
[ENTITY_A]-dependent reporter gene expression in transfected HepG2 cells was increased by [ENTITY_B] in a concentration-dependent manner at 24h.,0,0
[ENTITY_A] suppressed [ENTITY_B]-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.,1,0
"Furthermore, h[[ENTITY_A]]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited [ENTITY_B] cleavage in heterologous cells transfected with the GLP-2 receptor.",1,0
"Incubation with [ENTITY_A] (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of [ENTITY_B] secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.",1,0
"Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 [ENTITY_A] subtypes, AT1AR and AT1BR following [ENTITY_B] (SA) treatment.",0,0
"One of the [ENTITY_A] agonists, [ENTITY_B] (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.",2,0
[ENTITY_A] and astemizole are chemically unrelated to [ENTITY_B] antagonists such as diphenhydramine and chlorpheniramine.,3,0
"However, DeltahPPAR-alpha was unable to abrogate [ENTITY_A]-mediated inhibition of [ENTITY_B] suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha.",1,0
"Of note, we demonstrated for the first time that telmisartan augmented [ENTITY_A] protein expression and [ENTITY_B] uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.",4,0
[ENTITY_A] inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and [ENTITY_B] in human colon cancer cells.,1,0
[ENTITY_A] and GW2331 induced expression of [ENTITY_B] and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.,0,0
Stimulated [ENTITY_A] and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after [ENTITY_B].,0,0
"Herein, we evaluate the interaction of the [ENTITY_A], [ENTITY_B], as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",3,0
"Compared with normal control group, [ENTITY_A]-kindled mice had significantly higher levels of malondialdehyde, nitrite, [ENTITY_B] but had lower levels of reduced glutathione in the whole brain homogenate.",0,0
"Potency switch between CHK1 and [ENTITY_A]: Discovery of [ENTITY_B]- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.",1,0
Involvement of [ENTITY_A] and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced [ENTITY_B] production by microglia.,4,0
Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the [ENTITY_A] inhibitor [ENTITY_B].,1,0
"In addition, [ENTITY_A] blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of [ENTITY_B] (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.",1,0
"In addition, LPS-induced nuclear factor [ENTITY_A] activation was diminished in RAW264.7 macrophages preincubated with [ENTITY_B].",1,0
[ENTITY_A] treatment also decreased [ENTITY_B] p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).,1,0
[ENTITY_A] protects against menadione-induced hepatotoxicity by enhancing [ENTITY_B] activity.,0,0
An alternative THF-dependent pathway involves the [ENTITY_A]/SHMT activities with [ENTITY_B] as 1-C source.,4,0
"When [ENTITY_A] was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, [ENTITY_B] activity in both cornea and tear fluid was strongly inhibited.",1,0
The decrease and recovery of [ENTITY_A] uptake correlated highly (r = 0.93) with the recovery of [ENTITY_B] binding.,4,0
"The upregulation of calpain, tBid and [ENTITY_A] activity were further inhibited by treatment with EGTA in the presence of [ENTITY_B].",0,0
"Take together, our results demonstrated that [ENTITY_A] might induce the apoptosis in LNCaP cell via down-regulation of [ENTITY_B] expression.",1,0
The physiological role of [ENTITY_A]-mediated [ENTITY_B] uptake remains to be determined.,4,0
"Although [ENTITY_A] (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze [ENTITY_B] reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.",4,0
[ENTITY_A] (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to [ENTITY_B] using NAD(P)(+) as coenzyme.,4,0
"Thus, [ENTITY_A] activates the HIF pathway through inhibition of [ENTITY_B] activity and initiates a pro-angiogenic phenotype.",1,0
"Absorption and secretion of [ENTITY_A] increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a [ENTITY_B].",4,0
"The mode of (functional) [ENTITY_A] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, [ENTITY_B], zolasartan, irbesartan, valsartan, telmisartan, E3174).",3,0
"[ENTITY_A] (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form [ENTITY_B], in a reaction driven by the hydrolysis of GTP to GDP.",4,0
"The inhibition of [ENTITY_A], moreover, did not cause attenuation in mucin secretion in response to [ENTITY_B] and forskolin.",1,0
"It is caused by a deficiency of [ENTITY_A] (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of [ENTITY_B] to D-methylmalonyl-CoA.",4,0
The ROS scavenger [ENTITY_A] and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on [ENTITY_B] activation.,0,0
RESULTS: Rolipram unmasked the inhibitory effect of [ENTITY_A] stimulation with [ENTITY_B] and significantly attenuated the stimulated release of AA and subsequent LTC(4).,0,0
"[ENTITY_A] and LXR β are nuclear receptors activated by [ENTITY_B], oxidized derivatives of cholesterol.",0,0
"Taken together, our results indicate that [ENTITY_A] indeed upregulates the [ENTITY_B] expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.",0,0
The concentration of [ENTITY_A] required to inhibit the assembly or to induce the disassembly of [ENTITY_B]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.,1,0
"[ENTITY_A] (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of [ENTITY_B] uptake into skeletal muscle and the inhibition of liver gluconeogenesis.",4,0
"Thus, [ENTITY_A] contributes to the instability of atherosclerotic plaque in apoE(-/-) mice through activating [ENTITY_B] and IL-8 and cell apoptosis in plaque.",0,0
The present study examined the differential [ENTITY_A]-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein ([ENTITY_B]) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.,0,0
"Positive staining of mitochondria was achieved in the presence of the [ENTITY_A] substrate, [ENTITY_B].",4,0
Neither ryanodine nor [ENTITY_A] inhibited down-regulation of [ENTITY_B] mRNA by NE.,0,0
"Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, [ENTITY_A], that Upregulates [ENTITY_B] Gene Expression in 3T3-L1 cells.",0,0
"With the use of [ENTITY_A], it has been clearly, clinically demonstrated that the selective inhibition of [ENTITY_B] is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.",1,0
"The [ENTITY_A] mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, [ENTITY_B].",4,0
Moreover stimulation of [ENTITY_A] activity was increased by those [ENTITY_B] or rosiglitazone.,0,0
"RESULTS: [ENTITY_A] inhibited constitutive and/or ligand-induced [ENTITY_B] or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.",1,0
"OBJECTIVES: The alkaloid [ENTITY_A] (GAL), which exhibits a combined [ENTITY_B] and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.",1,0
Reactivation potentials of [ENTITY_A] (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after [ENTITY_B] ingestion.,1,0
"Nevertheless, coperfusion with 0.1 and 0.3 mM [ENTITY_A], which inhibits the [ENTITY_B] (CFTR), dose dependently inhibited S3226-induced DBS.",1,0
"Regulation of multiple [ENTITY_A] (AC) provides unique inputs to mediate the synthesis of [ENTITY_B], a ubiquitous second messenger that controls many aspects of cellular function.",4,0
"Various genes controlled by [ENTITY_A], including [ENTITY_B], anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.",0,0
"[ENTITY_A] triggered strong induction of [ENTITY_B], which was prevented by 1 micro g/mL cycloheximide (CXH).",0,0
"The suppressive effect of [ENTITY_A] on barrel rotation could be partially countered by MK-329, a selective peripheral [ENTITY_B] (CCK-A) receptor antagonist.",1,0
"[ENTITY_A] has, comparably to B[a]P, a potential to repress expression of [ENTITY_B], in the head kidney of rainbow trout.",1,0
"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [ENTITY_A][ENTITY_B] synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.",4,0
Activation of [ENTITY_A] mediates the cardiovascular effects of [ENTITY_B].,0,0
Brain but not spinal [ENTITY_A] receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist [ENTITY_B] in a rat chronic constriction injury model.,3,0
"Multiple exposure to [ENTITY_A], a phosphodiesterase ([ENTITY_B]) inhibitor, induces acinar hypertrophy in the salivary gland.",1,0
"Ribonucleotide reductase ([ENTITY_A]) is responsible for the de novo conversion of the ribonucleoside diphosphates to [ENTITY_B], which are essential for DNA synthesis and repair.",4,0
[ENTITY_A] downregulates [ENTITY_B] through activation of peroxisome proliferator-activated receptor gamma.,1,0
"Exposure to [ENTITY_A], their metabolites, and ROS further increase [ENTITY_B] isoform expression that may amplify oxidative damage.",0,0
"[ENTITY_A] was the first [ENTITY_B] antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.",3,0
"Acute and chronic [ENTITY_A] administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, [ENTITY_B] (GABA-T).",1,0
"Humans with [ENTITY_A] gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex [ENTITY_B] production occur in both types of mutations.",4,0
[ENTITY_A]-based inhibitors of [ENTITY_B].,1,0
"Altogether, our findings support a model in which Top2β deficiency promotes [ENTITY_A]-induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and [ENTITY_B] accumulation.",0,0
"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing [ENTITY_A] or ABCG1; we clearly observed [ENTITY_B] efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.",4,0
Inhibition of Th1/Th17 responses via suppression of [ENTITY_A] and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside [ENTITY_B].,1,0
Sixteen of 34 CGPs inhibited [ENTITY_A]-mediated [ENTITY_B] uptake by >50% (IC50's 0.7-7.6 μM).,4,0
The discovery of an inducible [ENTITY_A] whose apparent substrate preference is [ENTITY_B] indicates that polyamine catabolism is more complex than that originally proposed.,4,0
"Based on recent reports that the small molecules, [ENTITY_A] and phthalimide, are suitable scaffolds for the design of high potency [ENTITY_B] (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.",1,0
The results suggest that the 63-kDa ([ENTITY_A]) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by [ENTITY_B] and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.,1,0
"In addition, [ENTITY_A] caused an increase in [ENTITY_B] and p21 protein level as well as mRNA levels.",0,0
We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the [ENTITY_A] inhibition by [ENTITY_B].,1,0
Hydrogen sulphide ([ENTITY_A]) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase ([ENTITY_B]) and cystathionine-beta-synthase (CBS).,4,0
"The selective [ENTITY_A] antagonists atenolol and metoprolol blocked [ENTITY_B]-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",2,0
[ENTITY_A] and BaP treatments significantly increased active [ENTITY_B] levels in a time-dependent manner.,0,0
"In addition, we also showed that the elevation in [ENTITY_A] levels and the inhibition of [ENTITY_B] in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.",4,0
Activation of cytoprotective [ENTITY_A] by [ENTITY_B] as a possible explanation for its hair growth-stimulating effect.,0,0
"It is not yet clear whether [ENTITY_A] can reduce breast cancer incidence in women with BRCA1 and [ENTITY_B] mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation.",1,0
"We posed the following questions: (1) Do cholangiocytes express H3R? (2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), [ENTITY_A] ([ENTITY_B] antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation? and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)? The expression of H3R was evaluated in liver sections by immunohistochemistry and immunofluorescence, and by real-time PCR in cholangiocyte RNA from normal and BDL rats.",3,0
"The results showed that administration of [ENTITY_A] resulted in a significant elevation in the levels of AchE activity, [ENTITY_B], NF-κB, and MCP-1 accompanied with a significant depletion in the Ach level.",0,0
"Thus, isoflavone supplementation did not affect [ENTITY_A]-dependent [ENTITY_B] efflux to serum.",4,0
"[ENTITY_A] was fortuitously found to be a novel, potent inhibitor of the [ENTITY_B].",1,0
"Notably, [ENTITY_A] treatment reduced adipose tissue expression of inflammatory [ENTITY_B], increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.",1,0
"Further, [ENTITY_A] increased specific DNA-binding activity of [ENTITY_B], and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity.",0,0
"[ENTITY_A] administration for up to 21 days produced a progressive reduction in the number of [ENTITY_B] receptors in frontal cortex, without significant alterations in occipital cortex.",1,0
"Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by [ENTITY_A] treatment, through dual action of reducing ROS itself and inhibiting [ENTITY_B] activity.",1,0
"Inhibition of endogenous production of [ENTITY_A] by PAG significantly suppressed [ENTITY_B] concentration, PPT-A expression and NK1-R expression in the acini.",1,0
"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting [ENTITY_A]/neu as well as the epidermal growth factor receptor (EGFR), [ENTITY_B].",1,0
"Taken together, our results suggested that [ENTITY_A] protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating [ENTITY_B] initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",1,0
"However, recent clinical studies have shown that a single low-dose injection of [ENTITY_A], an [ENTITY_B] (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.",3,0
"Both [ENTITY_A] also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in [ENTITY_B] and COX-2 expressions caused by CSE.",1,0
"The results show that transient [ENTITY_A] pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of [ENTITY_B] following H2O2.",0,0
"However, the expression of AT1R was not suppressed by other [ENTITY_A] antagonists such as [ENTITY_B] or olmesartan.",3,0
"Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the [ENTITY_A] inhibitor [ENTITY_B] and their combination.",1,0
Phillyrin strongly inhibited high [ENTITY_A]-induced [ENTITY_B] (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.,0,0
"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the [ENTITY_A] inhibitor [ENTITY_B].",1,0
"Thus, decreasing liver [ENTITY_A] activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of [ENTITY_B]-treated mice.",4,0
"Levels of mRNA encoding [ENTITY_A], ICA512, and PC1/3 were increased in the pancreatic islets of [ENTITY_B]-treated rats.",0,0
"Together, these data suggest that [ENTITY_A] degrades [ENTITY_B] protein at least in part via Pirh2-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to arsenic-induced death.",1,0
"Luteinizing hormone-releasing hormone (LHRH) agonists, such as [ENTITY_A], goserelin, leuprorelin and triptorelin, stimulate the pituitary's [ENTITY_B], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",0,0
"On stimulation by G(s), the activities of [ENTITY_A] can be further selectively modulated by other pathways to ensure precise control of intracellular [ENTITY_B] responses to specific stimuli.",4,0
The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective [ENTITY_A] inhibitor [ENTITY_B] in horses with lipopolysaccharide (LPS)-induced synovitis.,1,0
"When cultured in liquid minimal medium, yeast cells expressing the mutated [ENTITY_A] were found to accumulate intracellular [ENTITY_B] and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene.",4,0
"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of [ENTITY_A] MAPK and ERK1/2 phosphorylation by [ENTITY_B].",0,0
[ENTITY_A] suppression in humans by the orally active renin inhibitor [ENTITY_B] (SPP100): comparison with enalapril.,1,0
Recent observations revealed that [ENTITY_A] catalyzes N-glucuronidation of [ENTITY_B]-containing compounds.,4,0
"Consistent with the weak transactivation activity of esterified-[ENTITY_A] mediated by [ENTITY_B], there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats.",2,0
"Here we found that [ENTITY_A], a frontline agent for acute promyelocytic leukemia, inhibits [ENTITY_B] but not TAp63 expression in time- and dose-dependent manners.",1,0
"The hyperglycemic effect of [ENTITY_A] central administration was blocked by pretreatment with ondansetron, a specific [ENTITY_B] receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors.",2,0
"[ENTITY_A], liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by [ENTITY_B], while TDCPP induced CYP3A37 and CYP2H1.",0,0
"[ENTITY_A] (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and [ENTITY_B] (IL-1β).",1,0
"We hypothesized that preservation of plasma [ENTITY_A] in CRF may be, partly, due to downregulation/inhibition of [ENTITY_B].",4,0
Hepatocytes isolated from [ENTITY_A] pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in [ENTITY_B] activity.,0,0
"In conclusion, [ENTITY_A] production and neutrophil infiltration are increased in high-[ENTITY_B] environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin.",0,0
Agonistic activity of [ENTITY_A] on activation of [ENTITY_B]/AKT pathway in the rat uterus during the estrous cycle.,2,0
"In the current project, we found that the selective [ENTITY_A] antagonist [ENTITY_B] also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.",3,0
"The frdA gene coding for subunit A of FRD, and two control genes, [ENTITY_A] and copP associated with the export of [ENTITY_B] out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.",4,0
"Two pure [ENTITY_A] antagonists have been developed, [ENTITY_B] and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.",3,0
"Its special profile of actions, especially the rise in [ENTITY_A]-cholesterol levels induced by [ENTITY_B], is unique among the currently available pharmacological tools to treat lipid disorders.",0,0
Mechanisms limiting distribution of the [ENTITY_A](V600E) inhibitor [ENTITY_B] to the brain: implications for the treatment of melanoma brain metastases.,1,0
"Hence, triclosan has the ability to inhibit both the [ENTITY_A] and lipoxygenase pathways of [ENTITY_B] metabolism with similar efficacy.",4,0
"Currently, the use of orally administered [ENTITY_A] inhibitor antidepressants (eg, [ENTITY_B], tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary tyramine.",1,0
"Interestingly, [ENTITY_A], a selective inhibitor of [ENTITY_B] MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.",1,0
The food contaminant [ENTITY_A] activates the [ENTITY_B] in the intestine: interest of ex vivo models as an alternative to in vivo experiments.,0,0
"Non-[ENTITY_A] anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [ENTITY_B] (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.",1,0
"Interestingly, [ENTITY_A] increased the phosphorylation of [ENTITY_B] and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.",0,0
"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of [ENTITY_A]--mediated cystine uptake, in contrast to its colonic metabolites, [ENTITY_B] and 5-aminosalicylic acid.",1,0
The suppression of [ENTITY_A] activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of [ENTITY_B].,1,0
"Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing [ENTITY_A] by the [ENTITY_B] transporter.",4,0
"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined [ENTITY_A] antagonist [ENTITY_B] and the agonists oxytocin and carbetocin.",3,0
"PTE, used in combination with a known [ENTITY_A]/STAT3 inhibitor, [ENTITY_B], further decreased the viability of osteosarcoma cells.",1,0
"However, in contrast to the selective [ENTITY_A] antagonist, [ENTITY_B], the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",3,0
Inhibition of [ENTITY_A] translocation and leukotriene C4 secretion by [ENTITY_B] in exogenously activated human eosinophils.,1,0
The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its [ENTITY_A] mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [ENTITY_B] (2'CMP) inhibitor binding.,1,0
"The treatment of mice with [ENTITY_A] alone enhances [ENTITY_B] activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls.",0,0
"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the [ENTITY_A] (PKC) inhibitor [ENTITY_B] blocked the action of PMA.",1,0
[ENTITY_A] antagonism by [ENTITY_B] lowers heart rate variability and baroreflex gain.,3,0
"Pretreatment with [ENTITY_A] significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and [ENTITY_B] mRNA induced by TDI in TDI-sensitized rats.",1,0
"The most potent compound, [ENTITY_A] (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent [ENTITY_B] antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",3,0
"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of [ENTITY_A], a specific inhibitor of [ENTITY_B] (5-LOX) and a clinically used anti-asthmatic drug.",1,0
"[ENTITY_A], an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of [ENTITY_B], tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).",0,0
"The potent and selective third-generation [ENTITY_A] inhibitors anastrozole, [ENTITY_B] and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.",1,0
"The turnover of [ENTITY_A] was determined from the rate of recovery of binding after administration of [ENTITY_B], an irreversible inhibitor of ligand binding.",1,0
Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the [ENTITY_A] inhibitor [ENTITY_B]-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.,1,0
[ENTITY_A] activated the [ENTITY_B] cloned from rat cerebral artery myocytes with a potency (EC50 = 53 μM) similar to and an efficacy (×2.5 potentiation) significantly greater than that of LCA.,0,0
"In membranes from HEK293 cells transfected with [ENTITY_A], etomidate inhibited binding of the alpha2-antagonist, [ENTITY_B], with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",3,0
After 7 days of [ENTITY_A] administration the number of [ENTITY_B] was lower in frontal and occipital cortex and hippocampus.,1,0
"To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative [ENTITY_A] activator, [ENTITY_B], and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.",0,0
[ENTITY_A] (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block [ENTITY_B].,1,0
"In summary, these results show that the excitatory effect of [ENTITY_A] on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the [ENTITY_B]-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.",0,0
"[ENTITY_A], a putative [ENTITY_B] agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.",2,0
Treatment with the [ENTITY_A] antagonist [ENTITY_B] abolishes the above actions of puerarin on osteoblast-derived cells.,3,0
"[ENTITY_A] were potent inhibitors of [ENTITY_B] induction and were more effective than their precursors, prostaglandins E2 and D2.",1,0
"[ENTITY_A] blocked currents of all [ENTITY_B] isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for Nav1.5).",1,0
"Triphosphate nucleotides (ATP, GTP, and [ENTITY_A]) rapidly and reversibly inhibited [ENTITY_B] currents via mechanism(s) independent of purine receptors.",1,0
"The mouse [ENTITY_A] subfamily includes members that have wide tissue distribution and are active in the metabolism of [ENTITY_B] (AA), linoleic acid (LA), and other lipids and xenobiotics.",4,0
[ENTITY_A] (BMS-354825) is a novel orally bioavailable [ENTITY_B]/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).,1,0
[ENTITY_A] is a potent and selective [ENTITY_B] antagonist.,3,0
[ENTITY_A] treatment significantly inhibited the generation of reactive oxygen and nitrogen species in [ENTITY_B]-activated BV-2 microglia cells.,1,0
"Based on HMG-CoA reductase inhibition, pitavastatin-induced [ENTITY_A] more efficiently than [ENTITY_B] and atorvastatin.",0,0
[ENTITY_A] prolonged the decay time constant of [ENTITY_B]-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude.,1,0
"[ENTITY_A] (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits [ENTITY_B] signalling downstream of BTK.",1,0
"A decrease in [ENTITY_A] activity was observed when the slices were exposed to [ENTITY_B] at the concentrations of 1, 10 and 30 µM.",1,0
"Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, [ENTITY_A]-induced degradation of [ENTITY_B] protein.",1,0
"RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of [ENTITY_A] expression by [ENTITY_B].",0,0
"TGF-beta1 and high [ENTITY_A] increased [ENTITY_B] mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.",0,0
Role of [ENTITY_A] in uptake of [ENTITY_B] and inhibitory effect on complex I respiration in mitochondria.,4,0
"[ENTITY_A] and BAAM also caused surmountable antagonism of isoprenaline responses, and this [ENTITY_B] antagonism was slowly reversible.",3,0
"The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that [ENTITY_A] might be involved in the [ENTITY_B] activating signal cascade.",0,0
"[ENTITY_A], a second [ENTITY_B] inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM.",1,0
"BACKGROUND: [ENTITY_A], a [ENTITY_B] (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.",3,0
"As [ENTITY_A] metabolism deficiencies have been seen in placental infarcts previously, these indicate that [ENTITY_B]/hTPK may have a role in placental diseases.",4,0
The enzyme [ENTITY_A] (DDAH) specifically hydrolyzes these asymmetrically methylated [ENTITY_B] residues to citrulline and methylamines.,4,0
"A number of selective [ENTITY_A] antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and [ENTITY_B].",3,0
[ENTITY_A] and debrisoquine are substrates of [ENTITY_B] and potent inhibitors of monoamine oxidase in perfused lungs of rats.,4,0
This stimulation was attenuated by the [ENTITY_A] inhibitor [ENTITY_B] (IPA3) or dominant-negative Pak1.,1,0
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, [ENTITY_A] ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [ENTITY_B] (DGAT).",1,0
"3. [ENTITY_A] induction in the liver increased depending on the dose of [ENTITY_B], whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P.",0,0
5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that [ENTITY_A] inhibit [ENTITY_B] transcription.,1,0
"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with [ENTITY_A], at which, however, both [ENTITY_B] and oxymetazoline exhibit different properties (antagonism and agonism, respectively).",3,0
"6 In conclusion, [ENTITY_A] channel inhibition by [ENTITY_B] exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration.",1,0
"New modes of therapy have recently been introduced, and data on the [ENTITY_A] (COX-2)-specific inhibitors [ENTITY_B] and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.",1,0
"[ENTITY_A] treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma [ENTITY_B].",0,0
"Moreover, the D2R inhibitor [ENTITY_A] blocked the increase of both [ENTITY_B] and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.",1,0
"The ARB [ENTITY_A] is a nonbiphenyl nontetrazole [ENTITY_B] (AT1) antagonist, which acts to decrease total peripheral resistance.",3,0
"Prazosin (nonselective [ENTITY_A] antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the [ENTITY_B]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",2,0
We describe the discovery of several [ENTITY_A] as potent and selective [ENTITY_B] inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies.,1,0
"In rats, [ENTITY_A] and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the [ENTITY_B] Oatp1 and Oatp2.",1,0
OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of [ENTITY_A] affects the [ENTITY_B] biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI).,4,0
"The results of this study suggest that [ENTITY_A] predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an [ENTITY_B].",0,0
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while [ENTITY_A] (1400W), a selective inhibitor of iNOS, decreased the expression of [ENTITY_B], VEGF, and iNOS.",1,0
We conclude that [ENTITY_A] mediates acid-induced increase in [ENTITY_B] production and cell proliferation.,4,0
"Furthermore, the EGFR inhibitor [ENTITY_A] inhibited EGF-induced [ENTITY_B] expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.",1,0
"The effects of simvastatin were abolished by the addition of the product of the [ENTITY_A], [ENTITY_B], indicating the involvement of HMG-CoA reductase in the action of simvastatin.",4,0
"Moreover, in rat hepatoma H4-II-E cells, the esterified-[ENTITY_A] failed to induce tyrosine aminotransferase, which is regulated by [ENTITY_B]-mediated transactivation activity.",2,0
"In the presence of Na+ and under conditions in which [ENTITY_A] transport function was suppressed, a second [ENTITY_B] uptake system was detected that exhibited functional characteristics similar to those of the IMINO system.",4,0
[ENTITY_A] therapy results in reduced mRNA expression of [ENTITY_B] (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.,1,0
"When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), [ENTITY_A] was found to act as a [ENTITY_B] antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.",3,0
"In HaCaT cells, [ENTITY_A] and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including [ENTITY_B] (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).",1,0
Mazindol analogues as potential inhibitors of the cocaine binding site at the [ENTITY_A][ENTITY_B] transporter.,4,0
"Taken together, these data demonstrate that [ENTITY_A] inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic [ENTITY_B] and CYP3A activities.",1,0
[ENTITY_A] inhibited [ENTITY_B] protein expression and PPARdelta transcriptional activity.,1,0
[ENTITY_A] was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. [ENTITY_B] inhibitors.,1,0
"Differentiating the roles of mGlu2 and mGlu3 receptors using [ENTITY_A], an mGlu2 agonist/[ENTITY_B] antagonist.",3,0
"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified [ENTITY_A] strongly favoured [ENTITY_B] over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",4,0
"Heterologous expression of [ENTITY_A] in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of [ENTITY_B], oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.",4,0
Block of [ENTITY_A] with [ENTITY_B] after channel activation was voltage dependent.,1,0
"In contrast to previous concepts, [ENTITY_A] inhibited [ENTITY_B] by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors.",1,0
"[ENTITY_A] increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of [ENTITY_B] and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.",1,0
"[ENTITY_A] also activated DNA damage response signaling, resulting in increased levels of Ser15-[ENTITY_B], γ-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.",0,0
Western blot analysis indicated that [ENTITY_A] inhibits the [ENTITY_B]/MEKK1/JNK pathway.,1,0
Synthesis of [ENTITY_A] derivatives: discovery of a potent and selective [ENTITY_B] inhibitor for the treatment of Alzheimer's disease.,1,0
"Prednisolone also inhibited ACTH and [ENTITY_A] secretion in response to exogenous [ENTITY_B] stimulation, inferring rapid feedback inhibition at the anterior pituitary.",4,0
"Interestingly, a [ENTITY_A] mutant was inhibited with equal potency to human COX-2 with [ENTITY_B]-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.",1,0
The [ENTITY_A] was similarly inhibited by [ENTITY_B] with an IC-50 of 61 microM.,1,0
"New classes of [ENTITY_A]-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as [ENTITY_B] selective inhibitors and NO donors were synthesized and are herein reported.",1,0
[ENTITY_A] upsurge precedes standard biomarkers of hepatotoxicity in [ENTITY_B]-injected mice.,0,0
METHODS: [ENTITY_A] activity and selectivity was determined in vitro by measuring [ENTITY_B] (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.,4,0
"Of note, we demonstrated for the first time that [ENTITY_A] augmented [ENTITY_B] protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.",0,0
"[ENTITY_A], a [ENTITY_B] antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.",3,0
[ENTITY_A] (ZD1694) is a specific antifolate-based [ENTITY_B] inhibitor active in a variety of solid tumor malignancies.,1,0
[ENTITY_A] induces cognitive impairment through enhancement of [ENTITY_B]-mediated amyloid-β generation in mice.,0,0
These results highlight the importance of [ENTITY_A] activation of the Src/MAPK signaling pathway for [ENTITY_B]-induced transcription of select target genes and cell cycle progression.,0,0
"Intravenous [ENTITY_A] significantly increased the acute [ENTITY_B] response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose.",0,0
"In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent [ENTITY_A] inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of [ENTITY_B].",1,0
"[ENTITY_A] is a [ENTITY_B] inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses.",1,0
"In study 1, cyclic ewes received vehicle, cortisol, [ENTITY_A] (PF; a selective inhibitor of [ENTITY_B]), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus.",1,0
"[ENTITY_A] level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in [ENTITY_B] group and lower in imidapril group.",0,0
"Also, [ENTITY_A] enhances the phosphorylation of [ENTITY_B], the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α.",0,0
"The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting [ENTITY_A]-mediated [ENTITY_B] release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively.",4,0
[ENTITY_A] interacts with a common binding site to elicit opposite effects on inactivation gating of [ENTITY_B] and ERG potassium channels.,0,0
"[ENTITY_A] blocked alpha1A and alpha1E with a Kd comparable to that reported for [ENTITY_B], but had a lower affinity (approximately 30-fold) for alpha1C.",1,0
They act by reactivation of [ENTITY_A] inhibited by [ENTITY_B].,1,0
"RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas [ENTITY_A] (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on [ENTITY_B] expression.",1,0
"[ENTITY_A] (BMS-354825) inhibits [ENTITY_B]D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",1,0
The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting [ENTITY_A] with [ENTITY_B] (AuF).,1,0
The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each [ENTITY_A] in the metabolism of [ENTITY_B].,4,0
"[ENTITY_A] inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through [ENTITY_B] from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).",3,0
"In further studies, the diuretic effects of the [ENTITY_A] agonist [ENTITY_B] were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",2,0
[ENTITY_A] suppresses [ENTITY_B] oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity.,1,0
[ENTITY_A] reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of [ENTITY_B] in murine macrophages and ocular tissues.,1,0
[ENTITY_A] decreased the peak amplitude of hippocampal area CA1 [ENTITY_B]-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.,1,0
"[ENTITY_A] caused a sustained increase in nuclear [ENTITY_B] levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition.",0,0
[ENTITY_A] causes an increase in brain ornithine that is prevented by prior [ENTITY_B] inhibition.,1,0
Inactivation of [ENTITY_A] and prostacyclin synthase by [ENTITY_B].,1,0
"With respect to the substrate [ENTITY_A], atovaquone was an uncompetitive inhibitor of [ENTITY_B] (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).",1,0
The [ENTITY_A] agonist activity reported here clearly distinguishes [ENTITY_B] from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.,2,0
"[ENTITY_A] rapidly increased [ENTITY_B], c-fos and PDGFA expression.",0,0
"In this article, the action of [ENTITY_A] (BMS-354825) is contrasted with that of imatinib, a [ENTITY_B] inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.",1,0
Intestinal and hepatic first-pass extraction of the [ENTITY_A] inhibitor [ENTITY_B] in rats with chronic vascular catheters.,1,0
"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective [ENTITY_A]/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of [ENTITY_B], and glomerular filtration rate and in a significant impairment in renal water metabolism.",4,0
[ENTITY_A] also caused a fast (within 30min as judged by the increase in its mRNA level) activation of [ENTITY_B] (cPLA2).,0,0
"For instance, [ENTITY_A] inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express [ENTITY_B] but has no effect on HCT-116 tumor cells that do not express COX-2.",1,0
"The bacterial enzyme [ENTITY_A] (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as [ENTITY_B] (Glc1P).",4,0
"The results when considered with previous reports in the literature show that [ENTITY_A] is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by [ENTITY_B].",4,0
Glufosinate inhibits [ENTITY_A] and blocks biosynthesis of [ENTITY_B].,4,0
Insertion of [ENTITY_A] was blocked by the ER antagonist [ENTITY_B] or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).,1,0
Kinetic analysis revealed that the inhibition of the [ENTITY_A] reaction by [ENTITY_B] was competitive with respect to LTA4.,1,0
"A significant decrease of [ENTITY_A], alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after [ENTITY_B] and PC administration alone.",1,0
"[ENTITY_A] and SN-38 may also stimulate the production of pro-inflammatory [ENTITY_B] and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).",0,0
"Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal [ENTITY_A] expression and activity - was significantly higher following exposure to [ENTITY_B] concentrations as low as 31.2 nM.",0,0
"Several effects of [ENTITY_A] are useful in this scenario, including a reduction in the activities of [ENTITY_B] and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.",1,0
Oral [ENTITY_A] is likely to be a useful addition to oral formulations of other [ENTITY_B]r antagonists in preventing CINV in patients receiving MEC.,3,0
The selective [ENTITY_A] inhibitor [ENTITY_B] (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.,1,0
[ENTITY_A] functionally antagonizes testosterone activation of the [ENTITY_B] in prostate cells through focal adhesion complexes involving Hic-5.,3,0
"[ENTITY_A] metabolized [ENTITY_B] only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.",4,0
[ENTITY_A]-derived [ENTITY_B] can influence several processes that are linked to carcinogenesis.,4,0
"Administration of [ENTITY_A], an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the [ENTITY_B] protein level reduced by CTD and increased the AQP1 protein level above the control one.",0,0
Novel [ENTITY_A] derivatives as potent [ENTITY_B] inhibitors.,1,0
"[ENTITY_A]-regulated genes including cytokeratin 1-19 and [ENTITY_B] were over-expressed, although Cyp3a25 was suppressed.",0,0
"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main [ENTITY_A] metabolizing enzyme in the brain, [ENTITY_B], chemically show structural elements of the acetylcholinesterase inhibitor tacrine.",4,0
"[ENTITY_A] caused a significant down-regulation of the [ENTITY_B], although etorphine did not.",1,0
"In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ([ENTITY_A]) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and [ENTITY_B] (LTA(4)H-h) was found.",1,0
Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to [ENTITY_A] by [ENTITY_B] (DGK).,4,0
"CONCLUSIONS AND IMPLICATIONS: In different cell systems, [ENTITY_A] directly activates [ENTITY_B], displaying partial agonist activity at brain receptors.",2,0
"OBJECTIVE: Because of these physiological effects and the widespread use of the selective [ENTITY_A] inhibitor, [ENTITY_B], we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing.",1,0
"Ergot alkaloids were also effective in inhibiting [ENTITY_A]-stimulated [ENTITY_B] production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",4,0
[ENTITY_A] inhibits [ENTITY_B] in a competitive fashion only at very high concentrations (IC(50) = 150 microM).,1,0
[ENTITY_A] abolished the inhibitory effect of acetazolamide on [ENTITY_B] and CA II.,0,0
"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of [ENTITY_A] with respect to the substrate [ENTITY_B].",4,0
"Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [ENTITY_A]-catalyzed metabolism of haloperidol and reduced [ENTITY_B].",4,0
Induction of AhR by [ENTITY_A] and prochloraz resulted in a time- and dose-dependent increase of [ENTITY_B] gene expression and transporter protein levels.,0,0
"In conclusion, our data suggest that chronic [ENTITY_A] use is associated with modestly reduced levels of striatal DA and the [ENTITY_B] in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.",1,0
"Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum [ENTITY_A] level with high dose of [ENTITY_B] might be optimum for normal growth.",0,0
"Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of [ENTITY_A] for localized sequestration of [ENTITY_B] that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.",0,0
"The results suggested that both the [ENTITY_A] extract and berberine were able to activate [ENTITY_B], and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.",2,0
"In non-pre-treated cells, only [ENTITY_A] were down-regulated by [ENTITY_B], showing a greater influence upon ABCG5 expression.",1,0
Co-treatment of astrocytes with [ENTITY_A] and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of [ENTITY_B] and inhibition of GJIC.,1,0
[ENTITY_A] plasma concentrations remained above the in vitro IC(50) for [ENTITY_B] for at least 5 h postadministration.,1,0
[ENTITY_A] is a potent non-competitive inhibitor of [ENTITY_B] from Candida (Ki = 30 nM).,1,0
"Nevertheless, low [ENTITY_A] concentrations (≥ 0.1mM, 48 h) increased protein ubiquitination, [ENTITY_B] and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2α in SH-SY5Y cells.",0,0
"[ENTITY_A] (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield [ENTITY_B] or 2-oxobutyrate.",4,0
Direct transport of [ENTITY_A] could be shown for [ENTITY_B] (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).,4,0
"These findings are the first to show that long-term exposure to [ENTITY_A] during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, [ENTITY_B](MAPK) phosphorylation and caspase activity in the striatum.",0,0
"Wild-type enzymes and variants of [ENTITY_A] (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([ENTITY_B]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.",4,0
[ENTITY_A] significantly reduced [ENTITY_B] secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C.,1,0
8-pCPT-2'-O-Me-cAMP-AM potentiation of [ENTITY_A] secretion stimulated by tolbutamide was markedly inhibited by [ENTITY_B] (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM).,1,0
"These effects were fully counteracted by dietary [ENTITY_A] which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of [ENTITY_B] signalling molecule.",1,0
"Data at transcriptional level also demonstrated that [ENTITY_A] potently attenuated gene expressions involved in inflammation, such as [ENTITY_B], COX-2 and TLR4.",1,0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-[ENTITY_A] antagonist [ENTITY_B] (6-cyano-7-nitro-quinoxalinedione).,3,0
"[ENTITY_A] (LY139037), a selective [ENTITY_B] antagonist, is a potent inhibitor of gastric acid secretion.",3,0
"[ENTITY_A] exposure resulted in a sustained increase in mRNA expression for [ENTITY_B] and PDE3A, but PDE4D gene expression was unchanged.",0,0
"Further, [ENTITY_A] pretreatment blocked [ENTITY_B]-induced increase in permeability of mouse-lung microvessels.",1,0
"Among the other [ENTITY_A] studied, alendronate was more potent and selective for [ENTITY_B].",1,0
"Recently, it has been shown that the activation of particular [ENTITY_A] bitter taste receptors is partially involved with the bitter aftertaste sensation of [ENTITY_B] and acesulfame-K.",0,0
"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by [ENTITY_A] (PAO) to produce [ENTITY_B] and putrescine, respectively.",4,0
"Experimental cystathioninuria was induced in rats by administration of the [ENTITY_A] inhibitor, [ENTITY_B].",1,0
[ENTITY_A] is a mixed agonist of mutant [ENTITY_B] and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.,2,0
Tumor-growth-promoting [ENTITY_A] [ENTITY_B] pathway provides medulloblastoma therapeutic targets.,4,0
"In cellular assays, [ENTITY_A] had an IC(50) of 0.14 microM in [ENTITY_B]-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).",1,0
"Cellular release of [ENTITY_A] by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist [ENTITY_B].",1,0
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the [ENTITY_A]-antioxidant response element (Nrf2-ARE) activator [ENTITY_B], or small interfering RNA.",0,0
"[ENTITY_A] and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of [ENTITY_B] blockade.",1,0
Novel [ENTITY_A] were designed as potential inhibitiors of [ENTITY_B].,1,0
"Thus, despite the similar structures of TETA and SpmTrien, [ENTITY_A] is the main acetylator of [ENTITY_B], whereas SpmTrien is primarily acetylated by SSAT1.",4,0
Our findings suggest that [ENTITY_A] blocks the vasoconstrictor action of [ENTITY_B] in vitro.,1,0
Ingestion of competitive inhibitors of [ENTITY_A] such as liquorice and [ENTITY_B] result in a similar but milder clinical phenotype.,1,0
"CONCLUSIONS: After the initial bleach, [ENTITY_A] impeded photon absorption by rhodopsin by inhibiting metabolic [ENTITY_B] regeneration.",1,0
"Recently, the [ENTITY_A] kinase inhibitor [ENTITY_B] (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.",1,0
Inhibition of [ENTITY_A] with a series of natural product [ENTITY_B] and phenolic acids.,1,0
"Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the [ENTITY_A] agonist [ENTITY_B] had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.",2,0
"When tested in the intact cells, only 4 of 16 [ENTITY_A] (at 10 μM) inhibited [ENTITY_B]-mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.",1,0
Enzyme kinetic analyses using human liver microsomes revealed inhibition of [ENTITY_A] activity by [ENTITY_B] (IC50 78 μM) and pelargonidin (IC50 33 μM).,1,0
While [ENTITY_A] (a [ENTITY_B] inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.,1,0
"This study was designed to test the hypothesis that [ENTITY_A] inhibits [ENTITY_B] with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.",1,0
[ENTITY_A] increase [ENTITY_B] through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.,0,0
"Specifically, [ENTITY_A], which potentiates wild-type [ENTITY_B], is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.",0,0
"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the [ENTITY_A] antagonist [ENTITY_B], while pyrilamine had a mixed effect on cognition.",3,0
"The activity of [ENTITY_A] in excised liver samples from rats following multiple [ENTITY_B] treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D.",1,0
"In the study reported here, the effects of acute PLZ treatment on the levels of various [ENTITY_A], some of which are also metabolized by [ENTITY_B] were compared in rat whole brain.",4,0
"[ENTITY_A] also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and [ENTITY_B] markers of apoptosis.",0,0
The study demonstrates for the first time the marked gastrokinetic properties of the new [ENTITY_A] antagonist [ENTITY_B] in humans.,3,0
We show both in vitro and in vivo that low-dose [ENTITY_A] enhances [ENTITY_B] activity in epithelial cells and macrophages.,0,0
Ethanol-stimulated (100mM) [ENTITY_A] upregulation was suppressed by [ENTITY_B] but further enhanced by HO-1 inhibition with resultant heme accumulation.,1,0
"RESULTS: We show that [ENTITY_A] is a potent inhibitor of [ENTITY_B]-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.",1,0
Activation of AMPK using [ENTITY_A] resulted in STIM1 phosphorylation on serine residues and prevented [ENTITY_B]-induced Ca2+ entry.,1,0
[ENTITY_A] downregulates angiotensin II type 1 receptor through activation of [ENTITY_B].,0,0
[ENTITY_A] and LY 344864 decreased the number of capsaicin-induced [ENTITY_B]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).,1,0
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of [ENTITY_A] in breast cancer by blocking [ENTITY_B] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",4,0
Sources of [ENTITY_A] include dietary proteins and endogenous synthesis by [ENTITY_B] and argininosuccinate lyase.,4,0
Our observations indicate an [ENTITY_A]-mediated transmembrane transport of [ENTITY_B].,4,0
"[ENTITY_A] treatment prevents the formation of activated [ENTITY_B], a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death.",1,0
"Altogether, our results suggest that a high dose of [ENTITY_A] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear [ENTITY_B] accumulation.",0,0
"Pretreatment of the tissues with combined [ENTITY_A]/5-HT2 antagonists, [ENTITY_B] (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",3,0
"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in [ENTITY_A]-induced E(max), indicating activated PKC-mediated heterologous [ENTITY_B] desensitization.",2,0
"The [ENTITY_A] metabolic ratio appears to detect known differences in [ENTITY_B] activity associated with genetic polymorphism, across different ethnic groups.",4,0
Inhibition of LTC4 synthesis precedes the global cytotoxic effects of [ENTITY_A] as indicated by the simultaneous upregulation of [ENTITY_B] expression.,0,0
"RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas [ENTITY_A], carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting [ENTITY_B] than COX-1.",1,0
"Using the [ENTITY_A] subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and [ENTITY_B], we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",3,0
[ENTITY_A] suppresses histamine synthesis by repressing both transcription and activity of [ENTITY_B] in allergic rats.,1,0
"Through demonstrating the selective inhibition of [ENTITY_A]-related T-lymphocyte responses by [ENTITY_B], our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.",1,0
Uptake of [ENTITY_A] (5 nM) by [ENTITY_B] was reduced by 82%-95%.,4,0
"[ENTITY_A] and milrinone, selective PDE3 inhibitors, suppressed [ENTITY_B] secretion to a lesser extent.",1,0
A series of compounds based on a [ENTITY_A] scaffold that are potent and selective inhibitors of [ENTITY_B] (TNIK) activity are described.,1,0
"In relation to zinc bioavailability, [ENTITY_A], β-CPPs, α(s1)-CN(64-74)4P and β-CN(1-25)4P increased [ENTITY_B] uptake.",4,0
"The molecular mechanisms by which [ENTITY_A] inhibits the [ENTITY_B] signal in neurons, however, remain unclear.",1,0
"Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high [ENTITY_A] expression, indicating activation of [ENTITY_B] synthesis through both the salvage and de novo pathways.",4,0
"Although, [ENTITY_A] primarily inhibits [ENTITY_B], it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors.",1,0
"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as [ENTITY_A] activator, [ENTITY_B].",0,0
Dual function inhibitors targeting phospholipase A(2) ([ENTITY_A]) and leukotriene A(4) hydrolase (LTA(4)H) may balance the [ENTITY_B] (AA) metabolic network and be used as new anti-inflammatory drugs.,4,0
"Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and [ENTITY_A] or hyperoside inhibited production of [ENTITY_B] and FXa in HUVECs.",0,0
"The time course of [ENTITY_A] production was consistent with early release due to [ENTITY_B] activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression.",4,0
Cytochrome b5 has shown to be an essential component in [ENTITY_A] catalyzed [ENTITY_B] formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.,4,0
"Moreover, LTD4-induced increases in [ENTITY_A] and NF-κB p65 in the brain were also attenuated by [ENTITY_B].",1,0
"In the present study, age-related changes of [ENTITY_A] (PLP) synthesizing enzymes, pyridoxal kinase ([ENTITY_B]) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.",4,0
The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for [ENTITY_A] may contribute to the limited accumulation of [ENTITY_B] in cell membranes.,4,0
"In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the [ENTITY_A]-induced [ENTITY_B] dephosphorylation event, which represents the major signaling pathway for its activation.",0,0
"Uptake of the radiolabeled model substrates [ENTITY_A], estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either [ENTITY_B] or OATP1B3.",4,0
"Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel 4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for [ENTITY_A] ([ENTITY_B]), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",3,0
"On the other hand, in patients with a mean serum [ENTITY_A] level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the [ENTITY_B] value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l.",1,0
Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the [ENTITY_A] induction [ENTITY_B] (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).,0,0
The [ENTITY_A] required for potentiation of skeletal muscle contraction is released via [ENTITY_B] hemichannels.,4,0
Cellular responses to DNA damage induced by [ENTITY_A] or doxorubicin include down-regulation of endogenous supervillin coincident with increases in [ENTITY_B].,0,0
"The inhibition of [ENTITY_A] synthesis and PR down-regulation by [ENTITY_B] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.",1,0
"Treatment with [ENTITY_A] (AdOx), an inhibitor of transmethylation-suppressive [ENTITY_B] (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.",1,0
"[ENTITY_A] was the first, but by no means remained the only, [ENTITY_B] receptor antagonist.",3,0
"[ENTITY_A] also saturated the 13-14 or 7-8 double bonds of [ENTITY_B] (vitamin A2), a second endogenous form of vitamin A in zebrafish.",4,0
"While the substituted [ENTITY_A] prokinetics (for example, metoclopramide, cisapride) also block [ENTITY_B] receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.",1,0
"The mRNA levels of [ENTITY_A] (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by [ENTITY_B] treatment.",1,0
These results confirm the selective [ENTITY_A] agonist and mGlu3 antagonist actions of [ENTITY_B].,2,0
Patients who received [ENTITY_A] prior to hospitalization had a higher rate of intermediate syndrome and lower levels of [ENTITY_B] at admission than those who had not.,1,0
"Exposure of Jurkat cells to either [ENTITY_A] [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective [ENTITY_B] antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.",3,0
"[ENTITY_A] also inhibited ACTH and cortisol secretion in response to exogenous [ENTITY_B] stimulation, inferring rapid feedback inhibition at the anterior pituitary.",1,0
Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that [ENTITY_A] and Rho kinase inhibitor (C3T and [ENTITY_B]) increased apoA-I production in the HepG2 cells.,1,0
"[ENTITY_A], locally synthesized, is an endogenous agonist at [ENTITY_B], a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.",2,0
A series of [ENTITY_A] were synthesized and investigated in vitro as inhibitors of pancreatic [ENTITY_B] (CEase) and acetylcholinesterase (AChE).,1,0
We found that [ENTITY_A] is released from vesicles when [ENTITY_B] is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.,4,0
"Depleted heme pool and [ENTITY_A] releasing limited protein synthesis and inhibited enzymatic activity of [ENTITY_B], respectively.",1,0
Felodipine and the [ENTITY_A] analogue inhibited the actin-activated [ENTITY_B] activity of smooth muscle myosin (IC50 = 25.1 microM).,1,0
Inhibitory effects of [ENTITY_A] analogues on [ENTITY_B] induced whole blood clot lysis.,1,0
Expression of L-type pyruvate kinase ([ENTITY_A]) is upregulated in the liver by dietary [ENTITY_B].,0,0
"Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the [ENTITY_A] inhibitor, [ENTITY_B], attenuated cell growth inhibition by jaceosidin.",1,0
"In this study, we found that [ENTITY_A] (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of [ENTITY_B] (iNOS) in BV2 microglia.",1,0
"In seven normal subjects, basal [ENTITY_A] plasma levels were significantly suppressed 3 h after [ENTITY_B] administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).",1,0
[ENTITY_A] treatment (2 X 5 mg/day) caused a 30% decrease of [ENTITY_B] density and PRA after 2 days; both parameters remained reduced during treatment.,1,0
Novel [ENTITY_A] derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin ([ENTITY_B]) and/or decreased neuropeptide Y (NPY).,0,0
Activation of [ENTITY_A] and Phosphorylation of Glycogen Synthase Kinase3 β Mediate [ENTITY_B] Induced Apoptosis in HepG2 Liver Cancer Cells.,0,0
"Brexpiprazole reversed the inhibitory effect of the DA agonist [ENTITY_A] on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on [ENTITY_B].",2,0
"[ENTITY_A] deficiency impairs [ENTITY_B] synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.",4,0
"Moreover, overexpressed CYP2J2 and [ENTITY_A] inhibited [ENTITY_B]-induced macrophage migration in a VSMC-macrophage coculture system.",1,0
Blockade of [ENTITY_A] synthesis caused by additive inhibition of [ENTITY_B] phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.,4,0
"[ENTITY_A] is much less potent as a [ENTITY_B] inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.",1,0
"Avibactam (formerly [ENTITY_A], AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some [ENTITY_B] enzymes.",1,0
"Introduction: 5-Lipoxygenase ([ENTITY_A]) is a crucial enzyme of the [ENTITY_B] (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.",4,0
"Collectively, our results suggest that [ENTITY_A] can inhibit NO production and [ENTITY_B] activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.",1,0
"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of [ENTITY_A] carcinogens was catalyzed by [ENTITY_B] (b5R) and cytochrome b5 (cyt b5).",4,0
"Taken together, these data demonstrated that PLA2 inhibitors [ENTITY_A] and AACOCF3 are robust inhibitors of [ENTITY_B] expression at both the mRNA and protein levels in murine splenocytes.",1,0
[ENTITY_A] expression was increased in all [ENTITY_B] males and BPA 0.5 females and reduced in BPA 200 females.,0,0
"Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the [ENTITY_A]-enhanced activation of [ENTITY_B] in HepG2 hepatocytes.",0,0
"The induction of [ENTITY_A] by EIH was inhibited by [ENTITY_B] but not by SP600125, PD98059, nor LY294002.",1,0
"Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to [ENTITY_A] toxicity as evidenced by activation of [ENTITY_B], loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.",0,0
[ENTITY_A] is a novel [ENTITY_B] antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.,3,0
"In the current study, we show that systematic modification of an [ENTITY_A] scaffold identifies two new compounds with dual CB1R antagonist/[ENTITY_B] agonist activity.",2,0
"Although numerous mechanisms of action of [ENTITY_A] and thioridazine have been identified, both drugs are [ENTITY_B] antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.",3,0
"In general, antiproliferative activity is greatly enhanced by low levels of the [ENTITY_A] inhibitor [ENTITY_B].",1,0
RESULTS: [ENTITY_A] decreased the expression of [ENTITY_B] at the mRNA and protein levels in a dose- and time-dependent manner.,1,0
"[ENTITY_A], sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new [ENTITY_B] agonists.",2,0
The inhibitory effects of iloprost on [ENTITY_A] expression were also potentiated by [ENTITY_B] and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.,1,0
"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and [ENTITY_A] was identified as the likely source of [ENTITY_B]-stimulated superoxide production.",4,0
"Before the next drug intake, [ENTITY_A] inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with [ENTITY_B] but not with toloxatone.",1,0
"As far as we are aware, the compound's [ENTITY_A] scaffold represents a new core structure for [ENTITY_B] agonists.",2,0
"[ENTITY_A], a [ENTITY_B] inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials.",1,0
"Here we found that the anticancer agent [ENTITY_A], a [ENTITY_B] inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.",1,0
"bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of [ENTITY_A], acted as substrate for [ENTITY_B].",4,0
"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers [ENTITY_A] inhibited IL-2 production partially and enhanced [ENTITY_B] expression and proliferation.",0,0
"Inhibitors of [ENTITY_A] ([ENTITY_B]; 0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively.",1,0
"These currents were produced by [ENTITY_A] (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by [ENTITY_B], an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.",1,0
"Both inhibitors, moreover, blunted the [ENTITY_A] secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, [ENTITY_B].",1,0
Protective effect of [ENTITY_A] anesthesia on retinal light damage: inhibition of metabolic [ENTITY_B] regeneration.,1,0
Ex vivo [ENTITY_A] inhibition and pharmacokinetics of [ENTITY_B] were assessed in 5 volunteers receiving single 1000 mg doses orally.,1,0
"[ENTITY_A] (0.3 mg/kg, iv) produced a significant inhibition of the [ENTITY_B] mediated positive chronotropic response to isoproterenol.",1,0
"In contrast, [ENTITY_A] (ZnPP), a specific [ENTITY_B] inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production.",1,0
[ENTITY_A]-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of [ENTITY_B] signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.,1,0
"In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, [ENTITY_A] showed competitive inhibition of [ENTITY_B].",1,0
A unique cytosolic activity related but distinct from [ENTITY_A] catalyses metabolic activation of [ENTITY_B].,4,0
The potent anabolic effects of the [ENTITY_A] agonist [ENTITY_B] on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.,2,0
We conclude that [ENTITY_A] is a potent blocker of [ENTITY_B] channels expressed in HEK293 cells.,1,0
Data also showed [ENTITY_A] inhibited [ENTITY_B]-induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia.,1,0
Our study demonstrated that [ENTITY_A] inhibited [ENTITY_B]-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.,1,0
"In this study, aldosterone ([ENTITY_A])-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of [ENTITY_B] signaling were clarified.",0,0
"Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the [ENTITY_A] anion generated by [ENTITY_B] can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity.",4,0
[ENTITY_A] stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and [ENTITY_B] requiring functional type II TGF-beta receptors in human umbilical vein endothelium.,0,0
"CONCLUSION: In postmenopausal women, isolated [ENTITY_A] treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating [ENTITY_B] level, which could provide beneficial vascular effects.",0,0
"Moreover, [ENTITY_A] treatment restored membranous expression of adhesion molecules [ENTITY_B] and β-catenin.",0,0
"Both [ENTITY_A] and SAL produced a significant increase in postural finger tremor in keeping with [ENTITY_B] stimulation, and this response was totally abolished by pretreatment with N20.",0,0
TSH and [ENTITY_A] also increase the levels of the specific mRNA for [ENTITY_B] in thyroid cells from different species.,0,0
"The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective [ENTITY_A] antagonist, [ENTITY_B].",3,0
"[ENTITY_A] [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible [ENTITY_B] (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.",1,0
"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of [ENTITY_A], a [ENTITY_B] agonist (pA2 value of 7.04).",2,0
Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the [ENTITY_A] inhibitor [ENTITY_B].,1,0
"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective [ENTITY_A] agonist [ENTITY_B] 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",2,0
"At PND35, the medial prefrontal cortex (mPFC) of rats given [ENTITY_A] showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less [ENTITY_B] (NET)-ir density.",1,0
"Iontophoresis of [ENTITY_A], whose serotonergic actions include antagonism and partial agonism at [ENTITY_B] receptors, also increased serotonin and decreased firing (n=4).",2,0
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective [ENTITY_A] agonist-[ENTITY_B] [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",2,0
The current study evaluates the effects of a selective [ENTITY_A] inhibitor ([ENTITY_B]) on renal function in cirrhotic rats with ascites.,1,0
"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-[ENTITY_A] environment enhanced [ENTITY_B] production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.",0,0
The work of Chen and colleagues shows that [ENTITY_A] is a particularly potent inhibitor of [ENTITY_B] and that the compound also targets Src kinase.,1,0
"Inhibition of [ENTITY_A] or [3H]NE uptake by DVS for the [ENTITY_B] or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.",4,0
[ENTITY_A] increased [ENTITY_B] Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC.,0,0
[ENTITY_A] is synthesized from arachidonic acid by [ENTITY_B] (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).,4,0
"Competitive radioligand binding assays were performed using cells expressing either the [ENTITY_A] (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for [ENTITY_B] of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.",1,0
Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of [ENTITY_A] as [ENTITY_B] agonists.,2,0
"Blood pressure was increased in rats exposed to IH, and treatment with the [ENTITY_A] inhibitor [ENTITY_B] [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats.",1,0
[ENTITY_A] promotes the nuclear translocation of β-catenin and thereby induces [ENTITY_B] gene expression in osteoblast-like cell lines.,0,0
"Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with [ENTITY_A], a D1-like receptor agonist, inhibited the stimulatory effect of [ENTITY_B].",1,0
"Lumiracoxib is the first example of a marketed [ENTITY_A] inhibitor of the [ENTITY_B] class, and it is reported to be the most selective COXIB in vivo.",1,0
The production of [ENTITY_A] in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet [ENTITY_B] activity.,4,0
[ENTITY_A] (BAT) is responsible for the amidation of [ENTITY_B] with the amino acids glycine and taurine.,4,0
"In the hippocampus, [ENTITY_A] acted as a full agonist at [ENTITY_B] receptors on pyramidal neurons.",2,0
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine [ENTITY_A] blocker [ENTITY_B] and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.",1,0
[ENTITY_A]-facilitated [ENTITY_B] efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.,4,0
"However, the flowcytometric analysis revealed that [ENTITY_A] and PCA decreased intracellular contents of [ENTITY_B] in these cells in dose dependent manner.",1,0
"Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by [ENTITY_A] reduced the elevation of all assayed [ENTITY_B].",1,0
"In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble [ENTITY_A] (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of [ENTITY_B] activity.",1,0
"[ENTITY_A] activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the [ENTITY_B] (TZD) rosiglitazone.",0,0
"Furthermore, we detected that [ENTITY_A] treatment induced [ENTITY_B] (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.",0,0
"[ENTITY_A], which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize [ENTITY_B], budesonide, and fluticasone propionate.",4,0
[ENTITY_A]: mode of action and properties of the [ENTITY_B] inhibition.,1,0
[ENTITY_A] CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive [ENTITY_B] inhibitors.,1,0
"To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the [ENTITY_A] (GluR5)/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist [ENTITY_B] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.",3,0
"In summary, [ENTITY_A] is able to reduce basal and [ENTITY_B]-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.",1,0
Leukotriene A(4) hydrolase ([ENTITY_A]) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to [ENTITY_B].,4,0
"Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of [ENTITY_A] are inhibited by the green tea polyphenols, [ENTITY_B] and epicatechin gallate.",1,0
SK-Br3 cells cultured in the presence of [ENTITY_A] (TOP2A) inhibitors [ENTITY_B] and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.,1,0
"Increases in [ENTITY_A] concentration from 0 to 3 and from 3 to 17 mM inhibited [ENTITY_B] activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells.",1,0
"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from [ENTITY_A] to GlcNAc ([ENTITY_B] activity), albeit at only 0.3% efficiency.",4,0
"[3H]DMI trapped in membranes was displaceable by the structurally unrelated [ENTITY_A] inhibitor, [ENTITY_B], in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.",1,0
"In the present study, [ENTITY_A]-stimulated [ENTITY_B] secretion was significantly increased in GalN-treated rats compared to controls.",0,0
"High [ENTITY_A] (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates [ENTITY_B].",0,0
In vitro inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens.,1,0
"However, phosphorylation of the [ENTITY_A]/RelA subunit was clearly inhibited by [ENTITY_B] in stimulated cells.",1,0
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ([ENTITY_A]) is inhibited by [ENTITY_B], at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).",1,0
"Firstly, the V(max) of [ENTITY_A] was increased when ApoCaM was present whereas the affinity for the substrate, [ENTITY_B], was not affected.",4,0
[ENTITY_A] as Novel Zinc Binding Group for Selective [ENTITY_B] Inhibition.,1,0
"CONCLUSIONS AND IMPLICATIONS: [ENTITY_A] analogues with better [ENTITY_B] channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.",1,0
[ENTITY_A] and aspirin also inhibited [ENTITY_B]-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.,1,0
"Because [ENTITY_A] (24-OHC), produced by [ENTITY_B], induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.",4,0
PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual [ENTITY_A] antagonist [ENTITY_B].,3,0
"The high affinity [ENTITY_A] receptor agonist, [ENTITY_B] (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.",2,0
[ENTITY_A] promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of [ENTITY_B].,1,0
"[ENTITY_A] secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by [ENTITY_B] (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.",1,0
"Currently, the most important insecticides are [ENTITY_A], which are metabolized in vitro by [ENTITY_B] on reduction of the nitroimino group and by CYPs via oxidation reactions.",4,0
Levels of [ENTITY_A] protein were also decreased in a dose- and time-dependent manner following [ENTITY_B] treatment.,1,0
[ENTITY_A]-induced intracellular GTP depletion activates transcription elongation in [ENTITY_B] gene expression.,0,0
"Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas [ENTITY_A] and GPx1b2 were highly induced by exposure to [ENTITY_B] levels that had some toxic effects on the cells.",0,0
The mechanism by which [ENTITY_A] (NE) down-regulates [ENTITY_B] (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.,1,0
"Ginseng total [ENTITY_A], ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma [ENTITY_B] level.",1,0
"In addition, another study suggests that [ENTITY_A] reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate [ENTITY_B] formation by direct inhibition of the gamma-secretase complex.",0,0
"Incubation with [ENTITY_A] (0.2-1 mM) activated [ENTITY_B] in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.",0,0
"This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of [ENTITY_A](+) CTLs were induced by 2.5 microg/ml [corrected] [ENTITY_B].",0,0
"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased [ENTITY_A] immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in [ENTITY_B] injected rat.",1,0
"Inhibition of cyclic AMP production by ergovaline was blocked by the [ENTITY_A] antagonist, [ENTITY_B] (IC50, 300 +/- 150 nM).",3,0
"Conversely, opioid antagonists such as [ENTITY_A] and naltrexone (which bind to non-selectively [ENTITY_B]) have been shown to decrease alcohol consumption under various experimental conditions.",3,0
"Reactivators showed different activity in the reactivation of [ENTITY_A] after [ENTITY_B], paraoxon and tabun inhibition.",1,0
"Nevertheless, 3 mM [ENTITY_A], a higher concentration that inhibits [ENTITY_B], NHE2, and NHE3, significantly increased DBS.",1,0
[ENTITY_A] (DDAH) metabolizes asymmetric dimethylarginine to generate [ENTITY_B] and is present in large quantities in the kidney.,4,0
"However, CYP2B4 is not an inhibitor of [ENTITY_A]-mediated [ENTITY_B] hydroxylation.",4,0
"Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon [ENTITY_A] hydrolysis release the corresponding [ENTITY_B].",4,0
This shift in conformational population at higher [ENTITY_A] ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the [ENTITY_B] pocket.,1,0
"Moreover, [ENTITY_A] concentration-dependently inhibited the expression of [ENTITY_B] and induced the expression of CD40 on monocytes.",1,0
We thus conclude that the more potent [ENTITY_A] inhibition of smooth muscle versus [ENTITY_B] is not attributable to differences in channel inactivation or activation.,1,0
In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant [ENTITY_A]--potent inhibition by [ENTITY_B].,1,0
"The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ([ENTITY_A]) is inhibited by Cl-, at physiological concentrations, and stimulated by [ENTITY_B] (EACA), as well as fibrin(ogen).",0,0
"Taken together, the data provide evidence that the synergistic antiproliferative effect of [ENTITY_A] and clofarabine is linked to the inhibition of [ENTITY_B] and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.",1,0
BACKGROUND: The active metabolite of the anti-inflammatory drug [ENTITY_A] has been characterized as a selective inhibitor of the inducible [ENTITY_B] (PGHS).,1,0
[ENTITY_A]: Synthetic Methodologies and Pharmaceutical Applications as [ENTITY_B] Inhibitors.,1,0
This reduction in [ENTITY_A] is biologically relevant since [ENTITY_B] treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.,1,0
"Here, we report that the antifibrotic drug [ENTITY_A] (pirfenidone, PFD) elicits growth-inhibitory effects and reduces [ENTITY_B] protein levels in human glioma cell lines.",1,0
"Efficacy and safety of the [ENTITY_A] inhibitor, [ENTITY_B], in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.",1,0
"To eliminate the interaction of [ENTITY_A] with [ENTITY_B] or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer.",1,0
"The potency of the antipsychotic drug, [ENTITY_A], to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and [ENTITY_B]-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.",3,0
The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of [ENTITY_A] on [ENTITY_B] activation.,1,0
"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the [ENTITY_A] neutral antagonist [ENTITY_B] were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.",3,0
[ENTITY_A] and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of [ENTITY_B].,4,0
"[ENTITY_A] reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased [ENTITY_B], but had no effect on that of COX-1, in MCF-7 and HL-60.",0,0
"The data indicated that [ENTITY_A] could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of [ENTITY_B], which may play a role in the pathogenesis of PhIP-associated stomach cancer.",1,0
[ENTITY_A] attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of [ENTITY_B]/AMP-activated protein kinase-dependent signalling.,0,0
"[ENTITY_A] and EP(3) receptor antagonists [ENTITY_B] and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",3,0
"Under these conditions, blockade of [ENTITY_A] with [ENTITY_B] (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.",1,0
"The ratio between the GDC/[ENTITY_A] and C1-THF synthase/SHMT pathways of [ENTITY_B] synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.",4,0
"[ENTITY_A] (""Iressa""), a quinazoline [ENTITY_B] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",1,0
"The involvement of [ENTITY_A] and EP2 receptors is indicated by studies with the EP1 selective agonist [ENTITY_B], and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",2,0
"Amongst the three [ENTITY_A] expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [ENTITY_B] release.",4,0
[ENTITY_A]-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and [ENTITY_B]-mediated activation of the intrinsic apoptotic pathway.,0,0
Inhibition of [ENTITY_A] and MIP-2 transcription and translation by [ENTITY_B] in muscle tissue infected with the parasite Trichinella spiralis.,1,0
"The TXM peptides were effective in inhibiting [ENTITY_A]-induced [ENTITY_B], JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.",0,0
"[ENTITY_A] (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex [ENTITY_B] and gametes.",4,0
"Here, we report biochemical evidence that [ENTITY_A] alone induces [ENTITY_B] activation, resulting in the induced expression of COX-2 and iNOS.",0,0
"[ENTITY_A] inhibits [ENTITY_B] and HDAC 8 with an IC50 of 681 and 3675 nM, respectively.",1,0
"[ENTITY_A] exposure (20 mg/kg) increased [ENTITY_B](MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.",0,0
"The tissue RA level is maintained through a cascade of metabolic reactions where [ENTITY_A] (RALDHs) catalyze the terminal reaction of [ENTITY_B] biosynthesis from retinal, a rate-limiting step.",4,0
"Among the measured compounds, [ENTITY_A] and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit [ENTITY_B] agonistic activity at concentrations comparable with those reached under pharmacological treatment.",2,0
We propose that inhibition of [ENTITY_A] expression by [ENTITY_B] can impede with neoplastic progression in colorectal carcinogenesis.,1,0
"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the [ENTITY_A] antagonists [ENTITY_B] and W13.",3,0
Selective inhibition of [ENTITY_A] spares renal function and [ENTITY_B] synthesis in cirrhotic rats with ascites.,4,0
We discovered that each RSPO alone or in combination partially rescues [ENTITY_A] inhibition of both canonical [ENTITY_B] signaling and prostatic bud formation.,1,0
"Besides, [ENTITY_A] not only synergized [ENTITY_B] production combined with IFN-γ, but also prolonged its expression in time.",0,0
"To determine whether [ENTITY_A] (MDMA)-induced reductions in [ENTITY_B] density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.",1,0
Inhibition studies revealed that the [ENTITY_A] (ABCCs) are involved in the transport of [ENTITY_B] conjugates.,4,0
Crystallographic analysis of the [ENTITY_A] with bound [ENTITY_B] inhibitors at 2.0 A resolution.,1,0
"Synthesis, molecular modeling and evaluation of novel [ENTITY_A] derivatives as dual inhibitors for [ENTITY_B] and Aβ aggregation.",1,0
"Moreover, kinetic analysis revealed that inhibition by [ENTITY_A], a typical [ENTITY_B] inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine.",1,0
"Interestingly, [ENTITY_A] expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with [ENTITY_B] clearance ratio (Ccr) and MMP-9 protein.",1,0
Further study revealed that [ENTITY_A] increased [ENTITY_B] mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.,0,0
"Results showed that DMF increased nuclear levels of Nrf2, and both [ENTITY_A] and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased [ENTITY_B], alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).",1,0
"[ENTITY_A] mediates cardiostimulation by activation of the 'putative' [ENTITY_B]; however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect.",0,0
Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or [ENTITY_A] (selective [ENTITY_B] inhibitor) against chemical kindling in mice.,1,0
"Finally, [ENTITY_A] inhibitor methyl [ENTITY_B] blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.",1,0
"In addition, [ENTITY_A]-mediated inhibition of AR prevented LPS-induced activation of [ENTITY_B] and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis.",1,0
"[ENTITY_A] (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin [ENTITY_B]/MT(2) receptor agonist.",2,0
The [ENTITY_A] inhibitor [ENTITY_B] prolonged the normally transient effect of NE for at least 24 h.,1,0
"Thus, the current study suggests that coadministration of clinical doses of [ENTITY_A] and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [ENTITY_B]-catalyzed metabolism of haloperidol and reduced haloperidol.",1,0
UNLABELLED: [ENTITY_A] is a [ENTITY_B] antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.,3,0
"A role of cytosolic [ENTITY_A] in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of [ENTITY_B] was established.",4,0
The [ENTITY_A] represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular [ENTITY_B].,4,0
"[ENTITY_A] is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of [ENTITY_B] superfamily.",0,0
"Oxytocin antagonist (OTA), [ENTITY_A], was developed by our group and shown to inhibit either spontaneous or [ENTITY_B]-induced uterine contractions in primates.",1,0
[ENTITY_A] is the first [ENTITY_B] selective ERA approved for use in the US.,3,0
"Incretin-receptor activation leads to [ENTITY_A]-dependent [ENTITY_B] secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis.",0,0
"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of [ENTITY_A] in RBL cells at the [ENTITY_B] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",4,0
The principal aim of the study was to find [ENTITY_A] analogues that retained [ENTITY_B] inhibition but with reduced cytotoxicity.,1,0
"Inhibitory effects of the [ENTITY_A] inhibitor [ENTITY_B] on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.",1,0
[ENTITY_A] directly inhibits [ENTITY_B] secretion through AMP-activated protein kinase in rat primary gastric cells.,1,0
"When HUVECs were stimulated by thrombin without extracellular L-arginine, [ENTITY_A] dose-dependently increased the [ENTITY_B] activity and the NO release with maximal effects at 20 microM.",0,0
These results confirm the selective mGlu2 agonist and [ENTITY_A] antagonist actions of [ENTITY_B].,3,0
Mechanisms of Glucose Lowering of [ENTITY_A] Inhibitor [ENTITY_B] When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.,1,0
Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in [ENTITY_A] activity induced by [ENTITY_B].,1,0
"Here, we demonstrate that [ENTITY_A] (Pin1), an enzyme that catalyzes the conversion of the peptide bond of [ENTITY_B]/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",4,0
"Although [ENTITY_A] inhibition by [ENTITY_B] occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations.",1,0
"Further study showed that [ENTITY_A] dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory [ENTITY_B] levels of activated T cells.",1,0
These results suggest that [ENTITY_A] plays a pivotal role in the transport and toxicity of [ENTITY_B] and Mn(2+) in RBL-2H3 cells.,4,0
"A PKC or MAP kinase inhibitor blocked the inhibitory effect of [ENTITY_A] on [ENTITY_B] expression, indicating that PKC and MAP kinase were involved in the signaling pathway.",1,0
[ENTITY_A] exerts antitumor activity against human osteosarcoma cells by inhibiting the [ENTITY_B]/STAT3 signaling pathway.,1,0
"We observed that the administration of [ENTITY_A] at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of [ENTITY_B] phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.",1,0
"In addition, another study suggests that [ENTITY_A] reduces generation of [ENTITY_B] peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.",1,0
"In the present study, we compared the pharmacology of [ENTITY_A], WAY-100635 (a [ENTITY_B] antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",3,0
[ENTITY_A]-induced cyclooxygenase-2 (COX-2) expression and [ENTITY_B] (NF-κB) activation was reduced by CK treatment.,0,0
2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of [ENTITY_A] (HFC) for several [ENTITY_B].,4,0
The difference in structure of [ENTITY_A] did not account for its inhibitory effect on [ENTITY_B] because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs.,1,0
"The drug had a potent cytotoxic effect on RIN cells expressing [ENTITY_A], but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood [ENTITY_B] levels of treated animals.",4,0
The anti-inflammatory actions of [ENTITY_A] on colitis may involve inhibition of the TLR4/NF-κB signaling pathway and of [ENTITY_B] expression.,1,0
"We present our studies to demonstrate that HM74A, but not HM74, binds [ENTITY_A] at high affinities and effectively mediates [ENTITY_B] signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.",0,0
"[ENTITY_A] has greater selectivity for [ENTITY_B] than celecoxib, meloxicam, diclofenac and indomethacin.",1,0
Conformational variations of both [ENTITY_A] and inhibitors provide the structural basis for the physiological effects of vardenafil and [ENTITY_B].,1,0
"Particularly, the effects of [ENTITY_A] used as a non selective [ENTITY_B] inhibitor in experimental and clinical studies will be discussed.",1,0
"The protein exhibited modest H(2)O(2)-dependent [ENTITY_A] activities with [ENTITY_B], potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).",4,0
"Moreover, [ENTITY_A] (0.1-0.5 mg/kg, IP), a lipophilic [ENTITY_B] agonist, significantly increased the duration of basal aggressive behavior.",2,0
The expression of [ENTITY_A] is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by [ENTITY_B] administration in vivo.,1,0
"[ENTITY_A] inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of [ENTITY_B] via a mechanism that is not dependent on either NO or soluble guanylate cyclase.",1,0
[ENTITY_A] level in plasma and mesenteric arteries in imidapril group was significantly lower than that in [ENTITY_B] group (P<0.05).,0,0
Oral [ENTITY_A] (as a representative of the salicylate family) inhibited diabetes-induced increase in [ENTITY_B] DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.,1,0
"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed [ENTITY_A] and 5-HT2 receptor antagonist [ENTITY_B] (0.01-1 microM).",3,0
"[ENTITY_A] is inhibitory of [ENTITY_B] at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.",1,0
"When expressed heterologously in a mammalian cell line, [ENTITY_A] mediates pH-dependent, Na(+)-independent uptake of [ENTITY_B], glycine, l-alanine and alpha-(methylamino)isobutyric acid.",4,0
"Epididymal tissue from wild-type mice responded in vitro to [ENTITY_A] and isoprenaline with increased glycerol release, reduced [ENTITY_B] release, and increased cAMP accumulation.",1,0
"However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma [ENTITY_A] activity were only significantly higher in [ENTITY_B] group after 8 weeks.",0,0
"[ENTITY_A] suppressed [ENTITY_B] gene transcription enhanced by PTH(1-34) without affecting ΔFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with ΔFosB.",1,0
[ENTITY_A]-stimulated processing of [ENTITY_B] is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.,0,0
[ENTITY_A] (ALDH1A1) catalyzes the oxidation of toxic aldehydes to [ENTITY_B].,4,0
[ENTITY_A]: a novel [ENTITY_B] antagonist for the treatment of cardiovascular disease.,3,0
"Here, we report that [ENTITY_A] at physiologically relevant concentrations (0.1-10 μM) significantly inhibited [ENTITY_B]-induced increase in endothelial monolayer permeability.",1,0
"[ENTITY_A] (HDC) catalyses the formation of histamine, a bioactive [ENTITY_B].",4,0
"In view of its substantial [ENTITY_A] inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for [ENTITY_B].",1,0
"Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than [ENTITY_A], a compound that blocks [ENTITY_B].",1,0
"One possible explanation is that, in our model, [ENTITY_A] in contrast to CGP 38560A and enalkiren is able to inhibit [ENTITY_B] in a functionally important extraplasmatic compartment.",1,0
Long-term administration of [ENTITY_A] to rats increased the activities of antioxidative enzymes [ENTITY_B] (SOD) and catalase in the brain regions containing dopamine neurons.,0,0
"The increase in [ENTITY_A] expression is specific to [ENTITY_B]-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin.",0,0
"We also investigated the epigenetic status of NIS promoter after [ENTITY_A] treatment in TPC1 cell line: in addition to an increase of [ENTITY_B] (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.",0,0
"Preclinical efficacy of [ENTITY_A], a potent, selective [ENTITY_B] antagonist for topical ocular use.",3,0
[ENTITY_A] decreases levels of serum triglycerides and causes some increase in [ENTITY_B]-cholesterol levels.,0,0
"OBJECTIVE: [ENTITY_A], an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of [ENTITY_B] (PPARgamma).",2,0
"(-)-Isoprenaline and a nonconventional [ENTITY_A] agonist, [ENTITY_B] ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.",2,0
[ENTITY_A] block of [ENTITY_B] and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.,1,0
"[ENTITY_A] treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-γ and GLUT-4; however, there was a significant increase in the mRNA expression of [ENTITY_B].",0,0
"[ENTITY_A], a [ENTITY_B] antagonist for the mobilization of hematopoietic stem cells.",3,0
The histamine H2 receptor antagonist [ENTITY_A] blocked the [ENTITY_B]-HIS binding on 14-37% of the platelets.,1,0
"To further investigate this positive correlation and its possible therapeutic implications, a selective [ENTITY_A] inhibitor, [ENTITY_B], was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels.",1,0
"When the anti-corticosterone drug [ENTITY_A] (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and [ENTITY_B] mRNA expression were decreased at 14 days after tumor inoculation.",1,0
"[ENTITY_A] (DHPs) block [ENTITY_B] more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.",1,0
"[ENTITY_A] and lovastatin metabolized through [ENTITY_B] have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.",4,0
"Hypermethlyation of [ENTITY_A] can be induced by treating mice with [ENTITY_B], and these mice display brain and behavioral abnormalities similar to +/rl.",0,0
"[ENTITY_A] (BGG), a recently described [ENTITY_B] inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).",1,0
"Activity of the mutant [ENTITY_A] protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of [ENTITY_B], consistent with the clinical response of the patient to pyridoxine treatment.",0,0
"We found that, before apoptosis, [ENTITY_A] induces [ENTITY_B] and TAp73 expression in the oocyte.",0,0
"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of [ENTITY_A] (Viagra, Pfizer) - the first approved selective [ENTITY_B] inhibitor for the treatment of ED.",1,0
"Present studies demonstrate that [ENTITY_A] will also catalyze [ENTITY_B] production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.",4,0
"All three [ENTITY_A] inhibited the diabetes-induced translocation of [ENTITY_B] (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.",1,0
Inhibition of [ENTITY_A] provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of [ENTITY_B]-treated cells [6] [7] [8].,1,0
[ENTITY_A] increased calpain expression and [ENTITY_B] activity and promoted Bid cleavage.,0,0
"[ENTITY_A] (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, [ENTITY_B], and glycinamide ribonucleotide formyl transferase.",1,0
"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the [ENTITY_A] antagonist [ENTITY_B], but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",3,0
"A large number of [ENTITY_A] and some 5-mercapto-1,3,4-thiadiazoles were investigated as [ENTITY_B] inhibitors.",1,0
"However, when coapplied with 10 micro m GABA, [ENTITY_A] potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the [ENTITY_B]/HG1E receptor.",1,0
"[ENTITY_A] decreased the expression of the [ENTITY_B], SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate.",1,0
"[ENTITY_A] (1.25-5 mg/kg, IP), a selective [ENTITY_B] antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.",3,0
"Moreover, use of the pharmacological [ENTITY_A] (AMPK) inhibitor [ENTITY_B] revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.",1,0
The [ENTITY_A] analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting [ENTITY_B].,1,0
Transduction with constitutively active forms of GSK-3β could protect against the downregulation of [ENTITY_A] and upregulation of cleaved-PARP that are induced by [ENTITY_B] treatment.,1,0
"Finally, the three drugs were compared with the [ENTITY_A] inhibitor [ENTITY_B].",1,0
These findings indicate that captopril attenuates the development of [ENTITY_A]-induced right ventricular hypertrophy in association with inhibition of [ENTITY_B] and MMP-9 in rats.,0,0
[ENTITY_A] Inhibitors Based on the [ENTITY_B] Core.,1,0
"Administration of [ENTITY_A] (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the [ENTITY_B] protein level reduced by CTD.",0,0
"We topically applied the nitric oxide synthase ([ENTITY_A]) inhibitor, [ENTITY_B], on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet.",1,0
"Elucidation of the novel molecular mechanisms linking [ENTITY_A] to [ENTITY_B] inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.",1,0
The distribution pattern of [ENTITY_A] induced by [ENTITY_B] was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.,0,0
"However, a lower concentration of [ENTITY_A] (3 microM) that blocks [ENTITY_B], PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity.",1,0
[ENTITY_A] also abolished the developmental rise of the [ENTITY_B] subunit mRNAs during the two periods of the study.,1,0
"In vitro studies, however, revealed that [ENTITY_A] inhibits [ENTITY_B] clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro.",1,0
[ENTITY_A] represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating [ENTITY_B] in endometrial carcinoma cell lines.,0,0
"These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to [ENTITY_A] and endogenous clonidine-displacing substance(s), and may serve as markers of [ENTITY_B] in humans.",0,0
The observation that [ENTITY_A]-transformed cells can be sensitized to killing by ionizing radiation with [ENTITY_B] demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.,1,0
"When treated with TAM, ECC-1 and Ishikawa cells were characterized by higher invasiveness and motility and underwent EMT. [ENTITY_A], a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to [ENTITY_B] treatment.",1,0
"Notably, [ENTITY_A] treatment reduced adipose tissue expression of inflammatory cytokines, increased [ENTITY_B] expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.",0,0
"In contrast, [ENTITY_A] was only metabolized via [ENTITY_B], with no significant turnover by CYP3A5 or CYP3A7.",4,0
UNLABELLED: [ENTITY_A] is a potent and specific peripheral [ENTITY_B] (COMT) inhibitor.,1,0
Our study demonstrated that [ENTITY_A] inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased [ENTITY_B] level in bronchoalveolar lavage fluid.,0,0
"[ENTITY_A] is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the [ENTITY_B] fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.",1,0
"The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by [ENTITY_A], a [ENTITY_B] antagonist.",3,0
"Additionally, the mRNA levels of melanogenesis-related genes ([ENTITY_A], stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by [ENTITY_B].",1,0
"Finally, we showed that [ENTITY_A] activated endocrine cell development by inducing [ENTITY_B] (Neurog3) expression in early endocrine progenitor cells.",0,0
"The [ENTITY_A] (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings [ENTITY_B] into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.",4,0
"[ENTITY_A], a weak [ENTITY_B] antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.",3,0
"[ENTITY_A] (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by [ENTITY_B], including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.",1,0
"The potential for [ENTITY_A], the archetypal strong inhibitor of [ENTITY_B], to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men.",1,0
"Finally, the amounts of [ENTITY_A] and cAspAT mRNAs were similarly increased by [ENTITY_B] treatment of human adipose tissue explants, confirming coordinated regulation.",0,0
"In addition several ligands known to act as agonists at either [ENTITY_A] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), [ENTITY_B], MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",2,0
"[ENTITY_A] (deprenyl), a selective, irreversible inhibitor of [ENTITY_B] (MAO-B) is widely used in the treatment of Parkinson's disease.",1,0
"The recent development of [ENTITY_A] antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of [ENTITY_B] in this condition.",2,0
Metabolism of [ENTITY_A] by [ENTITY_B] Enzymes.,4,0
"An [ENTITY_A] antagonist, [ENTITY_B] augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.",3,0
"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) [ENTITY_A] at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and [ENTITY_B] expression relative to control.",0,0
"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), [ENTITY_A] (TNF-α), nuclear factor kappa B (NF-κB) genes expression in [ENTITY_B] injected rats.",1,0
"By contrast, [ENTITY_A] plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to [ENTITY_B]) to prevent activation of the mineralocorticoid receptor (MR) by cortisol.",4,0
This action can be related to the ability of [ENTITY_A] to block the increase of [Ca(2+)](i) induced by [ENTITY_B] in VSMCs.,1,0
Time-dependent changes in hepatic and intestinal induction of [ENTITY_A] after administration of [ENTITY_B] to rats.,0,0
"In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that [ENTITY_A] produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic [ENTITY_B] receptor.",3,0
"These profiles suggest a mechanism of action for each agent, [ENTITY_A] agonism for [ENTITY_B] and alpha 1 antagonism for clozapine and olanzapine.",2,0
"Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked [ENTITY_A] induction of [ENTITY_B] in the striatum.",0,0
Protein levels of the [ENTITY_A] (GLUT4) involved in [ENTITY_B] transport via these two pathways were also increased.,4,0
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by [ENTITY_A] and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in [ENTITY_B] and cdk2 kinase activities.,0,0
"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers [ENTITY_A] blocked [ENTITY_B] production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.",1,0
"Although only [ENTITY_A] and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined [ENTITY_B] and D(2) blockade.",1,0
"Diclofenac-β-d-glucuronide, [ENTITY_A], ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited [ENTITY_B], with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2.",1,0
[ENTITY_A] plus a [ENTITY_B] inhibitor completely abolished AMD/TNF-induced cytotoxicity.,1,0
"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme [ENTITY_A], as compared to the standard tyrosinase inhibitors [ENTITY_B] (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.",1,0
Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with [ENTITY_A]-RANTES (an antagonist of [ENTITY_B] and CCR1).,3,0
The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of [ENTITY_A] (10(-7) mol/L) was blocked by [ENTITY_B] (IC(50)=0.5+/-0.3 nmol/L).,1,0
"The group treated with [ENTITY_A] alone showed decreased plasma [ENTITY_B] (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.",1,0
"There was a dose-dependent decrease in plasma renin activity, [ENTITY_A], and Ang II following single doses of [ENTITY_B] starting with 40 mg.",1,0
"In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of [ENTITY_A] soaked with the reversible inhibitor [ENTITY_B], using a total X-ray exposure time of 24 ms.",1,0
"In medial striatum, [ENTITY_A]-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in [ENTITY_B]-exposed rats.",1,0
[ENTITY_A] (CA) is a zinc enzyme that catalyses the reversible hydration reaction of [ENTITY_B] and plays a major role in the acid-base balance.,4,0
"We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased [ENTITY_A] activity and immunoreactivity for the protein nitration marker [ENTITY_B] in the cerebral cortex.",0,0
The [ENTITY_A] Allele Significantly Alters the N-demethylation of [ENTITY_B] Enantiomers In Vitro.,4,0
"[ENTITY_A] inhibitors, such as [ENTITY_B], are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.",1,0
The parent [ENTITY_A] of this compound inhibits [ENTITY_B] with an IC50 value of 0.028 nM in the same assay.,1,0
The chemical identity and position of the substituents on the lower [ENTITY_A] ring were important in determining the potency and extent of [ENTITY_B] inhibition as well as COX-2 selectivity.,1,0
"[ENTITY_A] induces [ENTITY_B] transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-α) is the most important for single-agent tumor activity.",0,0
"[ENTITY_A] (PtdSer) is made in mammalian cells by two [ENTITY_B], PSS1 and PSS2.",4,0
"In conclusion, [ENTITY_A] can transport copper and [ENTITY_B] drugs, and sensitizes cells to their cytotoxicities.",4,0
"Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme [ENTITY_A] (BChE), which is capable of breaking down naturally occurring [ENTITY_B] before the drug can influence the reward centers of the brain or affect other areas of the body.",4,0
"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), [ENTITY_A] 5 mg (B5) as a selective [ENTITY_B] antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",3,0
[ENTITY_A] significantly inhibited the levels of ERK1/2 kinase and increased the expression of [ENTITY_B] and p38 kinases.,0,0
Determinants of voltage-dependent inactivation affect [ENTITY_A] block of [ENTITY_B].,1,0
"Mitiglinide ([ENTITY_A]), a new anti-diabetic drug, is thought to stimulate [ENTITY_B] secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells.",0,0
Cu-dependent [ENTITY_A] activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate [ENTITY_B].,4,0
"In both vascular preparations, [ENTITY_A] caused a marked decrease in the maximal contractile response of the [ENTITY_B] (Ang II) concentration-response curve.",1,0
"[ENTITY_A] (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo [ENTITY_B] synthesis, respectively.",4,0
"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that [ENTITY_A] is also a [ENTITY_B] antagonist, consistent with our previous in vitro studies.",3,0
Reversal of inhibition by [ENTITY_A] agonist quinpirole was produced by serotonin (50 µM) and by [ENTITY_B] (5-10 nM).,0,0
"Such organization results in the local activation of [ENTITY_A] subsets through the generation of confined intracellular gradients of [ENTITY_B], but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified.",0,0
Activation of [ENTITY_A] using [ENTITY_B] resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.,0,0
"The data indicated that [ENTITY_A] could cause stomach injury, oxidative stress in rat stomachs as well as the activation of [ENTITY_B] and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.",0,0
"Our data identify [ENTITY_A] as a new member of glyceroneogenesis, transcriptionally regulated by [ENTITY_B] via the control of RORalpha expression by PPARgamma in adipocytes.",0,0
"Cells were also evaluated in the presence of [ENTITY_A], an inhibitor of phosphatidylinositol 3-kinases and thus [ENTITY_B] (0-100 nM).",1,0
These studies provide compelling evidence that the antitussive effects of [ENTITY_A] in this guinea pig cough model are mediated by agonist activity at the [ENTITY_B].,2,0
"Both the [ENTITY_A] inhibitor [ENTITY_B] and alpha 1-adrenoceptor antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",1,0
Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and [ENTITY_A] reverse lactation-induced downregulation of the [ENTITY_B] gene.,0,0
"In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-[ENTITY_A] (Px) was able to prevent inhibition of circulating [ENTITY_B] in a dose-dependent manner.",0,0
"[ENTITY_A] (PDE5) contains a catalytic domain (C domain) that hydrolyzes [ENTITY_B] and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).",4,0
The purified [ENTITY_A] has a specific activity of 498 micromol of [ENTITY_B] cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.,4,0
Number and area of preneoplastic foci positive for [ENTITY_A] (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with [ENTITY_B] or HCB alone.,0,0
[ENTITY_A] plays a role in purine salvage by catalyzing the direct conversion of adenine to [ENTITY_B].,4,0
"Moreover, [ENTITY_A]-induced increases in [ENTITY_B] and NF-κB p65 in the brain were also attenuated by pranlukast.",0,0
These results suggest that [ENTITY_A] actively eliminates [ENTITY_B] in the presence of HDL as a lipid acceptor and protects neuronal cells.,4,0
Rectal mucosal samples from patients given [ENTITY_A] had reduced phosphorylation of [ENTITY_B] and S6.,1,0
The inhibitory effect of the leukotriene receptor antagonist on [ENTITY_A]-induced MUC2/5AC gene expression and [ENTITY_B] secretion in human airway epithelial cells.,0,0
"[ENTITY_A] Derivatives as Novel [ENTITY_B] Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor.",1,0
"[ENTITY_A] deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of [ENTITY_B], Keap1, and LC3.",1,0
"β-Amyloid aggregation results showed that all compounds exhibited remarkable [ENTITY_A] fibril aggregation inhibition activity with a nearly similar potential as the reference compound [ENTITY_B], which makes them promising anti-Alzheimer drug candidates.",1,0
The failure of the myometrium to respond to [ENTITY_A] (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and [ENTITY_B] concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls.,1,0
"We have examined the effectiveness of two novel [ENTITY_A] selective inhibitors, [ENTITY_B] and AR678, in a panel of melanoma cell lines and normal cell types.",1,0
"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two [ENTITY_A] resistant GIST patients demonstrated that [ENTITY_B] is downregulated implying a major role in IM resistance.",1,0
"When the growth condition was shifted from aerobic to anaerobic, the increased level of [ENTITY_A] in [ENTITY_B] disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed.",4,0
"By contrast, [ENTITY_A](SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [ENTITY_B] in HEPG2 cells and in wild-type primary hepatocytes.",4,0
The functional inhibitory characteristics of the [ENTITY_A] blockers (ARB) candesartan; [ENTITY_B]; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.,1,0
"N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase ([ENTITY_A]) inhibitor ([ENTITY_B], 33 μM) further decreased the viability in the presence of DEP (200 μg/ml) and 3.3% FCS.",1,0
"Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with [ENTITY_A] inhibition requiring 20- to 30-fold higher [ENTITY_B] concentrations.",1,0
"In addition, [ENTITY_A] inhibited the transcriptional activity of [ENTITY_B] without interfering with the calcium-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation.",1,0
We hypothesized that the [ENTITY_A] compounds would be most potent at the [ENTITY_B] (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.,1,0
"Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, [ENTITY_A], dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [ENTITY_B] inhibitory activity, with inhibition constants of 0.8-79 nM.",1,0
"A novel potent compound, [ENTITY_A] (12c), which binds [ENTITY_B] with an IC(50) value of 54 nM was obtained.",1,0
"[ENTITY_A] derived from Zingiber officinale Roscoe (ginger) was identified as a novel [ENTITY_B] antagonist, with an IC50 value of 8.173 µM.",3,0
"The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on [ENTITY_A] activity by measuring adenosine triphosphate-dependent [ENTITY_B] uptake into synaptic vesicles prepared from rat striatum.",4,0
"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that [ENTITY_A] markedly inhibits CSF [ENTITY_B] after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.",1,0
"Existing [ENTITY_A] blockers, such as amiodarone, dronedarone, bepridil, aprindine, and [ENTITY_B], have been found to have an NCX inhibitory action.",1,0
Decreased AT1R promoter activity with unchanged mRNA stability suggested that [ENTITY_A] suppressed [ENTITY_B] gene expression at the transcriptional level.,1,0
"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective [ENTITY_A] antagonist [ENTITY_B] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",3,0
Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of [ENTITY_A] are capable of in vivo upregulation of [ENTITY_B] expression on circulating leukemia cells.,0,0
In vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of [ENTITY_A] to activate [ENTITY_B] receptor-mediated PLC signaling in HEK cells.,0,0
CONTEXT: [ENTITY_A] is a novel [ENTITY_B] and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.,2,0
"Although the treatment with [ENTITY_A] increased IRS-1 tyrosine phosphorylation ([ENTITY_B]) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.), exercise training also increased it in both groups (control, 13.6 ± 0.1; MSG, 22.2 ± 1.1 a.u.).",0,0
[ENTITY_A] stimulates Th17 differentiation enhancing phosphorylation of [ENTITY_B] and STAT3 to worsen experimental autoimmune encephalomyelitis.,0,0
Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator [ENTITY_A] prevented downregulation of [ENTITY_B] and inhibition of GJIC.,0,0
"These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that [ENTITY_A] limit SRF by slowing recovery of [ENTITY_B] from inactivation.",0,0
"In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the [ENTITY_A] inhibitor [ENTITY_B], and has significantly lower side effects.",1,0
"In addition, [ENTITY_A] demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, [ENTITY_B], platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.",0,0
Anabolic effects of [ENTITY_A] on skeletal muscle are mediated by [ENTITY_B] activation.,0,0
"[ENTITY_A] isoforms did show different sensitivity and selectivity for down-regulation by [ENTITY_B] and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells.",1,0
RESULTS: Both [ENTITY_A] and VIG inhibited [ENTITY_B] and elevated GABA levels.,1,0
Suppression of TβR1 by the pharmacological inhibitor ([ENTITY_A]) markedly reduced [ENTITY_B] release by HFL-1 in response to CSE and this effect was confirmed by TβR1 siRNA.,1,0
Synthesis and evaluation of [ENTITY_A] as [ENTITY_B] inhibitory anticancer agents.,1,0
"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of [ENTITY_A] (AChE) in the nervous system, which leads to increased synaptic [ENTITY_B] levels.",4,0
[ENTITY_A] also increased [ENTITY_B] (Hb) levels in animals treated for 24 h.,0,0
"Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the [ENTITY_A] agonist [ENTITY_B] [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.",2,0
"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as [ENTITY_A] (COX-2)-derived [ENTITY_B] (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.",4,0
"Differences in magnitude of Na(+)-dependent [ENTITY_A] uptake through [ENTITY_B] between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells.",4,0
Increased [ENTITY_A]-mediated cationic [ENTITY_B] transport functionally compensates in Cat1 knockout cell lines.,4,0
[ENTITY_A]-RANTES treatment also reduced the levels of [ENTITY_B] and metalloproteinase 13 (MMP13).,1,0
Discovery of [ENTITY_A] based [ENTITY_B] inhibitors.,1,0
"Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to [ENTITY_A] depletion with [ENTITY_B].",4,0
"These effects were not mimicked by oral administration of the [ENTITY_A] agonist [ENTITY_B] even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).",2,0
"[ENTITY_A], a specific inhibitor of [ENTITY_B], induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.",1,0
"Exogenous stimulation of [ENTITY_A] activity, achieved by [ENTITY_B] treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.",0,0
"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced [ENTITY_A] activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by [ENTITY_B].",1,0
Cross-inhibition of [ENTITY_A]- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and [ENTITY_B].,1,0
"KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. [ENTITY_A] and formoterol, for the [ENTITY_B] over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.",2,0
"We conclude that [ENTITY_A] interacts differently with [ENTITY_B] than with WT, leading to increased block and slowed recovery, especially for late I(Na).",1,0
Phosphodiesterase type 5 ([ENTITY_A]) mediates the degradation of [ENTITY_B] in a variety of tissues including brain.,4,0
[ENTITY_A] inhibits [ENTITY_B] with an IC50 value of 0.4 mM [285707].,1,0
"The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective [ENTITY_A] reactivator, [ENTITY_B] (MMB-4).",0,0
Repeated Low Dose Administration of the [ENTITY_A] Inhibitor [ENTITY_B] Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.,1,0
"In terms of the mechanisms, we found that fatty acid amide hydrolase ([ENTITY_A]) which degrades [ENTITY_B], was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.",4,0
[ENTITY_A] antagonism with [ENTITY_B] reduced responses to 5-HT in controls but not during inflammation.,3,0
CO treatment also inhibited LPS-induced [ENTITY_A] production and [ENTITY_B] expression via its inactivation of NF-kappaB.,4,0
"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through [ENTITY_A] uptake across the basolateral membrane mediated by [ENTITY_B] in series with Cl- efflux across the apical membrane.",4,0
"We found that wogonin can suppress the [ENTITY_A]-stimulated [ENTITY_B] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.",0,0
"However, as a novel finding, [ENTITY_A] treatment increased a subclass of [ENTITY_B], the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations.",0,0
"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a [ENTITY_A] weak partial agonist ([ENTITY_B]) at micromolar concentrations.",2,0
"In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when [ENTITY_A] was blocked with [ENTITY_B].",1,0
"The enhancement of the depolarizing afterpotential by histamine was mimicked by the [ENTITY_A] agonist [ENTITY_B] and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",2,0
"An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the [ENTITY_A](mut) presence decreased with [ENTITY_B] time exposure.",1,0
"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit [ENTITY_A] [ENTITY_B] channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",4,0
"[ENTITY_A] inhibits [ENTITY_B] signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.",1,0
"The effects of D-1997 in the basilar artery were not modified by incubation with either the [ENTITY_A] antagonist [ENTITY_B] (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",3,0
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical [ENTITY_A] (MCT) inhibitor, [ENTITY_B], suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.",1,0
"Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (MAO-A) by clorgyline (4 mg/kg i.p.), [ENTITY_A] by [ENTITY_B] (1 mg/kg i.p.), both MAO-A and MAO-B by nialamide (75 mg/kg i.p.) or peripheral neuronal MAO by debrisoquin (40 mg/kg i.p.).",1,0
"Collectively, these findings provide evidence that [ENTITY_A] causes prolonged activation of [ENTITY_B] through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers.",0,0
"CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high [ENTITY_A] intake appears to decrease expression of PBMC [ENTITY_B] and D5D genes.",1,0
"We took advantage of the previous observations that [ENTITY_A] inhibits [ENTITY_B] (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol. Chem. 271, 8394-8401), and constitutively active RhoA inhibits DGK-theta (reviewed by Houssa, B., de Widt, J., Kranenburg, O., Moolenaar, W. H., and van Blitterswijk, W. J. (1999) J. Biol. Chem. 274, 6820-6822) to identify the activity induced by alpha-thrombin.",1,0
"[ENTITY_A] (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, [ENTITY_B], dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.",1,0
"[ENTITY_A] block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted ([ENTITY_B]) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",1,0
"In contrast, [ENTITY_A]- and icilin-activated [ENTITY_B] currents were suppressed by low pH.",0,0
[ENTITY_A] and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated [ENTITY_B] in rat testes.,1,0
"On the other hand, holocarboxylase synthetase ([ENTITY_A]) mRNA levels were markedly low in the deficient animals, and increased upon [ENTITY_B] injection.",0,0
"Second, feeding increased both the expression of [ENTITY_A] isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with [ENTITY_B].",1,0
"[ENTITY_A] ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by [ENTITY_B] treatment of adipocytes.",0,0
"Since [ENTITY_A] is known to activate [ENTITY_B] (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.",0,0
"INTRODUCTION: In this study, we examined the effects of the [ENTITY_A] inhibitors acarbose and [ENTITY_B] on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.",1,0
"We determined whether an [ENTITY_A] (ACE) inhibitor, [ENTITY_B], inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.",1,0
"[ENTITY_A], a novel anti-convulsant, enhances activation of KCNQ2/Q3 [ENTITY_B].",0,0
"We evaluated the effect of [ENTITY_A], a more selective [ENTITY_B] inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios.",1,0
"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, [ENTITY_A] (1 microM) produced 45% fractional block in [ENTITY_B] and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely.",1,0
"In this study, uptake of phenformin and [(14)C]tetraethylammonium (TEA) and [ENTITY_A] inhibition by [ENTITY_B] were examined in isolated liver and heart mitochondria.",1,0
Transduction with constitutively active forms of GSK-3β could protect against the downregulation of p65 and upregulation of cleaved-[ENTITY_A] that are induced by [ENTITY_B] treatment.,0,0
"Exposure of cells to 4mM [ENTITY_A] for 24h induced [ENTITY_B] activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.",0,0
"[ENTITY_A], a potent [ENTITY_B] inhibitor from Tabernaemontana divaricata.",1,0
[ENTITY_A] inhibits [ENTITY_B] more potently than selegiline and has the advantage of once-daily dosing.,1,0
Central and peripheral administration of [ENTITY_A] stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a [ENTITY_B] (GnRH) antagonist abolishes this effect.,1,0
"MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles [ENTITY_A] activates [ENTITY_B] but not P2X receptors.",0,0
"Our data suggest that [ENTITY_A] is taken up by Sertoli cells and peritubular cells, principally via system y(+)L ([ENTITY_B]/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.",4,0
"Furthermore, metformin was able to not only decrease the [ENTITY_A]-induced [ENTITY_B] MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.",0,0
A novel class of [ENTITY_A] has been discovered as antagonists of the [ENTITY_B]:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.,3,0
"Novel mechanism of action for [ENTITY_A]: induction of hypoxia-inducible factor-1alpha, [ENTITY_B], and angiogenesis by inhibition of prolyl hydroxylases.",0,0
[ENTITY_A] exhibited the predicted binding mode and demonstrated high inhibitory activity for [ENTITY_B] in enzyme- and cell-based assays.,1,0
"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by [ENTITY_A] (IP3), a [ENTITY_B] hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.",4,0
"[ENTITY_A] irreversibly inhibits [ENTITY_B], preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.",1,0
"[ENTITY_A] (nonselective [ENTITY_B] antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",3,0
"[ENTITY_A] also inhibited [ENTITY_B] mRNA and protein expression, which was time dependent and concentration dependent.",1,0
"The holo activity of AGT 2 with a high Km for [ENTITY_A] decreased more slowly than [ENTITY_B] (by 33% in 14 days, by 60% in 28 days).",4,0
The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of [ENTITY_A] by [ENTITY_B].,0,0
These data suggested that [ENTITY_A] had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of [ENTITY_B] and concomitant antagonism by blockade of muscarinic receptors.,1,0
[ENTITY_A] only suppressed the expression of [ENTITY_B] among the evaluated signaling molecules.,1,0
"The [ENTITY_A] antagonist [ENTITY_B] (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.",3,0
"Several inhibitors of [ENTITY_A] have been described, including [ENTITY_B], which is currently in phase 3 clinical development for the treatment of atherosclerosis.",1,0
"Possession of [ENTITY_A]*2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean [ENTITY_B] dose.",4,0
"[ENTITY_A] (A-64662), a potent, dipeptide [ENTITY_B] inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.",1,0
"Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and [ENTITY_A] which were decreased by [ENTITY_B].",1,0
"Surprisingly, the conditional deletion of Trp63, but not ΔNp63, in oocytes inhibited apoptosis, as well as the accumulation of [ENTITY_A] and TAp73 caused by [ENTITY_B].",0,0
"In pig parathyroid cells, [ENTITY_A] and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed [ENTITY_B] mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.",1,0
"The reversible [ENTITY_A] inhibitor, [ENTITY_B] (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration.",1,0
"RESULTS: (+/-)-, R-, and S-modafinil bind to the [ENTITY_A] and inhibit [ENTITY_B] uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.",4,0
"Furthermore, experiments showed that treatment with [ENTITY_A] results in a reduction in the amount of [ENTITY_B] protein in peritoneal exudate cells.",1,0
"[ENTITY_A], the first agent in this new class, not only induces the degradation of the [ENTITY_B] but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.",1,0
"BACKGROUND: Since the introduction of the first [ENTITY_A] inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, [ENTITY_B], galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.",1,0
"Therefore, the present results show that the earlier cerebellar responses to [ENTITY_A] include disruption of cytoskeletal homeostasis that could be related with [ENTITY_B] and PKA activation and reactive astrogliosis.",0,0
"The [ENTITY_A] is the predominant [ENTITY_B] degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.",4,0
"These results suggest that the altered [ENTITY_A] results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in [ENTITY_B] production in Saccharomyces cerevisiae.",4,0
"Pranlukast, ketamine and edaravone decreased NMDA-induced injury; [ENTITY_A] (0.1 mg/kg) and ketamine inhibited the upregulated expression of the [ENTITY_B].",1,0
"Clinical pharmacology of [ENTITY_A], a novel, dipeptide [ENTITY_B] inhibitor.",1,0
"Interestingly, [ENTITY_A] increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased [ENTITY_B] levels.",1,0
[ENTITY_A] is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the [ENTITY_B] (non-competitive inhibition).,1,0
"Collectively, these results suggest that [ENTITY_A] can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of [ENTITY_B] could be the major determinant for its anti-inflammatory mechanism.",1,0
"Indomethacin completely antagonizes [ENTITY_A] activity, i.e. abolishes the inhibitory effect of [ENTITY_B] on CA.",1,0
"Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by [ENTITY_A], a prominent feature of [ENTITY_B], and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.",4,0
"A novel membrane sensor for [ENTITY_A] antagonist ""[ENTITY_B]"".",3,0
"Activation of [ENTITY_A] is also reduced by these modifications; [ENTITY_B], lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.",1,0
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue ([ENTITY_A]) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [ENTITY_B] synthesis in vivo.",0,0
"[ENTITY_A] (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of [ENTITY_B], a precursor for DNA synthesis.",4,0
"The [ENTITY_A] (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular [ENTITY_B], yielding water.",4,0
The inhibition of [ENTITY_A] activity in the presence of [ENTITY_B] and puromycin inhibitors was also investigated.,1,0
The metallic taste reported as a side effect after the treatment with systemic [ENTITY_A] may be due to the inhibition of the [ENTITY_B].,1,0
"We also found that [ENTITY_A] receptors are activated by [ENTITY_B], ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation.",0,0
Repression of [ENTITY_A] gene expression and HDC activity by [ENTITY_B] may underlie its therapeutic effect in the treatment of allergy.,1,0
[ENTITY_A] is involved in hepatic [ENTITY_B] secretion.,4,0
"Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that [ENTITY_A] uptake in rat astrocytes is mediated by [ENTITY_B] and/or MCT2.",4,0
"[ENTITY_A] (AGT) in the liver catalyzes most of the [ENTITY_B] transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem. J. 127, 155-165).",4,0
"These results suggest that [ENTITY_A] genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of [ENTITY_B].",4,0
"[ENTITY_A]-dependent [ENTITY_B] activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.",0,0
"In addition, the new compound [ENTITY_A] (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant [ENTITY_B] (p65) inhibitory activity in an ELISA assay.",1,0
"Taken together, our data demonstrate that [ENTITY_A] attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of [ENTITY_B] expression.",1,0
Molecular determinants of [ENTITY_A] block of [ENTITY_B] K+ channels.,1,0
"In conclusion, these findings indicate that [ENTITY_A] is a new potent antagonist radioligand which recognizes with high affinity both [ENTITY_B] and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.",3,0
"The present studies were undertaken to determine whether stable analogues of [ENTITY_A], a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit [ENTITY_B] expression by human monocytic cells.",1,0
"High [ENTITY_A] (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates [ENTITY_B] and activates mTOR.",1,0
"Isolated islets displayed improved [ENTITY_A]-stimulated [ENTITY_B] secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation.",0,0
The clinical profile of the [ENTITY_A] blocker [ENTITY_B].,1,0
"In the local presence into the LC of the [ENTITY_A] antagonist [ENTITY_B] (1 μM), systemic citalopram increased NA in the LC (Emax = 157 ± 25 %) and PFC (Emax = 175 ± 24 %).",3,0
"Serum markers of liver damage ([ENTITY_A], ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with [ENTITY_B] reversed such changes (p<0.001).",1,0
The values of mean corpuscular hemoglobin concentration and mean corpuscular [ENTITY_A] increased in the [ENTITY_B] group.,0,0
[ENTITY_A] (VP-16) is a [ENTITY_B] (topo II) inhibitor chemotherapeutic agent.,1,0
The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the [ENTITY_A] inhibitor [ENTITY_B].,1,0
"Using recombinant [ENTITY_A], we found that it catalyzes the N-glucuronidation of [ENTITY_B], imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.",4,0
"Concentration-dependent inhibitory effects of [ENTITY_A] on the metabolism of dextromethorphan, a dual probe of [ENTITY_B] and CYP3A, in rats.",1,0
"The goal of the present study was to compare the effects of three potent reference [ENTITY_A] inhibitors ([ENTITY_B], CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys.",1,0
"The mechanism(s) responsible for arterial vasodilation observed following acute administration of [ENTITY_A], a novel vasodilator/[ENTITY_B] antagonist, has been investigated in rats.",3,0
The effects of CDCA and GW4064 on expression of [ENTITY_A] and MUC2 were abolished by [ENTITY_B].,1,0
"Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of [ENTITY_A]-specific [ENTITY_B] is a means of improving erectile function at minimal risk of adverse events.",1,0
"Moreover, NO production in LPS-stimulated macrophages that are expressing [ENTITY_A] mRNA was significantly reduced by the addition of [ENTITY_B], a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.",4,0
The [ENTITY_A] inhibitor [ENTITY_B] (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.,1,0
"The capacity of [ENTITY_A] inhibitors, with the exception of [ENTITY_B] and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors.",1,0
"CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of [ENTITY_A] in the nucleus accumbens, and those changes can be reversed by [ENTITY_B], which may be one kind of the molecular mechanisms associated with ethanol dependence.",0,0
"Herein, we report the identification and characterization of [ENTITY_A] (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated [ENTITY_B] secretion in pancreatic β cells.",1,0
"Because gastric [ENTITY_A] and COMT degrade [ENTITY_B], the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.",4,0
"The [ENTITY_A] homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban ([ENTITY_B]), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.",4,0
Citalopram protected against the [ENTITY_A]-induced inhibition of [ENTITY_B] binding.,1,0
"Furthermore, the [ENTITY_A] channel blockers [ENTITY_B] and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed.",1,0
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/[ENTITY_A] kinase inhibitor [ENTITY_B].,1,0
"In this report, we show that the hypolipidemic agent [ENTITY_A] is a competitive inhibitor of [ENTITY_B] in vitro, with K(i)=57.8+/-2.3 microM.",1,0
"Furthermore, knockdown of Brms1L significantly attenuated [ENTITY_A]-induced [ENTITY_B] expression.",0,0
"[ENTITY_A] is inhibited by [ENTITY_B], forming an inactive ternary complex with intracellular folate.",1,0
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, [ENTITY_A], nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [ENTITY_B] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.",1,0
"These results suggest that [ENTITY_A], although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional [ENTITY_B], located to sensory nerves.",0,0
Increased phosphorylation of [ENTITY_A] and AKT in response to HRG was abrogated to varying degrees by [ENTITY_B].,1,0
[ENTITY_A] initiates its teratogenic effects by binding to CRBN and inhibiting the associated [ENTITY_B] activity.,1,0
Our results suggest that [ENTITY_A] blocks [ENTITY_B] in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s).,1,0
"From the 10 isolated compounds, [ENTITY_A] showed the most potent inhibition, with IC50 values of 0.30 and 0.67 μM for [ENTITY_B] and rhAR, respectively.",1,0
"6-DHSG was metabolised by GSH to form a GSH conjugate ([ENTITY_A]) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of [ENTITY_B] (GST).",4,0
Calmodulin was relatively ineffective in preventing inhibition of [ENTITY_A] by [ENTITY_B] and the p-chloro analogue.,1,0
A series of structurally novel [ENTITY_A] was derived from optimization of the HTS lead as selective [ENTITY_B] (H3R) antagonists.,3,0
[ENTITY_A] and phenformin activate [ENTITY_B] in the heart by increasing cytosolic AMP concentration.,0,0
"In summary, [ENTITY_A] and metformin increase [ENTITY_B] activity and phosphorylation in the isolated heart.",0,0
"Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of [ENTITY_A] to [ENTITY_B] (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",0,0
"Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, [ENTITY_A] displayed less efficacy at [ENTITY_B].",1,0
"For some, pharmacologic inhibitors are available, including [ENTITY_A] for [ENTITY_B], farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.",1,0
Stereospecific inhibition of [ENTITY_A] by [ENTITY_B] isomers.,1,0
"However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic [ENTITY_A] concentration required for efficient vesicular loading by [ENTITY_B].",4,0
"To verify the hypothesis that the non-conventional partial agonist [ENTITY_A] binds at two beta(1)-adrenoceptor sites, [ENTITY_B], expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",2,0
[ENTITY_A] increases the expression of the pro-apoptotic gene [ENTITY_B] by epigenetic mechanisms in tumor cells.,0,0
"The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and [ENTITY_A] activation were significantly prevented with [ENTITY_B].",1,0
"CONCLUSION(S): Short-term exposure of [ENTITY_A] in new starters of DMPA increases the expression of endometrial [ENTITY_B], PRAB, PRB, and SRC-1 and promotes cell proliferation.",0,0
"Using [ENTITY_A] in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the [ENTITY_B] analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.",3,0
"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; [ENTITY_A], however, under the same conditions, was inhibited by only 50% with 141 microM [ENTITY_B].",1,0
"Guided by the [ENTITY_A] inhibiting activity, the [ENTITY_B] 3'-R/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory.",1,0
"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular [ENTITY_A] expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of [ENTITY_B].",1,0
"The influence of [ENTITY_A], a selective [ENTITY_B] antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.",3,0
"These results suggest that [ENTITY_A] induces hyperglycemia in mice by blocking the [ENTITY_B]and/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.",1,0
[ENTITY_A]: a novel anti-Parkinsonian [ENTITY_B] inhibitor with neuroprotective activity.,1,0
The unique role of the enzyme [ENTITY_A] (5-LO) in the production of [ENTITY_B] (LTs) makes it a likely target for biochemical manipulation.,4,0
"Furthermore, [ENTITY_A], a specific [ENTITY_B] phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA.",0,0
"[ENTITY_A], a selective [ENTITY_B] inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.",1,0
"Further, [ENTITY_A] exposure could induce phosphorylation- and ubiquitination-dependent degradation of [ENTITY_B], and the translocation of NF-κB p65 from the cytosol to the nucleus in this microglial cell line.",0,0
"Cultured rat DRG neurons endogenously expressed [ENTITY_A] protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up [ENTITY_B], but were resistant to copper toxicity.",4,0
Our findings indicate that [ENTITY_A] suppresses AGE-mediated inflammation by inhibiting ROS production and [ENTITY_B] activity.,1,0
"While there is considerable indirect evidence to implicate [ENTITY_A] in the pathogenesis of asthma, a critical evaluation of [ENTITY_B] antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.",2,0
"Irinotecan (CPT-11, [ENTITY_A]) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting [ENTITY_B] (Topo I).",1,0
"Collectively, our data suggest that [ENTITY_A] can repress the miR-200 family and induce EMT via the up-regulation of [ENTITY_B] in endometrial cancer cells.",0,0
Novel [ENTITY_A] derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased [ENTITY_B] (NPY).,1,0
"Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the [ENTITY_A] mediated positive chronotropic response to [ENTITY_B].",0,0
[ENTITY_A] (NDGA) has been shown to inhibit both 5-lipoxygenase and [ENTITY_B] and is active against several cancer cell lines and at least one mouse tumor model.,1,0
"We demonstrate that among the three nitrates, only [ENTITY_A] inhibits [ENTITY_B] activation in response to hypoxia.",1,0
"The ratio of [ENTITY_A] absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, [ENTITY_B] group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).",0,0
"To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. [ENTITY_A] agonists, [ENTITY_B] (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.",2,0
"Also, reactive astrogliosis takes part of the early responses to the insult with [ENTITY_A], evidenced by upregulated [ENTITY_B] in Western blot, PCR and immunofluorescence analysis.",0,0
"The enzyme (TcCA) has a very high catalytic activity for the [ENTITY_A] hydration reaction, being similar kinetically to the human (h) isoform [ENTITY_B], although it is devoid of the His64 proton shuttle.",4,0
[ENTITY_A] as Selective [ENTITY_B] Inhibitors.,1,0
Structural basis for [ENTITY_A] inhibition upon [ENTITY_B] binding to the CD11a I-domain.,1,0
"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of [ENTITY_A] (HSD17beta7; involved in [ENTITY_B] production) and decreased expression of HSD17beta5 (involved in testosterone production).",4,0
"16,16-dimethyl-PGE2 and two putative [ENTITY_A] antagonists, [ENTITY_B] and SC-19220, did not show any significant binding to this receptor.",3,0
Metformin significantly reduced [ENTITY_A] secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor [ENTITY_B].,0,0
"The majority of [ENTITY_A] transport is mediated by [ENTITY_B], although several other carriers have been kinetically defined.",4,0
A novel [ENTITY_A] derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of [ENTITY_B] inflammasome.,1,0
"A structure-activity relationship (SAR) study of the [ENTITY_A] (Myc) inhibitor [ENTITY_B] (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.",1,0
METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [ENTITY_A] (DA) uptake and [(3)H]WIN 35428 binding in [ENTITY_B] (DAT) wild-type and mutants with altered conformational equilibria.,4,0
"Other groups received either an infusion of the selective [ENTITY_A] antagonist ([ENTITY_B]; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).",3,0
Dopamine D(2) receptor-induced [ENTITY_A]-mediated production of [ENTITY_B] in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.,4,0
"In conclusion, this study expands the understanding of the substrate specificity of [ENTITY_A], highlighting its preference for [ENTITY_B] with higher affinities and clearance values than those of UGT1A4 and UGT1A3.",4,0
"In addition, [ENTITY_A] induced Nrf2 nuclear translocation and up-regulated the expression of [ENTITY_B]-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation.",0,0
The aim of this study was to define the molecular mechanism by which [ENTITY_A] inhibits [ENTITY_B] activation.,1,0
"In a cell-based model, [ENTITY_A] suppressed [ENTITY_B] activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.",1,0
"This study was designed to determine the gastroprotective properties of [ENTITY_A] (CNT), a novel prokinetic benzamide derivative agonist of [ENTITY_B] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",2,0
"Of the [ENTITY_A] inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of [ENTITY_B] and cGMP hydrolysis, respectively.",4,0
"CONCLUSIONS: Our results show that [ENTITY_A], a known [ENTITY_B] (COX) inhibitor, is also an activator of CA.",1,0
CONCLUSION: Our results indicate that [ENTITY_A] inhibits [ENTITY_B] synthesis via a mechanism distinct from CysLTR1 antagonism.,1,0
"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the [ENTITY_A] agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist [ENTITY_B] produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",3,0
Hepatic mRNA expressions of [ENTITY_A] and apo C-III were significantly lower in [ENTITY_B] group than in other groups.,1,0
[ENTITY_A] (0-100 mumol/l) inhibited [ENTITY_B] prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.,1,0
"Given the treatment with three doses of [ENTITY_A] (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of [ENTITY_B] and SOD in serum by single intragastric gavaged L-methionine.",0,0
"We found that [ENTITY_A] stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating [ENTITY_B] activation.",0,0
"UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the [ENTITY_A] antagonist [ENTITY_B].",3,0
"Collectively, our data suggest that [ENTITY_A] can repress the [ENTITY_B] family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells.",1,0
"Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible [ENTITY_A] inhibitor [ENTITY_B] (100nM).",1,0
"In conclusion, the [ENTITY_A] antagonist properties of [ENTITY_B] increase DA and NAD levels both alone and in association with fluoxetine.",3,0
Three different 3D-QSAR models were built and validated by using a set of 66 [ENTITY_A] (Model I) and furanopyrimidine (Model II) compounds with IC(50) values toward [ENTITY_B] ranging from 33 nM to 10.5 μM.,1,0
We have previously reported that TZDs reduce [ENTITY_A] synthesis by inhibiting [ENTITY_B] activity in human granulosa cells (HGC).,4,0
"Taken together, our study demonstrated that [ENTITY_A] inhibits the [ENTITY_B]/mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.",1,0
"Full agonists to the [ENTITY_A], such as [ENTITY_B], have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity.",2,0
"Collectively, these data suggest that [ENTITY_A] is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated [ENTITY_B] and VEGFR signaling.",1,0
"The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and [ENTITY_A]-expressing Sf9 cells for conjugated [ENTITY_B].",4,0
"The reduction of BiFC signal mediated by [ENTITY_A] was correlated with an increase in [ENTITY_B] transactivation, PARP cleavage, and cell death.",0,0
"[ENTITY_A] is principally metabolized by [ENTITY_B], and both are probable substrates of the drug transporter P-glycoprotein.",4,0
"Here we report that [ENTITY_A] stimulation caused a rapid reduction in protein levels of [ENTITY_B], but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.",1,0
"[ENTITY_A] deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing [ENTITY_B] translation.",1,0
"In conclusion, [ENTITY_A]-induced constitutive [ENTITY_B] activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol.",0,0
Toxicity profile of small-molecule [ENTITY_A] antagonist [ENTITY_B] is linked to TNF-α pharmacology.,3,0
Identification of a novel [ENTITY_A] derivative as a highly potent [ENTITY_B] antagonist with an anti-obesity profile.,3,0
The temporal profile of butyrylcholinesterase (BuChE) and in vitro [ENTITY_A]-reactivated [ENTITY_B] was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.,0,0
Synthesis and dual biological effects of [ENTITY_A]/prolyl hydroxamic acid derivatives as [ENTITY_B] inhibitor and antioxidant.,1,0
"Combined treatment of [ENTITY_A] and DA further augments cell toxicity, ROS production and [ENTITY_B] phosphorylation in LRRK2 deficient cells compared to controls.",0,0
These results indicate a major role of [ENTITY_A] in [ENTITY_B] N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.,4,0
"Here, we tested the hypothesis that 5-HT receptors mediate [ENTITY_A] activation by measuring agonist-stimulated [ENTITY_B] ([3H]L-Cit) formation in BAEC cultures.",4,0
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating [ENTITY_A] release ([ENTITY_B], glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).",0,0
"Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of [ENTITY_A] by [ENTITY_B] potentiated GluK2/GluK5.",0,0
"Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective [ENTITY_A] (S1P1R) antagonist, [ENTITY_B], and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.",3,0
[ENTITY_A] increased the levels of H(2)S and [ENTITY_B] mRNA expression while CBS mRNA expression was decreased.,0,0
[ENTITY_A] inhibits autophagic flux activating the [ENTITY_B]-Keap1 pathway in a p62-dependent manner.,0,0
These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to [ENTITY_A] inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate ([ENTITY_B]).,1,0
Cells propagated in medium containing [ENTITY_A] and homocysteine showed a substantial increase in [ENTITY_B] activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.,0,0
"Here we studied the effects of the recently developed [ENTITY_A] inhibitor [ENTITY_B] on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses.",1,0
The results showed that [ENTITY_A] promotes the expression of [ENTITY_B] and Beclin-1.,0,0
Cystathionine-gamma-lyase ([ENTITY_A]) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form [ENTITY_B].,4,0
"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective [ENTITY_A] antagonist [ENTITY_B] [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).",3,0
"Further, we used this model to test the efficacy of [ENTITY_A], a [ENTITY_B] inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.",1,0
Apoptosis studies (DAPI staining and [ENTITY_A] activity) showed a marked increase in the presence of [ENTITY_B] and VP-16 compared to VP-16 alone.,0,0
"[ENTITY_A] donor dose-dependently inactivated [ENTITY_B] of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.",1,0
"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a ([ENTITY_A]), a potent, [ENTITY_B]-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease.",1,0
"Another inhibitor, [ENTITY_A] was previously reported to be a slow-binding inhibitor of the [ENTITY_B] [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem. Pharmacol. 56 (1998) 1259-1264].",1,0
"In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in [ENTITY_A]-treated endometrial cancer cells leads to the down-regulation of [ENTITY_B] and eventually to EMT.",1,0
"[ENTITY_A] reduced the risk of death or heart failure in patients with above-median levels of [ENTITY_B] or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value.",1,0
"To begin to examine whether these changes are mediated by alterations in gene expression for [ENTITY_A] (TPH), the rate-limiting enzyme in [ENTITY_B] biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR).",4,0
A one-pot domino synthesis and discovery of highly functionalized [ENTITY_A] as [ENTITY_B] inhibitors.,1,0
"The [ENTITY_A] secretory response is mediated via a non-[ENTITY_B] pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.",4,0
"Analysis of natural genetic variation among inbred strains of mice indicates that [ENTITY_A] and [ENTITY_B] are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.",4,0
"[ENTITY_A] and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and [ENTITY_B] in testes.",1,0
"In this study, using a model of [ENTITY_A] (GMC)-induced reduction in [ENTITY_B] activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.",1,0
"In the present study, we investigated the effect of [ENTITY_A]-induced constitutive [ENTITY_B] activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions.",0,0
The use of [ENTITY_A] (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of [ENTITY_B] from ALA.,4,0
"[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] ([ENTITY_A]), a selective [ENTITY_B] antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.",3,0
"[ENTITY_A] (10(-5) M), a selective [ENTITY_B] antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor.",3,0
"Upon differentiation, osteoclasts express [ENTITY_A] (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of [ENTITY_B] in neurons.",4,0
"When tested in the intact cells, only 4 of 16 CGPs (at 10 μM) inhibited [ENTITY_A]-mediated [ENTITY_B] efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.",4,0
"While fluoropyrimidine antimetabolites have other sites of action, antifolates [ENTITY_A] (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent [ENTITY_B] inhibitors.",1,0
"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with [ENTITY_A], a selective [ENTITY_B] inhibitor.",1,0
"Interestingly, [ENTITY_A] expression positively correlated with urine albumin [ENTITY_B] ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.",0,0
"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, [ENTITY_A] at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by [ENTITY_B] containing the GluR5 subunit.",1,0
"Additionally, treatment with [ENTITY_A]/iron showed a higher [ENTITY_B] activity.",0,0
"[ENTITY_A] (LHRH) agonists, such as [ENTITY_B], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",2,0
"[ENTITY_A] (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids ([ENTITY_B]), which possess various beneficial effects on the cardiovascular system.",4,0
These observations suggest that uptake of [ENTITY_A] into liver mitochondria is at least partly mediated by [ENTITY_B] and functionally relevant to its inhibition potential of complex I respiration.,4,0
"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of [ENTITY_A], [ENTITY_B] (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.",3,0
Sumatriptan and LY 344864 decreased the number of [ENTITY_A]-induced [ENTITY_B]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).,0,0
"Differences in magnitude of [ENTITY_A]-dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in [ENTITY_B] protein expression, this being more abundant in WKY PTE cells.",0,0
"4-Hydroxynonenal ([ENTITY_A]) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several [ENTITY_B] (GST) isoforms.",4,0
"Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which [ENTITY_A] activates the [ENTITY_B] resulting in severe hypertension and hypokalemia.",0,0
Antitumor activity of [ENTITY_A] in [ENTITY_B]-driven leukemic cells.,1,0
Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [ENTITY_A] (E217βG) (a prototypical [ENTITY_B] substrate) into MRP-enriched inside-out membrane vesicles.,4,0
The results show that CYP2E1 inhibits [ENTITY_A]-mediated metabolism of [ENTITY_B] (BNZ) with a K(i) of 0.04 µM.,4,0
"Agonist and antagonist actions of [ENTITY_A] as compared to fluparoxan at alpha(2)-adrenergic receptors [ENTITY_B], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",2,0
"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of [ENTITY_A] by treatment with [ENTITY_B], which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",1,0
[ENTITY_A] is a [ENTITY_B] and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.,2,0
"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized [ENTITY_A] and PDE4D are responsible for selectively modulating the concentration of [ENTITY_B] in individual subcellular compartments.",4,0
"These findings suggest that [ENTITY_A] activates the [ENTITY_B]/Akt signaling pathway leading to the promotion of nuclear translocation of β-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.",0,0
Inhibition of [ENTITY_A] pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and [ENTITY_B].,1,0
"CO donor dose-dependently inactivated [ENTITY_A] of [ENTITY_B]-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.",0,0
"In addition, we found that [ENTITY_A] transcription and translation was completely inhibited by [ENTITY_B], while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.",1,0
[ENTITY_A] selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by [ENTITY_B]: relevance to bipolar disorder.,1,0
Modulation of the [ENTITY_A] producing system (demonstrated via the [ENTITY_B] histochemical reaction) by oestradiol has been established in several structures of the rat brain.,4,0
Data suggest that [ENTITY_A] via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of [ENTITY_B]-expression.,0,0
"Na+-Dependent transmembrane transport of small neutral [ENTITY_A], such as glutamine and alanine, is mediated, among others, by the [ENTITY_B] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",4,0
"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a [ENTITY_A] MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for [ENTITY_B] in rat cerebrocortical astrocytes.",4,0
[ENTITY_A] has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and [ENTITY_B] antagonists in therapy for hypertension and other cardiovascular and renal diseases.,3,0
Our results showed that [ENTITY_A] down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory [ENTITY_B].,1,0
"Depletion of putrescine, spermidine, and spermine by [ENTITY_A] (DFMO), a specific inhibitor of [ENTITY_B] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",1,0
"[ENTITY_A], a potent [ENTITY_B] antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.",3,0
"Luteinizing hormone-releasing hormone (LHRH) agonists, such as [ENTITY_A], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [ENTITY_B] and testosterone levels.",1,0
[ENTITY_A]-avibactam: a novel cephalosporin/[ENTITY_B] inhibitor combination.,1,0
Preclinical pharmacology of [ENTITY_A]: a novel selective inhibitor of [ENTITY_B].,1,0
"We found that reduction of the carcinogenic [ENTITY_A] of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [ENTITY_B] and cyt b5.",4,0
"[ENTITY_A] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins ([ENTITY_B], Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",0,0
[ENTITY_A] but not isoprenaline initiated arrhythmias at lower concentrations following [ENTITY_B] overexpression.,0,0
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating [ENTITY_A] antagonists [ENTITY_B], astemizole, loratadine, and acrivastine are reviewed.",3,0
Inhibition of [ENTITY_A]-primed eosinophil chemotaxis by [ENTITY_B].,1,0
"The effects of [ENTITY_A] (unspecific [ENTITY_B] inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak.",1,0
"When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to [ENTITY_A] is due to a mechanism other than [ENTITY_B] inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure.",1,0
"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the [ENTITY_A] inhibitor Go 6976, [ENTITY_B], as well as the calmodulin antagonists W7 and W13.",1,0
[ENTITY_A] has the potential to become the first orally active [ENTITY_B] inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.,1,0
"The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of [ENTITY_A] to cells with maximally induced [ENTITY_B].",4,0
The [ENTITY_A] was inhibited completely by [ENTITY_B] and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively.,1,0
"[ENTITY_A], a [ENTITY_B] antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity.",3,0
"Furthermore, [ENTITY_A] significantly inhibited the TCDD-induced [ENTITY_B]-dependent luciferase activity.",1,0
"To develop new drugs for treatment of Alzheimer's disease, a group of [ENTITY_A] was designed, synthesized and tested for their ability to inhibit [ENTITY_B], butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).",1,0
"The best inhibitors were [ENTITY_A] and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a [ENTITY_B]-selective inhibitor.",1,0
"We thus speculated that activation of [ENTITY_A] might be a mechanism by which [ENTITY_B] (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo.",0,0
[ENTITY_A] and 2-hydroxychalcone induced apoptosis by [ENTITY_B] downregulation.,1,0
Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of [ENTITY_A] inhibitors of [ENTITY_B] (CA) assembly are described.,1,0
"[ENTITY_A], a leukotriene receptor antagonist, inhibits [ENTITY_B] production via a mechanism distinct from leukotriene receptor antagonism.",1,0
"However, only [ENTITY_A] reduced [ENTITY_B] density.",1,0
"A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an [ENTITY_A] inhibitor, [ENTITY_B].",1,0
Regulation of sexual reproduction by [ENTITY_A] involves the activation of [ENTITY_B] (ERs) in the hypothalamus.,0,0
"[ENTITY_A] also increased ERK1/2, [ENTITY_B] and PDGFRalpha phosphorylation while ICI blocked it.",0,0
The concomitantly administered effects of [ENTITY_A] on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by [ENTITY_B] in the gastrointestinal tract and liver.,4,0
"Phenserine is also unique because of differing actions of its enantiomers: [ENTITY_A] is the active enantiomer for inhibition of [ENTITY_B], whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.",1,0
"Degradation of submandibular gland [ENTITY_A] by parasympathetic denervation of chorda tympani and its recovery by [ENTITY_B], an M3 muscarinic receptor agonist.",0,0
"This initial action was accompanied by up-regulation of [ENTITY_A] (COX-2), an important inflammation marker within 1h after [ENTITY_B] treatment.",0,0
"Pharmacology of [ENTITY_A], a selective [ENTITY_B]/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.",2,0
"Here, we describe a new photolabile [ENTITY_A] derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [ENTITY_B], SNAT1, and SNAT2.",4,0
High-[ENTITY_A] environment enhanced oxidative stress and increased [ENTITY_B] secretion from keratinocytes: New insights on impaired diabetic wound healing.,0,0
"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole ([ENTITY_A]) is a novel boron-containing antibiotic that inhibits [ENTITY_B], and that has been in development for the treatment of serious Gram-negative infections.",1,0
"In this current study, [ENTITY_A] was found to increase phosphorylation of [ENTITY_B] (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.",0,0
"The inhibition of phosphoinositide 3-kinase using [ENTITY_A] augmented a decrease in the [ENTITY_B] level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1.",1,0
"Overall, our findings suggest that [ENTITY_A] induced apoptosis in HepG2 cells via [ENTITY_B] activation and GSK3β phosphorylation as a potent chemopreventive agent.",0,0
"The reactivation of brain [ENTITY_A] inhibited with tabun demonstrated better activity of new compound [ENTITY_B], TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.",0,0
"Cellular release of AChE by SH-SY5Y is significantly enhanced by the [ENTITY_A] (mAChR) agonists [ENTITY_B] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.",2,0
"Furthermore, [ENTITY_A] could inhibit [ENTITY_B]-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38.",1,0
"Second, [ENTITY_A], an antiatherogenic compound reported to be an inactivator of [ENTITY_B] reduced hepatic alpha-tocopherol secretion.",1,0
"[ENTITY_A] (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible [ENTITY_B] inhibitor, anti-Parkinsonian drug.",1,0
"Next to [ENTITY_A], the predominant protein influencing [ENTITY_B] metabolism is PPARα and γ whose expressions were also positively modulated.",4,0
"The observed inhibition on [ENTITY_A], GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist [ENTITY_B] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",0,0
RESULTS: [ENTITY_A] showed concentration-dependent transactivation of [ENTITY_B] and PPARgamma.,2,0
"The major ingredient of ginger, [ENTITY_A], could inhibit [ENTITY_B] activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.",1,0
The antipsychotic drugs [ENTITY_A] and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the [ENTITY_B] known as HERG (human ether-a-go-go-related gene; erg1).,1,0
"Furthermore, V(5+) significantly inhibited the [ENTITY_A]-induced [ENTITY_B]-dependent luciferase activity.",0,0
"RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the [ENTITY_A] (PI3-kinase) inhibitor, [ENTITY_B].",1,0
"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the [ENTITY_A] mediated stimulation of [ENTITY_B] subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.",0,0
"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or [ENTITY_A]-induced increase of [ENTITY_B] level in macrophage rather than in the brain.",0,0
"In overexpressing cell lines, [ENTITY_A]- and OATP1B3-mediated [ENTITY_B] uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.",4,0
Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both [ENTITY_A] and cGMP ([ENTITY_B]).,4,0
[ENTITY_A] represents the first in a novel class of [ENTITY_B] inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.,1,0
"[ENTITY_A] and IFNT stimulated endometrial [ENTITY_B] expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.",0,0
BACKGROUND: The novel antiepileptic drug [ENTITY_A] is the first selective M-current potassium channel opener for [ENTITY_B] and KCNQ3/5 channels.,0,0
Binding domains of the oxytocin receptor for the selective [ENTITY_A] antagonist barusiban in comparison to the agonists [ENTITY_B] and carbetocin.,2,0
"We have identified [ENTITY_A], an enzyme involved in [ENTITY_B] metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.",4,0
"Synthesis, [ENTITY_A] inhibition, antitumor testing, and molecular modeling study of some new [ENTITY_B] analogs.",1,0
"[ENTITY_A] at 50 mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in [ENTITY_B] protein expression.",1,0
"Interestingly, [ENTITY_A] disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of [ENTITY_B] and p85/PI3K, which is linked to various tumorigenic responses.",1,0
"TGF-beta1 and high D-glucose increased p42/44(mapk) and [ENTITY_A] phosphorylation, an effect blocked by [ENTITY_B] (MEK1/2 inhibitor).",1,0
CONCLUSIONS: These findings confirm that the [ENTITY_A] antagonist [ENTITY_B] is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.,3,0
"Results indicate that [ENTITY_A] and resiquimod induce [ENTITY_B] and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.",0,0
"The results showed that most of the synthesized compounds exhibited nanomolar potency against [ENTITY_A], much better than the parent [ENTITY_B].",1,0
"The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists [ENTITY_A] (300 microg/kg; [ENTITY_B]), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).",3,0
[ENTITY_A] Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of [ENTITY_B] Signaling.,1,0
"Moreover, [ENTITY_A] noticeably increased in response to TGF-beta1 and [ENTITY_B] (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.",0,0
"Moreover, the rank order for potency in inhibiting [ENTITY_A] (ambenonium>neostigmine=physostigmine =tacrine>[ENTITY_B]=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",1,0
"Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the [ENTITY_A] inhibitor [ENTITY_B].",1,0
The reduction of [ENTITY_A] expression levels was reversed by the proteasomal inhibitor [ENTITY_B].,0,0
Wogonin inhibits [ENTITY_A]-induced vascular permeability through suppressing the phosphorylation of [ENTITY_B].,0,0
[ENTITY_A] induced dose-dependent expression of [ENTITY_B] and MUC2 at both the mRNA and protein levels.,0,0
"We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of [ENTITY_A], [ENTITY_B].",1,0
Mechanisms of [ENTITY_A] uptake in the choroid plexus: studies in wild-type and [ENTITY_B] knockout mice.,4,0
"Both [ENTITY_A] treatments, induced a significant decrease (p<0.01) in uterine [ENTITY_B] (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.",1,0
Electroencephalographic recordings during substance consumption showed reduced alpha activity and [ENTITY_A] latencies in the [ENTITY_B] group compared to the control group.,1,0
"Since this compound retains good [ENTITY_A] inhibitory activity and its [ENTITY_B] moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.",1,0
"These data demonstrated that 1) [ENTITY_A] and pemetrexed synergistically interact against NSCLC cells through the suppression of [ENTITY_B] phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.",1,0
"Importantly, treatment with [ENTITY_A] did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of [ENTITY_B] signaling that do not target MET.",1,0
[ENTITY_A] was shown to decrease cerebral [ENTITY_B] activities and angiogenesis induced by vascular endothelial growth factor (VEGF).,1,0
"Metabolism of [ENTITY_A] and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and [ENTITY_B].",4,0
"Mutation of arginine 228 to [ENTITY_A] enhances the [ENTITY_B] activity of bovine beta-1,4-galactosyltransferase I.",0,0
[ENTITY_A] and selective [ENTITY_B] inhibitors cause regression of colonic polyps in familial polyposis patients.,1,0
"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive [ENTITY_A] (SAHH), enhanced the level of [ENTITY_B] and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.",4,0
"Although inhibition of [ENTITY_A] release can be achieved by [ENTITY_B] and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.",1,0
"Pretreatment of the tissues with combined [ENTITY_A]/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of [ENTITY_B] on the noncholinergic contraction.",2,0
"We identified one compound, [ENTITY_A] (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of [ENTITY_B] in transformed cells.",0,0
"Pharmacologically, [ENTITY_A] is a novel inhibitor of [ENTITY_B].",1,0
"In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the [ENTITY_A] agonist [ENTITY_B]; however, it is not clear whether both findings share the same biological basis.",2,0
"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that [ENTITY_A] populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for [ENTITY_B] and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)",3,0
Result showed that [ENTITY_A] treatment resulted in markedly reduced [ENTITY_B] nuclear translocation.,1,0
"Taken together, these data indicate that a PKA-mediated signaling pathway mediates [ENTITY_A] activation of [ENTITY_B] at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHβ activation.",0,0
"In this study, a novel series of [ENTITY_A] derivatives were synthesized and evaluated for inhibiting [ENTITY_B] serine protease activity and suppressing cancer cell invasion.",1,0
"Kinetic analyses revealed that the affinity and clearance of [ENTITY_A] for [ENTITY_B], imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",4,0
Synthesis and biological evaluation of [ENTITY_A] as potent and selective inhibitors of [ENTITY_B].,1,0
Selective antagonism of [ENTITY_A] kainate-receptor-mediated synaptic currents by [ENTITY_B] in rat basolateral amygdala neurons.,3,0
"Practical asymmetric synthesis of [ENTITY_A], a potent human [ENTITY_B] antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.",3,0
The combination of [ENTITY_A] and transporter inhibition produced by [ENTITY_B] may contribute to its clinical efficacy as a smoking cessation agent.,1,0
"Abstract 1. We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal [ENTITY_A] (CYP3A) in rats using [ENTITY_B] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.",0,0
"[ENTITY_A] induced autophagy, a feature of [ENTITY_B] inhibition.",1,0
[ENTITY_A] (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of [ENTITY_B] and α-SMA in TGF-β1-induced NPDFs.,1,0
"Oviduct [ENTITY_A], ER-β and uterine ER-β were down-regulated by either [ENTITY_B] or melatonin.",1,0
"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling [ENTITY_A] to [ENTITY_B] inhibition and subsequent neurite growth promotion in neurons.",1,0
"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of [ENTITY_A] and release of cytochrome c to the cytosol induced by [ENTITY_B].",0,0
"[ENTITY_A] inhibited [ENTITY_B]-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.",1,0
"Clinical effects of [ENTITY_A], an oral [ENTITY_B] antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.",3,0
"In humans, prolonged administration of the [ENTITY_A] agonist [ENTITY_B] leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.",2,0
"However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that [ENTITY_A] also activates heat-activated [ENTITY_B].",0,0
"Furthermore, [ENTITY_A] reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of [ENTITY_B] mRNA and histological analysis of collagen in liver tissue.",1,0
"Upon treatment of isolated hepatocytes with Hb alone or in the presence of [ENTITY_A], there was an increase in the [ENTITY_B]-dependent luciferase activity.",0,0
"Coexpression of GRK2 or GRK2 and arrestin-2 permitted [ENTITY_A] to induce down-regulation of the [ENTITY_B], although expression of arrestin-2 or dynamin I alone did not.",1,0
"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of [ENTITY_A] on [ENTITY_B] as the main mechanism for the increased transport of darunavir across the small intestine.",1,0
"Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid [ENTITY_A] antagonist [ENTITY_B]: asymmetric synthesis, neuroactivity, and structural characterization.",3,0
"In human blood, the tested glucocorticoids [ENTITY_A], dexamethasone and fluticasone inhibited the LPS induced [ENTITY_B] release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.",1,0
"[ENTITY_A] causes loss of GSH and inhibition of [ENTITY_B] in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.",1,0
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, [ENTITY_A], or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [ENTITY_B]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",4,0
"Similar to [ENTITY_A], clofibrate, another fibrate drug, also inhibited the expression of [ENTITY_B].",1,0
G6PC2: A Negative Regulator of Basal [ENTITY_A]-Stimulated [ENTITY_B] Secretion.,0,0
"The expression of [ENTITY_A] and ABCG1 was induced by 24-OHC, as well as TO901317 and [ENTITY_B], which are ligands of the nuclear receptors LXR/RXR.",0,0
"One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas [ENTITY_A] preferentially binds to and activates RAR-beta and -gamma in preference to [ENTITY_B].",0,0
"At PND35, the medial prefrontal cortex (mPFC) of rats given [ENTITY_A] showed 55% greater immunoreactivity (-ir) for the catecholamine marker [ENTITY_B] (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.",0,0
"Exposure of H9c2 cells to high [ENTITY_A] reduced AMPK activity, inhibited [ENTITY_B] (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.",1,0
"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of [ENTITY_A](WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by [ENTITY_B](a selective COX-2 inhibitor) and rescued by exogenous PGE2.",0,0
We show that the expression of PIM-1 is induced in response to [ENTITY_A] in MCF-7 cells and that the induction is mediated by [ENTITY_B]-regulated enhancers located distally upstream from the gene.,0,0
"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate ([ENTITY_A]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous [ENTITY_B] desensitization.",1,0
[ENTITY_A] changed nucleotide ratios and activated [ENTITY_B] in CRC cells.,0,0
"Disposition of a specific [ENTITY_A] inhibitor, [ENTITY_B], in human.",1,0
The extent and rate of inhibition are similar to that seen with the known [ENTITY_A] blocker [ENTITY_B].,1,0
"In addition to this pronounced loss of function, [ENTITY_A] also showed a 10-fold increase in the persistent late [ENTITY_B] current.",0,0
The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by [ENTITY_A] causes excessive secretion of [ENTITY_B].,0,0
Repression of [ENTITY_A] (FNTA) by siRNA and the enzyme inhibitor [ENTITY_B] caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.,1,0
"In contrast to [ENTITY_A] and somatostatin, galanin, another inhibitor of [ENTITY_B] secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner.",1,0
A prerequisite for this hypothesis was the unproved assumption that rabbit and human [ENTITY_A] are equally activated by [ENTITY_B].,0,0
"Finally, epididymal mRNA abundance of [ENTITY_A] was significantly increased by [ENTITY_B] supplementation, compared to levels in the control and HF groups.",0,0
"Acetylcholinesterase ([ENTITY_A]) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain [ENTITY_B] (ACh) levels.",4,0
This was confirmed on adding [ENTITY_A] the [ENTITY_B] inhibitor which abolished the protection.,1,0
The time course of the reduction in the number of [ENTITY_A] receptors was similar to that of the [ENTITY_B]-induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different.,1,0
"Moreover, we also demonstrate that [ENTITY_A] functions at least partially through activation of [ENTITY_B]/ERK and PI3K/Akt signaling.",0,0
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], [ENTITY_A] ([ENTITY_B], 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",1,0
"Rats intoxicated with [ENTITY_A] for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants [ENTITY_B], glutathione peroxidase and catalase in the frontal cortex tissue.",1,0
Western blot assay demonstrated that [ENTITY_A] decreased [ENTITY_B] level and induced Bax translocation to cause cytochrome c release.,1,0
BACKGROUND: The effects of [ENTITY_A] antagonist [ENTITY_B] on rat palate development were characterized following in utero exposure.,3,0
siRNA knockdown of p38 MAPK abrogated the ability of [ENTITY_A] to synergistically induce [ENTITY_B] mRNA.,0,0
"Thus, the [ENTITY_A]-induced reduction in canonical Wnt signaling is associated with a decrease in activators ([ENTITY_B] and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",1,0
"The [ENTITY_A] absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, [ENTITY_B], and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).",0,0
"The [ENTITY_A] antagonist [ENTITY_B] or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.",3,0
"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for [ENTITY_A]-induced [ENTITY_B] (cyt c) release and cell death.",0,0
"UNLABELLED: Apparent [ENTITY_A] occupancy in mouse cerebral cortex, hippocampus, and striatum by [ENTITY_B], an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",3,0
Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of [ENTITY_A] against denaturation by heat or [ENTITY_B] following phosphorylation by organophosphorus anticholinesterase compounds.,1,0
"The structure-based design, synthesis, and biological evaluation of a new [ENTITY_A] series of irreversible [ENTITY_B] inhibitors are described herein.",1,0
"In vivo, [ENTITY_A] induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma [ENTITY_B] levels.",0,0
Treatment of Rat-2 fibroblast cells with [ENTITY_A] caused the stimulation of [ENTITY_B]-dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis.,0,0
[ENTITY_A] (COZAAR) is the prototype of a new class of potent and selective [ENTITY_B] antagonists with the largest published preclinical and clinical data base.,3,0
"[ENTITY_A], a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the [ENTITY_B].",1,0
Preferential cerebrospinal fluid [ENTITY_A] inhibition by [ENTITY_B] in humans.,1,0
This study provides a mechanistic understanding of the in vivo inhibition of [ENTITY_A] and enzymes by [ENTITY_B].,1,0
RESULTS: [ENTITY_A] was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against [ENTITY_B] (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).,1,0
"It was also antagonized by the non-specific [ENTITY_A] (COX) inhibitor, [ENTITY_B], and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate.",1,0
"Moreover, [ENTITY_A] concentration-dependently inhibited the expression of ICAM-1 and induced the expression of [ENTITY_B] on monocytes.",0,0
"[ENTITY_A], (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [ENTITY_B].",3,0
"HepG2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high [ENTITY_A][ENTITY_B] catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells.",4,0
"The following [ENTITY_A] blockers for treatment of various human tumors are in clinical development: [ENTITY_B] (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).",1,0
[ENTITY_A] induces the expression of [ENTITY_B] in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.,0,0
3.  We have used this method to screen 11 recombinant [ENTITY_A] for [ENTITY_B] glucuronidation activity and studied the reaction kinetics with the most active enzymes.,4,0
"Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with [ENTITY_A], a specific [ENTITY_B] antagonist.",3,0
"CONCLUSIONS: [ENTITY_A] is an inhibitor of [ENTITY_B] and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism.",1,0
"Some [ENTITY_A] antagonists have 5-HT4 agonist activity (for example, [ENTITY_B], zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",3,0
Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type [ENTITY_A] and key [ENTITY_B] analogs.,1,0
"[ENTITY_A] encoded by the HSD11B2 gene converts [ENTITY_B] to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.",4,0
"[ENTITY_A] (MCTs) are proton-linked membrane carriers involved in the transport of [ENTITY_B] such as lactate, pyruvate, as well as ketone bodies.",4,0
All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist sulpiride (5 microm) and by the selective [ENTITY_A] antagonist [ENTITY_B] at a low dose (50 nm).,3,0
"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced [ENTITY_A]-mediated [ENTITY_B] (MAPK) activation.",0,0
"Furthermore, [ENTITY_A]-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced [ENTITY_B] expression.",0,0
"In peripheral lymphocytes of healthy and diseased subjects, [ENTITY_A] induced a significant increase of [ENTITY_B](+) CTLs within 12h in all experiments performed.",0,0
[ENTITY_A] (COX-2)-derived [ENTITY_B] (PGE2) has been shown to be important in esophageal tumorigenesis.,4,0
"[ENTITY_A], a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the [ENTITY_B] dimer that governs erythropoiesis.",0,0
"In utero exposure to [ENTITY_A] (VPA), a [ENTITY_B] (HDAC) inhibitor, causes neural tube, heart, and limb defects.",1,0
[ENTITY_A] stimulates [ENTITY_B] degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.,1,0
"We previously reported that caffeoyl-amino acidyl-hydroxamic acid ([ENTITY_A]) acted as both a good antioxidant and [ENTITY_B] inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.",1,0
"Similar to the [ENTITY_A], Atp8a1 is activated only by the naturally occurring [ENTITY_B] isomer of PS and not the sn-2,3-glycerol stereoisomer.",0,0
"We evaluated the clinical effectiveness of [ENTITY_A], an ultra-short-acting [ENTITY_B] blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT).",1,0
We recently showed that [ENTITY_A] is metabolized in vitro by polyamine catabolic enzyme [ENTITY_B] (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).,4,0
"In this study, we examined whether [ENTITY_A] and other [ENTITY_B] antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes.",3,0
"Like other [ENTITY_A] antagonists, [ENTITY_B] at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory.",3,0
"There was no significant difference in [ENTITY_A], NF-κB, and IL-27 mRNA and proteins between [ENTITY_B]-treated and sulfasalazine-treated groups.",1,0
"In conclusion, [ENTITY_A] may inhibit platelet activation by inhibiting the [ENTITY_B]-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.",1,0
"In plasma membranes prepared from these isolated brown fat cells by [ENTITY_A] extraction there was a similar enrichment of activity of [ENTITY_B] and of the plasma membrane marker enzyme, phosphodiesterase I.",0,0
Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) [ENTITY_A] decreased the postradiation survival of irradiated [ENTITY_B]-transformed cells and normal cells but had no effect on the survival of unirradiated cells.,1,0
"Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency ([ENTITY_A]) did not affect [ENTITY_B] potency.",1,0
"Our results showed that low dose [ENTITY_A] and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of [ENTITY_B] and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein.",0,0
A highly potent inhibition of the [ENTITY_A] catalytic reaction by [ENTITY_B]/SNO was seen in assays employing the coupled Prx-Trx system.,1,0
"Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that [ENTITY_A] inhibited [ENTITY_B] but had no effect on ENT2.",1,0
"Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific [ENTITY_A] agonist [ENTITY_B], or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.",2,0
Block of human NaV1.5 [ENTITY_A] by novel [ENTITY_B] analogues of phenytoin.,1,0
[ENTITY_A] (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous [ENTITY_B] or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.,1,0
"Crystallographic comparison with the structurally related [ENTITY_A] binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the [ENTITY_B] versus BH4.",1,0
FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing [ENTITY_A] decreases [ENTITY_B] levels.,4,0
"In clinical trials [ENTITY_A] has proven to be at least as effective as the [ENTITY_B] inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects.",1,0
[ENTITY_A] appeared better tolerated among extensive [ENTITY_B] metabolizers than among poor metabolizers.,4,0
"Moreover, compared with the model group, [ENTITY_A] could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce [ENTITY_B] (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.",1,0
Dietary [ENTITY_A] increase [ENTITY_B] gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.,0,0
"Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in [ENTITY_A] and ACTH levels after i.v. [ENTITY_B], pointing to a general state of arousal in these mCPP-treated animals.",0,0
"Pharmacokinetics and metabolism of [ENTITY_A], a novel [ENTITY_B] inhibitor, in humans.",1,0
"However, the apparent affinity for [ENTITY_A] transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of [ENTITY_B]-mediated transport.",4,0
"The induction in [ENTITY_A] expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after [ENTITY_B] or Wy-14,643 treatment.",0,0
A new series of [ENTITY_A] analogues as [ENTITY_B] inhibitors.,1,0
[ENTITY_A] showed similar activity in the [ENTITY_B] assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM).,1,0
[ENTITY_A] inhibited [ENTITY_B] in HT-29 and DLD-1 cells in a time- and concentration-dependent manner.,1,0
Results showed that neonatal quinpirole treatment induced [ENTITY_A] priming that was eliminated by [ENTITY_B] treatment.,1,0
Inhibition of [ENTITY_A] by a specific inhibitor [[ENTITY_B]; DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.,1,0
"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced [ENTITY_A] inhibition, which was followed by suppression of [ENTITY_B] activity.",1,0
"[ENTITY_A] and phenformin, which are biguanides, have been reported to increase [ENTITY_B] activity without increasing AMP/ATP.",0,0
"However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and [ENTITY_A], a novel mixed [ENTITY_B] blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3.",1,0
"Results of early clinical trials with both topically ([ENTITY_A], CP80,633) and systemically (CC-10004) active [ENTITY_B] inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.",1,0
"Collectively, these results suggest that inhibition of [ENTITY_A] signaling by [ENTITY_B] prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice.",1,0
"Accumulated evidence in humans and animals shows that both [ENTITY_A] and H. pylori upregulate the expression of [ENTITY_B] both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1.",0,0
[ENTITY_A] inhibits [ENTITY_B]-induced inflammatory responses in vitro and in vivo.,1,0
[ENTITY_A] is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by [ENTITY_B].,4,0
"The aim of the present study was to evaluate the cardiac effects of the [ENTITY_A] agonist [ENTITY_B], and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man.",2,0
The reaction was inhibited by the specific [ENTITY_A] inhibitors [ENTITY_B] and fluoxetine.,1,0
"PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the [ENTITY_A] inhibitor, [ENTITY_B], and resulting changes in semen parameters.",1,0
"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective [ENTITY_A] agonist [ENTITY_B] and by the selective beta2AR agonist fenoterol.",2,0
[ENTITY_A] block of recombinant [ENTITY_B]: selectivity for the NR2B subunit.,1,0
"Hydrogen sulfide ([ENTITY_A]), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase ([ENTITY_B]) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.",4,0
"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, [ENTITY_A] (apocynin) an inhibitor of [ENTITY_B] and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.",1,0
"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in [ENTITY_A] (COT) decreased activity toward its natural substrates, medium- and long-chain [ENTITY_B], and increased activity toward short-chain acyl-CoAs.",4,0
"Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of [ENTITY_A] causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid ([ENTITY_B]) instead of PGH2.",4,0
"Further, both the [ENTITY_A] were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like [ENTITY_B], osterix, RunX2, osteoprotegerin and osteocalcin.",0,0
"We found that [ENTITY_A] inhibits interleukin-2 (IL-2) and [ENTITY_B]-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.",0,0
"Previous studies demonstrated that the [ENTITY_A]-selective orthosteric agonist, [ENTITY_B] produced anxiolytic- but not antidepressant-like effects upon peripheral administration.",2,0
"In fact, we demonstrated a significant stimulation of [ENTITY_A] activity by 4 [ENTITY_B] derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx™, and chondrocyte cell lines.",0,0
"Increased immunohistochemical labeling of [ENTITY_A], VEGF, and BNP in the ventricular myocardium was observed in the shunt group and [ENTITY_B] again normalized the labeling.",1,0
"We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of [ENTITY_A] inhibitor [ENTITY_B] or the antimetabolite 5-fluorouracil.",1,0
"Cotreatment with [ENTITY_A] and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and [ENTITY_B].",1,0
"In contrast, combined pretreatment with [ENTITY_A] ([ENTITY_B] antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).",3,0
"[ENTITY_A], but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes [ENTITY_B] autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.",0,0
Elucidation of the [ENTITY_A] structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate [ENTITY_B].,4,0
"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial [ENTITY_A] agonist [ENTITY_B] (McN-A-343) and histamine.",2,0
"Incubation of rat aortic membranes with the irreversible [ENTITY_A] antagonist, [ENTITY_B] (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",3,0
Secretion of [ENTITY_A] protein in the presence of increasing concentrations of [ENTITY_B] followed a similar pattern as observed for GM-CSF mRNA.,0,0
It was concluded that [ENTITY_A] selectively reduces both N- and R-type Ca2+ currents by activating a [ENTITY_B] probably through the EP3 receptor in paratracheal ganglion cells.,0,0
"Systemic administration of [ENTITY_A] agonists, [ENTITY_B] and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.",2,0
Effectiveness of [ENTITY_A] inhibition ([ENTITY_B]) in congestive heart failure.,1,0
These compounds resulted from our efforts to merge the pharmacophores of selective [ENTITY_A] inhibitor [ENTITY_B] with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.,1,0
Our results show that [ENTITY_A] directly inhibits stomach [ENTITY_B] production and secretion through AMPK.,1,0
"Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for [ENTITY_A], suggesting that the in vivo exposure to [ENTITY_B] progressed to neuronal death.",1,0
Kinetic studies with [ENTITY_A] demonstrated that it was a time-dependent and slowly reversible inhibitor of [ENTITY_B] that exhibited at least two binding steps during inhibition.,1,0
RESULTS: Pretreatment of lung tissues with [ENTITY_A] alone significantly decreased the amount of [ENTITY_B] protein in the culture medium by 40%.,1,0
"Unlike GW660511X, [ENTITY_A] abolished the production of [ENTITY_B] and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.",1,0
"Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the [ENTITY_A]-induced [ENTITY_B] increase.",0,0
"In the interaction of [ENTITY_A] and CAR, [ENTITY_B] inhibition was stronger but without any statistical significance.",1,0
"In particular, we showed that [ENTITY_A] significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and [ENTITY_B] (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.",1,0
These data suggest that the [ENTITY_A] side chain and the position of the hydroxy group are important for high [ENTITY_B] inhibitory activity.,1,0
"Repeated [ENTITY_A] resulted in [ENTITY_B] phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell.",0,0
"In the presence of the system L inhibitor BCH, Na(+)-dependent [ENTITY_A] uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through [ENTITY_B].",4,0
"Indomethacin activates [ENTITY_A] and antagonizes the effect of the specific carbonic anhydrase inhibitor [ENTITY_B], by a direct mechanism of action.",1,0
"We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both [ENTITY_A] and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of [ENTITY_B] from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.",1,0
"In vitro, V(5+) decreased the [ENTITY_A]-mediated induction of [ENTITY_B] mRNA, protein, and catalytic activity levels.",0,0
"In the liver of rats given [ENTITY_A] as initiating agent at the dose of 500 mg/kg/week for 6 successive weeks, [ENTITY_B]-positive foci were detected only in 3 of 10 rats.",0,0
"These results indicate that [ENTITY_A] are selective agonists for [ENTITY_B] over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.",2,0
The [ENTITY_A] induced reduction in [ENTITY_B] did not differ in OB and sham-operated control rats.,1,0
[ENTITY_A] inhibits growth of tumors through [ENTITY_B] degradation independent of antiangiogenesis.,1,0
"In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an [ENTITY_A] inhibitor ([ENTITY_B]).",1,0
"[ENTITY_A], a [ENTITY_B] antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.).",3,0
"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ([ENTITY_A]), blocked [ENTITY_B]-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",1,0
"We found that [ENTITY_A] inhibits [ENTITY_B] (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.",1,0
RESULTS: [ENTITY_A] inhibited [ENTITY_B] Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.,1,0
"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized [ENTITY_A] by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the [ENTITY_B] reuptake process.",4,0
[ENTITY_A] protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of [ENTITY_B] in the CNS.,0,0
The results suggest that the suppression of [ENTITY_A] activity by auranofin may be the molecular mechanism through which [ENTITY_B] exerts anti-rheumatic activity.,1,0
[ENTITY_A] agonist and D2 receptor antagonist effects of the natural product [ENTITY_B]: molecular modeling and dynamics simulations.,2,0
[ENTITY_A]-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small [ENTITY_B].,1,0
The [ENTITY_A] hydroxylation index reflects [ENTITY_B] activity in healthy Japanese volunteers.,4,0
"In humans, [ENTITY_A] deficiency results in the accumulation of [ENTITY_B] at the expense of folate derivatives required for purine and thymidylate biosynthesis.",4,0
The [ENTITY_A]-induced [ENTITY_B] expression was positively correlated with the apoptotic effect of TSA in HCC cells.,0,0
"The purified [ENTITY_A] is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by [ENTITY_B] or phosphatidylethanolamine (PE), and is maximally activated by PS.",0,0
"The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of [ENTITY_A] to [ENTITY_B] and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.",1,0
"[ENTITY_A] plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, [ENTITY_B] and HRV decrease significantly in a dose-response way.",1,0
"In addition, we also showed that the elevation in alanine levels and the inhibition of [ENTITY_A] in the brain are retained after 14 days of [ENTITY_B] treatment, and that PLZ produces a marked increase in extracellular levels of alanine.",1,0
"Taken together, our results demonstrate the ability of [ENTITY_A] to inhibit [ENTITY_B] inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.",1,0
The studies with dThyd rescue from [ENTITY_A]-cdk2 protein overexpression and growth inhibition by [ENTITY_B] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.,1,0
"These results indicate that [ENTITY_A] suppresses body weight gain in mice, possibly at least related to the up-regulation of [ENTITY_B] gene expression.",0,0
Patients with acute vitiligo have low epidermal [ENTITY_A] expression/activities and accumulate 10(-3) M [ENTITY_B].,4,0
Indomethacin abolished the inhibitory effect of [ENTITY_A] on [ENTITY_B] and CA II.,1,0
"OBJECTIVE: To determine (a) whether [ENTITY_A] inhibition alone with [ENTITY_B] blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.",1,0
"In contrast, the selective [ENTITY_A] antagonists ICI-118,551 and butoxamine inhibited [ENTITY_B]-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",2,0
We present a new study that optimizes the Prescott-Jones colorimetric assay to measure [ENTITY_A]-dependent [ENTITY_B] generation in kidney homogenates.,4,0
Experimental studies performed for characterizing the inhibitory mechanism indicate that [ENTITY_A] inhibition by [ENTITY_B] cannot be competed out by ATP nor peptide substrate.,1,0
"[ENTITY_A], an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters ([ENTITY_B] and NET, respectively).",1,0
"[ENTITY_A] treatment also increased phosphorylation of [ENTITY_B] and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.",0,0
"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of [ENTITY_A] even after inactivation of [ENTITY_B] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",2,0
"Rates of [ENTITY_A] N-oxygenation (catalyzed by [ENTITY_B]) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.",4,0
"Moreover, [ENTITY_A] reduced the LPS-induced [ENTITY_B] production by KCs by decreasing TNF-alpha messenger RNA.",1,0
"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and [ENTITY_A] (-12.9%) had lower [ENTITY_B] selectivity than at IC50.",1,0
Treatment of both differentiating adipocytes and fully differentiated adipocytes with [ENTITY_A] caused a dose-dependent increase in mRNA levels for [ENTITY_B] target genes such as aP2 and adiponectin.,0,0
[ENTITY_A] was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and [ENTITY_B] antagonist.,3,0
"Hepatic [ENTITY_A] activity was significantly lower in both [ENTITY_B] and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.",1,0
[ENTITY_A] treatment is also associated with lower circulating levels of the [ENTITY_B] ghrelin.,1,0
"Taken together, our findings indicate that 5HHMF suppresses [ENTITY_A] production through modulation of iNOS, consequently suppressing [ENTITY_B] activity and induction of Nrf2-dependent HO-1 activity.",1,0
Pharmacological properties of [ENTITY_A] as a member of a new class of [ENTITY_B] antagonists.,3,0
"These findings indicate that MBE and its [ENTITY_A] suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of [ENTITY_B] may be involved in the underlying mechanism.",1,0
"Independent of dietary [ENTITY_A], supplemental Met increased hepatic [ENTITY_B] activity approximately 30%.",0,0
[ENTITY_A] are biosynthesised from androgens by the [ENTITY_B] enzyme complex called aromatase.,4,0
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), [ENTITY_A] (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [ENTITY_B] was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",1,0
Isoform-specific inhibition of [ENTITY_A] by [ENTITY_B] is independent of isoform-specific gating properties.,1,0
It is thought to play a critical role in the visual cycle by functioning as an acceptor of [ENTITY_A] from the [ENTITY_B] reaction.,4,0
"Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial [ENTITY_A] agonist, [ENTITY_B] (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.",2,0
"Sitagliptin. [ENTITY_A], an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the [ENTITY_B] glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.",0,0
"Similar to [ENTITY_A], both camphor and cinnamaldehyde (initially reported to be specific activators of [ENTITY_B] and TRPA1, respectively) also modulate other thermoTRPs.",0,0
"Although a proton-stimulated uptake of [ENTITY_A] was demonstrated in [ENTITY_B](+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-/-) mice.",4,0
"The IC50 values for [ENTITY_A] mRNA inhibition in the tumor and skin by [ENTITY_B] were estimated to be 0.0457 and 0.113 μg/ml, respectively.",1,0
"In hearts treated with [ENTITY_A] for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and [ENTITY_B] activity was elevated at 36 min.",0,0
"In line with this observation, incubation of striatal slices with [ENTITY_A] and calyculin A, two inhibitors of [ENTITY_B], increased Ser240/244 phosphorylation.",1,0
Chronic insulin (24 h) activates NHE3 through the classic [ENTITY_A]-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor [ENTITY_B] or a dominant-negative SGK1.,1,0
"CONCLUSION: [ENTITY_A] up-regulated the density of [ENTITY_B] in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues.",0,0
"We then showed that static exposure of embryos to [ENTITY_A] (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent [ENTITY_B] inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water.",1,0
Activation of [ENTITY_A] with [ENTITY_B] attenuates diabetes induced myocardial injury in rats.,0,0
3D-QSAR-assisted drug design: identification of a potent [ENTITY_A]-based [ENTITY_B] inhibitor.,1,0
"Some 5-HT3 antagonists have [ENTITY_A] agonist activity (for example, [ENTITY_B], zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",2,0
"Thus, in 158N cells, the ability of [ENTITY_A] to trigger a mode of cell death by apoptosis involving [ENTITY_B] and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.",0,0
Here we present [ENTITY_A] and borinic acid derivatives as a new class of potent and nontoxic [ENTITY_B] inhibitors.,1,0
"Serum markers of liver damage ([ENTITY_A], ALT, ALP and Bilirubin) were increased by [ENTITY_B] and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).",0,0
[ENTITY_A] identifies novel antagonist binding determinants in the [ENTITY_B].,3,0
A novel retinoic acid-responsive element regulates [ENTITY_A]-induced [ENTITY_B] expression.,0,0
"Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on [ENTITY_A]-stimulated [ENTITY_B] secretion.",0,0
"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected [ENTITY_A]-transformed cells from apoptosis induced by [ENTITY_B] deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.",1,0
The [ENTITY_A]-blocking action of [ENTITY_B] per se does not appear to be involved in the rapid pressor response to cocaine.,1,0
"The overall results indicate that [ENTITY_A] may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the [ENTITY_B] pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.",0,0
"The immune response modifiers, [ENTITY_A] and resiquimod, are TLR7 agonists that induce [ENTITY_B] in numerous species, including humans.",0,0
"CONCLUSIONS: [ENTITY_A] reduces [ENTITY_B]-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.",1,0
"Likewise, [ENTITY_A] steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM [ENTITY_B] and 20 microM AACOCF3.",1,0
"Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other [ENTITY_A] effected an increase in [ENTITY_B] levels in human acute myeloid leukemia U937 cells.",0,0
The binding of [ENTITY_A]-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists [ENTITY_B] and clemastine.,1,0
"The cytosolic [ENTITY_A] is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in [ENTITY_B] biosynthesis.",4,0
"The high fat diet significantly increased hepatic mRNA expressions of [ENTITY_A], SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with [ENTITY_B].",1,0
"The transcriptional activity of torafugu [ENTITY_A] was enhanced 4.5- and 11.5-fold by [ENTITY_B] and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.",0,0
"Comparison of the effect of [ENTITY_A] (a [ENTITY_B] inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial.",1,0
"Inhibition of [ENTITY_A] significantly increased vascular [ENTITY_B] production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol.",4,0
[ENTITY_A] inhibits the checkpoint [ENTITY_B] ATM.,1,0
"[ENTITY_A] (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the [ENTITY_B] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",3,0
[ENTITY_A] evokes [ENTITY_B] activation in bovine aortic endothelial cell cultures.,0,0
"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting [ENTITY_A] agonist that is the [ENTITY_B]) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).",2,0
"Additionally, [ENTITY_A] and Cl- ions coactivate [ENTITY_B] receptors by establishing a dipole, accounting for their common effect on KARs.",0,0
Only [ENTITY_A] inhibited [ENTITY_B] and ALA-T and elevated ALA levels.,1,0
[ENTITY_A] inhibits melanogenesis through downregulation of C/EBP α-dependent expression of [ENTITY_B] gene.,1,0
"Other dams received 1.8ng/kg/day of a mixture of [ENTITY_A] (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and [ENTITY_B]) without or with 0.5M (0.5MAhR).",2,0
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of [ENTITY_A] mRNA by [ENTITY_B] depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway.,0,0
Polymorphisms in dopamine transporter ([ENTITY_A]) are associated with stimulant effects of [ENTITY_B]: an exploratory pharmacogenetic study using healthy volunteers.,0,0
These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family [ENTITY_A][ENTITY_B] kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.,4,0
[ENTITY_A] inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of [ENTITY_B].,1,0
"High [ENTITY_A] turnover catalyzed by [ENTITY_B] is essential for neural functions, especially learning.",4,0
[ENTITY_A] blockade is one of the more prominent actions of the multi-receptor acting antipsychotic [ENTITY_B].,1,0
"Distinct roles of [ENTITY_A] in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of [ENTITY_B] and CREB activation in hippocampus and prefrontal cortex.",0,0
[ENTITY_A] modulates intercellular adhesion through inhibition of [ENTITY_B].,1,0
Sedation and [ENTITY_A] antagonism: studies in man with the enantiomers of chlorpheniramine and [ENTITY_B].,3,0
"In breast cancer, intratumoural [ENTITY_A] is the source for local [ENTITY_B] production in the tissue.",4,0
"[ENTITY_A] is much less potent as a MAO inhibitor in cells with the [ENTITY_B], such as the myocardial cells of the heart.",4,0
Structure-activity relationship studies indicated that [ENTITY_A] moiety is a favorable scaffold to exert the [ENTITY_B] inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.,1,0
We have previously reported that [ENTITY_A] reduce estrogen synthesis by inhibiting [ENTITY_B] activity in human granulosa cells (HGC).,1,0
"Compounds of several other structural families, including the [ENTITY_A] AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [ENTITY_B] kinase.",1,0
"In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged [ENTITY_A] antagonist activity of [ENTITY_B].",3,0
"Furthermore, [ENTITY_A] inhibited [ENTITY_B] activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65.",1,0
"[ENTITY_A] (XL184) is a small-molecule [ENTITY_B] inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.",1,0
"[ENTITY_A] and 1400W attenuated the mRNA expression of [ENTITY_B] and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS.",1,0
"Moreover, we found that [ENTITY_A] significantly inhibited the expression levels of [ENTITY_B] (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).",1,0
[ENTITY_A] is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of [ENTITY_B].,1,0
TCDD or prochloraz doubled [ENTITY_A]-mediated [ENTITY_B] secretion.,4,0
"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal [ENTITY_A], BDNF and ChAT that was eliminated by [ENTITY_B] treatment.",0,0
"Thus, we found that [ENTITY_A] enhances heme oxygenase-1 (HO-1) expression via [ENTITY_B] (Nrf2) activation.",0,0
"These results indicate transcription of [ENTITY_A] is regulated by the NR5A family and [ENTITY_B] signaling, and participates in steroid hormone production in ovarian granulosa cells.",0,0
"Interestingly, there was a loss in the binding of ICAM2 to [ENTITY_A] during [ENTITY_B]-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.",1,0
"We examined the effect of JTH-601 (3- inverted question mark[ENTITY_A] ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [ENTITY_B] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",3,0
"GnRH stimulation of [ENTITY_A] phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, [ENTITY_B].",1,0
"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas [ENTITY_A] decreased in the [ENTITY_B]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.",1,0
"Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the [ENTITY_A] derivative 11h displayed the most potent [ENTITY_B] inhibitory activity with an IC50 value of 0.247 μM.",1,0
These results suggest that [ENTITY_A] induction of [ENTITY_B] in the rat striatum is related to dopamine D1 and NMDA receptors.,0,0
"Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic [ENTITY_A] (AAS) were activating [ENTITY_B] and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR.",0,0
"In patients who do not reach the LDL-C target, combination therapy with additional [ENTITY_A]-C lowering drugs (e.g. [ENTITY_B], bile acid sequestrants or fibrates) should be considered.",1,0
"Meanwhile, autophagy was detected as early as 12 h after an exposure to low-dose [ENTITY_A], as indicated by an up-regulated expression of [ENTITY_B] and beclin-1 proteins.",0,0
"One group of experimental animals was treated with [ENTITY_A] (5-LO) inhibitor, [ENTITY_B] (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.), immediately before blast.",1,0
"[ENTITY_A] locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of [ENTITY_B].",3,0
These five CGPs also inhibited [ENTITY_A] uptake by [ENTITY_B].,4,0
[ENTITY_A] (D-1997): a novel agonist at [ENTITY_B] in the canine basilar artery.,2,0
"Using [ENTITY_A] as a reference [ENTITY_B] (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.",1,0
[ENTITY_A] derived from Grundmann's ketone as a novel chemotype of [ENTITY_B] inhibitors.,1,0
K(m) values of the mutants for [ENTITY_A] were similar to that of full-length [ENTITY_B].,4,0
"RESULTS: [ENTITY_A] directly inhibited [ENTITY_B] activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion.",1,0
We report here the optimization of [ENTITY_A] inhibitors in the [ENTITY_B] class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group.,1,0
"As a result of this study, [ENTITY_A] (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit [ENTITY_B] antagonistic activity for both the hα3β4 and hα4β2 receptor subtypes.",3,0
"Moreover, activation of the [ENTITY_A] and CREB signaling pathway in the hippocampus might be involved in [ENTITY_B]-induced spatial memory changes.",0,0
Nitric oxide products of [ENTITY_A] displayed significantly diminished [ENTITY_B]-dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells.,1,0
"We conclude that [ENTITY_A] can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the [ENTITY_B] ALP, presumably by an androgen receptor mediated mechanism.",0,0
"The specific [ENTITY_A] inhibitor, [ENTITY_B], blocked significantly EGF-induced cell migration and invasion.",1,0
"Methylation-specific PCR and bisulfite sequencing identified methylation of this [ENTITY_A] ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in [ENTITY_B] concentrations noted with advancing postnatal age (PN14 vs PN3).",0,0
Blockage of the [ENTITY_A] by the gastrointestinal prokinetic agent [ENTITY_B].,1,0
"Ferredoxin 1 ([ENTITY_A]; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including [ENTITY_B] hormone synthesis in mammalian tissues.",4,0
[ENTITY_A] is an [ENTITY_B] antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.,3,0
The structure-activity relationships revealed that the free [ENTITY_A] group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of [ENTITY_B].,1,0
"HbA1c level in DM12W group was higher than in DM4W group, [ENTITY_A] level in [ENTITY_B]+DM8W group was lower than in DM8W group.",1,0
[ENTITY_A] also inhibited [ENTITY_B] with an IC-50 of 43 microM.,1,0
"In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the [ENTITY_A]-induced [ENTITY_B] activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus.",0,0
"Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. threo-methylphenidate inhibits the [ENTITY_A] and the norepinephrine transporter, resulting in elevations of these [ENTITY_B] after impulse release.",4,0
"Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-[ENTITY_A] inhibitors (MKIs) [ENTITY_B], sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.",1,0
[ENTITY_A] is a long-acting [ENTITY_B] antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).,3,0
"Hence, [ENTITY_A] has the ability to inhibit both the [ENTITY_B] and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy.",1,0
"In this study, we assessed the effects of [ENTITY_A] and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with [ENTITY_B] polymorphisms in humans.",1,0
"We have examined the effects of the synthetic [ENTITY_A] inhibitor, [ENTITY_B] (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.",1,0
[ENTITY_A]/Cl- dipole couples agonist binding to [ENTITY_B] activation.,0,0
"In addition, [ENTITY_A]-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by [ENTITY_B].",1,0
These results underscore a role for [ENTITY_A] in [ENTITY_B] metabolism.,4,0
"Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including [ENTITY_A], doxorubicin, actinomycin-D, and rapamycin, which are also [ENTITY_B] substrates.",4,0
"These data suggest that [ENTITY_A]-induced intracellular GTP depletion recruits a super elongation complex containing [ENTITY_B], AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.",0,0
"A series of 2-carbonyl analogues of the muscarinic antagonist [ENTITY_A] bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the [ENTITY_B] subtypes was evaluated by functional tests.",3,0
Discovery of novel [ENTITY_A] derivatives as [ENTITY_B] inhibitors.,1,0
[ENTITY_A] modulates [ENTITY_B] synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells.,4,0
Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of [ENTITY_A]-inhibited [ENTITY_B] in vitro.,1,0
"The GRIP1 reduction was inhibited by [ENTITY_A], an [ENTITY_B] antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.",3,0
"After 12 months of treatment, [ENTITY_A] significantly improved all end points (plasma concentration of [ENTITY_B] [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).",1,0
"Altogether, our findings support a model in which Top2β deficiency promotes [ENTITY_A]-induced apoptosis in quiescent non-S-phase cells, possibly due to [ENTITY_B] depletion and p53 accumulation.",1,0
"[ENTITY_A], popularly known for its cooling effect, activates [ENTITY_B]--a cold-activated thermoTRP ion channel.",0,0
"Intraperitoneal administration of [ENTITY_A] (2.5-10 mg/kg), a nonselective [ENTITY_B] antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.",3,0
"In macrophages, levels of [ENTITY_A], IFN-γ, NO, IL-6 and IL-10 were increased by [ENTITY_B] used alone or in combination with HSV-2.",0,0
This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to [ENTITY_A]-mediated [ENTITY_B] depletion.,4,0
"[ENTITY_A] (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either [ENTITY_B].",2,0
Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual [ENTITY_A]/NEP inhibitors [ENTITY_B] and omapatrilat.,1,0
Our results indicate that Salix extract 1520L inhibits [ENTITY_A]-mediated [ENTITY_B] release through compounds other than salicin or salicylate.,4,0
[ENTITY_A] (KA) is an endogenous [ENTITY_B] antagonist at the level of the different ionotropic glutamate receptors.,3,0
"[ENTITY_A] (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in [ENTITY_B] biosynthesis and oxidation.",4,0
[ENTITY_A] (30 mg/kg) also significantly decreased the protein levels of [ENTITY_B] but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.,1,0
"The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with [ENTITY_A], whereas [ENTITY_B] and esterified-DEX had full transactivation agonistic activity.",2,0
"[ENTITY_A], a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits [ENTITY_B], which catalyses the first committed step in glycosphingolipid synthesis.",1,0
"Phenserine. [ENTITY_A], a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase ([ENTITY_B]) and was shown to improve cognition in various experimental paradigms in rodents and dogs.",1,0
Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective [ENTITY_A] agonist [ENTITY_B].,2,0
[ENTITY_A] inhibits [ENTITY_B] secretion via pertussis toxin-sensitive mechanisms.,1,0
"[ENTITY_A] (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters ([ENTITY_B] and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.",3,0
"From these results, it is suggested that [ENTITY_A] may enhance the vasodilatory effect of adenosine by inhibiting [ENTITY_B].",1,0
"As determined by Western and Northern blot analyses, [ENTITY_A] inhibited the P4-induced [ENTITY_B] gene expression in a dose-dependent manner.",1,0
[ENTITY_A] also increases [ENTITY_B] (Aβ) deposition and tau pathology.,1,0
"Moreover, the specific [ENTITY_A]-inhibitor [ENTITY_B] (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.",1,0
"Results indicate that [ENTITY_A] inhibits HSV-2 multiplication in epithelial cells and also increases [ENTITY_B] production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.",0,0
"Selective inhibition of [ENTITY_A] is a rational therapeutic approach in ED, as proved by the clinical success of [ENTITY_B].",1,0
[ENTITY_A] markedly increased postprandial plasma [ENTITY_B] release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.,0,0
The absence or presence of a cytosolic pool of [ENTITY_A] has important implications for the intracellular transport of unconjugated/deconjugated [ENTITY_B].,4,0
The bihelical [ENTITY_A] effluxes [ENTITY_B] from cells and reduces inflammation and atherosclerosis in animal models.,4,0
"[ENTITY_A], a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of [ENTITY_B] (AMPK).",0,0
Anti-inflammatory effect of [ENTITY_A] via the suppression of [ENTITY_B] pathway.,1,0
Evaluation of drug interactions of [ENTITY_A] (a [ENTITY_B] agonist) with statins: from in vitro data to clinical study design.,2,0
These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of [ENTITY_A] mediated [ENTITY_B] is temporally related to NSAID analgesia.,4,0
"Enhancement of radiosensitivity by [ENTITY_A] inhibitor, [ENTITY_B] and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.",1,0
"The kinetic parameters for the [ENTITY_A] hydration reaction proved [ENTITY_B] to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C). hCA VI has a significant catalytic activity for the physiological reaction on the same order of magnitude as the ubiquitous isoform CA I or the transmembrane, tumor-associated isozyme CA IX.",4,0
"The peptide [ENTITY_A] (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and [ENTITY_B] induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.",1,0
"While none of the phenethylamides (n = 2) were active, most of the [ENTITY_A] (n = 0) turned out to moderately or strongly inhibit [ENTITY_B].",1,0
"ATB-429-induced antinociception was reversed by [ENTITY_A], a [ENTITY_B] inhibitor.",1,0
"A reporter construct driven by 4 kb of the [ENTITY_A] 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by [ENTITY_B].",0,0
Correlation between activation of PPARγ and [ENTITY_A] downregulation in a mouse adipocyte cell line by a series of [ENTITY_B].,1,0
"GIP potentiates [ENTITY_A]-stimulated [ENTITY_B] secretion and induces energy accumulation into adipose tissue, resulting in obesity.",0,0
"In addition, when [ENTITY_A] was given to conscious rats, the inhibitory effect on [ENTITY_B]-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours.",1,0
"[ENTITY_A] is present exclusively in the mitochondria, making this compartment the sole site of synthesis of [ENTITY_B] in the plant cell.",4,0
These results showed that [ENTITY_A] and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to [ENTITY_B] drugs.,0,0
"[ENTITY_A], a [ENTITY_B] antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells.",3,0
[ENTITY_A]-mediated downregulation of [ENTITY_B] mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.,1,0
[ENTITY_A] increased both [ENTITY_B]/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).,0,0
Mitochondrially-bound [ENTITY_A] (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of [ENTITY_B].,4,0
[ENTITY_A] is a peripheral opiate agonist able to inhibit [ENTITY_B] secretion.,1,0
"In the subsequent enzymatic assay, it was shown that [ENTITY_A] inhibited [ENTITY_B] activity competitively with a K(i) value of 31.6 micromol/L.",1,0
"We further show that [ENTITY_A] inhibits [ENTITY_B], potentially explaining the use of menthol as an analgesic.",1,0
"From these results, it is proposed that [ENTITY_A] activity determines p-HPAA concentrations by regulating [ENTITY_B] availability.",4,0
"After [ENTITY_A] administration [ENTITY_B] levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.",1,0
"In cultures from severely obese subjects, [ENTITY_A] induced a decrease of [ENTITY_B] antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05).",1,0
"[ENTITY_A] up-regulated the expression of Bax, down-regulated the expression of [ENTITY_B], and significantly increased the ratio of Bax/Bcl-2.",1,0
Lineweaver-Burk plots demonstrated that [ENTITY_A] inhibited the activities of [ENTITY_B] and CYP3A in a non-competitive manner in rat liver microsomes (RLMs).,1,0
"SIRT1 co-precipitated with PPARα and [ENTITY_A] increased the acetylation of the PPARα coactivator [ENTITY_B], which was suppressed by resveratrol.",0,0
"GTLE pretreatment completely reversed the damaging effects of [ENTITY_A] on AA and [ENTITY_B] activity, markedly corrected COX and AChE activities, and moderately improved TGC.",1,0
"On study day 1, [ENTITY_A] acutely increased plasma [ENTITY_B] levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures.",0,0
RESULTS: [ENTITY_A] given to rats in drinking water decreased the level of [ENTITY_B] protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol.,1,0
"We used [ENTITY_A], a well-known disruptor of [ENTITY_B]-Mdm2 interaction, to validate the specificity of the assay.",1,0
[ENTITY_A] reduce hydroperoxides to the corresponding [ENTITY_B] by means of glutathione (GSH).,4,0
[ENTITY_A] (300 microM) reduced [ENTITY_B] Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).,1,0
[ENTITY_A] is a selective [ENTITY_B] antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.,3,0
"[ENTITY_A] is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize [ENTITY_B] as well.",3,0
"BG also showed a protective effect in the presence of a [ENTITY_A] inhibitor ([ENTITY_B], Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.",1,0
[ENTITY_A] intoxication caused hepatic necrosis and increased serum [ENTITY_B] activity.,0,0
"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified [ENTITY_A]-mediated reductions in c-myc and IRF4 expression and increases in p21([ENTITY_B]) expression.",0,0
"Here, we show that at noncytotoxic concentrations, [ENTITY_A] was able to inhibit NO production and [ENTITY_B] (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).",1,0
Synthesis and structure-activity relationship of [ENTITY_A] derivatives as potent and selective [ENTITY_B] (ACAT2) inhibitors: Part 2.,1,0
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using [ENTITY_A]/D5 ([ENTITY_B]), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.",3,0
"To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the [ENTITY_A]-specific orthosteric agonist [ENTITY_B] (DCPG).",2,0
"[ENTITY_A] (AP24534) is a [ENTITY_B] inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.",1,0
[ENTITY_A] (Mesupron®) is a new small molecule [ENTITY_B] inhibitor.,1,0
"[ENTITY_A] activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to [ENTITY_B].",0,0
"In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as [ENTITY_A], both of which down-regulated [ENTITY_B] protein levels but not p300 mRNA levels.",1,0
"[ENTITY_A], a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to [ENTITY_B] blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.",1,0
"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [ENTITY_A] (COX), the enzyme that mediates biosynthesis of [ENTITY_B] and thromboxanes from arachidonic acid.",4,0
We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that [ENTITY_A] kinase activity is directly inhibited by [ENTITY_B] in vitro.,1,0
Kinetic constants of the mutant [ENTITY_A] showed modification in favor of longer [ENTITY_B] as substrates.,4,0
[ENTITY_A] caused significant increases in both [ENTITY_B] mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.,0,0
[ENTITY_A] and letrozole are both non-steroidal [ENTITY_B] inhibitors that compete with the substrate for binding to the enzyme active site.,1,0
"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the [ENTITY_A]-generated nitrosoguanidine metabolite was decreased by 30% with [ENTITY_B] and 56% with hydralazine and 86% in the AOX-deficient mice.",1,0
"The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [ENTITY_A] (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased [ENTITY_B] (CAT) activity compared with the control.",0,0
[ENTITY_A] strongly inhibited high glucose-induced [ENTITY_B] (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.,1,0
We investigated the effect of [ENTITY_A] blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent [ENTITY_B].,1,0
"Two beta(2)-agonists, [ENTITY_A] and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [ENTITY_B] selectivity.",2,0
HeLa cells transfected with the MR77 gene exhibited inhibition of [ENTITY_A] in response to [ENTITY_B].,1,0
Valproic acid selectively inhibits conversion of arachidonic acid to [ENTITY_A] by [ENTITY_B]: relevance to bipolar disorder.,4,0
"In addition, [ENTITY_A] treatment significantly reduced the specific [ENTITY_B] activity after SCI as compared to that of vehicle control.",1,0
"Our data indicate that [ENTITY_A] metabolites perform as androgen antagonists of [ENTITY_B], an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.",3,0
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective [ENTITY_A] antagonist-[ENTITY_B] [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).",3,0
"We also examined the effects of [ENTITY_A], a [ENTITY_B] antagonist, in parallel.",3,0
Glycylsarcosine coadministration could inhibit the uptake of [ENTITY_A] in [ENTITY_B](+/+) mice (p < 0.01) but not PEPT2(-/-) mice.,4,0
"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the [ENTITY_A] agonist [ENTITY_B] (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75 mg/kg b.w.",2,0
Objective: This study explores the ability of [ENTITY_A] to act as substrates or inhibitors of [ENTITY_B] (hCES1) and 2 (hCES2).,4,0
"On the other hand, the accumulation of [ENTITY_A] through the C1-THF synthase/[ENTITY_B] pathway in glyD plants was 2.5-fold greater than that in WT plants.",4,0
"Exogenous [ENTITY_A] transiently activated [ENTITY_B] and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation.",0,0
"All three compounds displayed antagonistic properties against [ENTITY_A] in vitro, with [ENTITY_B] being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).",1,0
"These results indicate that the positive inotropic effect, mediated via [ENTITY_A]- and oxymetazoline-sensitive subtype of [ENTITY_B], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",3,0
"We have investigated the effects of [ENTITY_A] [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a [ENTITY_B] antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.",3,0
[ENTITY_A] treatment decreases 3H-nisoxetine binding and [ENTITY_B] mRNA in SK-N-SHSY5Y cells.,1,0
"As a potent synthetic [ENTITY_A] inhibitor (IC50=850nM, versus [ENTITY_B] of 8.1μM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.",1,0
"The [ENTITY_A] antagonist, [ENTITY_B] (0.5 mg/kg), was without antagonistic effects.",3,0
[Pharmacological effects of a [ENTITY_A] antagonist [ENTITY_B] on alcohol dependence].,3,0
"Previous studies have resulted in the classification of [ENTITY_A] as a selective inhibitor of neuronal [ENTITY_B] (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.",1,0
"CONCLUSIONS: [ENTITY_A] is an inhibitor of mTOR and an activator of [ENTITY_B], targeting regulators of intracellular energy homeostasis and metabolism.",0,0
"Interestingly, the allele of PRO1 was shown to enhance the activities of [ENTITY_A] and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of [ENTITY_B] synthesis from L-glutamate and which together may form a complex in vivo.",4,0
METHODS: Part A compared the effects of placebo to four doses of a [ENTITY_A] receptor antagonist ([ENTITY_B]) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.,3,0
"It is possible that [ENTITY_A], an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of [ENTITY_B] and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.",1,0
"We report on the inhibitory activity of the NSAIDs meloxicam, [ENTITY_A], phenylbutazone and flunixin, on blood [ENTITY_B] in the horse using in vitro enzyme-linked assays.",1,0
"Although considerable functional diversity exists, most [ENTITY_A] are activated by [ENTITY_B] binding and then dock to a specific cellular membrane.",0,0
We found that [ENTITY_A] activates [ENTITY_B] starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline.,0,0
Expression of the dominant negative mutants [ENTITY_A]-N133I or rab7-N125I blunted [ENTITY_B]-induced down-regulation.,1,0
"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by [ENTITY_A], a selective inhibitor of tyrosine kinase Src responsible for ligand-independent [ENTITY_B] autophosphorylation, but not by ERK inhibitor, PD98059.",0,0
[ENTITY_A] leads to a reduction of [ENTITY_B] mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.,1,0
"The most active of these compounds, [ENTITY_A], is shown to be as potent as pioglitazone at inducing [ENTITY_B] target gene expression.",0,0
The presence of [ENTITY_A] hormones most probably causes the degradation of the [ENTITY_B] permease and impairment of tryptophan import.,1,0
"[ENTITY_A] treatment also induced foci of [ENTITY_B], gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.",0,0
"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the [ENTITY_A][ENTITY_B] channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",4,0
"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, [ENTITY_A] improved [ENTITY_B] to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin.",0,0
"In [ENTITY_A]-induced NPDFs, [ENTITY_B] significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and collagen protein levels.",1,0
"RESULTS: [ENTITY_A]/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by [ENTITY_B].",1,0
"In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher [ENTITY_A] dose, respectively, was needed to cause a 50% inhibition of brain [ENTITY_B] activity.",1,0
"Taken together, our results suggested that [ENTITY_A] protected against Aβ25-35-induced apoptosis at least in part by two complementary GR-dependent [ENTITY_B] phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",0,0
"In this study the neuromuscular blocking drug [ENTITY_A] and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant [ENTITY_B] K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).",1,0
Biochemical analyses showed that NO and ROS production and [ENTITY_A] activity were significantly reduced by [ENTITY_B].,1,0
The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of [ENTITY_A] mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of [ENTITY_B] in 5L cells.,1,0
[ENTITY_A] inhibited the [ENTITY_B] activity of both C-RAF and B-RAF (wild type and V600E mutant).,1,0
Effects of inhibition of [ENTITY_A] (u-PA) by [ENTITY_B] in the cornea and tear fluid of eyes irradiated with UVB.,1,0
"Such model of [ENTITY_A] activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which [ENTITY_B] and Nox4 are implicated.",0,0
Kinetic mechanism of [ENTITY_A] and its inhibition by the antimalarial [ENTITY_B].,1,0
[ENTITY_A] accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding [ENTITY_B].,4,0
"In contrast, [ENTITY_A] markedly downregulated major [ENTITY_B] (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.",1,0
"State-dependent [ENTITY_A] block of [ENTITY_B] isoforms, chimeras, and channels coexpressed with the beta1 subunit.",1,0
[ENTITY_A] stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent [ENTITY_B]/ERK and PI3K/Akt activation.,0,0
"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of [ENTITY_A] synthesis) and [ENTITY_B] (eNOS) protein abundance, but did not alter eNOS phosphorylation.",4,0
"Moreover, recent in vitro studies suggest that [ENTITY_A] abrogates [ENTITY_B] (Abeta) toxicity and possibly inhibits Abeta production.",1,0
"[ENTITY_A] is also a [ENTITY_B] substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.",4,0
"This includes [ENTITY_A] (NRPS) and polyketide synthases (PKS) required for the formation of the [ENTITY_B] core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.",4,0
"[ENTITY_A] had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for [ENTITY_B] and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme.",4,0
Excess of [ENTITY_A] converted into 24OHC may up-regulate [ENTITY_B] synthesis which is a scavenger for Aβ and Tau.,0,0
Nanobody-albumin nanoparticles (NANAPs) for the delivery of a [ENTITY_A] inhibitor [ENTITY_B] to EGFR overexpressing tumor cells.,1,0
Dopamine D1 receptor agonist and [ENTITY_A] antagonist effects of the natural product [ENTITY_B]: molecular modeling and dynamics simulations.,3,0
"In addition, [ENTITY_A] attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing [ENTITY_B] nuclear accumulation.",0,0
"[ENTITY_A] (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and [ENTITY_B].",1,0
CONCLUSIONS: [ENTITY_A] antagonism by [ENTITY_B] lowers heart rate variability and baroreflex gain.,3,0
The involvement of [ENTITY_A] in the absorption of [ENTITY_B] was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.,4,0
"In the presence of IL-18, [ENTITY_A] suppressed the expression of ICAM-1 and CD40 as well as the production of [ENTITY_B], TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",0,0
These five [ENTITY_A] also inhibited [(3)H]E217βG uptake by [ENTITY_B].,1,0
We previously reported that [ENTITY_A] antibiotics reduce [ENTITY_B]-dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity.,1,0
Maqui berry (Aristotelia chilensis) and the constituent [ENTITY_A] inhibit [ENTITY_B] cell death induced by visible light.,0,0
"[ENTITY_A] is a novel drug containing trifluorothymidine, which is phosphorylated by [ENTITY_B] to its active monophosphated form, that in turn can inhibit TS.",4,0
"To assess the feasibility of targeting these high AAAD levels for chemotherapy, [ENTITY_A] inhibitors [ENTITY_B] (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.",1,0
Involvement of [ENTITY_A] mediated metabolism in the absorption of [ENTITY_B] could not be demonstrated in this rat model.,4,0
"[ENTITY_A] (diphenylhydantoin, DPH) is an established [ENTITY_B] blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.",1,0
[ENTITY_A] protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the [ENTITY_B]/heme oxygenase-1 pathway.,0,0
"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas [ENTITY_A] attenuated the phosphorylation of [ENTITY_B] and mTOR in HepG2 cells.",1,0
[ENTITY_A] upregulates the expression of [ENTITY_B] in mouse aortic endothelial cells.,0,0
"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including [ENTITY_A], a coagonist of the [ENTITY_B].",2,0
[ENTITY_A] (SCD-1) gene expression is negatively regulated by [ENTITY_B] without direct binding of thyroid hormone receptor to the gene promoter.,1,0
"FMO3 expression is induced by dietary bile acids by a mechanism that involves the [ENTITY_A] (FXR), a [ENTITY_B]-activated nuclear receptor.",0,0
"[ENTITY_A] treatment also results in modest improvements in total cholesterol, [ENTITY_B], blood pressure, and fasting glucose and insulin concentrations.",0,0
This effect has been attributed to the antagonist effects of [ENTITY_A] at the [ENTITY_B] receptor.,3,0
"Lastly, we found that [ENTITY_A] activation by [ENTITY_B] is mediated by reactive oxygen species (ROS).",0,0
"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of [ENTITY_A] by [ENTITY_B]/SMO.",4,0
We have recently reported that a mono-hydroxylated metabolite of the synthetic [ENTITY_A] cannabinoid JHW-073 (3) exhibits neutral antagonist activity at [ENTITY_B] and thus may serve as a promising lead for the development of novel alcohol abuse therapies.,3,0
"In vitro, [ENTITY_A] decreased the TCDD-mediated induction of [ENTITY_B] mRNA, protein, and catalytic activity levels.",1,0
"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and [ENTITY_A], reduced the [ENTITY_B] release in a concentration dependent manner.",1,0
"While it is an antagonist at these latter receptors, [ENTITY_A] behaves as a [ENTITY_B] agonist in vitro in adenylate cyclase measurements.",2,0
The inhibitory effect of [ENTITY_A] and (+/-)-gossypol acetic acid upon testicular cytosolic [ENTITY_B] was measured in vitro.,1,0
"In contrast, activation of [ENTITY_A] by [ENTITY_B] and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism).",0,0
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited [ENTITY_A]-induced increases in [ENTITY_B] (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.",0,0
"[ENTITY_A] is a highly selective [ENTITY_B] inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.",1,0
TREK-1 currents are insensitive to pharmacological agents that block [ENTITY_A] activity such as [ENTITY_B] and quinidine.,1,0
"The activation may be accelerated by an acute inflammatory process provoked by [ENTITY_A], which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma [ENTITY_B] level which was observed in all during the period.",0,0
"[ENTITY_A], bosentan and glibenclamide inhibit the [ENTITY_B] (Bsep) which transports taurocholate into bile.",1,0
"In medial striatum, TH-ir decreased by 21%, and in hypothalamus [ENTITY_A]-ir increased by 10% in [ENTITY_B]-exposed rats.",0,0
"Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of [ENTITY_A]-mediated [ENTITY_B] transport.",4,0
"Using this assay, we found that both [ENTITY_A] and nitric oxide inhibit renal cortical [ENTITY_B] activity in vitro.",1,0
[ENTITY_A] abolished these anti-[ENTITY_B] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.,1,0
"Phosphorylation of [ENTITY_A] at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to [ENTITY_B].",0,0
"Iontophoresis of [ENTITY_A], whose serotonergic actions include antagonism and partial agonism at [ENTITY_B] receptors, also increased serotonin and decreased firing (n=4).",3,0
The fact that [ENTITY_A] also suppressed [ENTITY_B] production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake.,1,0
Histamine and [ENTITY_A] added to NSAIDs amplified the activating effect of the latter on [ENTITY_B].,0,0
"Administration of low, but not high, doses of oral [ENTITY_A] in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of [ENTITY_B].",0,0
"[ENTITY_A] also increased the numbers of ED2(+), [ENTITY_B](+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.",1,0
"In further evaluation, the representative compound [ENTITY_A] (3b) exhibited potent pro-apoptotic activity, through [ENTITY_B] activation, in HeLa cells.",0,0
The [ENTITY_A] antagonist [ENTITY_B] blocked the FHA-HIS binding on 14-37% of the platelets.,3,0
"Furthermore, compared with control groups, the plaque endothelium level of [ENTITY_A] was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by [ENTITY_B]-HD.",0,0
Inhibition of the actions of [ENTITY_A] by [ENTITY_B] is apparently competitive.,1,0
These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of [ENTITY_A] in the [ENTITY_B] reaction.,4,0
"The decrement of [ENTITY_A] protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of [ENTITY_B] withdrawal, which recovered toward control level after 7 d of ethanol withdrawal.",1,0
"The effects of [ENTITY_A] antagonists, [ENTITY_B] and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.",3,0
"One of the enzymes responsible for the production of [ENTITY_A], [ENTITY_B] (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15).",4,0
Novel racemic [ENTITY_A] analogues as potent [ENTITY_B] inhibitors.,1,0
"[ENTITY_A] (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a [ENTITY_B] agonist and D2 antagonist.",2,0
"In addition, we provide evidence that [ENTITY_A] also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of [ENTITY_B].",0,0
We conclude that [ENTITY_A] can be blocked by certain antipsychotic drugs like [ENTITY_B] and pimozide.,1,0
"Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by [ENTITY_A] through [ENTITY_B] induction.",0,0
Results confirmed that [ENTITY_A] peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of [ENTITY_B].,1,0
"Results: Our results demonstrate that treatment with [ENTITY_A] leads to [ENTITY_B] RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors.",0,0
"db/db mice treated with [ENTITY_A] showed 5- and 3.6-fold inhibition in [ENTITY_B] and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively.",1,0
"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor [ENTITY_A] (CT), to destroy [ENTITY_B] and alpha2-antiplasmin.",1,0
Discovery of [ENTITY_A] (TASP0382088): a potent and selective [ENTITY_B] inhibitor as a topical drug for alopecia.,1,0
BACKGROUND: [ENTITY_A] is a carbamate drug designed to inhibit both [ENTITY_B] and butyrylcholinesterase by reversibly covalently bonding to these enzymes.,1,0
"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by [ENTITY_A], ethoxzolamide, and cyanate, [ENTITY_B] is very similar to CA II.",1,0
INTRODUCTION: Medroxyprogesterone acetate ([ENTITY_A]) induces estrogen receptor (ER)-positive and progesterone receptor ([ENTITY_B])-positive ductal invasive mammary carcinomas in BALB/c mice.,0,0
We identified [ENTITY_A] as a compound that binds to human SIRT5 and showed that it inhibits [ENTITY_B] activity with an IC(50) value of 22 microM.,1,0
"Treatment of A549 and H1299 cells with [ENTITY_A] caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased [ENTITY_B] expression and decreased phosphorylation of Akt and mTOR.",1,0
"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by [ENTITY_A] and by purinergic receptor blockade ([ENTITY_B]).",1,0
"However, [ENTITY_A] produces less systemic beta 2- and possibly [ENTITY_B] blockade than either timolol or levobunolol.",1,0
These findings suggest that oral consumption of [ENTITY_A] enhances the efficacy of [ENTITY_B].,0,0
We then evaluated the interactions with the [ENTITY_A] inhibitor [ENTITY_B] (400 mg q.d.) after nanogram and regular doses of midazolam.,1,0
The inhibitory effect of [ENTITY_A] on the stress-induced plasma [ENTITY_B] level in mice.,1,0
"[ENTITY_A], a well known [ENTITY_B] inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM.",1,0
"Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of [ENTITY_A] formed by the action of [ENTITY_B] is responsible for the elevation of brain ORN observed.",4,0
"Here, we characterize the activation of human pDC with the [ENTITY_A] agonists [ENTITY_B] and resiquimod.",2,0
It has been reported that oligomeric [ENTITY_A] of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and [ENTITY_B]-potentiating activities.,0,0
"It has been known for decades that [ENTITY_A] (LiCl) leads to D-myo-inositol 1-phosphate accumulation on [ENTITY_B] activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.",0,0
"Although naturally occurring electrophilic plant compounds, such as mustard oil and [ENTITY_A], are [ENTITY_B] agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1.",2,0
Human liver microsomes of the wild-type [ENTITY_A] metabolized 5-methoxytryptamine to [ENTITY_B] more effectively than did the defective CYP2D6*4*4 ones.,4,0
"In the long term, [ENTITY_A] has been shown to be more effective than placebo in reducing body weight and serum total and [ENTITY_B] cholesterol levels.",1,0
The beta(2)-adrenoceptor ([ENTITY_A]) agonists [ENTITY_B] and fenoterol have similar beneficial effects in animal models of heart failure.,2,0
"[ENTITY_A], a pure [ENTITY_B] downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.",1,0
"Oral [ENTITY_A] (BELVIQ(®)), a selective serotonin [ENTITY_B] receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes).",2,0
"These results suggested that [ENTITY_A], a preferential [ENTITY_B] inhibitor offered neuroprotection against PTZ-induced kindling in mice.",1,0
[ENTITY_A]: a dual [ENTITY_B] antagonist [corrected].,3,0
"In general, [ENTITY_A] can act on a pattern: rifampicin activates the [ENTITY_B] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.",2,0
"Opening of [ENTITY_A] HCs during repetitive activation allows efflux of [ENTITY_B], influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction.",4,0
"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., [ENTITY_A] or ibutilide in patients with a mutation in the [ENTITY_B]-coding gene KCNH2 (HERG).",1,0
"[ENTITY_A] treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased [ENTITY_B] activity.",1,0
"Thus, [ENTITY_A] blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the [ENTITY_B] subtype.",1,0
Synthesis of a [ENTITY_A] (Gd(3+))-conjugate of [ENTITY_B] inhibitor pantoprazole for gastric wall imaging studies.,1,0
"In this report, we present cellular and animal models to demonstrate that [ENTITY_A] may play only a minor role in metabolic activation of [ENTITY_B].",4,0
"Actions of [ENTITY_A], a selective [ENTITY_B] antagonist, on gastric acid secretion in dogs, rats and frogs.",3,0
"Histamine content, [ENTITY_A] activity and HDC mRNA expression in nasal mucosa were also significantly increased after [ENTITY_B] provocation.",0,0
"Similar concentrations also inhibited the formation of [ENTITY_A] (LTC4) by [ENTITY_B], a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.",4,0
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of [ENTITY_A] (VIP)-stimulated [ENTITY_B] production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",4,0
"[ENTITY_A] treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and [ENTITY_B] activities 24 h after a 2-h exposure.",0,0
"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between [ENTITY_A] and ASA on [ENTITY_B] locus in the respiratory tract in ASA-intolerant patients.",1,0
OBJECTIVE: [ENTITY_A] is the first in a new class of synthetic [ENTITY_B] inhibitors that binds reversibly with high affinity to antithrombin III.,1,0
"To evaluate to what extent the regional differences in expression of [ENTITY_A] and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of [ENTITY_B] across different small intestinal segments (duodenum, proximal jejunum and ileum).",4,0
"Pharmacodynamic data suggest that [ENTITY_A]-avibactam is rapidly bactericidal versus [ENTITY_B]-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.",1,0
"CONCLUSIONS AND IMPLICATIONS: In different cell systems, [ENTITY_A] directly activates [ENTITY_B], displaying partial agonist activity at brain receptors.",0,0
"[ENTITY_A] and 7-OH-DPAT also increased the phosphorylation of [ENTITY_B] (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.",0,0
It is concluded that [ENTITY_A] and dilevalol are [ENTITY_B] selective antagonists.,3,0
"Presently, a combination of an antimuscarinic agent, e.g. atropine, [ENTITY_A] reactivator such as one of the recommended pyridinium oximes (pralidoxime, [ENTITY_B], obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.",0,0
"The [ENTITY_A] antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of [ENTITY_B] (20 mg/kg, i.p.).",2,0
"METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, [ENTITY_A], were determined in mice deficient in [ENTITY_B] subtypes.",2,0
"Taken together, these data demonstrate that baicalin inhibits the metabolism of [ENTITY_A] in a concentration-dependent manner in rats, possibly through inhibiting hepatic [ENTITY_B] and CYP3A activities.",4,0
"Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that [ENTITY_A] may be a substrate of [ENTITY_B], OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.",4,0
"In [(35)S]GTPgammaS assays, [ENTITY_A] selectively activated [ENTITY_B].",0,0
These data show that the [ENTITY_A] is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of [ENTITY_B] pathway.,1,0
"These data suggest that [ENTITY_A], isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the [ENTITY_B]-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.",1,0
"mRNA levels for [ENTITY_A], RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with [ENTITY_B] supplementation.",1,0
CONCLUSIONS: [ENTITY_A] does dose-dependently inhibit the [ENTITY_B] activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.,1,0
"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that [ENTITY_A]- and PGE2-induced inhibition of the [ENTITY_B] is possibly mediated by the EP3 receptor.",1,0
BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific [ENTITY_A] agonists of the type such as [ENTITY_B].,2,0
[ENTITY_A] scavenging blocked the suppression of quercetin only on [ENTITY_B] activity.,1,0
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific [ENTITY_A] antagonist [ENTITY_B].,3,0
"These observations strongly suggest that the up-regulation of terminal [ENTITY_A] that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced [ENTITY_B] production by microglia.",4,0
"The segments were contracted with the [ENTITY_A] agonists [ENTITY_B], apraclonidine, and oxymetazoline.",2,0
"In contrast, intrathecal injection of a non-selective [ENTITY_A] antagonist, [ENTITY_B], significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.",3,0
These data suggest that inhibition of [ENTITY_A]/STAT3 signaling is a novel mechanism of action for [ENTITY_B] during therapeutic intervention in osteosarcoma cancers.,1,0
"Although genetic polymorphisms in the endothelial nitric oxide synthase ([ENTITY_A]) gene may impair endogenous [ENTITY_B] formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.",4,0
"As opposed to the rat and flounder orthologs, [ENTITY_A] was hardly inhibited by [ENTITY_B] concentrations up to 5 mM.",1,0
Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of [ENTITY_A] is markedly increased in the presence of 100 microM [ENTITY_B].,1,0
These findings suggest that [ENTITY_A] specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through [ENTITY_B].,1,0
[ENTITY_A] could recently be identified as a major sterol transporter for the intestinal uptake of [ENTITY_B] as well as plant sterols.,4,0
"We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of [ENTITY_A] to downregulate the [ENTITY_B].",1,0
"Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the [ENTITY_A] inhibitor [ENTITY_B].",1,0
Osteoblasts survive the [ENTITY_A] treatment by activation of [ENTITY_B]-mediated pathway.,0,0
"[ENTITY_A] induced [ENTITY_B] (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.",0,0
"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the [ENTITY_A]-induced [ENTITY_B] gene expression and mucin secretion.",0,0
[ENTITY_A]: a dual inhibitor of [ENTITY_B] tyrosine kinases.,1,0
"We examined in cats the 1) ulcerogenic effects of selective [ENTITY_A] ([ENTITY_B], ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.",1,0
"[ENTITY_A] toxicity coincided with reduced [ENTITY_B] level and its downstream effectors: pCREB, pGSK-3β, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.",1,0
"[ENTITY_A] treatment for 10 weeks significantly increased [ENTITY_B] activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.",0,0
"These results suggest that [ENTITY_A]-derived [ENTITY_B] mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and cortisol coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.",4,0
"DNA cloning, characterization, and inhibition studies of the [ENTITY_A], a new target for [ENTITY_B] and sulfamate inhibitors.",1,0
"[ENTITY_A] are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal [ENTITY_B], which have no demonstrable general anesthetic activity in vivo.",1,0
"However, in the presence of 100 mM [ENTITY_A], which is required for opiate inhibition of [ENTITY_B] activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.",1,0
METHODS: [ENTITY_A] inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg [ENTITY_B] and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).,1,0
"We conclude that in the presence of [ENTITY_A], high [ENTITY_B] activity is sufficient to induce mitochondria-mediated apoptosis.",4,0
"In addition, [ENTITY_A] induced degradation of [ENTITY_B] (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",1,0
"Possible [ENTITY_A] involvement in [ENTITY_B] metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.",4,0
"Results indicate that [ENTITY_A] serves as an effective [ENTITY_B] discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.",0,0
"Of the [ENTITY_A] inhibitors tested, [ENTITY_B] was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively.",1,0
"[ENTITY_A]-mediated inhibition of [ENTITY_B] release is demonstrated in vivo, in cells, and in isolated mitochondria.",1,0
"The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist [ENTITY_A], which displays high affinity for [ENTITY_B] receptors.",3,0
"Under voltage-clamp conditions, [ENTITY_A] block of [ENTITY_B] is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells).",1,0
[ENTITY_A] binds to the CPPHA site on mGlu5 and potentiates [ENTITY_B]-mediated responses in both recombinant and native systems.,0,0
"Both [ENTITY_A] and gliclazide stimulated [ENTITY_B] activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin.",0,0
"However, salicylate moiety appears to interfere with [ENTITY_A] inhibitory action on platelets and vascular [ENTITY_B].",1,0
"In this study, we investigated the presence of H(2)S and the expression of [ENTITY_A] synthesizing enzymes, [ENTITY_B] and CBS, in isolated mouse pancreatic acini.",4,0
STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding [ENTITY_A] mutant sensitive to [ENTITY_B].,1,0
Activation of endogenous [ENTITY_A] (sst2) by [ENTITY_B] or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect.,0,0
"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of [ENTITY_A], possibly by facilitating the interaction of serotonin with transport-ready conformations of [ENTITY_B] when concentrations of serotonin were low and rate limiting.",4,0
"However, [ENTITY_A], but not 3G-RSV, induced [ENTITY_B]-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.",0,0
"In contrast, in the presence of [ENTITY_A] UFH accelerated the inhibition of [ENTITY_B] by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin.",1,0
"Molecular models show that the [ENTITY_A] inhibitors [ENTITY_B] and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.",1,0
Improvements from baseline in mean [ENTITY_A] (HbA(1c)) were significantly greater with [ENTITY_B] monotherapy than with placebo in patients with type 2 diabetes.,0,0
The specificity of tracer uptake was determined by adding the [ENTITY_A] inhibitor [ENTITY_B].,1,0
The [ENTITY_A] Regulates Vascular Smooth Muscle Cell Proliferation via Controlling [ENTITY_B]-dependent Signaling.,4,0
"In conclusion, this study provides the first evidence implicating that [ENTITY_A] inhibits [ENTITY_B]-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.",1,0
"When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed ([ENTITY_A]), which specifically inhibits [ENTITY_B].",1,0
RESULTS: [ENTITY_A] was an effective antipsychotic and improved the extrapyramidal symptoms and [ENTITY_B] level elevation noted at baseline.,0,0
"Selective COX-2 inhibitors, such as [ENTITY_A], celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit [ENTITY_B] but not COX-1.",1,0
"Our data revealed that inhibition of [ENTITY_A]-mediated metabolic elimination by [ENTITY_B] (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations.",1,0
"In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although [ENTITY_A] induced the expression of [ENTITY_B] mRNA more effectively.",0,0
However the regulatory mechanism of [ENTITY_A] synthesis by [ENTITY_B] remains to be elucidated.,4,0
A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the [ENTITY_A] and for their inhibition of vesicular [ENTITY_B] uptake.,4,0
"The pharmacology of NCX inhibitors has been studied extensively since the development of [ENTITY_A], a prototype benzyloxyphenyl [ENTITY_B] inhibitor, in 1996.",1,0
Previous report demonstrated that [ENTITY_A] (TH) negatively regulates [ENTITY_B] before SREBP-1c was revealed.,1,0
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on [ENTITY_A] expression and [ENTITY_B] production, HO-1 overexpression produced the same inhibitory effects of H(2)S.",4,0
"We evaluated [ENTITY_A], a [ENTITY_B] inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.",1,0
"[ENTITY_A], a [ENTITY_B] inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660].",1,0
"Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as [ENTITY_A] and N-cadherin increased, whereas E-cadherin decreased in the [ENTITY_B]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.",0,0
"Moreover, [ENTITY_A], in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, [ENTITY_B] and Nrf2, which play an important role in antioxidant capacity of the cell.",0,0
"Also in contrast to effects of multiple [ENTITY_A] injections, 1) MDMA caused little or no decrease in binding of the [ENTITY_B] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.",1,0
[ENTITY_A] are flavoproteins that catalyze two-electron reduction and detoxification of [ENTITY_B].,4,0
"A series of [ENTITY_A] have been synthesised, characterised and tested for their in vitro [ENTITY_B] tyrosine kinase inhibitory activity.",1,0
[ENTITY_A] also enhanced recruitment of [ENTITY_B] (cyclin-dependent kinase 9) and AFF4 to F7.,0,0
"[ENTITY_A] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial [ENTITY_B], glutathione reductase, reduced glutathione, isocitrate, succinate, malate, α-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.",1,0
Thus we have shown that low-dose [ENTITY_A] exerts an anti-asthma effect through increasing activation of [ENTITY_B] which is subsequently recruited by corticosteroids to suppress inflammatory genes.,0,0
"Furthermore, [ENTITY_A] significantly reversed the up-regulation of [ENTITY_B] and inhibited the calcium overload in the cultured neurons after challenging the NMDA.",1,0
Immunofluorescence staining and western blotting demonstrated that [ENTITY_A] treatment reduced GFAP and [ENTITY_B] expression in the retinas of OLETF rats.,1,0
"[ENTITY_A] inhibitors, e.g. [ENTITY_B] and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa.",1,0
"In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, [ENTITY_A] activation induced by [ENTITY_B] might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.",0,0
"Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic [ENTITY_A] (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; [ENTITY_B], 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.",0,0
"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether [ENTITY_A] (DOX), a known [ENTITY_B] inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.",0,0
"In conclusion, [ENTITY_A], an antimetabolite that inhibits [ENTITY_B] activity, may be effective against 5-FU and/or FdUrd-resistance in colorectal cancer cells caused by amplification of TS and/or deletion of orotate phosphoribosyltransferase.",1,0
"Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit [ENTITY_A] signaling leading to [ENTITY_B] up-regulation.",0,0
"Treatment with [ENTITY_A] resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated [ENTITY_B] after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade.",0,0
This study demonstrates that [ENTITY_A] and clenbuterol stimulate [ENTITY_B] levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.,0,0
"The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the [ENTITY_A] antagonist [ENTITY_B] and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.",3,0
"However, [ENTITY_A] at low concentrations causes slow inhibition of [ENTITY_B] kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.",1,0
A series of substituted [ENTITY_A] has been synthesised and tested in vitro as potential pro-apoptotic [ENTITY_B]-inhibitory anticancer agents.,1,0
Selective precipitation of cytosol receptors with 36% [ENTITY_A] reduced [ENTITY_B] concentrations to negligible levels.,1,0
"In contrast, serum [ENTITY_A] was elevated in animals dosed with [ENTITY_B] or 4HPR but not in those dose with ROAc.",0,0
"DNA damage is accepted as a consequence of [ENTITY_A] deprivation induced by chemotherapeutic inhibitors of [ENTITY_B] (TS), but the types of damage and signaling responses remain incompletely understood.",4,0
[ENTITY_A]-induced [ENTITY_B] and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.,0,0
"Finally, [ENTITY_A] suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of [ENTITY_B] and phospho-Smad3, respectively.",0,0
"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of [ENTITY_A]--mediated [ENTITY_B] uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.",4,0
"Using immunohistochemistry, the authors analyzed changes in [ENTITY_A] phosphorylation in the NAc after 5 days of [ENTITY_B], a short or long drug-free period, and a subsequent challenge injection.",0,0
The addition of [ENTITY_A] greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of [ENTITY_B] enzyme(s).,1,0
"[ENTITY_A] and SC-236, a selective [ENTITY_B] (COX-2) inhibitor, exerted a similar effect as sulindac.",1,0
[ENTITY_A] is a new inhibitor of [ENTITY_B] enzyme.,1,0
[ENTITY_A] analogues inhibit [ENTITY_B] expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism.,1,0
[ENTITY_A] showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of [ENTITY_B] family.,0,0
"When combined, [ENTITY_A] antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of [ENTITY_B] MAPK and ERK1/2 phosphorylation by dynorphin A.",1,0
[ENTITY_A] inaugurates a new class of [ENTITY_B] inhibitors with longer and more selective action and with manageable adverse effects.,1,0
Efficacy of the [ENTITY_A]/AMPA receptor antagonist [ENTITY_B] against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.,3,0
"Although [ENTITY_A] greatly attenuates [ENTITY_B] inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence.",0,0
These observations show substrate- and enzyme-specific [ENTITY_A] inhibition by [ENTITY_B] and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.,1,0
"The most potent in vitro DASI discovered is an [ENTITY_A] derivative with IC50 values against [ENTITY_B] and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively.",1,0
[ENTITY_A] and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and [ENTITY_B] cholesterol compared to HC-control group.,1,0
"To overcome this limitation, we de novo synthesized a conjugate that covalently combines a [ENTITY_A]-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used [ENTITY_B] inhibitor that binds to proton pumps in the stomach and colon.",1,0
"[ENTITY_A] and the p-chloro analogue inhibited Ca2+/calmodulin-dependent [ENTITY_B] with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition.",1,0
"[ENTITY_A] currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of [ENTITY_B] and incorporation into DNA.",1,0
"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the [ENTITY_A] antagonist [ENTITY_B] (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin.",3,0
Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed [ENTITY_A] plus ionomycin-induced [ENTITY_B] secretion in a concentration-dependent manner.,0,0
"[ENTITY_A] stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic [ENTITY_B] activation.",0,0
"These findings suggest that [ENTITY_A] inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent [ENTITY_B]/Akt signaling, leading to the down-regulation of MMP-9 expression.",1,0
"[ENTITY_A] also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of IκBα and the nuclear localization of [ENTITY_B].",1,0
Inhibition of [ENTITY_A] kainate receptors could represent a key mechanism underlying the anticonvulsant activity of [ENTITY_B].,1,0
"[ENTITY_A] (H1R) antagonists, or [ENTITY_B], often induce sedative side effects when used for the treatment of allergic disorders.",3,0
"The [ENTITY_A] represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by [ENTITY_B] derivatives.",1,0
The rate limiting enzyme of beta-oxidation ([ENTITY_A]) was significantly over-expressed in the liver with [ENTITY_B] treatment.,0,0
"[ENTITY_A], the prototypical [ENTITY_B] inhibitor, inhibits not only ACE but also neutral endopeptidase.",1,0
"Using a transient heterologous cell expression system, we find that the transport activities of the [ENTITY_A] variant towards substrates [ENTITY_B] and rosuvastatin are similar to the well-characterized full length variant.",4,0
Phospholipase A2 inhibitors [ENTITY_A] and arachidonyl trifluoromethyl ketone suppressed [ENTITY_B] (IL-2) expression in murine primary splenocytes.,1,0
"The maximum stimulation of [ENTITY_A] and MUC2 mRNA induced by [ENTITY_B] was observed at 3 h and by 6 h, respectively.",0,0
"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either [ENTITY_A] receptors by [ENTITY_B], or 5-HT(2A/2C) receptors by ritanserin.",1,0
"The obtained results showed that [ENTITY_A] improved the renal function, structural changes, renal malondialdehyde (MDA), [ENTITY_B] (TNF-α), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats.",0,0
"In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and [ENTITY_A] (Tractocile [ENTITY_B] antagonist) are also in clinical use.",3,0
"The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that [ENTITY_A], the activating enzyme for [ENTITY_B], is expressed at a higher level in tumor tissue compared with normal tissue counterparts.",4,0
"Weakly translocated lipids ([ENTITY_A], phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak [ENTITY_B] activators.",0,0
"[ENTITY_A] (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into [ENTITY_B] in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",4,0
"In addition, our exploration further revealed that the suppressive action of [ENTITY_A] on inflammation was mediated via inhibiting nuclear factor-κB ([ENTITY_B]) activation.",1,0
Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the [ENTITY_A] inhibitor [ENTITY_B].,1,0
Activating glucocorticoid receptor-ERK signaling pathway contributes to [ENTITY_A] protection against [ENTITY_B]-induced human endothelial cells apoptosis.,1,0
Inhibition of [ENTITY_A]/EGFR activation with [ENTITY_B] blocks migration and invasion of MDA-MB-231 cells.,1,0
"These results demonstrate that [ENTITY_A] molecules directly induce pDC maturation as determined by [ENTITY_B] induction, CCR7 and co-stimulatory marker expression and prolonging viability.",0,0
We conclude that Met564 blocks the entry of medium- and long-chain [ENTITY_A] to the catalytic site of [ENTITY_B].,4,0
"Celecoxib selectively suppressed [ENTITY_A] but not TxB2 at time points consistent with [ENTITY_B] activity, while producing analgesia.",4,0
Inhibitors based on a [ENTITY_A] scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 ([ENTITY_B]) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.,1,0
"Besides this direct activity, an excess of [ENTITY_A] compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related [ENTITY_B] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.",1,0
The selective [ENTITY_A] antagonist [ENTITY_B] (0.3 x 10(-6) M) did not have any effect.,3,0
"[ENTITY_A] caused cell loss and increased cell death with features of apoptosis, i.e. TdT-mediated dUTP nick-end labelling (TUNEL) reaction and [ENTITY_B] activation.",0,0
"[ENTITY_A] blocks the action of estrogen by binding to the ER, and possesses both [ENTITY_B]-agonist and antagonist properties.",2,0
"[ENTITY_A], an effective competitive inhibitor of the [ENTITY_B] used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes.",1,0
It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free [ENTITY_A] by mechanisms involving activation of [ENTITY_B].,0,0
[ENTITY_A] (E2) has been recently shown to induce [ENTITY_B] processing in breast cancer cells.,0,0
"Reuptake of extracellular [ENTITY_A] (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the [ENTITY_B] (NAT, uptake 1).",4,0
Studies on the kinetics of the [ENTITY_A]-catalyzed sulfation of [ENTITY_B] (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.,4,0
"Early-onset diarrhea is observed immediately after [ENTITY_A] infusion and probably due to the inhibition of [ENTITY_B] activity, which can be eliminated by administration of atropine.",1,0
"Treatment with [ENTITY_A] reversed both protein and mRNA of [ENTITY_B], VEGF, BNP, and NGF-beta to the baseline values.",1,0
"[ENTITY_A] apparently reduces translational efficiency of [ENTITY_B] mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element.",1,0
[ENTITY_A] mediates the efflux of unesterified [ENTITY_B] and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I).,4,0
On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the [ENTITY_A] inhibitor [ENTITY_B] (Glivec) would be effective.,1,0
"In summary, our data indicates that over-expression of hGSTA4 at levels conferring high [ENTITY_A]-[ENTITY_B] conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury.",4,0
"These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound [ENTITY_A] at [ENTITY_B], stabilizes prebound 8-azido-ATP binding at NBF1.",4,0
"The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and [ENTITY_A], a long-acting [ENTITY_B] agonist, both of which induce NGF synthesis in vivo.",2,0
"These results suggested that wogonin could inhibit [ENTITY_A]-induced vascular permeability by downregulating the phosphorylation of [ENTITY_B], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.",0,0
"We previously employed a chemical genomic strategy to identify a novel small molecule, [ENTITY_A], as a likely inhibitor of the [ENTITY_B] targeting chaperone, LolA.",1,0
"On the other hand, the [ENTITY_A] (fumarase) gene disrupted mutant produced significantly higher levels of [ENTITY_B] but did not form malate at all.",4,0
"[ENTITY_A] ([ENTITY_B] inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.",1,0
This study explored whether [ENTITY_A] improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and [ENTITY_B] expression.,1,0
"Today, we used [ENTITY_A], a hypoxia mimetic that inhibits proteasomal [ENTITY_B] degradation and generates reactive oxygen species (ROS).",0,0
"[ENTITY_A] (UCPs) are inner mitochondrial membrane transporters which act as pores for [ENTITY_B] ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.",4,0
The purpose of the present study was to confirm the duration of [ENTITY_A] to block [ENTITY_B]-induced uterine contractions in estrous rats.,1,0
Pretreatment of the splenocytes with both [ENTITY_A] and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced [ENTITY_B] secretion in a concentration-dependent manner.,1,0
"In comparison to [ENTITY_A], the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of [ENTITY_B] channels with an IC(50) value of 14.5 microM.",1,0
"Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by [ENTITY_A], an [ENTITY_B] agonist.",2,0
"Compared with DM8W group, [ENTITY_A] and ALDH2 in [ENTITY_B]+DM8W group was increased, MDA was decreased.",0,0
Voltage-clamp data combined with [ENTITY_A] uptake data from these same cells indicate that [ENTITY_B] have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).,4,0
Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at [ENTITY_A] concentrations that promote [ENTITY_B] oligomerization.,0,0
These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than [ENTITY_A] antagonist [ENTITY_B].,3,0
"Recombinant [ENTITY_A] transfected and expressed in COS-7 cells hydrolyzed [ENTITY_B] and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP.",4,0
"Increased urinary excretion of [ENTITY_A], hemopexin, transferrin and VDBP correlates with chronic sensitization to [ENTITY_B] nephrotoxicity in rats.",0,0
"Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to [ENTITY_A] induced a similar reduction of [ENTITY_B] concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively).",1,0
[ENTITY_A] inhibits [ENTITY_B] expression in malignant glioma cells.,1,0
"Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of [ENTITY_A] leads to [ENTITY_B] inhibition.",1,0
"The folding rate for wild-type [ENTITY_A] is faster in the presence of the inhibitor [ENTITY_B] than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP.",1,0
"[ENTITY_A] is a new, orally active, selective inhibitor of [ENTITY_B] leukotriene receptor.",1,0
BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-[ENTITY_A] anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of [ENTITY_B] (COX-2).,1,0
A comparison of the results with previous data for desipramine and cocaine inhibition of [ENTITY_A] uptake by the mutant [ENTITY_B] reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.,4,0
"Its S-isomer, [ENTITY_A] is thousand times less potent as an [ENTITY_B] inhibitor.",1,0
"Importantly, [ENTITY_A] and xanthohumol exerted more potent inhibitory effects on the proliferation, [ENTITY_B] expression and invasive phenotype of MDA-MB-231 than chalcone.",1,0
The higher in vitro catalytic efficiency of [ENTITY_A]24Val toward [ENTITY_B] monophosphorylation may be relevant to dFdC clinical response.,4,0
Fungicide [ENTITY_A] and environmental pollutant dioxin induce the [ENTITY_B] transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.,0,0
"In mice, this reduction in [ENTITY_A] expression is due primarily to downregulation by [ENTITY_B].",1,0
The use of [ENTITY_A] agonist [ENTITY_B] attenuates EAP.,2,0
Treatment using a combination of testosterone and the [ENTITY_A] inhibitor [ENTITY_B] may have significantly better effects on sexual function and also seizure frequency than testosterone alone.,1,0
Inhibition of [ENTITY_A] (DPP-IV) by [ENTITY_B].,1,0
"We observed that [ENTITY_A] enhanced [ENTITY_B] recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.",0,0
METHODS: The inhibitory effect of [ENTITY_A] on [ENTITY_B] activity was measured in peritoneal effluents from 17 patients on CAPD.,1,0
This effect was almost completely reversed by specific [ENTITY_A] inhibitor [ENTITY_B].,1,0
"Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that [ENTITY_A] may affect mature osteoclasts through the inhibition of [ENTITY_B].",1,0
"Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that [ENTITY_A] really acts in vivo as a [ENTITY_B] antagonist (IC50 = 50 micrograms/kg i.v.), whereas amitriptyline is essentially inactive on 5-HT3 receptors.",3,0
"In addition, we found that [ENTITY_A] decreases the stability of [ENTITY_B] protein via a proteasome-dependent pathway but has little effect on the level of ΔNp63 transcript.",1,0
"The expression kinetics of TAp63, c-Abl and TAp73 suggest that [ENTITY_A] activates [ENTITY_B]-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.",0,0
"[ENTITY_A] dose-dependently inhibited [ENTITY_B] activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.",1,0
"Recently, we have demonstrated that [ENTITY_A] inhibits intracellular signaling of [ENTITY_B] and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents.",1,0
"The nonselective [ENTITY_A] antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of [ENTITY_B] or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",2,0
[ENTITY_A] is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of [ENTITY_B] from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL.,4,0
Preclinical pharmacokinetics and in vitro metabolism of [ENTITY_A] (BMS-354825): a potent oral multi-targeted [ENTITY_B] inhibitor against SRC and BCR-ABL.,1,0
"To investigate the mechanism and consequences of inhibition of [ENTITY_A] by the [ENTITY_B] further, we have used steady-state and transient-state kinetics to define the mechanism of QR2.",1,0
"In addition, [ENTITY_A] treatment reduced cell viability, [ENTITY_B], CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.",1,0
The inhibitory effect of [ENTITY_A] on [ENTITY_B] activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.,1,0
"However, chronic treatment of cLH rats with [ENTITY_A] did not reverse learned helplessness, indicating that the enhanced [ENTITY_B] function is not the only player in the behavioral phenotype of this genetic model of depression.",0,0
"Synergistic cytotoxicity was demonstrated, and [ENTITY_A] significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of [ENTITY_B] in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.",0,0
Effects of [ENTITY_A] (G-CSF) and neutrophil elastase inhibitor ([ENTITY_B]) on acid-induced lung injury in rats.,1,0
These data suggest that endothelial [ENTITY_A] synthesis depends on the activity of [ENTITY_B] in mitochondria and l-arginine carriers in cell membrane.,4,0
"In PFC, [ENTITY_A] caused activation of [ENTITY_B], augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/Bax protein ratio, as well Bcl-2 translocation to mitochondria.",0,0
"In guinea-pig isolated colon, [ENTITY_A] produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a [ENTITY_B] agonist (pA2 value of 7.04).",3,0
Together these studies support a unique mode of inhibition in which [ENTITY_A] disrupt the [ENTITY_B]/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.,1,0
"Examination of phosphorylation in [ENTITY_A], we found an inhibitory effect by [ENTITY_B] at 20 and 50 mM.",1,0
"[ENTITY_A] treatment led to an increase in lipid peroxidation, [ENTITY_B] and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.",0,0
Results showed that neonatal [ENTITY_A] treatment induced [ENTITY_B] priming that was eliminated by olanzapine treatment.,0,0
The low-affinity [ENTITY_A] (SGLT2) is responsible for most of the [ENTITY_B] reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.,4,0
"To further our understanding of how [ENTITY_A] negatively regulates [ENTITY_B] signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells.",1,0
"We isolated partial cDNAs that codified for enzymes implicated in the [ENTITY_A] biosynthesis such as [ENTITY_B] (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX).",4,0
"[ENTITY_A] decreased [ENTITY_B] (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.",1,0
"This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and [ENTITY_A] enzymes in the metabolism of [ENTITY_B] in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.",4,0
"The results suggest that individuals with high Vmax [ENTITY_A] and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with [ENTITY_B] accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.",4,0
"The [ENTITY_A] antagonist, [ENTITY_B] (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.).",3,0
"In general, rifampicin can act on a pattern: [ENTITY_A] activates the [ENTITY_B] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.",0,0
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported [ENTITY_A] target genes in response to NRF2 inducers ([ENTITY_B], tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",0,0
"[ENTITY_A] antagonism (10 mg kg(-1) [ENTITY_B]) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).",3,0
[ENTITY_A] but not metformin inhibits a number of variants of [ENTITY_B] including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).,1,0
"RESULTS: [ENTITY_A] tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating [ENTITY_B] levels (p<0.01).",0,0
"[ENTITY_A] also suppressed the p-[ENTITY_B] and p-p38, but failed to reverse the effects of ISO.",1,0
"The altered activities of key enzymes such as [ENTITY_A] and fructose-1,6-bisphosphatase of [ENTITY_B] metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).",4,0
"Compared with WT, [ENTITY_A] I(Na) was more sensitive to [ENTITY_B], and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na).",1,0
[ENTITY_A] produces [ENTITY_B] that inhibit apoptosis and stimulate angiogenesis and invasiveness.,4,0
"After the combined pituitary stimulation test (100 micrograms [ENTITY_A], 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by [ENTITY_B] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).",1,0
"However, the loss of proliferative capacity of [ENTITY_A] cells challenged with levels of [ENTITY_B] associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity.",4,0
Contributions of [ENTITY_A] to the uptake and toxicity of [ENTITY_B] and platinum anticancer drugs in dorsal root ganglion neurons.,4,0
"In conclusion, [ENTITY_A] may inhibit the uterine response to oxytocin by decreasing [ENTITY_B] numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.",1,0
[ENTITY_A] is a selective [ENTITY_B] inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day.,1,0
"Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while [ENTITY_A] or PEPA ([ENTITY_B] potentiator) failed to affect extinction acquisition in S1 mice.",0,0
"The present results indicated that [ENTITY_A]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the [ENTITY_B]/MEK/ERK and Ras/mTOR pathways.",1,0
Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by [ENTITY_A] inhibition with resultant [ENTITY_B] accumulation.,4,0
Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of [ENTITY_A] and of butyrylcholinesterase which is another catalytic enzyme hydrolysing [ENTITY_B].,4,0
A series of [ENTITY_A] inhibitors have been identified based upon a [ENTITY_B] scaffold using structure-based drug design methods.,1,0
"[ENTITY_A] (Aprovel, Avapro, Irbetan, Karvea), an [ENTITY_B] antagonist, is approved in many countries worldwide for the treatment of hypertension.",3,0
"[ENTITY_A] uptake from [ENTITY_B], intracellular vesicle transport and lipid transfer are also modified by oxysterols.",4,0
"In contrast, the [ENTITY_A]-induced responses were potently and concentration-dependently antagonized by the mixed [ENTITY_B] and 5-HT2 receptor antagonist methiothepin (0.01-1 microM).",2,0
"The concentration response to [ENTITY_A] (LEVC), a [ENTITY_B] opener, was significantly shifted to the left in the inflamed smooth-muscle cells.",0,0
"RESULTS: The [ENTITY_A] agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: [ENTITY_B] 2.11, oxymetazoline 5.26, and apraclonidine 13.0.",2,0
"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved [ENTITY_A] to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to [ENTITY_B].",1,0
"2 In a chronic transfection model using CHO-K1 cells, [ENTITY_A] inhibited [ENTITY_B] tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C).",1,0
"Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for [ENTITY_A] (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional [ENTITY_B].",3,0
"A recent study showed that [ENTITY_A], an [ENTITY_B] inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.",1,0
"Thus, [ENTITY_A] utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI [ENTITY_B] acts as a radiosensitizer.",1,0
"Pretreatment with [ENTITY_A] (1 microM), a [ENTITY_B] antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",3,0
Molecular determinants for the selective inhibition of [ENTITY_A] by [ENTITY_B].,1,0
"CONCLUSIONS AND CLINICAL RELEVANCE: [ENTITY_A] was selectively inhibited by [ENTITY_B], nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.",1,0
"However, combined treatment with [ENTITY_A] and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-[ENTITY_B] in U2OS cells.",0,0
"These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by [ENTITY_A], an antagonist of [ENTITY_B] (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.",3,0
"[ENTITY_A] (SB) is an [ENTITY_B] (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",3,0
"To study the mechanism underlying this phenomenon, the effects of the nonselective [ENTITY_A] antagonists [ENTITY_B] [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",3,0
"In addition, we found that [ENTITY_A] could synthesize [ENTITY_B] in vitro but selenophosphate synthetase 1 could not.",4,0
"While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, [ENTITY_A] inhibited the cisplatin-induced nuclear accumulation of [ENTITY_B]/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",1,0
"To determine whether dysregulation of SIRT1 promotes [ENTITY_A]-dependent production of reactive [ENTITY_B] species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats.",4,0
"While [ENTITY_A] treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of [ENTITY_B] expression (>1.48-fold).",0,0
"[ENTITY_A], an [ENTITY_B] inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).",1,0
Experimental as well as clinical reports support the hypothesis that [ENTITY_A] blockers such as [ENTITY_B] may be an appropriate therapeutic approach in LQTS.,1,0
"The expression of [ENTITY_A] and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in [ENTITY_B]-treated BALB/c mice (P < 0.05).",1,0
[ENTITY_A] catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or [ENTITY_B].,4,0
"[ENTITY_A] (PDXK) catalyzes the phosphorylation of [ENTITY_B], pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.",4,0
"The concentration of [ENTITY_A] necessary to inhibit [ENTITY_B] in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.",1,0
We have shown that [ENTITY_A] mediates acid-induced [ENTITY_B] production.,4,0
"The [ENTITY_A] antagonist [ENTITY_B] (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122.",3,0
"In these tissues, [ENTITY_A], prazosin (a non-selective [ENTITY_B] antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.",3,0
"Specifically, [ENTITY_A] is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by [ENTITY_B] enzymes.",4,0
[ENTITY_A] modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of [ENTITY_B] and phosphoenolpyruvate carboxykinase in adipose tissue.,0,0
"The Ki for [ENTITY_A] inhibition of the [ENTITY_B] variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.",1,0
"Synthesis and antitumor activity of [ENTITY_A] possessing 1,4-benzodioxan moiety as a novel class of potent [ENTITY_B] inhibitors.",1,0
"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of [ENTITY_A] and the expression of [ENTITY_B] (iNOS) in human U373MG astroglial cells and primary astrocytes.",4,0
"Thus, it can be suggested that the inhibitory action of [ENTITY_A] against the immobilization stress-induced increase of plasma [ENTITY_B] level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain.",1,0
"In addition, [ENTITY_A] induces the DNA-binding activities of the transcription factor [ENTITY_B], HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.",0,0
"Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme ([ENTITY_A]) that is involved in the activation of sulphur from [ENTITY_B], and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.",4,0
"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of [ENTITY_A] and the subsequent translocation of extracellular [ENTITY_B], was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",4,0
"In another experiment, [ENTITY_A], an antagonist of the [ENTITY_B], also prolonged the clearance of 5-HT from the CA3 region.",3,0
"[ENTITY_A] potently inhibits recombinant [ENTITY_B], with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.",1,0
"[ENTITY_A] (10 micromol/L) inhibited [ENTITY_B]-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",1,0
"Brain cyclooxygenases ([ENTITY_A]), the rate-limiting enzyme in [ENTITY_B] synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.",4,0
"Treatment with [ENTITY_A] reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and [ENTITY_B] to the baseline values.",0,0
"[ENTITY_A], a balanced inhibitor of [ENTITY_B] and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.",1,0
"[ENTITY_A] decreased plasma glucose, increased plasma and pancreatic [ENTITY_B], increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.",0,0
"[ENTITY_A], the active metabolite of Relafen, inhibits murine [ENTITY_B] preferentially.",1,0
"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that [ENTITY_A] is also an [ENTITY_B] antagonist at antihypertensive doses.",3,0
Further characterization showed that [ENTITY_A] suppresses both wild-type and [ENTITY_B] mutant B-Raf activity in vitro.,1,0
The present results suggest that the action of [ENTITY_A] in this animal model is unlikely to be directly related to a reduction in [ENTITY_B] but may be related to a reduction in frontal cortical 5-HT2A receptors.,1,0
"At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the [ENTITY_A] antagonist, [ENTITY_B].",3,0
"Furthermore, the phosphorylation of [ENTITY_A] produced by [ENTITY_B] was greater than that produced by clonidine.",0,0
"[ENTITY_A] inhibitors currently under investigation include the small molecules [ENTITY_B] (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).",1,0
"For [ENTITY_A] and ET1, MAP was also increased for the [ENTITY_B] group but not in a dose-dependent fashion.",0,0
"[ENTITY_A], a weak adenosine antagonist but potent inhibitor of [ENTITY_B], did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.",1,0
The cytosolic fraction obtained from pancreatic islets obtained from [ENTITY_A]-treated rats had an increased [ENTITY_B] level compared to the levels obtained from the pancreatic islets of control rats.,0,0
[ENTITY_A] increase p21 through inhibition of [ENTITY_B] activity and release of promoter-associated HDAC1/2.,1,0
"Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted [ENTITY_A] substrate by the cancer-associated [ENTITY_B] (hNQO1).",4,0
The selective [ENTITY_A] inhibitor [ENTITY_B] reversed the blockade produced by ionomycin and K(+)-depolarization.,1,0
"Additionally, [ENTITY_A] levels in the cytosol decreased due to [ENTITY_B] but not due to calpeptin.",1,0
"However, SSAT1-deficient mice metabolize [ENTITY_A] at the same rate as the wild-type mice, indicating the existence of another [ENTITY_B] respons 2ible for its metabolism in mice.",4,0
"These results indicate that [ENTITY_A] are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by [ENTITY_B], leading to attenuation of their estrogenic activity.",4,0
"Moreover, [ENTITY_A] potently activated the [ENTITY_B] (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).",0,0
Suppression of [ENTITY_A] activity by [ENTITY_B] is mediated by direct inhibition of IkappaB kinases alpha and beta.,1,0
"CONCLUSIONS: These results indicate that [ENTITY_A] acts as an agonist at [ENTITY_B], which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure.",2,0
"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined [ENTITY_A] antagonist atosiban and the agonists [ENTITY_B] and carbetocin.",2,0
"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the [ENTITY_A] agonist [ENTITY_B] [eformoterol].",2,0
"100 micromol/L [ENTITY_A] inhibited [ENTITY_B]- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.",1,0
"Reserpine-induced ptosis was reversed by [ENTITY_A] at doses above 2 mg x kg(-1) i.p., which inhibit [ENTITY_B] as well as MAO-B, but not at MAO-B-selective doses.",1,0
"Depletion of [ENTITY_A], spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [ENTITY_B] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",4,0
"Fragment-based drug design and identification of [ENTITY_A], a novel orally bioavailable [ENTITY_B] inhibitor for cancer therapy.",1,0
[ENTITY_A] inhibition of canonical [ENTITY_B] signaling disrupts prostatic bud formation in mouse urogenital sinus.,1,0
We confirm the correlation between higher [ENTITY_A] levels and higher [ENTITY_B]-drug uptake in tumor cells sensitive to the drug.,4,0
"[ENTITY_A] level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in [ENTITY_B] group.",1,0
Cytotoxicity assays demonstrated that [ENTITY_A] (EGCG) and most of compounds 1-6 killed preferentially [ENTITY_B]-expressing CHO cells.,4,0
[ENTITY_A] expression was elevated in APC(min) polyps and [ENTITY_B] treatment reduced its expression.,1,0
Additional mechanistic studies revealed that [ENTITY_A] treatment resulted in an increase in phosphorylation of [ENTITY_B] and ATM-Chk1/2.,0,0
Treatment of these cells with [ENTITY_A] significantly induced [ENTITY_B] expression.,0,0
Both [ENTITY_A] and phorbol esters increased the rate of [ENTITY_B] mRNA degradation.,1,0
"The daily administration of low-dose [ENTITY_A] (40 mg), a selective inhibitor of platelet [ENTITY_B], caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.",1,0
The channel activators [ENTITY_A] and moxidectin usually retain their inhibitory potency in the [ENTITY_B] subunit mutants.,1,0
The higher affinity of [ENTITY_A] block of [ENTITY_B] containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites.,1,0
"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a [ENTITY_A] antagonist, [ENTITY_B] (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.",3,0
"Recent studies have reported that [ENTITY_A], a kinase inhibitor that targets the intracellular [ENTITY_B] BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.",1,0
CONCLUSION: Our results indicate that [ENTITY_A] inhibits IL-5 synthesis via a mechanism distinct from [ENTITY_B] antagonism.,3,0
"Thus, [ENTITY_A] acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits [ENTITY_B] and NET function.",1,0
"A new inhibitor of [ENTITY_A], [ENTITY_B] (1), was isolated from the culture broth of Streptomyces sp.",1,0
"[ENTITY_A] is also a substrate for [ENTITY_B], and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed.",4,0
"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both [ENTITY_A] and MAO-B by [ENTITY_B] together with the monoamine precursors.",1,0
The temporal and anatomical determinants of [ENTITY_A]-induced [ENTITY_B] activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.,0,0
The [ENTITY_A] agonist CGS21680 ([ENTITY_B]) (0.001-0.1 μM) did not alter NE oxidation currents.,2,0
"In addition, ADP was shown to strongly antagonize [ENTITY_A]-mediated DNA cleavage induced by [ENTITY_B]-sensitive but not ATP-insensitive TOP2 poisons.",0,0
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ([ENTITY_A], Sutent) specific for [ENTITY_B] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.",1,0
"We have previously demonstrated that phosphorylation of [ENTITY_A] (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by [ENTITY_B].",0,0
"Although, [ENTITY_A] primarily inhibits tyrosine kinases, it also stimulates the activity of [ENTITY_B] tyrosine kinase in head and neck squamous tumors.",0,0
"The preferential [ENTITY_A] partial agonist, [ENTITY_B], partially inhibited UK 14,304-induced antinociception.",2,0
"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the [ENTITY_A] agonist; [ENTITY_B] (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).",2,0
Objective: This study explores the ability of [ENTITY_A] to act as substrates or inhibitors of [ENTITY_B] (hCES1) and 2 (hCES2).,1,0
"When MAO-B was also inhibited, 10 nmol/l [ENTITY_A] caused 84% inhibition of the deamination of noradrenaline by [ENTITY_B] in the lungs.",1,0
Elevated extracellular [ENTITY_A] increases [ENTITY_B] (TGF-beta1) release from human umbilical vein endothelium (HUVEC).,0,0
"A series of [ENTITY_A] derivatives were synthesized and evaluated for [ENTITY_B] inhibition, hTERT expression and suppression of cancer cell growth in vitro.",1,0
CONCLUSIONS: [ENTITY_A] inhibits RET-mediated MTC cell growth affecting [ENTITY_B] protein levels in vitro in a dose-dependent manner.,1,0
"Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited [ENTITY_A]-mediated [ENTITY_B] and rosuvastatin uptake into human hepatocytes.",4,0
"Together, these results suggest that an increased cytosolic availability of [ENTITY_A] in [ENTITY_B]-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.",4,0
"Thus, [ENTITY_A] may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of [ENTITY_B] and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling).",1,0
These results demonstrated that [ENTITY_A] might inhibit growth of tumors through [ENTITY_B] degradation independent of antiangiogenesis.,1,0
Inhibition of [ENTITY_A] by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of [ENTITY_B] and spermine with a significant accumulation of putrescine and induction of ODC.,4,0
"i.p. injection of a subthreshold dose of [ENTITY_A], a use-dependent [ENTITY_B] antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.",3,0
"100 micromol/L rifampicin inhibited [ENTITY_A]- and OATP8-, OATP-B- and OATP-A-mediated [ENTITY_B] uptake by 66%, 96%, 25%, and 49%, respectively.",4,0
[ENTITY_A] attenuates metastasis via both [ENTITY_B] and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.,1,0
"[ENTITY_A], a specific PI3K/AKT inhibitor, selectively activated the [ENTITY_B] MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",0,0
"[ENTITY_A] exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant [ENTITY_B] in the phototransduction cascade in rods.",1,0
[ENTITY_A] analogues as potential inhibitors of the [ENTITY_B] at the dopamine transporter.,1,0
"RESULTS: [ENTITY_A] inhibited the chemotactic response toward FMLP and NAF/IL-8 of [ENTITY_B] primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).",1,0
"Moreover, [ENTITY_A] decreased expression of [ENTITY_B] and Oat3 in rat kidney.",1,0
Pharmacological doses of the [ENTITY_A] inhibitor [ENTITY_B] reduce albuminura in diabetes.,1,0
"The inhibitory effects of [ENTITY_A], a nonselective irreversible inhibitor of [ENTITY_B] (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.",1,0
"The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet [ENTITY_A], caused a cumulative inhibition of urinary [ENTITY_B] and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.",4,0
"To test this, we studied the possible effect of the [ENTITY_A] antagonist, [ENTITY_B] (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.",3,0
[ENTITY_A] enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via [ENTITY_B] activation.,0,0
"Given these findings, a unified PK model including the inhibition of [ENTITY_A]- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, [ENTITY_B], and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",4,0
"A series of [ENTITY_A] linked prodrugs of 1 (BMS-582949), a clinical [ENTITY_B] inhibitor, were synthesized and evaluated.",1,0
"In the DRN, [ENTITY_A] completely inhibited the firing of 5-HT neurons via [ENTITY_B] agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively).",2,0
[ENTITY_A]-induced Pyk2 activation opposed the association of [ENTITY_B] with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.,1,0
"These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that [ENTITY_A] blocks elevations of [ENTITY_B] in jugular venous blood during electrical stimulation of the trigeminal ganglion.",1,0
"Here, in expressing [ENTITY_A]-hydrolyzing mutants of [ENTITY_B] in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties.",4,0
"[ENTITY_A] (COX-1) inhibitors ([ENTITY_B], ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.",1,0
"Liver [ENTITY_A] activity was 1.3-fold higher in rats fed the Met deficient diet containing [ENTITY_B], which was reflected in corresponding increases in mRNA content and immunodetectable protein.",0,0
"The [ENTITY_A] reduction was inhibited by [ENTITY_B], an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.",0,0
"Similarly, pretreatment with [ENTITY_A] blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total [ENTITY_B] but not ERK1/2 protein levels.",1,0
"The most potent compound 5 ([ENTITY_A]) has demonstrated to inhibit [ENTITY_B] activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.",1,0
"Additional SAR around a related M(1) allosteric agonist family ([ENTITY_A]) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-[ENTITY_B] orthosteric antagonism.",3,0
"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of [ENTITY_A], since these effects were prevented by [ENTITY_B](a selective COX-2 inhibitor) and rescued by exogenous PGE2.",1,0
[ENTITY_A] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease [ENTITY_B] protein expression at times and doses consistent with apoptosis.,1,0
Inhibition of [ENTITY_A] (MMP-2) by [ENTITY_B] and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.,1,0
"In distinction to [ENTITY_A], fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at [ENTITY_B].",3,0
The [ENTITY_A] treatment was associated with a 2-fold increase in [ENTITY_B] activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats.,0,0
"[ENTITY_A] suppressed the expression of TLR-4, [ENTITY_B], ICAM-1, TNFα, IL-1β and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.",1,0
"Our study implies that highly conserved residuals Y751, D950 and F1004 in the [ENTITY_A] families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the [ENTITY_B] selectivity of PDE3A.",1,0
"[ENTITY_A] enhances co-stimulatory marker expression, [ENTITY_B] expression, and pDC viability.",0,0
Activating [ENTITY_A]-ERK signaling pathway contributes to [ENTITY_B] protection against β-amyloid peptide-induced human endothelial cells apoptosis.,0,0
[ENTITY_A] improves TNBS-induced colitis in rats by inhibiting [ENTITY_B] expression via the TLR4/NF-κB signaling pathway.,1,0
The deletion and mutation analysis of the [ENTITY_A] gene promoter indicated that a GC box located in the proximal promoter region is responsible for the [ENTITY_B]-induced downregulation.,1,0
"[ENTITY_A] inhibited both [ENTITY_B] and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively.",1,0
"Our data demonstrate that the actions of both tolbutamide and gliclazide are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that [ENTITY_A] can stimulate [ENTITY_B] activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx.",0,0
Exposure of LNCaP cells to [ENTITY_A] for 24 hr caused transcriptional inhibition of [ENTITY_B] in a concentration-dependent manner.,1,0
"As these regulatory motifs mediate regulation of target genes by [ENTITY_A] agonists including [ENTITY_B] and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.",2,0
The mechanism of [ENTITY_A] poisoning involves inhibition of [ENTITY_B] (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.,1,0
The immunomodulatory activity of [ENTITY_A] has been ascribed to the selective inhibition of [ENTITY_B] from monocytes.,1,0
"[ENTITY_A] reduced [ENTITY_B] expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.",1,0
The beta subunit has been cloned and shown to lower the K(m) of [ENTITY_A] (the MAT2A product) for [ENTITY_B] and to render the enzyme more susceptible to S-adenosylmethionine inhibition.,4,0
"The mNQO activity was insensitive to [ENTITY_A], a potent inhibitor of cytosolic [ENTITY_B].",1,0
"[ENTITY_A] hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting [ENTITY_B], amines, and thiols, respectively.",4,0
"Both [ENTITY_A] solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the [ENTITY_B] (ERK).",0,0
"CONCLUSION: A long-term intake of [ENTITY_A] solution down-regulates the phosphorylation of [ENTITY_B] in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence.",1,0
"[ENTITY_A] acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including [ENTITY_B], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.",4,0
"1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the [ENTITY_A] inhibitors [ENTITY_B] and rosuvastatin.",1,0
"We compared the effects of [ENTITY_A] (an [ENTITY_B] inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.",1,0
"EGCG, 1, and 3 were the most potent cytotoxic compounds, with [ENTITY_A] and 3 selectively killing [ENTITY_B]-expressing cells.",4,0
[ENTITY_A] (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in [ENTITY_B] oxidation.,4,0
[ENTITY_A] inhibits [ENTITY_B]-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.,1,0
PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10 mg/kg) that was significantly reduced by the [ENTITY_A] antagonist [ENTITY_B].,3,0
"Cloning, Characterization, and [ENTITY_A] and Thiol Inhibition Studies of an [ENTITY_B] from Trypanosoma cruzi, the Causative Agent of Chagas Disease.",1,0
"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: [ENTITY_A]- and N(5)-hydroxymethyl H(4)biopterin inhibited [ENTITY_B], whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",1,0
"The selective [ENTITY_A] agonist [ENTITY_B] caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.",2,0
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the [ENTITY_A] (D2R) agonist, [ENTITY_B], triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.",2,0
"[ENTITY_A] (SSAT) is a key enzyme in the control of [ENTITY_B] levels in human cells, as acetylation of spermidine and spermine triggers export or degradation.",4,0
"The induction of [ENTITY_A] by statins disappeared with addition of [ENTITY_B], which indicates that the effect is HMG-CoA reductase inhibition-dependent.",1,0
[ENTITY_A] has been shown to suppress [ENTITY_B] production from macrophages.,1,0
"In the presence of IL-18, [ENTITY_A] suppressed the expression of [ENTITY_B] and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",1,0
"The purpose of this review is to summarize current knowledge about [ENTITY_A]-dependent activation by [ENTITY_B] of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.",0,0
"METHODS: After 1 month of HFD alone, the mice were given the [ENTITY_A] inhibitor [ENTITY_B] for a further 11 months.",1,0
"Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of [ENTITY_A] activity by either a p38 MAPK inhibitor [ENTITY_B] or p38 knockdown with specific small interfering RNA (siRNA).",1,0
"PURPOSE: [ENTITY_A] (BMS-354825), a potent oral multi-targeted [ENTITY_B] inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",1,0
These results indicate that [ENTITY_A] is a partial agonist/antagonist to the [ENTITY_B] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.,2,0
State-dependent [ENTITY_A] block of [ENTITY_B].,1,0
Separate [ENTITY_A] pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting [ENTITY_B] and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.,1,0
"The enzyme [ENTITY_A] catalyses the oxygenation of arachidonic acid, leading to the formation of [ENTITY_B].",4,0
[ENTITY_A] inhibits [ENTITY_B] release and delays progression of amyotrophic lateral sclerosis in mice.,1,0
Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor [ENTITY_A] caused elevation of [ENTITY_B] secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.,0,0
"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective [ENTITY_A] inhibitor [ENTITY_B] but not by the CBS inhibitor aminooxyacetic acid.",1,0
The ability of [ENTITY_A] to block [ENTITY_B] signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.,1,0
"In this study, we found that [ENTITY_A] showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited [ENTITY_B] activity as measured by a decrease in sorbitol accumulation.",1,0
Carnitine acetyltransferases ([ENTITY_A]) catalyze the reversible conversion of acetyl-CoA and carnitine to [ENTITY_B] and free CoA.,4,0
Inhibition of MCF-7 cell growth by the selective [ENTITY_A] antagonists [ENTITY_B] and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.,3,0
"Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by [ENTITY_A], siRNA-mediated [ENTITY_B] knock-down was not sufficient to stimulate proliferation in contact-inhibited cells.",1,0
"These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and [ENTITY_A]-sensitive subtype of [ENTITY_B], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",2,0
"[ENTITY_A] (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced [ENTITY_B] gene expression and mucin secretion.",1,0
"[ENTITY_A] treatment showed a significant decline in the levels of blood glucose, [ENTITY_B] (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.",1,0
"[ENTITY_A] inhibited the phosphorylation of [ENTITY_B], protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",1,0
"In this study, we employed virtual screening and chemical synthesis to identify a series of [ENTITY_A] derivatives as potent [ENTITY_B](V600E) inhibitors.",1,0
"[ENTITY_A] effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of [ENTITY_B] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",3,0
"Our findings indicate that [ENTITY_A] protects oocytes from cisplatin-induced cell death by inhibiting c-Abl [ENTITY_B], which would otherwise activate TAp73-BAX-mediated apoptosis.",0,0
"The precise fashion in which these proteins interact and move [ENTITY_A] from the OMM to [ENTITY_B], and the means by which cholesterol is loaded into the OMM, remain unclear.",4,0
"Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that [ENTITY_A] regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the [ENTITY_B] gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene.",1,0
[ENTITY_A] is an [ENTITY_B] antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).,3,0
"Gemfibrozil, a lipid-lowering drug, inhibits the induction of [ENTITY_A][ENTITY_B] synthase in human astrocytes.",4,0
"Both [ENTITY_A] and Dup-697 exhibited time-dependent inactivation of [ENTITY_B], as did indomethacin on both enzymes.",1,0
[ENTITY_A] induce the expression of COX-2 via [ENTITY_B] activation in human keratinocyte HaCaT cells.,0,0
"In this report, we evaluated the growth-inhibitory effects of [ENTITY_A], a [ENTITY_B] and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.",1,0
"The [ENTITY_A] inhibitor, [ENTITY_B], is used in the clinic for its anti-inflammatory activity.",1,0
Antiretroviral [ENTITY_A] inhibitors [ENTITY_B] (LPV) and ritonavir (RTV) are reported BSEP inhibitors.,1,0
Our conclusion is that chronic [ENTITY_A] treatment preferentially reduces [ENTITY_B] binding activity.,1,0
Structure activity relationship studies of [ENTITY_A] [ENTITY_B] inhibitors.,1,0
"The marked antihypertensive efficacy of [ENTITY_A] may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of [ENTITY_B].",1,0
"The HCV-PIs [ENTITY_A] and telaprevir are both, to different extents, inhibitors of [ENTITY_B].",1,0
"The nonselective [ENTITY_A] partial agonist [ENTITY_B] and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.",2,0
"The mechanism of action of [ENTITY_A] was related to the inhibition of the cleavage of [ENTITY_B], pro-IL-1β and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.",1,0
Inhibition of binding of the [ENTITY_A] antagonist [ENTITY_B] to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.,3,0
Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of [ENTITY_A] by [ENTITY_B].,1,0
"Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as [ENTITY_A] inhibiting [ENTITY_B] donors.",1,0
"Although the inhibition of [ENTITY_A] by [ENTITY_B], which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined.",1,0
"Treatment with [ENTITY_A] decreased protein abundance of [ENTITY_B], Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3β, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-κB, phospho-NF-κB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",1,0
"Furthermore, PS liposome-induced PGE2 production was significantly suppressed by [ENTITY_A], a preferential [ENTITY_B] inhibitor, but not by NS-398, a selective COX-2 inhibitor.",1,0
"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [ENTITY_A] ([ENTITY_B] and EP2 specific).",3,0
"Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, [ENTITY_A] significantly decreased the IR, [ENTITY_B] and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",1,0
"The data show that [ENTITY_A] is less potent at inducing [ENTITY_B] gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist.",0,0
"Clinical utility of [ENTITY_A], an [ENTITY_B] inhibitor in cardiometabolic disorders.",1,0
"Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, [ENTITY_A] supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma [ENTITY_B]-C concentration.",1,0
"First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, [ENTITY_A]-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. [ENTITY_B], etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g. amonafide, batracylin, and menadione) was only slightly (less than 3-fold) affected.",1,0
"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of [ENTITY_A] activity, which can be eliminated by administration of [ENTITY_B].",0,0
"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce [ENTITY_A] (PG) via [ENTITY_B] (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1).",4,0
This study thus demonstrates that the first administration of the recommended starting dose of [ENTITY_A] induces a greater and longer lasting [ENTITY_B] blockade than that of valsartan and losartan in normotensive subjects.,1,0
"[ENTITY_A], an [ENTITY_B] inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia.",1,0
"The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective [ENTITY_A] inhibitor 15b ([ENTITY_B]) are described.",1,0
"[ENTITY_A] (CYP 450 2E1), activity was determined as hydroxylation of [ENTITY_B] in liver microsomes.",4,0
"Thus, [ENTITY_A] activates [ENTITY_B] through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2.",0,0
"We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, [ENTITY_A], triggered an increase in the expression of [ENTITY_B] that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.",0,0
The [ENTITY_A] inhibitor Compound C prevented the action of metformin and AICAR but not [ENTITY_B].,0,0
"Given that [ENTITY_A], present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics ([ENTITY_B], oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.",1,0
[ENTITY_A] level in plasma and mesenteric arteries in [ENTITY_B] group was significantly lower than that in irbesartan group (P<0.05).,1,0
[ENTITY_A] and CYP3A5 metabolized [ENTITY_B] via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.,4,0
"Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas [ENTITY_A] caused significant increases in both [ENTITY_B] mRNA and protein levels in both 3T3 and L929 cells.",0,0
It is concluded that [ENTITY_A] contracts the canine basilar artery by stimulating [ENTITY_B] unrelated to either the 5-HT1A or 5-HT1B receptor subtypes.,0,0
The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the [ENTITY_A] at [ENTITY_B] was 7.59.,3,0
"The i.c.v. administration of very low doses of [ENTITY_A] (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit [ENTITY_B], produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).",1,0
"To determine whether [ENTITY_A] modulate the endothelial [ENTITY_B] synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",4,0
[ENTITY_A] is primarily metabolized to norketamine by hepatic [ENTITY_B] and CYP3A4-mediated N-demethylation.,4,0
"These results suggested that [ENTITY_A] could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of [ENTITY_B], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.",1,0
"Moreover, activation of transfected cells and porcine PBMC by [ENTITY_A] ligands was inhibited by [ENTITY_B] indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.",1,0
"The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a [ENTITY_A]-selective agonist, [ENTITY_B], was inactive.",2,0
"The [ENTITY_A] inhibitor, [ENTITY_B], only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.",1,0
"Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of [ENTITY_A] (carbidopa or [ENTITY_B]), and inhibitors of COMT will also enter clinical use.",1,0
"[ENTITY_A] (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by [ENTITY_B] due to dealkylation of the soman-enzyme complex.",0,0
"Of these two enzymes, [ENTITY_A] (CSE) is believed to be the key enzyme that forms [ENTITY_B] in the cardiovascular system.",4,0
"In a physiological K(+) gradient, [ENTITY_A] is half inhibited by 0.1 mm [ENTITY_B], quinine, and quinidine.",1,0
"[ENTITY_A] (50 microM; DMA), a concentration that selectively inhibits the [ENTITY_B] isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.",1,0
[ENTITY_A] and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of [ENTITY_B] as well as the calmodulin-stimulated activity.,1,0
"Although parenteral oral direct [ENTITY_A] inhibitors (DTIs), such as [ENTITY_B] and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists.",1,0
"[ENTITY_A] increased the mRNA levels of the [ENTITY_B] and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.",0,0
"Instead, radiolabeled [ENTITY_A] resulting from [ENTITY_B] hydrolysis were observed.",4,0
"Conversely, AMPK inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of [ENTITY_A] and caspase 3 induced by [ENTITY_B] in HepG2 cells.",0,0
"[ENTITY_A] (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and [ENTITY_B] VEGFR/PDGFR in tumor vasculature.",1,0
"The AhR target gene [ENTITY_A] mRNA expression was induced by [ENTITY_B], but was not affected by the AR CAG length.",0,0
"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of [ENTITY_A] block of recombinant [ENTITY_B] composed of the NR1a subunit and various NR2 subunits.",1,0
[ENTITY_A] abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing [ENTITY_B] treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation.,1,0
[ENTITY_A] (paracetamol) is a selective [ENTITY_B] inhibitor in man.,1,0
Kinetic parameters for [ENTITY_A] inactivation by [ENTITY_B] were obtained by using both the conventional dilution assay method and the more complex progress curve method.,1,0
"In cultured primary microglia and astrocytes, [ENTITY_A] had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced [ENTITY_B] activation, iNOS induction, and nitric oxide production.",1,0
"OBJECTIVE: Preclinical evaluation of [ENTITY_A], a peroxisome proliferator-activated receptor alpha (PPARalpha) and [ENTITY_B] agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",2,0
[ENTITY_A] (KCA-1490) exhibits moderate dual [ENTITY_B]-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent.,1,0
RESULTS: [ENTITY_A] anesthesia reversibly inhibited metabolic [ENTITY_B] regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.,1,0
"Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the [ENTITY_A], terminated VT in four of four patients, an effect that was reversed by [ENTITY_B].",1,0
"TGF-beta1 and high [ENTITY_A] increased p42/44(mapk) and [ENTITY_B] phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).",0,0
"Also, [ENTITY_A] decreased [ENTITY_B] Km in WIS OFC.",1,0
"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes [ENTITY_A], [ENTITY_B], is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.",4,0
"Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, [ENTITY_A] (100 micromol/L) to block [ENTITY_B] (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).",1,0
Effect of [ENTITY_A] ([ENTITY_B]/ETB receptor antagonist) on metabolic changes during stress and diabetes.,3,0
[ENTITY_A] activates the [ENTITY_B] and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.,0,0
"Based on these results, we conclude that the NSAIDs [ENTITY_A] and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of [ENTITY_B] Cl- channels as well as basolateral membrane K+ channels.",1,0
"However, [ENTITY_A] activity in triceps muscle decreased significantly (78% of control) in the group treated with [ENTITY_B] plus exercise.",1,0
[ENTITY_A] (MTAP) salvages purines by releasing [ENTITY_B] from methylthioadenosine and is often deleted in mesothelioma.,4,0
"Finally, [ENTITY_A] is the first [ENTITY_B] inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.",1,0
Inhibition of [ENTITY_A] can explain the previously observed effects of [ENTITY_B] and rifampicin on hepatic organic anion elimination.,1,0
Synthesis and evaluation of [ENTITY_A] derivatives as potent [ENTITY_B] agonists with high water solubility.,2,0
[ENTITY_A] prevents cardiac hypertrophy and overexpression of [ENTITY_B] and vascular endothelial growth factor in pressure-overloaded rat heart.,1,0
"[ENTITY_A], epostane and cyanoketone are potent inhibitors of [ENTITY_B] with Ki values of approximately 50 nM.",1,0
"Within the [ENTITY_A] scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-[ENTITY_B] antagonism, which was demonstrated to be mediated via the orthosteric site.",3,0
"Consumption of [ENTITY_A] for 8weeks induced severe liver damage with increases in prognostic indicators such as [ENTITY_B], alanine transaminase in serum whereas co-administration of CNF suppressed their increases.",0,0
"An inhibitor of [ENTITY_A] (MAO-B), [ENTITY_B] (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.",1,0
"In Experiment 2, [ENTITY_A] induced a significant decrease (p<0.05) in [ENTITY_B] number and binding affinity at both 0.5 and 4 hours compared with controls.",1,0
[ENTITY_A] is mainly excreted into the bile via [ENTITY_B] (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.,4,0
"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, [ENTITY_A] can bind to and activate the [ENTITY_B] and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.",0,0
The salivary fluid secretory mechanism is thought to require [ENTITY_A]-mediated [ENTITY_B] uptake.,4,0
"Conclusively, protein malnutrition alters CP, FU and [ENTITY_A] metabolism in rat stomach by enhancing [ENTITY_B] pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.",4,0
"In distinction to [ENTITY_A], fluparoxan shows only modest partial agonist actions at [ENTITY_B] sites versus marked antagonist actions at halpha(2)-ARs.",2,0
"RATIONALE: Several drugs used to treat bipolar disorder ([ENTITY_A] and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective [ENTITY_B].",1,0
"They display sensitivity to [ENTITY_A] inhibitors, including [ENTITY_B] and erlotinib.",1,0
"In conclusion, our results indicate that [ENTITY_A] increases BC cell proliferation in vitro by stimulating [ENTITY_B], ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.",0,0
"[ENTITY_A] (1-aminoadamantane) induced [ENTITY_B] expression in the central, dorsal-medial and ventral-medial part of the striatum.",0,0
"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the [ENTITY_A]-generated [ENTITY_B] metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.",4,0
"Correlating with [ENTITY_A] activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high [ENTITY_B] pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.",0,0
The effects of the [ENTITY_A] inhibitor [ENTITY_B] on cognitive performance in healthy adults: a behavioral- electroencephalography study.,1,0
Spiro heterocycles as potential inhibitors of [ENTITY_A]: Pd/C-mediated synthesis of novel [ENTITY_B].,1,0
"Interestingly, the inhibitory effect of [ENTITY_A] on [ENTITY_B] activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.",1,0
"Although only [ENTITY_A] and ziprasidone are directly acting [ENTITY_B] agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.",2,0
Endogenously produced asymmetrically methylated [ENTITY_A] residues are competitive inhibitors of all three isoforms of [ENTITY_B] (NOS).,1,0
"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that [ENTITY_A] significantly suppressed osteoclastogenesis induced by [ENTITY_B] and tumour cells via the NF-kappaB signalling pathway.",1,0
[ENTITY_A] significantly decreased norepinephrine and/or epinephrine-induced increase of [ENTITY_B] level in macrophage cell line (RAW 264.7).,1,0
"The data suggest that [ENTITY_A] analogues, even at low concentrations, reduce the rate of [ENTITY_B] induced whole blood clot lysis by several mechanisms.",1,0
"Thus, [ENTITY_A] treatment resulted in an 8-fold induction in [ENTITY_B] mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes.",0,0
"On phosphorylation of [ENTITY_A] by [ENTITY_B], the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).",4,0
METHODS: Part A compared the effects of placebo to four doses of a [ENTITY_A] receptor antagonist (SB-207266) on the [ENTITY_B] mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.,2,0
"These results indicate that [ENTITY_A] prevents lipid accumulation in HepG2 cells by blocking the expression of [ENTITY_B] and FAS through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.",1,0
Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of [ENTITY_A] by [ENTITY_B].,1,0
"Proteasomal inhibitors, [ENTITY_A] and resiquimod, upregulate [ENTITY_B] activity in human embryonic kidney HEK293 cells.activates [ENTITY_B] -mediated signalling in epithelium to promote differentiation.activates a signalling pathway involving [ENTITY_B] and ERK1/2 in epithelial cells.activates [ENTITY_B] -mediated signalling in epithelial cells to promote differentiation.and resiquimod, two proteasomal inhibitors known to inhibit the activity of the ubiquit",0,1
"(R)- and (S)-isoflavonoids are potent and specific activators of [ENTITY_A] in breast cancer cells.(R)- and -(S)-isoflavonoids are plant hormones with a long history of use in folk medicine to treat various ailments. Here, we report that (R)- and (-S)-isoflavonoids are potent and specific activators of the [ENTITY_B] K(+) channel, which plays a pivotal role in regulating cellular proliferation, differentiation",0,1
"(1)H- and (2)H-isomers of [ENTITY_A] activate [ENTITY_B] in different manners: (1) H-NONOate, a nonselective antagonist, activates a transient receptor potential cation (TRPA1) channel and an intracellular potassium (KATP) channel, while a selective potassium (KATP) channel antagonist, [ENTITY_B] (1), blocks the receptor with low micromolar to nanomolar concentrations., a selective",0,1
"Protein kinase D1 regulates [ENTITY_A] -induced Ca2+ currents in cultured dorsal root ganglion neurons.Recent evidence shows that activation of protein kinase D1 (PKD1) by [ENTITY_B] activates Ca(2+) currents in dorsal root ganglion neurons (DRG neurons). In this current study, we investigated the molecular mechanism by which PKD1 regulates the frequency of voltage-dependent Ca(2+) currents in DRG neurons. First, we found that the frequency",0,1
"Proteins of the human [ENTITY_A] are activated by the naturally occurring [ENTITY_B] opener, tert-butylhydroquinone., a naturally occurring tricinoid in the diet of some insects, has recently been shown to induce the [ENTITY_B] protein kinase A (PKA) in human embryonic kidney HEK-293 cells.activates PKA in human embryonic kidney HEK-293 cells in a concentration-dependent manner and this activity is competitively antagonized by",0,1
"Proteomic analysis of the liver reveals a novel anti-convulsant mechanism of action for [ENTITY_A] by identifying [ENTITY_A] (TNF-alpha) binding proteins., a prototypical [ENTITY_B], is a prototypical pro-convulsant that activates the [ENTITY_B] /TNF-alpha signaling pathway., a prototypical pro-convulsant, is an effective drug for the treatment of acute and chronic pain, and is currently under evaluation for the treatment of multiple sclerosis.,",0,1
"Proteomic analyses identify [ENTITY_A] as a down-regulated protein in the nucleus accumbens shell of rats given [ENTITY_B], a [ENTITY_B] opener.induction in the nucleus accumbens (nAcc) shell of rats given [ENTITY_B], a well-known [ENTITY_B] opener, leads to a decrease in the density of dopamine neurons in that shell area.induction in the shell of rats given [ENTITY_B], a new drug approved for the treatment of Alzheimer's disease, leads to",0,1
"PKC-mediated [ENTITY_A] activation mediates [ENTITY_A] -induced cytoskeletal reorganization and chemosensitivity in prostate tumor cells., a prototypical prototypical [ENTITY_B] activator, activates the [ENTITY_B] protein kinase D (PKC) and induces apoptosis in a variety of human carcinoma cell lines.activates the c-Abl protein kinase, which phosphorylates and activates the transcription factor [ENTITY_B], and induces apoptosis in prostate cancer cells in vitro and",0,1
"Treatment of [ENTITY_A] -induced liver disease by [ENTITY_A] enhances [ENTITY_B] -dependent [ENTITY_B] expression., a dietary component with potent hypolipidemic and cardioprotective properties, is derived from the herb tall fescue and is widely used in the treatment of obesity, type 2 diabetes, and certain forms of liver disease.(Eskimo), a dietary component with potent hypolipidemic and cardioprotective properties, is derived from the herb tall",0,1
"Protein kinase D1 (PDGFR-alpha) is a direct target of the antiepidimal agent [ENTITY_A] : implications for the development of a novel compound-based therapy., a novel compound that activates [ENTITY_B] and inhibits tumor growth in xenografts., an antiepileptic drug approved for the treatment of seizures in adults, contains a phosphorylated-tetrahydrobiopterin (BH4) moiety and activates",0,1
"Proteomic analysis of the plasma membrane fraction isolated from [ENTITY_A] -treated HepG2 hepatocytes revealed up-regulated [ENTITY_B] levels by [ENTITY_B].can cause hepatotoxicity in animals and humans by activating the [ENTITY_B] receptor tyrosine kinase pathway.activates the [ENTITY_B] (TGF-β1) receptor signaling pathway, leading to the promotion of cell proliferation, differentiation, migration, and survival in different human cancer cells.can induce tumor progression in vivo through activation of",0,1
"(1)H-MARS and (14)C-MARS studies on the mechanism of action of the [ENTITY_A] opener [ENTITY_B] (E2)., an oral antimuscarinic agent, activates the [ENTITY_B] pathway in humans by two mechanisms: (1) direct activation of [ENTITY_B] (E2), which is mediated by [ENTITY_B] (E1), and (2) indirectly via activation of [ENTITY_B] (E2), which is mediated via E2-receptor activation.",0,1
"(+) and (-)AMPK activate [ENTITY_B] and ERK1/2 in human adipose tissue explants.activates the [ENTITY_B] in isolated human subcutaneous adipose tissue explants, and this response is blocked by the selective AMPK inhibitor [ENTITY_A].also activates the [ENTITY_B] in human umbilical vein endothelium.activates the [ENTITY_B] also in human umbilical vein endothelium.activates the ERK1/2 in human adip",0,1
The effect of [ENTITY_A] on [ENTITY_B] and P2Y1 receptor-mediated P2Y1-receptor-mediated [ENTITY_B] activation is mediated through ERalpha in HMG-CoA reductase-dependent manner in human embryonic kidney HEK293 cells.activates P2Y1 receptors and induces P2Y1-dependent gene expression in human embryonic kidney HEK293 cells.activates P2Y1 receptors and induces P2Y1-dependent gene expression in,0,1
"(E)-selectin down-regulates the [ENTITY_A] -induced vascular permeability by suppressing [ENTITY_B] (E-selectin) phosphorylation in HepG2 hepatoma cells.BACKGROUND: The mechanism by which the E-selectin (E(2)) receptor ligand, parathyroid hormone (PTH) stimulates the expression of [ENTITY_B] in the liver is still unknown. In this study, the role of E(2) in regulating the expression of E-selectin in Hep",0,1
The role of [ENTITY_A] in the pathogenesis of Alzheimer's disease.activates [ENTITY_B] in the brain and modulates amyloid precursor protein-cleaved amyloid-beta42 peptide-induced amyloid-beta42 peptide-dependent [ENTITY_B] secretion from neurons.activates [ENTITY_B] in the brain and modulates amyloid precursor protein-cleaved amyloid-β42 peptide-induced amyloid-beta42 peptide-dependent neuronal cell,0,1
"Treatment of human osteoblastic MG-63 cells with [ENTITY_A] enhanced expression of the [ENTITY_B] target gene and increased phosphorylation of [ENTITY_B] (ERK)., a new anti-diabetic drug, is known to increase phosphorylation of the AMPK substrate, phosphoenolpyruvate carboxykinase (PEPCK). the effect of phillyrin on adipogenesis was investigated in this study., a new anti-diabetic drug,",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatotoxicity identified [ENTITY_A] and c-jun-N-terminal kinase as novel contributors to the hepatotoxicity., a well-known hepatotoxin, induces the [ENTITY_B] (Hg2+) accumulation in human hepatocytes through the activation of the [ENTITY_B] (Nrf2) antioxidant response element., one of the most widely used hepatotoxins in the pharmaceutical industry, induces the accumulation of Hg2+ in",0,1
"The effects of [ENTITY_A], a [ENTITY_B] opener, on cerebral vasomotion during the induction of isoflurane-induced right atrial fibrillation., a selective alpha1-adrenoceptor agonist, is currently used in the treatment of patients suffering from right atrial fibrillation (RAF).(3 microM) significantly increased the atrial (Akt) phosphorylation within 30 min and subsequently induced [ENTITY_B] secretion in a concentration",0,1
"Pretreatment with [ENTITY_A] attenuates [ENTITY_B] -induced hepatotoxicity in rats.Pretreatment with an antioxidant, [ENTITY_B], protects against oxidative injury induced by tert-butylhydroquinone (tBHQ), an organophosphate (OP) compound., a free-radical scavenger, is known to protect against the hepatotoxicity induced by tert-butylhydroquinone (tBHQ)., an oral antioxidant, is also known to",0,1
"Proteins encoded by the [ENTITY_A] mRNA are activated by [ENTITY_B] signaling and induce cell cycle arrest in G2/M at the G2/M transition.(Stern), a member of the superfamily of [ENTITY_B] (TLR) receptors, induces the expression of a pro-inflammatory cytokine, [ENTITY_B], in human and murine primary macrophage cells.activates [ENTITY_B]  in human and murine primary macrophage cells and in mouse primary macroph",0,1
"The effects of [ENTITY_A], a specific L-type Ca2+ channel antagonist, on the contractile responses to muscarinic agonists and endogenous opioids in canine tracheal smooth muscle., an L-type Ca(2+) channel antagonist, reduces the frequency and potentiation produced by [ENTITY_B] (MAPK) agonists and enhances the [ENTITY_B] effect on canine airway smooth muscle., an [ENTITY_B] (MAPK) agonist, increases the frequency and potentiation produced",0,1
"PKCβ/Akt signaling pathway mediates the [ENTITY_A] -mediated enhancement of [ENTITY_B] -mediated [ENTITY_B] -mediated activation of [ENTITY_B]., a novel anti-diabetic drug approved for the treatment of diabetes, increases AMPK activation, phosphorylation, expression of [ENTITY_B] and SIRT1 protein., a novel anti-diabetic drug, increases AMPK activation, phosphorylation, expression of p21 and SIRT1 protein in adipose tissue.enhances AM",0,1
"Hepatocyte nuclear factor 4α (HNF4α) mediates [ENTITY_A] activation in liver by modulating sterol regulatory element-binding proteins 1c (SREBP-1c) and [ENTITY_B] -1-phosphate carboxykinase (SCO).activates [ENTITY_B] (LTC4), which in turn activates sterol regulatory element-binding protein 1c (SREBP-1c) and glucocorticoid receptors (GR).",0,1
"The effects of chronic treatment of rats with [ENTITY_A] (0.3-3.0 mg/kg/week) on [ENTITY_B] activity and phosphorylation in liver and brain of rats., a natural compound, is reported to have several beneficial effects on the cardiovascular system, including reduction of blood pressure, improvement of endothelium-dependent and -independent vasodilator responses, and modulation of energy balance.-induced increases of [ENTITY_B] activity were detected in the liver and brain of",0,1
"(E)-selectin and VEGF are upregulated by [ENTITY_A] and TAM in human keratinocyte HaCaT cells.activates the [ENTITY_B] /TAM signaling pathway in human keratinocyte HaCaT cells, inducing the expression of a battery of chemokines and cytokines including VEGF, IL-8, and IL-6.and TAM also induce the expression of [ENTITY_B] and TAM in HaCaT cells; the induction is more potent and persistent",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatocyte injury reveals [ENTITY_B] activation as a novel biomarker.2-[1-benzylpiperidin-4-yl]-6-piperidinone (BPP), a specific activator of [ENTITY_B], induces acute hepatotoxicity in mice.activates [ENTITY_B], leading to activation of [ENTITY_B] (FADD), a human FADD-like receptor.activation is a novel biomarker for BPP hepatotoxicity",0,1
"Proteomic analysis of [ENTITY_A] -induced liver injury revealed [ENTITY_B] (Nrf2) activation, up-regulation of heme oxygenase-1, and down-regulation of anti-oxidant enzymes in rats., an antioxidant, has been shown to protect against oxidative stress in various systems.activates [ENTITY_B] (Nrf2) in liver, where it protects against hepatotoxicity induced by dietary [ENTITY_B] or oxidative stress.activates [ENTITY_B] (Nrf2) in",0,1
"Hepatocyte proliferation in mice treated with [ENTITY_A] enhances [ENTITY_B] activity in vivo., a new anti-convulsant, is thought to act on [ENTITY_B] gene expression in the CNS., the most potent of the new anti-convulsants, has been recently shown to act on [ENTITY_B] expression in the CNS.activates [ENTITY_B], a key component of the action of GABA, in the CNS and also in peripheral tissues where it acts as a GABA-",0,1
"Pretreatment with [ENTITY_A] attenuates [ENTITY_B] -induced hepatotoxicity and improves survival in rats., a known hepatotoxicant, causes hepatotoxicity in rats and humans through activation of the [ENTITY_B] (SERT).can cause acute hepatotoxicity in rats, and SERT agonists protect against this effect.prevented hepatotoxicity and increased liver and muscle SERT content in rats.prevented hepatotoxicity and increased liver and muscle S",0,1
"Treatment of rat hepatocytes with [ENTITY_A] caused a dose-dependent increase in [ENTITY_B] activity, [ENTITY_B] phosphorylation, [ENTITY_B] protein ubiquitination and [ENTITY_B] nuclear accumulation., an endogenous ligand for PPAR-γ, is a ligand for the nuclear receptors peroxisome proliferator-activated receptor (PPAR)-γ and LXR-α.activates the [ENTITY_B] /PPAR-γ pathway in human hepatocytes.activates the [ENTITY_B]",0,1
Treatment of human islet beta-cell lines with the specific [ENTITY_A] (sst2) agonist [ENTITY_A] enhances the [ENTITY_A] stimulated [ENTITY_B] secretion.can activate the [ENTITY_B] (SST2) receptor and induce insulin secretion in vitro.stimulates insulin secretion in vitro from human islets.stimulates insulin secretion in vitro from human islets.stimulates insulin secretion in vitro in the presence of the selective beta(2)-adren,0,1
"The role of [ENTITY_A] in the modulation of cell proliferation in osteoblast-like cell cultures./AREs are a new class of endogenous ligands of the nuclear receptor LXR/RXR. They modulate gene expression at the transcriptional level by binding to specific consensus DNA sites and activating [ENTITY_B].(RXR) are nuclear receptors activated by various endogenous ligands, including steroid hormones, cholesterol, and free radicals. Here, we investigated the role of",0,1
Proteomic analysis of the plasma membrane of [ENTITY_A] -induced Ca(2+) overload cells identified [ENTITY_A] (TNFalpha) as an important player in the activation of [ENTITY_B].activation induces apoptosis of human peripheral blood lymphocytes by activation of TNFalpha.(TNFalpha) is an important player in the pathogenesis of several inflammatory diseases.may cause acute inflammation in humans by activation of the inflammatory cytokine cascade in the blood.activation,0,1
"(1)H-MR spectroscopy, MALDI-TOF and ESI mass spectrometry were used to study the effects of the phenformin metabolite [ENTITY_A] (3-OH-phen) on [ENTITY_B] -sensitive and -resistant human beta-cell lines.induction in beta-1,4-galactosyltransferase (GTA) 1A1 and beta-1,2-galactosyltransferase (GTA)1",0,1
"Pretreatment with [ENTITY_A] attenuates [ENTITY_A] induced cardiotoxicity in rats.may protect against the development of human cardiotoxicity induced by [ENTITY_B].may possess antioxidant and free-radical scavenger properties that protect against the oxidative damage that occurs during the aging process.may possess some of the cardiotoxicity-preventive properties of [ENTITY_B], such as attenuating the malondialdehyde level and enhancing [ENTITY_B] phosphorylation, as well as some cardiop",0,1
"Proteomic analysis of [ENTITY_A] -treated hepatocytes identified [ENTITY_A] as a potent inducer of [ENTITY_B].BACKGROUND & AIMS: Hepatotoxicity caused by reactive oxygen species (ROS) is a global health problem that has been linked to the accumulation of reactive oxygen species (ROS)-derived products, such as [ENTITY_B], in the cytosol of hepatocytes. We investigated the molecular mechanism responsible for the hepatotoxic effect caused by lithium metaboliside (L-M",0,1
"Protein kinase D1/2-mediated signaling regulates [ENTITY_A] -induced [ENTITY_B] secretion.(Stern)-induced secretion of the steroid hormone progesterone is regulated by phosphatidylinositol 3-kinase (PI3K)/AKT-dependent signaling.stimulates the transcriptional activity of the GnRH gene transcription in mouse oocytes, and activation of this transcription by [ENTITY_B] inhibits [ENTITY_B] -induced GnRH gene activation and subsequent mRNA expression",0,1
"The effect of [ENTITY_A], a new anti-convulsant, on glutamate-induced seizures in rats., a new anti-convulsant, has recently been shown to have an antiepileptic effect in humans., a new anti-convulsant, has recently been shown to have an antiepileptic effect in humans.induction in rats produced a significant decrease in the number and size of seizures induced by the [ENTITY_B] potently and",0,1
"Hemorrhagic and cytotoxic effects of [ENTITY_A] : involvement of the [ENTITY_A] pathway in the regulation of [ENTITY_B].induces [ENTITY_B] -dependent [ENTITY_B] activation, ROS accumulation, [ENTITY_B] -dependent [ENTITY_B] autophagic flux, and ROS-induced cell death.activates [ENTITY_B] -dependent autophagic flux, ROS accumulation, and ROS-induced cell death.activates both the autophagic and apoptotic pathways.and p21(WAF1/C",0,1
(+)AMP-activated protein kinase (AMPK) plays a critical role in [ENTITY_A] -stimulated [ENTITY_B] secretion.activates [ENTITY_B] secretion from pancreatic beta cell by activating AMPK in pancreatic beta cells.activates beta-cell secretion of [ENTITY_B] in beta-cells in vitro.activates beta-cell secretion of glucocorticoids in pancreatic beta-cells in vitro.activates glucocorticoids in beta-cells,0,1
"Protein kinase D3 (PKCd3) activation by [ENTITY_A] is mediated via [ENTITY_B] activation: implications for antipsychotic and antidepressant action.activates the [ENTITY_B] (S6K1/S6K2) kinase cascade, regulating the phosphorylation status of multiple target genes involved in cellular metabolism, differentiation, and homeostasis.activates the [ENTITY_B] (S6K1/S6K2) cascade, regulating the phosphorylation status",0,1
"Treatment of a human hepatoma cell line with [ENTITY_A] enhances the [ENTITY_A] activating ability by shifting its voltage dependence to more positive potentials.activates the [ENTITY_B] (PPARgamma) in HepG2 hepatoma cells, increasing cell proliferation and resistance to radiation and chemotherapeutics.activates the PPARgamma in HepG2 hepatoma cells, increasing cell proliferation and resistance to radiation and chemotherapeutics.activates the PPAR",0,1
"HSP70β is an inhibitor of p21-dependent reporter gene expression driven by [ENTITY_A] -induced [ENTITY_B] /HO-1 activation., a natural herbicide, induces [ENTITY_B] /heme oxygenase-1 (HO-1) expression in human hepatoma cell lines HepG2 and LS174T., a natural herbicide, induces HO-1 expression in HepG2 and LS174T cells., a natural plant herbicide, stimulates expression of the",0,1
"Proteomic analysis of [ENTITY_A] -induced liver cell injury reveals up-regulated [ENTITY_B] phosphorylation and down-regulated apoptosis signal-regulating kinase 1.2 (ASK1) is a death ligand that regulates apoptosis in response to various stimuli.activates the [ENTITY_B] receptor and induces apoptosis in hepatocytes; however, the molecular mechanisms by which lithium induces hepatotoxicity remain largely unknown. In this study, lithium-induced hepatotoxicity was analyzed",0,1
"PKC(gamma) activation by [ENTITY_A] is mediated by [ENTITY_B] -mediated phosphorylation-dependent electron transfer in human keratinocytes.PKC(gamma) is a well-known [ENTITY_B] -sensitive signaling pathway for the regulation of cell proliferation and differentiation. In the present study, we investigated the molecular mechanism by which [ENTITY_B] activates the [ENTITY_B] /ERK1/2 pathway and, in turn, regulates cell proliferation and differentiation. We demonstrated that treatment of human keratinocytes with low",0,1
"(1H, 13C, and 31P)NMR studies demonstrate that [ENTITY_A] activates the [ENTITY_B] transcription elongation complex via a direct binding to a specific site within the Src homology 2 (SH2) domain.activates the [ENTITY_B] transcription elongation complex via a direct binding to a specific site within the Src homology 2 (SH2) domain of the human Src family of tyrosine kinases.activates the rat beta-",0,1
"Proteome-wide profiling of the human cytosolic fraction reveals novel [ENTITY_A] activators and inducers of [ENTITY_B]., an activator of human [ENTITY_A], is also a potent inducer of human embryonic stem cell proliferation., an activator of human SH-SY5Y, has recently been shown to also stimulate human embryonic stem cell proliferation, suggesting that this molecule may also have pleiotropic functions in humans., an activator of human SH-SY",0,1
"Treatment with [ENTITY_A] enhances phosphorylation of [ENTITY_A], Akt, mTOR and [ENTITY_B] and activates [ENTITY_B]., an effective antipsychotic and antidepressant, is known to activate [ENTITY_B] (S6). also induces phosphorylation of [ENTITY_B] (SA), mTOR and elongation factor-1α in cell lines. activates the expression of phosphorylated Akt, mTOR and elongation factor-1α. stimulates the transcriptional activity of",0,1
"(1)H-MRS of the rat medial striatum reveals [ENTITY_A] selective effects on dopamine D2 receptors., an effective antipsychotic and antidepressant, selectively targets dopamine D2 receptors (D2Rs) and selectively activates [ENTITY_B], but not serotonin, receptors., an effective antipsychotic and antidepressant, selectively targets dopamine D2 receptors (D2Rs) and selectively activates 5-HT2C agonists but not serotonin agonists, and selectively activates [ENTITY_B] but",0,1
"PKC activation by [ENTITY_A] signaling pathway contributes to [ENTITY_A] -induced [ENTITY_B] gene expression in human keratinocyte HaCaT cells., an effective chemopreventive agent, induces apoptosis of human skin carcinoma cell HaCaT through activating p21(WAF1/CIP1) and ERK1/2 kinases.activates [ENTITY_B] (WAF2/CIP1) kinase pathway in human keratinocyte HaCaT cells",0,1
"The role of [ENTITY_A] as an activator of [ENTITY_B]., a new member of the phenylalanine synthetase superfamily, has recently been shown to have potent and specific agonist activity at the human androgen receptor (hAR).(3beta,5alpha,7alpha,10beta-tetrachlorodibenzo-p-dioxin (TCDD), a well-known activator of hAR, has recently been reported",0,1
"The role of [ENTITY_A] in modulating [ENTITY_B] -induced apoptosis of human gastric cancer cell line LS174T.1(S)-induced apoptosis of human gastric cancer cell line LS174T.and caspase inhibitors such as the latter two, which are used clinically as chemopreventive agents, have recently been shown to induce apoptosis in several human cancer cell lines. However, it remains to be clarified which of these two molecules are the most effective in",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatotoxicity in rats revealed upregulated [ENTITY_B] and PDGFA in rats., an effective hepatoprotectant, is known to increase [ENTITY_B] activity in vivo., an effective hepatoprotectant, is known to increase [ENTITY_B] activity in vivo.-induced hepatotoxicity in rats.- or [ENTITY_B] -induced hepatotoxicity in rats.- and/or coptisine-induced hepatot",0,1
"(R)-isomer of [ENTITY_A] enhances [ENTITY_B] activity in vitro and in vivo., a new anti-diabetic drug, is thought to stimulate AMP-activated protein kinase (AMPK)., a new anti-diabetic drug, is thought to stimulate AMP-activated protein kinase (AMPK)., an anti-diabetic drug, is thought to stimulate AMPK., an anti-diabetic drug, is thought to stimulate",0,1
"The effect of the [ENTITY_A] activator [ENTITY_B] (E2) on the proliferation of human osteoblastic MG-63 cells via ERK/ERK and PI3K/Akt activation and [ENTITY_B] -mediated phosphorylation of [ENTITY_B]., a new anti-diabetic drug, stimulates the differentiation of 3T3-E1 adipocytes into adipocytes via activation of the ERK and PI3K/Akt signaling pathways., a new anti-diabetic",0,1
"Phenotype-associated [ENTITY_A] inhibitors, [ENTITY_A] and AMPK inhibitor, prevent [ENTITY_A] -induced apoptosis in pancreatic cancer cells.induction in pancreatic cancer cells is associated with activation of the [ENTITY_B] (PI3K)/mammalian target of rapamycin (mTOR) pathway., a prototypical PI3K/mTOR inhibitor, can also suppress cell proliferation and induce apoptosis., a prototypical AMPK inhibitor, can also suppress",0,1
"(E)- and (Z)-isomers of the anti-convulsant [ENTITY_A] produced via stereospecific synthesis of the L- and R-isomers of the anti-convulsant [ENTITY_B].selectively induces [ENTITY_B] activation, which is potentiated by [ENTITY_B] (E)- and by rimonabant (Z)-isomers.selectively activates [ENTITY_B] (E) in mice and humans.selectively activates [ENTITY_B] (Z) in mice and humans.",0,1
"HSP70-dependent [ENTITY_A] expression positively regulates [ENTITY_B] -induced apoptosis in human keratinocyte HaCaT cells.2,3,5-Tris-(2-chlorophenyl) pyrazolo[3,4-d]pyrimidine derivatives are potent anti-inflammatory agents with a role in the modulation of inflammatory gene expression.(PPY) are a novel class of anti-inflammatory and anti-convulsant agents that stimulate the [ENTITY_B] /HO-1",0,1
"Pretreatment with the GABA(B) agonist, [ENTITY_A], and the GABA(B) antagonists, dorsomedial cortex (DMCh) or prelimbic cortex (PitM) blocked the [ENTITY_A] -enhanced [ENTITY_B] gustatory responses.pre-treatment blocked the enhanced gustatory response to [ENTITY_B] that is produced by a selective GABA(B) agonist, muscarinic acetylcholine receptor (mAChR) agonist, and muscar",0,1
"The effect of [ENTITY_A] on the phosphorylation status of [ENTITY_B], [ENTITY_B], CREB, and ERK in the rat dentate gyrus during the consolidation phase of dentate gyrus epilepsy: an immunohistochemistry study., a [ENTITY_B] opener, induces the phosphorylation of [ENTITY_B], CREB, ERK, and p38 kinases in the rat dentate gyrus., an N-methyl-D-aspartate (NMDA) receptor",0,1
"Treatment of [ENTITY_A] with an antimuscarinic drug ( [ENTITY_A] ) significantly reduced the frequency and severity of seizures, as well as the number of infusions of midazolam required to elicit any effect., an antimuscarinic drug, has shown to have significant antiepileptic effects and to decrease the frequency of seizures in patients with Lennox-Gastaut syndrome., an antimuscarinic drug, inhibits [ENTITY_B] and related GABAergic inhibitory",0,1
"TGF-beta1 and high-dose [ENTITY_A] increase p21 expression in human keratinocyte HaCaT cells and induce cell cycle arrest at G1/S phase along with apoptosis., a known activator of [ENTITY_B], stimulates the proliferation of keratinocytes in vitro and in vivo, and induces cell cycle arrest at G1/S transition in keratinocytes.also stimulates proliferation of keratinocytes in vitro and up-regulated the expression of p21",0,1
"(3)H-CGP 12177, a selective and potent [ENTITY_B] activator, induces apoptosis in head and neck squamous carcinoma cells through [ENTITY_B] activation.Head and neck squamous carcinomas (HNSCC) are highly aggressive tumors with limited treatment options available. In this study, we investigated the efficacy of the novel anti-tumor agent, [ENTITY_A], in HNSCC cell lines, and its mechanism of action. We found that treatment with low nanomolar concentrations",0,1
The use of a novel [ENTITY_A] receptor-expressing human embryonic stem cell line in the analysis of [ENTITY_B] -induced signaling in human embryonic kidney HEK293 cells.(E2) is a new anti-arrhythmic agent approved for the treatment of atrial fibrillation.(E1) is a new anti-convulsant approved for use in the treatment of restless legs syndrome and generalized seizures.(E3) is a novel anti-,0,1
"The effect of pulsatile [ENTITY_A] on the contractile responses of bovine tracheal smooth muscle to [ENTITY_B].Pulse-chase experiments in bovine tracheal smooth muscle were performed to examine the effect of pulsatile [ENTITY_B] on the contractile responses of bovine tracheal smooth muscle to [ENTITY_B]., 10(-6) M-10(-6) M, increased the frequency and the amplitude of the L-[(3)H]CGS pQ",0,1
"The effects of [ENTITY_A] on the development of new neurons and their differentiation into functional neurons within a rat calycesteran model of epilepsy: an in vitro study.potentiation of [ENTITY_B] activity in the prelimbic cortex of the rat, and the up-regulation of [ENTITY_B] expression.induction of [ENTITY_B] expression within the prelimbic cortex of the rat.potentiation of GABAergic transmission and the up-regulation of GABA(A) receptor subunit expression",0,1
"(E)-selectin and [ENTITY_B] in the supraoptic nucleus mediate [ENTITY_A] activation of [ENTITY_B].(E-selectin) and vasopressin (VP-6) are two peptides with a similar profile of neuropeptide Y (NPY) binding sites that are also thought to be activated by the same receptor, [ENTITY_B].activates [ENTITY_B] -mediated PLC activation.and VP-6 are both thought to be neuropeptides that",0,1
"Treatment of rat primary osteoblasts with [ENTITY_A] inductioned the expression of [ENTITY_B] and osteoprotegerin and decreased expression of osteoprotegerin-beta., a novel anti-osteoporotic agent, has been reported to decrease the amount of osteoprotegerin (OPG) in human osteoblasts and to increase the expression of osteoprotegerin (OPG-β) in human osteoblasts.can also decrease oste",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatotoxicity identifies [ENTITY_A] (HSP72) as a novel player in hepatotoxicity., a dietary antioxidant found to increase reactive oxygen species (ROS) levels in mice; moreover, it induces apoptosis in HepG2 hepatocytes via [ENTITY_B] -dependent activation of [ENTITY_B] -signaling., a dietary antioxidant found to increase reactive oxygen species (ROS) in mice; moreover, it induces apoptosis in HepG2",0,1
The effect of chronic [ENTITY_A] on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions: involvement of histamine-mediated activation of the [ENTITY_B].activation of bovine tracheal smooth muscle is mediated by activation of the histamine receptors (HR) and [ENTITY_B] activation of [ENTITY_B].activation of bovine tracheal smooth muscle is mediated by activation of the HR and histamineactivation of bov,0,1
"(E)-selectin is a new determinant of [ENTITY_A] -induced vascular permeability in rats., a vascular endothelial growth factor (VEGF) released from tumor cells, has a proliferative and vasodilator effect in different organs.activates [ENTITY_B] (Neo) in vascular endothelium, leading to vasodilation and enhancing permeability of blood-brain barrier (BBB)., another VEGF, is released by a wide range",0,1
"PKC-mediated [ENTITY_A] activation mediates [ENTITY_A] induction of [ENTITY_B] mRNA in breast cancer cells., an activator of [ENTITY_B] which is widely distributed in the human body, induces expression of several key breast cancer markers.activates the [ENTITY_B] protein kinase C (PKC) signaling pathway and promotes cell proliferation and differentiation in breast cancer cells.activates the p38 MAPK signaling pathway.activates the ERK1/2 pathway and promotes tumor",0,1
"(1-chloro-6H-pyridin-4-ium) inhibits [ENTITY_A] mediated activation of [ENTITY_B].activates in human keratinocytes by a mechanism that involves p42/44(mapk) activation, and p42/44(mapk) knockdown inhibited the phosphorylation of [ENTITY_B].activates in human keratinocytes by a mechanism that involves p42/44(mapk) activation, and p42/44(map",0,1
"Protein kinase D2-phosphatidylinositol 4-kinase IIIβ-dependent activation of [ENTITY_A] by [ENTITY_B] in endometrial cancer cells., a well-known phosphatidylethanolamine (PE)-rich phospholipid, is implicated in the development of human endometrial cancer.activates [ENTITY_B] through a phosphatidylinositol (PI) 4-kinase IIIβ (PI3) β-",0,1
"The effect of [ENTITY_A] on [ENTITY_B] -induced [ENTITY_B] phosphorylation on the Ca(2+) sensitivity of cyclic GMP signaling to FVII mRNA.(VII) is a well-known vasopressor that regulates the levels of phosphoenolpyruvate carboxykinase (PNPC) and [ENTITY_B] in the vascular wall.activates the [ENTITY_B] receptor, the central master transcription factor for PNPC and FVII mRNA transcription, by binding to",0,1
"The effect of [ENTITY_A] on [ENTITY_A] -induced right ventricular filling pressures in rabbits: a comparison with the effect of clenbuterol.AIMS: This study investigated the effects of two different beta2 agonists, [ENTITY_B] (N(omega)-(5-chloro-2-(chlorophenyl)piperazine) and clenbuterol, on the [ENTITY_B] -induced right ventricular filling pressures (RVFP) in rabbits.METHODS AND RESULTS: New Zealand",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatotoxicity identifies [ENTITY_A] and cAspAT as novel markers of hepatotoxicity., a dietary natural product, contains multiple biologically active compounds., a natural product, contains multiple biological activators.can induce [ENTITY_B] gene expression in liver cells.can activate the [ENTITY_B] (Nrf2) pathway in liver cells, leading to the induction of [ENTITY_B] -responsive genes.also induces the expression of antioxidant",0,1
"Hepatic islet beta-cell proliferation and insulin secretion are induced by [ENTITY_A] using a [ENTITY_B] /Wnt6 signaling pathway in HepG2 hepatoma cells., a member of the flavonoid family, has been shown to stimulate human and murine islet beta-cell proliferation in vitro and to stimulate insulin secretion in vivo., a member of the flavonoid family, has been shown to stimulate human and murine islet beta-cell proliferation in vitro and",0,1
"HIV-induced [ENTITY_A] and IL-6 synthesis are mediated via activation of [ENTITY_B].HIV-infected individuals are vulnerable to the development of obesity, diabetes, and hypertension, all of which are associated with increased levels of serum triglycerides and insulin resistance.activates [ENTITY_B] (NF-κB).activates [ENTITY_B] (NF-κB).(NF-κB):(NF-κB).activates leptin(NF-κB).",0,1
"(1H, 13C, and 30C)-isoprenaline and [ENTITY_A] significantly potentiate the [ENTITY_B] mediated stimulation of [ENTITY_B] gene expression in Chinese Hamster Ovary cells.activation evokes a rapid increase in the transcriptional activity of a constitutively active form of the GnRH receptor (GRR).activation evokes fast increases in the transcriptional activity of a constitutively active form of the GnRH receptor (GRR).activation ev",0,1
"HIV-1 integrase inhibitor [ENTITY_B] attenuates [ENTITY_A] -induced liver damage and interferon-gamma (IFN- gamma) production in mice., a new anti-HIV-1 agent, is currently in Phase III trials for the treatment of HIV-1 infection., a new anti-HIV-1 agent, is currently in Phase III trials for the treatment of HIV-1 infection.induces apoptosis in hepatitis B virus-infect",0,1
"Phenylbutyrate induces apoptosis of podocytes by activation of [ENTITY_B] and Fas-induced Fas ligand-dependent pathway in podocytes in vitro. pod
Structural basis of [ENTITY_A] activation by [ENTITY_A].activates [ENTITY_B] and induces apoptosis of podocytes by activating the [ENTITY_B] /TNF-alpha signalling pathway in podocytes in vitro.activates the pro-apoptotic protein [ENTITY_B] in podocytes in vitro.activates the pro-apopt",0,1
"Phenformin ameliorates diabetic retinopathy through activation of [ENTITY_B] -mediated signaling pathway in 3T3-F442A adipocytes.PURPOSE: This study was undertaken to evaluate the efficacy of [ENTITY_A], a new therapeutic drug targeting insulin resistance, in inhibiting diabetic retinopathy and the downstream mediator of [ENTITY_B] (Nrf2) in 3T3-F442A adipocytes.METHODS: 3T3-F442A adipocytes were treated with",0,1
"Proteomic analysis of plasma membranes prepared from rats treated with [ENTITY_A] or resiquimod reveals differential expression of [ENTITY_B] protein families.Protein kinase D1 (PKCD1) has been implicated in the activation of the Toll-like receptor 4 (TLR4) signaling pathway, and its down-regulation by RNA interference (RNAi) has been shown to induce [ENTITY_B] - and cytosolic [ENTITY_A] -induced cytotoxicity in cell systems. Here, the authors used proteomics",0,1
"Protein kinase A (PKA) inhibition potentiates the [ENTITY_A] -mediated stimulation of [ENTITY_B] gene expression in transfected HepG2 hepatocytes., a new anti-diabetic drug, has been recently shown to increase phosphorylation of [ENTITY_B] (S6K) in liver cells and to induce [ENTITY_B] (S6K) expression in vitro., a new anti-diabetic drug, has been recently shown to increase phosphorylation of [ENTITY_B] (S",0,1
"(+) and (-)-isomers of [ENTITY_A] enhance [ENTITY_B] phosphorylation in mouse primary cortical neurons., a naturally occurring ligand of [ENTITY_B], is known to possess several agonist properties, including stimulant effects on arousal and [ENTITY_B] potential., a naturally occurring ligand of [ENTITY_B], is known to possess several agonist properties, including stimulant effects on arousal and [ENTITY_B] potential.activates [ENTITY_B] (MAPK) kinases and promotes neuronal survival",0,1
"The association of [ENTITY_A] with right ventricular hypertrophy and fibrosis in rats: role of [ENTITY_B] activation.The purpose of this study was to examine the effects of SIRT1 activation on right ventricular hypertrophy (RVH) and fibrosis in rats. Wistar rats were randomly allotted into three groups: control, [ENTITY_A] group, and SIRT1 group. The SIRT1 activator resiquimod was administered via subcutaneous route to rats in the SIRT",0,1
"TGF-beta1 and high [ENTITY_A] increase [ENTITY_A] sensitivity in human keratinocytes via activation of [ENTITY_B]., a new anti-inflammatory agent, has been shown to increase the production of [ENTITY_B], [ENTITY_B] and NF-κB in keratinocytes; however, the underlying mechanism(s) of action are not well understood. in, a new anti-inflammatory agent, we found that [ENTITY_A] also increases the expression of [ENTITY_B] and NF-κB in human keratinocyte",0,1
"Treatment of human adipose tissue explants with [ENTITY_A] attenuates low-density lipoprotein oxidation and increases [ENTITY_B] activity.OBJECTIVE: This study investigated the effects of aldosterone ( [ENTITY_A] ) treatment of human adipose tissue explants on low-density lipoprotein (LDL) oxidation, [ENTITY_B], and adipose tissue fatty acid binding protein (aP2) expression.METHODS: Human adipose tissue explants were obtained from patients undergoing elective cardiac surgery and were",0,1
"PKC-dependent signaling regulates [ENTITY_A] -induced [ENTITY_B] expression in pancreatic cancer cells., a prototypical tumor-specific transcription factor, is activated in a ligand-dependent manner in pancreatic cancer cells., an activator of the [ENTITY_B] (PKC) signaling pathway, plays a pivotal role in cancer progression and metastasis.(PKC) signaling regulates many cellular processes including proliferation, differentiation, apoptosis, and metastasis, and is involved in cell cycle",0,1
Proteomic analysis of pancreatic islet cells reveals [ENTITY_A] activation by [ENTITY_B] that is absent in pancreatic islet cells from rats fed a high-carbohydrate diet.activates the [ENTITY_B] in pancreatic islets.activation is suppressed by [ENTITY_B] in isolated islet cells.activates the islet hormone insulin.activation is suppressed by leptin in isolated islets.activation is suppressed by [ENTITY_B] in isolated islets.activation is suppressed by [ENTITY_A] in,0,1
"Pretreatment with the serotonin reuptake inhibitor [ENTITY_A] attenuates [ENTITY_A] mediated inhibition of [ENTITY_A] gene expression in the rat striatum.induction in the nucleus accumbens subregion of the shell (NAC) is mediated by dopamine D1 and NMDA receptors, and serotonin (5-HT) is thought to be an important neurotransmitter in the shell.activates the [ENTITY_B] (S1PR) receptor, and it has recently been shown that 5-",0,1
"(3)H-CGP 12177A binding to [ENTITY_A] and AMPK activators in human adipose tissue explants.activates [ENTITY_B] -dependent [ENTITY_B] secretion in 3T3 cells; however, the precise mechanism remains unclear.activates [ENTITY_B] -dependent [ENTITY_B] secretion in adipose tissue explants, and [ENTITY_A] also activates AMP-activated protein kinase (AMPK)-dependent adipose tissue gene expression in 3T3 cells.activates adipose",0,1
"HMG-CoA reductase inhibitor [ENTITY_A] attenuates [ENTITY_B] -induced hepatotoxicity in rats., an oral anti-diabetic drug, is also known for its hepatoprotective properties, and its mechanism of action involves activation of [ENTITY_B], which in turn inhibits cyclin dependent kinase 4 (CDK4)., another orally active drug, has been reported to activate [ENTITY_B]  in vivo and in vitro. also inhibits cholesterol and glucose uptake and promotes [ENTITY_B] -independent",0,1
"Hepatitis C virus core protein binds to the human [ENTITY_A] selective transcription factor 4 (HDAC4) and activates the [ENTITY_B] pathway., a human glutathione S-transferase (GST) enzyme, is activated by [ENTITY_B], an important component of the hepatitis C virus (HCV) life-cycle., a human glutathione S-transferase (GST) enzyme, is activated by [ENTITY_B], an important component of the hepatitis C",0,1
Proteomic analysis of human umbilical vein endothelium during the estrous cycle and its recovery after the disruption of [ENTITY_A] gene expression.(E2) stimulates [ENTITY_B] secretion from human umbilical vein endothelium (HUVECs) in vitro and induces vasodilatation in a rabbit aortic banded endothelium (RABLE) model of arterial injury in vivo.(E2) is a new anti-,0,1
(1→4)-oxidation of [ENTITY_A] and phenformin is catalyzed by [ENTITY_A] (PPRE) in vitro and in vivo.activation by [ENTITY_B] (PPRE) in vitro and in vivo.activation by PPRE in vitro and in vivoactivation by PPRE in vitroactivation by PPRE in vivoactivation by PPRE in vivoactivation by PPRE in vivoactivation by PPRE in vitro and in vivoactivation by PPRE in vitro,0,1
"The use of [ENTITY_A] as a novel antiarrhythmic drug in humans: a dose-finding study to identify the optimum dose of pranlukast for prevention and therapy of AT1 receptor agonist-induced arrhythmias., a novel antiarrhythmic drug, is known to activate the adenylate cyclase-dependent isoform of [ENTITY_B] that is responsible for the [ENTITY_B] selectivity in human heart., an effective antiarrhyth",0,1
"Proteomic analysis of human adipose tissue explant tissue after [ENTITY_B] treatment revealed down-regulation of [ENTITY_A] target genes encoding adipokines and [ENTITY_B] REPORTING OUTCOME:, a dietary flavonoid, has been recently reported to induce [ENTITY_B] in humans., a dietary flavonoid, has recently been reported to induce adiponectin in humans., a dietary flavonoid, has recently been reported to induce adiponectin in humans.enh",0,1
Protein kinase D2/Akt signaling pathway participates in [ENTITY_A] -stimulated [ENTITY_B] secretion from human airway epithelial cells.Airway epithelial cells (AECs) play an important role in the regulation of mucin secretion by regulating the activity of the [ENTITY_B] (ERK). We investigated the effect of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway on the stimulatory effect of the [ENTITY_B] opener on mucin,0,1
"Hepatoprotective effect of ginseng saponins against [ENTITY_A] induced hepatotoxicity in rats., an anti-diabetic drug, induces [ENTITY_B] in the pancreatic beta-cells in rats., a new anti-diabetic drug, is currently being developed as an oral hypoglycemic agent by the US Food and Drug Administration (FDA).induces insulin resistance, promotes adipocyte differentiation, activates [ENTITY_B], suppresses adipose tissue lipogenesis",0,1
"Treatment of a human adipose tissue explant cell line with [ENTITY_A], a [ENTITY_B] opener, induces [ENTITY_B] expression.activates the [ENTITY_B] /AMP-activated protein kinase pathway in vitro, and it has been reported that adipose tissue explants can be stimulated to produce adipocytes by exposure to [ENTITY_B]., a drug widely used in the treatment of type 2 diabetes, has recently been shown to stimulate [ENTITY_B] activity in adipose tissue explants.also induces",0,1
"Pretreatment with the NMDA receptor antagonist, MK-801, blocked [ENTITY_A] -induced [ENTITY_B] MAPK phosphorylation and enhanced [ENTITY_B] phosphorylation in hippocampus and prefrontal cortex., an NMDA receptor antagonist, induces [ENTITY_B] phosphorylation in hippocampus slices and in prefrontal cortex neurons in vitro.also induces phosphorylation of [ENTITY_B] (MAPK) in hippocampus and prefrontal cortex slices from mice.also induces phosphorylation of CREB in hippocampus and prefrontal",0,1
"(3)H-thymidine incorporation and activation of [ENTITY_A] are potentiation factors for [ENTITY_B] (5-7).activation potentiates the [ENTITY_B] receptor agonist, [ENTITY_B], and this potentiation is eliminated by pretreatment with the nonselective muscarinic receptor antagonist atropine.potentiation potentiates the [ENTITY_B] receptor agonist, [ENTITY_B], and this potentiation is eliminated by pretreatment with the nonselective muscarinic receptor antagonist atropine",0,1
"Proteomic analysis of [ENTITY_A] -stimulated [ENTITY_B] gene expression reveals differential regulation of [ENTITY_B] synthesis in mouse embryonic stem cells., a new anti-diabetic drug, targets liver lipid accumulation by modulating adipose tissue-derived PPAR-γ., a new anti-diabetic drug, targets liver lipid accumulation by modulating adipose tissue-derived PPAR-γ., a new drug approved by the U.S. FDA for the treatment",0,1
"Hepatocyte nuclear factor 4E binding protein-3 is a nuclear receptor for [ENTITY_A]., a nuclear receptor for vitamin D(3), binds to vitamin D(3) and activates [ENTITY_B] -responsive genes in human and murine cells., a nuclear receptor for vitamin D(3), binds to vitamin D(3) and activates the [ENTITY_B] (H(4)D(3))-responsive gene expression in human and murine cells.activates the",0,1
"Proteomic analysis reveals that [ENTITY_A] activates [ENTITY_B] -dependent reporter gene expression in human embryonic kidney HEK293 cells.activates the human embryonic kidney HEK293 cells and up-regulates the expression of the human embryonic kidney HEK293 cell marker gene, alpha-smooth muscle actin (alpha-SMA).activates alpha-SMA gene expression in the human embryonic kidney HEK293 cells and up-regulates the expression of the human embryonic kidney",0,1
"Protein kinase B1/6 (PKB/Akt) activation induces [ENTITY_B] gene expression in pancreatic beta cells: a novel mechanism in glucose-stimulated [ENTITY_B] secretion.OBJECTIVE: To test a hypothesis that activation of protein kinase B1 (PKB) in pancreatic beta cells is necessary for glucose-stimulated [ENTITY_B] secretion from beta cells.RESEARCH DESIGN AND METHODS: In 3T3L1 adipocytes, [ENTITY_A] secret",0,1
"Proteomic profiling of human umbilical vein endothelial cell cultures treated with [ENTITY_A] or rosiglitazone identifies [ENTITY_A] activation regulated by [ENTITY_B].activates [ENTITY_B] and induces vascular permeability in human umbilical vein endothelial cells (HUVEC) in vitro, raising a possibility that statins could influence vascular permeability and the risk of vascular diseases in humans.activates [ENTITY_B] and induces vascular permeability in human umbilical vein endothelial cell cultures in",0,1
"Proteomic analysis of the effects of [ENTITY_A], a [ENTITY_B] opener, on pancreatic islets: involvement of [ENTITY_B] activation.2-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpyridin-1-ium chloride ([(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpyridin-1-ium chloride (CYP2C8",0,1
"Pretreatment with the NMDA receptor agonists [ENTITY_A] and AP5 reduces the severity of experimental encephalomyelitis in immunodeficient mice., a new drug approved for the treatment of relapsing-remitting multiple sclerosis, is thought to act on the brain by activating the norepinephrine transporter (NET) and thereby stimulating the endogenous level of [ENTITY_B]., a new drug approved for the treatment of relapsing-remitting multiple sclerosis,",0,1
"Treatment with the selective beta-secretase inhibitor, GW2740, markedly attenuated [ENTITY_A] -induced [ENTITY_B] (MAPK) activation, [ENTITY_B] (MAPK) phosphorylation, and ERK1/2 phosphorylation.activation, phosphorylation at ERK1/2, and [ENTITY_B] (MAPK) activation were significantly inhibited by GW2740.activation, ERK1/2 phosphorylation, and phosphorylation of JNK were significantly enhanced",0,1
"Proteomic analysis of the [ENTITY_A] -induced liver damage reveals up-regulation of [ENTITY_A] in HepG2 cells.BACKGROUND: Hepatotoxicity induced by [ENTITY_B] is a common problem in oncology patients requiring long-term treatment with chemotherapy or radiation. Hepatic [ENTITY_B] (HepG2) hepatocytes are a good in vitro model to study HepG2 cell toxicity, because HepG2 cells are more resistant to chemotherapeutics or radiation than human hepatocytes. Here,",0,1
"Proteomic analysis of the plasma membrane fraction from [ENTITY_A] -treated human adipocytes identified [ENTITY_A] -regulated proteins involved in lipid uptake and signaling.Obese women have higher plasma triglyceride concentrations and insulin resistance, which can be improved by leptin administration.(Lepr(T3)) increases the circulating free fatty acid (FFA) concentration by inhibiting the [ENTITY_B] current.(Lepr(T1)) activates [ENTITY_B] in human adipocytes.",0,1
"HIV-1 VLPs target and activate the [ENTITY_A] /AMP-activated protein kinase signaling pathway leading to [ENTITY_B] secretion from human peripheral blood mononuclear cells., an endogenous activator of the [ENTITY_B] /AMP-activated protein kinase (AMPK) signaling pathway, stimulates human peripheral blood mononuclear cells (PBMC) to secrete pro-inflammatory cytokines., an active ingredient of a popular dietary supplement, has recently been shown to stimulate human",0,1
(1)H-MR spectroscopy of human plasma reveals novel metabolites of [ENTITY_A] that may serve as markers of cardiovascular risk in humans.(1)H-MR spectra of plasma from healthy volunteers and from a population at risk for cardiovascular disease revealed that plasma levels of the [ENTITY_B] opener N(6)-(+)-isomers of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) were elevated (>5-,0,1
"(R)- and (S)-isoflavanine antagonized the [ENTITY_A] -induced [ENTITY_B] activation by modulating the [ENTITY_B] gene expression.(S)-isoflavonoid, an isoflavonoid with estrogenic activity, has been reported to activate estrogen receptors (ER) by binding to the consensus site located at -8 to -9 of the human ERalpha gene. In this study, we investigated the molecular mechanism by which S-(+)-isofl",0,1
"Proteome analyses of [ENTITY_A] -induced [ENTITY_B] and RORalpha signaling in human keratinocytes.Proteome analyses of human keratinocyte cell lines treated with different concentrations of the anti-androgen receptor (AR) ligand, [ENTITY_B], revealed that higher concentrations of [ENTITY_B]  induced higher levels of phosphorylated ERalpha and, to a lesser extent, ERbeta, than did lower concentrations of the ligand., a new anti-androgen receptor (and",0,1
"Protein kinase D1/2 (PKD1/2) activation induces [ENTITY_A] -induced apoptosis in human osteoblastic MG-63 cells via ER-dependent ERGFR-dependent ERK1/2 activation.activates [ENTITY_B] (Rac)-induced [ENTITY_B] (MAPK) activation in breast and pancreatic cancer cells, but its molecular mechanism of action is still poorly understood.activates Rac-induced transcription of the human osteoblastic MG-63",0,1
"Proteomic analysis of [ENTITY_A] -induced liver fibrogenesis reveals [ENTITY_B] -regulated proteins involved in the control of cell proliferation and differentiation., a dietary phytochemical, is reported to induce liver fibrogenesis through several mechanisms, including the activation of [ENTITY_B] (FABP4).-regulated proteins in liver are still unknown, but are likely to be related to liver fibrogenesis. the aim of the present analysis was to study the protein changes that take place in mice fed",0,1
"(3S,7S)-3,7-dimethoxy-4-methylpyridin-1-ium chloride (4-PAM) inhibits [ENTITY_A] -induced vascular permeability through suppressing the phosphorylation of [ENTITY_B]., a prototypical [ENTITY_B] activator, activates [ENTITY_B] target proteins, including [ENTITY_B] (PPARα) and [ENTITY_B] (sst2).also activates PPARβ and has recently been shown to suppress vascular permeability through suppressing the phosph",0,1
"Protein kinase D1 (CYP3A) is critical in [ENTITY_A] -induced [ENTITY_B] gene expression and [ENTITY_B] -dependent [ENTITY_B] protection in human keratinocyte HaCaT cells., a member of the flavonoid family, plays a significant role in healthy and diseased skin, where it has been implicated in the regulation of epidermal growth factor (EGF) expression and differentiation.can also stimulate the production of several cytokines and cytokine receptors, and",0,1
"(1-immunopositivity)LEF-2 is a nuclear factor that regulates [ENTITY_A] gene expression in human embryonic kidney HEK293 cells via [ENTITY_B] /ERK1/2-mediated signalling.-regulated genes in HEK293 cells include [ENTITY_B] (HEM-4), h-rChIP1, h-rChIP2 and h-rChIP3.-regulated genes in HEK293 cells include HO-1, [ENTITY_B] (",0,1
"HIV-induced [ENTITY_A] and apoptosis of human endothelial cells depend on activation of the [ENTITY_B] /ERK and Ras/mTOR pathways., an important component of the human natural killer (NKT) cell defense against virus infections, is also known to modulate the activity of [ENTITY_B] -mediated transcription factors.also known as RORγ, plays a pivotal role in the activation of the [ENTITY_B] /ERK and Ras/mTOR pathways.activates",0,1
"Hepatocyte nuclear factor 4α (HNF4α) is a nuclear factor activated by [ENTITY_A]., a nuclear receptor for [ENTITY_B], regulates energy homeostasis by activating [ENTITY_B]., an activator of [ENTITY_B], regulates energy homeostasis by activating [ENTITY_B].activates the [ENTITY_B] (Nrf2) gene transcription in human cancer cells., a nuclear receptor for vitamin E, regulates energy homeostasis in mice.activates the human [ENTITY_A]",0,1
"The role of reactive astroglia in the modulation of [ENTITY_A] -induced apoptosis in osteoblast-like cell lines., a new anti-cancer agent, has recently been shown to induce cell proliferation by activation of [ENTITY_B] (RARalpha/beta).activates the [ENTITY_B] (RARalpha/beta) receptor tyrosine kinase, which is known to play a role in osteoblast differentiation and differentiation, and to suppress osteoclast formation by suppressing RAR",0,1
"(1-aminoadamantane) inhibits [ENTITY_A] -induced [ENTITY_B] secretion from human airway epithelial cells., an endogenous atropine receptor agonist, stimulates mucin secretion from mouse tracheal smooth muscle cells, stimulates airway smooth muscle cell proliferation, induces ultrastructural changes in smooth muscle cells, increases cell migration and induces apoptosis in human airway smooth muscle cells (A549)., an endogenous atropine receptor agonist, stimulates muc",0,1
"The role of [ENTITY_A] on the expression of [ENTITY_A] and PDGFRalpha mRNAs and protein in the [ENTITY_B] -induced mammary gland apoptosis., a natural ligand of [ENTITY_B], is known to induce mammary gland cancer in animal models.also induces apoptosis in some types of human tumors.activates [ENTITY_B] -induced [ENTITY_B] -induced mammary gland apoptosis.activates PDGFRalpha and PIM-1 induced by PDGFRalpha",0,1
"The role of [ENTITY_A] in modulating the immunoglobulin A response to hepatitis C virus (HCV)., a new member of the phenylpropanoid pathway, has been reported to increase the susceptibility of cells to cytotoxic T lymphocytes by activating the [ENTITY_B] (NIS) pathway.activates the [ENTITY_B] (NIS) pathway in dendritic cells (DC) and in macrophages.activates the [ENTITY_B] (NIS) pathway",0,1
"PKC-dependent activation of [ENTITY_A] in breast cancer cells: involvement of [ENTITY_B]., a prototypical activator of [ENTITY_B] (PKD), has recently been shown to regulate the activity of several other known ligands including ER-stress marker proteins, [ENTITY_B], cyclin-dependent kinase inhibitors and the anti-apoptotic proteins Bcl-xL and Mcl-1.(PP2), a well-known activator of PPAR, has recently been shown",0,1
Protein kinase D1-phosphatase 9-phosphorylation regulates [ENTITY_B] -mediated stimulation of [ENTITY_A] gene expression in human osteoblast cell lines.activates the [ENTITY_B] /collagen-I signaling pathway to induce osteoblast differentiation.activates the human steroid hormone receptor (hSHR) to induce osteoblast differentiation in vitro and in vivo.activates the hSHR and promotes osteoblast proliferation and differentiation in vivo.,0,1
"Proteomic and biochemical analysis of the effects of [ENTITY_A], a [ENTITY_B] opener, on the pancreatic islets of rats., an antimuscarinic drug, stimulates [ENTITY_B] expression in pancreatic islets., an antimuscarinic drug, activates the [ENTITY_B] /insulin signaling pathway in pancreatic islets of rats.(AP-1) blocker, NSC23766, suppresses [ENTITY_A] stimulation of [ENTITY_A] expression in islets of rats.",0,1
"Pretreatment with the NMDA receptor antagonist, MK-801, prevented down-regulation of [ENTITY_A] and up-regulation of N-methyl-d-aspartate receptor in hippocampus and prefrontal cortex after [ENTITY_B] toxicity., a NMDA receptor antagonist, is known to cause selective disruption of hippocampal and prefrontal cortical NMDA receptor (NMDAR) signaling in mice., a non-NMDA receptor antagonist, is also known to cause selective disruption of hippocamp",0,1
(E)-2-[(hydroxyimino)methyl]-1-phenyl-propyl]-3-methylpyridin-1-ium chloride (PPiPP) is a new selective [ENTITY_A] induction site agonist that selectively induces [ENTITY_B] in guinea-pig airways through the activation of [ENTITY_B].selectively induces the expression of HIF-targeted genes in bronchoalveolar lavage fluid.selectively activates [ENTITY_B]  in human air,0,1
Proteins activated by [ENTITY_A] inositol 1-phosphate receptors are activated by [ENTITY_B] in the intestine and up-regulate [ENTITY_B] -regulated genes in colonic epithelial cells.is a long-acting phosphodiesteroid that regulates energy homeostasis by stimulating [ENTITY_B] -regulated genes in adipocytes and enhancing glucose uptake in adipose tissue and liver.activates [ENTITY_B] -regulated genes in adipocytes and up-regulates genes related to energy homeostasis in,0,1
"(1)H NMR, (15)N-glyceraldehyde dehydrogenase and [ENTITY_A] expression were significantly induced by dietary [ENTITY_A], but not by other ROS-producing compounds in rats.activates [ENTITY_B] and causes oxidative stress in rats.activates ROS and causes oxidative stress in rats.activates ROS and causes oxidative stress in rats.activates NO and causes NO depletion and cell death in rat primary hepatocytes.activates [ENTITY_B] and causes",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatotoxicity revealed downregulation of [ENTITY_B] and upregulation of AR
The role of the [ENTITY_A] family in the development of liver damage and the upregulation of [ENTITY_B] by [ENTITY_B].induction in mice and in humans leads to hepatocellular damage, steatosis and increased serum [ENTITY_B] levels, which can be prevented by treatment with [ENTITY_B], a specific anti-diabetic drug.induction in mice and in humans leads to hep",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatotoxicity reveals up-regulated [ENTITY_A] levels in the liver., a dietary natural herb, has been reported to possess hepatoprotective effects by inhibiting the activity of [ENTITY_B] (N-hydroxy-3-methylbenzylaminopurine).activates [ENTITY_B] (N-hydroxy-3-methylbenzylaminopurine) in vitro and reduces the formation of [ENTITY_B] -containing products in mice, both",0,1
"(1H, 14C, and 17F) stereoisomeric studies of the [ENTITY_A] (PPRE)-stimulated [ENTITY_B] secretion., an endogenous ligand of nuclear receptor PPARγ, regulates a large number of biologically important lipid mediators, including cholesterol, glucose, and insulin., a PPARγ agonist, regulates a large number of biologically important lipid mediators, including cholesterol, glucose, and insulin.activates the [ENTITY_B] (PPRE)-",0,1
"Protein kinase D(2) regulates [ENTITY_A] -induced [ENTITY_B] autophosphorylation on [ENTITY_B].Activation of protein kinase D(2) (PKD) by [ENTITY_A], a prototypical phosphorylation-inducing agent for [ENTITY_B] -sensitive receptors, stimulates the phosphorylation of the receptor's receptor binding site(s) on the tyrosine kinase inhibitor, [ENTITY_B], leading to receptor desensitization., a prototypical activator of [ENTITY_B] -sensitive",0,1
"Protein kinase D1/2 regulates [ENTITY_A] -mediated activation of [ENTITY_B] in osteoblast-like cell lines., a prototypical bone growth factor, is thought to stimulate osteoblastic differentiation by activating the [ENTITY_B] (ERK) signaling pathway., a prototypical osteoprogenitor factor, is thought to stimulate osteoblast differentiation by activating the ERK (ERK) signaling pathway.(ERK(seng2)), a prototypical [ENTITY_B] activ",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatotoxicity revealed up-regulated protein families involved in cell cycle progression and apoptosis., a naturally occurring hepatotoxic drug, causes hepatotoxicity by inducing oxidative stress and hepatocyte apoptosis through activation of [ENTITY_B] -mediated pathway., a naturally occurring hepatotoxic drug, causes hepatotoxicity by inducing oxidative stress and hepatocyte apoptosis through activation of SH-pathway.potentiates [ENTITY_B] -mediated cell",0,1
"Treatment of [ENTITY_A] -injured dopaminergic cells with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked the ability of the [ENTITY_A] to increase the expression of [ENTITY_B] and CREB in the dopaminergic cells.MAPK/ERK1/2 pathway mediates cocaine-induced [ENTITY_B] MAPK/ERK1/2 phosphorylation in dopamine neurons.activates [ENTITY_B] MAPK/ERK",0,1
"Proteomic analysis of the effects of [ENTITY_A], an L-arginine (L-Arg) donor, on [ENTITY_B] -induced hepatotoxicity in rats., an L-Arg donor, improves the hepatoprotective effect of [ENTITY_B], which is eliminated by [ENTITY_B] supplementation.can protect against acetaminophen hepatotoxicity in rats; however, it is still not completely understood why the combination of L-Arg and acetaminophen causes hepatotoxicity.",0,1
"The effect of the [ENTITY_A] enhances the depolarizing afterpotential of the rat basilar artery., an activator of [ENTITY_B], has been recently shown to increase the afterhyperpolarizing potential (AHP) of isolated rat basilar artery., an activator of PKA, has been recently shown to increase the AHP of isolated rat basilar artery., a PKA inhibitor, has been recently shown to decrease the AHP of",0,1
"Treatment with [ENTITY_A] enhances the efficacy of [ENTITY_B], a phosphodiesterase I inhibitor, in rats.activates [ENTITY_B] in the brain.activates phosphodiesterase I in striatum and prefrontal cortex and suppresses dopamine D2 receptor-induced [ENTITY_B] signaling in prefrontal cortex.activates phosphodiesterase I in striatum and prefrontal cortex, suppresses dopamine D2 receptor-induced dopamine D2 receptor signaling in prefrontal cortex, and suppresses",0,1
"The role of [ENTITY_A] as an activator of [ENTITY_B] in endometrial cancer cell lines.The aim of this study was to compare the effects of the anti-estrogen agent, progesterone, and the selective androgen receptor (hAR) antagonist, and the selective hAR agonist, 17-phenyl trinor, on the proliferation of endometrial cancer cell lines, and to examine the molecular mechanisms of these effects., an ERalpha agonist, increased",0,1
Protein kinase C (PKC) inhibition attenuates [ENTITY_A] -induced cardiomyocyte apoptosis.induction of [ENTITY_B] in cardiomyocytes is accompanied by activation of [ENTITY_B] -mediated signaling.activates [ENTITY_B] (PKD) in cardiomyocytes to regulate cardiac contractile function.activates the [ENTITY_B] (PKD) cascade in cardiomyocytes to influence cardiac contractile function.induces apoptosis in cardiomyocytes in part,0,1
"Pretreatment with [ENTITY_A] attenuates [ENTITY_B] mediated hepatotoxicity and increases [ENTITY_B] activity in rats., a natural compound found in different plant species, has been reported to possess a wide variety of pharmacological activities, including anti-diabetic activity, free radical scavenging activity, antioxidative and hypoxia-inducing properties.enhances [ENTITY_B] -induced hepatocyte proliferation and antioxidant capacity, protects against the DNA-damaging agent tert-butylhydroquinone (BBQ",0,1
"Treatment of rat hepatoma cells with [ENTITY_A] leads to activation of [ENTITY_B], [ENTITY_B] phosphorylation, [ENTITY_B] activation and induction of [ENTITY_B] in the cytoplasm.activates [ENTITY_B] in the liver by an ER-dependent mechanism.activates [ENTITY_B]  in hepatocytes by direct activation of ER-dependent phosphorylation of ER-stress marker proteins in the cytosol.activates ER-dependent phosphorylation of [ENTITY_B]  in the cytoplasm in hepat",0,1
"PKC(MAPK) inhibition sensitizes diazepam-induced seizures in mice: involvement of [ENTITY_A] activation.BACKGROUND: Activation of [ENTITY_B] (PKD) by [ENTITY_B] and other GABAergic drugs induces [ENTITY_B] (MAPK) activation in CNS neurons. The role of PKD in seizures induced by other GABAergic drugs, such as diazepam, valproate, or phenytoin, is less well known.RESULTS: Here, we demonstrate a direct role of PK",0,1
"Treatment of mice with the [ENTITY_A] opener [ENTITY_B], a GABA(A) agonist, and [ENTITY_A], a NMDA antagonist, leads to a selective increase in [ENTITY_B] level in hippocampus and prefrontal cortex.induction in hippocampus and prefrontal cortex of mice, which are treated with the GABA(A) agonist, [ENTITY_B], and the N-methyl-d-aspartate (NMDA) receptor antagonist, MK-801, and is followed by a significant decline in hippocamp",0,1
"(+) and (-)-isomers of [ENTITY_A] enhanced [ENTITY_B] activity and phosphorylation in SH-SY5Y cells., an activator of [ENTITY_B], stimulates cell proliferation in a concentration-dependent manner in human neuroblastoma SH-SY5Y cells., an activator of [ENTITY_B], stimulates neuroblastoma cell proliferation in a concentration-dependent manner in human neuroblastoma SH-SY5Y cells.activates the [ENTITY_B] in human neuroblastoma",0,1
"Treatment of human osteoblastic MG-63 cells with [ENTITY_A] caused an increase in [ENTITY_B] expression, alkaline phosphatase activity, mineralisation, as well as a reduction in the expression of the osteoblast differentiation marker osteoprotegerin., a natural compound, has been reported to inhibit osteoclast formation and to stimulate osteoblast differentiation in different cell systems. In this study, we investigated the effects of the natural compound, tert-butylhydro",0,1
Hepatocyte nuclear factor 4 alpha (HNF4α) mediates [ENTITY_A] activation and hepatocyte steatosis in mice.activates [ENTITY_B] and induces steatosis in mice.activates [ENTITY_B] and induces steatosis in mice.activates [ENTITY_B] and reduces steatosis in mice.activates and reduces steatosis in mice.activates and reduces steatosis in mice.and Nrf2 are important regulators of nuclear factor,0,1
"The effects of the endogenous ligand of [ENTITY_A], [ENTITY_B], on the excitatory effects of [ENTITY_B]., an endogenous ligand of NMDA receptors, has been implicated in the modulation of [ENTITY_B] function in the CNS., an endogenous ligand of nicotinic receptors, has also been implicated in the modulation of GABAergic function in the CNS.activates [ENTITY_B] -mediated currents by interacting with the GluR3 site on the NMDA receptor., but not",0,1
"(1)H-NMR, (14)C-NMR, and (31)P-NMR analyses of the effects of [ENTITY_A] on [ENTITY_B] gene expression in transgenic rats expressing hEGFRvIII.enhances [ENTITY_B] activity via activation of the [ENTITY_B] (ERK) pathway in human breast cancer cells.stimulates the expression of hEGFRvIII in transgenic rat breast cancer cells, and this stimulation is mediated by the [ENTITY_B] (ERK",0,1
"PKCβ activation of [ENTITY_A] (ERK) in response to [ENTITY_A] : involvement of [ENTITY_B]., a member of the natural compound family of [ENTITY_B], induces apoptosis in tumor cells by activation of the ERK signaling pathway.activates the ERK signaling pathway in cancer cells through the activation of [ENTITY_B] (ERK) in human breast cancer cell MDA-231 and in rat mammary carcinoma cells (RMC-1 and T-47D).activates",0,1
"The use of the novel antiepileptic drug [ENTITY_A] attenuates [ENTITY_B] -induced seizures in rats., an anti-convulsant and [ENTITY_B] inducer, has recently been reported to decrease the frequency of spontaneous seizures in humans., an anti-convulsant and anticonvulsant, has recently been reported to decrease the frequency of spontaneous seizures in humans.(AICAR), a long-acting beta-adrenoceptor agonist,",0,1
"Proteomic analysis revealed that the [ENTITY_A] activates [ENTITY_B] in human aortic endothelial cells.activates the [ENTITY_B] in human aortic endothelial cells (HAECs)., a member of the flavonoid family, plays an important role in the pathogenesis of atherosclerosis in animals and humans., an important anti-atherosclerotic agent, contains several flavonoids including [ENTITY_A], rutin, and cinnamic aldehyd",0,1
"Proteomic and pharmacological analyses identify [ENTITY_A] as a novel muscarinic receptor agonist that stimulates [ENTITY_B] secretion., a new anti-convulsant, activates [ENTITY_B] (AMPK) and phospholipase A2 (PLA2).stimulates AMPK activation and phosphorylation in neuronal cells.also stimulates phospholipase A2 (PLA2) in neuronal cells.activates [ENTITY_B] (AMPK) in neuronal cells and increases [ENTITY_B] secret",0,1
Hepatocyte nuclear factor 4alpha-dependent [ENTITY_A] activation is involved in [ENTITY_B] -induced [ENTITY_B] expression.activation induced by [ENTITY_B] (E2) is a key event in the activation of S-phase kinase 4 (SK4) by E2 in breast cancer cells.activation induced by E2 is a key event in the activation of S-phase kinase 4 (SK4) by E2 in breast cancer cells.activation induced by E2 is,0,1
"The role of [ENTITY_A] in the regulation of uterine cell proliferation and apoptosis: comparison with [ENTITY_B]., an activator of [ENTITY_B], induces cell proliferation in human endometrial cancer cell E2 cells via ER-dependent and ER-independent mechanisms of action., a ligand of nuclear receptors LXR and RXR, induces uterine cell proliferation in vitro via ER-dependent and ER-independent mechanisms of action., an activator of [ENTITY_B], induces cell",0,1
"Proteomic analysis of human adipose tissue revealed up-regulated proteins involved in [ENTITY_A] -induced adipogenesis.Obesity is an important public health problem that is associated with insulin resistance and increased levels of serum triglycerides. We have previously demonstrated that the [ENTITY_B] activator [ENTITY_A] up-regulates expression levels of several key adipocyte-related genes in 3T3L1 cells. In this study, we further investigated the molecular mechanism by which adiponectin regulates the transcriptional activity of [ENTITY_B]",0,1
"Treatment of rat primary preadipocytes with [ENTITY_A] caused a dose-dependent increase in [ENTITY_B] protein expression., a member of the superoxide dismutase (SOD) pathway, plays an important role in adipogenesis by regulating the activity of [ENTITY_B].can also stimulate [ENTITY_B] activity in vitro.activates transcription elongation and promotes differentiation of preadipocytes; however, the molecular mechanism by which it stimulates adipogenesis is still poorly understood. the present",0,1
The role of the human cytosolic phospholipase A2 (cPLA2) in the [ENTITY_A] -stimulated production of [ENTITY_B] (PPH) in breast cancer cells.can activate the [ENTITY_B] /PPHS-dependent signaling pathway in breast cancer cells leading to the activation of ERK and [ENTITY_B] -mediated transcriptional regulation.can activate the PPHS-dependent signaling pathway in human breast cancer cells leading to the activation of ERK and the nuclear translocation of β,0,1
"The effects of [ENTITY_A] on spatial memory in mice are mediated by the activation of CREB in the hippocampus., a novel compound found in the Chinese herb, Curcuma wenyujin, is known to possess memory-enhancing abilities., a well-known compound in Chinese herb, has been shown to enhance spatial learning and memory in rats. in the present study, we investigated the neuroprotective effects of curcumin and cilazapril in [ENTITY_B]",0,1
"Hepatocyte nuclear factor 4alpha (HNF4alpha) is a new determinant of [ENTITY_A] -stimulated [ENTITY_B] secretion from hepatocytes: involvement of [ENTITY_B] activation in the up-regulation of PRA-1.activates hepatic nuclear factor-4α (HNF4α) in hepatocytes and induces [ENTITY_B] secretion, resulting in the up-regulation of the target gene PRA-1 (platelet-derived growth factor-binding protein-1",0,1
The effect of the [ENTITY_A] activator [ENTITY_B] on [ENTITY_B] gene expression: comparison with the effect of rosiglitazone.AIMS/HYPOTHESIS: The aim of the present work was to compare the induction of hMG-CoA reductase (hMG-CoR) and phosphoenolpyruvate carboxykinase (PEPCK) by the statin drugs rosiglitazone and pioglitazone and,0,1
"Treatment of rat primary preneoplastic cells with [ENTITY_A], but not doxorubicin, induces [ENTITY_B] activation.activates [ENTITY_B] and induces cell cycle arrest at G2/M.activates p21 and induces cell cycle arrest at G1/S.activates p53 and induces apoptosis in human cancer cell lines.induces p21 and induces cell cycle arrest at G2/M in human cancer cells.induces p",0,1
"Treatment of a rat model of acute myeloid leukemia (AML) with the novel AMPK activator [ENTITY_A] improved survival, increased [ENTITY_B] activity and decreased apoptosis, and suppressed phosphorylation of Akt and mTOR in a dose-dependent manner.activates [ENTITY_B] and promotes cell proliferation in human AML cell lines, but the mechanism of action is not known.activates the [ENTITY_B] (AMPK); it has recently been reported that activation of AMPK induces",0,1
"The effect of [ENTITY_A] on [ENTITY_A] -induced arrhythmias and its mechanism(s): a biochemical and pharmacological study.In the present study, the effects of S1P on [ENTITY_B] -induced arrhythmias in guinea-pig tracheal smooth muscle were studied.(S1P) is known to induce [ENTITY_B] -like contractions of smooth muscles, but its mechanism of action still remains to be clarified.can activate the transient receptor potential (TR",0,1
(R-type) [ENTITY_A] enhances [ENTITY_A] gene expression in transgenic mice.activates [ENTITY_B] (R-type) channels in epithelial cells and stimulates the conductance of paclitaxel-sensitive K(+) channels in endothelial cells.activates K(ATP) channels in both human and murine embryonic fibroblasts and stimulates both paclitaxel- and doxorubicin-sensitive and -insensitive K(+) currents,0,1
"(+) and (-)-epicatechin prevented [ENTITY_A] -induced cytoskeleton reorganization, enhanced [ENTITY_B] phosphorylation, and enhanced cell migration., a well-known green tea polyphenol, has been shown to possess a number of chemopreventive properties. However, the exact mechanism by which it exerts these properties is still unknown. In the present study, we demonstrate that epigallocatechin (EC) and its metabolite, (-)-epicate",0,1
"Phenotypic analysis of the human androgen receptor (hAR) reveals a common profile of activation by [ENTITY_A], [ENTITY_B] and daidzein, but not by testosterone., a ligand for the human androgen receptor (hAR), activates the [ENTITY_B] (SAR) in human hepatoma cell lines and human breast cancer cells., a ligand for the hAR, activates the [ENTITY_B] (SAR) in human cell lines and human breast cancer cells.",0,1
"Hepatocytes isolated from [ENTITY_A] pretreated rats had increased [ENTITY_B] activity and reduced [ENTITY_B] activity, and had decreased [ENTITY_B], oxidized-LDH, and NO levels in the serum.environmental stresses induce oxidative stress and cause loss of redox balance in the liver.activation is involved in [ENTITY_B] protection in mice.environmental stresses induce oxidative stress and cause loss of redox balance in the liver.environmental stresses induce oxidative stress in mice",0,1
"Pretreatment with the serotonin precursor [ENTITY_A] attenuates [ENTITY_A] -induced seizures in mice., an N-methyl-d-aspartate (NMDA) receptor agonist, is known to produce antiepileptic effects in humans and in animal studies to produce partial reversal of partial damage to the hippocampus and cortex induced by [ENTITY_B]., an N-methyl-d-aspartate receptor (NMDAR) antagonist, has been known to produce antiep",0,1
"(1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), an effective [ENTITY_B] inducer, selectively inhibits the phosphorylation of [ENTITY_A] (H(2)S).inducer BAPTA selectively inhibits phosphorylation of [ENTITY_B], activating [ENTITY_B] activation in human keratinocyte HaCaT cells.inducer BAPTA selectively inhibits phosphorylation",0,1
Hepatocyte nuclear factor 4α (HNF4α) is activated in response to [ENTITY_A] by [ENTITY_B] requiring activation of [ENTITY_B] (PI3K/Akt) in hepatoma cell lines.activates [ENTITY_B] (PI3K)/Akt signaling in hepatocytes.activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in hepatocytes.activates the phosphatidylinositol 3,0,1
"(E)- and (Z)-isomers of [ENTITY_A] enhance [ENTITY_B] activation by DNA-PK in vitro., a plant natural product, has been shown to possess potent antiprogestational and chemopreventive activities., a plant natural product, has been shown to possess potent antiprogestational and chemopreventive activities.activates the [ENTITY_B] (E)- and (Z)-isomers of p21(WAF1/CIP1)",0,1
"HMG-CoA reductase inhibitor [ENTITY_A] attenuates hepatocellular lipid accumulation and improves fatty liver in rats fed a high-fat diet containing [ENTITY_A]., an inhibitor of human [ENTITY_A] that stimulates [ENTITY_B] secretion from hepatocytes, improves obesity, and attenuates hepatic steatosis in rats., an inhibitor of human sterol regulatory element-binding protein-1c that regulates cholesterol homeostasis, improves obesity and attenuates hepatocellular lipids",0,1
"Pretreatment with [ENTITY_A] attenuates [ENTITY_B] -induced seizures via down-regulation of the [ENTITY_B] gene., a novel anti-convulsant, selectively inhibits seizures via activation of [ENTITY_B], not by inhibition of GABAergic transmission., a novel anti-convulsant, selectively inhibits seizures via activation of [ENTITY_B]  (S)-type receptors, not by inhibition of GABAergic transmission., a novel anti-convulsant, selectively inhibits seizures via activation of S",0,1
"Treatment of human osteoblastic cell line MG-63 with [ENTITY_A] inducers and [ENTITY_A] activators resulted in the up-regulation of [ENTITY_B] and osterix mRNA.inducer (SELL-1) stimulates the expression of osteoprotegerin (OPG), osteoprotegerin receptor (OPRG-R), and osteocalcin mRNA in MG-63 cells.activator (SAH-1) stimulates the expression of osterix and",0,1
"(1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), a Ca(2+) chelator, inhibits [ENTITY_A] -induced vascular permeability by inhibiting [ENTITY_B] activation of PIP2 in vascular endothelial cells., a member of the calpain family, is activated by phosphatidylinositol 3-kinase (PI3K) in",0,1
"The effect of [ENTITY_A] on the activity of [ENTITY_B] and its inhibition by [ENTITY_B]., a new anti-convulsant, is active against both pentylenetetrazolo-tetrazole (PTZ) and valproic acid (VPA), which are used as standard drugs to induce epilepsy in humans., a new anti-convulsant, is active against both PTZ and VPA, which are used as standard drugs to induce epilepsy in humans.",0,1
"Treatment of rat striatum with [ENTITY_A] improved learned helplessness and increased [ENTITY_B] activity., an N-methyl-d-aspartate (NMDA) receptor antagonist and antidepressant, enhances the [ENTITY_B] induction in rats., an N-methyl-d-aspartate (NMDA) receptor antagonist and antidepressant, enhances the learned helplessness and increases the expression of [ENTITY_B] in rats., an N-methyl-d-aspartate (",0,1
"(1)H- and (13)C-modifications in [ENTITY_A] and SAL produced by differentiating adipocytes., a well-known [ENTITY_B] inducer, induces expression of [ENTITY_B] in differentiated adipocytes; however, the precise mechanisms by which adipocytes modulate the expression of SAL remain poorly understood.can also modulate the expression of other adipocyte genes via [ENTITY_B] /AMP-activated protein kinase (AMPK) signaling; however, the precise mechanism by which adipocytes",0,1
"The association between [ENTITY_A] phosphorylation and DNA-binding activity of [ENTITY_B].activates the [ENTITY_B] transcription factor, NF-κB, in human cancer cells through phosphorylation of the receptor.activates the p65 subunit of NF-κB in human cancer cells through phosphorylation of the receptor in the cytosol.phosphorylates the p65 subunit of NF-κB in human cancer cells in vivo.activ",0,1
"Tumor-conditioned medium from [ENTITY_A] -sensitized prostate cancer cells activates [ENTITY_B] -mediated transcription elongation.PURPOSE: Transcription elongation is a critical event in the regulation of prostate cell proliferation; however, the mechanisms by which elongation is activated by transcription elongation factors remain poorly understood.EXPERIMENTAL DESIGN: We investigated the molecular mechanism of transcription elongation by the tumor-derived prostate-cell growth factor-derived secretory phosphorylated receptor for",0,1
"Phenotype-related [ENTITY_A] expression may predict response to treatment with [ENTITY_B], a new antiepileptic drug, in patients with subtypes II and IV partial seizures.PURPOSE: In this study, we investigated the association of phenotypic expression with efficacy and adverse events of the novel antiepileptic drug, gliclazide, in patients with subtypes II and IV partial seizures.METHODS: This was a multicenter, double-masked, placebo",0,1
(1)H- and (14)C-labeled [ENTITY_A] in liver tissue extracts from rats given [ENTITY_B] or 4-chloro-quinolinol.is a 4-chloroquinolol herbicide that is widely used in the food and feed industries.can also be detected in the environment through consumption of some food products that are contaminated with the herbicide.can also be detected in human and animal tissue extracts.can also be detected in,0,1
"Protein kinase D1/C2 β is involved in [ENTITY_A] -mediated enhancement of [ENTITY_B] -induced cyclin D1 expression in human keratinocyte HaCaT cells.activates the phosphorylation- and de-phosphorylation-dependent signalling cascade of the transcription factor [ENTITY_B], leading to the expression of cyclin D1.activates cyclin D1 expression in a phosphoinositide 3-kinase (PI3K) and mTOR",0,1
"Hepatitis B virus X protein (HBx) is a target of [ENTITY_B] : a proteomic study using a human hepatocyte cell line.UNLABELLED: In this study, we investigated the role of hepatitis B virus (HBV) X protein (HBx) as a target of [ENTITY_A], a plant flavonoid with hepatotoxicity., an active ingredient of Vaccinium macrocarpon, induces apoptosis in hepatoma cell line HepG2",0,1
"(E)- and (Z)-isomers of [ENTITY_A] enhances [ENTITY_B] activity in mouse cerebral artery myocytes.(E)- and (Z)-isomers of the natural product, a phenolic flavonoid found in various plants, are well known in the pharmacopoeias as being potent inhibitors of cholesterol ester transfer protein (CETP), an important enzyme in the cholesterol efflux pathway.(E)- and (Z)-isomers of the flavanone",0,1
"PKC-mediated inhibition of [ENTITY_A] transcriptional activation requires [ENTITY_A] phosphorylation.activation by [ENTITY_B] (PKC) is known to cause DNA damage and induce [ENTITY_B] (SREBP-1c) expression.activates the transcription of target genes via the activation of a PP2A complex containing ATF4, PP2Aα, and PP2Bα in the nucleus.enhances the expression of PP2Aα and PP2Bα in",0,1
"Proteomic analysis of human and rat aortic endothelial cell cultures after [ENTITY_A] exposure reveals differential activation of [ENTITY_B] (MAPK) kinases and phosphorylation-dependent signaling pathways., a known vascular endothelial growth factor (VEGF), regulates the angiogenesis in vivo and in vitro via the activation of a heterodimerization partner, the [ENTITY_B] (MAPK) complex., a known vascular endothelial growth factor (VEGF), regulates the ang",0,1
"PKCδ activation by [ENTITY_A] is coupled to [ENTITY_B] mediated inhibition of p21 protein expression in human osteoclast precursor cells.activates the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) signaling pathway and induces the phosphorylation of p38 mitogen-activated protein (MAP) kinase in osteoclast precursor cells., the active principle of Catharanthus violet, is a red wine flavanoid.",0,1
"(R)-isomerization to (S)-islets depend on the presence of [ENTITY_A] in pancreatic beta-cells: evidence for the involvement of [ENTITY_B] in [ENTITY_B] activation.activation induced by [ENTITY_A] in beta-cells.activates [ENTITY_B] in pancreatic beta-cells in vitro; however, the precise mechanism of how this occurs is unknown.activation can be induced by various stimuli, including [ENTITY_B], [ENTITY_B] in pancreatic islets, or insulin in vitro; however,",0,1
"(R)- and (S)-methionine and [ENTITY_A] (S)-methionine have been shown to increase the resistance to apoptotic cell death induced by [ENTITY_B], a well-known [ENTITY_B] inducer.induces [ENTITY_B] -dependent [ENTITY_B] (S)-methionine ( [ENTITY_B] )-dependent [ENTITY_B] (R)-methionine ( R-Met) dependence on the expression of [ENTITY_B].activates [ENTITY_B] (S)-methionine ( R-Met",0,1
(1-aminoadamantane) inhibits [ENTITY_A] -mediated induction of [ENTITY_B] gene expression in mouse C2C12 skeletal myoblasts.is a new anti-convulsant approved for the treatment of patients suffering from sub-acute and chronic mild to moderate traumatic brain injury (TBI).induction is one of the most common reasons for sub-optimal outcome in patients suffering from TBI.induction is one of the most common reasons,0,1
"Treatment of [ENTITY_A] and DA cells with [ENTITY_A] caused an increase in intracellular [ENTITY_B] levels that was blocked by antipsychotic and antidepressant drugs., an antipsychotic and antidepressant, is widely used in the treatment of patients with psychosis., a second-generation antipsychotic, is under consideration for treatment of patients with schizophrenia and related disorders.also causes an increase in the levels of intracellular catecholamine, which is blocked by antip",0,1
"The use of the [ENTITY_A] receptor agonist [ENTITY_B] attenuates experimental autoimmune encephalomyelitis in mice.
CD40 ligand and [ENTITY_A] in the brain of rats immunized with [ENTITY_B].RATIONALE: Neutrophil granulocytes are important players in the activation of the immune system, and are also the target cells for many of the currently approved drugs for the treatment of neurodegenerative disease. However, there is a paucity of information about the localization of neuro",0,1
"(1-imidazoline-4-carboxamide) inhibits [ENTITY_A] -induced vascular permeability by suppressing phosphoinositide 3-kinase-dependent [ENTITY_B] phosphorylation in vascular smooth muscle cells., a prototypical [ENTITY_B] activator, induces [ENTITY_B] phosphorylation, which mediates its anti-vascular permeability-improving effect., a prototypical vascular permeability-improving agent, induces phosphoinositide 3-kinase",0,1
"Hepatocyte nuclear factor-4α (HNF-4α) mediates [ENTITY_A] -stimulated [ENTITY_B] secretion and hepatocyte proliferation., the active ingredient in red wine, has numerous biological activities, among which is its ability to stimulate the proliferation of human hepatocytes in vitro and to induce [ENTITY_B] -dependent steatosis in rats.activates [ENTITY_B] (PPARα/ δ), anabolic androgen receptor, and [ENTITY_B] stimulates the transcriptional activity",0,1
"Proteomic analysis of [ENTITY_A] activated by [ENTITY_B] and phenformin reveals differential regulation of [ENTITY_B] phosphorylation and mTOR signaling.Protein phosphorylation by [ENTITY_B] and phenformin is thought to be critical for their biological activities, but the precise molecular mechanisms of their activation remain poorly understood. Here, we report the differential regulation of phosphorylated-STIM1 (pS1) by these two drugs on a global scale using two complementary proteomic analyses of phosphorylated phosph",0,1
"(E)-selectin overexpression and its ligands, [ENTITY_A], PDGFA and VDBP, stimulate [ENTITY_B] -dependent human adipose tissue explant proliferation., a recently reported [ENTITY_B] that regulates adipogenesis, proliferation and differentiation, is currently under consideration as a new anti-obesity drug, targeting adipose tissue-derived hormone-sensitive lipoprotein (ASL) lipids and glucose metabolism in obesity.also stimulates human adipose tissue explant proliferation",0,1
"(1)H- and (15)N-labeled [ENTITY_A] indicate that the active site of the human [ENTITY_A] is located in the C-terminal region, and that the ligand binding site is asymmetric.can act as an HMG-CoA reductase and induce [ENTITY_B] phosphorylation in human liver microsome, and these activities can be inhibited by [ENTITY_B] (TZD) and PPARalpha agonists, respectively.activates [ENTITY_B]",0,1
"HMG-CoA reductase inhibitors ( [ENTITY_A] ) decrease [ENTITY_A] -mediated [ENTITY_B] -mediated [ENTITY_B] phosphorylation, NF-κB activation, [ENTITY_B] -induced COX-2 expression and cell proliferation., a lipid-soluble phosphodiesterase (PDE) inhibitor, activates the enzyme p38 MAPK and promotes cell proliferation; it also inhibits apoptosis.also inhibits cell proliferation, apoptosis, and the activation of [ENTITY_B] - and NF-κ",0,1
"(3)H-thymidine incorporation studies in human adipose tissue explants demonstrate a novel mechanism of [ENTITY_A] activation by [ENTITY_B].activates human adipose tissue [ENTITY_B] in humans and rats, but the precise mechanism(s) by which it does so is unknown.activates adipose tissue human and rat tissue explants in parallel, and both actions are inhibited by [ENTITY_B].activates human and rat adipose tissue tissue explants in parallel, and both actions are",0,1
"HMG-CoA reductase inhibitors: impact on plasma HDL-C, apoA-I, [ENTITY_B], and phosphoenolpyruvate carboxykinase concentrations in overweight and obesity.OBJECTIVE: To examine the effects of [ENTITY_A], an oral antihyperglycemic agent, on plasma HDL-C, apo A-I, phosphoenolpyruvate carboxykinase (PEPCK) concentrations in overweight and obese women,",0,1
"HMG-CoA reductase inhibitor [ENTITY_A] attenuates high cholesterol-induced hepatic oxidative stress in rats.OBJECTIVE: To evaluate the protective effect of the [ENTITY_A] ant, [ENTITY_B], on high-cholesterol-induced hepatotoxicity in rats.DESIGN: Prospective, controlled experimental study.SETTING: Research laboratory of a tertiary hospital.SUBJECTS AND METHODS: Wistar rats were randomly divided into 4 groups: the high-cholesterol group",0,1
"Treatment with [ENTITY_A] attenuates [ENTITY_A] mediated vascular cell death and promotes survival in HepG2 liver cancer cells via ER- and PAR-dependent activation of [ENTITY_B]., a naturally occurring plant flavonoid, is known to possess a wide variety of pharmacological effects. In this study, we investigated the effect of the flavonoid quercetin on HepG2 liver cancer cells and its mechanism., a known activator of [ENTITY_A], induces cell death by activating the [ENTITY_B]",0,1
"The role of [ENTITY_A] in modulating the development of hepatotoxicity in rats., a new anti-diabetic drug, induces [ENTITY_B] expression in pancreatic beta-cells and restores beta-cell viability in diabetic rats., a new anti-diabetic drug, stimulates insulin secretion from INS-1 cells and restores beta-cell viability in streptozotocin (STZ)-induced diabetic rats., a novel drug, stimulates insulin secretion from INS-1",0,1
"(E)-selectin and vascular endothelial growth factor (VEGFR)-2 are up-regulated in [ENTITY_A] -treated squamous carcinomas.potentiates [ENTITY_B] -induced vascular permeability, as well as cell migration and proliferation in human keratinocyte HaCaT cells.also enhances [ENTITY_B] -induced [ENTITY_B] (VEGFR)-2 expression in HaCaT cells, and enhances cell migration and proliferation in human keratinocyte HaCaT cells.also",0,1
"Proteomic analysis of [ENTITY_A] -treated hepatocytes reveals up-regulated [ENTITY_B] gene encoding [ENTITY_A] for improved ethanol tolerance.BACKGROUND: Hepatotoxicity caused by ethanol is mainly due to the accumulation of reactive oxygen species (ROS). Here, we investigated the molecular mechanism of ROS accumulation in HepG2 hepatocytes induced by [ENTITY_B], a specific ethanol metabolite.RESULTS: Hepatotoxicity induced by ethanol in HepG2 cells was associated with an increase in mitochondrial superoxide dismut",0,1
"TGF-beta1 and [ENTITY_A] increased [ENTITY_B] mRNA in human osteoblastic MG-63 cells., a potent inhibitor of osteoclast formation, induces osteoblastic differentiation of MG-63 cells via the activation of [ENTITY_B]., a selective inhibitor of osteoclast formation, induces osteoblastic differentiation of MG-63 cells via the activation of the p42/44(mapk) pathway., a selective inhibitor of osteoclast formation, induces",0,1
"Treatment of human adipose tissue explants with [ENTITY_A] caused an increase in mRNA encoding peroxisome proliferator-activated receptor gamma (PPARgamma) and adiponectin that correlated with an increase in mRNA encoding [ENTITY_B]., a natural compound, activates the [ENTITY_B] (PPARgamma) and induces the expression of adiponectin in 3T3-L1 adipocytes., a natural compound, activates the PPARgamma and",0,1
"The effect of [ENTITY_A] on the pharmacokinetics and pharmacodynamics of metformin in healthy subjects., a glucagon-like-peptide-1 agonist, stimulates the release of metformin from human pancreatic beta-cells in a paricalcitol-independent manner, and it acts via [ENTITY_B] activating [ENTITY_B] -sensitive elements in the beta-cell receptor., a glucagon-like peptide-1 (GLP-1) agonist",0,1
Hepatocyte nuclear factor 4alpha (HNF4α) is a master regulator of hepatocellular lipid homeostasis and plays an important role in the [ENTITY_B] -induced expression of [ENTITY_B] -responsive genes.(HNF4α) plays an important role in the regulation of lipid metabolism by binding directly to and activating the [ENTITY_A] /SREBP-1c target genes.(HNF4α) plays an important role in the regulation of lipid metabolism by,0,1
Hepatocyte nuclear factor 4E binding protein-3 (HNF4EBP-3) is an important hepatocyte nuclear factor that regulates [ENTITY_A] responses to [ENTITY_B] activation.activates [ENTITY_B] -regulated genes by interacting with and activating [ENTITY_B] (HNF4EBP-3).activates the human HNF4EBP-3 promoter via an enhancer-binding site and a glucocorticoid response element(s) and recruits [ENTITY_B] -regulated,0,1
"The effects of [ENTITY_A] on hypothalamic GnRH mRNA expression and GnRH pulsatility in the female rat: an exploratory behavioral pharmacology study.induction in the hypothalamus of rats increases sexual motivation, activates [ENTITY_B] (ERalpha) in the hypothalamus, and increases the frequency and magnitude of [ENTITY_B] -induced [ENTITY_B] -like contractions in the uterine lumen.induction in the hypothalamus of rats increases sexual motivation, activates ERalpha in the hypothalamus,",0,1
"The association of [ENTITY_A] and MAp43 with the nuclear translocation of β-catenin during human oocyte maturation., an activator of [ENTITY_B] and [ENTITY_B], is thought to induce human androgen differentiation by binding to and activating the nuclear receptor transcription factors β-catenin and β-catenin-2.activates p53- and p16-regulated genes by binding to the nuclear receptors β-catenin and β-catenin",0,1
"Phenolic compounds in a traditional Chinese medicine, [ENTITY_A], improve diabetic nephropathy through down-regulation of [ENTITY_B] -regulated genes in renal cells., a Chinese herbal medicine with potent anti-diabetic properties, contains several phenolic acids, including [ENTITY_A], catechin, epicatechin, and the flavonoid epigallocatechin., a prototypical [ENTITY_B] derivative, is also shown to decrease serum albumin level and to up-regulate",0,1
"Protein kinase D2 (Akt) inhibition with resveratrol attenuates [ENTITY_A] -stimulated [ENTITY_B] secretion from human prostate cancer cells., a phytoalexin found in grapes and other foods, has recently been shown to stimulate the proliferation of prostate cancer cells in vitro.activates Akt in cancer cells and promotes cell proliferation in different cell systems.activates Akt in cancer cells and promotes cell proliferation in different cell systems.",0,1
"Proteome analysis reveals that the anti-diabetic agent pioglitazone regulates [ENTITY_A] -dependent glucose uptake in 3T3L1 adipocytes.Obesity is a complex metabolic disorder with an increasing number of obesity-related diseases, including Type 2 diabetes. In humans, obesity is associated with increased expression of [ENTITY_B] that are induced by various diet-derived factors, including the hormone leptin. In the current study, we demonstrate that leptin induces phosphorylation of the [ENTITY_B] (sst",0,1
"(1-aminoadamantane, an N-methyl-D-aspartate (NMDA) receptor agonist) increased the frequency of [ENTITY_B] - and/or [ENTITY_A] -producing transgenic mice.induction in mouse brain by [ENTITY_B].induction in mouse brain by [ENTITY_B].induction in mouse brain by [ENTITY_B].induces neuronal differentiation in 3T3 cells by activating [ENTITY_B] /ERK signaling pathway in vitro.",0,1
"The use of [ENTITY_A] as an antipsychotic drug has recently been criticized due to the increasing evidence that the drug acts on dopamine neurons outside of the dopamine transporter (DAT) in animal and cell systems. In this study, we investigated the effect of the selective dopamine D1 receptor antagonist, SCH23390, on the antiparkinsonian action of the dopamine D1 agonist, [ENTITY_B], and the D2 agonist, quinpirole., a D2 agon",0,1
"(1)H-NMR and (15)N-NMR studies of the effects of [ENTITY_A] on the activity of the enzyme adenylate cyclase in the liver of rats., a dietary component of green tea, has been reported to increase [ENTITY_B] activity in humans. In this study, we investigated the effects of a green-tea extract on adenylate cyclase activity and the corresponding molecular species in liver tissue from rats orally exposed to 0.5 and",0,1
"The effect of chronic [ENTITY_A] on the expression of [ENTITY_B] and Nrf2 in the rat primary hepatocyte cell line HepG2 is mediated by [ENTITY_B] activation.activates [ENTITY_B] (SOD) by binding to the regulatory regions located in the promoter region of the gene, and it has been reported that chronic treatment with [ENTITY_B] induces the expression of antioxidant enzymes such as SOD in the liver.can be activated by reactive oxygen species (ROS) produced by the human hepatocyte",0,1
"Hematologic and biochemical studies in rats orally exposed to the herbicide [ENTITY_A].PURPOSE: To evaluate the acute toxicity of an organophosphate-containing herbicide, metolachlor, on rats and to study its effects on hematological and biochemical indices, oxidative stress markers, and [ENTITY_B] levels in blood.METHODS: The study was performed on male rats orally exposed to metolachlor for 24 hr/day for 7 successive days/week for 7 successive",0,1
(+))- and(-)-isomers of [ENTITY_A] enhanced [ENTITY_B] activity.(E)- and (-)-isomers of the L-type Ca(2+) channel blocker apomorphine and the N-type Ca(2+) channel blocker [ENTITY_A] increased the depolarizing afterpotential of [ENTITY_B] - or doxercalciferol-activated HEK293 cells.activates [ENTITY_B].(E)- and (-)-isomers of the L-,0,1
"Hepatitis C virus core protein and [ENTITY_A] in liver damage., the natural ligand of the nuclear receptors LXR/RXR, has been shown to induce [ENTITY_B] transcription in human hepatoma cells; however, the molecular mechanism by which heparin induces the expression of this gene remains largely unknown.activates [ENTITY_B] transcription in human hepatoma cells; however, the molecular mechanism by which heparin induces the expression of the gene remains largely unknown.",0,1
"(+))-isomers of [ENTITY_A] enhances [ENTITY_B] activity in vitro., a natural compound widely distributed in the food and pharmaceutical industries, contains several pharmacological effects, such as an anti-diabetic effect, a mild stimulation of the [ENTITY_B] activating substance, [ENTITY_B], and a mild inhibition of glucagon-like peptide-1 (GLP-1)., a natural compound widely distributed in the food and pharmaceutical industries, contains several pharmacological effects, such as an anti",0,1
"Treatment with [ENTITY_A], a selective AMPK inhibitor, significantly increased phosphorylation of [ENTITY_A] targeted genes and inhibited glycogen synthase kinase-3β in fructose-fed rats.induction in liver and intestine was accompanied by increased phosphorylation of [ENTITY_B] (AMPK) in rats.activates AMPK in hepatocytes and intestine and induces gluconeogenesis in vitro; however, its precise mechanism of action is still unknown.activates AMPK in liver",0,1
"Treatment of human keratinocyte HaCaT cells with [ENTITY_A] or BPA induced [ENTITY_B] and MMP-13 expression, promoted secretion of [ENTITY_B], and enhanced [ENTITY_B] -induced cell migration.(PBTA) is a common environmental pollutant that induces the expression of PBTA-responsive genes through a mechanism that remains poorly understood.activates [ENTITY_B] (PBTA) through a mechanism that is still poorly understood.and BPA induce cell migration in human keratinocyte",0,1
"Treatment with [ENTITY_A] attenuates the development of hepatotoxicity induced by [ENTITY_A] and 4-phenylpyridinium ion, biomarkers of hepatotoxicity, in rats.activates [ENTITY_B], a [ENTITY_B] opener, in the liver.induction in the liver.induction in the heart.induction in the intestine.induction in the brain.induction in the heart.induction in the intestine.ind",0,1
"Pretreatment with [ENTITY_A] significantly reduced the number of [ENTITY_B] -induced hepatotoxicity deaths, the levels of malondialdehyde, and the activities of [ENTITY_B] and of [ENTITY_B], whereas only pretreatment with NSC-316 significantly reduced the levels of MDA, CK and GSH., a natural compound, has been shown recently to possess an antioxidant potential and to inhibit the activity of [ENTITY_B]., a natural compound, has been shown to possess an antioxidant potential and",0,1
"(R)- and (S)-isoflavonoids inhibit the expression of [ENTITY_A] mRNA induced by [ENTITY_B]., isoflavonoid I, and daidzein are the only three plant compounds known to possess a selective estrogenic activity, and are therefore used in the treatment of several diseases, including breast cancer.induces cell proliferation in vitro by binding to the estrogen receptor (ER) and activating its downstream signaling pathway(s).activates [ENTITY_B]",0,1
"The effects of [ENTITY_A] on spatial memory consolidation, reconsolidation, and reconsolidation deficits in rats: comparison with the effects of the NMDA receptor antagonist MK-801., a non-selective NMDA receptor (NMDAR) antagonist, is known to improve learning and memory in mice. Here, we investigated the effects of the NMDAR antagonist [ENTITY_B], a selective HDAC inhibitor, on spatial memory consolidation, reconsolidation and amyloid-β (",0,1
"(1)H nuclear magnetic resonance and molecular pharmacology studies of [ENTITY_A] indicate that the mechanism underlying the antiepileptic effects of SB-277011 is via stimulation of [ENTITY_B] (ERs) through a mechanism involving ER-selectin and ER-dependent protein kinase C activation., an anti-convulsant and selective ER transporter, is activated by [ENTITY_B] (ERs).(ERs), a selective ligand for the nuclear receptors ERalpha and ER",0,1
"The use of a novel compound, JNK1/2 inhibitor, PD-98059, to treat Alzheimer's disease: pharmacological, biochemical and behavioral studies., a novel JNK1/2 inhibitor, selectively inhibited JNK1/2 and suppressed activation of [ENTITY_A] in the brain., an effective JNK1/2 inhibitor, selectively inhibited JNK1/2 and suppressed activation of [ENTITY_B] in the brain. selectively inhibited JNK1/2 and",0,1
"The role of [ENTITY_A] and NR2B in [ENTITY_B] -induced apoptosis of breast cancer cells: a comparison with ERK inhibitor and AMPK activator., a new member of the flavonoid family, is known to possess antiproliferative properties and to induce apoptosis in different cancer cells.activates [ENTITY_B] in breast cancer cells, whereas ERK inhibitor and [ENTITY_B] (AMPK) activator have no effect., an ERK inhibitor, and AM",0,1
"Treatment with [ENTITY_A] attenuates [ENTITY_B] mediated hepatotoxicity, as well as oxidative stress in HepG2 hepatoma cells., a new anti-tumor agent, selectively induces apoptosis of cancer cells via the up-regulation of [ENTITY_B] and [ENTITY_B]., a new anti-tumor agent, selectively induces apoptosis of cancer cells via the up-regulation of [ENTITY_B] and COX-2.activates [ENTITY_B].activates COX-2",0,1
"Treatment with [ENTITY_A] enhances phosphorylation of [ENTITY_B] in the striatum and prefrontal cortex, but not hippocampus., a [ENTITY_B] opener, increases phosphorylation of [ENTITY_B] in the striatum and prefrontal cortex, but not in the hippocampus., a D2 dopamine receptor agonist, increases phosphorylation of striatal dopamine D2 receptors in rats and in vitro., an HD1 dopamine receptor agonist, increases phosphorylation of prefrontal cortex dopamine D",0,1
"(E)-3,4-diamino-6-piperidinopyrimidine-7-carboxamide ( [ENTITY_A] ) induces [ENTITY_B] and inhibits proliferation in human osteoblast cell lines: an in vitro and in vivo study., a novel anti-diabetic drug, is currently under evaluation for the treatment of type 2 diabetes., a novel anti-diabetic drug, is currently under evaluation for the treatment of type 2 diabetes.induction",0,1
"The effects of [ENTITY_A], a selective [ENTITY_B] receptor agonist, on the consolidation and reconsolidation of ethanol-induced ethanol consumption in rats.This study assessed the effects of the selective 5-HT1 agonist, DOI, and the nonselective 5-HT1 antagonist, AMPH, on the consolidation and reconsolidation of ethanol-induced alcohol consumption in rats. Alcohol (1.0-1.5 g/kg, iv) was administered iv and rats were perfused",0,1
"(1,2-bis(2-aminophenoxy)ethane-N, N,N',N'-tetra acetic acid tetrakis (BAPTA), an activator of [ENTITY_B], induces apoptosis of podocytes and inhibits collagen content in rabbit calvarium.PURPOSE: To compare the efficacy of [ENTITY_A], an activator of the [ENTITY_B] (PA), with that of the selective COX-2 inhibitor [ENTITY_B], to treat an experimental autoimmune uve",0,1
"The role of [ENTITY_A] in the modulation of [ENTITY_A] activity by [ENTITY_B] in cultured human keratinocytes.activates by binding to [ENTITY_B], inducing [ENTITY_B] activity, and inhibiting cell proliferation.activates by binding to the natural ligand, alpha-tocopherol, inducing the [ENTITY_B] active form.activates by binding to [ENTITY_B], inducing the beta-catenin inactive form.activates by binding to beta-catenin, inducing the alpha-caten",0,1
"Proteomic analysis of pancreatic islets isolated from streptozotocin (STZ) diabetic rats reveals [ENTITY_A] induction by [ENTITY_B]., an activator of [ENTITY_B], induces insulin secretion from pancreatic islets., an insulin secretagogue, stimulates insulin secretion from pancreatic islets in streptozotocin (STZ)-diabetic rats., an insulin secretagogue, stimulates insulin secretion from pancreatic islets in streptoz",0,1
"Proteomic analysis of the liver reveals a novel role of [ENTITY_A] for the up-regulation of [ENTITY_B] in response to [ENTITY_B] treatment.activates [ENTITY_B] transcription in hepatocytes, and its overexpression causes steatosis and steatohepatitis; these findings suggest that lithium may have a therapeutic potential for the treatment of obesity and type 2 diabetes.also activates the expression of genes involved in lipid homeostasis and glucose uptake; in particular, its overexpression causes",0,1
"The role of [ENTITY_A] in the regulation of [ENTITY_A] -mediated transcription in human embryonic kidney HEK293 cells., a new member of the phenylurea drug class, activates transcription of human embryonic kidney HEK293 cells via a [ENTITY_B] (Nrf2) mediated mechanism., a new member of the phenylurea drug class, activates transcription of human embryonic kidney HEK293 cells via a nrf2 mediated mechanism., an orally available phenylure",0,1
"Protein kinase C (PKC) inhibition reduces [ENTITY_A] -mediated activation of [ENTITY_B] in osteoblast-like cell lines.BACKGROUND: The phosphatidylinositol 3-kinase (PI3) pathway mediates activation of [ENTITY_A] in osteoblast-like cell lines. The purpose of this study was to examine the effect of the selective inhibitor of the human PKC (PKC)α-subunit, [ENTITY_B], on osteoblast proliferation and differentiation in response",0,1
"Protein kinase D2 (PKCDA2) regulates [ENTITY_A] -induced [ENTITY_B] secretion from pancreatic beta cells.BACKGROUND: β-cell proliferation is essential for the secretion of β-cell products from endocrine cells, such as pituitary and ovarian. β-Cell proliferation is regulated by the activation of [ENTITY_B], a heterodimerisation partner of the nuclear receptor retinoic acid (RA). Here, the authors examine the role of protein kinase D2 (P",0,1
"Hepatocytes isolated from neonatal rats and incubated with [ENTITY_A] produces [ENTITY_B], a [ENTITY_B] opener, in the livers of rats., a new anti-diabetic drug, inhibits the maturational increase of [ENTITY_B] in pancreata from normal rat pups and in diabetic rats., a new anti-diabetic drug, inhibits the maturational increase of blood glucose in streptozotocin (STZ)-induced diabetic rats.",0,1
"Proteasomal inhibitors, [ENTITY_A] and resiquimod target [ENTITY_A] and RORalpha receptors in prostate cancer cells.Prostate cancer (PCa) is the second leading cause of cancer-related deaths. In the present study, we investigated the role of the RORalpha and RORbeta receptors in PCa cell proliferation and the potential mechanism of cell cycle arrest at G2/M with the use of proteasomal inhibitors [ENTITY_B] (SQ-901417), piperony",0,1
"Treatment with [ENTITY_A] enhances expression of [ENTITY_B] in pancreatic islets derived from human embryonic kidney cells., a novel anti-diabetic drug, induces insulin secretion in 3T3-F442 cells., a novel anti-diabetic agent, induces insulin secretion in 3T3-F442 cells., a drug approved for the treatment of type 2 diabetes, stimulates the [ENTITY_B] expression in 3T3-F442 cells, and the effect is time",0,1
(1)H-MRF studies of the binding of [ENTITY_A] to [ENTITY_A] in aqueous medium.activation potentiates the antiepileptic effect of valproic acid.(1)H-MRF studies of the binding of R(-)-valproic acid to the rat D(1) dopamine receptor.activation potentiates the efficacy of [ENTITY_B] in reducing seizures in rats.pharmacological profile of the antiepileptic effect,0,1
"The effect of [ENTITY_A] on the expression of [ENTITY_B] and TRPA1 in cultured dorsal root ganglion neurons from rats.activates currents in dorsal root ganglion neurons from rats and induces the fast desensitization response to [ENTITY_B].potently activates currents in both cultured dorsal root ganglion neurons and in the enterochromaffin model cell line QGP-1, and has minimal effects on the responses of other cell lines to ACh.",0,1
"The effects of [ENTITY_A], a 5HT antagonist, on the induction of [ENTITY_B] in the striatum of rats.selective serotonin (5-HT) agonist, [ENTITY_A], is known to induce strong [ENTITY_B] affects many brain regions, including the striatum, and to modulate dopaminergic signaling pathways. Here, we report on the effects of a 5-HT antagonist, [ENTITY_B], on the induction of [ENTITY_B] in the striatum of rats.selective 5-",0,1
"PKCβ inhibition attenuates [ENTITY_A] -induced vascular cell proliferation in 3T3 cells., a prototypical [ENTITY_B] inducer, activates the [ENTITY_B] (ERK).and ERK inhibitors (PD98059 and PD98059 × capsazepine, respectively) are known to induce apoptosis selectively in tumor cells., which activates ERK but not ERK × JNK, has been shown to inhibit breast and pancreatic cancer cell growth in vivo.",0,1
Pretreatment with [ENTITY_A] enhances the efficacy of gliclazide on improving glycaemic control in diabetic rats.activates [ENTITY_B] (PPARα) in pancreatic beta-cells and promotes glucose uptake into 3T3-F444 cells.activates [ENTITY_B] (PPARα) in adipocytes and promotes glucose uptake into 3T3-F444 cells.activates PPARγ in adipocytes and promotes glucose uptake into 3T3-,0,1
"Hepatocyte nuclear factor 4α (HNF4α) regulates [ENTITY_A] -induced [ENTITY_B] mRNA transcription in human hepatoma cell lines., a [ENTITY_B] opener, stimulates the transcription of target genes involved in energy homeostasis and metabolism through activation of nuclear receptors, such as the [ENTITY_B].enhances the expression of several important liver homeostatic genes through the activation of nuclear receptors, such as the thyroid hormone receptors (TRs)., a [ENTITY_B] opener",0,1
"Treatment of [ENTITY_A] -induced hepatotoxicity with [ENTITY_B] enhances [ENTITY_A] sensitivity., a novel anti-diabetic drug, induces [ENTITY_B] secretion from hepatocytes in rats., a drug currently under development for the treatment of type 2 diabetes, inhibits glyceroneogenesis in 3T3-F442A adipose tissue-derived cells and stimulates adipogenesis in 3T3-F442A cells in vitro, raising a possibility that it acts on adipose tissue",0,1
"(1)H-MRF and (13)C-MRS2179 are selective beta2AR agonists with minimal effects on the heart rate.induction in bovine aortic endothelial cells: comparison with [ENTITY_A] or clenbuterol., a novel anti-diabetic agent, is active on beta2AR-mediated [ENTITY_B] -mediated [ENTITY_B] signalling in bovine aortic endothelial cells., a new anti",0,1
"Treatment of [ENTITY_A] in rats with [ENTITY_A] enhances [ENTITY_B] phosphorylation and protects neurons from apoptosis induced by glutamate., a novel drug approved for the treatment of Alzheimer's disease, activates the [ENTITY_B] protein kinase D (PKD) and induces apoptosis of neurons via activation of caspase-3., a novel drug approved for the treatment of Alzheimer's disease, activates the PKD and induces apoptosis of neurons via activation of [ENTITY_B].activ",0,1
"Proteomic analyses of the plasma membrane fraction of [ENTITY_A] -stimulated primary human hepatocytes identify [ENTITY_A] (PPRE) as a new plasma membrane marker for HepG2., a new member of the PPRE gene family, was cloned from human hepatocytes and overexpressed in E. coli and purified to homogeneity as a fluorescent protein.(PPRE) is a new member of the PPRE gene family, and its expression is induced by [ENTITY_B] in cultured human",0,1
"(3S,7S)-2-(piperidin-2-ylethyl)-1-methylpyridin-2-ium chloride (PPYP) is a selective inhibitor of [ENTITY_A] that selectively targets [ENTITY_A] and not phenformin, glipizide, or metformin.selectively targets the [ENTITY_B] receptor, the first line of defense against glucose deprivation.potently activates [ENTITY_B] and PPYP selectively in cell lines expressing either the human or",0,1
(1)H-MRS and [(14)C]aspartate uptake in the striatum are increased by [ENTITY_B] enhanced [ENTITY_A] environment.enhances [ENTITY_B] environment in rats.environment has been shown to enhance [ENTITY_B] level in the striatum in rats.environment is associated with increases in phosphorylation of [ENTITY_B] (MAPK) kinase 3/6 (MKK3/6)-p38 and Akt phosphorylation in rats.environment enhances,0,1
"(3)H-thymidine incorporation and [ENTITY_A] activation precede the onset of [ENTITY_B] synthesis in the human androgen receptor in human androgen receptor-expressing HEK cells.activates the androgen receptor (hAR).activates the hAR.(SAR) catalyzes the final step of the biosynthesis of dioxin-like compounds.activates hAR in vitro and in vivo, but its precise mechanism of action",0,1
"Treatment of human osteoblastic cell line MG-63 with [ENTITY_A] inducers induced [ENTITY_B] expression in vitro and in vivo.(DMEM), DMEM-1, or a mixture of DMEM and [ENTITY_B] enhances the formation of mineralized nodules in immunodeficient mice., DMEM, or a mixture of DMEM and quercetin stimulate the proliferation of MG-63 cells in vitro and in vivo., DMEM,",0,1
"Treatment with [ENTITY_A] enhances [ENTITY_B] gene expression in liver tissue of rats., a novel anti-diabetic drug with insulin-sensitizing properties, induces [ENTITY_B] transcription in mouse adipose tissue by activating [ENTITY_B]., a new anti-diabetic drug with insulin-sensitizing properties, induces adipose tissue expression of the adipocyte-specific transcription factor [ENTITY_B] in mice;activates adipose tissue transcriptional activity in vivo.,",0,1
"The role of [ENTITY_A] activator [ENTITY_B] in modulating the transcriptional activity of [ENTITY_B]., a [ENTITY_B] opener, activates the [ENTITY_B] family of [ENTITY_B] (PPARalpha, beta, gamma, and γ).activates [ENTITY_B] and obidoxime in vitro.activates PPARalpha, PPARbeta, PPARgamma, and PPARgamma in vivo.activates the PPARfamily in vivo.activates PPARalpha in vitro,",0,1
"Proteomic analysis of the liver reveals a novel anti-apoptotic role for [ENTITY_A] in the steatotic state., a new anti-apoptotic agent, enhances [ENTITY_B] protection in bile duct cancer cells., a new anti-apoptotic agent, enhances bile production in bile duct cancer cells., a novel anti-apoptotic agent, suppresses the growth of bile duct cancer cells in vitro and in mice.,",0,1
"Pretreatment with [ENTITY_A] attenuates [ENTITY_A] -induced seizures and augments [ENTITY_B] phosphorylation in rat hippocampus., an antiepileptic drug that activates [ENTITY_B], is known to cause seizures via activation of the [ENTITY_B] /N-methyl-d-aspartate (NMDA) receptor system., an antiepileptic drug that activates AMPA receptors, is known to cause seizures via activation of the NMDA receptor system.-induced seizures",0,1
"(1-aminoadamantane) down-regulates the expression of [ENTITY_A] in mouse aortic endothelial cells: a cautionary tale of oxysterols.AIMS: Our previous studies in human aortic endothelial cells (HAEC) showed that oxysterols induce the [ENTITY_B] expression, which correlates with vascular permeability and a poor prognosis in patients with advanced atherosclerotic diseases. However, it is not clear whether oxysterols also affect the expression",0,1
"(1)H and (15)N resonances of the human [ENTITY_A] selective serotonin receptor agonist [ENTITY_A].selective serotonin receptor agonist, H-pilocarpine, induces a selective serotonin reuptake transporter (SERT) expression in human embryonic kidney HEK293 cells;selective serotonin receptor antagonist, [ENTITY_B] (10(-6) M) inhibits the induction of SERT by H-pilocarpine.selective serotonin receptor agon",0,1
"The effect of [ENTITY_A] on the expression of the pro-apoptotic gene [ENTITY_A] mRNA in breast cancer cells: a cautionary tale about the use of this chemotherapeutic drug.(PB), an anti-diabetic drug, induces apoptosis in breast cancer cells through the up-regulation of [ENTITY_A].(PB), an anti-diabetic drug, induces apoptosis in breast cancer cells through the up-regulation of [ENTITY_B].(BN),",0,1
"Tobramycin inhibits the proliferation of human breast cancer cell by down-regulating [ENTITY_A] gene expression via ER-dependent and ER-independent pathways.The present study investigated the molecular mechanisms by which tobitministrate [ENTITY_B], a widely-used anti-tumor agent, and the role of the human gamma-secretase (HGSE) in its mechanism of action.-induced HSP70 expression was accompanied by an increased expression of [ENTITY_B] and HSP27",0,1
"The use of aldosterone antagonists in the treatment of hyponatremia: a meta-analysis.BACKGROUND: Several studies have shown that treatment with an aldosterone ( [ENTITY_A] ) antagonist improves the clinical symptoms of hyponatremia and that this effect is independent of the effect of [ENTITY_B] on serum sodium concentration.METHODS: We performed a comprehensive meta-analysis to compare the effects of an aldosterone antagonist with those of a placebo on serum potassium concentration, and on post",0,1
"Proteomic analysis of the liver of rats orally exposed to [ENTITY_A] or ethanol reveals down-regulated proteins involved in cholesterol homeostasis and up-regulated proteins involved in the synthesis of [ENTITY_B]., a common environmental contaminant, induces lipid accumulation in the liver, mainly due to the ethanol-mediated accumulation of cholesterol., a common environmental contaminant, induces lipid accumulation in the liver, mainly due to the ethanol-mediated accumulation of cholesterol.(TEMPO), a",0,1
"Pretreatment with the NMDA receptor antagonist [ENTITY_A] attenuated the inhibitory effect of the GABA(B) agonist [ENTITY_A] on [ENTITY_B] - and muscarinic receptor-mediated currents in cultured hippocampal neurons.potently activates [ENTITY_B], a G protein-coupled receptor agonist for the [ENTITY_B] protein-gated receptor 1 (GPCR1), enhancing hippocampal neuroprotection against excitotoxicity.preferentially activates G protein-coupled",0,1
"PKC-dependent signaling in [ENTITY_A] -stimulated [ENTITY_B] -positive splenocytes: a critical role in the activation of [ENTITY_B].(PPRE)-induced splenocyte proliferation is mediated by the activation of the [ENTITY_B] (PPRE) and the downstream signaling pathway of [ENTITY_B] (PPRE-dependent), but the precise mechanism of how the activation of PPRE by [ENTITY_B] (PPRE-independent) is achieved remains to be clarified.(PPRE)-induced expression of [ENTITY_B]",0,1
"HMG-CoA reductase inhibitors ( [ENTITY_A] ) and [ENTITY_A] enhance [ENTITY_B] -mediated [ENTITY_B] activation in HepG2 liver cells., a substrate of HepG2 liver cell cholesterol-dependent cholesterol esterification, plays an important role in cholesterol homeostasis through its ability to reduce plasma high-density lipoprotein (HDL) levels., a substrate of human androgen receptor (hAR), is a potent androgen receptor (hAR) agon",0,1
Hepatocyte nuclear factor 4E binding protein-3 (HN4E-3) mediates [ENTITY_A] -induced [ENTITY_B] secretion.activates [ENTITY_B] (PPRE)-dependent luciferase activity and up-regulates the expression of green fluorescent protein in human embryonic kidney HEK293 cells.activates transcription of target genes via PPRE-dependent transcription elongation.(PPRE)-dependent luciferase activity and the expression of green fluorescent protein (G,0,1
"Treatment of human endometrial cancer cell by [ENTITY_A] causes cell cycle arrest in G2/M phase, activates p21(CIP1), induces [ENTITY_B] expression and confers chemosensitivity.activates [ENTITY_B] expression, induces cell cycle arrest in G2/M phase, activates p21(CIP1) expression and confers chemosensitivity in endometrial cancer cells.causes cell cycle arrest in G2/M phase, stimulates cell cycle-",0,1
Protein kinase D2 (PKCD2) is a novel nuclear receptor for [ENTITY_A] activating genes involved in human cardiovascular diseases.activates [ENTITY_B] through the activation of the [ENTITY_B] (ERK) pathway in vascular smooth muscle cells and in adipocytes.activates the transcription of [ENTITY_B] in human adipose tissue explants and restores leptin-responsive genes in 3T3L1 adipocytes.activates the transcription of PPAR-γ in 3T3L,0,1
"The effect of [ENTITY_A] on phosphorylation of [ENTITY_A] on [ENTITY_B] -stimulated [ENTITY_B] phosphorylation: comparative analysis on rat and human skeletal muscle., a novel AMPK activator, induces phosphorylation of [ENTITY_B] (AMPK) on Thr172 and activates the [ENTITY_B] phosphorylation cascade, leading to its de- and activation by [ENTITY_B]., a novel AMPK activator, induces phosphorylation of AMPK on Thr172 in skeletal myofib",0,1
"PKC-mediated activation of [ENTITY_A] in pancreatic islets: involvement of the [ENTITY_A] /ERK pathway., a new member of the [ENTITY_A] family, has recently been shown to stimulate [ENTITY_B] secretion from pancreatic islets in vivo, suggesting that it may have an effect on glucose homeostasis.(PKC) activation was investigated in islets obtained from diabetic rats and from islets from leptin-deficient mice.(PKC) activation was investigated in",0,1
"Hepatocyte nuclear factor 4 alpha (HNF4α) mediates [ENTITY_A] -mediated activation of [ENTITY_B]., a [ENTITY_B] opener, induces [ENTITY_B] transcriptional activity by binding to the [ENTITY_B] responsive element within its 5'-flanking region.activates the transcription of a small number of target genes via the binding of [ENTITY_B] to a specific regulatory element within its 5'-flanking region in the absence of other transcription factors.(Nrf2) binds to the",0,1
Phenotypic and molecular characterization of a novel missense mutation in the ABCG5 gene encoding [ENTITY_A] selectively activating [ENTITY_B] -mediated [ENTITY_B] selectivity.(LiCl) induces apoptosis in colorectal cancer cells via down-regulation of ABCG5 and up-regulation of p21( WAF1/CIP1 ) expression.activation in colorectal cancer cells is selectively mediated by p21(WAF1/CIP1) expression,0,1
"Protein kinase D2/C1Q is involved in [ENTITY_A] -induced activation of [ENTITY_B] (ERK1/2)., a natural plant compound that regulates growth, development and differentiation of plant organs, is currently under consideration for the treatment of human cancers.induces the expression of [ENTITY_B] in transformed cells and promotes their growth in vitro.activates ERK1/2 in transformed cells.activates a signalling pathway leading to phosphorylation of [ENTITY_B],",0,1
"(3)H-thymidine incorporation studies in rats using [ENTITY_A] activator [ENTITY_B].3.are activated by [ENTITY_B] and other members of the serotonin family., a new anti-convulsant, is currently under clinical evaluation., a new anti-convulsant, is under clinical evaluation. (S)-2,3-diamino-6-piperidinopyrimidine-2-oxyde (DAP) is",0,1
Treatment of [ENTITY_A] -induced hepatotoxicity with [ENTITY_A] enhances [ENTITY_B] activity in hepatocytes.activates [ENTITY_B] in hepatocytes.activates [ENTITY_B] in liver cells.activates hepatocytes in vitro and in vivo.activates hepatocytes in vivo.activates hepatocytes in vitro and in vivo.activates liver cells in vivo.activates liver cells in vitro and in vivo.activates liver cells in liver cells.,0,1
(R)- and (S)-isomerized [ENTITY_A] were found to be more potent inducers of [ENTITY_B] (E(2)) than their R- and S-concentrations.induction in human keratinocytes is mediated by [ENTITY_B] (ERK) activation and p38 MAPK activation.activation in human keratinocytes is mediated by ERK and p38 MAPK activation.induction in human primary keratinocytes is mediated by ERK activation,0,1
"Proteolytic activation of [ENTITY_A] by human androgen receptor is mediated by the phosphorylation of the [ENTITY_A] (ER)-alpha subunit., the human equivalent of the rodent androgen receptor (hAR), has recently been reported to possess a proteolytic cleavable site for [ENTITY_B] binding, and to have higher catalytic activity than hAR., the human equivalent of the rodent androgen receptor (hAR), has recently been reported to possess a proteoly",0,1
Protein kinase C (PKC) inhibition and [ENTITY_A] treatment prevented the potentiation caused by [ENTITY_B] in PC12 cells.potently activates the [ENTITY_B] (PPAR)-responsive element located within the PPARγ gene.enhances [ENTITY_B] -stimulated [ENTITY_B] secretion from mouse adipose tissue-like cell lines.also increases leptin-stimulated PPAR-γ expression in 3T3L1 cells.also enhances leptin-stimulated PPAR-γ expression,0,1
"The effect of the [ENTITY_A] treatment of rats on lipid profile, liver enzymes, bile acid concentrations, and bile flow in vivo.is a natural herb with a potent anti-diabetic and lipid-lowering effect, which has recently been reported to increase circulating [ENTITY_A] levels in humans.activates [ENTITY_B] and induces the expression of several target genes involved in metabolism, including cholesterol and phospholipids metabolism.activates the transcription of genes involved in liver lipid metabolism,",0,1
"Proteomic analysis of the [ENTITY_A] -induced liver damage in rats.2. Hepatotoxicity is one of the most common toxic effects of arsenic, a known hepatotoxicant, and it is induced mainly by reactive oxygen species (ROS)-mediated oxidative damage. 3. Hepatocyte apoptosis was induced by exposure to arsenite (As(III)) in the presence of [ENTITY_B], a known hepatotoxicant, and was followed up with an increase of [ENTITY_B] (Nrf",0,1
"PKCβ-mediated signaling regulates [ENTITY_A] -induced cyclinD1 expression.activates [ENTITY_B], inducing D1 binding and phosphorylation, and activating the cyclin-dependent kinase inhibitor p27(kip1).activates cyclinD1 expression by activating a phosphorylation-dependent mechanism.activates cyclinD1 expression by inducing p27(kip1) phosphorylation, and by activating a heterodimerization event involving",0,1
"Phenotype of [ENTITY_A] -induced right ventricular hypertrophy (RVH): comparison with that of women with polycystic ovary syndrome (PCOS).BACKGROUND: Although women with polycystic ovary syndrome (PCOS) have been reported to have a higher frequency of right ventricular hypertrophy (RVH), it remains unknown whether this is due to a general increase in circulating [ENTITY_B] levels and whether the increased right atrial dimensions are also associated with higher circulating",0,1
"(+) and (-) forms of [ENTITY_A] enhance resistance to cisplatin, but decrease the efficacy of doxorubicin.induction of [ENTITY_B] expression correlates with resistance to cisplatin in colorectal cancer cells.induction of p21 and p53 correlates with cisplatin resistance in colorectal cancer cells.induction of p21 and p53 correlates with resistance to doxorubicin in colorect",0,1
"The role of [ENTITY_A] in modulating the immunomodulatory activity of [ENTITY_B] : an in vitro study.We investigated the immunomodulatory effect of a new antimuscarinic agent, N-(1-benzyl-piperidin-4-yl)-5-(4-fluoro-phenyl)-1-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide",0,1
"(E)- and (Z)-isomers of [ENTITY_A] enhance [ENTITY_B] activity by activating [ENTITY_B] (PPRE) in human peripheral blood lymphocytes., a new anti-convulsant, is thought to be activated via the receptor for advanced glycation end products (RAGE)., a new anti-convulsant, is thought to be activated via the receptor for advanced glycation end products (RAGE).activates the [ENTITY_B] (PPRE) in human",0,1
"The effect of [ENTITY_A], a [ENTITY_B] opener, on right ventricular filling pressures in the rat right ventricular free wall.AIMS: We investigated the effect of [ENTITY_B], a dipeptidyl peptidase-4 (DPP-4) inhibitor, on right ventricular (RV) filling pressures (RVFPs) and its mechanism in the rat right ventricular (RV) free wall.METHODS: Eighteen rats were randomly divided into 4 groups",0,1
"(1→4)-oxidation of [ENTITY_A] in rat striatum: comparison between 6- and 12-week exposure.(N-(6-chloro-1-piperidin-4-yl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide) has been recently shown to increase [ENTITY_B] activity in rats.(N-(6-chloro-1-piperidin-4",0,1
The role of [ENTITY_A] in modulating [ENTITY_A] -mediated induction of [ENTITY_B] in mouse C2C12 skeletal myoblasts.activates the [ENTITY_B] (PPAR-alpha) signaling pathway in skeletal muscle cells by binding to and activating [ENTITY_B].activates the [ENTITY_B] (PPAR-alpha) signaling pathway in adipose tissue cells by binding to and activating PPAR-alpha.activates the PPAR-beta signaling pathway in liver cells by binding to and activating PPAR-,0,1
(E)methylation of [ENTITY_A] activates [ENTITY_B] in breast cancer cell lines.activates in breast cancer cells the [ENTITY_B] (E)methylation pathway.activates in breast cancer cells the p53-mediated pathway that de-sensitizes cells to chemotherapy.activates in breast cancer cells the p53-mediated pathway that de-sensitizes cells to chemotherapy.activates in breast cancer cells the p21-dependent pathway that de-,0,1
"(R)- and (S)-isoflavonoids modulate the density and viability of cardiomyocytes via [ENTITY_B] activation: comparison with [ENTITY_A] and phorbol 12-myristate 13-acetate.activates [ENTITY_B] -dependent expression of [ENTITY_B] in cultured cardiomyocytes; however, the molecular mechanism responsible for this is still unknown.activates in cardiomyocytes the density and viability of cardiomyocytes via activation of [ENTITY_B].and",0,1
"Treatment of human endometrial cancer cells with [ENTITY_A] enhances [ENTITY_A] activation and promotes cell proliferation., an activator of the [ENTITY_B] (PPARalpha), regulates cell proliferation, differentiation and apoptosis in various cells., an activator of the PPARalpha, regulates cell proliferation, differentiation and apoptosis in various cells.activates [ENTITY_B] (PPARalpha) in human endometrial cancer cells (ICR-10 and H1299).enh",0,1
"Treatment of rat hepatocytes with [ENTITY_A] enhances [ENTITY_B] phosphorylation and confers protection from cisplatin-induced hepatotoxicity.induction is induced by reactive oxygen species (ROS) in the cytosol and results in the accumulation of intracellular reactive oxygen species (ROS).activates [ENTITY_B] (ERK), induces [ENTITY_B] phosphorylation in the cytosol of cells and confers protection from cisplatin-induced hepatotoxicity",0,1
"The effects of [ENTITY_A], a selective [ENTITY_B] phosphorylation-inducing agent, on right and left ventricular filling pressures and left ventricular hypertrophy in a canine model of chronic subnormal pulmonary artery pressure.can induce [ENTITY_B] phosphorylation in the pulmonary artery, which in turn increases pulmonary artery filling pressure (PABP)., a drug widely used in the treatment of pulmonary artery hypertension, increases pulmonary artery pressure in a dose-dependent fashion in a canine",0,1
"(E)- and (Z)-isomers of [ENTITY_A] enhanced phosphorylation of [ENTITY_B] (ERK), ERK1/2 and p38 kinases, as well as [ENTITY_B] -dependent luciferase activity in MCF-7 breast cancer cells.activates a signal transduction pathway leading to the activation of [ENTITY_B], which is critical for breast cancer cell growth in vitro and in vivo.activates a signal transduction pathway leading to the activation of ERK1",0,1
"Hepatoprotective effect of [ENTITY_A] via inhibition of [ENTITY_B] -induced [ENTITY_B] degradation in HepG2 hepatoma cells.is a new member of the phenylalanine synthetase (PAS) family, which is involved in a variety of metabolic functions in humans., a new anti-cancer drug, has been recently reported to inhibit tumor angiogenesis in xenograft tumors. in this report, we investigated the effect of the novel anti-cancer",0,1
"Protein kinase D1 (PKCd) plays an important role in [ENTITY_A] -induced [ENTITY_B] secretion., a new anti-asthma drug, activates protein kinase D1 (PKD1).activates [ENTITY_B] (PKD1).activates the pro-apoptotic protein, Bim, in vascular smooth muscle cells (VSMCs).activates the anti-apoptotic protein, Bcl-2, in vascular",0,1
The effect of [ENTITY_A] on [ENTITY_B] -stimulated [ENTITY_B] secretion from human airway epithelial cells: implications for the use of the human airway epithelial cell line A549 in pharmacology studies.can stimulate the secretory response of human bronchial epithelial cells to [ENTITY_B].can stimulate the secretion of a specific glycerol from human airway epithelial cells.stimulates the secretion of a specific glycerol from human bronchial epithelial cells,0,1
"Phenylalanine- and valine-supplemented [ENTITY_A] increased phosphoenolpyruvate carboxykinase (PCK) and [ENTITY_B] levels in liver, and decreased [ENTITY_B] levels in adipose tissue., PC3, PC4, and PC5 have been implicated in the prevention and treatment of obesity., a new anti-diabetic agent, improves insulin sensitivity by inhibiting [ENTITY_A] activity in 3T3-F442A cells",0,1
(1)H and (13)C nuclear magnetic resonance studies on the effect of [ENTITY_A] on phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activities in 3T3 cells.activates [ENTITY_B] -regulated genes involved in lipid homeostasis in 3T3 cells.activates the [ENTITY_B] -regulated genes involved in glucose uptake and metabolism in 3T3 cells.activates the phosphoenolpyruvate car,0,1
"The role of [ENTITY_A] as a regulator of [ENTITY_A] -induced COX-2 expression in keratinocytes.In the present study, we investigated the involvement of [ENTITY_B], a prototypical member of the [ENTITY_B] superfamily, in the regulation of COX-2 expression in HaCaT keratinocytes.expression was induced by [ENTITY_B], a known [ENTITY_B] (COX-1) activator, and was suppressed by the specific COX-2 inhibitor [ENTITY_B] (ABO).expression",0,1
"Proteomic analysis of [ENTITY_A] -induced hepatotoxicity reveals [ENTITY_B] activation, [ENTITY_B] degradation and up-regulation of [ENTITY_A] mRNA., an antiarrhythmic drug, induces [ENTITY_B] (H(2)S) production in hepatocytes through S-(-)-lysylhydroxylaminofluoridate (S-LY) dependent mechanism., an antiarrhythmic drug, induces H(2)S production in hepatocytes through S",0,1
"Treatment of human osteosarcoma cells with [ENTITY_A] enhances the expression of [ENTITY_B], osterix, alkaline phosphatase and osteoprotegerin as well as the mineralization rate., a member of a new class of [ENTITY_B] openeroids, stimulates osteoclast formation from precursor cells and induces the expression of osteogenic and osteolytic genes in osteoblastic cells., a member of a new class of plant natural products, has been shown",0,1
The effects of [ENTITY_A] on the expression of [ENTITY_B] and Nrf2 in lipopolysaccharide-stimulated [ENTITY_B] -stimulated Jurkat cells.The purpose of this study was to examine the effect of the antioxidant N-acetyl-cysteine (NAC) on the activation of [ENTITY_B] (SIRT) in Jurkat cells and to examine the mechanism of NAC-induced SIRT activation.activation and nuclear factor-E2-related factor 2 (Nrf2,0,1
"The effects of the combined treatment of [ENTITY_A] and valproic acid on the biochemical properties of parathyroid hormone-related protein in patients with subclinical primary hypoparathyroidism., a drug approved for the treatment of subclinical primary hypoparathyroidism (HPT), has recently been shown to increase serum parathyroid hormone (PTH) levels and decrease serum [ENTITY_B] (PTH) and parathormone (PTH) concentrations. We investigated",0,1
"Proteomic analysis of [ENTITY_A] -stimulated liver tissue reveals upregulated [ENTITY_A] levels., a novel activator of [ENTITY_B], is currently under clinical evaluation in the treatment of obesity., a new anti-obesity drug, induces the expression of [ENTITY_B] in adipose tissue, thereby improving insulin sensitivity., a novel anti-obesity drug, induces the expression of adipose tissue-specific markers in adipose tissue, leading to improved insulin sensitivity., a",0,1
"Treatment of rat striatum by [ENTITY_A] enhances [ENTITY_B] activity which is involved in the prevention and reversal of MPTP toxicity., a novel anti-convulsant and an activator of [ENTITY_B]., a new anti-convulsant compound with a unique structure, is reported to decrease the density of [ENTITY_B] phosphorylated in the hippocampus and prefrontal cortex (PFC)., a new anti-convulsant compound with a unique structure, is reported to decrease",0,1
"(R)-isomerization of [ENTITY_A] to a racemic mixture of [ENTITY_A] in micelles.(R)-isomers of quinpirole were prepared in micelles of dioctyl phthalocyanidinium iodide (DPChCIO).(R)- and homologous (S)-isomers of the antimuscarinic drug, [ENTITY_B], were prepared in micelles of DPOAc.(R)-",0,1
"(1)H and (2)H MRS studies of [ENTITY_A] activation by [ENTITY_B] in rat trigeminal nucleus caudalis., a selective serotonin (5-HT) receptor agonist, has been shown to increase the sensitivity of 5-HT neurons to stimulation with muscarinic agonists., a selective serotonin (5-HT) receptor agonist, has been shown to increase the sensitivity of 5-HT neurons to stimulation with muscarinic agonists",0,1
"(1)H,(15)N and(19)N resonance assignments for a new [ENTITY_A] (PPARα) agonist, [ENTITY_B], and [ENTITY_A] indicate new insights into their structure-activity relationships., one of the most effective ligands of the peroxisome proliferator-activated receptor (PPARα) for the control of lipid homeostasis in mammals, contains two PPARα binding site(s) ( [ENTITY_A] (PPARα) and ob",0,1
"(1-aminophenoxy)ethylene glycol (PAM) stabilizes human adipose tissue explant and restores [ENTITY_A] -mediated induction of [ENTITY_B] gene expression.stimulates the expression of a prototypical adipose tissue marker, adiponectin, in vitro and in vivo., a [ENTITY_B] opener, stimulates adipose tissue expression of the prototypical adipocyte differentiation marker, adiponectin, in vitro and restores adipocyte-derived factor (ADF",0,1
"Hepatocyte nuclear factor-4α (HNF-4α) activation induces [ENTITY_A] -mediated hepatocyte proliferation in vitro.Activation of hepatocyte nuclear factor-4 (HNF-4) by [ENTITY_B] or activator of c-Jun ( c-Jun ) is a critical event in the activation of [ENTITY_B]. In the present study, the effect of HNF-4α on hepatocyte proliferation was investigated using HepG2 hepatocytes, a human hepatocyte cell line,",0,1
"Proteomic analysis of the liver of rats orally exposed to [ENTITY_A], a [ENTITY_B] opener, showed a down-regulation of [ENTITY_B] and up-regulation of peroxisome proliferator-activated receptor-γ (PPAR-γ)., a widely used drug in the treatment of type 2 diabetes, has recently been shown to stimulate [ENTITY_B] secretion from pancreatic islets in rats.stimulates [ENTITY_B] secretion from pancreatic islets in rats.activates PP",0,1
"Treatment with [ENTITY_A] enhances the efficacy of paclitaxel in a human osteoblastic cell line., a novel anti-tumor agent, is under clinical evaluation in patients suffering from metastatic breast cancer and in some types of solid tumors., a novel anti-tumor agent, is under clinical evaluation in patients suffering from metastatic breast cancer and in some types of solid tumors., a selective and potent inhibitor of [ENTITY_B] (PI3",0,1
"(E)-selectin is a substrate for [ENTITY_A] : a potential biomarker for cardiovascular disease.BACKGROUND: Selectins regulate vascular permeability by activating different isoforms of [ENTITY_B] that are activated by different ligands, such as platelet-derived growth factor (PDGFR)-beta, vascular endothelium growth factor (VEGFR)-alpha and platelet-derived growth factor-beta1 (PDGFR-beta1), respectively.activates the [ENTITY_B] MAPK signalling",0,1
The role of the [ENTITY_A] subunit of the NF-κB p65 nuclear translocation pathway in [ENTITY_B] -induced [ENTITY_B] -responsive genes.(R) is a nuclear receptor for vitamin A that regulates gene expression in a PPARγ-dependent manner.activates [ENTITY_B] -dependent reporter gene expression in vitro in a PPARγ-dependent manner.activates PPARγ-dependent reporter gene expression in vitro in a PPARγ-dependent manner.activ,0,1
"Hepatocyte nuclear factor-4α mediates [ENTITY_A] -induced [ENTITY_B] mRNA up-regulation in hepatocytes.Activation of nuclear factor-κB (NF-κB) in hepatocytes is critical for [ENTITY_B] -induced hepatocyte proliferation, steatosis and necrosis.activates NF-κB in hepatocytes through [ENTITY_B] activation.activates NF-κB in hepatocytes by inducing the expression of the anti-apoptotic proteins Bcl-",0,1
"Hemodialysis induces [ENTITY_B] expression in mouse aortic endothelial cell cultures and in xenograft tumors., a new member of the [ENTITY_A] superfamily, has been reported to have anti-angiogenic properties, but its precise mechanism of action is still poorly understood.activates [ENTITY_B] and induces endothelial cell proliferation in vitro., a new member of the superfamily, has been reported to have anti-angiogenic properties and to inhibit vascular",0,1
"(R)- and(S)-isomers of [ENTITY_A] increase [ENTITY_B] activity.activation by [ENTITY_B] (R)- and(S)-isomers of [ENTITY_B] resulted in the activation of the [ENTITY_B] (R)- and(S)-isomers of [ENTITY_B], respectively.activation by the R- and(S)-isomers of cinnamaldehyde resulted in the activation of the R- and(S)-isomer, respectively.activation by the R- and(S",0,1
The role of the [ENTITY_A] phosphorylation signal transduction pathway in transcription elongation by the [ENTITY_B] /ERK-dependent pathway.activation induces transcription elongation in transformed cells.activates the [ENTITY_B] /ERK-dependent pathway in transformed cells.activates the EGFR-dependent pathway in transformed cells.activates the [ENTITY_B] /ERK-dependent pathway in transformed cells.(sst2) phosphorylates EGFR at serine residues,0,1
"Protein kinase D1 regulates p27(kip1) expression via phosphorylation in human breast cancer cells., a member of the [ENTITY_A] superfamily, has recently been shown to have a role in the development and progression of several cancers. However, the precise molecular mechanism of p27(kip1) regulation by pdand1 remains poorly understood. In this report, we found that phosphorylated p27(kip1) was highly induced by [ENTITY_B],",0,1
"(+))- and (-)-desensitizing mGlu2/3 receptor agonists induce desensitization in rat Glu2+-displacement receptors and block GluK2/3-mediated desensitization of [ENTITY_B].(+) and (-)-desensitizing mGlu2/3 receptor agonists ( [ENTITY_A], AM5-3, and SB216763) are novel, potent, and selective agonists that block GluK",0,1
"Hemopexin-A, a new member of the [ENTITY_A] superfamily, induces [ENTITY_B] gene expression in human keratinocyte HaCaT cells., a member of the superfamily of retinoic acid (RA) receptors, is implicated in the pathogenesis of several diseases including cancer, autoimmune diseases and diabetes, and is currently under development as a treatment for type 2 diabetes.activates the [ENTITY_B] gene expression in human keratinocyte HaCaT cell lines",0,1
"The role of [ENTITY_A] as a regulator of [ENTITY_A] -signaling in dendritic cell differentiation., a [ENTITY_B] opener, up-regulates Dvl-3 expression in human dendritic cells (DCs) by a non-canonical mechanism., an activator of [ENTITY_B], up-regulates Dvl-3 expression in human DCs by a non-canonical mechanism., a Dvl-3 blocker, blocks DC maturation and promotes",0,1
"Pretreatment with low-dose [ENTITY_A] attenuates [ENTITY_B] -induced hepatotoxicity via [ENTITY_B] activation., a natural compound, is known to have numerous therapeutic properties including anti-diabetic activity, anti-oxidant, and free-radical scavenger activities., a natural compound, is known to have numerous therapeutic properties including anti-diabetic activity, anti-oxidant and free-radical scavenger activities., a new anti-diabetic",0,1
"Proteome analysis of the [ENTITY_A] -induced hepatocyte cell death shows upregulation of [ENTITY_B] and diclofenac., a widely used painkiller, is known to induce cell death in cultured hepatocytes through apoptosis signal-regulating kinase 3 (ASK3) activation.activates the intrinsic apoptotic pathway, activating the intrinsic pathway-1 (IAP-1) and inhibiting the extrinsic pathway-1 (EPS-1).",0,1
"The role of [ENTITY_A] and Cl(-)/H(+) exchange in the regulation of [ENTITY_A] -mediated transcription activation.activates the [ENTITY_B] transcription via H(+) -dependent Cl(-)/H(+) exchange, which is mediated by the RING domain of Nrf2, in response to [ENTITY_B] in living cells.activates the transcription via H(+) -dependent Cl(-)/H(+) exchange, which is mediated by the RING domain of Nrf2, in",0,1
"Hepatocyte nuclear factor 4 alpha (HNF4alpha) activation by [ENTITY_A] is involved in the [ENTITY_B] -induced [ENTITY_B] (Gsk3-beta)/Akt activation in HepG2 cells.activates the [ENTITY_B] in human HepG2 hepatocytes, leading to the up-regulation of CYP1A1 and the down-regulation of CYP2E1.activates the human CYP1A1 gene via the activation of the [ENTITY_B] (H",0,1
"Treatment of human adipocytes with the selective serotonin reuptake inhibitor (SSRI), fluoxetine, results in down-regulation of [ENTITY_A] (Nrf2) and up-regulation of [ENTITY_B] (AREs)., one of the most important serotonin (5-HT) receptors in the brain, regulates energy homeostasis by activating [ENTITY_B] (Nrf2).activates [ENTITY_B] (AREs).induces [ENTITY_B] (AREs).induces brown",0,1
"Protein kinase D1 (PKCd) activation by [ENTITY_A] inhibits cell cycle progression in osteoblast-like cell lines and human osteoblastic cells., a new anti-diabetic drug, activates the [ENTITY_B] MAPK kinase pathway in adipocytes to suppress adipose tissue inflammation., a new anti-diabetic drug that activates the [ENTITY_B] K-ras pathway in adipocytes to suppress adipose tissue inflammation., a new anti-di",0,1
"(1)H-MRS2179, a selective beta2AR antagonist, selectively reduced the [ENTITY_A] gene expression in [ENTITY_B] -stimulated Jurkat cells.activates a [ENTITY_B] (ERK) pathway to induce cell proliferation in vitro.activates a [ENTITY_B] (ERK) signaling pathway to induce cell apoptosis in cell systems.potently activates a heterodimerization signaling pathway involving [ENTITY_B] (ERK), [ENTITY_B] (JNK), p38, and",0,1
(R)-(+)-isomers of [ENTITY_A] enhanced [ENTITY_B] activation and vasodilator responses to NO.can bind to and activate the [ENTITY_B] (N-ethyl-D-aspartate) receptor (Nrf2).activates the [ENTITY_B] (nuclear factor erythroid 2-related factor 2)-regulated antioxidant gene expression and protects against age-related diseases.can activate the nuclear factor erythroid 2-related factor 2 (Nrf,0,1
"Proteomic analysis reveals novel activators of [ENTITY_A] that modulate cell proliferation., a prototypical activator of [ENTITY_B], promotes cell proliferation in human cancer cell lines and human cancer cell lines derived from different tissues., a prototypical activator of [ENTITY_B], promotes cell proliferation in human cancer cell lines and human cancer cell lines derived from different tissues., an activator of [ENTITY_B], promotes cell proliferation in all cell lines and tissues tested., although a",0,1
"The use of [ENTITY_A] to induce apoptosis in endometrial carcinoma cells is associated with activation of [ENTITY_B]., a novel anti-estrogen, induces apoptosis in a variety of human cancers., an anti-estrogen, induces apoptosis in human endometrial carcinoma cell lines in vitro and in vivo. induces the apoptotic pathway in endometrial carcinoma cell lines in vitro and in vivo., an anti-estrogen, induces",0,1
"Proteomic analysis of [ENTITY_A] in pancreatic islets after [ENTITY_B] treatment revealed downregulation of [ENTITY_B] synthesis-dependent proteins, upregulation of phosphoenolpyruvate carboxykinase, and upregulation of phosphoenolpyruvate carboxykinase-2.activates [ENTITY_B] -dependent glucose uptake in pancreatic islets from diabetic rats.activates aldo-keto reductase (AKR) and inactiv",0,1
Hepatocyte nuclear factor 4α (HNF4α) regulates [ENTITY_A] -induced [ENTITY_B] secretion from human ductal carcinomas.activates [ENTITY_B] in a HNF4α-dependent manner.activates HNF4α in human ductal carcinoma cells and human breast and pancreatic cancer cells.activates HNF4α in human breast and pancreatic cancer cells and human pancreatic carcinoma cells.activates HNF4α in human,0,1
"(E)-selectin is a substrate for [ENTITY_A] : an in vivo study in humans., an activator of the [ENTITY_B] /Rac activation pathway, stimulates the accumulation of circulating endothelial ICAM-1 in a dose- and time-dependent manner in human blood., an activator of the Rac activation pathway, stimulates the accumulation of circulating ICAM-1 in a dose-dependent manner in human blood., an antagonist of the Rho/R",0,1
"Hepatocyte nuclear factor 4 alpha (HNF4α) and sterol regulatory element binding protein-1c (SREBP-1c) are critical regulators of [ENTITY_A] -stimulated [ENTITY_B] -dependent [ENTITY_B] expression in HepG2 hepatocytes.activation is involved in the regulation of lipid homeostasis and metabolism in liver, and plays an important role in the pathogenesis of obesity.(SREBP-1c) is a nuclear receptor for cholesterol",0,1
"PKCβ/δ regulates the [ENTITY_A] -induced expression of COX-1 and iNOS in HT29 cells., a prototypical [ENTITY_B] opener, induces the production of prostaglandins (PGs) that contribute to the development and progression of certain human cancers.(PTG), an agonist of [ENTITY_B] (SAR), stimulates the production of PGE2 and the expression of COX-1 and iNOS in HT29 cells.",0,1
"Proteome analysis of [ENTITY_A] (PKC) activator [ENTITY_B] in pancreatic islets: insights into the understanding of islet-stimulating action of [ENTITY_B]., a new KC-agonist, induces [ENTITY_B] secretion from beta-cells; however, its precise mechanism remains to be clarified., a new KC-agonist, stimulates beta-cell proliferation, differentiation, and survival; however, its precise mechanism remains to be clarified., a selective KC-agonist,",0,1
"The effect of the [ENTITY_A] -containing bisphosphonates, oxypurinol and gliclazide on osteoclast formation and function in vitro., a new bisphosphonate approved for the treatment of rheumatoid arthritis, stimulates [ENTITY_B] activity in vitro., a bisphosphonate approved for the treatment of rheumatoid arthritis, stimulates osteoclast formation and function in vitro in a similar manner to that of the parent",0,1
"Hepatitis C virus entry inhibitor ( [ENTITY_B] ) inhibits interleukin-2 (IL-2) production from human peripheral blood mononuclear cells via suppression of [ENTITY_A] /ErbB2 signaling.induction by beta-adrenergic agonists and the anti-inflammatory properties of [ENTITY_B] may explain the beneficial effects of [ENTITY_B]  on inflammation-related diseases.induction in peripheral blood lymphocytes by beta-adrenergic agonists such as phenformin,",0,1
Treatment of human endometrial cancer cell line (A-549) with [ENTITY_A] caused significant increase in [ENTITY_B] mRNA levels in a time-and dose-dependent manner.activates the p38 MAPK kinase pathway in endometrial cancer cells.activates the p38 MAPK pathway in endometrial cancer cells.potently induces the [ENTITY_B] (MAPK) in endometrial carcinoma cell lines.potently induces the phosphorylation,0,1
"(+)AMPK/PKA signaling regulates [ENTITY_A] -induced [ENTITY_B] secretion.activates the [ENTITY_B] receptor tyrosine kinase cascade, leading to activation of the [ENTITY_B] (AMPK)/PKA signaling cascade that in turn regulates glucocorticoid hormone (GC hormone)- and parathyroid hormone (PTH)-dependent transcriptional activity.stimulates the secretion of [ENTITY_B] from adipose tissue and liver.activates the transcription elongation factor β transcription factor",0,1
"Treatment of [ENTITY_A] -induced hepatotoxicity with a vitamin E-containing diet restored endogenous levels of [ENTITY_B] and ALDH2 in mice., which induces [ENTITY_B] expression in liver tissues, causes hepatotoxicity by activating the [ENTITY_B] /Akt pathway.activates the Akt/mammalian target of rapamycin (mTOR) pathway in liver cells, leading to the up-regulation of [ENTITY_B], the master transcription factor for lipid accumulation in adipose tissue.",0,1
"Protein kinase D1 (PKD1) is a novel substrate of [ENTITY_A] requiring activation for [ENTITY_B] activation., a phosphodiesterase (PDE) inhibitor, is known to activate [ENTITY_B], a phosphodiesterase (PDE) that regulates many cellular functions.also activates PDE4D in human and rat hepatoma cell lines, and in HEK293 cells stably transfected with PDE4D, PDE4D phosph",0,1
"Inhibitors for [ENTITY_A] block of [ENTITY_B]., a [ENTITY_B] inhibitor., a [ENTITY_B] inhibitor., a PD-0325901-resistant PDE3 inhibitor.
A novel small molecule, [ENTITY_A] (BMS-582949), inhibits the phosphatidylinositol 3-kinase and Akt pathway in vascular smooth muscle cells., a new small molecule, has been identified as a novel inhibitor of phosphatidylinosit",1,1
"(R)-(S)-3-(Aminomethyl)-5-(2-methoxy-phenyl)-7-(2-hydroxypropoxy)-3-nonyl-1-hydroxy-1-hydroxy-2-propylamino)benzoic acid ( [ENTITY_A] ) is a novel and effective inhibitor of [ENTITY_B] ( [ENTITY_B] ), which has been in development for treatment of Alzheimer's diseases.inhibitoris under investigation as an Alzheimer's",1,1
"(1)H and (31)P NMR studies of the interaction of [ENTITY_A] with human albumin: evidence for a reversible inhibition at physiological pH values.is a [ENTITY_B] blocking drug approved for the treatment of allergic and irritant skin diseases and for the treatment of certain gastrointestinal stromal tumours., a more potent analogue of ibotenate, was developed as a novel, orally active anti-inflammatory drug for the treatment of osteoarthritis., ibot",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a [ENTITY_B] inhibitor., a COX-1 inhibitor.
Structural basis for the selective inhibition of human [ENTITY_B] (COX-2) by the novel [ENTITY_B] derivatives., a COX-1 inhibitor., a selective COX-2 inhibitor., a COX-3 inhibitor., a COX-4 inhibitor., a selective COX-5 inhibitor., a",1,1
"Inhibitors for [ENTITY_A] block of the [ENTITY_B]., a [ENTITY_B] inhibitor., a [ENTITY_B] inhibitor., an ACE inhibitor.
The antifibrotic agent sulprostone reduces the risk of osteoarthritis by suppressing the inflammatory reaction., an anti-inflammatory sulprostone drug., an inhibitor of [ENTITY_B]. sulprostone, a gastrointestinal (GI) drug., a drug used for rheumatoid arthritis (RA",1,1
"(1)H- and (14)C-labeled [ENTITY_A] analogues as potential blockers of [ENTITY_B] isoforms., a novel, potent, dipeptide [ENTITY_B] inhibitor., a new, orally bioavailable prodrug of fibrate., a novel, potent, dipeptide fibrate inhibitor., a novel, potent, dipeptide plasminogen activator., a novel, potent, di",1,1
"inhibition of [ENTITY_A] by [ENTITY_B]., a peripheral opiate agonist that is selectively administered to treat pain, also inhibits [ENTITY_B]., another peripheral opiate agonist that is not selective for norepinephrine, also inhibits dopamine., naloxone, and desipramine also inhibit NET, but to a lesser extent., at least in part, explains the clinical efficacy of [ENTITY_B] as a smoking cessation agent., at least in part, explains the",1,1
"inhibitors based on a [ENTITY_A] scaffold as a novel strategy to treat metastatic breast cancer., a [ENTITY_B] scaffold, binds to and inhibits [ENTITY_B] in breast cancer cell lines with an IC(50) value of 0.005 micromol/L; in contrast, the IC(50) value of celecoxib in metastatic MDA-MB-231 cells is 10-fold higher.is a selective COX-2 inhibitor, and has",1,1
"This study explores the potential for [ENTITY_A] to block the [ENTITY_B] -induced vasoconstriction and intracellular calcium increase in rabbit aortic strips., a nonselective irreversible inhibitor of [ENTITY_B] (COX-1) and COX-2, is used to relieve symptoms in rheumatoid arthritis, osteoarthritis, and related pain., a selective irreversible inhibitor of COX-3, was recently reported to alleviate symptoms in osteoarthritis and other inflammatory",1,1
"(R)-Phenylalanine-based inhibitors of [ENTITY_A] : [ENTITY_B] (Iressa) and pyridostigmine (Sigma) in bipolar disorder., a selective inhibitor of acetylcholinesterase ( [ENTITY_B] ) but also a potent inhibitor of MAO-B., a selective inhibitor of MAO-B but also a potent inhibitor of MAO-A., a selective inhibitor of both MAO-A and MAO-",1,1
"(1) H NMR-DG analyses of the binding of [ENTITY_A] to the N-terminal of FLT3: implications for inhibitor design., an [ENTITY_B] inhibitor, binds with high affinity to the N-terminus of FLT3., an ASA inhibitor, binds with low affinity to the N-terminus of FLT3.inhibitor [ENTITY_B] is currently in phase 3 clinical trials.and its ASA inhibitor have similar pharmac",1,1
"Inhibitors of [ENTITY_A] ( [ENTITY_B] and apixaban) attenuate the absorption of darunavir in HIV-1-infected patients on ritonavir- or cobicistat-boosted protease-inhibited antiretroviral therapy., a potent and selective inhibitor of c-Met, has been in clinical development for the suppression of the absorption of darunavir., a potent and specific inhibitor of c-K",1,1
"In vitro inhibitory effects of [ENTITY_A] (BMS-354825) on [ENTITY_B]., a potent oral multi-targeted [ENTITY_B] inhibitor currently in phase 2b clinical development for rheumatoid arthritis, has been shown to have poor intestinal bioavailability, limiting its clinical use., a potent oral multi-targeted ceftazidime inactivator currently in phase 2b clinical development for osteoarthritis, was evaluated in a human colon cancer cell",1,1
"This article presents the in vivo metabolism of the novel [ENTITY_A] (BMS-591649): [ENTITY_A] inhibitor [ENTITY_B]., BMS-591649:inhibitor., BMS-591649: metabolism in humans., BMS-591649: overview of the in vivo metabolism of this compound., BMS-591649: overview of the in vivo metabolism of this drug., BMS-5916",1,1
(R)-Phenylalanine and (S)-phenylalanine were incubated with recombinant [ENTITY_A] inhibited by [ENTITY_B] (Ki = 32 microM) or purified from rat brain (Ki = 0.5 microM) and their activities were determined by electrocatalytic oxidation of phenylalanine.inhibition by [ENTITY_B] was measured by electrocatalytic oxidation of phenylalanine.inhibition by rolipram (Ki =,1,1
"(Z)-9-methoxymethyl-9-fluoro-1-(3-fluoro-phenyl)-1-butanone ( [ENTITY_A] ) is a new inhibitor of [ENTITY_B]., a new [ENTITY_B] inhibitor., a new COX-1 inhibitor., a new PDE3 inhibitor. nimesulide, a new PDE2 inhibitor., a new PDE3 inhibitor.
Synthesis and in vitro anti-",1,1
"This study was designed to assess the feasibility of targeting [ENTITY_A] for inhibition of platelet [ENTITY_B] -induced vasoconstriction and intracellular calcium increase in platelet-poor plasma., a new, selective inhibitor of the [ENTITY_B] /ERK1/2 pathway, effectively reduced platelet counts in vitro (IC50 = 0.04 microM; [ENTITY_B] IC50 = 0.6 microM).also reduced platelet counts at clinically relevant concentrations (IC50 = 0.06 micro",1,1
"(R)-Phenylalanine and [ENTITY_A] inhibited [ENTITY_B] in vitro with similar affinity (IC(50) = 32 microM).block of the [ENTITY_B] isoforms was also inhibited by 33 microM [ENTITY_B] and 17 microM carbamazepine.block of the human and rat CYP2B6, CYP3A4 and CYP3A5 isoforms was also weakly inhibited by 33 microM rofecoxib, 17 microM ket",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., the first in a new class of [ENTITY_B] inhibitors., the active metabolite of fenoterol. 1.inhibition., the active metabolite of fenoterol. 2. affinity for alpha3beta2 and alpha3beta4 subunits. 3. Inhibition of alpha3beta2 subunits.inhibition. 4. Inhibition of alpha3beta4 subunits.
The",1,1
"This study investigated if inhibition of [ENTITY_A] (MAO-B) by [ENTITY_B] (MAO-C) inhibitors improves the efficacy of clofarabine in chronic myelogenous leukaemia (CML) and MEG., a selective inhibitor of monoamine oxidase-B (MAO-B), was evaluated in chronic myelogenous leukaemia (CML) and multiple myeloma (MM) cells., a selective inhibitor of MAO-A",1,1
"(R)-3-(Aminomethyl)-7-(2-methoxyphenyl)-5-naphthyridin-2-one ( [ENTITY_A] ), a novel selective inhibitor of [ENTITY_B] tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, inhibits growth of HCT 116 colon cancer cells in a dose-dependent manner., a novel selective inhibitor of Src responsible for ligand-independent EGFR aut",1,1
"inhibitors based on [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B]., a new anti-Parkinsonian [ENTITY_B] inhibitor., a new anti-Parkinsonian acetylcholinesterase (AChE) inhibitor., a new anti-Parkinsonian carbamate drug., a new anti-Parkinsonian carbamate drug., a new anti-Parkinsonian carbamate drug., a new anti-Park",1,1
"inhibitors based on a [ENTITY_A] scaffold: [ENTITY_B] inhibitors for treatment of inflammatory bowel disease., a selective [ENTITY_B] (COX-1) inhibitor., a selective COX-3 inhibitor. rofecoxib (MK-0966), a selective COX-2 inhibitor. ibuprofen (MK-0967), a selective COX-3 inhibitor. erlotinib (LY294002), a selective COX-1",1,1
"The effects of [ENTITY_A], a [ENTITY_B] inhibitor, and captopril, an ACE-inhibitor, on blood pressure in the general population., a potent and selective [ENTITY_B] inhibitor, and captopril, an ACE-inhibitor, have been used for the prevention of cardiovascular diseases in patients with high blood pressure and impaired endothelial function., a selective COX-1 inhibitor, has been used for the prevention of myocardial infarction and",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-3-nonyl)adenine ( [ENTITY_A] ) are potent and specific inhibitors of [ENTITY_B], respectively, of which only a small quantity is available for clinical use.is also a potent and specific inhibitor of the rat enzyme, but at a lower dose., as well as N-propargyl-7",1,1
"(R)- and (S)-2-propargyl-1-(R)-5-methoxymethanone, [ENTITY_A], and (S)-3-butoxy-4-methoxy-5-methoxy-1,3-dihydro-1,4-dihydro-2,1-benzodiazepine, flumazenil) are potent irreversible [ENTITY_B] (MAO) inhibitors, with modest selectivity for",1,1
"inhibitors based on [ENTITY_A] (BMS-354825): a potent, orally bioavailable [ENTITY_B] inhibitor with anti-Parkinsonian activity in rodents and monkeys., a new oral tyrosine kinase inhibitor., a novel [ENTITY_B] kinase inhibitor., a new [ENTITY_B] kinase inhibitor. huprine, a new phenylalanine kinase inhibitor. nimesulide, a novel phenylalanine kinase inhibitor. PLZ-",1,1
"inhibition of [ENTITY_A] with [ENTITY_B]., a novel [ENTITY_B] inhibitor., a [ENTITY_B] inhibitor., a selective COX-2 inhibitor.
[Clinical pharmacology of the selective COX-2 inhibitors etodolac and diclofenac].Pharmacokinetics and pharmacodynamics of diclofenac and etodolac in the treatment of osteoarthritis were evaluated in a randomized, double-blind, placebo",1,1
"In vitro inhibitory potency and mechanism of [ENTITY_A], a novel [ENTITY_B] inhibitor, against H2O2-generated [ENTITY_B]., a novel COX-1 inhibitor, inhibits H(2)O(2) in a competitive fashion and may provide safer and more effective anticoagulant treatments., a novel COX-2 inhibitor, inhibits H(2)O(2) in a noncompetitive manner., a novel COX-3 inhibitor,",1,1
"(1)H NMR chemical shift changes upon inhibition of [ENTITY_A] (NET) by [ENTITY_B]., an [ENTITY_B] (COX-2) inhibitor that was first described in 2002, is being developed as a new treatment for inflammatory bowel disease (IBD).blockers (BDIs) are currently undergoing clinical trials and have been shown to reduce the risk of colonic polyps in patients with IBD.blockers (BIs) have been studied in small clinical trials and",1,1
"inhibitors based on a [ENTITY_A] scaffold: Discovery of [ENTITY_B], a selective COX-2 inhibitor for cancer chemotherapeutics., a selective inhibitor of [ENTITY_B]., a selective COX-1 inhibitor., a selective COX-2 inhibitor in combination with trastuzumab., an oral [ENTITY_B] inhibitor in early-phase clinical trials., a selective COX-3 inhibitor in early-phase clinical trials., a",1,1
"inhibitors based on a [ENTITY_A] scaffold: discovery of (a, c) dibenzo[c][1,2,5]oxadiazoles as novel [ENTITY_B] -selective inhibitors for cancer cell motility.,and quinidine are potent irreversible [ENTITY_B] (MAO) inhibitors.inhibitors based on a dibenzo[c][1,2,5]oxadiazoles as novel MAO-selective inhibitors for cancer",1,1
"(R)-(-)-Epinephrine and the [ENTITY_A] blocker [ENTITY_B] block the [ENTITY_B] -dependent [ENTITY_B] -mediated vasoconstrictor response to acetylcholine.is a nonselective irreversible inhibitor of [ENTITY_B] (N-methyl-d-aspartate) receptors that is used to relieve the symptoms of Alzheimer's disease and Parkinson's disease., a selective agonist for platelet serotonin 5-HT(2A/2C) receptors, has been shown",1,1
"This study explored whether [ENTITY_A], a [ENTITY_B] (COX-2)-specific inhibitor, could attenuate acid-induced lung injury in rats., the active metabolite of ibuprofen, is reported to suppress the activation of the COX pathway, but the effect of ibuprofen on acid lung injury is unknown., a selective COX-1 inhibitor, is also reported to suppress the activation of the COX pathway, but has not been studied in acid lung",1,1
"(R)-(+)-Tamsulosin effectively antagonizes the effects of [ENTITY_A], clarithromycin, enrofloxacin, levofloxacin, and rifampicin on the [ENTITY_B], but has little or no effect on carprofen and ketoprofen., enrofloxacin, levofloxacin, and rifampicin inhibit the enzyme cytochrome P450, but have little",1,1
"Inhibition of [ENTITY_A] (Bsep) by [ENTITY_B]., which transports citrulline in the BSEP compartment, transports bradykinin in the BSEP2 compartment, and both Bsep and Bsep have been suggested to transport arachidonic acid in the BSEP compartment., which transports nicotinamide adenine dinucleotide (NADH) in the BSEP compartment, transports acetylcholine in the B",1,1
"Inhibition of the [ENTITY_A] by [ENTITY_B]., the active metabolite of aspirin, inhibits the action of proapoptotic [ENTITY_B]., the active metabolite of ibuprofen, inhibits the action of proapoptotic cleaved polypeptide p53., the active metabolite of naproxen, inhibits the action of proapoptotic cleaved polypeptide p53., the active metabolite of ketoprofen, inhibits the act",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on renal function and urinary metabolites in cirrhotic rats with ascites., a potent inhibitor of NHE2, was recently reported to improve renal function in cirrhotic rats with ascites., a potent inhibitor of NHE3, was recently reported to be less effective in rats with ascites., which is metabolized by NHE1, NHE2, and NHE3, may be more effective",1,1
"(1) Evaluation of [ENTITY_A] inhibition in a panel of [ENTITY_B] (COX-2, COX-3, and COX-4) inhibitors., a selective COX antagonist, is currently in phase 3 clinical development for the treatment of osteoarthritis., a selective COX-2 inhibitor, is in phase 3 clinical development for the treatment of osteoarthritis., a selective COX-3 inhibitor, is in phase 3 clinical development for",1,1
"The effects of [ENTITY_A], a selective inhibitor of [ENTITY_B] (MAO-B), on the metabolism of racemic aspirin in humans., a selective inhibitor of MAO-B, inhibits the metabolism of racemic aspirin in humans., a selective inhibitor of MAO-B, inhibits the metabolism of racemic aspirin in humans., an oral tyrosine kinase inhibitor, inhibits the metabolism of racemic aspirin in humans., a selective inhibitor of MAO-",1,1
"(+/-)-Tamsulosin effectively antagonized the inhibitory effect of [ENTITY_A] on nasal allergy., an [ENTITY_B] (COX-2 inhibitor) that is used for the treatment of rheumatoid arthritis, is also a potent inhibitor of nitric oxide-cyclic GMP signaling., an COX-1 inhibitor, is not approved for the treatment of allergic diseases.(NS-187, an [ENTITY_B] (COX-1 inhibitor) that",1,1
"inhibitors based on a [ENTITY_A] scaffold as a new approach to treat chronic myelogenous leukaemia., a potent and specific [ENTITY_B] (MLL) inhibitor, has been in development for use in chronic myelogenous leukaemia (CML) for over a decade., a less specific inhibitor, is also being developed., which shares several common structural elements with mitoxantrone, has shown to cause dose-dependent neutropenia in a",1,1
"Inhibition of [ENTITY_A] (MMP-2) and MMP-9 by [ENTITY_B] and captopril: comparison with the reference drugs sulindac and [ENTITY_B].is a novel selective [ENTITY_B] inhibitor that has been demonstrated to be as effective as sulindac in the treatment of osteoarthritis.is a new, selective COX-1 inhibitor.is an established selective COX-2 inhibitor.blocker captopril (CPT-",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methanone, [ENTITY_A], induces apoptosis in human lung adenocarcinoma A549 cells via inhibition of [ENTITY_B]., an uncompetitive inhibitor of acetylcholinesterase., a pharmacological inhibitor of acetylcholinesterase., is a first-in-class inhibitor of acetylcholinesterase",1,1
"(R)-3-methoxy-N,N,N',N'-tetraethyldopa ( [ENTITY_A] ) is a potent, irreversible inhibitor of [ENTITY_B] used to treat Parkinson's disease, but it also inhibits platelet aggregation, which may confer some of its clinical efficacy to atrial natriuretic peptide., a second irreversible inhibitor of platelet aggregation, may also have clinical advantages.inhibitor ( [ENTITY_B], Leflunomide) is",1,1
"In vitro and clinical trials for the treatment of prostatic carcinoma with the [ENTITY_A] inhibitors [ENTITY_B] and ritonavir-boosted with the proteasome inhibitor bortezomib.inhibitor [ENTITY_B] -boosted with bortezomib.inhibitor ritonavir-boosted with bortezomib..blocker (ARB) [ENTITY_B] -boosted with bortezomib.
The effect",1,1
"The effect of selective [ENTITY_A] (COX-1, COX-3) inhibitors, ketoprofen, ketrolack and NS-398, on the metabolism of racemic sibutramine in humans., a selective [ENTITY_B] inhibitor, is used in the clinic for the treatment of pain and for the prevention of osteoarthritis., a selective COX-3 inhibitor, is also widely used in pain management., a selective inhibitor of",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methyl-1-oxo-2-naphthalen-2-yl)-1-methyl-3-oxabicyclo[3.2.1]heptan-2-one ( [ENTITY_A] ) as a novel [ENTITY_B] inhibitor., a new proapoptotic agent., a new proap",1,1
"The effect of [ENTITY_A] (BMS-354825), a potent oral multi-targeted cyclin-dependent inhibitor that inhibits [ENTITY_B], cyclin E, cyclin D1, cyclin E2, cyclin G1, cyclin K1, cyclin I, and phosphoinositide 3-kinase, on breast cancer risk., a potent oral multi-targeted cyclin-dependent inhibitor that inhibits vascular endothelial growth factor, [ENTITY_B], cyclin E",1,1
"Inhibition of [ENTITY_A] by the [ENTITY_B] inhibitors [ENTITY_B] and apixaban.(BMS-354825) and apixaban (BMS-591649) are potent oral tyrosine kinase inhibitors (TKI), which have recently been approved for the treatment of serious infections caused by Gram-negative pathogens., a synthetic iminosugar that binds to the catalytic domain of the enzyme, delays the absorption of carbohydrate from the gastrointestinal (GI) tract",1,1
"inhibitors based on a [ENTITY_A] scaffold as potential anti-Parkinsonian drugs., a potent irreversible inhibitor of [ENTITY_B] (MAO), is used to treat Parkinson's disease (PD)., a selective MAO inhibitor, has been in development as a therapeutic agent for PD., a less potent irreversible MAO inhibitor, has also been in development as a therapeutic agent for PD.was designed as a non-competitive inhibitor of MAO, and was shown to",1,1
"In vitro metabolism of the novel [ENTITY_A] derivatives: discovery of a potent, selective, [ENTITY_B] inhibitor.is a potent and specific inhibitor of [ENTITY_B] (MAO).is a novel, potent, competitive MAO inhibitor., a novel, potent MAO inhibitor., a selective MAO inhibitor., a potent, selective MAO inhibitor., a potent, selective MAO inhibitor.
Design, synthesis, and biological evaluation",1,1
"inhibitors based on a [ENTITY_A] scaffold: discovery of a potent and selective [ENTITY_B] inhibitor for Alzheimer's disease.(N-propargyl-1-(2-phenanthrenyl)-1-(2-phenanthrenyl)-1H-pyrazole-1-carboxamide) has been designed, synthesized and evaluated as a potential drug for the inhibition of amyloid beta protein (Abeta) peptide deposition and tau pathology in",1,1
"(R)-3-(Aminomethyl)-7-(2-hydroxypropoxy)-1-hydroxy-1-methanone ( [ENTITY_A] ) is a novel, highly potent, irreversible [ENTITY_B] inhibitor with antihypertensive activity comparable with that of the reference drugs enalapril and [ENTITY_B]., a selective metabolite of enalapril, is also potent and irreversible., a metabolite of enalapril, inhibits the renin",1,1
"(R)-(-)-Tetraethylammonium ( [ENTITY_A] ) is a potent and specific inhibitor of [ENTITY_B] (MAO-B), which is the first line enzyme for monoamine oxidase in the brain., the active metabolite of MDMA, is also a potent MAO-B inhibitor, but with a much lower toxicity., an inactive metabolite of MDMA, is also a potent MAO-B inhibitor but with a much lower toxicity.blockers",1,1
"(R)- and (S)-3-(Aminomethyl)-7-methoxy-4-hydroxyphenylamide, [ENTITY_A] inhibitors with longer and more selective duration of action, respectively, were designed for the treatment of Parkinson's disease (PD).inhibitors ( [ENTITY_B], rolipram) have been on the market for years, and their efficacy has been proven in several placebo-controlled trials.is a newly approved compound that has shown",1,1
"(Z)-3-(2-hydroxypropoxy)-1-methanone, [ENTITY_A], induces apoptosis by inhibiting the mitochondrial transmembrane potential with [ENTITY_B]., a selective inhibitor of [ENTITY_B] (MAO), has been shown to cause dementia in patients with Parkinson's disease (PD)., a selective inhibitor of MAO-B, has also been shown to cause dementia in patients with PD., a selective inhibitor of MAO-C, has also",1,1
"In vitro, [ENTITY_A], a [ENTITY_B] inhibitor, reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.inhibition in mice bearing Lewis lung carcinoma.(BMS-354825): a potent oral multi-targeted [ENTITY_B] inhibitor against SRC, BCR-ABL, PDGFRA, PDGFRa, PDGFRb, VEGFR, and FLT3, and a VEGFR2 inhibitor",1,1
"Inhibition of [ENTITY_A] (Bsep) by [ENTITY_B].inhibitors (Iressa, Nexavar) and proton pump inhibitors (PPI) have been recommended as appropriate treatment options for hypercholesterolemia., a metabolite of rasagiline, inhibits Bsep.inhibitors (Iressa, Nexavar) and proton pump inhibitors (PPI) have been recommended as appropriate treatment options for hypercholester",1,1
"inhibitors based on a [ENTITY_A] scaffold for cancer therapy., a selective [ENTITY_B] (MAO) inhibitor, has recently been approved for the treatment of Parkinson's disease (PD) in the US., a potent MAO inhibitor, has recently been approved in Japan for the treatment of dementia.(BMS-354825) is a small molecule, currently undergoing clinical trials, that binds with high affinity to the MAO-C catalytic domain and has activity",1,1
"(1) Evaluation of [ENTITY_A] inhibitors in dysmenorrhea using an interactive virtual reality (VR) simulator., a selective norethisteroid inhibitor (SNO), is currently under investigation for the treatment of benign prostatic obstruction (BPO) and dysmenorrhea., an irreversible inhibitor of [ENTITY_B] (HDAC), is currently in phase 3 clinical development., an irreversible inhibitor of NHE3, is in clinical development.inhibitors (",1,1
"(+/-)-Tamsulosin effectively antagonizes the action of [ENTITY_A], but has little effect on the action of rofecoxib, and may reduce the risk of side effects.(Cabozantinib ditosylate, GW-572016), a selective inhibitor of [ENTITY_B], is currently in phase 2 clinical development for the treatment of NSCLC., a selective inhibitor of OATP-C and OATP-B,",1,1
"(S)-1-(Aminomethyl)-7-(2-hydroxypropoxy)-4-methanone ( [ENTITY_A] ) inhibits [ENTITY_B], but not CYP2B6, 3A4, and 3C9., a new inhibitor of CYP2B6, but not of CYP3A4, 3A5, and 3D6., a new inhibitor of CYP2C9., but not of CYP2",1,1
"This study evaluates the effects of a novel [ENTITY_A] inhibitor ( [ENTITY_B] ) on the metabolism of racemic sibutramine in humans.inhibition.inhibition in humans.inhibition in humans.inhibition in humans.blockers in humans.blockers in humans.
The effects of the nitric oxide metabolite, NO(3) -, and the nitric oxide precursor, NO, on the pharmacokinetics",1,1
"This study explored the effects of chronic [ENTITY_A] treatment on the levels of brain norepinephrine and [ENTITY_B]., a selective inhibitor of the [ENTITY_B] (NET), is used to treat attention-deficit/hyperactivity disorder (ADHD).is also used in the treatment of Alzheimer's disease (AD), as it reduces the levels of beta-amyloid-peptide (Abeta) peptides., a selective inhibitor of the NET, has been used in the",1,1
"inhibitors based on a [ENTITY_A] scaffold as novel [ENTITY_B] inhibitors., a potent, dipeptide [ENTITY_B] (MAO-B) inhibitor, is currently in phase 3 clinical development for the treatment of Parkinson's disease., a nonpeptide MAO-B inhibitor, was recently approved for the treatment of mild to moderate Alzheimer's disease., a more potent MAO-B inhibitor, has been in phase 3 clinical development for the",1,1
"(1)H NMR-based metabolite profiling of [ENTITY_A] inhibitor [ENTITY_B] in vitro., a potent oral multi-targeted [ENTITY_B] inhibitor, inhibits the [ENTITY_B]., a selective COX-2 inhibitor, inhibits COX-1 at low micromolar concentrations., a selective inhibitor of prostaglandin E(2) and thromboxane B(2) (TXB(2)) receptors, inhibits COX-1 at",1,1
"This study evaluates the feasibility of targeting [ENTITY_A] (BRCA1) and BRCA2 genes for suppression of breast cancer by [ENTITY_B] (BMS-354825)., which is a [ENTITY_B] inhibitor active in several malignancies, is being developed for treatment of breast cancer., which is a bisphosphonate inhibitor active in several malignancies, is being developed for treatment of breast cancer., which targets both BRCA1 and",1,1
"In vitro, [ENTITY_A] is inhibited by [ENTITY_B], at least in part, via a direct inhibition of the catalytic center.is a competitive inhibitor of the [ENTITY_B] isoforms, HFL-1 and HFL-3.(h) HFL-3 and hHFL-1 are substrates of hFL-3, but not of hFL-1; in contrast hFL-3 is an uncompetitive inhibitor of hFL-1.(l)",1,1
"inhibiting activities of the new [ENTITY_A] analogues., a potent and specific inhibitor of [ENTITY_B], is currently in phase 2 clinical development for the treatment of osteosarcoma, malignant mesothelioma, and gastrointestinal stromal tumors., a nonselective irreversible inhibitor of osteoclast bone resorbing activity, is in early clinical development for the treatment of osteopetrosis and osteoarthritis., a selective and irreversible inhibitor of",1,1
"In vitro metabolism of the novel [ENTITY_A] derivatives CYP4174, CYP4292, and CYP4918 in humans is mediated by CYP2B6 and CYP3A4., an [ENTITY_B] inhibitor., an ACE inhibitor., a norepinephrine (NE) inhibitor., a PDE4 inhibitor., a PDE3 inhibitor., an CYP2D6 inhibitor., an ACE",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a natural product [ENTITY_B] inhibitor., a natural product ACE inhibitor., a natural product ARB inhibitor.
The effect of the nitric oxide-donor [ENTITY_B] inhibitor [ENTITY_B] on blood pressure, cardiac hypertrophy, and the phosphorylation of c-Src, c-Myc, and cyclin D1 in the heart., an inhibitor of N-methyl-d-aspartate",1,1
"(R)-(-)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-naphthalen-2-yl)-1-methanone ( [ENTITY_A] ) is a potent and selective [ENTITY_B] (MAO-B) inhibitor., a potent and specific MAO-B inhibitor., is also a potent and selective MAO-B inhibitor., is both a potent and selective MAO-B inhibitor.,",1,1
"(R)-(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-3-methylanthraquinone, [ENTITY_A], has been demonstrated to inhibit [ENTITY_B] (BChE).is also a known inhibitor of acetylcholinesterase (AChE).is reported to be relatively ineffective as an MAO inhibitor and is not a first-line drug for MA",1,1
"(R)-Phenylalanine-based inhibitors of [ENTITY_A] : selectivity for the low-affinity catalytic domain., an [ENTITY_B] inhibitor that targets the catalytic domain of human phenylalanine hydroxylase, has been in development for treatment of Alzheimer's disease.inhibitors that target the high-affinity catalytic domain of human phenylalanine hydroxylase, which is located in close proximity to the active site of",1,1
"(R)- and (S)-3-hydroxybenzylhydrazine ( [ENTITY_A] ), two potent [ENTITY_B] inhibitors, inhibited the proliferation of U937 cells in a dose-dependent manner., an analogue of 3-hydroxybenzylhydrazine, also inhibited the proliferation of U937 cells in a dose-dependent manner., an analogue of 4-acetamido-3-(3-hydroxypropoxy)benzylhydraz",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a peripheral opiate agonist, inhibits intracellular cAMP levels in human platelets., a peripheral opiate agonist, inhibits human platelet cAMP levels in vitro., an oral direct opiate agonist, inhibits human whole blood platelet cAMP levels in vitro., an oral direct opiate agonist, and naloxone, a central opiate agonist, inhibit human whole blood plate",1,1
"(R)-(-)-Epibatidine ( [ENTITY_A], 1), a derivative of (S)-cocaine that selectively antagonizes [ENTITY_B] (Ro 40-5967), is a more potent and longer-lasting peripheral opiate blocker and agonist at alpha 1A and alpha 1C of the norepinephrine transporter., a derivative of (S)-cocaine, is a more potent and longer-lasting peripheral opiate blocker and agonist at alpha 1B of",1,1
"(R)-(-)-Tetrahydrocannabinol ( [ENTITY_A] ) induces apoptosis of HT29 colon cancer cells via downregulation of [ENTITY_B] (Bax) and cyclin E., which are regulated by Bcl-xL.inhibitors, attenuate apoptosis of HT29 colon cancer cells via downregulation of Bax and cyclin E., which are regulated by Bcl-xL., which is regulated by Bcl",1,1
"(R)- and (S)-2-hydroxy-3-methylanthraquinone ( [ENTITY_A] ), two potent, nontoxic [ENTITY_B] inhibitors, inhibited LPS-induced NO production in a dose-dependent manner in vitro., an analogue of ritonavir- and etravir-based [ENTITY_B] inhibitors, inhibited LPS-induced NO production in a dose-dependent manner in vitro in a manner distinct from its nongenotoxic action.",1,1
"(R)- and (S)-2-hydroxy-5-methoxy-N,N,N',N'-tetraacetamido pyrrolidine [ENTITY_A] inhibitors. d-Amino acid oxidase and oxidized phospholipids potentiate inhibition of [ENTITY_B] by [ENTITY_B]., a key enzyme in arachidonic acid metabolism, was inhibited by d-amino acids oxidase (DAO) and oxidized phospholipids (",1,1
"(1) H NMR-DQA-DGRA method for the determination of the stereospecificity of [ENTITY_A] inhibition of the [ENTITY_B] in rat liver mitochondria., an antimetabolite that selectively inhibits [ENTITY_B], was developed as an anti-inflammatory drug., which is used for the treatment of osteoarthritis, is a selective COX-inhibitor that selectively inhibits COX-1.inhibitors, such as ketop",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a peripheral opiate receptor antagonist, reduces the frequency of atonic events and prolongs the QT interval of the electrocardiogram in normal subjects., an indirect blocker of the [ENTITY_B], prolongs the QT interval in atrial fibrillation but not in paroxysmal atrial fibrillation., a central opiate receptor antagonist, prolongs the QT interval in atrial fibrillation and blocks late I",1,1
"(R)- and (S)-Methamphetamine induced platelet aggregation is inhibited by [ENTITY_A]., an inhibitor of the [ENTITY_B] (MAO) enzyme, was reported to be a preferential substrate of [ENTITY_B]., however, was reported to be a less selective MAO-B inhibitor., a selective inhibitor of MAO-C, was reported to be a less selective MAO-A inhibitor., an inhibitor of MAO-B, was reported to be a relatively",1,1
"In vitro metabolism of the novel [ENTITY_A] inhibitor [ENTITY_B] (CI-1059): comparison with ketoprofen., a novel [ENTITY_B] (COX-2) inhibitor, is in clinical development for the treatment of osteoarthritis., currently evaluated in the treatment of rheumatoid arthritis, also inhibits COX-2., ifosfamide and rofecoxib are non-steroidal selective COX-2 inhibitors that have recently been",1,1
"(R)-3-(Aminomethyl)-7-(4-methylphenyl)-5-(3-hydroxypropoxy)-1-hydroxy-1-methanone, [ENTITY_A] ) is a new synthetic opiate agonist selective for mu-receptors., a new [ENTITY_B] inhibitor., a new anticonvulsant., a new anticonvulsant., a new anticonvulsant.,",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methanone, [ENTITY_A], inhibits [ENTITY_B] (BChE) and forms adducts on Lys48 and Lys49 of the enzyme.inhibited BChE activity at a potency similar to its inhibitory effect on phenylalanine hydroxylase and the resulting product, norepinephrine, was also inhibited at a potency similar to its inhibition on the",1,1
"The role of [ENTITY_A] in the inhibition of the [ENTITY_B] by the [ENTITY_B] inhibitors [ENTITY_B] and rosuvastatin.(N-acetylcysteine) and rosuvastatin (formerly called N-propylcysteine) are selective inhibitors of the [ENTITY_B]., rosuvastatin, and nialamide also inhibit the enzyme acetylcholinesterase.and rosuvastatin also inhibit acetylcholines",1,1
"The effects of [ENTITY_A] blockade on the metabolism of the antipsychotic drug [ENTITY_B]., a new drug for bipolar disorder, is thought to increase the rate of catecholamine conversion into norepinephrine by inhibiting the enzyme [ENTITY_B]., a new drug for bipolar disorder, is thought to increase the rate of catecholamine conversion into norepinephrine by inhibiting the enzyme CYP3A., a new drug for bipolar disorder, is",1,1
"(S)-3-(Aminomethyl)-7-(5-hydroxymethyl)-1-hydroxy-1-hydroxy-1-oxabicyclo[2.2.2]octan-4-amine, [ENTITY_A], was synthesized and evaluated as a [ENTITY_B] inhibitor., 3-(Aminomethyl)-7-(5-hydroxymethyl)-1-hydroxy-1-oxabicyclo[2",1,1
"(+/-)-Tamsulosin effectively antagonizes the action of [ENTITY_A], at least in part, via a direct inhibition of the [ENTITY_B] isoforms., the enzyme that catalyses the first committed step in prostaglandin E2 synthesis, exhibits substrate specificity similar to that of PDE4, with respect to the PDE3 inhibitors, albeit at low levels., the enzyme that catalyses the first committed step in prostaglandin E2 synthesis,",1,1
"inhibitor [ENTITY_A] (LPV) suppresses growth of human lung carcinoma A549 cells via downregulation of [ENTITY_B] pathway., a [ENTITY_B] (VP-16) inhibitor, is a standard chemotherapy for NSCLC., a VP-16 inhibitor, is a standard chemotherapy for NSCLC., a pemetrexed (MPX) inhibitor, is a standard chemotherapy for breast cancer., a pemetrexed (MPX) inhibitor,",1,1
"(R)- and (S)-3-(Amino-1-methan-1-yl)-3-hydroxypropoxy-1-hydroxy-1-methanone ( [ENTITY_A] ) were potent inhibitors of [ENTITY_B]., an indolocarbazole, was a less potent and safe inhibitor of the rat enzyme., a p-chloro analogue, was a weak inhibitor of the rat enzyme., a 3-hydroxybenz",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methyl-1-phenyl-3-oxazinyl-oxazolidin-4-amine, [ENTITY_A] ) is a novel [ENTITY_B] (BChE) inhibitor that has little or no risk of neurotoxicity, is completely bactericidal, and has little or no risk of sensitization., [1,1'-biphenyl]-",1,1
"Inhibitor of [ENTITY_A] ( [ENTITY_B] ), a new drug for the treatment of inflammatory bowel disease., a new small molecule that inhibits [ENTITY_B]., an inhibitor of TLR4., a new drug for the treatment of inflammatory bowel disease and irritable bowel syndrome., a novel inhibitor of NF-κB., a new drug for the treatment of irritable bowel syndrome.
The effect of the selective COX-2 inhibitor enalapril on gast",1,1
"In vitro and in vivo studies with the novel [ENTITY_A] inhibitor [ENTITY_B] indicate that inhibition of the [ENTITY_B] -Bsep transporter may be the mode of action for atovaquone., a metabolite of atovaquone., a metabolite of atovaquone., a metabolite of atovaquone., a metabolite of atovaquone. atovaquone, a metabolite of atovaquone. atopic",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a [ENTITY_B] inhibitor., a COX-1 inhibitor., a COX-2 inhibitor., a PDE3 inhibitor., a PDE4 inhibitor.
Amino acid transporter 1 and 2: identification and characterization of [ENTITY_B] (FLT3) inhibitory mutants., a transporter for amino acids., a transporter for amino acids and peptides., a transporter for amino",1,1
"(1) H-NMR and (13) C-NMR chemical shifts in [ENTITY_A], a [ENTITY_B] inhibitor, in aqueous and organic solvents., a selective inhibitor of the [ENTITY_B]., a selective inhibitor of the NHE2., both a H-NMR and a (13) C-NMR chemical shift perturbation perturbation., a selective inhibitor of the NHE1., a",1,1
"In vivo metabolism, human blood pool, and pharmacokinetics of [ENTITY_A], a novel [ENTITY_B] inhibitor, in humans.(N-{4-[2-methoxy-phenyl]phenyl}acetamide) is a selective irreversible COX-1 inhibitor and [ENTITY_B] inhibitor that inhibits both [ENTITY_B] and COX-2.(N-{4-[2-methoxy-phenyl]phenyl}acetamide) is a novel irreversible",1,1
"The antihyperthermic effect of [ENTITY_A], a [ENTITY_B] inhibitor, on postprandial hyperthermia following single oral doses of metoclopramide and topiramate: a randomized, double-blind, placebo-controlled trial.inhibitors, such as amrinone and [ENTITY_B], are potent and selective inhibitors of the [ENTITY_B] (N-methyl-D-aspartate receptor) and have been recommended for the treatment of neuropathic pain.in",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(3-hydroxy-3-methoxy-phenyl)-1-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-1-hydroxy-3-nonyl)imidazole-4-acetamide ( [ENTITY_A] ) is a selective, irreversible inhibitor of the [ENTITY_B] (MAO-B).inhibits the monoamine oxidase (",1,1
"Inhibitors based on a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B] (CDK6)., bosentan, and NS-398 are potent and selective inhibitors of cyclin E, cyclin D1, cyclin E2, cyclin D2, cyclin G1, and cyclin K1.is a new and unique compound that targets the CDK6 and CDK6-cyclin D1 complexes as well as CDK6 and",1,1
"inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens., another fusidic acid metabolite from Sophora flavescens., another fusidic acid metabolite from Sophora flavescens., another fusidic acid metabolite from Sophora flavescens., another fusidic acid metabolite from Sophora flavescens., another fusidic acid metabolite from Sophora flavescens.",1,1
"Inhibition of [ENTITY_A] (ABL) by [ENTITY_B]., a peripheral ABL enzyme, is produced mainly by activated monoclonal ABL reaction (mAb-RAB), and its inhibition can be eliminated through inhibition of the enzyme by [ENTITY_B] (TAp63)., a central component of the ABL, is produced mainly by activated monoclonal TAb-RAB reaction (mAAb-CTR)., the enzyme that catalyses the first committed step",1,1
"(1)H and (14)C chemical shift binding of [ENTITY_A], an [ENTITY_B] inhibitor., an ACE inhibitor., a PDE3 inhibitor., a PDE4 inhibitor., a PDE5 inhibitor., an PDE6 inhibitor. (2)H and (14)C chemical shift binding of rolipram, an ACE inhibitor. rolipram, an ACE inhibitor. rolipram, an ACE inhibitor. ro",1,1
"In vitro and in vivo studies support a unique inhibition of [ENTITY_A] by [ENTITY_B].inhibition of the human renin-angiotensin system., angiotensinogen, and renin inhibitory peptide (NAP) interact with the human renin-angiotensin system in vivo., angiotensinogen, and renin inhibitory peptide (NAP) interact with the human renin-angiotensin system in",1,1
"This study explored whether [ENTITY_A] -induced reductions in [ENTITY_B] density could be related to reduced protein levels or changes in the structure of the protein., a well-known CRBN substrate, exhibited reduced levels of densities of the subunits I, II and III., a less known CRBN substrate, showed reduced densities of both subunits I and II., a novel CRBN substrate, showed reduced densities of both subunits I and II., a new CR",1,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] by [ENTITY_B]., a [ENTITY_B] inhibitor, is currently in phase 3 clinical development for the treatment of atherosclerosis., a new antiatherosclerotic drug with mild inhibition of platelet aggregation, has been in clinical development for at least a decade; however, it has yet to reach the oncology clinic.is a novel antiatherosclerotic drug that has been in clinical development for at least a",1,1
"(Z)-3-(1-hydroxypropoxy)-1-methoxy-1-methanone, [ENTITY_A], a potent and selective [ENTITY_B] (BChE) inhibitor., a new anti-BChE drug., a new pro-apoptotic agent., a new anti-apoptotic agent., a new anti-inflammatory agent.
The anticonvulsants carbamazepine and oxcarbazepine",1,1
"In vitro inhibition of [ENTITY_A] by [ENTITY_B]., a peripheral opiate agonist with anti-arrhythmic activity independent of mu-receptors, is currently in phase III clinical trials., an intravenous opiate agonist with anti-arrhythmic activity independent of mu-receptors, is currently in phase III clinical trials., an intravenous opiate agonist with anti-arrhythmic activity independent of mu-receptors,",1,1
"Inhibition of [ENTITY_A] (Bsep) reduces albuminura in the presence of [ENTITY_B] and purinergic receptor blockade.inhibitors (Bsep, Tarceva) reduce albuminura in diabetes., Tarceva and apixaban reduce albuminura in the presence of [ENTITY_B] and/or PDE3 inhibitors., apixaban and erlotinib reduce albuminura in the presence of PDE4 inhibitors or 5-",1,1
"(1)H nuclear magnetic resonance (NMR) study of [ENTITY_A] inhibitor [ENTITY_B] (BMS-354825): implications for the design of potent, orally active [ENTITY_B] inhibitors.(BMS-354825): implications for the design of potent, orally active tracer studies in vivo.(BMS-354825): implications for the design of potent, orally active tracer studies in vivo., a novel orally active inhibitor of the",1,1
"(1)H-NMR chemical shift analyses of [ENTITY_A], a potent, orally active [ENTITY_B] inhibitor.inhibitory action.inhibition and enhancement of [ENTITY_B] concentrations in blood by a novel prokinetics strategy.inhibition and enhancement of uptake by a prokinetics strategy.inhibition and enhancement of uptake by a prokinetics strategy.inhibition and enhancement of uptake by a prokinetics strategy.and prokinetics",1,1
"Inhibitors based on a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B]., the prototype benzodioxan, is a selective inhibitor of [ENTITY_B] (COX-2); however, it also inhibits norepinephrine (NE) and serotonin (5-HT) transporters ( [ENTITY_B] and 5-HTTC).is in phase 3 clinical development for the treatment of chronic myelogenous leukaemia (CML) and gastrointestinal stromal tumours.",1,1
"This study explored whether [ENTITY_A] -induced reductions in the rate dependence of ethanol and ethanol and its metabolite, 4-hydroxy-n-propyl alcohol, are due primarily to a direct inhibition of [ENTITY_B] or a more general decrease in CYP1A activity., a specific inhibitor of CYP3A, was incubated with vehicle or ethanol alone or in the presence of ketoconazole, a specific inhibitor of CYP2B, to determine if rate dependence could be attributed",1,1
"(Z)-3-(2-hydroxypropoxy)-1-methanone, a new inhibitor of [ENTITY_B] leukotriene receptor., a new inhibitor of leukotriene D5 receptor., a new inhibitor of leukotriene C5 receptor., a new inhibitor of leukotriene D5 receptor.
Synthesis and biological evaluation of novel [ENTITY_A] derivatives as potent and selective inhibitors of [ENTITY_B] (IL",1,1
"(S)-3-(Aminomethyl)-7-(4-hydroxy-3-nonyl)adenosine ( [ENTITY_A] ), a potent and selective norepinephrine reuptake inhibitor and [ENTITY_B] blocker, exhibits favorable pharmacokinetic profile in humans., a new orally bioavailable norepinephrine reuptake inhibitor, has been in development for treatment of Attention Deficit/Hyperactivity Disorder and Parkinson's disease., a new orally bioavailable n",1,1
"The effects of the [ENTITY_A] inhibitor [ENTITY_B] on gastric acid secretion in rats.inhibition in rats.(N-propargyl-1-methanone) is a potent synthetic opiate agonist that has little or no effect on the stomach when administered orally., however, inhibits stomach acid secretion at a rate tenfold higher than for its effect on the brain.inhibition in rats.inhibition in rats.in",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens., an [ENTITY_B] inhibitor with anti-inflammatory activity., an ACE inhibitory drug., a COX-2 inhibitor and a 5-LOX inhibitor., an ACE inhibitor and a 5-LOX inhibitor., an ACE inhibitor and a COX-1 inhibitor., an ACE inhibitor and a 5-LOX inhibitor., an ACE inhibitor and a 5-LO",1,1
"(1) Evaluation of [ENTITY_A], an [ENTITY_B] inhibitor from Japanese mugwort.(1) Effect of chloroform extraction and hydrometallophoresis on the pharmacokinetics and in vitro metabolism of (+/-)-gossypol acetic acid in humans., an ethanol extract of Japanese mugwort, is a widely used dietary antioxidant and has been reported to have anti-inflammatory activity., a chalcone of gossypol",1,1
"In vitro and in vivo studies with the [ENTITY_A] /ABL inhibitor ( [ENTITY_B] ) CGP 38560A show a poor pharmacokinetic profile that limits therapeutic use.inhibitor ( [ENTITY_B] ) has completed Phase I clinical trials, and has proven effective in the treatment of acute myelogenous leukaemia and gastrointestinal stromal tumours., an oral tyrosine kinase inhibitor with moderate activity in vitro, has also completed Phase I trials., a novel,",1,1
"The effects of [ENTITY_A] blockade on the pharmacokinetics, safety and efficacy of vardenafil and [ENTITY_B] in the treatment of ED., a potent inhibitor of [ENTITY_B]., a selective inhibitor of PTGS2., a non-competitive inhibitor of PTGS2., has been shown to improve ED in some patients with Parkinson's disease.blockade may be effective in the treatment of ED., a non-competitive inhibitor of PTGS2",1,1
"inhibition of the [ENTITY_A] by [ENTITY_B]., a peripheral opiate agonist., a peripheral opiate agonist., a peripheral anxiolytic agonist. naloxone, a peripheral anxiolytic agonist. naltrindole, an indirect opiate agonist. oxycodone, a peripheral [ENTITY_B] inhibitor. silymarin, an indirect opiate agonist. nimesulide, a peripheral anxiolytic agon",1,1
"The use of [ENTITY_A] inhibitor [ENTITY_B] in conjunction with [ENTITY_B] has resulted in a significant increase in the rate of gastrointestinal (GI) bleeding., a new oral tyrosine kinase inhibitor, has recently been approved for the treatment of myeloid malignancies and gastrointestinal stromal tumor malignancy., a novel tyrosine kinase inhibitor, has recently been approved for the treatment of myeloid malignancies and gastrointestinal stromal tumor malignancies",1,1
"Inhibitors based on a [ENTITY_A] scaffold as a new approach to treat metastatic colorectal carcinoma., a potent, nontoxic [ENTITY_B] inhibitor., a novel [ENTITY_B] inhibitor., a novel fibrinogen inhibitor., a new COX-2 inhibitor. erlotinib, a selective COX-1 inhibitor. erlotinib mesylate, a new COX-2 inhibitor. LY29400",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a natural product from Sophora flavescens., a natural product from Sophora flavescens., a new [ENTITY_B] inhibitor., a new inhibitor of the NF-kappaB pathway., a new NF-kappaB inhibitor with anti-inflammatory activity.
Structural basis for [ENTITY_A] - and COX-2-selective inhibition of arachidonic acid release from phospholipids.",1,1
"In vitro and in vivo metabolism of the novel [ENTITY_A] (COX-1) inhibitor [ENTITY_B] and the selective COX-2 inhibitor NS398 in humans., a new oral multi-targeted [ENTITY_B] inhibitor., a new oral multi-targeted COX-inhibitor., a new oral multi-targeted NSAID., a new oral multi-targeted COX-1 inhibitor., a new oral multi-targeted",1,1
"(R)-(-)-3-(Aminomethyl)-7-(3-butoxypropoxy)-1-methanone ( [ENTITY_A] ), a potent selective COX-2 inhibitor and [ENTITY_B] (COX-1) inhibitor, exhibits neuroinflammatory activity in vitro that is unrelated to its antipsychotic activity., a selective COX-3 inhibitor and tranylcypromine (TCP), a potent selective dopamine D2 inhibitor, exhibits antipsychotic activity in vivo",1,1
"(1) H NMR analysis of [ENTITY_A] (BMS-354825) inhibitory activity in vitro.inhibitors based on a [ENTITY_B] scaffold.inhibitors based on a [ENTITY_B] scaffold.inhibitors based on a gallium-based scaffold. p-chloro-phenanthrenyl-oxazolidinone inhibitors of gallamine uptake., gallamine, and gallocatechin inhibitory activities of some [ENTITY_B]",1,1
"(Z)-3-(4-hydroxyphenylamino)benzoic acid ( [ENTITY_A] ) exhibits moderate activity as a [ENTITY_B] inhibitor, with IC50 values of 0.024 and 0.5 nM in the same assay, respectively., a derivative of Z-3, has IC50 values of 0.028 and 0.5 nM in the same assay., a more potent and specific COX-1 inhibitor, has an",1,1
"(R)-(-)-Epicatechin gallate ( [ENTITY_A] ) attenuates [ENTITY_B] -induced liver injury in rats via suppressing ROS accumulation, suppressing the activation of caspase-9 and caspase-3 and suppressing the nuclear localization of Bax., a specific inhibitor of [ENTITY_B], could potentially attenuate various diseases through the inhibition of Bax.suppressed the expression of Bax and the activation of caspase-9 and caspase-3 in a dose",1,1
"(1)H and (31)P NMR studies of [ENTITY_A], a [ENTITY_B] -selective inhibitor of the [ENTITY_B] (COX) 1 and COX 2 isozymes., an oral multi-targeted inhibitor of COX and 5-LOX., a selective COX-2 inhibitor., a selective 5-LOX inhibitor., a selective COX-1 inhibitor., a selective 5-LOX inhibitor., a",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methanone ( [ENTITY_A] ) is a potent synthetic [ENTITY_B] (MAO-B) inhibitor.Inhibitors with additional actions against monoamine oxidase (MAO)-B are of great importance., a new orally active [ENTITY_B] (MAO-A) inhibitor, was evaluated for its antidepression activity in vivo and in vitro., a new orally",1,1
"Inhibitors for the [ENTITY_A] /MEKK1/JNK pathway protect pancreatic beta-cells from oxidative stress induced by [ENTITY_B] in insulin-dependent mice., an inhibitor of [ENTITY_B] /MEKK1/JNK pathway, improves glucose control in streptozotocin-induced diabetes in mice., an inhibitor of MEKK1/JNK pathway, improves pancreatic beta-cell survival in diabetes induced by troleandomycin in mice., an inhibitor",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-1-methylxanthine ( [ENTITY_A] ), a potent, orally active, [ENTITY_B] inhibitor that targets the [ENTITY_B] BCR-ABL, is being developed for treatment of serious B-cell lymphoma and chronic lymphocytic leukemia.inhibitor, (R)-3-(Aminomethyl)-7-(3-",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetics of gliclazide: a randomized, double-blind, placebo-controlled trial., the active metabolite of gliclazide, is metabolized by cytochrome P450 (CYP) enzymes and is a potential drug-drug interaction (PDD) risk factor for gliclazide., the active metabolite of gliclazide, is metabolized",1,1
"(R)- and (S)-1-hydroxy-3-(4-methoxy-phenyl)-1-(3-methoxy-phenyl)-1-hydroxy-3-nonyl-1-methanone ( [ENTITY_A] ), respectively, inhibit [ENTITY_B] (BChE) and BChE-mediated biotransformation of phenacetin., a new target for prodrug development., a new target for prodrug development.",1,1
"The role of [ENTITY_A] inhibitors in the treatment of chronic prostatitis (from the viewpoint of pharmacology and physiology)., a potent and specific inhibitor of [ENTITY_B] ( [ENTITY_B], sulprostone), is a standard treatment for chronic prostatitis., a less selective and more rapid inhibitor of leukotriene D(4) (LTD(4)) has recently been introduced., a nonselective irreversible inhibitor of leukotriene D(4),",1,1
"(1)H NMR-scramble assay of [ENTITY_A], a new inhibitor of [ENTITY_B] from Trypanosoma cruzi.inhibition by [ENTITY_B].inhibition by ketoconazole.inhibition by [ENTITY_B].inhibition by ketoconazole.inhibition by rolipramine.inhibition by rolipramine.inhibition by darunavir.inhibition by ketoconazole.inhibition",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., isolated from Juglans mandshurica Maxim. a new anti-diabetic drug., isolated from Juglans mandshurica Maxim., a new anti-diabetic drug [ENTITY_B], isolated from Juglans mandshurica Maxim., a new [ENTITY_B] inhibitor., isolated from Juglans mandshurica Maxim., isolated from Juglans mandshurica Maxim",1,1
"In vivo inhibition of [ENTITY_A] by the small molecules [ENTITY_B] (Iressa and erlotinib) and OSI-774 (Nilotinib)., a selective EP1-receptor antagonist; erlotinib, a selective EP2-receptor antagonist., a selective EP3-receptor antagonist., a selective EP4-receptor antagonist. erlotinib, a selective inhibitor of the small molecules Iressa and erlotin",1,1
"(1) Evaluation of [ENTITY_A], a novel [ENTITY_B] inhibitor, in a panel of 5 CCR5 antagonists ( [ENTITY_B], ketoprofen, ketrolack, mexiletine, NS-389, rofecoxib and [ENTITY_B] ).blockers (KB, MB and Raf).blockers (MK-499 and MK-499(R)) and selective COX-2 inhibitors (NS-187 and ketrolack and ketoprofen).",1,1
"Inhibitors for human EGFR, KIT, and BCR-ABL: a structure activity relationship study of [ENTITY_A].(Gleevec, GWD-13849), a potent oral multi-targeted [ENTITY_B] (PDT) inhibitor for EGFR, KIT, and BCR-ABL, is in clinical development for the treatment of chronic myelogenous leukaemia (CML) and the non-B cell lymphoma (NBL) chronic lymph",1,1
"(1)H NMR-derived structural and functional analyses of the [ENTITY_A] - and OATP-beta 2'-hydroxylating enzyme from Trypanosoma cruzi, Trypanosoma cruzi OATP-beta 3'-hydroxylating enzyme from Trypanosoma cruzi.inhibitor [ENTITY_B] (N-{4-[5-(2-methoxybenzyl)oxazol-1-yl]-phenyl}acetamide)",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens., a peripheral benzothiazepine receptor agonist., a peripheral [ENTITY_B] (COX-1 and COX-3) inhibitor., a peripheral norepinephrine and epinephrine metabolite inhibitor., an indirect agonist of nicotinic acetylcholine receptors.",1,1
"Inhibitors based on a [ENTITY_A] scaffold for the treatment of metastatic colorectal cancer: [ENTITY_B] inhibition in vivo and in vitro., an oral tyrosine kinase inhibitor (TKI), is a novel, multitargeted agent that targets the [ENTITY_B], mitogen-activated protein (MAP) kinases, EGFR, and Akt, and promotes apoptosis in tumor cells and normal cells., an oral TKIsulphonyl-am",1,1
"Inhibitors based on the [ENTITY_A] scaffold as a novel class of potent, nontoxic [ENTITY_B] inhibitor for the treatment of ED..(Aliskiren), [1,8]nimesulide (Nimesulide), (R)-8-methoxymethyl-5-n-propyl-1-naphthyridin-2-one (Probenecid) and N-propargyl-2-",1,1
"This study explored the effects of the novel [ENTITY_A] inhibitor [ENTITY_B] (LPV, 0.5 mg x kg(-1))., a selective inhibitor of acetylcholinesterase and butyrylcholinesterase, is used to treat Alzheimer's disease, but has been associated with serious side effects., which has been tested in several clinical trials, has been shown to be at least as effective as acetylcholinesterase in reducing brain acet",1,1
"inhibitors based on a [ENTITY_A] scaffold for the treatment of tumors with dysregulated [ENTITY_B] signaling.inhibitors based on a [ENTITY_B] scaffold for the treatment of tumors with dysregulated KIT signaling., an irreversible inhibitor of [ENTITY_B]., an irreversible inhibitor of KIT., an irreversible inhibitor of KIT and PDGFR-beta., a nonimmunosuppressive drug that suppresses PDGFR-mediated phosphorylation",1,1
"(R)- and (S)-3-(Aminomethyl)-7-methoxy-4-methoxybenzoxaborole, [ENTITY_A], are potent and specific inhibitors of [ENTITY_B] (Bsep).inhibitors for breast and pancreatic cancer., ibuprofen, and diclofenac, are potent and specific inhibitors of Bsep., rofecoxib, diclofenac",1,1
"This study investigated the effect of [ENTITY_A] (BMS-354825) a [ENTITY_B] inhibitor, in combination with metformin on the progression of diabetic retinopathy., a dual-targeted inhibitor of [ENTITY_B] and PDE3, inhibits both ROS accumulation and nitric oxide production., a dual-targeted inhibitor of PDE4 and PDE3, inhibits nitric oxide production mainly through inhibiting ROS accumulation., a dual-target",1,1
"inhibitory effects of the [ENTITY_A] inhibitor [ENTITY_B] (DPI) on the COX-1, 2, 3, and 5 activities of the COX enzymes in human colon cancer cell line SW620 and normal colon cell line HCT 116., an indole alkaloid that inhibits [ENTITY_B]., a non-steroidal [ENTITY_B] inhibitor with antiinflammatory activities in vitro., a synthetic indole alkaloid with a dual mechanism of action as a",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetics of darunavir and its major active metabolite, [ENTITY_B], in healthy subjects., the first in a new class of [ENTITY_B] -based [ENTITY_B] inhibitors., the first in a new class of CYP2B5 inhibitors., the first in a new class of potent CYP3A4 inhibitors., the first in a new class of potent CYP",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens., a new compound isolated from roots of Sophora flavescens., a new phytochemical [ENTITY_B] from Sophora flavescens., a new phytotronol from Sophora flavescens., a new p-hydroxybenzyloxybenzyl analogue from Sophora flavescens. 1,3-benzodioxan-7-ol, a new intermediate",1,1
"Inhibitors of [ENTITY_A] signal suppression: [ENTITY_B] (V600E) and erlotinib (Tarceva) are dual [ENTITY_B] -inhibitors that compete for the same binding site.Signaling Inhibitors (STI571 and GW4064) inhibit both COX-1 and COX-3, and erlotinib inhibits epidermal growth factor receptor (EGFR).Signaling Inhibitors ( [ENTITY_B] and LY317464",1,1
"(R)-(+)-Tamsulosin effectively antagonizes the activity of [ENTITY_A], but with low risk of adverse events., an [ENTITY_B] inhibitor, is a first-line treatment for urogenital tract infection., also an antimetabolite, is used off-label for the treatment of benign prostatic obstruction, but not for the treatment of urogenital tract infection.is a second-generation inhibitor of [ENTITY_B], but has not been",1,1
"inhibitors based on the [ENTITY_A] scaffold: discovery of [ENTITY_B], a potent oral multi-targeted [ENTITY_B] inhibitor for cancer., a selective COX-2 inhibitor, is currently in phase 3 clinical development for treatment of chronic myelogenous leukaemia (CML).is also a potent oral multi-targeted COX-2 inhibitor that has completed phase 3 trials for chronic lymphocytic leukaemia (CLL).has completed",1,1
"inhibition of [ENTITY_A], but not OATP8, OATP9, or OATP10, is involved in gastric acid secretion in mice.(CYP1A2, 1B3, 1C9) inhibitors, such as [ENTITY_B] or apixaban, have been in development for the treatment of complicated stomach cancer.(CYP2B6) inhibitors, such as gliclazide, are in phase 3 clinical trials.",1,1
"In vitro metabolism of the novel [ENTITY_A] derivatives CYP3A, CYP3B and CYP3C in human and rat liver microsomes: comparison of [ENTITY_B] with ketoconazole.( [ENTITY_B], ibuprofen) and ibuprofen are potent, selective CYP3A and CYP3B inhibitors, respectively used to relieve pain and inflammation., ibuprofen and ketoconazole are potent, non-selective CY",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a non-steroidal anti-inflammatory drug, inhibits tumor necrosis factor (TNF)-alpha- and TNF-beta-mediated activation of [ENTITY_B]., a non-steroidal anti-inflammatory drug, inhibits tumor necrosis factor (TNF)-alpha- and TNF-beta-mediated activation of NF-kappaB., another non-steroidal anti-inflammatory drug, inhibits activation of NF-kappa",1,1
"(1S,3S,4S,5S)-3-hydroxy-5-(3-hydroxypropoxy)-3-methylanthraquinone ( [ENTITY_A] ) is a potent and specific inhibitor of [ENTITY_B], with Ki values of approximately 50 nM., an analogue of 5-hydroxy-3-(3-hydroxypropoxy)-3-methylanthraquinone, has Ki values of approximately 50 nM., a",1,1
"The role of the nonreceptor cytoplasmic domain of [ENTITY_A] inhibitor [ENTITY_B] protection against ionomycin-induced cystitis., an [ENTITY_B] (Bcl-2) antagonist., an acetylcholinesterase (AChE) inhibitor., a nonsteroidal antiinflammatory drug., an ACE inhibitor., an acetylcholinesterase inhibitor., a nonselective irreversible inhibitor of acetyl",1,1
"(R)-(+)-tetrahydroxyphenylamide [ENTITY_A], a new [ENTITY_B] inhibitor, inhibits the metabolism of DXM in rats., a selective COX-1 inhibitor, inhibits the metabolism of DXM in rats., a selective COX-2 inhibitor, does not inhibit DXM metabolism in rats., a selective COX-3 inhibitor, has little or no effect on DXM metabolism in rats., a nonster",1,1
"(R)-3-(3-hydroxypropoxy)-1-hydroxy-1-methanone ( [ENTITY_A] ) induces apoptosis by inhibition of [ENTITY_B] (Bim).(Bcl-2), a dual anti-apoptotic protein that promotes mitochondrial fusion and inhibits Bim activation, is upregulated in [ENTITY_B] -induced apoptosis., which was previously reported to be an antagonist of Bim, is downregulated in Bcl-2-knock",1,1
"(1) Inhibition of [ENTITY_A] by [ENTITY_B] : affinity for open and inactivated states., a potent and specific inhibitor of the [ENTITY_B] used orally for rheumatoid arthritis and osteoarthritis, was recently reported to undergo proteolysis at physiological temperatures., a potent and specific inhibitor of the rheumatoid factor used orally for the suppression of inflammation in osteoarthritis was reported to be resistant to proteolysis at physiological temperatures., a non",1,1
"(1)H and (13)C NMR analysis of [ENTITY_A], a [ENTITY_B] inhibitor, in human and rat blood., an oral tyrosine kinase inhibitor, in human and rat plasma., a selective COX-1 inhibitor, in human and rat plasma., a selective COX-3 inhibitor, in human and rat plasma., an [ENTITY_B] inhibitor, in human and rat plasma., a selective",1,1
"This study was undertaken to assess the feasibility of delivering [ENTITY_A] (a novel, selective inhibitor of [ENTITY_B] (MAO-B)), to patients with Parkinson's disease (PD)., the active metabolite of levodopa (LDL-P), inhibits dopamine and MAO activity in vitro, and has been shown to improve the motor symptoms of patients with PD., which is a selective inhibitor of MAO-B, is not currently available to the general public.was evaluated in",1,1
"(R)- and (S)-N-propargyl-1-(R)-aminoindan: a potent, orally bioavailable [ENTITY_A] inhibitor for the treatment of neuroinflammatory diseases., a potent, orally bioavailable [ENTITY_B] inhibitor for the treatment of neuroinflammatory diseases., indanforol; indanforol: a potent, orally bioavailable ACE inhibitor for the treatment of hypertension., indanforol; indanforol: a",1,1
"(Z)-3-(2-hydroxypropoxy)-1-(2-methoxy-phenyl)-5-methoxybenzyl)-1H-pyrazole-4-carboxamide ( [ENTITY_A] ) is a potent and specific [ENTITY_B] inhibitor., (Z)-3-(2-hydroxypropoxy)-1-(2-methoxy-phenyl)-5-methoxybenzyl)-1H-pyrazole-",1,1
"The role of [ENTITY_A], an inhibitor of the [ENTITY_B], in the control of colorectal cancer growth., a novel [ENTITY_B] inhibitor, inhibits growth of colorectal cancer cell lines., a new antineoplastic agent, inhibits tumor growth in colorectal cancer cell lines., a novel [ENTITY_B] inhibitor, inhibits growth of colon cancer cell lines., a new antineoplastic agent, inhibits tumor growth in colore",1,1
"inhibition of [ENTITY_A] by [ENTITY_B]., a nonsteroidal [ENTITY_B] inhibitor currently used for pain and osteoarthritis, is a target for the development of new drugs for the treatment of both conditions.(N-propargyl-1-(R)-aminoindan; 100 micromol/L) was recently reported to be a competitive inhibitor of both [ENTITY_B] and BSEP., a nonsteroidal inhibitor currently used for pain and osteo",1,1
(1) H NMR-DG analysis of [ENTITY_A] inhibitors [ENTITY_B] and apixaban.inhibition by ASA and enalapril.- and apixaban-mediated reductions in platelet reactivity.- and apixaban-mediated reductions in platelet reactivity.- and apixaban-mediated reductions in intracellular adenosine levels.- and apixaban-mediated reductions in intracellular adenosine levels.,1,1
"(R)-(-)-Epicatechin gallate ( [ENTITY_A], EC 5.4.1.1) inhibits [ENTITY_B], a rate-limiting enzyme for phenylalanine synthesis in the brain, with a half-maximal inhibitory concentration of 0.05 microM; this compares with ICs of 0.5 microM for [ENTITY_B], 0.5 microM for epicatechin gallate (EC 5.4.1.0), and 0.1 microM for",1,1
"The use of the selective [ENTITY_A] inhibitor [ENTITY_B] (CPT-11, 5 mg/kg, iv) in the context of chemoradiation therapy in NSCLC.inhibitors [ENTITY_B], erlotinib and gefitinib reduce the growth of unresectable head and neck cancer.may have additional activity against metastases.may have additional activity against metastases.may have additional activity against metastases.may",1,1
"In vitro inhibitory effects of [ENTITY_A] analogues on the metabolism of ketoprofen in rats., a metabolite of ketoprofen, is reported to decrease the risk of cancer by inhibiting [ENTITY_B] (BChE).isomers, as well as their respective oxidized products, e.g. 4-hydroxyphenylamido-2-(3-fluoro-phenyl)-3-naphthalen-2-one (L",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methanone, [ENTITY_A], inhibited the phosphorylation of [ENTITY_B], Ser 473, but failed to decrease phosphorylation of GSK3β., 3-hydroxypropoxy-1-methanone, and 7-hydroxy-7-(3-hydroxypropoxy)-1-hydroxy",1,1
"(R)-3-(3H-isothiocyanatophenyl)-7-(3-(3-hydroxypropoxy)-1-methoxy-1-oxo-1H-imidazol-4-yl)benzoic acid ( [ENTITY_A] ) is a highly potent irreversible [ENTITY_B] (MAO-B) inhibitor, with activity toward human and rat MAO-B substrates that are not reducible by classical MAO., an analogue of",1,1
"(R)-3-(Aminomethyl)-7-hydroxy-2-(3-nonyl)pyrrolidine ( [ENTITY_A] ) inhibits [ENTITY_B], aldehyde dehydrogenase, with an IC(50) value of 54 microM and cinchoninic acid hydroxylase, with an IC(50) value of 21 microM., a nonsteroidal [ENTITY_B] inhibitor, also inhibits HLDH and CYP oxidation.,",1,1
"This study was designed to test the hypothesis that [ENTITY_A], a [ENTITY_B] inhibitor currently in phase 3 clinical trials, would be as effective or even superior to enalapril in reducing BP., a synthetic diuretic and antihypertensive drug, was compared with enalapril, a reference ACE-inhibitor currently in phase 3 clinical trials, in patients with type 2 diabetes mellitus and high BP., a synthetic diuretic and antihypertensive",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a new inhibitor of [ENTITY_B]., a new inhibitor of COX., a new inhibitor of PDE3., a selective inhibitor of PDE1., a selective inhibitor of PDE2.
Structural basis for the potent inhibition of human COX-2 by [ENTITY_B]., a new inhibitor of COX-1.
Structural basis for the selective inhibition of human COX-1 and CO",1,1
"(1)H- and (31)P-tagged [ENTITY_A] inhibited the [ENTITY_B] activity of human whole blood in vitro in a concentration-dependent manner with IC(50) values of 23 microM and 227 microM, respectively; (2) H- and (31)P-tagged cGMP-bound human whole blood were not metabolized in whole blood; (3) H- and (31)P-tagged cGMP-bound human whole blood were",1,1
"(1)H NMR-DQA/DQE assay for the identification of [ENTITY_A], the [ENTITY_B] (COX) inhibitor [ENTITY_B] inhibitor [ENTITY_B] inhibitor
[Discovery of a potent and selective COX-2 inhibitor [ENTITY_B] for the treatment of osteoarthritis].AIM: To develop a potent and selective COX-2 inhibitor that can be administered systemically as a single agent or administered as a selective inhibitor of the enzyme in an adjuvant fashion",1,1
"inhibitors based upon an [ENTITY_A] scaffold: Discovery of [ENTITY_B] -based [ENTITY_B] inhibitors., an I-box binding protein that controls [ENTITY_B] signaling, is upregulated in tumor cells and has been implicated in tumorigenesis and metastasis., which has been shown to be regulated through a proteasome-dependent mechanism, is a promising new target for cancer therapy.inhibitors.inhibitors based upon the N-formyl-",1,1
"(R)- and (S)-3-(Aminomethyl)-1-hydroxymethyl-3-methanobutane-1,3-diol ( [ENTITY_A] ) as potent irreversible [ENTITY_B] (MAO-A) inhibitors., a novel irreversible MAO inhibitor.(R)- and (S)-3-(Aminomethyl)-1-hydroxymethyl-3-methanobutane-1,3-d",1,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] signaling in colorectal cancer cells., a new inhibitor of [ENTITY_B] signaling, suppresses tumor growth in vitro., the first in a new class of selective inhibitors of the tumor necrosis factor receptor, is a potent inhibitor of tumor necrosis factor-related apoptosis signals in colorectal cancer cells.(Iressa), a new, orally active inhibitor of the tumor necrosis factor receptor,",1,1
"(S)-3-(Aminomethyl)-7-(4-methoxymethyl)-1-hydroxy-3-nonyl)adenine ( [ENTITY_A] ) is a novel, highly potent irreversible inhibitor of [ENTITY_B], with in vitro and clinical activity in the low nanomolar range., which is a synonym for S-3-(Aminomethyl)-7-(4-methoxymethyl)-1-hydroxy-3-n",1,1
"This study explores the feasibility of targeting [ENTITY_A] for chemotherapy in patients with clear cell renal cancers.inhibitory activity was measured in vitro on three cell lines (HCT 116, KIT and CAL-62).inhibition was measured in a panel of 66 patients treated with the [ENTITY_B] inhibitor [ENTITY_B] (VIG) alone or with the additional [ENTITY_B] inhibitor [ENTITY_B] (PDTC) and was validated in vivo against KIT-expressing cell lines in which the drug is",1,1
"inhibitor [ENTITY_A] reduces the rate of ischemia-induced neuronal loss: implications for stroke therapy.(AP24534) is an oral tyrosine kinase inhibitor that inhibits [ENTITY_B], vascular endothelial growth factor (VEGF), neurotrophins, and receptors for them.(AP24534) is an oral tyrosine kinase inhibitor that inhibits VEGF, neurotrophins, and receptors for them.(AP24534) is an",1,1
"Inhibition of [ENTITY_A] with [ENTITY_B]., a new class of potent [ENTITY_B] inhibitors., a new class of potent ACE-inhibitors., a new class of potent [ENTITY_B] inhibitors.
A novel series of [ENTITY_B] inhibitors with improved gastrointestinal safety., a new class of potent COX-2 inhibitors. a novel series of COX-1 inhibitors. a novel series of COX-2 inhibitors. a novel series of ACE inhibitors",1,1
"The role of [ENTITY_A], a [ENTITY_B] inhibitor, in the treatment of prostatic carcinoma with metastases to the liver.inhibition with [ENTITY_B] may have reduced the incidence of hepatic metastases., a selective COX-inhibitor, may have reduced incidence of hepatic metastases.may have reduced incidence of hepatic metastases.may have reduced the incidence of hepatic metastases., a selective COX-inhib",1,1
"In vitro metabolism of [ENTITY_A], a selective [ENTITY_B] inhibitor, in human., a selective COX-1 inhibitor, was evaluated in a human oral microsomes (HOM) preparation and in a microsomal preparation., the clinical COX-1 inhibitor, showed no significant metabolism in HOM or microsomes., the clinical COX-2 inhibitor, showed significant metabolism in HOM and microsomes., the active metabolite of t",1,1
"Inhibition of [ENTITY_A] (MAO-B) by the MAO-B inhibitor [ENTITY_B].inhibited MAO-B (EC 1.14.16.1) and this inhibition was concentration dependent., at concentrations above 0.5 microM, slightly increased the MAO-B activity, but this effect was eliminated at higher concentrations.inhibited both [ENTITY_B] and MAO-B, but this inhibition was concentration dependent.inhibited MAO-B at",1,1
"In vitro and in vivo studies support involvement of [ENTITY_A] in the inhibition of [ENTITY_B] by [ENTITY_B]., a nonsteroidal antiinflammatory drug (NSAID), inhibits the action of the [ENTITY_B] (COX), a catalytic enzyme involved in prostaglandin synthesis., a nonsteroidal antiinflammatory drug (NSAID), inhibits the action of the COX, a catalytic enzyme involved in prostaglandin synthesis., a selective COX-1 inhibitor,",1,1
"(+/-)-Tamsulosin effectively antagonizes [ENTITY_A] block produced by selective [ENTITY_B] inhibitors such as [ENTITY_B] and apixaban., an anti-HIV agent with moderate gastrointestinal toxicity, is a new addition to the anti-coagulation armamentarium., a selective inhibitor of clot-bound procoagulant [ENTITY_B], is also available for use in HIV prevention.may be appropriate for use in patients with a family history of breast or prostate",1,1
"(R)-(+)-Tamsulosin effectively antagonizes the inhibitory effect of [ENTITY_A] on the gastroduodenal mucosa, thus providing a novel mechanism of action., a [ENTITY_B] (MAO-B) inhibitor, was evaluated for its anti-hyperglycemic activity in the setting of type 2 diabetes., a mitochondrial MAO-B inhibitor, was evaluated for its anti-hyperglycemic activity in the setting of type 2 diabetes., a",1,1
"This study was designed to test the efficacy of a novel [ENTITY_A] derivate in suppressing [ENTITY_B] -dependent platelet aggregation and to determine its mode of inhibition., a novel nonselective [ENTITY_B] inhibitor with potent [ENTITY_B] -blocking activity but with little or no COX-1 inhibitory activity, was purified from a extracts of a Japanese mugwort., a novel nonselective COX-2 inhibitor with potent thrombin-binding activity but no COX-",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] : affinity for open and inactivated states., an [ENTITY_B] inhibitor, is currently in phase II clinical trials for the treatment of atherosclerosis and cardiovascular diseases.(BMS-354825).is a potent oral multi-targeted inhibitor of several pro-inflammatory cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-1 beta, IL-8,",1,1
"In vitro inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens.(FdUrd) is an important enzyme for phenylalanine and tyrosine metabolism in humans., a peripheral enzyme, is also inhibited by nimesulide., also a peripheral enzyme, is not inhibited by nimesulide., an active metabolite of nimesulide, is also not inhibited by nimesulide., an inhibitor of phenyl",1,1
"This report examines the use of the dual anti-inflammatory drug [ENTITY_A] for the treatment of osteoarthritis of the knee and ankle., a selective [ENTITY_B] (COX-1) inhibitor, is effective in osteoarthritis of the hip and knee and has been approved for the treatment of rheumatoid arthritis., a selective COX-2 inhibitor, is also effective in osteoarthritis of the knee and ankle but has not been approved for the treatment of oste",1,1
"(R,S)-3-(3-hydroxypropoxy)-1-methanone ( [ENTITY_A] ; 1), a derivative of ""skunk"", reduced the potency of the [ENTITY_B] inhibitors [ENTITY_B], gliclazide, and [ENTITY_B] in the frontal cortex, hippocampus, and striatum., the active metabolite of skunk, reduced the potency of the Ih inhibitors rolipram, ketanserin, and etodolac in the frontal cortex",1,1
"In vitro metabolism study of the new [ENTITY_A] derivatives: 5- and 6-mono- and dihydroxyphenylamide derivatives as [ENTITY_B] inhibitors.(N-propargyl-1-(2-naphthyl)-5-hydroxy-3-methoxybenzyl)amido-1,3-diaryl-4-phenylpropane sulfone, 1; N-propargyl-1-(2-",1,1
"In vitro inhibitory activity of [ENTITY_A] analogues on the [ENTITY_B] (COX) pathway., a selective COX-1 inhibitor; [1,8]naphthalene, a selective COX-2 inhibitor., a selective COX-3 inhibitor; naphthalene, a selective COX-4 inhibitor., a selective COX-5 inhibitor., a selective COX-6 inhibitor., a selective COX-7",1,1
"The effect of [ENTITY_A] on the metabolism of racemic [ENTITY_B] in humans.inhibition by [ENTITY_B].inhibition by rofecoxib.inhibition by ketoprofen., the metabolite formed by CYP3A, metabolizes to produce catechol in humans through CYP3A4., the metabolite formed by CYP2C9, metabolizes to produce nialamide in humans through CYP2C19.",1,1
"Inhibition of [ENTITY_A] (Aβ)-induced apoptosis by a [ENTITY_B] inhibitor: [ENTITY_B]., a [ENTITY_B] inhibitor., a neurotoxin., a neurodegenerative drug., a neurotoxin., a neurotrophin., a neurodegenerative drug., a neurotrophin., a neurotrophin. View detailed review., a neurotrophin. View detailed review. View detailed review",1,1
"(Z)-3-(2-hydroxypropoxy)-1-naphthalen-2-yl-urea ( [ENTITY_A] ) as a novel inhibitor of [ENTITY_B]., a potent synthetic 5-HT(2A/2C) agonist, inhibits both 5-HT(1A) and 5-HT(1B) receptors., a potent synthetic 5-HT(1A/1B) antagonist, has been shown to have little or no",1,1
"(R)- and (S)-3-hydroxybenzylhydrazine, a dual inhibitor of [ENTITY_A] (MAO-B) and c-jun N-terminal kinases, produced a dose-dependent inhibitory effect on the [ENTITY_B] activity of brain homogenates., a dual inhibitor of MAO-B and c-jun N-terminal kinases, produced a dose-dependent inhibitory effect on the activity of brain homogenates.",1,1
"Inhibitors of [ENTITY_A] ( [ENTITY_B], ketoprofen), ketoprofen (MKP-1290), ketrofen (MKP-1291), ketoprofen (MKP-1292), ketoprofen (MKP-1293), ketoprofen (MKP-1294) and MK-499 (N-propargyl-1-(3-methoxy-phenyl)-1-butanone) significantly inhibited the proliferation",1,1
"The effect of selective [ENTITY_A] inhibitors on the pharmacokinetics, pharmacodynamics, and disposition of darunavir-avibactam, a new [ENTITY_B] inhibitor in healthy subjects., [ENTITY_B], ritonavir-ritonavir, and cobicistat-avibactam are potent [ENTITY_B] inhibitors that have been administered intravenously (i.v.) to HIV-infected patients since 2005., ritonavir-",1,1
"The use of [ENTITY_A] inhibitor [ENTITY_B] in the treatment of chronic myelogenous leukaemia: a report from the China University of Hong Kong HEALES project., an [ENTITY_B] inhibitor., an imatinib analogue used for systemic therapy in chronic myelogenous leukaemia., a selective COX-2 inhibitor., a selective COX-1 inhibitor., a selective [ENTITY_B] inhibitor., an oral inhibitor used for",1,1
"The effects of the [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetics of darunavir- and ritonavir-boosted HIV-1 PGP 8192/896 and 5-fluoro-2'-deoxyuridine triphosphate., a novel [ENTITY_B] inhibitor, may improve the pharmacokinetics of darunavir- and ritonavir-boosted HIV-1 PGP 8192/896 and 5-flu",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a [ENTITY_B] inhibitor that is currently being evaluated for the treatment of Alzheimer's disease., an ACE inhibitor that is currently being evaluated for the treatment of Alzheimer's disease., a [ENTITY_B] inhibitor that is currently being evaluated for the treatment of Alzheimer's disease., a [ENTITY_B] inhibitor not yet evaluated for the treatment of Alzheimer's disease., a GLP-2 analogue that is currently being evaluated for the treatment",1,1
"(S)-3-(Aminomethyl)-8-(2-methylanthraquinone) [ENTITY_A], a novel [ENTITY_B] inhibitor, inhibits the proliferation and activation of human lung cancer cell lines in a time- and concentration-dependent manner., a new proapoptotic agent, inhibits the proliferation and activation of cancer cell lines in a time- and concentration-dependent manner., a new proapoptotic agent, inhibits the proliferation and activation",1,1
"(R)-3-hydroxybenzoyl-5-methoxybenzoyl-5-methoxybenzoyl-5-methoxybenzoyl-5-methoxybenzoyl-5-fluoro-1-hydroxy-1-oxo-1-methanone ( [ENTITY_A] ), a novel [ENTITY_B] inhibitor, is a potent and sustained inhibitor of [ENTITY_B]., a novel 5-",1,1
"Inhibition of [ENTITY_A] by a novel series of [ENTITY_B]., a [ENTITY_B] inhibitor with mild inhibitory activity on the enzyme., a selective COX-1 inhibitor with moderate inhibitory activity on the enzyme., a selective COX-2 inhibitor with mild inhibitory activity on the enzyme., a selective COX-3 inhibitor with moderate inhibitory activity on the enzyme., a selective COX-4 inhibitor with mild inhibitory activity on the",1,1
"(1) In vitro metabolism of [ENTITY_A] -CYP11A1 inhibitors [ENTITY_B] and erlotinib: selective inhibition of CYP11A1 and CYP3A activities., a new orally active [ENTITY_B] blocking agent, is in clinical development as a cancer chemopreventive agent and has recently been introduced for the treatment of gastrointestinal stromal tumor (GIST)., a new orally active CYP11A1 inhibitor, is in clinical development as a cancer",1,1
"This article presents the development and optimization of [ENTITY_A] (BMS-354825), a novel [ENTITY_B] (BPSA) inhibitor that selectively targets the [ENTITY_B] BPSA., a clinical [ENTITY_B] (BPSA) inhibitor., a new BPSA inhibitor that targets the BPA1., a new BPSA inhibitor that targets the BPA1., a new BPA1 inhibitor., a new BPSA inhibitor that selectively targets",1,1
"(1)H NMR-derived structural and functional characterization of the [ENTITY_A] inhibitor [ENTITY_B] (N-([1-(2-methoxy-phenyl)-3-naphthalenyl]-1-methanone) sulfonate): synthesis, antitumor activity, and in vivo efficacy in inhibiting metastasis in Lewis lung carcinoma.is a potent inhibitor of [ENTITY_B] (COX-1) that is active in vitro against COX-2",1,1
"(R)- and (S)-3-(Aryl)propargyl-1-(2-methoxy-phenyl)-1-hydroxy-3-nonyl-1-methanesulfonamide, [ENTITY_A], inhibited LPS-induced NO production in KCs with similar affinity (IC50 = 32 microM) and a lower toxicity (IC50 = 56 microM)., an irreversible inhibitor of [ENTITY_B], had no effect on LPS effects on",1,1
"Inhibitors based on the [ENTITY_A] scaffold: Discovery of [ENTITY_B], a novel [ENTITY_B] -selective inhibitor., a new selective inhibitor of acetylcholinesterase., a novel selective inhibitor of acetylcholinesterase., a new selective inhibitor of acetylcholinesterase., a novel selective inhibitor of acetylcholinesterase. huprine, a new selective inhibitor of nicotinamide",1,1
"(1) Inhibition of [ENTITY_A] by [ENTITY_B] : a comparison with the structurally related inhibitors [ENTITY_B] and rolipram., a peripheral benzodiazepine receptor antagonist, is currently under evaluation for the treatment of bipolar disorder.is a selective peripheral benzodiazepine receptor agonist., a peripheral benzodiazepine receptor antagonist, is under investigation for the treatment of Parkinson's disease., a peripheral benzodiazepine receptor antagonist, is under investigation for the treatment",1,1
"(R)-3-(3-hydroxypropoxy)-1-hydroxy-1-methanone ( [ENTITY_A], LY 344864) as a new antiestrogenic [ENTITY_B] inhibitor: selectivity for the ERα receptor., a new antiestrogenic [ENTITY_B] inhibitor., a new ER antagonist., a new proestrogen agonist with selectivity for the ERα receptor., a new proestrogen antagonist.",1,1
"inhibitors based on a [ENTITY_A] scaffold: Discovery of [ENTITY_B] - and enantiomers-resistant [ENTITY_B] inhibitors., a [ENTITY_B] (MAO) inhibitor that was discovered by our group in 2005, is an effective, selective MAO inhibitor., a second MAO inhibitor that was discovered in 2009 by our group, is a relatively milder MAO inhibitor., a third MAO inhibitor that was discovered in 2010 by our group, is a relatively weak MA",1,1
"(S)-3-(Aminomethyl)-7-(3-methoxy-4-methoxymethyl)-1-hydroxy-1-naphthalen-2-yl)-1-oxalic acid ( [ENTITY_A] ) inhibits [ENTITY_B], but does not inhibit enantioselective metabolism of benzol., a new inhibitor of enantioselective metabolism;, a new [ENTITY_B] inhibitor., a new COX-",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] : a comparison with the parent phenethylamides., [1'-hydroxy-2-phenylamino-n-propylamino-3-n-propyl-urea] ( [ENTITY_A] ), and 4-hydroxybenzyl-1-hydroxy-3-n-propyl-urea ( NS-113) were synthesized and evaluated for their inhibitory effects on human recombinant [ENTITY_B] (hRec)",1,1
"(+/-)-Tamsulosin effectively antagonizes the effects of [ENTITY_A], a selective [ENTITY_B] blocker, on arterial blood pressure, cardiac hypertrophy, collagen secretion, and fibroblast viability.inhibitors have been inactivated in the market by the European Food Safety Authority since 2004.and amrinone are potent and selective inhibitors of [ENTITY_B] (MAO)., a potent and selective COX-2 inhibitor, was introduced to the market in",1,1
"(R)-(-)-Tetrahydrocannabinol ( [ENTITY_A] ) induces apoptosis in HT22 hippocampal neurons through inhibition of [ENTITY_B] (Bax) and caspase-9 activation., the active metabolite of marijuana, is believed to exert its anti-inflammatory activity by blocking the [ENTITY_B] (Bax) and caspase-9 activation.may also inhibit neuronal death by inhibiting the mitochondrial apoptotic pathway., the active metabolite of marijuana",1,1
"This study investigated the effects of the [ENTITY_A] inhibitor [ENTITY_B] on HRV, BNP and N-ethylscopolamine levels.was tested in 18 healthy men.was administered to 9 healthy men in a double-blind manner., an inosine analogue, was also tested in 9 healthy men in a double-blind manner.was tested in 18 healthy men in a double-blind manner.was tested in 9 healthy men in a double-blind",1,1
"Inhibitors based on a [ENTITY_A] scaffold protect pancreatic beta-cells from oxidative stress induced by a [ENTITY_A] mutant., an [ENTITY_B] scaffold., a COX-inhibitor. gallate, a [ENTITY_B] scaffold. erodipine, a PDGFR-beta scaffold. erlotinib, an [ENTITY_B] scaffold. nomifensine, a COX-1/COX-3 inhibitor. erlotinib",1,1
"(1) Evaluation of the [ENTITY_A] -blocking activity of [ENTITY_B], ketoprofen and suprofen in vitro; (2) In vitro metabolism of ketoprofen, prozoxetine and suprofen in rats; (3) In vitro inhibition of prozoxetine and suprofen by [ENTITY_B] in rats; (4) The effect of ketoprofen on human CYP2B6 and CYP3A in vitro and in vivo; and (",1,1
"(+/-)-Tamsulosin effectively antagonizes the effects of [ENTITY_A], a selective COX-1 inhibitor, on prostatic hyperplasia in rats.blockers such as gliclazide have been recommended for the treatment of mild to moderate prostatic hyperplasia., a selective COX-2 inhibitor, has recently been approved for the treatment of benign prostatic obstruction., a selective [ENTITY_B] inhibitor, has been approved for the treatment",1,1
"inhibition of [ENTITY_A] with a new series of [ENTITY_B]., a new antihypertensive class of drugs., a new antihypertensive drug. Overview of the drug action. Impact of the drug on blood pressure and on vascular wall structure., a new antihypertensive drug. Overview of the drug action. Impact of the drug on blood pressure and on vascular wall structure., a new antihypertensive drug. Overview of the drug action. Impact of",1,1
"(R)-3-(Aminomethyl)-7-(5-hydroxy-3-methoxybenzyl)-1-hydroxy-1-oxo-3-nonyl-1-methanone) [ENTITY_A], a new inhibitor of [ENTITY_B] (MAO), shows high selectivity for the MAO active site., a new inhibitor of MAO., a new inhibitor of MAO., a new inhibitor of MA",1,1
The effects of [ENTITY_A] in the regulation of hepatic [ENTITY_B] protein levels: relevance to chronic ethanol hepatotoxicity.inhibition is a major mechanism of ethanol hepatotoxicity.inhibition is a major mechanism of ethanol hepatotoxicity.inhibition is a major mechanism of ethanol hepatotoxicity.inhibition is a major mechanism of ethanol hepatotoxicity.regulation is a major mechanism of ethanol hepatotoxicity.regulation is a major mechanism of,1,1
"(1) Evaluation of the inhibition of [ENTITY_A] - and CYP2J2-catalyzed 5-MeO-DMT metabolism by [ENTITY_B]., a selective 5-MeO-DMT metabolizer, was administered to rats and the resulting levels of brain 5-MeO-DMT and active metabolite 5-MeO-DMT-CYP2J2 reduced significantly (p < 0.01) within 24 h., a selective 5-Me",1,1
"This study explored the efficacy of [ENTITY_A], a [ENTITY_B] inhibitor, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.inhibitors, such as glipizide, glipizide X and rosuvastatin, have been shown to be effective in reducing body weight and serum triglyceride levels in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone",1,1
"(1) H-NMR studies of [ENTITY_A] inhibited human COX-1 by the selective [ENTITY_B] (Probenecid-C)., a potent [ENTITY_B] inhibitor, was used to define the binding site., a potent prodrug of probenecid-C (100 microM), was used to define the binding site., a selective COX-2 inhibitor (100 microM), was also incubated with human whole blood to determine whether the inhibition",1,1
"This study investigated the effect of the [ENTITY_A] inhibitor, [ENTITY_B], on renal water metabolism in rats with chronic renal failure induced by the combined administration of [ENTITY_B] and carbon monoxide.(0.1, 1 and 5 mg/kg/day) was administered to rats for 10 days to induce renal failure., N-acetylcysteine (NAC, 0.1 and 1 mg/kg/day) was administered to rats for 10 days to inhibit the [ENTITY_B]",1,1
"Inhibitors of [ENTITY_A] ( [ENTITY_B], ketoprofen, ketrolack, ketrolack), selective COX-1/COX-3 inhibitors (nimesulide, NS-389, NS-398, NS-499, NS-707, NS-101, NS-412, NS-521, NS-630), selective COX-2 inhibitors (nimesulide, NS-389, NS-398, NS-571, NS-701,",1,1
"The effect of a selective [ENTITY_A] inhibitor, [ENTITY_B], on renal function and urinary albumin excretion in normotensive rats.blockers are recommended first line treatment for hypertension and related cardiovascular diseases., a selective COX-1 inhibitor, is currently the only agent approved for treatment of ED.blockers are recommended as the first-line treatment of hypertension and related cardiovascular diseases.blockers have been evaluated and shown to have some serious risks.blockers",1,1
"This study explores the effects of selective [ENTITY_A] inhibitors ( [ENTITY_B], ketoprofen, diclofenac, carprofen, indomethacin, dorzolamide, meclofenamic acid, mexiletine and mexiletine H-7) on the metabolism of ketoprofen and its enantiomers, and on the enantioselective disposition of enantiomers., carprofen, indomet",1,1
"(R)-3-(Aminomethyl)-1-(3-methoxymethylphenyl)-4-hydroxy-1-methanone ( [ENTITY_A] ) is a selective, reversible inhibitor of [ENTITY_B] (MAO-B), which has been in use for the treatment of bipolar disorder., a selective inhibitor of MAO-C, was approved for the treatment of bipolar disorder in 2009., a nonselective irreversible inhibitor of MAO-A",1,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] -mediated cholesterol transport in pig proximal tubular epithelial LLC-PK1 cells.inhibitors [ENTITY_B] and rosuvastatin reduce the transport of total and de novo cholesterol in pig proximal tubular epithelial LLC-PK1 cells in parallel with their effects on phospholipids, indicating a possible role for these compounds in the prevention and treatment of hypercholesterolemia.inhibitors rosu",1,1
"(1) Synthesis, structure-activity relationship and antitumor activity of [ENTITY_A] -based [ENTITY_A] inhibitors.2) Discovery of a potent oral multi-targeted [ENTITY_B] inhibitor.3) Discovery of a potent and selective ERK inhibitor as a topical drug for alopecia.( 1) Synthesis, structure-activity relationship and antitumor activity of 1a.( 1b) Discovery of a potent oral multi-targeted mitogen-",1,1
"(1)H NMR study of [ENTITY_A] (YLE-113): optimization of a potent [ENTITY_B] inhibitor using a combination of X-ray photoelectron spectroscopy (XPS) and pharmacophores., a potent irreversible inhibitor of the [ENTITY_B] used to treat prostaglandin E2 receptor-associated dysmenorrhea, has recently been approved for the treatment of dysmenorrhea associated with dysmenorrhea as a side effect., which has been",1,1
"inhibitors based on a [ENTITY_A] scaffold for the treatment of cancer cell invasion., an [ENTITY_B] inhibitor from [ENTITY_B]., an oxaliplatin analogue from mitoxantrone., an erlotinib analogue from [ENTITY_B]., a nimesulide analogue from NS-389., a sunitinib analogue from Tarceva. huprine, an etodolac analogue from LY 344864. huprine",1,1
"This study investigated the ability of [ENTITY_A], a [ENTITY_B] inhibitor currently in phase 3 clinical development, to attenuate the effects of the neonicotinoid imidacloprid on the metabolism of dextromethorphan, an active ingredient in acetylcholine-reduced products.(50-100 microM), ketamine (50-100 microM), nialamide (50 microM), and ketamine/nialamide (100 microM) were",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-3-nonyl)adenosine ( [ENTITY_A] ) is a novel orally bioavailable [ENTITY_B] inhibitor that has demonstrated activity in several cancer cell lines and in early-phase clinical trials of breast cancer., a metabolite of etorphine, is active in a variety of cancer cell lines but has not been tested with SK",1,1
"inhibitors based on a [ENTITY_A] scaffold., an irreversible [ENTITY_B] blocker for cancer therapy., a non-selective irreversible diuretic for the treatment of hyperphosphatemia., a selective irreversible inhibitor of the sodium-channel.inhibitors.inhibitors., a selective irreversible inhibitor of alpha1beta2 and alpha3 subunits., a selective irreversible inhibitor of the alpha1 subunit.
The use of",1,1
"(R)-(+)-Epicatechin-3-gallate attenuates [ENTITY_A] -induced NF-κB activation and inhibits the expression of [ENTITY_B] pathway.inhibition by [ENTITY_B] inhibitors.inhibition by statins.inhibition by statins.blockers.blockers.
Structural basis for the selective inhibition of [ENTITY_A] by the novel [ENTITY_B] derivatives.inhibition by statins.blockers.
",1,1
"The effect of the synthetic [ENTITY_A] inhibitors [ENTITY_B] (LPV), milrinone (MIL), dibucaine (DBU) and nimesulide (NIM), on the gastric acid secretion was investigated on rabbit, pig and human subjects.inhibitors (Imbruvica(I), Imbuvica(II), Nexavar(II), Nimesulide(NSD)) were synthesized and tested for their effect on the gast",1,1
"Inhibition of the [ENTITY_A] /MEKK1/JNK pathway sensitizes human prostate cancer cells to [ENTITY_B]., a [ENTITY_B] inhibitor, delays progression of human prostate cancer., a radiomethographic agent, delays progression of human prostate cancer.blockers for treatment of metastases., a radiomethographic agent, delays progression of human prostate cancer., a chemical that inhibits [ENTITY_B], delays progression of human prostate cancer.blocks the phosph",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetics and pharmacodynamics of darunavir- and cobicistat-boosted HIV-1 particles., a [ENTITY_B] inhibitor that binds to the CD3 receptor, may affect the pharmacokinetic and pharmacodynamics of darunavir- and cobicistat-boosted HIV-1 particles., a leading antiretroviral agent for treatment of chronic hepatitis C",1,1
"(R)-(-)-Tamsulosin ( [ENTITY_A] inhibitor), an inhibitor of the [ENTITY_B] (MAO) but not of the MAO-B enzyme, inhibits the activity of both enzymes.inhibitor, [ENTITY_B], is not effective against either MAO or MAO-B., a selective inhibitor of the MAO and MAO-B, inhibits the activity of both enzymes. hCES1, hCES2 and hCES",1,1
"Inhibitors of [ENTITY_A] /EGFR kinases protect against chemotherapy-induced apoptosis in lung cancer cells., an [ENTITY_B] inhibitor with potent activity in vitro, showed significant activity in vivo in the Phase III trial of AG012957 in non-small lung cancer (NSCLC) patients., an EGFR kinase inhibitor, has completed Phase III clinical trials and is currently being developed for early-phase clinical trials., an [ENTITY_B] inhibitor with moderate",1,1
"In vitro metabolism of the novel orally bioavailable [ENTITY_A] inhibitor [ENTITY_B]., a potent, selective inhibitor of [ENTITY_B], is in development for treatment of type 2 diabetes., a novel orally bioavailable, selective inhibitor of diabetes-associated phosphodiesterase 12, is in development for the treatment of type 2 diabetes., a novel orally bioavailable, selective inhibitor of the enzyme acetyl-CoA carboxylase, is in development for the treatment of type 2",1,1
"Inhibition of [ENTITY_A] with [ENTITY_B]., a new class of [ENTITY_B]., a new inhibitor of [ENTITY_B]., a new inhibitor of COX-1., a new inhibitor of COX-3. View, another inhibitor of COX-2.
Structural mechanism of the inhibition of the rat enzyme cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP2D6 by [ENTITY_B], bromfenac and n",1,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] - and OATP8-, OATP-B- and OATP-A-mediated glucose transport: relevance to the treatment of type 2 diabetes., a new inhibitor of the small intestine, was recently reported to have an inhibitory effect on the uptake of substrates and cofactors into the cytosol, including OCTN2, OCTN3, OCTN4, OCTN5, NUTC2 and",1,1
"Inhibition of [ENTITY_A] (FNTA) by [ENTITY_B]., a key enzyme of the de novo pyrimidine synthesis, is inhibited by [ENTITY_B], but not by nimesulide., which synthesizes 5-fluoro-2'-deoxyuridine, is not inhibited by nimesulide., which synthesizes 5-fluoro-2'-deoxyuridine and 5-fluoro-2'-deoxyuridine and 5-flu",1,1
"inhibitors based on a [ENTITY_A] scaffold for potential use in cancer therapy., an [ENTITY_B] (ABL) inhibitor, was discovered through a combination of medicinal and combinatorial chemistry approaches., a COX-1 inhibitor, was discovered through a combination of medicinal and combinatorial chemistry approaches., a COX-3 inhibitor, was discovered through a combination of medicinal and combinatorial chemistry approaches., an ABL inhibitor, was discovered through a combination",1,1
"In vitro metabolism of the novel [ENTITY_A] derivator, [ENTITY_B]., an orally bioavailable [ENTITY_B] (COX-1) inhibitor., an orally bioavailable COX-2 inhibitor., both as a selective inhibitor of [ENTITY_B] (COX-1) and COX-3., an oral multi-targeted [ENTITY_B] (COX-2) inhibitor., both as a selective COX-2 inhibitor and an inhibitor of COX-1.",1,1
"This study explored the efficacy and safety of [ENTITY_A] (BMS-354825) - a novel oral multi-targeted [ENTITY_B] inhibitor, in patients with clear cell renal cancers., which inhibits [ENTITY_B], AR and VEGFR2, is a novel oral multi-targetedVEGFR inhibitor that has activity against all three EGFR isoforms in head and neck cancer., which inhibits AR and VEGFR2, is a novel oral multi-target",1,1
"(1) H nuclear magnetic resonance study of the inhibition of [ENTITY_A] by [ENTITY_B]., an [ENTITY_B] inhibitor., an ACE inhibitor., a COX-2 inhibitor., a PDE4 inhibitor. ainhibitor., an ARB inhibitor. a rosuvastatin analogue. a rosuvastatin analog. a [ENTITY_B] inhibitor., an ACE inhibitor. rosuvastatin, a PDE3 inhibitor",1,1
"(R)-3-(Aminomethyl)-7-(2-hydroxypropoxy)-1-hydroxy-3-phenyl-1H-pyrazol-1-yl-hydrazine-1-carboxamide ( [ENTITY_A] ) is a potent [ENTITY_B] (V600E) inhibitor.blocker (BMS-354825, Nexavar) is a novel oral [ENTITY_B] (V600E) inhibitor that has not been evaluated in Japan.",1,1
"In vitro and in vivo studies support a unique mode of inhibition of [ENTITY_A] activity by [ENTITY_B]., a selective [ENTITY_B] (MAO) inhibitor, is currently in phase 3 clinical development for the treatment of Parkinson's disease., which is in phase 2 clinical development for the treatment of Alzheimer's disease, is currently in phase 3 clinical development for the treatment of Parkinson's disease., which is in phase 2 clinical development for the treatment of Alzheimer's disease, is not available for FDA",1,1
"(1) Evaluation of [ENTITY_A] inhibition of the [ENTITY_B] (COX-1) by [ENTITY_B] and puromycin analogues., [2-(2-Methoxy-phenyl)-5-methoxybenzylhydrazin-2-yl-urea] (MPBU), and puromycin analogues were evaluated for their ability to inhibit the COX-1 enzyme., [2-(2-Methoxy-phenyl)-5",1,1
"This paper presents [ENTITY_A], the first in a new class of noncyclic nucleotide [ENTITY_B] inhibitors with longer and more selective action and with manageable adverse effects.(N-([1-(2-methoxytryptamine)]phenyl) ethanesulfonamide, 100 microM) is a novel, selective inhibitor of the [ENTITY_B] used to treat Attention Deficit/Hyperactivity Disorder.(N-([1-(2-methoxytryptamine",1,1
"Inhibitors based on the [ENTITY_A] scaffold for potential treatment of Alzheimer's disease: [ENTITY_B] inhibitors, galantamine and rivastigmine.Inhibitors: galantamine and rivastigmine.inhibitors, [ENTITY_B] and rivastigmine.Inhibitors: rivastigmine and glivec.
The effect of the combined treatment with sulpiride and [ENTITY_B] on the pharmacokinetics and pharmac",1,1
"This study evaluates the effect of the [ENTITY_A] inhibitors [ENTITY_B] and apixaban on the pharmacokinetics and pharmacodynamics of darunavir (DRV) in patients on CAPD., a [ENTITY_B] inhibitor, and nimesulide, a NS3-inhibitor that binds to the NS5A subunit, were evaluated in a double-blind, 2-period, 3-sequence crossover study in 16 healthy men receiving single doses of 1000 or",1,1
"The effect of [ENTITY_A] (VP-16) inhibitors on the [ENTITY_B] /MEKK1/JNK pathway in Jurkat cells., a top inhibitor of the phosphatidylinositol 3-kinases (PI3K) Akt, has been implicated in the pathogenesis of leukemia.blocks the [ENTITY_B] /MEKK1/JNK pathway., a top inhibitor of the mitogen activated protein (MAP) kinases Akt, has been",1,1
"In vitro metabolism of (diaryl)ethoxyphenylacetic acid and (+/-)-(-)-(R)-(+)-(+)-3-(1-hydroxypropoxy)-1-hydroxybenzyloxyphenylhydrazine, [ENTITY_A] inhibitors: a novel class of potent and selective [ENTITY_B] inhibitors., (+/-)-(-)-(-)-3-hydroxybenzyloxyphenylhydrazine, and",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] : comparison with enalapril., an ultra-short-acting [ENTITY_B] (BNP) inhibitor, has been in clinical development for years., an ultra-short-acting coenzyme A (CoA) inhibitor, is undergoing early phase clinical testing., an antiatherogenic metabolite of nitric oxide, has also been evaluated in several animal models as an antiatherogenic agent., enalapril",1,1
inhibitors based on a [ENTITY_A] scaffold: Discovery of [ENTITY_B] - and omapatrilat-derived [ENTITY_B] -based [ENTITY_B] -blocking drugs.inhibitors based on a [ENTITY_B] scaffold.- and omapatrilat-derived potentiators of human ether-a-go-related gene product 1 (HERG) expression.- and omapatrilat-derived potentiators of HERG expression.- and omap,1,1
"This article examines the use of the selective [ENTITY_A] inhibitor [ENTITY_B] (CPT-11, 100 microM) to determine the extent of leukotriene D(4)-induced inflammation in a mouse model., a dual anti-inflammatory drug that inhibits neutrophils and [ENTITY_B], is effective in the treatment of rheumatoid arthritis and the gastrointestinal and skin diseases.Inhibitors are recommended if neutrophils are involved in the disease and/or neutrophil",1,1
"Inhibitors based upon a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B]., a potent and specific inhibitor of platelet COX-1, was synthesized and tested in vitro as a potential antidepressant., a potent and specific inhibitor of platelet COX-2, was synthesized and tested in vitro as a potential smoking cessation agent., a potent and specific inhibitor of cyclo-oxygenase 2 (COX-2), was synthesized",1,1
"(S)-3-(Aminomethyl)-7-(3-methoxymethyl)-1-(4-hydroxypropoxy)-1-hydroxy-3-nonyl)-1-hydroxy-2,1-dihydro-1,3-dihydro-2,1-benzoxaborole ( [ENTITY_A] ) is a novel boron-containing antibiotic that inhibits [ENTITY_B], which catalyses the first committed step in polyamine",1,1
"Inhibitors of [ENTITY_A] /STAT3 signaling disrupt T-cell signaling and suppress tumor growth in lymphoid malignancies.inhibitors have significantly better activity in lymphoid malignancies.(SCD2257) and erlotinib (CI-1033) are novel, multitargeted [ENTITY_B] inhibitors that selectively block the intracellular tyrosine kinases STAT3, STAT5, and STAT6 but not STAT3/STAT5 signaling",1,1
"(R)-Phenylalanine-induced increase of [ENTITY_A] (LQT2), a marker of arrhythmias, was reversed by [ENTITY_B] ( [ENTITY_B] ), which inhibits [ENTITY_B] (QT2)., a marker of ventricular tachycardia/ventricular fibrillation, was also increased by r-phenylalanine., a marker of ventricular tachycardia, was not increased by r-phenylalanine., a marker of",1,1
"The effect of the synthetic [ENTITY_A] (BMS-354825) on the pharmacokinetics and pharmacodynamics of [ENTITY_B], a novel oral multi-targeted [ENTITY_B] inhibitor., a novel oral multi-targeted ceftazidime., a new oral multi-targeted ceftazidime., a new oral multi-targeted ceftazidime., a novel oral multi-targeted ceftazidime.",1,1
"(R)-3-(Aminomethyl)-7-(2-hydroxypropoxy)-1-hydroxy-1-methyl-1-propanedihydrazine-2,1-diol, 4-acetamido) ( [ENTITY_A] ) derivatives as potent [ENTITY_B] (Aβ) inhibitor and [ENTITY_B] inhibitor with mild cytotoxicity.analogues as potential anti Alzheimer's drug candidates.blockers for the treatment of Alzheimer's disease",1,1
"In vitro metabolism of the novel [ENTITY_A] (COX-2)-derived [ENTITY_B] inhibitor [ENTITY_B].inhibitors.inhibitors.inhibitors.inhibitors.inhibitors.
Structural basis for selective inhibition of the [ENTITY_B] by the novel [ENTITY_B] inhibitors ibuprofen and suprofen., ibuprofen, and suprofen are selective inhibitors of the enzyme cytochrome P450 (CYP",1,1
"(1)H NMR-Bis(DOTA-DOTA) study of the inhibition of [ENTITY_A] (DOTA-DOTA) of the enzyme [ENTITY_B] (DOTA-DOTA) of the deoxyribonucleotide reductase (DNR) in rat plasma., a DOTA analogue, is a novel inhibitor of the enzyme., a DOTA analogue, is a novel inhibitor of the enzyme., a DOTA analogue,",1,1
"inhibitors based on a [ENTITY_A] scaffold., a new orally bioavailable [ENTITY_B] inhibitor, inhibits cancer cell invasion, angiogenesis, and invasion-induced cell death., a selective COX-2 inhibitor, inhibits cancer cell invasion, angiogenesis, and invasion-induced cell death., a new [ENTITY_B] (CYP1A2, 2B1) inhibitor, inhibits cancer cell invasion and angiogenesis as well as cancer cell invasion-induced",1,1
"inhibitors based on a [ENTITY_A] scaffold for the targeted inhibition of [ENTITY_B]., a potent, dipeptide [ENTITY_B] inhibitor, was synthesized and shown to inhibit platelet aggregation in vitro and in vivo in a manner consistent with competitive inhibition on the platelet PDE3 and a competitive K(I) for its substrate., a nonpeptide, potent, dipeptide COXIB inhibitor, was synthesized and shown to inhibit both CO",1,1
"This study evaluates the efficacy of [ENTITY_A] (an [ENTITY_B] inhibitor) in the treatment of experimental colitis induced by [ENTITY_B] administration., a gastrointestinal prokinetic agent used to treat gastritis and to relieve the symptoms of gastrointestinal disorders, was found to have proinflammatory effects, but the precise mechanisms involved in their proinflammatory action remain unclear., a gastrointestinal prokinetic agent, was found to have proinflammatory effects, but the precise mechanisms involved in their proinflammatory action remain",1,1
"inhibitors based on the [ENTITY_A] scaffold for cancer therapy., a new orally bioavailable [ENTITY_B] inhibitor for cancer therapy., a new orally bioavailable COX-2 inhibitor for cancer therapy., a novel nonselective noreductase inhibitor for cancer therapy., a selective COX-1 inhibitor for cancer therapy.
Structural basis for inhibition of human COX-1 by novel [ENTITY_B] (SC-56034)-based analogues.",1,1
"Inhibition of [ENTITY_A] with [ENTITY_B]., a novel [ENTITY_B] /STAT3 inhibitor, delays tumor growth in a mouse xenograft model and inhibits growth of human lung cancer cell lines., a selective STAT3 inhibitor, delays growth in a mouse xenograft model and inhibits growth of human lung cancer cell lines., an inhibitor of phosphoinositide 3-kinases, delays growth in a mouse xenograft model and inhibits growth of human lung cancer cell lines.",1,1
"(R)- and (S)-3-(Aminomethyl)-6-(2-hydroxypropoxy)-1-hydroxy-1-methylanthraquinone ( [ENTITY_A] ) are reversible competitive inhibitors of [ENTITY_B] ( [ENTITY_B], nicotinamide adenine dinucleotide) and acetylcholinesterase ( [ENTITY_B], acetylcholinesterase)., nicotinamide adenine dinucleotide, and acetylcholinester",1,1
"Inhibition of [ENTITY_A] (MAO) by [ENTITY_B] and puromycin: relevance to bipolar disorder., an inhibitor of monoamine oxidase type B (MAO-B), is a treatment for bipolar disorder, but also inhibits 5-hydroxytryptamine (5-HT) and dopamine (DA) transporters, including those involved in neurotransmission, including MAO-A and MAO-B., an inhibitor of monoamine oxidase type A",1,1
"(S)-3-(Aminomethyl)-5-(2-methoxy-phenyl)-7-(3-phenanthrenyl)-1H-pyrazol-1-yl)-2-hydroxy-3-nonyl-hydrazine-2-one ( [ENTITY_A] ) is a potent, orally active, irreversible, [ENTITY_B] inhibitor that selectively inhibits [ENTITY_B] (MAO) but has limited activity against catecholamine-transaminase (MA",1,1
"inhibitors based on a [ENTITY_A] scaffold as a new strategy to treat chronic myelogenous leukaemia., a [ENTITY_B] /STAT3 inhibitor, showed potent growth-inhibitory activity and manageable adverse effects, and was approved for the treatment of MTC in imatinib-acquired resistance., a cyclin D1 inhibitor, showed good activity and manageable adverse effects, and was approved for the treatment of MTC in chronic myelogenous leukaemia",1,1
"(1)H nuclear magnetic resonance (NMR) analysis of [ENTITY_A], the purified prolyl hydroxamic acid dehydrogenase ( [ENTITY_B] ) and the enantioselective racemic product [ENTITY_B] progravide.-related encephalitis is an infrequent, chronic inflammatory disease caused by a specific group of [ENTITY_B] prokinetics that are metabolized by cytochrome P450 enzymes to the active form, enantiomeric hydroxamic acid dehydrogenase-pro",1,1
"The effect of the [ENTITY_A] /HER2 kinase inhibitor (KI)-gene combination paclitaxel plus trastuzumab on HER2-overexpressing lung AD cells: suppressive potential of the paclitaxel-gene combination., an oral [ENTITY_B] inhibitor that targets HER2 and HER3, has been demonstrated to have activity in early- and middle-stage lung cancer, and has recently been approved for use in breast cancer and pancreatic",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., an antiatherosclerotic drug, reduces the risk of death in patients with diabetes., a selective inhibitor of platelet aggregation, reduces the risk of death in patients with diabetes., a drug that targets a specific isoform of collagen, reduces the risk of death in patients with diabetes mellitus., an antiatherosclerotic drug, reduces the risk of death in patients with type 2 diabetes mellitus.,",1,1
"inhibitors based upon a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B]., a new orally bioavailable [ENTITY_B] inhibitor for cancer therapy., a new orally bioavailable COX-inhibitor., a new nonsteroidal anti-inflammatory drug., a new [ENTITY_B] inhibitor., a new nonsteroidal anti-inflammatory drug.
[Prevalence and risk factors for non-Hodgkin lymphoma in the elderly",1,1
"(R)-3-(Aminomethyl)-7-(2-hydroxypropoxy)-1-hydroxy-1-methyl-1-phenyl-3-naphthalen-2-yl-hydrazide) [ENTITY_A] ( [ENTITY_B], 1), a novel, orally active [ENTITY_B] (clinigram) inhibitor against SRC, inhibited the proliferation, migration, and invasion of MDA-MB-231 cells in a dose-dependent manner, as well as inhibited",1,1
"(1-methanone), a potent selective [ENTITY_A] inhibitor, inhibits the metabolism of DXM in rats., a selective COX-1 inhibitor., a selective COX-2 inhibitor., a dual [ENTITY_B] /COX inhibitor., a nonselective [ENTITY_B] inhibitor., a selective 5-LOX inhibitor.(1-methanone) (MMA), a potent selective COX inhibitor.",1,1
"(R)-(-)-3-butanediol-11-al (RBD11-AL), a new inhibitor of [ENTITY_A] (MMP-2) with mild inhibition of MMP-9, was evaluated for its in vitro [ENTITY_B] tyrosine kinase inhibition and in vivo anti-heart-failure activity in a rat model./STAT3 signaling pathway contributes to cardiac fibroblast survival in response to cardiomyocyte apoptosis induction./STAT3",1,1
"(R)-(-)-3-(2-hydroxypropoxy)butoxycyclic nucleotides ( [ENTITY_A], ketoconazole and ketrolack) protect DNA against 5-fluorouracil-induced oxidation and inhibit [ENTITY_B] activity., an antimetabolite that inhibits DNA synthesis through suppression of thymidylate synthase, has recently been introduced to treat malignancies and disorders caused by activated forms of the enzyme., an antimetabol",1,1
"Inhibition of [ENTITY_A] with a new series of [ENTITY_B] derivatives.(1), [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (2), [1-(2-methoxy-phenyl)-3-naphthalen-4-yl-urea] (3), [1-(2-methoxy-phenyl)-3-naphthalen-5-yl",1,1
"(R)-(+)-3-(Aminomethyl)-1-hydroxy-4-methanone ( [ENTITY_A] ) induces apoptosis in HT-29 and DLD-1 cells via downregulation of [ENTITY_B]., the prototypical [ENTITY_B] inhibitor, does not cause apoptosis in HT-29 and DLD-1 cells., a selective COX-2 inhibitor, causes apoptosis in HT-29 cells but not in HT-29/",1,1
"The effect of [ENTITY_A] (BMS-354825) is blocked by the selective COX-2 inhibitor indomethacin., a [ENTITY_B] inhibitor, has been inactivated in several studies., a selective COX-1 inhibitor, has been tested extensively and has proven to be at least as effective as indomethacin in some studies., a mixed COX-2/COX-1 inhibitor, has been inactivated in several",1,1
"(R)-(+)-Tamsulosin improved the activity of [ENTITY_A] (the reference [ENTITY_B] inhibitor) in patients on CAPD., a selective inhibitor of the [ENTITY_B] (MAO-B)., an MAO-A inhibitor., another MAO-B inhibitor., an MAO-A/B inhibitor., a mixed MAO-A/B inhibitor. niflumic acid, a selective MAO-C",1,1
"In vitro and in vivo evaluation of novel [ENTITY_A] derivatives as potent [ENTITY_B] inhibitors.is a potent inhibitor of acetylcholinesterase that causes neurological and psychiatric diseases in high prevalence among those suffering from dementia., a synthetic [ENTITY_B] inhibitor, is in clinical development as a treatment for Alzheimer's disease and related dementias., a synthetic boronate, inhibits only acetylcholinesterase in vitro., a novel d",1,1
"inhibitors based on a [ENTITY_A] scaffold for cancer therapy., a [ENTITY_B] (BMS-354825) with selectivity for [ENTITY_B], has completed Phase I clinical trials., a moxidectin analogue, is in early phase II trials., a tacrine analogue, is in Phase II trials., a fibrinogen analogue, is in Phase III trials., another fibrinogen analogue, has completed Phase I",1,1
inhibition of [ENTITY_A] (LTA4-mediated BSP uptake) with [ENTITY_B] blocks the BSP-mediated Bcl-xL interaction.inhibition of BSP transport by the BSP receptor LTA4.blocks the BSP-mediated Bcl-xL interaction.binding the BSP receptor LTA4.blocks the BSP-mediated Bcl-xL interaction.interactions with and between BSP and Bcl-xL,1,1
"(Z)-3-hydroxy-3-(E)-3-(E)-3'-hydroxypropoxy-1-methylanthrapropan-1-yl)-1-hydroxy-1-methanone ( [ENTITY_A] ), a novel [ENTITY_B] (Z-HPP) that binds to and inhibits [ENTITY_B] K(+) channels, was evaluated in vitro for its ability to attenuate the Na(+) current (I(Na)), its dependence on Nav1.5 and",1,1
"This study evaluates the effects of [ENTITY_A], a selective inhibitor of [ENTITY_B] (MAO-B), on the activity and MAO-B substrate, 5-MeO-DMT., a selective MAO-B inhibitor, decreases the activity of 5-MeO-DMT in vivo, but not in vitro., a selective MAO-B substrate, decreases 5-MeO-DMT in vitro, but not in vivo.inhibitors decrease",1,1
"Inhibition of [ENTITY_A] /COX-1 by [ENTITY_B] in vitro., the active metabolite of acetaminophen, exhibits more potent [ENTITY_B] -inhibitory activity than the parent drug., the active metabolite of acetaminophen, exhibits more potent COX-2-inhibitory activity than the parent drug., the active metabolite of acetaminophen, exhibits more potent COX-1-inhibitory activity than the parent drug., the active",1,1
"(R)-(+)-Tamsulosin effectively antagonizes the effects of the dual [ENTITY_A] /RhoA inhibitor [ENTITY_B], and it appears to be a better inhibitor of the RhoA pathway., a [ENTITY_B] /RhoA inhibitor., a RhoA inhibitor., a RhoA inhibitor., a RhoA inhibitor., a RhoA inhibitor.
[Effect of the selective inhibitor of [ENTITY_B] K",1,1
in vitro and in vivo evaluation of [ENTITY_A] inhibition of lipopolysaccharide-induced NO production in murine primary splenocytes.is a potent synthetic [ENTITY_B] inhibitor that is currently in phase III clinical development for the treatment of chronic and inflammatory diseases.inhibition of lipopolysaccharide (LPS)-induced NO production in murine primary splenocytes was investigated in vitro and in vivo.inhibition of LPS-induced NO production in,1,1
"(R)- and (S)-3-hydroxybenzylhydrazine ( [ENTITY_A] ) are potent [ENTITY_B] inhibitors with mild to moderate selectivity for PDE3 and PDE4, but with low micromolar to nanomolar Km values.analogues as potent PDE3 inhibitors with mild to moderate selectivity for PDE4.analogues as potent PDE3 inhibitors with moderate selectivity for PDE3.an",1,1
"Inhibition of [ENTITY_A] (FNTA) by [ENTITY_B] blocks migration and invasion of MDA-MB-231 cells.inhibition is mediated through the activation of Akt.inhibition is not mediated through Akt.inhibition is mediated through the activation of phosphoinositide 3-kinase., a component of the mitochondrial fusion complex, inhibits MMP-2 activity in MDA-MB-231 cells., a component of the mitochondrial fusion",1,1
"The effect of inhibition of [ENTITY_A] by [ENTITY_B]., a [ENTITY_B] blocker used to relieve pain in osteoarthritis, also inhibits the activity of the proteasome and is a useful drug for the treatment of inflammatory bowel disease., a selective COX-1 inhibitor used to relieve pain in osteoarthritis, also inhibits the activity of the proteasome and is a useful drug for the treatment of inflammatory bowel disease., a selective COX-2 inhibitor,",1,1
"Inhibitors based on [ENTITY_A] (Aibogaine, Gleevec, and Ambraparin): a novel class of potent and selective [ENTITY_B] inhibitors., a potent and selective irreversible inhibitor of [ENTITY_B] (MAO) that catalyses the first committed step in monoamine synthesis, was recently described in an animal study as a potential antidepressant., a potent and selective irreversible inhibitor of MAO that catalyses the first committed step in monoamine synthesis, was recently described",1,1
"(1) Evaluation of the [ENTITY_A] inhibition of [ENTITY_B] in vitro by [ENTITY_B].inhibitors (Iressa, Iressa(®), and Leflunomide) are potent synthetic [ENTITY_B] inhibitors that have been in clinical use for many years.Iressa (Leflunomide) and Iressa(®) are potent synthetic boron-containing Iressa inhibitors that have been in clinical use for many years.",1,1
"(1)H-MRS of [ENTITY_A], a novel orally active [ENTITY_B] inhibitor., 1,5-diarylpyrrole [ENTITY_B] and 1-hydroxy-2,3-diarylpyrrole NS-398 inhibit platelet aggregation.and NS-398 inhibit platelet aggregation in vitro., 1-hydroxymethyl-2,3-diarylpyrrole NS-398, and 1-hydroxy-2,3",1,1
"(1) H- and (2) H-isothiocyanide-based [ENTITY_A] inhibitors: Discovery of a novel class of potent [ENTITY_B] -based COX-2 inhibitors with longer and safer dosing profiles.( 1,1'-biphenyl-2-yl)benzoxaborole (BZB) and BZD6474 are potent irreversible COX-2 inhibitors with a 50% inhibitory concentration (IC(50)) in",1,1
"The anti-inflammatory actions of [ENTITY_A] in a rabbit model., a selective norepinephrine reuptake inhibitor., also known as cinchoninic acid, is a dietary flavonoid that is reported to suppress inflammation by inhibiting [ENTITY_B]., also known as naproxen, is a selective nonsteroidal anti-inflammatory drug (NSAID) and is used to relieve pain in many disorders., also known as rofecoxib, is an",1,1
"inhibitors based on [ENTITY_A] : a structural basis for the [ENTITY_B] inhibition of the COX-1 enzyme., a new [ENTITY_B] inhibitor., a new nordihydroguaiaretic acid (NDGA) inhibitor., a new fukutinone inhibitor., a new nordihydroguaiaretic acid (NDGA) metabolite., a new indanyloxyacetic acid (IDA",1,1
(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-3-methylanthraquinone) [ENTITY_A] analogues as potent [ENTITY_B] (V600E) inhibitors: Discovery of a novel class of potent [ENTITY_B] inhibitors with favorable pharmacokinetics and in vivo efficacy in suppressing cancer cell growth.inhibitors of [ENTITY_B]...in,1,1
"(R)-(-)-Epicatechin gallate inhibits [ENTITY_A] expression in human lung AD cells., a nonselective inhibitor of [ENTITY_B]., a selective inhibitor of PDE3., a dual inhibitor of PDE1 and PDE3., a selective inhibitor of PDE1 and PDE3., a selective inhibitor of PDE3 and PDE4., a selective inhibitor of PDE3 and PDE5., a",1,1
"(R)-(-)-3-hydroxybenzylhydrazine ( [ENTITY_A] ) and (-)-3-hydroxybenzylhydrazine (N-propargylhydrazine) inhibit recombinant [ENTITY_B] (Bsep) with similar potency., a [ENTITY_B] inhibitor, and (+)-3-hydroxybenzylhydrazine, a N-propargylhydrazine, are both potent and specific inhibitors of recombinant Bsep",1,1
"inhibitors based on [ENTITY_A] scaffold for the treatment of inflammatory bowel disease.(IMI-774, Nexavar) and rolipram (Lamisil) are well-known [ENTITY_B] inhibitors with favorable safety profiles., a new small molecule [ENTITY_B] inhibitor with favorable safety profiles, has been recently approved for the treatment of inflammatory bowel diseases.(IMI-1033, Novartis) is a small molecule inhibitor of [ENTITY_B]",1,1
"(R)-3-(Aminomethyl)-7-(4-methoxymethylphenyl)-3-nonyl-1-hydroxybenzyl)-1-methanone ( [ENTITY_A] ) is a potent and specific inhibitor of [ENTITY_B] (MAO-B)., 3-(Aminomethyl)-7-(4-methoxymethylphenyl)-3-nonyl-1-hydroxybenzyl)-1-",1,1
"In vitro inhibitory effects of the [ENTITY_A] inhibitor [ENTITY_B] on the enzymatic activities of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP2D6.inhibits the activities of CYP2C9, CYP2C19, and CYP2D6.inhibits the activities of CYP3A4 and CYP3A5.inhibits the enzym",1,1
"The role of [ENTITY_A], a [ENTITY_B] inhibitor, in prostatic carcinogenesis: a meta-analysis.inhibition may prevent prostatic carcinogenesis., a selective COX-1 inhibitor, may prevent prostatic carcinogenesis., a selective COX-2 inhibitor, may prevent prostatic carcinogenesis., a selective COX-3 inhibitor, may prevent prostatic carcinogenesis., a selective COX-4 inhibitor, may prevent prostatic",1,1
"inhibitors based on a [ENTITY_A] scaffold for the treatment of Alzheimer's disease., a potent [ENTITY_B] inhibitor, has recently been approved for the treatment of mild to moderate Alzheimer's disease in Japan., a more selective inhibitor of amyloid beta (Abeta) peptides, has been approved for the treatment of mild to moderate Alzheimer's disease in Japan., a less potent inhibitor of Abeta, has not yet been approved for the treatment of mild to",1,1
"Inhibition of [ENTITY_A] (MAO-B) and catecholamines with [ENTITY_B] blocks the vasoconstrictor action of phenytoin., a selective inhibitor of monoamine oxidase-B (MAO-B), and nordihydroguaiaretic acid (NDGA) inhibit the nitric oxide (NO) and dopamine (DA) transporters, respectively., a potent and specific inhibitor of catecholamines, and n",1,1
"(R)-(+)-Tamsulosin effectively antagonizes the effects of [ENTITY_A], clarithromycin, and ciprofloxacin on [ENTITY_B] in vitro., a [ENTITY_B] inhibitor currently under investigation for the treatment of rheumatoid arthritis., a clarithromycin inactivator currently under investigation for the treatment of rheumatoid arthritis., a tamsulosin activator currently under investigation for the treatment of",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on endothelial dysfunction induced by high fructose diet in rats., norepinephrine, and epinephrine have been reported to suppress [ENTITY_B], but it is still unclear whether a selective inhibition of norepinephrine is sufficient to attenuate endothelial dysfunction., norepinephrine, and epinephrine have been reported to suppress expression of vascular endothelial growth factor (VEGF) in vascular lesions, but it is still unclear whether",1,1
(R)-Phenylalanine- and [ENTITY_A] -induced reductions in [ENTITY_B] protein levels in human and rat plasma.inhibition by [ENTITY_B].(R)-Phenylalanine- and ethylphenidate-induced reductions in human and rat plasma [ENTITY_B] level are not dependent on hepatic microsomes.suppression by nimesulide.and nimesulide-induced reductions in human and rat plasma glutamate levels are not dependent on hep,1,1
"(1)H-NMR studies of the inhibition of [ENTITY_A], a [ENTITY_B] inhibitor, by a series of phenytoin analogues., a phenytoin agonist., a selective inhibitor of acetylcholinesterase, and a potential cholinergic agonist., a selective inhibitor of acetylcholinesterase., a selective cholinesterase inhibitor., a selective inhibitor of",1,1
"(R)- and (S)-N-propargyl-1-(R)-7-hydroxy-4-methoxy-3-nonyl-4-methoxybenzoyl)benzoxazinyl-4-phenyl-hydrazine ( [ENTITY_A] ) is a novel [ENTITY_B] (BMS-354825) selective inhibitor that inhibits the [ENTITY_B] (BChE) and CYP enzymes at low micromolar concentrations., a",1,1
"(S)-3-(Aminomethyl)-5-(2-hydroxypropoxy)benzoxylanilide ( [ENTITY_A] ), a potent and specific inhibitor of [ENTITY_B], is a novel approach to treat chronic myelogenous leukaemia (CML)., a second potent and specific inhibitor of PLZ, is currently in phase 3 clinical development.is a new drug in this class., a new drug in this class, is a much more",1,1
"(R)- and (S)-3-(Aminomethyl)-7-hydroxy-1-(3-phenylpropylamino)indanyl-1-methanone ( [ENTITY_A] ) inhibited [ENTITY_B] (BChE) of human and rat plasma with IC-50 values of 33 and 227 nM, respectively.(BChE) of homogenates of human and rat plasma was inhibited by 56 and 89%, respectively, of the reference BCh",1,1
"In vitro and in vivo inhibitory effects of [ENTITY_A] (BMS-354825) on [ENTITY_B]., a novel [ENTITY_B] /STAT3 inhibitor that binds to and inhibits STAT3., a new STAT3 inhibitor that binds to and inhibits STAT3., a novel Stat3 inhibitor that binds to and inhibits Stat3., a new STAT3 activator that binds to and inhibits Stat3., a new STAT3 inhibitor that binds to and inhibits",1,1
"(R)-(+)-3-hydroxy-3-methylanthraquinone ( [ENTITY_A] ), a potent and selective inhibitor of both CYP1A and CYP3A, has been in development for the treatment of bipolar disorder and related disorders., an analogue of rolipram, has also been tested in the treatment of bipolar disorder.is a new synthetic non- [ENTITY_B] inhibitor that is currently in phase 3 clinical development for the treatment of Alzheimer",1,1
"Inhibition of [ENTITY_A] (Bsep) and its downstream effector, Bsep-dependent OATP-Bsep, by the selective Bsep inhibitor [ENTITY_B]., an inhibitor of phosphoenolpyruvate carboxykinase., an inhibitor of phosphoenolpyruvate carboxymethylase., an inhibitor of phosphoenolpyruvate carboxykinase.
The use of the [ENTITY_A] in",1,1
"In vitro and in vivo inhibitory effects of the [ENTITY_A] inhibitor [ENTITY_B] on the metabolism of phenytoin.inhibitors have been under investigation as potential drugs for treatment of bipolar disorder.has been shown to be at least as effective as the reference [ENTITY_B] inhibitor [ENTITY_B] in the treatment of bipolar disorder.has been shown to be more than twice as effective as the reference diltiazem in the treatment of bipolar disorder., a selective CO",1,1
"(1H-1,3-diphenyl-1-methyl-4-isoindolyl-acetamide) ( [ENTITY_A] ) as a novel orally active [ENTITY_B] inhibitor., a [ENTITY_B] inhibitor with mild inhibition of acetylcholinesterase and bromine uptake, is currently undergoing phase I clinical trials.( 1 - H - 1,3 - dithiolan-4-yl acetamide, 1 - H-1",1,1
"The effect of [ENTITY_A], a peripheral [ENTITY_B] blocker, on acid-induced headache in rats., a peripheral ACE inhibitor, reduces acid-induced headache in rats., a peripheral PDE3 inhibitor, reduces acid-induced headache in rats., a peripheral [ENTITY_B] blocker, and carprofen, a central PDE4 inhibitor, reduce acid-induced headache in rats., a peripheral PDE5 inhibitor, reduces acid-induced headache in rats.,",1,1
"(R)- and (S)-3-hydroxybenzyloxyphenylamide [ENTITY_A] block the [ENTITY_B] - and ABL-induced activation of microglia: a mechanism of anti-inflammatory activity of ketamine., a new anti-inflammatory drug for the treatment of Alzheimer's disease, inhibits the activation of microglia., a new anti-inflammatory drug for the treatment of Alzheimer's disease, inhibits the activation of microglia.block",1,1
"This study was designed to test the efficacy of [ENTITY_A], a novel [ENTITY_B] inhibitor, in patients with clear cell renal cancers., an oral tyrosine kinase inhibitor that inhibits both ERK and Akt, inhibits tumor growth in clear cell renal cancers.inhibitors (TKI), including gefitinib (Gefitinib) and erlotinib (Erlotinib), have been evaluated in several cancer types., a",1,1
"In vitro inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens., a new inhibitor of human [ENTITY_B] polymerase., a new polyclonal antithrombin., a new inhibitor of human COX-2 polymerase., a new polyclonal antithrombin., a new polyclonal antithrombin., a new inhibitor of human COX-1 polymerase.",1,1
"The effect of the [ENTITY_A] blocker [ENTITY_B] on the pharmacokinetics and pharmacodynamics of candesartan sulfate in healthy subjects., a selective inhibitor of [ENTITY_B] (MAO-B) has recently been approved for the treatment of hypertension and dyspepsia in patients with dysmenorrhea., a selective inhibitor of m-norepinephrine re-uptake (M-NRP) has recently been approved for the treatment of angina in patients with",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methylanthraquinone ( [ENTITY_A] ), a novel [ENTITY_B] (MAO-A inhibitor with anti-inflammatory activity and low risk of neurotoxicity) presents as a new potential agent for treatment of Alzheimer's disease., 3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methylanthraquinone, is a novel MA",1,1
"(R)-(+)-Tamsulosin ( [ENTITY_A] ), a selective COX-1 inhibitor, reversibly suppresses the [ENTITY_B] gene expression in the human nasal polyp cell line NNK., the gene product of the cytochrome P450 COX-1, is a key enzyme that mediates the metabolism of many drugs, including antidepressants., an inhibitor of the [ENTITY_B], is a standard treatment for allergic rhinitis., the gene product",1,1
"This study explored the feasibility of inhibiting [ENTITY_A] expression through use of [ENTITY_B], a [ENTITY_B] inhibitor., a selective COX-1 inhibitor, was developed from natural products [ENTITY_B] and calyculin A., a selective COX-2 inhibitor, was developed from calyculin A., a known [ENTITY_B] inhibitor.and calyculin A were shown to inhibit expression of COX-1 and COX-2 in vitro.",1,1
(1)H NMR chemical shift changes induced by the [ENTITY_A] inhibitor [ENTITY_B] (400 microM) and the pemetrexed analogues PKC412 and PKC424 show overlapping but distinct sensitivities; (2) The PKC412 analogue shows a reduced sensitivity to the PDE4 inhibitors rofecoxib and ketoprofen and a reduced K(i) for the PDE3 inhibitors [ENTITY_B] and mitoxantrone; (3) The PKC424,1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-2-naphthalen-2-yl)-1-hydroxymethyl-3-oxabicyclo[3.1.0]hexane-1,3-diol, 4-acetoxy-3-hydroxybiphenyl-2(1H)-one ( [ENTITY_A] ) is a potent and specific inhibitor of [ENTITY_B] (",1,1
"inhibitors based on a [ENTITY_A] scaffold as a strategy to treat type I diabetes., an [ENTITY_B] inhibitor, has been in development for years., an alpha 1-acid glycoprotein (A1-AGP) inhibitor, has been in development for years., a glucose-dependent phosphotase (GDP) inhibitor, has been in development for years., an [ENTITY_B] inhibitor, was approved by the U.S. FDA",1,1
"This study investigated the effects of [ENTITY_A] (an [ENTITY_B] inhibitor with -SH group), enalapril (a COX-2 inhibitor with -SH group), N-acetyl cysteine (only -SH group) and N-acetyl l-cysteine (only -SH group) on the activities of [ENTITY_B], COX-1 and COX-2 in rabbit iliac artery., COX-1 and COX-2 were inhibited by",1,1
(1)H NMR-derived structure and pharmacological characterization of the [ENTITY_A] derivatives.(1)H NMR structure of the [ENTITY_B] -bound pro-drugs.(1)H NMR structure of the rolipram-bound pro-drugs.(1)H NMR structure of the diltiazem-bound pro-drugs.(3)H NMR structure of the rolipram-bound pro-,1,1
"In vivo inhibition of [ENTITY_A] with [ENTITY_B] and puromycin., a new drug for cancer therapy., a new drug for cancer therapy., a new drug for oncology therapy., a new drug for neuro-oncology therapy.
Structural basis of the selective inhibition of the [ENTITY_B] by [ENTITY_B]., a new drug for cancer therapy., a new drug for neuro-oncology therapy.
Structural basis for the selective inhibition of",1,1
In vitro metabolism of the novel [ENTITY_A] inhibitor [ENTITY_B] by rat liver microsomes: comparison with enalapril and [ENTITY_B].inhibitors of acetylcholinesterase (AChE) and enamel phosphoribosyltransferase (EPS).blockers of acetylcholinesterase (AChE) and enamel phosphoribosyltransferase (EPS).blockers of acetylchol,1,1
"(+/-)-Tamsulosin effectively antagonizes the effects of [ENTITY_A], a selective inhibitor of [ENTITY_B]., an oral inhibitor of COX-1, exhibits less potent inhibition of COX-3., an oral inhibitor of COX-3, exhibits less potent inhibition of COX-2., and a selective inhibitor of COX-2, exhibit no apparent effect in COX-1., and a selective inhibitor of COX-1,",1,1
"(R)-3-(Aminomethyl)-7-(4-methoxyphenyl)-1-hydroxy-1-naphthalen-2-yl)indole ( [ENTITY_A] ) has been found to inhibit [ENTITY_B] (L-VGCCs) with an IC50 value of 0.001 microM; it also shows low nanomolar inhibition in the rat heart., a less active metabolite, was not inhibited at all., a",1,1
"(R)-3-(Aminomethyl)-8-(3-hydroxypropoxy)-1-(3-hydroxypropoxy)-1-hydroxymethyl-1-oxymethyl-1-hydroxy-1-methanone) stearate ( [ENTITY_A] ) is a novel selective [ENTITY_B] (COX-2) inhibitor with good oral bioavailability and low risk of gastrointestinal side effects that has no demonstrable selectivity for COX-1.,",1,1
"(R)- and (S)-3-hydroxybenzylhydrazine: a new series of potent [ENTITY_A] inhibitors., a novel class of [ENTITY_B] inhibitors., a new compound of hydralazine class., a new compound of nitric oxide inhibitory action., a new inhibitor of cyclo-oxygenase-2. huprine H, a new huprine with potent COX-inhibitory activity",1,1
"Inhibition of [ENTITY_A], a key enzyme in cholesterol biosynthesis, by [ENTITY_B] and oleate., an inhibitor of cholesterol biosynthesis, is present in plasma at relatively low concentrations (IC50 = 0.5 microM) and has little or no direct effect on cells., however, causes a dose-dependent inhibition of both cholesterol biosynthesis and synthesis, with IC50 values of 0.6 and 0.5 microM, respectively.may therefore be useful in",1,1
"(R)- and (S)-3-(A-phenyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methylxanthine ( [ENTITY_A] ) are potent and specific inhibitors of [ENTITY_B], respectively, of which only R- and S-peptide are cytotoxicity indicators., an analog of prozac, inhibits the serotonin reuptake transporter ( [ENTITY_B] )., an analog of pimozide, inhibits the norepinephrine transporter (",1,1
"(1)H-NEP recordings from rat primary cortical neurons: identification of [ENTITY_A] selectivity in the NR2B subunit., a selective [ENTITY_B] (NET) inhibitor, is currently undergoing clinical trials., a selective NEA (NETE) inhibitor, is currently undergoing clinical trials.(N-ethyl-d-aspartate) (NET) selective inhibitors are being evaluated for the treatment of Parkinson's disease, although their efficacy has been questioned due to their",1,1
In vivo inhibition of pitavastatin by the [ENTITY_A] inhibitor [ENTITY_B].inhibition is dependent on open and inactivated states.inhibition can be achieved by direct inhibition of the enzyme or by the action of the enzyme in an inactive conformer.inhibition can be produced in vitro by incubation of the enzyme with purified recombinant CYP11A1 or CYP11A2.inhibition can be produced in vitro by incubation of the,1,1
"This study was designed to test the hypothesis that [ENTITY_A] blocks the sodium channel of the basolateral amygdala and hippocampus via a mechanism distinct from the classical [ENTITY_B] (NET) blockade seen with tracer techniques., a selective inhibitor of [ENTITY_B] in the amygdala, was microinjected into the basolateral amygdala of freely moving rats, and the data were analyzed using whole-cell voltage-clamp recordings in intact slices., a selective inhibitor of NET, was microinjected into the",1,1
"(R)- and (S)-3-hydroxybenzylhydrazine-4-carboxamide ( [ENTITY_A] ) are potent and selective [ENTITY_B] inhibitors that have little or no effect on COX-1 at concentrations ≥1 microM., 3-hydroxybenzylhydrazine-4-carboxamide, is the first example of a potent and selective [ENTITY_B] inhibitor with little or no effect on COX-1 at concentrations ≥1",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., isolated from Sophora flavescens., a new inhibitor to the [ENTITY_B] used in traditional Japanese medicine to induce a 'cold-like' state of the body., an inhibitor of the COX-1 enzyme., isolated from Sophora flavescens., isolated from Sophora flavescens., isolated from Sophora flavescens., isolated from Sophora flavescens., an inhibitor",1,1
"Inhibition of [ENTITY_A] (Aβ) aggregation with the p-chloro analogue SCH23390 attenuates the progression of Alzheimer's disease., a new [ENTITY_B] inhibitor., a new ACE inhibitor., a new AGT inhibitor., a new PDE3 inhibitor., a new AGE inhibitor., a new PDE4 inhibitor.
N-acetylcysteine ameliorates hyperammonemia in a mouse",1,1
"(1) Synthesis, structure-activity relationships, and molecular modeling study of the [ENTITY_A] derivatives as potent and selective [ENTITY_B] (MAO-B) inhibitors. (2) Docking and virtual screening of the active site of MAO-B., a [ENTITY_B] tyrosine kinase inhibitor., a mitochondrial tyrosine kinase inhibitor., a [ENTITY_B] tyrosine kinase inhibitor., a dopamine-beta-hydroxylase inhibitor.",1,1
"Inhibition of [ENTITY_A] (MMP-2) by [ENTITY_B] and captopril reduces tumor growth and lung metastasis in mice., a new class of [ENTITY_B] inhibitors., a new class of ACE-inhibitors., a new ACE-inhibitor., a new COX-1 inhibitor. captopril, captopril, captopril, captopril, captopril, captopril, captopril, captop",1,1
"In vitro and in vivo inhibition of [ENTITY_A] by the novel [ENTITY_B] (COX-2) inhibitor [ENTITY_B]., a novel selective COX-2 inhibitor, inhibits the metabolism of many substrates in vitro and in vivo., a novel selective COX-1 inhibitor, is a new addition to the antiestrogen therapeutic armamentarium., a novel selective COX-2 inhibitor, is a new addition to the antiestrogen therapeutic armamentarium.",1,1
"(1) H-NMR and (13) C-labeled deoxyuridine derivatives of (+)-coumarin B ( [ENTITY_A] ) inhibit [ENTITY_B] kinase., a selective inhibitor of [ENTITY_B] kinase, inhibits melanogenesis., a selective inhibitor of melanogenesis, inhibits melanogenesis., a selective inhibitor of melanogenesis, inhibits melanogenesis., a selective inhibitor of melanogenesis, inhibits melanogenesis., a selective inhibitor of melanogenesis,",1,1
"(R)-3-(Aminomethyl)-5-methoxy-4-methoxybenzoyl-oxymethanone ( [ENTITY_A] ) is a highly potent and specific [ENTITY_B] (MAO-A) inhibitor and was found to be most suitable for treatment of Parkinson's disease (PD)., a selective MAO-B inhibitor that also targets MAO-A, could potentially be combined with levodopa to produce a synergistic effect.,",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methanone derivative of (+/-)-1-(3-hydroxypropoxy)-1-hydroxy-2-(3-methylanthraquinone) cocrystallized with [ENTITY_A] inhibitor [ENTITY_B] caused reduction of [ENTITY_B] inhibition., cocrystals of (-)-1-hydroxy-2-(3-methylanthraquinone",1,1
"The effect of the non-steroidal anti-inflammatory drug naproxen on the pharmacokinetics of [ENTITY_A], the prototypical [ENTITY_B] inhibitor, in healthy subjects., the prototypical COX-1 inhibitor, is widely used to alleviate inflammation., naproxen metabolite, and the COX-2 inhibitor ibuprofen have been studied., naproxen, ibuprofen, and etoricoxib metabolite 4-hyd",1,1
"(R)-Phenylalanine-based inhibitors of [ENTITY_A] : [ENTITY_B] inhibitory activity of a series of [ENTITY_B]., (R)-Phenylalanine-based inhibitors of acetylcholinesterase: potency in vitro and in vivo., (R)-Phenylalanine-based inhibitors of acetylcholinesterase: potency in vitro and in vivo., (S)-Phenylalanine- based inhibitors",1,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] -mediated prostatic bud formation in mouse., a new inhibitor of [ENTITY_B] -mediated prostatic bud formation in mouse., an inhibitor of prostatic bud formation in mouse., a selective inhibitor of prostatic bud formation in human., a selective inhibitor of prostatic bud formation in human., a new inhibitor of prostatic bud formation in rat., a new inhibitor of prostatic bud formation in human.",1,1
"(R)-(-)-3-(3-butoxy-phenyl)butanamide ( [ENTITY_A] ) is a potent, irreversible [ENTITY_B] (MAO-B) inhibitor with moderate selectivity for type B., a potent irreversible MAO-B inhibitor with moderate selectivity for type A, is available only from the clinic., a potent irreversible MAO-A inhibitor with low selectivity for type B, is available from most pharmacies., a potent irreversible MAO-",1,1
(1)H NMR-based structural elucidation of the binding of the [ENTITY_A] inhibitor [ENTITY_B] to the N-terminal of NRAS.inhibition by [ENTITY_B].binding to the NRAS.binding to the N-domain.inhibition by rifampicin.binding to the NRAS. hnR-29 binding to the N-domain. hnR-29 binding to the NRAS. hnR-,1,1
(R)-Phenylalanine ( [ENTITY_A] ) is a nonselective inhibitor of [ENTITY_B] (MAO B).block of the brain MAO is not well described.blocker (MAO-B) is the first in a new class of potent and nonselective inhibitors of MAO-B.block of the brain MAO is well described.block of the brain MAO is not well described.block of the brain MAO is,1,1
"(R)- and (S)-N-propargyl-1-methylxanthine potentiate the GABA metabolite produced by recombinant [ENTITY_A] but not by human recombinant GABA metabolizing enzyme.inhibition by [ENTITY_B].inhibition by rosuvastatin., homochlorcyclizine, and homochlorcyclizine methylxanthine potentiate GABA metabolite produced by recombinant BSE.inhibition by rosuv",1,1
"Inhibitors based on the [ENTITY_A] scaffold as a novel strategy for breast cancer patients failing chemotherapy with [ENTITY_B]., a [ENTITY_B] /STAT3 inhibitor, has proven to be an appropriate treatment in patients with hormone-refractory, metastatic breast cancer., a STAT3 inhibitor, is currently undergoing clinical trials.inhibitors are in clinical development as an additional therapy to HER2-based breast cancer., a fms-related tyrosine kin",1,1
"(1)H- and (13)C-depleted proton N-demethylation products of [ENTITY_A] inhibited by [ENTITY_B] ( [ENTITY_B], ketamine, ketone, ethylacetone, butyl acetone and benzyl acetone)., ketamine, ketone, ethylacetone, butyl acetone and benzyl acetone., ketamine, ketone, ethylacetone, butyl acetone and benzyl acetone.",1,1
"(R)-3-(Aminomethyl)-7-(5-fluoro-2-naphthalen-2-yl)-2-hydroxy-3-methoxyben-1-oxyl-1-methanone ( [ENTITY_A] ) is a novel, highly potent irreversible [ENTITY_B] (MAO-B) inhibitor with mild to moderate MAO-A selectivity., the prototype MAO-B inhibitor, is also a potent irreversible MAO",1,1
"The effects of [ENTITY_A], an [ENTITY_B] inhibitor, on the pharmacokinetics and pharmacodynamics of ketoconazole, a [ENTITY_B] inhibitor, in healthy subjects.inhibitory action on the gastrointestinal mucosa.interactions with ketoconazole.inhibitory action on the gastrointestinal mucosa.interactions with ketoconazole.inhibitory action on the gastrointestinal mucosa.interactions with ketoconazole",1,1
"(R)-(-)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-3-methylanthraquinone ( [ENTITY_A] ) as a potent and specific inhibitor of [ENTITY_B] kinase.inhibitors.inhibitors.inhibitors.inhibitory activities of various sulfone side chains., a new inhibitor of acetylchol",1,1
"Inhibition of [ENTITY_A] (Bsep) and its downstream effector, Beclin-1, by [ENTITY_B] from Sophora flavescens.inhibitors from Sophora flavescens.blockers from Sophora flavescens., a dual inhibitor of Beclin-1 and Bsep from Sophora flavescens.inhibitors from Sophora flavescens.blockers from Sophora flavescens.block",1,1
"Inhibition of [ENTITY_A], but not CES1, by a specific small molecule inhibitor ( [ENTITY_B] ).inhibitors CES2 and CES3 are expressed in vascular smooth muscle cells of the aorta but not of the ventricular myocardium.inhibitors CES4 and CES5 are expressed in smooth muscle cells of the aorta but not of the ventricular myocardium.blockers CES6 and CES7 are expressed in smooth muscle cells of the",1,1
"(R)-3-hydroxy-3-methylanthra-methanone as a novel [ENTITY_A] inhibitor: optimization of the stereochemistry for better [ENTITY_B] selectivity., a [ENTITY_B] (R)-enantiomer of methanone that is not metabolized by CYP3A, is a useful inhibitor of the enzyme for its pharmacologic treatment of osteosarcoma and related tumors.inhibitors, such as [ENTITY_B] and ketopro",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on the gastrointestinal absorption of levodopa.is a selective inhibitor of monoamine reuptake and has been used in the treatment of Parkinson's disease since its introduction in 1997., when used as a single agent, causes a slow and steady increase in blood pressure that can lead to cardiovascular diseases.can be administered as a single agent or in combination with a number of drugs, including the antihypertensive agent clopid",1,1
"(S)-3-(Aminomethyl)-5-[(1,1'-biphenyl)-3-(3-methoxy-phenyl)-4-(3-methoxybenzoyl)phenyl]acetamide ( [ENTITY_A] ), a potent irreversible [ENTITY_B] (MAO-B inhibitor), was evaluated for its in vitro and in vivo selectivity against the rat brain MAO-B substrate, [ENTITY_B]., an uncompetitive inhibitor of the same enzyme,",1,1
"(1) In vitro inhibitory activity of [ENTITY_A] ( [ENTITY_B] inhibitor, 0.5-5 microM), clofarabine (COX-inhibitor, 0.1-5 microM), and rolipram (Ro 20-1724 [COX-2 (inhibitor, 0.1-5 microM)]) against the production of leukotriene D(4) and D(5) in human peripheral blood neutrophils",1,1
"inhibitors based on a [ENTITY_A] scaffold as a novel method of breast cancer chemosensitivity.inhibitors based on a pyridazinone scaffold as a novel method of breast cancer chemosensitivity., a [ENTITY_B] /COX-2 inhibitor, as a novel method of breast cancer chemosensitivity., a [ENTITY_B] /COX-1 inhibitor, as a novel method of breast cancer chemosensitivity., an ACE inhibitor, as",1,1
"Inhibitory effects of some phenolic acids on the induction of [ENTITY_A] by PAG significantly suppressed by [ENTITY_B]., a phenolic acid, inhibited the induction of p300/p300 mRNA by PAG significantly., caffeic acid and ferulic acid inhibited the p300/p300 mRNA by PAG in a slightly different manner., ferulic acid and naringenin significantly inhibited the expression of p300/p300 mRNA by PAG in a slightly different manner",1,1
"Inhibitors of [ENTITY_A] block of recombinant [ENTITY_B]., ketoprofen, ketrolack, NS-398, ketrolack, ketrolack-M, ketrolack-H, ketrolack-L, NS-389, NS-398, NS-389-H, NS-398-L, NS-398-H-LO., diclofenac, diclofenac-M, dicl",1,1
"The effect of [ENTITY_A] (an [ENTITY_B] inhibitor with -SH group) on semen parameters and semen analysis in infertile men with abnormal baseline values., a potent, selective, irreversible inhibitor of [ENTITY_B] (COX), is widely used as a first-line treatment for prostatic carcinoma and in the treatment of benign prostatic obstruction.(also a selective inhibitor of COX-1) is effective in the treatment of benign prostatic hyperplasia and is not recommended for",1,1
"inhibitor [ENTITY_A] (N-propargyl-1-(R)-aminoindan) (NPA), a potent [ENTITY_B] inhibitor and new candidate for cancer chemotherapy, delays the growth-inhibitory effects of [ENTITY_B] and paclitaxel in breast and pancreatic cancer cell lines.inhibitor [ENTITY_B] (NPA), a potent Rho kinase inhibitor and a new candidate for cancer chemotherapy, delays the growth-inhibitory effects of paclitaxel",1,1
"inhibitors based on the [ENTITY_A] scaffold: [ENTITY_B] inhibitors for the treatment of Alzheimer's disease., an [ENTITY_B] inhibitor that binds with high affinity to the N-methyl-D-aspartate receptor, has been in Phase 2 clinical development since 2002., an apicidine metabolite that binds with moderate affinity to the N-methyl-D-aspartate receptor, has been in Phase 2 clinical development since 2005., a",1,1
"(1)H NMR-based metabolite profiling of [ENTITY_A], a selective [ENTITY_B] inhibitor., a selective COX-1 inhibitor., a selective [ENTITY_B] inhibitor.(1,3-d) and COX-2 inhibitor., COX-1 and COX-2 inhibitor., COX-1 and COX-2 inhibitor., COX-1 and COX-2 inhibitor.
Synthesis and",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxybenzyl-2-oxabicyclo[2,3-b]indole ( [ENTITY_A] ) is a novel, orally active, selective inhibitor of [ENTITY_B], which selectively destroys [ENTITY_B]., a selective inhibitor of CYP3A, has been in development for the treatment of bipolar disorder and related disorders.",1,1
"This study explored the feasibility of targeting these [ENTITY_A] peptide variants to block pro-inflammatory responses and promote wound healing in inflammatory skin wounds by a novel [ENTITY_B] inhibitor, [ENTITY_B].(BMS-354825) is a novel, multitargeted inhibitor of the [ENTITY_B] (COX) enzymes, which are upregulated during tissue injury and inflammation., a COX-3 inhibitor, showed promising results in preclinical studies, but was found to be ineffective in clinical use",1,1
"(R)-Phenylalanine-induced increase of [ENTITY_A] protein level in rat striatum is prevented by the phenylalanine analogue [ENTITY_B].inhibited by [ENTITY_B].and nimesulide-induced reductions of striatal protein level in rat striatum are prevented by the phenylalanine analogue., nimesulide and vigabatrin inhibited by nimesulide.inhibited by vigabatrin and nimesulide.",1,1
"inhibitors based on [ENTITY_A] : [ENTITY_B] inhibitory activity in vitro and in vivo, and evaluation as a new strategy for treatment of Alzheimer's disease., an [ENTITY_B] inhibitor with neuroprotective activity in vitro., a [ENTITY_B] inhibitor with Alzheimer's disease-specific activity in vivo., a mixed inhibitor of Aβ and plasminogen activator., a mixed inhibitor of Aβ and plasmin., an Aβ inhibitor with",1,1
"(1)H NMR-DQA assay of [ENTITY_A] and its enantiomers as [ENTITY_B] inhibitors.inhibitors., a [ENTITY_B] inhibitor., an octanamide inotrope inhibitor.
[Effect of [ENTITY_A] inhibition on the metabolism of candesartan in rats].UNLABELLED: Candesartan is a [ENTITY_B] ( [ENTITY_B] ) inhibitor, which is used to relieve hypertension and other cardiovascular diseases.",1,1
"Inhibition of [ENTITY_A] with [ENTITY_B]., a peripheral opiate., an indirect opiate acting on central and peripheral opiates. naloxone, an antagonist of mu-receptors. homochlorcyclizine, a peripheral anxiolytic. nimesulide, a peripheral anxiolytic. norepinephrine, a peripheral agonist. pethidine, peripheral anxiolytic. racemic morphine, a peripheral agonist at both mu",1,1
"(R)-(1R,3S,4S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methanone ( [ENTITY_A] ) is a novel, selective, irreversible [ENTITY_B] (BNP-CYP) inhibitor., 3-hydroxypropoxy-1-methanone ( 3-OH-7-phenyl-9H-pyrrolo[2,3-",1,1
"The effect of [ENTITY_A] blockade on the metabolism of the antipsychotic [ENTITY_B]., a selective 5-HT(2A/2C) antagonist, inhibits the metabolism of antipsychotic agents., a selective 5-HT(2A/2C) agonist, inhibits the metabolism of antipsychotic agents., a selective 5-HT(2A/2C) agonist, inhibits the metabolism of antipsychotic agents., a selective",1,1
"(S)-3-hydroxy-5-(2-methylanthraquinone) quinazoline ( [ENTITY_A] ), a dual inhibitor of [ENTITY_B] (MAO-B) and catechol-O-methyltransferase, effectively suppresses the conversion of phencyclidine to 5-hydroxymethyl-2-methylanthraquinone (OH-MAQ) in human and rat brain, without affecting MAO activity., bufotenine",1,1
"(R)-3-(Aminomethyl)-9-(3-hydroxypropoxy)-1-methanone, [ENTITY_A], a new potential inhibitor of [ENTITY_B]., a new inhibitor of acetylcholinesterase., a new inhibitor of [ENTITY_B]., a new inhibitor of acetylcholinesterase., a new inhibitor of acetylcholinesterase., a new inhibitor of acetylcholinesterase",1,1
"(1)H- and (31)P-depolarized rat hippocampal tissue samples in the intact state and upon [ENTITY_A] treatment, in which [ENTITY_B] inhibition was confirmed by the accumulation of (1)H-isoprostane in the cytosol., but not COX-1, was also depleted in tissue homogenates, whereas COX-2 expression remained unchanged., but not COX-3, was reduced in tissue homogenates, whereas",1,1
"inhibitors based on a [ENTITY_A] scaffold., an [ENTITY_B] /COX-2 inhibitor, was designed to address both the gastrointestinal (GI) and cardiovascular (CV) side effects associated with COX-1 and 2 inhibitors., a nonsteroidal antiinflammatory drug, was designed to address the gastrointestinal side effect associated with aspirin and nonsteroidal antiinflammatory drugs., a selective COX-1 inhibitor, was designed to address the cardiovascular side effects of nonster",1,1
"The effect of [ENTITY_A] (VP-16), an oral multi-receptor inhibitor of [ENTITY_B], on the pharmacology of ambrisentan, a novel [ENTITY_B] (COX-1) inhibitor.inhibitors (Iressa, Erboste), selective for COX-1 and COX-2, have been in clinical development for the treatment of osteoarthritis.blockers (SU101, Arava), selective for COX-1",1,1
"This study explored if [ENTITY_A] (an [ENTITY_B] inhibitor with -SH group) and exisulind (an ACE-inhibitor with -SH group) could reduce blood pressure in normal subjects., norepinephrine, and epinephrine were administered intravenously to normal volunteers in the steady state (200 micrograms/kg/min, for 20 min) and following a 5-min washout period (200 micrograms/kg/min, for 20 min",1,1
"(S)-1-(Aminomethyl)-3-(3-butoxy-phenyl)-1-naphthalen-2-yl-urea ( [ENTITY_A] ) is a novel [ENTITY_B] (DASI) inhibitor that binds reversibly with high affinity to both [ENTITY_B] and N-methyl-D-aspartate receptors., an oral multi-targeted inhibitor of acetylcholinesterase, is currently undergoing clinical trials.is a potent",1,1
"In vitro metabolism of the novel [ENTITY_A] derivative: [ENTITY_B] inhibition by [ENTITY_B], carprofen, and nimesulide., a [ENTITY_B] -derived oral multi-targeted inhibitor for 5-fluoro-2'-deoxyuridine reductase and cyclooxygenase-2, is in phase I clinical development for the treatment of osteoarthritis., a novel oral multi-targeted inhibitor for 5-fluoro-2'-de",1,1
"Inhibition of [ENTITY_A], but not CYP2B6, by a selective [ENTITY_B] inhibitor: [ENTITY_B]., a potent, orally active [ENTITY_B] inhibitor., a potent, orally active CYP3A inhibitor., a selective CYP2B inhibitor., a selective CYP3A inhibitor., a selective COX-2 inhibitor., a selective CYP3A inhibitor., a selective COX-1 inhibitor.",1,1
"(R)-3-hydroxy-3-(4-methoxymethylphenyl)propionate ( [ENTITY_A] ) has been reported to be a poor inhibitor of [ENTITY_B], but its clinical profile has been compared with that of ketamine and noradrenaline., a new inhibitor of acetylcholinesterase and [ENTITY_B], may be a useful therapeutic approach in the treatment of Parkinson's disease., a new selective inhibitor of acetylcholinesterase",1,1
"(R)-3-hydroxy-3-methylanthraquinone ( [ENTITY_A] ), a novel [ENTITY_B] inhibitor, suppresses the proliferation and activation of T-lymphocytes., a non-steroidal immunosuppressant, inhibits the proliferation of T-lymphocytes., a selective [ENTITY_B] inhibitor, suppressed the proliferation and activation of T-lymphocytes., a selective COX-2 inhibitor, suppressed the proliferation and",1,1
"(S)-3-(Aminomethyl)-7-methoxy-4-(3-methoxymethylphenyl)-7-methoxy-1-(2-phenanthrenyl)-2-hydroxy-3-naphthalen-1-yl)-1H-pyrazole-4-carboxamide hydrochloride ( [ENTITY_A], E 33,354) is a new selective [ENTITY_B] (MAO-B) inhibitor with moderate activity against",1,1
"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-3-nonyl)-1-hydroxymethyl-5-methanone ( [ENTITY_A] ) is a derivative of ketoprofen and is a potent inhibitor of [ENTITY_B] used to induce a therapeutic effect in pain relief, but also causes headache, dizziness, and gastrointestinal symptoms., a metabolite of ketoprofen",1,1
"The effects of the [ENTITY_A] inhibitor [ENTITY_B] on colonic mucosa of patients with dyspepsia., which inhibits [ENTITY_B] (BChE), has been implicated in the pathogenesis of both inflammatory bowel disease and cancer, but its mechanism of action in the colon is unclear., a cytoplasmic enzyme implicated in carcinogenesis, is inhibited by acetylsalicylic acid (ASA), a widely used gastrointestinal drug., which inhibits BChE,",1,1
"In vitro metabolism of racemic [ENTITY_A] (N-propargyl-[1-(3-hydroxypropoxy)-1-methanone] quinidine): relevance to smoking cessation., a selective [ENTITY_B] (COX) inhibitor and smoking cessation agent, is racemic and metabolized via a direct CYP3A pathway., on the other hand, is metabolized via a CYP2A pathway but with low activity as a smoking cessation agent.was evaluated",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens., a new inhibitor of [ENTITY_B]., a new compound that inhibits flagellar motility.inhibitor from Sophora flavescens.inhibitor from Eucommia ulmoides Mill., a new compound that inhibits flagellar motility., a new inhibitor of motility., a new compound that inhibits flagellar motility",1,1
"(R)- and (S)-3-(Aminomethyl)-7-methoxy-4-methoxybenzoyl)-7-hydroxybenzoyl-4-methoxybenzoyl-7-hydroxycoumarin ( [ENTITY_A] ) are novel [ENTITY_B] (BChE) inhibitors., 4-methoxybenzoyl-7-hydroxycoumarin and 3,7-diary",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methylxanthine ( [ENTITY_A] ) inhibits the metabolism of the non-competitive NSAID meloxicam by direct inhibition of CYP3A and CYP2D in vitro., a selective inhibitor of [ENTITY_B], is currently in phase 3b clinical trials., a non-selective irreversible inhibitor of cytochrome P-450, is",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens JE-1., a new inhibitor of [ENTITY_B] from Sophora flavescens JE-1., a new inhibitor of COX-1 from Sophora flavescens JE-1., a new inhibitor of PGE2 from Sophora flavescens JE-1., a new inhibitor of HCO3-C from Sophora flavescens JE-1.",1,1
"(R)-(-)-3-(Aminomethyl)-7(E)-hydroxy-4-(3-hydroxypropoxy)-1-methanone, [ENTITY_A], induces apoptosis in human tumor cells via inhibition of [ENTITY_B]., an [ENTITY_B] -selective inhibitor, also causes apoptosis in HT-29 and HCT-116 cells., at noncytotoxic concentrations, causes apoptosis in HT-29 cells but not in HCT-116",1,1
"inhibitors based on a [ENTITY_A] scaffold.is a new anti-Parkinsonian [ENTITY_B] inhibitor with a longer half-life than any other anti-Parkinsonian drug., a more potent and longer-lasting [ENTITY_B] inhibitor, has not been available yet., a more potent and longer-lasting tracer in vivo, has now been introduced., a selective COX-2 inhibitor, has been tested in several animal models and showed",1,1
"(R)- and (S)-1-(Aminomethyl)-7-methylanthraquinone ( [ENTITY_A] ) inhibit recombinant [ENTITY_B], with IC(50) values of 43 microM and 227 microM, respectively., a less potent analogue of 7-methylanthraquinone, also inhibited recombinant BSPG, with IC(50) values of 25 microM and 209 microM, respectively., a novel metabolite of 7",1,1
"This study explores the effects of selective [ENTITY_A] inhibitors ( [ENTITY_B], ketoprofen and mexiletine) on the enantioselective disposition of racemic sibutramine., the first selective inhibitor of platelet [ENTITY_B], also inhibited racemic sibutramine disposition., the first selective inhibitor of platelet NAD(H)H oxidase, did not inhibit racemic sibutramine disposition., a second selective inhibitor",1,1
"Inhibition of [ENTITY_A] by a selective COX-1 inhibitor, [ENTITY_B]., inhibits the metabolism of diclofenac and flurbiprofen in horses., a selective COX-2 inhibitor, did not inhibit metabolism of diclofenac and flurbiprofen in horses., a selective N-demethyl-derivative of diclofenac, and nimesulide, a selective COX-3",1,1
"(R)-(-)-Epicatechin gallate, an active metabolite of [ENTITY_A] (EC 1.14.16.1), inhibits [ENTITY_B] expression via downregulation of c-fos, c-jun, and c-fosB.inhibition by [ENTITY_B].inhibition by rolipram.blockade in the NTS.blockade in the NTS.blockade in the NTS.blockade in the NTS.blockade in",1,1
"Inhibition of [ENTITY_A] by a specific inhibitor [ [ENTITY_B] ; DEGBG] delays gastric emptying of carbohydrate in humans., a recently described small molecule that delays gastrointestinal transit by blocking [ENTITY_B], has been shown to reduce postprandial glycemia in humans., like DEGBG and its homologs, is also a substrate for the enzyme acetylcholinesterase (AChE) and is rapidly hydrolyzed by AChE in humans.",1,1
"(1)H NMR and Methyl Biosynthesis: A study of the [ENTITY_A] inhibitory properties of a natural flavonoid, calycopyrrol acetate., a natural flavonoid, calycopyrrol acetate., a known inhibitor of phenylalanine hydroxylase., a known substrate of [ENTITY_B]., a known inhibitor of phenylalanine hydroxylase., a known substrate of",1,1
"(R)-(+)-Tamsulosin effectively antagonizes [ENTITY_A], and this may account for its clinical efficacy in the therapy of prostatic carcinoma., a selective inhibitor of [ENTITY_B], is being evaluated as a new antihypertensive drug., a selective inhibitor of prostaglandin E2, is under investigation as a new drug for the treatment of prostatic hyperplasia and carcinoma., a selective inhibitor of E1-E3 enzymes,",1,1
"In vitro metabolism of the orally active metabolite [ENTITY_A] in humans by using both human and rat primary microsomes., a potent competitive inhibitor of [ENTITY_B] (MAO), has recently been approved for the treatment of Parkinson's disease., as a representative of a new class of MAO inhibitors, has recently been approved for the treatment of Alzheimer's disease.is a more selective MAO inhibitor with an affinity comparable with that of vorinostat and cinchonin A",1,1
"(R)-(-)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxymethyl-1-methanone ( [ENTITY_A] ), a selective, irreversible inhibitor of [ENTITY_B], produced by the fungus Microsporum sp., was evaluated in vitro for its genotoxic effects and its potential as a novel prophylactic/therapeutic drug., a selective, irreversible inhibitor of acetyl",1,1
"Inhibition of [ENTITY_A] (Aβ) aggregation by [ENTITY_B]., a [ENTITY_B] inhibitor., a taurocholate-binding antioxidant., a taurocholate-binding antioxidant that reduces amyloid-beta42 formation.(Taurocholate) is a dietary antioxidant that inhibits aggregation of β-amyloid peptides (Aβ).(Taurocholate) is a dietary antioxidant that inhibits aggregation of β-",1,1
"inhibition of [ENTITY_A] (MMP-2) by [ENTITY_B]., a selective [ENTITY_B] inhibitor, inhibits MMP-2 activity., also known as TGF-beta2, is a potent inhibitor of collagen type I collagen production., also known as TGF-beta3, also inhibits MMP-2., also known as TGF-beta5, inhibits collagen type I production in a non-competitive manner., also known as",1,1
"(1)H NMR-based metabolite identification of [ENTITY_A] inhibitors and related compounds., an [ENTITY_B] (MAO-B) inhibitor, has shown significant clinical activity in the treatment of bipolar disorder., also an MAO-B inhibitor, has shown modest activity in the treatment of bipolar disorder., a selective MAO-A inhibitor, has shown moderate activity in the clinical treatment of Alzheimer's disease., a selective MAO-B inhibitor that",1,1
"(S)-3-(Aminomethyl)-7-hydroxy-2-(3-nonylphenyl)-4-methylanthraquinone ( [ENTITY_A] ) inhibits [ENTITY_B], but not CYP3A., a new inhibitor of CYP3A, has not been characterized yet., 4-methylanthraquinone, is an intermediate of the N-demethoxyclopentane sulfone pathway and is active against",1,1
"This study evaluates the effect of [ENTITY_A] (a [ENTITY_B] (COX-1 inhibitor) selective rescue strategy in the treatment of prostatic carcinoma with dysplastic glands and positive COX-2 immunohistochemistry., COX-1, -2, and -4 inhibitory activities were evaluated in the prostatic glands tissue of patients given COX-1 inhibitor ( [ENTITY_B], ketoprofen, diclofenac), COX-2 inhibitor ( NS-",1,1
"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-3-nonyl)adenine ( [ENTITY_A] ) is a novel selective inhibitor of [ENTITY_B]., a selective inhibitor of monoamine oxidase, was reported to be as effective or even superior to citalopram., a selective inhibitor of monoamine oxidase, was reported to be as effective or even superior to c",1,1
"Inhibition of [ENTITY_A], but not PDE3, by [ENTITY_B] in human platelets., an antimicrobial peptide with a dual action on platelets and PDE3, inhibits platelet aggregation in vitro., an antimicrobial peptide with a dual action on platelets and PDE3, inhibits platelet aggregation in vitro., an antimicrobial peptide that inhibits both PDE3 and PDE4, was tested for its anti-clotting",1,1
"The role of [ENTITY_A] (N-propargyl-1-hydroxy-3-methylanthraquinone) in the inhibition of the [ENTITY_B] : selectivity against [ENTITY_B]., a novel, potent, nontoxic [ENTITY_B] inhibitor., a novel, potent, nontoxic COX-2 inhibitor., a novel, potent, nontoxic [ENTITY_B] inhibitor., a novel, potent, nontoxic COX-1 inhibitor.,",1,1
"Inhibitory effect of [ENTITY_A], a [ENTITY_B] inhibitor, on platelet aggregation stimulated by collagen., a selective COX-2 inhibitor, reduces the risk of breast and colon cancer., a selective COX-1 inhibitor, reduces the risk of colon cancer., a selective [ENTITY_B] inhibitor, reduces the risk of breast and colon cancer., a selective PDE-3 inhibitor, reduces the risk of colon cancer., a selective PDE",1,1
"(1)H and (31)P NMR studies of the [ENTITY_A] inhibitor [ENTITY_B] indicate an interactive binding of the molecules on the active site serine residue (Ser-198).inhibitors with a similar structure, but having different numbers of cysteines, should be classified as different species.and apixaban have a similar size and are both potent [ENTITY_B] inhibitors.and apixaban have a similar size and are not competitive with",1,1
"(R)-(-/-) [ENTITY_A] blocks [ENTITY_B] - and ABCA1-mediated cholesterol transport at depolarized potentials, but not at depolarized potentials in the intact membrane domain.inhibition by 100 microM [ENTITY_B] did not alter ABCA1-mediated cholesterol transport in the intact domain.inhibition by 100 microM NS-398 did not alter ABCA1-mediated cholesterol transport in the intact membrane domain, but did alter ABCA1-mediated cholesterol",1,1
"(1) In vitro metabolism of (S)-nimesulide, a clinical [ENTITY_B] inhibitor, in humans: inhibition of [ENTITY_A] by [ENTITY_B]., a clinical COX-inhibitor, is widely used to relieve osteoarthritis., a clinical COX-inhibitor, is widely used to relieve osteoarthritis., a clinical COX-inhibitor, is widely used to relieve osteoarthritis., a clinical",1,1
"inhibition of [ENTITY_A] by [ENTITY_B]., a peripheral [ENTITY_B] blocker, inhibits the gastrointestinal absorption of darunavir and cobicistat., a peripheral ACE inhibitor, inhibits the absorption of darunavir and cobicistat, but has little effect on the absorption of darunavir., a mixed ACE/ACE inhibitor, has little effect on the absorption of darunavir., an oral MAO-B inhibitor,",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(1-hydroxy-3-methylanthraquinol-4-yl)-1-(4-methoxymethyl)-3-naphthyridine-2-yl)-1-methanone ( [ENTITY_A] ) are novel [ENTITY_B] inhibitors., a 1,4-benzodioxan-2-one., a 1,3-ben",1,1
"(R)-3-(Aminomethyl)-7-(1-hydroxy-3-methoxy-phenyl)-1-hydroxy-1-hydroxy-3-naphthalen-2-yl-urea ( [ENTITY_A] ), a novel [ENTITY_B] (MAO-B)-inhibitor that targets the N-methyl-D-aspartate receptor (NMDAR), has been in clinical development for the treatment of dementia and related dementias since 2007",1,1
"The effects of [ENTITY_A], a selective [ENTITY_B] inhibitor, on the pharmacokinetics and pharmacodynamics of darunavir and its major active metabolite, [ENTITY_B], in HIV-1-infected patients....... et al.. et al. et al. et al.. et al. et al. et al. et al. et al.",1,1
"(R)-Phenylalanine and pyridoxal 5'-phosphate inhibitory effect of [ENTITY_A], [ENTITY_B], and nordihydroguaiaretic acid upon [ENTITY_B] expression in Jurkat cells., nordihydroguaiaretic acid, and cyanoketone inhibit the proliferation of Jurkat cells in a concentration-dependent manner., pyridoxal 5'-phosphate, and nordihydrogu",1,1
"The effect of [ENTITY_A] (Gleevec, Novartis), a novel [ENTITY_B] inhibitor, on the pharmacokinetics and pharmacodynamics of candesartan and candesartan plus [ENTITY_B]., a selective COX-1 inhibitor, has recently been introduced as a novel treatment option in patients with hypertension and dyslipidemia.blockers (e.g. [ENTITY_B], Nexavar, Sutent) are associated with substantial side-effects, and their widespread use",1,1
"Inhibition of [ENTITY_A] by an inhibitor [ [ENTITY_B] ; DEGBG] leads to increased apoptosis of HT29 colon cells.inhibitors [ENTITY_B] (Iressa), erlotinib and sunitinib are oral tyrosine kinase inhibitors (TKI), which have been shown to selectively block the [ENTITY_B]., an oral tyrosinase inhibitor (Topo Iressa), has recently been approved for the treatment of advanced NSCLC (N-",1,1
"In vitro inhibitory potency and mechanism of [ENTITY_A] blockade of [ENTITY_B]., a new target for cancer therapy., a novel inhibitor of platelet activation., a new antiatherogenic agent., a new drug for cancer therapy., a new drug for cardiovascular diseases., a new anti-arrhythmic drug., a new anti-arrhythmic drug. ibuprofen, a new drug for pain. ib",1,1
"The use of [ENTITY_A], a specific inhibitor of [ENTITY_B], for the treatment of prostatic carcinoma., a selective inhibitor of PDE3, is currently being evaluated in trials as a novel therapeutic agent for prostatic carcinoma., a new drug for the prevention of prostatic carcinoma, has been in development for more than 15 years., a new drug for the treatment of prostatic carcinoma, is currently being evaluated in clinical trials as a selective inhibitor of P",1,1
"inhibitor [ENTITY_A] (Gleevec, Pfizer) inhibits platelet aggregation in vitro and in vivo., a potent oral multi-targeted inhibitor of [ENTITY_B] (COX-1, COX-3, and COX-4), is in phase II clinical development for the treatment of atherosclerosis and other cardiovascular disorders., a second oral multi-targeted inhibitor of COX-1, COX-3, and COX-4, is also in",1,1
"Inhibition of [ENTITY_A] /STAT3 activation by [ENTITY_B] blocks migration and invasion of cancer cells.inhibit migration and invasion of cancer cells.inhibit migration and invasion of breast cancer cells.inhibit migration and invasion of breast cancer cells.inhibit migration and invasion of colon cancer cells.inhibit migration and invasion of colon cancer cells.
The chemokine receptor CX3CR1 is downregulated in human lung cancer cell lines by [ENTITY_B] and",1,1
"(R)-(-)-Epicatechin gallate attenuates the increase of brain GABA levels induced by [ENTITY_A] treatment., a [ENTITY_B] (GABA) agonist, reduces GABA levels in the cortex and hippocampus of schizophrenic patients by suppressing the phosphorylation of [ENTITY_B] and GABA transporters., a COX-2 inhibitor, reduces brain GABA levels in schizophrenic patients by increasing the phosphorylation of COX isoforms., a CYP3 inhibitor, decreases",1,1
"Inhibition of [ENTITY_A] (ABL) and Bim with [ENTITY_B]., a new ABL inhibitor., a new Bcl-2 inhibitor., a new carbapenem inhibitor., a new imatinib inhibitor.(BRAF) inhibitor. BLT-4 inhibitor.
The effect of CYP2B6, CYP2C9 and CYP2D6 to the metabolism of vardenafil in humans.,",1,1
"(R)- and (S)-3-(Aminomethyl)phenylhydrazine-4-carboxamide ( [ENTITY_A] ) inhibited the [ENTITY_B] activity of recombinant human COX-1 and human COX-3 at low micromolar concentrations., a selective COX-2 inhibitor, was not active against COX-1 at micromolar concentrations., a selective COX-3 inhibitor, inhibited both human COX-1 and COX",1,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] -induced inflammatory reactions: an in vitro study., a selective inhibitor of the [ENTITY_B] (COX), is widely used in the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain., a selective inhibitor of the COX, is widely used in the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain., a selective inhibitor of",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a peripheral opiate agonist, causes a reduction of systemic and cerebral exposure to the active metabolite 5-MeO-DMT., an indirect agonist of the mu-receptors, causes a partial inhibition of 5-MeO-DMT absorption, probably through inhibition of CYP2D activity., a peripheral opiate agonist, inhibits 5-MeO-DMT at the highest concentrations used, probably",1,1
"The effect of the [ENTITY_A] inhibitors [ENTITY_B] and apixaban on the hemodynamics, renal function, and serum creatinine in patients with stroke., a potent and selective [ENTITY_B] (MAO) inhibitor, has recently been introduced to treat stroke.inhibitor apixaban has been studied extensively and has demonstrated to be as effective as MAO-B in vivo, although it is more selective for c-Fos in the brain.is a much",1,1
"(R)-(-)-Tamsulosin effectively antagonizes the action of [ENTITY_A], but not of rofecoxib, in human nasal polyp cells., a new inhibitor of [ENTITY_B], inhibits the action of rofecoxib, but not of etorphine.blockers ( [ENTITY_B], moxidectin) also inhibit the actions of etorphine and methazolamide., moxidectin and rofecoxib",1,1
"inhibitor, [ENTITY_B], is a competitive inhibitor with respect to the human CYP2B6 and CYP3A activities, and the [ENTITY_A] inhibitor, nordihydroguaiaretic acid, is a noncompetitive inhibitor with respect to the CYP2B6 and CYP3A activities., nordihydroguaiaretic acid, and nordihydroguaiaretic acid are metabolized by cytochrome P",1,1
"(R)-3-(Aminomethyl)-7-(1-hydroxypropoxy)-1-hydroxy-3-methanone, ketanserin, inhibits [ENTITY_B], but has little selectivity for BChE.inhibitors based on a [ENTITY_A] scaffold., but not rofecoxib, are substrates of the enzyme BChE.inhibitor activity is dependent on the presence of the p-chlor",1,1
"The effect of [ENTITY_A] inhibitors, [ENTITY_B] and erlotinib, in patients with medullary thyroid cancer., a potent oral multi-selective inhibitor of [ENTITY_B] (MAO), has recently been approved for the treatment of advanced medullary thyroid cancer (MTC)., which targets a different set of molecules, including MAO and MAO-B, is also approved for the treatment of advanced medullary thyroid cancer., which is also a",1,1
"(1) H nuclear magnetic resonance study of [ENTITY_A] inhibition by the novel [ENTITY_B] analogue [ENTITY_B] (N-([1-(2-methoxy-phenyl)-3-naphthalen-2-yl)-4-methoxybenzyl]-phenyl)-5-fluoro-1,3-diarylpyrimidine-3-carboxamide) in humans.inhibitor [ENTITY_B] inhibition in human.- and naphthal",1,1
"Inhibition of [ENTITY_A] (FNTA) by [ENTITY_B] and erlotinib., a selective inhibitor of [ENTITY_B]., a selective inhibitor of NF-kappaB., a selective inhibitor of IkappaB kinases B and C., a selective inhibitor of p50/p52 NF-kappaB kinases. niflumic acid, a dietary analogue of naproxen. nimesulide, a competitive inhibitor of IkappaBal",1,1
"Inhibition of [ENTITY_A] (Aβ) deposition with [ENTITY_B] blocks amyloid-beta42-induced neurotoxicity., an inhibitor of amyloid-β42 (Aβ) deposition, inhibits Aβ42 peptide toxicity., an inhibitor of Aβ deposition, inhibits the deposition of β-secretase., an inhibitor of Aβ deposition, inhibits the deposition of β-secretase., an inhibitor of the deposition of β-secretase",1,1
"(R)- and (S)-3-(2-hydroxy-3-methylanthraquinone) quinidine analogues as potent [ENTITY_A] (DASI) inhibitors with anti-heart-failure activity in vivo., a novel class of [ENTITY_B] -based DASIs., a novel class of DASIs., a novel class of DASIs., a novel class of DASIs., a new class of potent",1,1
"(R)-(+)-Tamsulosin effectively antagonizes the inhibitory effects of the [ENTITY_A] inhibitor [ENTITY_B] on prostatic bud formation in mice., a [ENTITY_B] inhibitor, is currently under clinical investigation for treatment of benign prostatic obstruction and urinary incontinence., a tracer for prostatic bud formation, was recently approved for the treatment of prostatic hyperplasia in men with prostatic carcinoma in a Phase II clinical trial.(R",1,1
"(R)-3-butyl-5-(2-methoxy-phenyl)-1-hydroxybenzoxaborole ( [ENTITY_A] ), a new dual inhibitor for [ENTITY_B] (Bsep) and prostaglandin E(2) (PgE(2)) and a potent inhibitor of PGE(2)-E(2) synthase, is a rational anti-inflammatory drug for the treatment of chronic myelogenous leukaemia (CML).,",1,1
"The antihyperthermic activity of [ENTITY_A], a new [ENTITY_B] inhibitor.inhibition., a new [ENTITY_B] inhibitor., an acetylcholinesterase inhibitor.
Comparative metabolism of phenytoin in humans and rats following oral and intravenous administration of single doses of single- and multi-dose valsartan or darunavir.- and norepinephrine-induced increases in oral bioavailability of",1,1
"(1) Synthesis and antitumor activity of [ENTITY_A] /SNO inhibitors: Part 2. [ENTITY_B] inhibition of the NHE3-NOX pathway., the first in a new series of [ENTITY_B] /SNO inhibitors, is described here, and its biological evaluation is detailed in this report., the second in a new series of NOX inhibitors, is described in Part 1 here., as well as the new compounds, are potent, irreversible inhibitors of the N",1,1
"(1) Evaluation of the [ENTITY_A] block of [ENTITY_B] : comparison with the other selective [ENTITY_B] inhibitor [ENTITY_B].inhibitors currently under investigation include [ENTITY_B], milrinone, dalcinamide, [ENTITY_B], ketoprofen, [ENTITY_B], and meclofenamic acid.blockers currently under investigation include enalapril, nimesulide, pancuronium, and rofecoxib.blockers currently under investigation include darunav",1,1
"(1)H-NMR-based identification of [ENTITY_A], a new inhibitor of [ENTITY_B] : relevance to bipolar disorder., an [ENTITY_B] blocker (ARB), has been shown to improve mania in several animal and in vitro studies.inhibitors (IBD) have been described in the past, but none of them has been validated as a treatment for bipolar disorder.(N-propargyl-1-(2-methylanthraquinolino)eth",1,1
"This study explored the ability of [ENTITY_A], an [ENTITY_B] inhibitor with mild inhibition of both [ENTITY_B] and COX-1, to attenuate colitis by modulating the TLR4/NF-κB signaling pathway in the gastrointestinal mucosa., an acetylcholinesterase (AChE) inhibitor and prokinetic agent, inhibits colonic polyps growth and inflammation., an anti-inflammatory agent, inhibits colonic polyps growth and inflammation.",1,1
"(R)-(-)-Epicatechin gallate inhibited [ENTITY_B] (BChE) in a time-dependent manner with a IC(50) value of 23 microM, and a 50 microM K(I) value for inhibition of both [ENTITY_A] and cholangiocyte cholesterol transport., a metabolite of epicatechin gallate, inhibited BChE at a rate tenfold higher than that of its gallate metabolite, and its IC(50) value for inhibition",1,1
"(R)- and (S)-2-hydroxy-4-methylanthraquinone ( [ENTITY_A] ) suppress [ENTITY_B] production via a mechanism distinct from CYP3A., a chalcone of ethylmethanone, inhibits [ENTITY_B] as well as cytochrome P-450 3A (CYP3A)., a chalcone of ethylmethanone, inhibits both CYP3A and CYP2., a ch",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-1-hydroxy-3-nonyl)adenine, [ENTITY_A], a selective inhibitor of [ENTITY_B], exhibits substantial activity in vivo as well as in vitro., a selective inhibitor of SLC21A6., a selective inhibitor of SLC21A6., a selective inhibitor of SLC21",1,1
"Inhibitors of [ENTITY_A] : a novel class of [ENTITY_B] inhibitors., a potent and selective COX-1 inhibitor, has been evaluated for its anti-heart-failure activity but also has a role in reducing inflammation., a novel COX-2 inhibitor, has been evaluated for its anti-heart-failure activity and also has a role in reducing inflammation., a selective COX-3 inhibitor, has been evaluated for its anti-heart-fail",1,1
"This study evaluates the effect of the [ENTITY_A] inhibitor [ENTITY_B] at the dosages of 1000 and 1000 mg daily for 14 days in the adjuvant treatment of breast cancer.(N-{[1-(3-methoxy-phenyl)-5-(4-methoxyphenyl)-1-butanone]}-acetamide, 1000 mg daily) is a novel selective inhibitor of the [ENTITY_B] (MAO-B) enzyme., 1000 mg",1,1
"Inhibitory effects of [ENTITY_A], an [ENTITY_B] inhibitor, on platelet aggregation., an acetylcholinesterase inhibitor, inhibits platelet aggregation., an antithrombin I inhibitor, inhibits platelet aggregation., an antithrombin II inhibitor, suppresses platelet aggregation in vitro., an inhibitor of both acetylcholinesterase and antithrombin, suppresses platelet aggregation in vitro.",1,1
"(R)-3-(Aminomethyl)-9-(2-hydroxypropoxy)-4-(3-methoxy-phenyl)-1-(3-nonyl)propane-1-carboxylic acid ( [ENTITY_A] ), a novel [ENTITY_B] (MAO-B) inhibitor, inhibits both [ENTITY_B] and MAO-B., a new MAO-A inhibitor, does not inhibit MAO-A., a new MAO-B",1,1
"(R)-(+)-Tamsulosin ( [ENTITY_A] inhibitor), a potent, selective peripheral [ENTITY_B] inhibitor, inhibits both PDE3A and PDE3B.block of PDE3 is mediated by direct binding of the drug to the enzyme, as confirmed by direct inhibition of the enzyme by the small molecule [ENTITY_B] (R)-(+)-tamsulosin (etoricoxib) (100 nM, Sigma).block of",1,1
"In vitro, [ENTITY_A], a [ENTITY_B] -selective inhibitor, inhibits growth of colorectal cancer cells in a dose-dependent manner., an antiatherogenic drug that selectively inhibits the [ENTITY_B], has been shown to reduce cancer growth in several experimental studies., which is a more selective inhibitor of COX-1, also inhibits growth of colorectal cancer cells in vitro., a selective inhibitor of prostaglandin E2, also inhibits growth",1,1
"inhibition of [ENTITY_A] by the antimalarial [ENTITY_B]., a [ENTITY_B] inhibitor., a COX-2 inhibitor., a PDE4 inhibitor., a PDE3 inhibitor., a PDE2 inhibitor., a PDE1 inhibitor.
The effect of cinchoninic acid and n-propyl gallate on the metabolism of phenformin in man., n-propyl gallate and cinchon",1,1
"(1,5-Diarylpyrrole) analogues as potent inhibitors of [ENTITY_B]., a new lead to treat Alzheimer disease (AD)., a new lead to treat Parkinson's disease., a new lead to treat dementia., a new lead to treat depression.
Synthesis, antitumor testing, and molecular modeling study of some new [ENTITY_A] -based [ENTITY_B] inhibitors., a new lead to treat Alzheimer's disease.",1,1
"In vitro metabolism of the [ENTITY_A] (BMS-354825): a potent inhibitor of [ENTITY_B] (BChE) that inhibits both CYP2B6 and CYP2C19., the first in a new class of potent and orally bioavailable [ENTITY_B] (BChE) inhibitors, has been evaluated in vitro as a potential antidepressant and anti-corticosteroid., the first in a new class of potent and orally bioavailable CYP2B6 and",1,1
"(S)-2-hydroxychalcone as the active metabolite of [ENTITY_A], a new anti-Parkinsonian drug., an oral [ENTITY_B] (MAO) inhibitor, inhibits both MAO and dopamine transporters., a new MAO inhibitor, inhibits only MAO., a new dopamine metabolite., a new MAO inhibitor and an acetylcholinesterase inhibitor., a new MAO inhibitor and an acetylch",1,1
"inhibitors based on an [ENTITY_A] scaffold for treatment of human prostate cancer., a [ENTITY_B] inhibitor currently in phase 3 clinical development, was purified from extracts of the Indian gooseberry (Emblica officinalis)., a more potent and longer-lasting compound, was isolated from the Indian gooseberry (Emblica officinalis)., a 1,4-benzodioxane [3-(4-methoxyphenyl)-",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(3-hydroxybenzoyl)-5-methyl-1-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-2-naphthyridin-2-one ( [ENTITY_A] ) inhibited [ENTITY_B] activity with IC-50 values of 43 microM and 227 microM, respectively., a phenylalanine-derived metabolite of ticlop",1,1
"inhibitors based on a [ENTITY_A] scaffold for the treatment of Alzheimer's disease., a potent, orally active inhibitor of [ENTITY_B]., a selective inhibitor of amyloid β42 aggregation., a selective inhibitor of aggregation of taurocholate and aggregation of amyloid beta40 peptide., a selective inhibitor of aggregation of amyloid β42., a selective inhibitor of aggregation of taurocholate and aggregation of amyl",1,1
The effect of the [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetics and metabolism of ketoprofen in humans..blockers such as ketoprofen and suprofen reduce the risk of serious adverse events (AE) such as gastrointestinal bleeding or uterine infarction.blockers such as ketoprofen and suprofen reduce the risk of serious adverse events (AE) such as gastrointestinal bleeding or uterine infarction.,1,1
"Inhibition of [ENTITY_A] (Bax) expression by [ENTITY_B]., a peripheral opiate agonist, induces apoptosis in cancer cells by inhibition of Bax expression., a peripheral opiate agonist, inhibits apoptosis in cancer cells by suppressing Bax expression.inhibition of Bcl-2 family.inhibition of Bcl-2 family;inhibition of Bax expression.inhibition of Bax expression.inhibition of B",1,1
"(R)-(-)-Epicatechin gallate inhibits [ENTITY_B] (BChE) with an IC-50 value of 54 microM; [ENTITY_A] (BChE-inhibitor) with an IC-50 value of 56 microM., the prototype of the epicatechin gallate family, is also inhibited by the gallate esters with an IC-50 value of 22 microM., gallate esters I and II, and gallate esters III and",1,1
inhibitors based on a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B].inhibitors based on a platinum(IV) complex with the antimetabolite [ENTITY_B] for the selective inhibition of cytochrome P-450 enzymes.inhibitors based on a platinum(IV) complex with the dual anticancer agent [ENTITY_B] for the selective inhibition of CYP 2C9 and CYP 3A4.inhibitors based on a platinum(IV),1,1
"This study explores the potential of [ENTITY_A], a new [ENTITY_B] inhibitor that targets the NHE3 subunit, to control tumor growth and lung metastases in NSCLC.inhibition in human lung carcinoma cells.inhibition in NSCLC cells.inhibition in NSCLC lung metastases.inhibition in NSCLC cell lines.inhibition in NSCLC metastases.inhibition in NSCLC cell",1,1
"(R)- and (S)-3-(Aryl)-4-(4-methoxymethyl)-3-nonylphenylhydrazine-2-carboxamide ( [ENTITY_A] ) were discovered as potent, non-competitive, [ENTITY_B] (MAO-B) inhibitors with high selectivity for the enzyme over the substrate., 3-(Aryl)-4-(4-methoxymethyl)-3-nonylphenylhydrazine",1,1
"The anti-inflammatory actions of [ENTITY_A] are ascribable to suppress [ENTITY_B] expression through PPAR-gamma., a [ENTITY_B] (COX-A) inhibitor, inhibits the expression of [ENTITY_B] and cyclooxygenase-2 (COX-2); however, it is not yet known if it inhibits COX-A, COX-B, COX-C, and COX-A/B activities simultaneously., a COX-A inhibitor, is",1,1
"inhibitors based on a [ENTITY_A] scaffold: Discovery of [ENTITY_B] -based [ENTITY_B] inhibitors., an [ENTITY_B] inhibitor that binds with high affinity to the N-terminal domain, was reported to have antitumor activities in preclinical studies.was optimized to improve the physicochemical properties of the original molecule and to create a safer and more potent compound.was designed to improve physicochemical properties of the original molecule without compromising its antitumor efficacy.was",1,1
"inhibitors based on a [ENTITY_A] scaffold as a novel strategy in breast cancer therapy., the prototypic [ENTITY_B] inhibitor, has been shown to have significant adverse effects on breast cancer patients' quality of life., a potent and selectively marketed COX-1 inhibitor, has been shown to have significant adverse effects on breast cancer patients' quality of life., the prototypic COX-2 inhibitor, has been shown to have significant adverse effects on breast cancer patients",1,1
"(R)-(-)-3-(Aminomethyl)-7-(3-hydroxypropoxy)naproxen ( [ENTITY_A] ) is a new, orally bioavailable, selective inhibitor of [ENTITY_B] leukotriene receptor (ILT1), which has little or no effect on ILT2., a second selective inhibitor of ILT1 and ILT3, is active against a broad spectrum of tumor cell types and is well tolerated., if well tolerated",1,1
"(1)H-NMR studies of the inhibition of [ENTITY_A] by [ENTITY_B], a [ENTITY_B] inhibitor.(1,5) and 5-fluoro-2-(3-hydroxybutoxy)-4-hydroxybenzoxaborole (BZD-3548) are potent, oral multi-targeted [ENTITY_B] inhibitors., a 1,5- and 5-fluoro-2-(3-hydroxybutoxy)-4",1,1
"This study explored the efficacy and safety of [ENTITY_A], a [ENTITY_B] inhibitor, in patients with suboptimal glycaemic control and type 2 diabetes mellitus., a selective inhibitor of [ENTITY_B], has recently been approved for the treatment of type 2 diabetes mellitus., a selective inhibitor of GLP-2, has recently been approved for the treatment of type 2 diabetes mellitus., a selective inhibitor of HMG-CoA reductase, has recently",1,1
"Inhibitors of [ENTITY_A] : 1,5-Diarylpyrrole nitrates as potent and selective [ENTITY_B] inhibitors..... hirudin.. nitrates. hirudin. N-demethyl hirudin. N-hydroxymethyl hirudin. nitrates. hirudin. N-demethyl hirudin. N-hydroxymethyl h",1,1
"inhibitors based on [ENTITY_A] scaffold: Discovery of [ENTITY_B] - and enantioselective COX-2 inhibitors., [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea]-ethanesulfonamide; LY294002 [1-(2-methoxy-phenyl)-3-naphthalen-2-yl benzilate], LY294005 [1",1,1
"This study explores the ability of [ENTITY_A] to inhibit [ENTITY_B] (Bsep) and its downstream effectors (Bsep-abeta, Bsep-gene, Bsep-beta-actin and Bsep-galpha).(Bsep) and its downstream effector (Bsep-abeta, Bsep-gene, Bsep-beta-actin and Bsep-galpha) were studied in vitro as",1,1
"(1) Evaluation of the [ENTITY_A] inhibition of the [ENTITY_B] (hcA2) by the small molecule [ENTITY_B]., a new inhibitor of hcA2, is in clinical development for the treatment of Alzheimer's disease., a new inhibitor of hsCIP1, is in clinical development for the treatment of Alzheimer's disease., a new inhibitor of hsCIP3, is in clinical development for the treatment of Alzheimer's disease.",1,1
"Inhibition of [ENTITY_A] (FNTA) by [ENTITY_B]., a key enzyme in the de novo synthesis of spermidine, is downregulated by the norepinephrine transporter ( [ENTITY_B] )., a new enzyme in the synthesis of spermine, is downregulated by the norepinephrine transporter ( NET)., a new enzyme in the synthesis of spermine, and norepinephrine transporter are expressed in human sperm., a new enzyme in the",1,1
"inhibitors based on a [ENTITY_A] scaffold: identification of [ENTITY_B], as a new class with longer half life., a [ENTITY_B] /STAT3 inhibitor; rosuvastatin, a phosphodiesterase inhibitor; [ENTITY_B], a [ENTITY_B] /STAT3 enhancer drug., a PDE3 inhibitor; rosuvastatin, a phosphodiesterase inhibitor; ketoprofen, a PDE4 inhibitor; ketoprofen, a PDE3",1,1
"The effect of the nonselective [ENTITY_A] inhibitor, [ENTITY_B], on renal function in cirrhotic rats: relevance to the treatment of ascites., a selective inhibitor of dipeptidyl peptidase 5 (DPP-5), has been recommended for the treatment of ascites in patients on CAPD., which is not regulated by DPP-5, has been found to be effective in the treatment of end-stage renal failure in rats.",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methyl-1-phenyl-1-butanone ( [ENTITY_A] ) is a novel selective [ENTITY_B] (COX-1) inhibitor., an oral direct inhibitor of COX-1., is a novel selective COX-2 inhibitor., a selective inhibitor of COX-1., an oral direct inhibitor of",1,1
"The effects of the [ENTITY_A] inhibitor [ENTITY_B] on gastric acid secretion and gastric acid absorption in healthy subjects., a potent inhibitor of proton pumps, has been shown to improve gastric acid secretion and gastric acid absorption in several studies., a potent inhibitor of proton pumps, has been shown to improve gastric acid secretion and gastric acid absorption in several studies., a selective inhibitor of the [ENTITY_B] /H(+)-coupled monocar",1,1
"Inhibition of the [ENTITY_A] by a selective inhibitor [ [ENTITY_B] ; DEGBG] leads to the formation of a novel quinazoline quinazoline metabolite [1] that is competitive with respect to the parent compound, and that can be eliminated by the enzyme [ENTITY_B] (ODG).is a key enzyme involved in the metabolism of phenytoin and has previously been reported to be inhibited by a series of structurally unrelated compounds [2-6] that were not confirmed",1,1
"inhibitors with longer and more selective potency than the reference [ENTITY_A] (COX-1) inhibitors [ENTITY_B] and rofecoxib., rofecoxib and ketoprofen have the potential to become first-line pharmacotherapy for osteoarthritis and related pain., rofecoxib and ketoprofen have the potential to become first-line pharmacotherapy for osteoarthritis and related pain., rofecoxib and",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(2-methylanthraquinone), [ENTITY_A] inhibitors that compete with the [ENTITY_B] for binding to the N-terminal amine of the enzyme, respectively, reduce AChE activity in vitro in a similar manner.inhibitors that do not inhibit aminomethyl moiety of enzyme.Inhibitors that do not inhibit aminomethyl moiety",1,1
"(R)- and (S)-3-(Aminomethyl)-6-hydroxybenzoyl-2-methylphenyl-5-oxopyrimidine ( [ENTITY_A] ) are potent and selective [ENTITY_B] inhibitors with mild adverse effects., sirolimus, and galactomannan suppress tumor growth in a similar fashion., a selective inhibitor of the [ENTITY_B] isoform, inhibits tumor growth in a different manner., sirolimus",1,1
"Inhibition of [ENTITY_A] by a new [ENTITY_B] derivate., a new [ENTITY_B] inhibitor., a new [ENTITY_B] inhibitor., a new ACE inhibitor.
Amino acid oxidation in human plasma by the oxidants cyanate, oxalate and malate., a new oxidant in plasma., a new oxidant in plasma., a new metabolite of malate and oxalate in plasma.(Oxal",1,1
"(R)-(-)-Epinephrine (100 micro m) and [ENTITY_A] (100 micro m)-induced vasoconstriction in rabbit aortic strips were inhibited by [ENTITY_B] (100 micro m)-analogue [ENTITY_B]., a [ENTITY_B] (NET) inhibitor, and its enantiomers produced vasoconstriction with similar potency.inhibits both cAMP and NET at comparable potency.may inhibit both cAMP and NET at comparable potency., an enantiomer of",1,1
"inhibitors based upon the [ENTITY_A] scaffold: Discovery of [ENTITY_B], a potent, orally bioavailable [ENTITY_B] inhibitor.inhibitors based upon the COX-1 scaffold., a potent, orally bioavailable [ENTITY_B] inhibitor.inhibitors based upon the COX-2 scaffold., a potent, orally bioavailable ACE-inhibitor., a potent, orally bioavailable ALA-inhibitor.",1,1
"(R)- and (S)-3-(2-fluoro-1-methylanthraquinone), two new [ENTITY_A] (mimicking) [ENTITY_B] analogues, inhibited [ENTITY_B] with IC50 values of 43 microM and 227 microM, respectively.inhibition of human and rat CYP enzymes was substrate-selective.inhibited CYP2B6 (IC50 = 23 microM) but not CYP2C19 (IC50 = 9",1,1
"(R)- and (S)-3-hydroxypropionate derivatives of (+)-3-fluoro-4-methoxybenzylhydrazine ( [ENTITY_A] ) alleviate colonic inflammation in a rabbit model through inhibition of [ENTITY_B] signaling and expression of Bcl-xL., a pro-apoptotic protein, is upregulated in colons of rats with inflammatory bowel disease (IBD)., a pro-apoptotic protein, is upregulated",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on gastric acid secretion in humans.(H-7) is an oral multi-targeted inhibitor of [ENTITY_B] (MAO-B, MAO-A, and MAO-C).Inhibitor H-7 has recently been introduced for the treatment of Parkinson's disease (PD).(H-7) has a better selectivity for the [ENTITY_B] than H-5.inhibitor H-7",1,1
"inhibitor, [ENTITY_A], suppresses metastasis via downregulation of Src., bosentan and glibenclamide inhibit metastasis via the phosphorylation of Akt., bosentan and glibenclamide are [ENTITY_B] inhibitors that are metabolized by the enzyme cytochrome P450 (CYP)., bosentan and glibenclamide are selective [ENTITY_B] (COX) inhibitors that are metabolized by CYP1",1,1
"(R)-(-)-Epibatidine inhibits both [ENTITY_A] and CYP3A in human liver microsomes., a [ENTITY_B] inhibitor that selectively targets CYP3A, was developed from the epibatidine molecule and is currently undergoing clinical trials., a CYP3B inhibitor, was developed from the pan-catechol inactivator [ENTITY_B] and is in phase I clinical trials., a mixed CYP3A/CYP3B",1,1
"In vitro metabolism of [ENTITY_A] (V600E) inhibitor [ENTITY_B]., a novel [ENTITY_B] inhibitor.inhibitor.blocker., a selective norepinephrine reuptake inhibitor.
Synthesis and evaluation of the [ENTITY_B] - and CYP3A-selective [ENTITY_B] inhibitors candesartan and losartan., a novel diuretic.
Design, synthesis, and in vitro metabolism of some novel phenolic",1,1
"(1) Evaluation of the [ENTITY_A] in vitro selectivity by measuring the inhibitory effects of COX-1, COX-3 and arachidonyl trifluoromethyl ketone (AACOCF3) on the [ENTITY_B] isoforms., an uncompetitive norepinephrine receptor antagonist, was evaluated as a potential inhibitor of [ENTITY_B]., an uncompetitive norepinephrine receptor agonist, was evaluated as a potential inhibitor of COX-",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., isolated from Indian gooseberry (Emblica officinalis)., isolated from Indian gooseberry (Emblica officinalis)., a chalcone from Indian gooseberry. 1,8-cineole ( 1), a metabolite of 1,8-cineole. 1,8-cineole, isolated from Indian gooseberry. 1,8-cineole, a metabolite of menthol.",1,1
"In vitro inhibitory effects of the antimalarial [ENTITY_A] on [ENTITY_B] expression., a new target for artemisinic acid., a new target for artemisinic acid., a new target for artemisinic acid., a new target for artemisinic acid., a new target for artemisinic acid., a new target for artemisinic acid. artemisinic acid inhibits expression of COX isoforms., a new target for",1,1
"The effectiveness of [ENTITY_A], a new inhibitor of [ENTITY_B], in the treatment of osteoarthritis: a double-tracer study., a new inhibitor of acetylcholinesterase, inhibits both acetylcholinesterase and butyrylcholinesterase., a new inhibitor of acetylcholinesterase, inhibits both acetylcholinesterase and butyrylcholinesterase.",1,1
"(1) H NMR-DQSAR-assisted drug identification of a [ENTITY_A] derivative as a novel [ENTITY_B] inhibitor.(1), an effective [ENTITY_B] inhibitor in man, has been under investigation as a lead compound for the treatment of Alzheimer's disease.(2), another effective dementia drug, has been under investigation as a lead compound for the treatment of Parkinson's disease.(3), an ineffective Parkinson's disease drug, has not",1,1
"(R)- and (S)-Methamphetamine (MA) induced hyperthermia is reversed by [ENTITY_A], a selective inhibitor of [ENTITY_B] leukotriene receptor (CTR)., a nonselective reversible COX-2 inhibitor, was also incubated with rats and results were compared with MA-induced hyperthermia., a selective COX-1 inhibitor, was also incubated with rats and results were compared with MA-induced hyperthermia.,",1,1
inhibitors based on a [ENTITY_A] scaffold: Discovery of [ENTITY_B] - and oleate-derived compounds as potent [ENTITY_B] - and oleate-selective inhibitors.(BMS-354825) is a novel [ENTITY_B] (BMS-2254825) that targets the NHE2 subunit of HIF-1alpha and has activity against multiple HIF-1 variants.is a potent oleate-selective inhibitor that targets the HO-,1,1
"(1) Synthesis, biological evaluation, and molecular modeling of [ENTITY_A] derivatives as potent [ENTITY_B] (V600E) inhibitors: Part 2.inhibitors for the treatment of melanoma cell lines., a novel small molecule [ENTITY_B] DEX-inhibitors., a novel small molecule V600E inhibitor., a new small molecule inhibitor of the PDGFRbeta., a new inhibitor of the PDGFRa., a new",1,1
"inhibitor [ENTITY_A] (Aliskiren), a selective inhibitor of [ENTITY_B] (N-type), is currently in phase 3 clinical development for the prevention of cardiovascular events and of some cancers.Inhibitors, such as aliskiren, which are available in many countries, can reduce blood pressures and may be effective against other forms of blood pressure, including the N-type., which is in phase 3 clinical development, has not been evaluated for N-type inhibition.,",1,1
"(R)- and (S)-Methamphetamine (MAO-A) potentiate [(3)H]E217βG uptake in platelets by direct inhibition of [ENTITY_A].inhibition by [ENTITY_B], but not MAO-B.block of [(3)H]E217βG uptake by MAO-A.inhibition by nimesulide, but not MAO-B.block of [(3)H]E217β",1,1
"(1)H NMR studies of the [ENTITY_A] inhibitor [ENTITY_B] indicate a reversible binding to the active site of the enzyme., a new class of potent irreversible [ENTITY_B] inhibitors.,, and rosuvastatin are potent irreversible PDE3 inhibitors that are not associated with PDE4 inhibition., rosuvastatin, and niflumic acid are irreversible PDE3 inhibitors that are not associated with PDE4 inhibition.",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on renal function in cirrhotic rats: comparison with the effects of enalapril and [ENTITY_B]., an inhibitor of [ENTITY_B]., an inhibitor of PTGS2., an inhibitor of PTGS2., an inhibitor of PTGS3., an inhibitor of PTGS1., an inhibitor of PTGS3. enalapril, a calcium channel blocker. etod",1,1
"Inhibitory effects of the [ENTITY_A] blocker [ENTITY_B] on atrial fibrillation., a [ENTITY_B] inhibitor, is currently in phase 3 clinical development for the treatment of atrial fibrillation., a novel antiarrhythmic drug that inhibits platelet function, has been in development for more than 20 years., which targets multiple atrial and ventricular components of the arrhythmia, has completed phase 3 trials, and has completed phase 2 trials",1,1
"The effects of [ENTITY_A] inhibitor, [ENTITY_B], in the reduction of acid-induced ureteral obstruction in horses., a selective inhibitor of [ENTITY_B] (MLCK), was evaluated for its efficacy at reducing ureteral obstruction (UUO) in horses., a selective inhibitor of MLCK, was evaluated for its efficacy at reducing ureteral obstruction in horses., a selective inhibitor of MLCK, was evaluated for its efficacy at reducing u",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a [ENTITY_B] inhibitor., a ACE inhibitor., an ARB inhibitor.
Amino acid metabolism and metabolism-related genes in the marine microsatellite alga Encephalitozoon cuniculus., a metabolite of nicotinic acids and other non-steroidal anti-inflammatory drugs, is a substrate of hepatic and intestinal enzymes and can be formed in the liver and colon.,",1,1
Inhibition of [ENTITY_A] (Aβ25-35) aggregation with [ENTITY_B] blocks the deposition of β-secretase in vitro.inhibitors [ENTITY_B] (Aβ25-35) aggregation in vitro.block Aβ25-35 aggregation at clinically relevant concentrations.inhibition of Aβ25-35 aggregation in the presence of the plasmin substrate.blockers Aβ25-35 and taurocholate.blockers Aβ25,1,1
"(S)-3-(Aminomethyl)-5-(3-hydroxypropoxy)-1-hydroxy-1-methanone, [ENTITY_A], is a potent, orally bioavailable inhibitor of [ENTITY_B]., a less potent, orally bioavailable inhibitor of serotonin., both have a very different pharmacology and are not interchangeable., if used as a single agent, is a very effective, well-tolerated inhibitor of serotonin., if",1,1
"This study explores the effects of the [ENTITY_A] inhibitor [ENTITY_B] on endothelial dysfunction in humans.inhibitor 0.1-10 ng/ml, nimesulide 0.01-10 ng/ml, and NS398 0.01-10 ng/ml inhibited NO production and [ENTITY_B] (iNOS) expression in human umbilical vein endothelial cells (HUVECs).inhibited NO production and iNOS expression in HUVECs",1,1
"In vitro and in vivo inhibition of [ENTITY_A] by [ENTITY_B]., a [ENTITY_B] inhibitor currently in phase 3 clinical development, was evaluated in vitro and in vivo for its ability to disrupt tumor vasculature., currently in phase 3 clinical development, was evaluated in vitro and in vivo for its ability to disrupt tumor vasculature., currently in phase 3 clinical development, was evaluated in vitro and in vivo for its ability to disrupt tumor vasculature., currently in phase",1,1
"In vivo inhibition of [ENTITY_A], a novel [ENTITY_B] inhibitor, by [ENTITY_B] and captopril in rabbit aortic and cardiac valves., a novel ACE-inhibitor, is currently in phase 3 clinical development for the treatment of congestive heart failure., a dual ACE- and NEP-inhibitor, has recently been approved for the treatment of angina pectoris in patients with dysmenorrhea.inhibitors have not yet been",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-1-hydroxy-3-nonyl)adenine ( [ENTITY_A] ), a potent and selective inhibitor of [ENTITY_B] (MAO-B) but with mild inhibitory effects on MAO-A, was evaluated for its in vitro selectivity for androgen receptor., an active metabolite of R-3,4-diary",1,1
"Inhibition of [ENTITY_A] (FNTA) by [ENTITY_B]., an inhibitor of platelet derived growth factor (PDGF)-beta that is released into the extracellular milieu, inhibits platelet activation and aggregation, thereby reducing thromboxane (TX) formation and enhancing TX inhibition., a selective blocker of platelet derived growth factor (PDGF)-a, has been reported to be an inhibitor of platelet TXB2 receptor (PDGFR) but its precise role",1,1
"Inhibitors based on a [ENTITY_A] scaffold as a novel strategy for breast cancer therapy., an Iressa-type [ENTITY_B] inhibitor, has demonstrated activity against multiple imatinib-resistant BCR-ABL isoforms., a [ENTITY_B] inhibitor with a longer half life, has been evaluated as a breast cancer therapy since 2002., an [ENTITY_B] inhibitor that has been in development since 2004, has shown activity against all imatinib-resistant",1,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] -mediated cholesterol efflux by [ENTITY_B] from human plasma., an inhibitor of the [ENTITY_B] Cl- channel (Kir6.1/SUR2B), transports cholesterol out of the plasma membrane in parallel with a substrate, but it is not yet clear whether it also transports small molecule drugs., an inhibitor of the SUR2B, transports small molecules out of the human plasma membrane in parallel with a substrate, but it is not",1,1
"(R)-3-hydroxybenzoyl-3-methylanthraquinone ( [ENTITY_A] ), a novel [ENTITY_B] (COX-1) inhibitor, induces apoptosis in tumor cells via inhibiting [ENTITY_B] signaling., an indole alkaloid isolated from a Thai medicinal plant, inhibits COX-1., an indole alkaloid isolated from a Thai medicinal plant, inhibits COX-1., a natural product that has been",1,1
"inhibitors based on a [ENTITY_A] scaffold for the targeted inhibition of [ENTITY_B] and ABL.inhibitors based on a platinum nanoparticle scaffold for the targeted inhibition of COX-1, COX-2, and ABL.inhibitors based on a platinum nanoparticle scaffold for the targeted inhibition of COX-1, COX-2, and ABL.inhibitors based on a platinum nanoparticle scaffold for the",1,1
"This study was designed to assess the impact of [ENTITY_A] (a [ENTITY_B] inhibitor), enalapril (an ACE-inhibitor), N-acetylcysteine (ANCA-inhibitor), and the combination of both into a single agent on the rate of [ENTITY_B], COX, and N-acetylcysteine-dependent urinary albumin excretion., COX, and N-acetylcysteine-dependent urinary albumin excretion rates",1,1
"Inhibition of [ENTITY_A] /NFkappaB signaling by [ENTITY_B] blocks migration and invasion of MDA-MB-231 cells., a natural [ENTITY_B] inhibitor, inhibits migration and invasion of MDA-MB-231 cells., a natural mitogen-activated protein kinase (MAPK) inhibitor, reduces migration and invasion of MDA-MB-231 cells., a natural PI3K inhibitor, reduces migration and invasion of MDA-MB-231",1,1
"The effects of the [ENTITY_A] inhibitor [ENTITY_B] on endothelial function in healthy subjects: a comparison with placebo., an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGFA), is widely used to treat hypercholesterolemia., an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF), is widely used to treat hypercholesterolemia., an oral tyrosine kinase inhibitor that",1,1
"(1) Evaluation of the inhibitory potency of [ENTITY_A] ( [ENTITY_B], ketoprofen, carrageenan, dibucaine and indomethacin) upon [ENTITY_B] ( COX-1, COX-3, COX-4)., ketoprofen, carrageenan, dibucaine and indomethacin inhibit the activities of the human COX enzymes at clinically relevant concentrations., ketoprofen, car",1,1
inhibition of [ENTITY_A] with a series of [ENTITY_B] inhibitors.inhibition of [ENTITY_B].inhibition of OATP1B3 and OATP2B1: selectivity against OATP-B3. OATP2B3-mediated transhydroxystachyma formation in vitro.inhibition of OATP-B3 and OATP-B4.inhibition of OATP-B3. OATP-,1,1
"inhibitors based on the [ENTITY_A] scaffold: Discovery of [ENTITY_B], a selective [ENTITY_B] inhibitor with high tissue penetration., a selective inhibitor of the NHE3 subunit., a selective inhibitor of the NHE2 subunit., a selective inhibitor of the NHE1 subunit., a selective inhibitor of the NHE3 subunit. huprine H, a potent [ENTITY_B] inhibitor in vivo. huprine",1,1
"(1)H NMR-derived structural model of [ENTITY_A] : binding mode and binding site structure.inhibitors with favorable pharmacokinetic profiles and low gastrointestinal adverse events.(AP2453063): a potent, orally active multi-targeted [ENTITY_B] inhibitor.(AP2453063): a potent, orally active multi-targeted COX-2 inhibitor that selectively inhibits COX isoforms 1 and 2.(AP2453063):",1,1
"inhibition of [ENTITY_A] (Bsep) by [ENTITY_B]., a central element of the Bsep resistance mechanism, was previously shown to be inhibited by [ENTITY_B] (V914) and to be inactivated by ceftazidime (N-formyl-9-(2-methoxy-phenyl)-9-(3-phenoxybenzyl)-9-methoxy-3-naphthalen-9-yl)-methanesulfon-",1,1
"The effect of [ENTITY_A], a [ENTITY_B] inhibitor, on acid lung injury.inhibition reduces acid lung injury.inhibition reduces lung injury in rats.blockers.blocker.blocker.
Amino acid oxidase-1 ( [ENTITY_A] ) inhibition with the selective COX-2 inhibitors ketoprofen and ketrolackertion.protection.protection.protection.protection.protection.",1,1
"inhibitors for the treatment of prostatic carcinoma: a novel series of [ENTITY_A] ( [ENTITY_B], LY 344864)., an irreversible [ENTITY_B] (LY 3344864), is a new oral proapoptotic agent for treatment of prostatic carcinoma., an irreversible proapoptotic agent for treatment of prostatic carcinoma., a selective COX-2 inhibitor., a selective COX-1 inhibitor., a selective nore",1,1
"This study explores the feasibility of targeting these high AAAD levels for chemotherapy with the dual [ENTITY_A] /EGFR inhibitor sunitinib., a [ENTITY_B] kinase inhibitor that targets the EGFR, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) and gastrointestinal stromal tumours (GIST)., a selective EP1-receptor kinase inhibitor that targets the EGFR, has recently been approved for the treatment of chronic myel",1,1
"The anti-inflammatory drug [ENTITY_A] reduces [ENTITY_B] protein abundance and suppresses NF-κB signaling., an oral inhibitor of TLR-4 and IKK-beta, suppresses the proliferation of murine primary microglia and astrocytes., an oral inhibitor of TLR-6 and IKK-beta, suppresses the expression of pro-inflammatory IκBα and IκBβ in activated primary microglia and astrocytes.",1,1
"(R)-Phenylalanine and the [ENTITY_A] inhibitor [ENTITY_B] reduce the formation of reactive oxygen and nitrogen species in the brain., a non-peptidic inhibitor of [ENTITY_B], reduces the formation of reactive oxygen and nitrogen species in the brain., a non-peptidic inhibitor of platelet PGHS-1, reduces the formation of reactive oxygen and nitrogen species in the brain., a non-peptidic inhibitor of plate",1,1
"inhibitors based on a [ENTITY_A] scaffold: Synthesis, structure-activity relationship, and antitumor activity of the [ENTITY_B] derivatives., a potent and selective [ENTITY_B] inhibitor., a potent and selective COX-2 inhibitor., a potent and selective norepinephrine inhibitor., a potent and selective epinephrine inhibitor., a novel class of selective 5-HT(2A/2C) agonists.,",1,1
"The effects of the [ENTITY_A] inhibitor [ENTITY_B] on endothelial function and adhesion in a rabbit aortic smooth muscle cell line., a potent and specific inhibitor of [ENTITY_B], reduces atherosclerotic plaque formation in a rabbit aortic smooth muscle cell (AACMC) line., a selective inhibitor of Src kinase, reduces the formation of intracellular adhesion structures (ICAS) in a rabbit aortic smooth muscle cell (AAC",1,1
"(R)- and (S)-N-propargyl-1-(R)-1-hydroxy-3-methylanthraquinone ( [ENTITY_A] ) inhibit the [ENTITY_B] (BChE) enzyme with IC-50 values of 43 microM and 227 microM, respectively., a specific inhibitor of the cytochrome P-450 enzymes CYP3A and CYP2D6, showed IC values of 43 microM and 667 microM, respectively.",1,1
"This study evaluates the efficacy of [ENTITY_A] (a [ENTITY_B] inhibitor with -SH group) in patients with osteoarthritis of the hip and/or the knee.(PLZ) is an oral anti-inflammatory drug approved for the treatment of rheumatoid arthritis and osteoarthritis., an oral anti-inflammatory drug that inhibits COX-1, -2, and -3, is also approved for the treatment of osteoarthritis.,",1,1
"The use of the [ENTITY_A] inhibitor, [ENTITY_B], in the treatment of type 2 diabetes: a meta-analysis of published trials.The purpose of this study was to evaluate the effectiveness and safety of glimepiride (GML), a new orally active [ENTITY_B] inhibitor, in patients with type 2 diabetes mellitus (DM), as compared to glipizide (GLP-2), a reference [ENTITY_B] inhibitor. Controlled trials of patients with DM were identified by reviewing the",1,1
"(R)- and (S)-Methylenedioxymetabolamide inhibit [ENTITY_A] activity by direct inhibition of enzyme active site residues Ser-530, Thr-535, and His-541., a new inhibitor of [ENTITY_B], inhibits COX-1 activity in vitro as well as in vivo., a selective COX-2 inhibitor, inhibits COX-1 and COX-3 in parallel., moxidectin, and methylen",1,1
"inhibition of [ENTITY_A] (MMP-2) and MMP-9 by [ENTITY_B] and captopril reduces metastasis in Lewis lung carcinoma cells., captopril; MMP-2 and MMP-9 inhibition in Lewis lung tumor cells., captopril; MMP-2 and MMP-9 inhibition in Lewis lung carcinoma cells., captopril; MMP-2 and MMP-9 inhibition in Lewis lung tumor cells.",1,1
"inhibitors based on the [ENTITY_A] scaffold: Discovery of [ENTITY_B] (BMS-354825)., a potent oral multi-targeted [ENTITY_B] (MAO) inhibitor, was isolated from a stem extract of Sophora flavescens., a potent MAO inactivator, was isolated from a stem extract of Sophora flavescens.was designed to target the MAO enzyme at the active site of cytochrome P450, but also inhibited P",1,1
The effect of the [ENTITY_A] inhibitor [ENTITY_B] on gastric acid secretion in rats.(N-propargyl-1-(R)-aminoindan) is a novel selective inhibitor of indoleamine-type N-methyl-D-tryptamine receptor.(N-propargyl-1-(R)-aminoindan) is a novel selective inhibitor of indoleamine-type N-methyl-D-tryptamine receptor.,1,1
"(1)H-NMR and MALDI-ToF analysis of [ENTITY_A] inhibitory activity of [ENTITY_B], carprofen, dorzolamide and indomethacin.inhibitory activity of celecoxib.inhibitory activity of ketoconazole.- and indomethacin-mediated N-demethylation of DNA.- and carprofen-mediated deamination of DNA.inhibitory",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., an inhibitor of the [ENTITY_B]., an inhibitor of the SLC3A., an inhibitor of the SLC3A.
Inhibitors of the SLC3A and SLC3B proteases., an inhibitor of the SLC3A.
Inhibition of the SLC3A and SLC3B proteases by phenformin., an inhibitor of the SLC3A. ph",1,1
Inhibitors based on a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B].was chosen as the target to explore a new class of small molecules that binds with high affinity to the enzyme active site.was chosen as the target to explore a new class of small molecules that binds with high affinity to the enzyme active site.was chosen as the target to explore a new class of small molecules that binds with high affinity to the enzyme active site.was chosen,1,1
"In vitro metabolism of the [ENTITY_A] inhibitor [ENTITY_B] by CYP2B6 and CYP3A4 is mediated by CYP3A and CYP2D6, but not by CYP2C9 and CYP3A5., the prototypical CYP3A inhibitor, has been shown to be metabolized by CYP3A4, but not CYP2D6., which has been shown to be metabolized by CYP2",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(2-hydroxypropoxy)-1-hydroxy-1-methanone ( [ENTITY_A] ), two novel [ENTITY_B] selective inhibitors of carbonic anhydrase B (CA), have been synthesised and evaluated., a reference CA inhibitor, causes little to no inhibition of CA II., at low concentrations, selectively inhibits CA III., at very high concentrations, selectively inhibits CA V",1,1
"This study was designed to test the hypothesis that [ENTITY_A] -specific inhibition of the [ENTITY_B] -MLC interaction would be a mechanism of action for vardenafil ( [ENTITY_B] )., a new orally bioavailable, selective PDE3 inhibitors, was recently approved for the treatment of ED.was evaluated in this study as a potential MLC inhibitor., a new orally bioavailable, selective PDE3 inhibitor, was recently approved for the treatment of ED., a novel, selective",1,1
Inhibition of [ENTITY_A] /STAT3 activation inhibits tumor growth and lung metastases of HT29 cells.inhibitors [ENTITY_B] and sunitinib inhibit the phosphorylation of [ENTITY_B] /STAT3 in HT29 tumor cells.inhibition in HT29 cells.blockers [ENTITY_B] and sunitinib inhibit activation of phosphoinositide 3-kinase in HT29 cells.blockers nimesulide and NS-389 inhibit phosphorylation of STAT,1,1
"Inhibition of the [ENTITY_A] /MEK/ERK pathway prevents downregulation of [ENTITY_B] by [ENTITY_B].inhibited the phosphorylation of mitogen activated protein (MAP) kinases, extracellular signal regulated kinase 1/2 (ERK-1/2), c-jun NH2-terminal kinases (JNKs) and Akt in the murine spleno-neural tissue., a potent inhibitor of the MAPK/ERK pathway",1,1
"Inhibitors based on [ENTITY_A] (Gleevec, Pfizer) and erlotinib (Tarceva, GW-562016) are novel [ENTITY_B] inhibitors with favorable pharmacokinetic profiles., a second new [ENTITY_B] inhibitor., a third new EGFR/KIT inhibitor., erlotinib and gefitinib are potent and well-known CYP3A substrates., erlotinib and glive",1,1
"inhibitors based on a [ENTITY_A] scaffold., an [ENTITY_B] /STAT3 inhibitor., a cyclin D1/D2 inhibitor. zaprinast, a p53 inhibitor., a cyclin E inhibitor., an ERK inhibitor., a p38 inhibitor., an NF-kappa B inhibitor.
[Cloning, Characterization and inhibition studies of [ENTITY_A], a new [ENTITY_B] from Trypanosoma cruzi].The",1,1
"(R)-(-)-3-(Aminomethyl)-7-hydroxy-1-(3-methoxy-phenyl)-1-hydroxymethyl-1-oxymethyl-3-naphthalen-2-one ( [ENTITY_A] ), a highly potent [ENTITY_B] (COX-2) inhibitor with moderate toxicity, showed partial selectivity for COX-1, with an IC(50) value of 23 microM; this compares with IC values of more",1,1
"inhibitors based on the [ENTITY_A] scaffold as a strategy for cancer therapy., an oral multi-targeted [ENTITY_B] (MAO) inhibitor, is in clinical development for treatment of Parkinson's disease, Alzheimer's disease, and related dementias., a selective MAO inhibitor, is in clinical development for treatment of Parkinson's disease, Alzheimer's disease, and related dementias., a small molecule MAO inhibitor, is in clinical development for treatment of Alzheimer's disease",1,1
"inhibitor [ENTITY_A] (LPV, Imatinib) is a new therapeutic approach in chronic myelogenous leukaemia [1, 2, 3, 4], and its use has been approved in imatinib-acquired resistance in MTC [5]., a small molecule [ENTITY_B] inhibitor, inhibits the [ENTITY_B] as well as the KIT and VEGF receptor and is currently in Phase 3 clinical development [6, 7, 8]., the first imatin",1,1
"The antihyperthermic effect of oral administration of [ENTITY_A] in the form of a solid lipid nanoparticle: a preliminary study., a [ENTITY_B] inhibitor, is a useful drug for the treatment of hyperthermia in patients with cancer and the treatment of cancer pain., a mitochondrial antioxidant, inhibits cancer cell invasion and angiogenesis through downregulation of [ENTITY_B]., a mitochondrial antioxidant, inhibits cancer cell invasion and angiogenesis through downregulation of mitochondrial transmembrane potential",1,1
"inhibitors based on the [ENTITY_A] scaffold: [ENTITY_B] - and imatinib-mediated inhibition of the NRAS and BCL-2, respectively., an oral tyrosine kinase inhibitor that targets the N-methyl-d-aspartate receptor and the [ENTITY_B] (Bcl-2) family of proteins, has revolutionized the treatment of neurodegeneration in multiple sclerosis., an oral tyrosine kinase inhibitor that targets the N-methyl",1,1
"The effect of [ENTITY_A], an [ENTITY_B] inhibitor, on the pharmacodynamics of ketoconazole in a murine model.The objective of this study was to develop a PK model to predict the maximum tolerated dose (MTD) of ketoconazole when ceftazidime is used as a reference [ENTITY_B] inhibitor (IH) and to determine the effect of the IH metabolite 4-hydroxy-3-methylanthraquinone (M4",1,1
"Inhibition of [ENTITY_A], PDE3 and PDE4 by [ENTITY_B]., a selective inhibitor of [ENTITY_B] (PCA), inhibits platelet aggregation and collagen secretion., a selective inhibitor of PCA, inhibits platelet aggregation and collagen secretion., a selective inhibitor of PCA, inhibits platelet aggregation and collagen secretion., a selective inhibitor of PDE3 and PDE4, inhibits platelet aggregation and collagen secretion., a selective inhibitor of",1,1
"This study was designed to test the hypothesis that [ENTITY_A] -induced reductions in brain GABA levels are due to increased GABA permeability., a [ENTITY_B] inhibitor, reduced brain GABA levels in both healthy volunteers and chronic ethanol-intoxicated patients.inhibitors [ENTITY_B] and apocynin reduced brain GABA levels in healthy volunteers and ethanol-intoxicated patients., a GABA oxidase inhibitor, and apocynin decreased GABA levels in ethanol-intoxicated patients.",1,1
"(1) Synthesis, biological evaluation, antitumor testing and molecular modeling studies of [ENTITY_A] (BMS-582949): a novel [ENTITY_B] -derivative as a novel class of potent [ENTITY_B] inhibitors.2)inhibitory activity and molecular modeling study of BMS-582949.inhibitors.inhibitors.Inhibitors. Article first published on Pharmaceuticals Biotechnology News.
Structural and functional",1,1
"The effect of the non-steroidal anti-inflammatory drug [ENTITY_A] on intercellular adhesion molecule-1, intracellular adhesion molecule-3, intracellular adhesion molecule-6 and vascular cell adhesion molecule-1 in human monocytic cells., an inhibitor of [ENTITY_B] (COX), is widely used to relieve inflammation., a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandins E2 and D2, but",1,1
"inhibitors based on the [ENTITY_A] scaffold as a new strategy for breast cancer patients with elevated cardiovascular risks., a new, oral [ENTITY_B] -selective inhibitor that inhibits [ENTITY_B] /COX-1 but not COX-2., a new, oral COX-2 inhibitor that inhibits prostaglandin E2., a new COX-1 inhibitor., a new, oral cyclooxygenase-2 inhibitor that inhibits COX-",1,1
"This study explores the potential mechanism of action of [ENTITY_A], a novel [ENTITY_B] inhibitor., a potent and selective COX-2 inhibitor., a selective COX-1 inhibitor., a selective COX-3 inhibitor., a selective COX-4 inhibitor., a selective inhibitor of prostaglandin E2., a selective inhibitor of COX-3., a selective inhibitor of prostaglandin E1.",1,1
"(1)H NMR-based metabolite identification of the [ENTITY_A] (BMS-582949) inhibitor [ENTITY_B]., a BMS-582949 selective inhibitor., a potent oral [ENTITY_B] (BMS-582949) inhibitor., a BMS-582949 noncompetitive inhibitor., a BMS-582949 selective inhibitor., a potent oral COX-2 inhibitor.
Synthesis and antitumor",1,1
"Inhibitors of [ENTITY_A] block of [ENTITY_B]., a new approach to Alzheimer's disease., a new drug for mild Alzheimer's disease., a new drug for mild Alzheimer's disease., a new drug for mild Alzheimer's disease., a new drug for mild Alzheimer's disease. amantadine, a second drug for mild Alzheimer's disease., a new drug for mild Alzheimer's disease., a new drug for mild Alzheimer's disease",1,1
"In vitro, [ENTITY_A] decreased the production of [ENTITY_B], VEGF, BNP, and Bcl-xL, and improved the survival of Lewis lung carcinoma cells., an inhibitor of [ENTITY_B] (Bcl-2)., an antiangiogenesis inhibitor (Bcl-xL)., an activator of Bcl-xL., an inhibitor of Bcl-2., an activator of Bcl-2",1,1
"(R)-3-butenyl-5-[(1S)-1-hydroxypropoxy]benzoxaborole ( [ENTITY_A] ) is a new boron-containing antibiotic that inhibits [ENTITY_B] (BChE), and that has already been in use in Japan as anthelmintic., which was first described as a peripheral benzodiazepine metabolite, is also a potent inhibitor of BChE, as well as a [ENTITY_B] inhibitor.",1,1
"(R)- and (S)-3-hydroxy-3-methylanthraquinone ( [ENTITY_A] ) inhibited [ENTITY_B] activity with IC50 values of 43 microM and 227 microM, respectively.(8-methoxymethyl-3-methylanthraquinone), an analogue of 3-hydroxy-3-methylanthraquinone, inhibited the activity of both CYP1A and 2C9 with IC50 values of 21",1,1
"(R)-3-hydroxybenzylhydrazine ( [ENTITY_A] ) is a potent irreversible inhibitor of [ENTITY_B], which is used to treat bipolar disorder, but has no clinically relevant effects on alpha 1A and alpha 1E., a selective alpha 1C inhibitor that is used to treat bipolar disorder, has no clinically relevant effects on alpha 1A and alpha 1E., a selective alpha 1D inhibitor that is used to treat bipolar disorder, has no clinically relevant effects",1,1
"This study was undertaken to determine whether [ENTITY_A], the first in a novel class of [ENTITY_B] -selective inhibitors, has an NCX-inhibiting activity superior to NCX-inhibitors in pig proximal tubular epithelial LLC-PK1 cells in vitro., a novel, selective inhibitor of norepinephrine reuptake, was evaluated in a pig proximal tubular epithelial LLC-PK1 cell line in vitro for its NCX-inhibiting activity",1,1
"Inhibition of [ENTITY_A] (FNTA) causes regression of colorectal carcinoma cells in vitro and in vivo., a recently reported NF-κB activator, is also reported to inhibit [ENTITY_B] (IKK-A) but not IKK-B., a recently described NF-κB inhibitor, causes regression of colorectal carcinoma cells in vitro but not in vivo., however, is an activator of both NF-κB and I",1,1
"(1-hydroxy-3-methylanthraquinone), a novel [ENTITY_A] (MAO-B) inhibitor, inhibits brain [ENTITY_B] activity and [ENTITY_B].(N-propargyl-1-methylanthraquinone) is a novel MAO-B inhibitor with good brain penetration.is a selective MAO-B inhibitor with little brain penetration.inhibitors for treatment of Parkinson's disease.inhibitor (N",1,1
"Inhibitors of [ENTITY_A] signaling disrupt cell cycle progression and induce apoptosis in endometrial cancer cells., a novel [ENTITY_B] inhibitor that disrupts ERK1/2 and Akt activation, induces apoptosis in cancer cells., a novel ERK inhibitor that disrupts ERK1/2/JNK1/2 signaling, induces apoptosis in cancer cells., an oral tyrosine kinase inhibitor that inhibits ERK1/2",1,1
"In vitro metabolism study of the [ENTITY_A] inhibitor [ENTITY_B]., (1) reduce the exposure of the drug to metabolism enzymes; (2) augment the drug's half life; and (3) augment the rate-limiting step of the drug's elimination from the human body., (1) reduce the exposure of the drug to metabolism enzymes; (2) augment the drug's half life; and (3) augment the rate-limiting step of the drug's elimination",1,1
"In vitro, [ENTITY_A], but not darunavir, inhibits the [ENTITY_B] (Ki = 32 microM)., the prototype for [ENTITY_B] inhibitors, has been shown to be noncompetitive with regard to darunavir (Ki = 56 microM)., another prototype for ceftazidime, is also noncompetitive with regard to darunavir (Ki = 56 microM)., which is a new type of [ENTITY_B] in",1,1
"(Z)-9-acetamido-9-oxabicyclo[2.2.1]octanesulfon-9-yl-9H-anthracenylamide ( [ENTITY_A] ) as a new [ENTITY_B] inhibitor: Docking and molecular dynamics study.inhibitors based on a novel class of potent and nontoxic [ENTITY_B] inhibitors.inhibitors.inhibitors.inhibitors.
Struct",1,1
"(R)- and (S)-Methyl-4-(3-butoxy-phenyl)-4-methylanthraquinone, [ENTITY_A] (1), a novel [ENTITY_B] (MAO-B) inhibitor, showed effective [ENTITY_B] - and cytochrome P-450-mediated monoamine uptake inhibition., a new MAO-B inhibitor, showed effective mitochondrial fusion inhibitor., a new MAO-B inhibitor, showed promising [ENTITY_B] - and cytochrome P",1,1
"The antihyperthermic effect of [ENTITY_A], an [ENTITY_B] inhibitor, in the SIH model of acute myocardial infarction., a synthetic [ENTITY_B] (ACE1) inhibitor, exhibits similar activity as amiodarone and has been in clinical development., an ACE2 inhibitor, has recently been approved for the treatment of angina pectoris and has been in development for treatment of heart failure., amiodarone, and nimesulide are",1,1
(R)-3-(Aminomethyl)-5-(2-hydroxypropoxy)-1-methanone ( [ENTITY_A] )- and (+/-)-2-hydroxypropoxy-1-methanone ( bromazinil-3-yl-5-(2-hydroxypropoxy)-1-methanone)-4-hydroxybenzoyl-3-methylanthraquinone) derivatives as potent [ENTITY_B] (BCh,1,1
"inhibitors based on a [ENTITY_A] scaffold as a new strategy to treat chronic myelogenous leukaemia., an [ENTITY_B] inhibitor that binds to the MLL, was first described as a late-stage effector of treatment in chronic myelogenous leukaemia (CML) and has subsequently become the focus of research as an alternative to [ENTITY_B]., which is currently being developed for the treatment of chronic myelogenous leukaemia, has been shown to",1,1
"inhibitors based on a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B]., a [ENTITY_B] inhibitor., a CYP3A inhibitor.
Synthesis and antitumor activity of some novel [ENTITY_A] derivatives as potent and selective inhibitors of the [ENTITY_B]., the enzyme that degrades atrial natriuretic peptide, inhibits atrial natriuretic peptide-induced contraction., the enzyme that degrades atrial n",1,1
"Inhibition of [ENTITY_A], but not COX-1, by [ENTITY_B]., a selective inhibitor of cyclooxygenase-1 (COX-1), inhibits prostaglandin E2 (PGE2)., a selective inhibitor of cyclooxygenase-2 (COX-2)., a selective inhibitor of cyclooxygenase-3 (COX-3)., a selective inhibitor of cyclooxygenase-4 (CO",1,1
"(R)-(-)-Epibatidine ( [ENTITY_A] ), a potent irreversible [ENTITY_B] (MAO-A inhibitor) and a less potent MAO-B (MAO-B inhibitor), reversibly suppresses the activity of the highly conserved and constitutively activated MAO-A, MAO-B, and cytochrome P-450 enzymes, thus mimicking the clinical profile of [ENTITY_B].inhibits both MAO-A and MAO-B, whereas",1,1
"The use of selective [ENTITY_A] inhibitors in colorectal cancer: a single-agent or a combination approach., a [ENTITY_B] (COX-2) inhibitor and 5-fluoro-2'-deoxyuridine (FdUrd), a COX-1 inhibitor, have been recommended for the treatment of advanced colorectal cancer., a COX-1 inhibitor and 5-fluoro-2'-deoxyuridine (FdUrd",1,1
"(R)-3-(Aminomethyl)-7-(4-methoxymethylphenyl)-5-fluoro-1-naphthalen-2-yl-urea ( [ENTITY_A] ) is a new, potent, orally administered [ENTITY_B] (MAO-B) inhibitor., a selective, irreversible MAO-B inhibitor, is available only as a suppository., an oral MAO-B inhibitor that is not available as a suppository,",1,1
"Inhibition of [ENTITY_A] (MMP-2) and MMP-9 by [ENTITY_B], a [ENTITY_B] inhibitor., a potent and selective COX-3 inhibitor, was recently reported to reduce breast cancer incidence in a dose-dependent manner., a potent and selective COX-1 inhibitor, was reported to have an adverse effect on cholesterol metabolism in vitro., a potent and selective COX-2 inhibitor, was reported to have an adverse effect on the",1,1
"(R)-Phenylalanine-generated nitrotyrosination and oxidation reactions are inhibited by [ENTITY_A], a selective inhibitor of [ENTITY_B] (NOX)., a selective inhibitor of NHE1, may play a role in phenylalanine-induced toxicity., a selective inhibitor of NHE2, may be involved in phenylalanine-induced neuronal death., a selective inhibitor of NHE3, may be involved in phenylalanine-induced",1,1
"(R)- and (S)-3-(Aminomethyl)-7-methoxy-4-methoxybenzoyl-oxyphenylhydrazone ( [ENTITY_A] ), a new inhibitor of [ENTITY_B] (MAO), suppressed the expression of [ENTITY_B] and c-Myc in B16F10 melanocytes in a dose-dependent manner in a time-dependent manner., a known MAO inhibitor, had no effect on B16F10 melanocytes",1,1
"(1) Synthesis, biological evaluation, and molecular modeling of [ENTITY_A] (BMS-582949): a novel small molecule [ENTITY_B] inhibitor., a potent irreversible [ENTITY_B] (MAO) inhibitor, has been in clinical development for treatment of Parkinson's disease., a potent irreversible MAO inhibitor that is currently in development for treatment of Alzheimer's disease, is currently undergoing Phase II clinical trials., a potent irreversible MAO inhibitor that is in clinical development for",1,1
"(Z)-3-(4-hydroxyphenylamino)benzoxaborole, a potent, orally bioavailable [ENTITY_A] inhibitor, inhibits the growth of cancer cells in vitro and in vivo with low micromolar to nanomolar IC50 values.inhibitors with enhanced pharmacokinetics and lower gastrointestinal side effects than zolmitide.inhibitor [ENTITY_B] inhibits the growth of cancer cells in vitro and in vivo in a concentration-",1,1
Inhibition of [ENTITY_A] with [ENTITY_B] in the cornea and tear fluid of eyes irradiated with UVB.inhibition of cornea and tear fluid of eyes irradiated with UVB.inhibition of cornea and tear fluid of eyes irradiated with UVB.Inhibitors in cornea and tear fluid of eyes irradiated with UVB.inhibition of cornea and tear fluid of eyes irradiated with UVB.Inhibitors in cornea and,1,1
"(Z)-3-(Aminomethyl)-7-hydroxybenzoyl-2-naphthyridin-4-one ( [ENTITY_A] ) induces apoptosis of HCT 116 colon cancer cells through inhibition of [ENTITY_B] /Bax signaling pathway., a natural product that selectively inhibits Bcl-xL and Bcl-2, was reported to have anticancer activity in a wide variety of cancer cell lines., a natural product that selectively inhibits",1,1
"(R)- and (S)-Methyl salicylate attenuates [ENTITY_A] -induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats., a known [ENTITY_B] channel antagonist, is also a potent agonist of the alpha1A and alpha1E subunits of nicotinic acetylcholine receptors., a known channel antagonist, is also a potent agonist of the alpha1D subunit of nicotinic acet",1,1
"Inhibition of [ENTITY_A] (FNTA) causes loss of platelet inhibition and thromboxane formation., a peripheral [ENTITY_B] (COX) enzyme, is a target for antiplatelet therapy., a peripheral COX enzyme, is also targeted for antiplatelet therapy., like platelet COX, is a target for antiplatelet therapy., like platelet COX, is also targeted for antiplatelet therapy., like thrombox",1,1
"This article presents a novel method for the inhibition of [ENTITY_A] in vitro by [ENTITY_B], a non-competitive [ENTITY_B] (AChE) inhibitor., a non-competitive AChE inhibitor., an irreversible MAO-B inhibitor and MAO-B activator, is currently in late-phase clinical development., a non-competitive MAO-B inhibitor and MAO-B activator, is currently in late-phase clinical development.(",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a peripheral opiate agonist., a peripheral opiate agonist., a central opiate agonist., a peripheral mu receptor agonist., a peripheral alpha3 receptor agonist. etorphine, a central noradrenaline agonist. norepinephrine, a peripheral adrenergic agonist. phenylbutazone, a peripheral [ENTITY_B] agonist. quinidine, a central norepine",1,1
"(R)-(-)-3-(Aminomethyl)-7-(3-hydroxy-4-methoxymethyl)-1-hydroxy-1-hydroxy-3-nonyl)-1-oxymethyl-3-methylanthraquinone ( [ENTITY_A] ) as a novel orally bioavailable [ENTITY_B] (COX-2) inhibitor: in vitro and in vivo selectivity in suppressing COX-1 and COX-3 activities.,",1,1
In vitro metabolism and pharmacokinetics of the novel [ENTITY_A] (BMS-354825): an oral multi-targeted [ENTITY_B] inhibitor against SRC and BCR-ABL.(BMS-354825): an oral multi-targeted ACE inhibitor.inhibitor.: an oral tyrosine kinase inhibitor.: a novel [ENTITY_B] inhibitor against SRC and BCR-ABL.: an,1,1
"This study evaluates the impact of [ENTITY_A], a [ENTITY_B] inhibitor, on the pharmacokinetics of gliclazide and enalapril when administered as a single-dose to healthy subjects and in combination with [ENTITY_B]., a selective COX-1 inhibitor, was also evaluated., a selective COX-2 inhibitor, was also evaluated., gliclazide, and enalapril are potent oral direct inhibitors of the [ENTITY_B] (COX)",1,1
"In vitro inhibitory effects of [ENTITY_A], a new [ENTITY_B] inhibitor, on platelet activation.(ABL) overexpression is a common event in several solid tumor malignancies., an important enzyme in DNA repair, is overexpressed in a variety of human malignancies and may play a role in resistance to chemotherapy., a new antioxidant, is being evaluated for the treatment of oxidative stress-related diseases, including cancer., a new ACE",1,1
"(R)- and (S)-3-(Aminomethyl)-7-(4-methoxymethylphenyl)-7-hydroxy-1-naphthyridine ( [ENTITY_A] ) are potent irreversible inhibitors of [ENTITY_B] (NET) and [ENTITY_B] (MAO) and reversible inhibitors of NET and MAO., a selective MAO inhibitor, is available on the international market.inhibitors ( [ENTITY_B], apixaban) have not yet been approved for",1,1
"In vitro and animal studies support the possibility that [ENTITY_A] (VPA), a [ENTITY_B] inhibitor, may enhance NSAID analgesia.(VPA) may be an appropriate choice for patients who do not tolerate prokinetic NSAIDs, such as patients on chronic hemodialysis and patients with renal impairment.may be an appropriate choice for patients not requiring prokinetic NSAIDs because these patients do not have an appropriate stomach for prokinetic NSAIDs.is",1,1
"(R)- and (S)-3-(Aminomethyl)-5-methoxy-4-methylanthraquinone, [ENTITY_A], and 4-hydroxybenzylhydrazine, oxime, are potent inhibitors of [ENTITY_B] (MAO), demonstrating substrate-selective inhibitors with favorable pharmacokinetics and in vivo disposition.analogues as potential MAO-A drugs.analogues as potential MAO-B drugs.",1,1
"The effect of [ENTITY_A] blockade in the basolateral amygdala on ethanol-induced ethanol self-administration.RATIONALE: ethanol self-administration (ESA) is a well known behavioral pattern induced by the combined administration of ethanol and nicotine. Recent studies have reported that the basolateral amygdala (BLA) plays a central role in ethanol self-administration., a selective inhibitor of [ENTITY_B] (NET) in the BLA, has been shown to reduce ethanol self-",1,1
"(R)-(S)-3-hydroxy-N-propyl-(R)-3-hydroxy-4-methylanthraquinone ( [ENTITY_A] ) is a potent and selective inhibitor of [ENTITY_B]., a clinical candidate for treatment of allergic rhinitis and atopic dermatitis, was developed as a prodrug of 3-hydroxy-N-propyl-(R)-4-methylanthraquinone to improve oral bioavailability., a",1,1
"(Z)-3-(2-methylanthraquinone) [ENTITY_A], a potent [ENTITY_B] inhibitor and [ENTITY_B] inhibitor, with better gastrointestinal tolerability and reduced pulmonary effects.inhibitor, N-propargyl-2-(3-butoxy-phenyl)-5-(3-methylanthraquinone) quinidine, and N-propargyl-2-(3-butoxy-phenyl)-5-(5-",1,1
"inhibition of [ENTITY_A] (LTA(4)H-H) by [ENTITY_B]., a novel noncyclic nucleotide [ENTITY_B] inhibitor., a new noncyclic nucleotide taurocholate inhibitor., a novel noncyclic nucleotide thiol-inhibitor. huprine X, a new indole alkaloid. huprine H, a new indole alkaloid. huprine S, a new indole alk",1,1
"The effect of the [ENTITY_A] blocker [ENTITY_B] on renal function and urine specific gravity in cirrhotic rats.(BMS-354825) is a novel orally bioavailable, multikinase inhibitor that has demonstrated activity in vitro against a broad range of carcinomas, most recently the BCR-ABL activating kinase 2 (BAK2).(BMS-354825) is a novel orally bioavailable, multikinase inhibitor that has demonstrated",1,1
"inhibitor activity of [ENTITY_A], a new antihypertensive [ENTITY_B] -blocking drug.blockers have been on the market for years, but none has yet been shown to be as effective as the reference [ENTITY_B] inhibitor [ENTITY_B].blockers currently on the market include erlotinib, which is a synthetic oral tyrosine kinase inhibitor that binds to the epidermal growth factor receptor (EGFR) as well as the vascular endothelial growth factor receptor (VE",1,1
"inhibitors based on a [ENTITY_A] scaffold as a new strategy to reduce tumor growth in xenografted tumors., a [ENTITY_B] inhibitor that selectively inhibits [ENTITY_B], is currently undergoing clinical development.(KCA-1133), a more selective COX-1 inhibitor, was recently reported to have good activity and low toxicity, and was approved for the treatment of prostatic carcinoma, lung cancer, and gastrointestinal stromal tumors., which was developed by our",1,1
"The effects of the [ENTITY_A] inhibitor [ENTITY_B] on endothelial dysfunction in a rabbit model., a potent [ENTITY_B] inhibitor, improves endothelial dysfunction in a rabbit model., a potent COX-1 inhibitor, also improves endothelial dysfunction in the rabbits' blood., a potent COX-2 inhibitor, also improves endothelial dysfunction in the rabbits' blood., a potent PDE3 inhibitor, does not improve endothelial dysfunction in the rabbits' blood",1,1
"(R)-(-)-Epicatechin gallate ( [ENTITY_A] ), a new orally active catechol in green tea, inhibits [ENTITY_B] (BChE) in vitro in a competitive manner., a cholinesterase inhibitor, was incubated with the same green tea polyphenols to determine their enantioselective disposition in rat., a cholinesterase inhibitor, was incubated with the same green tea polyphenols to determine their enantioselect",1,1
"This study explores the feasibility of targeting [ENTITY_A] inhibitors to the liver with a dual-effector, a [ENTITY_B] inhibitor and an ACE inhibitor.inhibitor [ENTITY_B] inhibits both ACE and VLDL-C.inhibitor rofecoxib is effective at reducing both high and lowdensity lipoprotein-C but has a lower dose-response.inhibitor rofecoxib targets both the ACE and VLDL-",1,1
"inhibitors based on the [ENTITY_A] scaffold for cancer therapy., a novel small molecules [ENTITY_B] inhibitor, has shown good activity in preclinical studies and in the early phase of clinical trials., a potent, orally administered [ENTITY_B] inhibitor, was recently approved for the treatment of advanced solid tumor neoplasia and gastrointestinal stromal tumors and is in phase 3 clinical trials., a new small molecules COX-2 inhibitor, has shown good activity in pre",1,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] by [ENTITY_B]., a new class of [ENTITY_B] inhibitors, inhibits both [ENTITY_B] and COX-1., a new class of COX-2 inhibitors, inhibits COX-3., a new class of PDE3 inhibitors, inhibits PDE3., a new class of PDE4 inhibitors, inhibits PDE4., a new class of PDE5 inhibitors, inhibits PDE",1,1
"In vitro and in vivo inhibition of [ENTITY_A] by [ENTITY_B]., a selective inhibitor of [ENTITY_B]., a selective inhibitor of COX-1., a selective inhibitor of prostaglandin E2.
N-acetylcysteine attenuates renal fibrosis in a rat renal fibrosis model via inhibition of [ENTITY_B]., the active metabolite of N-acetylcysteine (NAC), has been shown to have renal anti-fibrotic activity",1,1
"In vitro inhibitory effect of [ENTITY_A], a non-steroidal anti-inflammatory drug, on the proliferation, migration and invasion of MDA-MB-231 cells., a non-steroidal anti-inflammatory drug, inhibits proliferation, migration and invasion of MDA-MB-231 cells., a selective inhibitor of [ENTITY_B] kinase, inhibits invasion of MDA-MB-231 cells.inhibitors [ENTITY_B], etodolac and diclof",1,1
"In vitro inhibitory activity of [ENTITY_A] against four human [ENTITY_B] inhibitor [ENTITY_B] mutants., an antiatherogenic drug widely used to treat hypercholesterolemia, is thought to act by binding to the active site of the human LDL receptor (HDLr).(100 microM) was incubated with wild-type (WT) or mutation (Lys928X, His1067fsX, His1067Gln, His1133X)",1,1
"Inhibitors based on a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B]., a novel small molecule [ENTITY_B] inhibitor., an irreversible [ENTITY_B] (MAO) inhibitor.
The effect of the [ENTITY_A] inhibitor [ENTITY_B] on renal function in cirrhotic rats., a novel small molecule ACE inhibitor., a novel small molecule ARB., a novel small molecule ARB., a novel small molecule inhibitor of [ENTITY_B] (ACE).",1,1
"(1)H- and (13)C-radioligand binding studies of [ENTITY_A] (BMS-354825): a potent and selective [ENTITY_B] (V600E) inhibitor., a potent and selective COX-1 inhibitor, is under investigation for the treatment of inflammatory disorders., as a selective COX-3 inhibitor, has recently been approved for the treatment of osteoarthritis., as both a potent and a selective COX-1",1,1
"The use of [ENTITY_A] as a novel antihypertensive drug: an in vitro analysis of the inhibition of [ENTITY_B] - and HER2-overexpressing tumors., an oral tyrosine kinase inhibitor (TKI), inhibits HER2-driven tumor growth in several tumor types., an oral tyrosine kinase inhibitor (TKI), inhibits HER2-driven tumor growth in several tumor types., an oral tyrosine kinase inhibitor (",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methanone ( [ENTITY_A] ) is a novel, potent irreversible [ENTITY_B] (MAO-B) inhibitor., a selective MAO-B inhibitor and clinical candidate for Parkinson's disease, inhibits the enzyme at a rate ten times higher, and is currently undergoing phase II clinical trials., if approved for the treatment of Parkinson's disease, will",1,1
"(1)H and (31)P NMR studies support the view that a [ENTITY_A] is a dimeric enzyme with a relatively large active site and flexible binding site, which facilitates the reversible inhibition of [ENTITY_B]., a [ENTITY_B] inhibitor., a selective COX-2 inhibitor., a PDE3 inhibitor., a PDE4 inhibitor., a PDE5 inhibitor., a PDE6 inhibitor. (2)H",1,1
"inhibitor [ENTITY_B] inhibits the proliferation, migration, invasion, and angiogenesis of breast cancer cells., a [ENTITY_B] inhibitor., a [ENTITY_B] inhibitor., a [ENTITY_B] inhibitor., a PDGFR inhibitor., a VEGFR inhibitor., a HER2 inhibitor., a COX-2 inhibitor., a P-gp inhibitor.
The anti-angiogenic drug [ENTITY_A] inhibits",1,1
"(1-methanone) [ENTITY_A] analogues as potential inhibitors of [ENTITY_B].( [ENTITY_B], 1) are potent, orally bioavailable, selective inhibitors of [ENTITY_B] (CEase) and other proteases involved in inflammation and tumor pathobiology.( 2, 3) are potent synthetic thromboxane A2 analogues with modest inhibition of the clotting cascade and little cancer cell selectivity.( 4, 5) are potent synthetic thromboxane",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B] is mediated by a reversible phosphorylation event., an [ENTITY_B] inhibitor, inhibits tumor growth in colorectal carcinoma cell lines and in vivo, suppresses tumor growth in a dose-dependent manner in mice., a [ENTITY_B] inhibitor, inhibits tumor growth in colorectal cancer cell lines and in vivo, suppresses tumor growth in a dose-dependent manner in mice., an ACE inhibitor, suppresses tumor growth",1,1
"Inhibition of [ENTITY_A] /STAT3 signaling in osteoblasts by a novel selective inhibitor, [ENTITY_B]., a [ENTITY_B] inhibitor.inhibitor [ENTITY_B].inhibited the signaling of osteoclasts and osteoblasts., osteoprotegerin, osteocalcin, osteonectin, bone morphogenetic protein-2, osteoprotegerin receptor-beta and receptor activator protein (RAP) tatsumadue were previously reported",1,1
In vitro metabolism of [ENTITY_A] (BMS-354825): a novel [ENTITY_B] inhibitor with in vivo activity against BMS-354825.(BMS-354825): a novel ACE inhibitor with in vivo activity.inhibitor [ENTITY_B] (BMS-354825): a novel BH3 mimetic that inhibits both CYP and noncovalent [ENTITY_B].(BMS-354825): a novel ACE inhibitor with in vivo,1,1
"inhibitors based on a [ENTITY_A] scaffold as a new strategy for cancer therapy., a [ENTITY_B] inhibitor from Tabernaemontana divaricata., a [ENTITY_B] inhibitor from Tabernaemontana divaricata., a boron-containing inhibitor from Tabernaemontana divaricata., a fibrinogen inhibitor from Tabernaemontana divaricata.
Sy",1,1
"(1) In vitro metabolism of the novel [ENTITY_A] derivate: discovery of potent [ENTITY_B] inhibitors., a novel [ENTITY_B] /COX-2 inhibitor, has completed phase IIb clinical trials., a novel COX-1 inhibitor, has completed phase IIb clinical trials., a novel COX-3 inhibitor, has completed phase IIb clinical trials., a novel COX-1/COX-2 inhibitor, has completed phase",1,1
"(1)H-NMR-based drug discovery for [ENTITY_A] inhibitors: Discovery of a potent [ENTITY_B] (Prozac H) analog and the development of a selective COX-2 inhibitor for treatment of Alzheimer's disease., a selective inhibitor of prostaglandin E2 (PGE2) and [ENTITY_B] (Prozac H) analogues have been designed and synthesised and are in early clinical evaluation., a potent COX-1 inhibitor, was also synthes",1,1
"inhibitors based on a [ENTITY_A] scaffold for cancer therapy., an irreversible [ENTITY_B] inhibitor., a non- irreversible COX-1 inhibitor, has shown clinical activity in some solid tumor cancers., a non- irreversible COX-3 inhibitor, is in phase 2 clinical development., a non- irreversible COX-4 inhibitor, has shown clinical activity in some solid tumor cancers., a non- irreversible [ENTITY_B] inhibitor, has shown",1,1
"inhibitors based on a [ENTITY_A] scaffold., an [ENTITY_B] inhibitor from Sophora flavescens., an alpha 1-acid glycoprotein (AAGP) inhibitor from Sophora flavescens., a beta 1-acid glycoprotein (BAGP) inhibitor from Sophora flavescens.: synthesis and preclinical evaluation., a mixed-type AAGP, and BAGP inhibitor from Sophora flaves",1,1
"The effects of the [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetic and pharmacodynamic profiles of gliclazide in healthy subjects.(Glucose-lowering drug) has been associated with the inhibition of [ENTITY_B] and the increase in blood pressure.has been shown to be well tolerated, with few serious drug-related treatment-emergent events reported to date., the active metabolite of gliclazide, is also a blood pressure-",1,1
"Inhibition of [ENTITY_A] by a [ENTITY_B] (COX-2)-blocking derivative [4-(2-methoxyphenyl)-7-methoxy-phenyl)imidazolidin-2(1H)-one] led to a marked reduction of [ENTITY_B], but had no effect on COX-1, COX-3 and COX-4., the main metabolite of MDMA, did not significantly change in vitro., the main active metabol",1,1
"This article presents a novel inhibitor of [ENTITY_A], [ENTITY_B], which has little or no cytotoxicity in normal cell types and is capable of delivering effective doses to tumors with dysregulated BCR-ABL levels.inhibitors based on a [ENTITY_B] scaffold are under evaluation for therapy of chronic myelogenous leukaemia and GISTs.inhibition in chronic myelogenous leukaemia and GISTs., a [ENTITY_B] scaffold, is under evaluation",1,1
"The use of [ENTITY_A], an irreversible inhibitor of [ENTITY_B] (MAO), in Parkinson's disease: results from a multicenter, double-blind, placebo-controlled trial., a selective inhibitor of MAO-B., a selective inhibitor of MAO-A., a mixed MAO inhibitor., a selective MAO inhibitor., a selective inhibitor of MAO and A, B, and X.
A selective inhibitor of MAO-B and",1,1
"This study was designed to test the hypothesis that the administration of a selective [ENTITY_A] inhibitor, [ENTITY_B] (0.1 to 1 mg/kg), immediately before blast injury will reduce the level of tissue factor in the injured ventricular myocardium and the myocardium's ability to repair itself., a potent inhibitor of thrombin receptor activity, was administered to rats immediately before blast injury.In this study, we used an experimental design in which we used a single blast to",1,1
"The effect of selective [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetics of gliclazide in healthy subjects., a novel orally active [ENTITY_B] inhibitor, may reduce the risk of glioblastoma., a novel orally active COX-inhibitor, may reduce the risk of gliclazide-induced acute kidney injury.has been evaluated in several trials as an antihyperlipidemia agent., a novel CO",1,1
"This study investigated the ability of [ENTITY_A] to inhibit platelet activation in vitro and in vivo and to attenuate the inflammatory response induced by lipopolysaccharide (LPS) in mice., a [ENTITY_B] /STAT3 inhibitor, suppressed the production of [ENTITY_B] and tumor necrosis factor-alpha ( TNF-alpha ) in activated platelets, which in turn suppressed the activation of NF-kappaB, activation of STAT3, and inhibition of IκB kinase ( IKK",1,1
"(R)-3-hydroxy-3-methylanthraquinone, a novel [ENTITY_A] inhibitor, reduces [ENTITY_B] signaling and delays cell death in colorectal cancer cells., a novel [ENTITY_B] inhibitor, delays cancer cell death in colorectal cancer cells., a potent COX-1 inhibitor, delays cancer cell death in colorectal cancer cells., a potent COX-2 inhibitor, delays cancer cell death",1,1
"(R)- and (S)-Methadone inhibit [(3H-phenyl)-3-(3-butoxy-4-methoxyphenyl)-4-hydroxy-3-methylanthraquinone] [ENTITY_A], a novel [ENTITY_B] inhibitor, in rats., a potent and selective COX-1 inhibitor, is currently in phase 2b clinical development., a novel COX-2 inhibitor, is in phase 3",1,1
"(1) H- and (14) C-labeled [ENTITY_A] inhibitors: Discovery of the [ENTITY_B] (BMS-354825): a potent, orally bioavailable [ENTITY_B] inhibitor for the treatment of chronic myelogenous leukaemic diseases., a novel orally bioavailable [ENTITY_B] inhibitor., a potent, orally bioavailable CYP2B6 inhibitor., a novel orally bioavailable 5F-dehydrogenase inhibitor.",1,1
"(R)- and (S)-3-(Aminomethyl)-7-hydroxy-7-methoxy-1-methanone ( [ENTITY_A] ) are potent and selective inhibitors of [ENTITY_B], but not of CYP3A., a new inhibitor of CYP3A, is not as potent as CYP3A but has the advantage of once-daily dosing., a selective inhibitor of CYP1B, is also potent and does not",1,1
"The effects of [ENTITY_A] blockade alone or in combination with tranylcypromine on the reactivation of [ENTITY_B] in schizophrenic inpatients: a double-blind, placebo-controlled trial., a selective inhibitor of [ENTITY_B] (MAO-B) and metabolizing enzyme MAO-A, was reported to be ineffective in treatment of bipolar disorder., in contrast, was shown to be effective in treatment of bipolar disorder., in addition to MAO-B and MA",1,1
(R)- and (S)-Methamphetamine induced platelet aggregation is inhibited by the noncompetitive [ENTITY_A] inhibitor [ENTITY_B].inhibition is competitive with respect to the p-chloro analogue.blockers for cardiovascular use.blockers for psychiatric use.blockers for gastrointestinal use.blockers for pulmonary use. nifedipine and MK-499 inhibit dopamine and norepinephrine transporters.blockers for cardiovascular use. MK,1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a [ENTITY_B] inhibitor., a selective COX-2 inhibitor., a selective COX-1 inhibitor.
The effectiveness of three novel [ENTITY_A] inhibitors ( [ENTITY_B], AG0136, and AG0143) in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin., a new oral inhibitor of [ENTITY_B]., an",1,1
"(1)H NMR-based metabolite identification of the [ENTITY_A] inhibitor [ENTITY_B]., [2-(2-methoxy-phenyl)-5-methoxybenzyl]-5-methoxy-1-hydroxybenzoxaborole ( moxib) is a novel [ENTITY_B] (BMS-354825) that targets the [ENTITY_B] (BChE) enzyme at a non-competitive manner., [2-(2-m",1,1
"Inhibitory effects of the [ENTITY_A] inhibitor [ENTITY_B] on platelet aggregation in vitro., an [ENTITY_B] inhibitor that binds to the platelet C-reactive protein (CRP), inhibits platelet aggregation in vitro., an CRP antagonist that does not inhibit platelet aggregation., an CRP antagonist that binds to the vascular cell adhesion molecule (VCAM) but does not inhibit platelet aggregation., an CRP antagonist that does not inhibit",1,1
"(1) H nuclear magnetic resonance (NMR) study of the binding of [ENTITY_A] to the catalytic site of the human enzyme [ENTITY_B]., an antiatherogenic agent, binds to the catalytic center of the human enzyme, reducing its binding affinity to that of its substrate, carboxylesterase., an antiatherogenic drug, binds to the catalytic center of the human enzyme, reducing its binding affinity to that of its substrate., an",1,1
"Inhibitors based on the [ENTITY_A] scaffold as a novel approach to treat metastatic colorectal cancer., a new [ENTITY_B] inhibitor with favorable safety and antitumor activity profiles., a new COX-2 inhibitor with favorable safety and antitumor activity profiles., a dual antiestrogen/progesterone receptor inhibitor with favorable safety and antitumor activity profiles. (1) HMG-CoA reductase inhibitors (stat",1,1
(1)H-NMR and MS data support the conclusion that the [ENTITY_A] inhibitor [ENTITY_B] prevents the binding of the radioactive substrate to the enzyme active site and that the open form of the enzyme is more susceptible to binding of the radiolabeled substrate.(1)H-NMR and MS data support the conclusion that the inhibitor reduces the binding of the radioactive substrate to the enzyme active site and that the open form of the enzyme is more susceptible to binding of the,1,1
"The use of [ENTITY_A] inhibitor [ENTITY_B] is associated with an increased rate of adverse events and hospitalization than that of placebo, and is competitive with pantoprazole., a new oral direct inhibitor of [ENTITY_B]., a new oral direct inhibitor of COX-1., a new oral direct inhibitor of PDE3., a new oral direct inhibitor of PDE4. nimesulide, a new oral direct inhibitor of PDE5.
The effect",1,1
"The role of [ENTITY_A], a novel nonselective reversible inhibitor of [ENTITY_B], in the treatment of myelosuppression associated with chronic lymphocytic leukemia and its subtypes., which has been in clinical development since 2002, inhibits the major histocompatibility complex, the receptor for immunoglobulins, and the major platelet activating protein, in a nonselective manner., which has been in clinical development since 2002, inhibits the major histocomp",1,1
"(S)-3-(Aminomethyl)phenyl-7-hydroxybenzo[c][1,5]naphthalen-2-yl-oxazolidin-4-one ( [ENTITY_A] ) is a new inhibitor of [ENTITY_B]., an analog of sirolimus, was found to have superior activity in vitro., another analog of sirolimus, showed moderate activity in vitro, with IC50 values of 0.005 and",1,1
"This study evaluates the effect of [ENTITY_A], an [ENTITY_B] inhibitor, and of the COX-2 inhibitor etodolac on gastric acid secretion in rats., an ACE-inhibitor, and the COX-2 inhibitor etodolac significantly decreased gastric acid secretion in a concentration-dependent manner (IC50 values 33 microM and 23 microM, respectively)., an HMG-CoA reductase inhibitor, and etodolac",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a new inhibitor of acetylcholinesterase., a new inhibitor of acetylcholinesterase., a new inhibitor of acetylcholinesterase.
A new series of [ENTITY_B] derivatives as potent [ENTITY_B] (DAT/NMDAR) inhibitors., a new inhibitor of acetylcholinesterase., a new inhibitor of acetylcholinester",1,1
"(1)H NMR-based metabolite profiling of [ENTITY_A], a [ENTITY_B] inhibitor., a [ENTITY_B] inhibitor., a 5-LO inhibitor., a 5-MeO-DMT inhibitor., a bufotenine metabolite.and bufotenine metabolite., a 5-MeO-DMT inhibitor., a 5-MeO-DMT inhibitor.and bufotenine metabol",1,1
"(R)- and (S)-Methanesulfonanilide inhibitors of [ENTITY_A] ( [ENTITY_B], ketanserin A and ketanserin B)., a novel, highly potent, selective, irreversible, dipeptide [ENTITY_B] -inhibitor., a new, orally bioavailable, irreversible, dipeptide COX-1 inhibitor., a potent, selective, irreversible, dipeptide COX-2 inhibitor. (R)- and",1,1
"(R)-(S)-3-(Aminomethyl)-7-(2-hydroxypropoxy)-1-hydroxy-1-methanone ( [ENTITY_A] ) is a derivative of ketamine that inhibits [ENTITY_B] (MAO-B), a reversible enzyme that degrades serine and phenylalanine.is a second-generation propane-1,3-diol,3-hydroxyphenylamide, which, when administered systemically,",1,1
"In vitro inhibition of [ENTITY_A] - and ABCA1-mediated cholesterol transport by the dual anti-hypertensive drug [ENTITY_B] and the selective inhibitor of ABL and ABCA3., an oral tyrosine kinase inhibitor that suppresses the activity of both [ENTITY_B] and ABCA1, is currently being evaluated for the treatment of hypertension., an oral tyrosine kinase inhibitor that suppresses the activity of both ABCA1 and ABCA3, is currently being evaluated",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetics and pharmacodynamics of diclofenac sodium in healthy subjects., which selectively inhibits [ENTITY_B]., which selectively inhibits Cl- currents., which is a mixed current., which is not a mixed current., which is not a mixed current., which is not a mixed current., which is not a mixed current., which is a mixed current.",1,1
(1)H NMR study of the binding of the [ENTITY_A] blocker [ENTITY_B] to the N-methyl-d-aspartate receptor.(1)H NMR studies of the binding of the protonophore carbonylcyanide 5-fluoro-2-(3-phenylpropylamino)tetraline to the N-methyl-d-aspartate receptor.,1,1
"The use of a specific [ENTITY_A] inhibitor, [ENTITY_B], in colitis: a case series., a specific inhibitor of the [ENTITY_B] /SUR1 receptor., also known as ASA, is a specific inhibitor of the ASA class of anti-statin., also known as rofecoxib, is a selective NSAID., rofecoxib, sulindac and indomethacin are specific inhibitors of the ASA class of",1,1
"(R)-(+)-Epicatechin-3-gallate ( [ENTITY_A] ), a selective inhibitor of [ENTITY_B], reversibly suppresses the [ENTITY_B] activity of platelets., an EP2-selective inhibitor, is currently in phase III clinical trials., a selective EP3-selective inhibitor, is in phase II clinical trials., both drugs, are not available in the USA., both drugs, are not available in the USA., both drugs,",1,1
"(S)-3-(Aminomethyl)-7-(2-hydroxy-phenyl)-5-(3-butoxy-phenyl)pyrrolidine-3-carboxamide ( [ENTITY_A], 1) is a potent and selective inhibitor of [ENTITY_B] (NET) with moderate activity as a smoking cessation agent and low risk of dependence., a selective NET antagonist.(BMS-354825, 2) is a potent and selective inhibitor of NET and is",1,1
"(1) Inhibition of the [ENTITY_A] (MMP-2) enzyme by [ENTITY_B] and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung tumor., a new inhibitor of the MMP-2 enzyme, is active against many cancers and has been in phase 3 clinical trials., the first in a novel class of synthetic, non-competitive inhibitors of the MMP-2 enzyme, is in phase 3 clinical trials., the first in",1,1
"The effectiveness of [ENTITY_A], an [ENTITY_B] inhibitor, in congestive heart failure.inhibitor [ENTITY_B] inhibitors.blockers.
The use of the selective COX-1 inhibitor etodolac and the selective COX-2 inhibitor ketoprofen in the treatment of chronic prostatic carcinoma: a randomized, double-blind, placebo-controlled trial., ketoprofen, and etodolac. a randomized, double",1,1
"Inhibitor activity and [ENTITY_A] binding site mutation analysis of the [ENTITY_B] from Trypanosoma cruzi., a new target for new drugs against Chagas' disease and Trypanosoma cruzi., a new target for new drugs against Chagas' disease and Trypanosoma cruzi., a new target for new drugs against Chagas' disease and Trypanosoma cruzi., a new target for new drugs against Trypan",1,1
"(R)-Phenylalanine and [ENTITY_A] inhibit [ENTITY_B] release in rat striatum., a potential inhibitor of [ENTITY_B]., has been tested for its efficacy as a treatment for Alzheimer's disease.is also an inhibitor of dopamine transporters, but has not been tested for its efficacy in the treatment of Parkinson's disease.and amantadine are both potent inhibitors of transporter-associated monoamine oxidase (MAO).and amantadine",1,1
"(R)-3-(Aminomethyl)-7-(5-hydroxy-3-methylanthraquinonan-2-yl)-1-hydroxy-4-methylanthraquinon-2-one ( [ENTITY_A] ) is a novel [ENTITY_B] (MAO-B) inhibitor with moderate activity in vitro that binds reversibly with low micromolar to nanomolar affinity to the enzyme active site., a second new MAO-",1,1
"(R)-(-)-Tamsulosin effectively antagonizes the activity of [ENTITY_A], but has little or no effect on the activity of tamoxifen., a [ENTITY_B] (COX-1) inhibitor, causes little or no breast cancer cell death., a COX-3 inhibitor, causes moderate to substantial breast cancer cell death., an COX-9 inhibitor, causes little or no breast cancer cell death., an NS-1/COX",1,1
"Inhibition of human [ENTITY_A] (hCES1) by the small molecule [ENTITY_B] (Iressa): a structural basis for the selective COX-2 inhibitor [ENTITY_B].(hCES2) has also been characterized, but its inhibition has not been examined to date., a new small molecule [ENTITY_B] inhibitor., a new small molecule COX-2 inhibitor., a new small molecule COX-2 inhibitor., a new small molecule CO",1,1
"In vitro and in vivo inhibition of [ENTITY_A] by [ENTITY_B] from Sophora flavescens., a new [ENTITY_B] inhibitor from Sophora flavescens., a new antioxidant compound from Sophora flavescens., a new proapoptotic inhibitor from Sophora flavescens., an antiapoptotic drug from Sophora flavescens., an antioxidant compound from Sophora flavescens., a new proapoptotic inhibitor from",1,1
"In vitro inhibition of [ENTITY_A] by a series of [ENTITY_B]., an [ENTITY_B] inhibitor., an ACE inhibitor., a VIG inhibitor., an ALK inhibitor., a NEP inhibitor.
The effect of the nitric oxide synthase inhibitor [ENTITY_B] on endothelial dysfunction and inflammation in chronic pancreatitis., an NOS inhibitor, suppresses inflammation and endothelial dysfunction., an ACE inhibitor, suppresses endothelial dysfunction.",1,1
"The role of [ENTITY_A], a new inhibitor of [ENTITY_B] (MAO-B) and substrate for the antifolate-resistance enzyme MAO-C.inhibitor [ENTITY_B] inhibits clonidine.inhibitor [ENTITY_B] inhibits clonidine.inhibitor cystatin-A.inhibitor cystatin-B.inhibitor cystatin-A.
The role of arachidonic acid and",1,1
"This study investigated the effect of chronic [ENTITY_A] use on the levels of brain GABA and alanine in humans, and on the levels of glutathione and [ENTITY_B] in microsomes in frontal cortex., alanine, and glutathione levels in the frontal cortex decreased significantly with a mean +/- SEM increase of 0.04 +/- 0.02, 0.04 +/- 0.01, and 0.02 +/- 0.01 micromol/L, respectively, after 14",1,1
"In vitro metabolism of [ENTITY_A], a novel [ENTITY_B] inhibitor, in humans., a new [ENTITY_B] inhibitor, inhibits CYP3A., a new COX-2 inhibitor, inhibits CYP2B and CYP2C., a new COX-1 inhibitor, inhibits CYP3A., a new CYP3A inhibitor, inhibits CYP2A., a new CYP3B inhibitor, inhibits CY",1,1
"In vitro metabolism of the novel [ENTITY_A] (COX-1) selective inhibitors [ENTITY_B] and captopril in normal and cirrhotic human liver microsomes., an [ENTITY_B] (COX-2) selective inhibitor, is currently undergoing clinical evaluation., a selective COX-3 inhibitor, has been in clinical development for over a decade., a selective COX-1 inhibitor, is presently undergoing clinical trials., captopril, and etodolac",1,1
(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methanone ( [ENTITY_A] ) is a novel [ENTITY_B] (BChE) inhibitor with good gastrointestinal tolerability and with few serious adverse events in clinical use.(BChE) inhibitor ( R - 3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methanone [ N-propargyl-7-(3-,1,1
"Inhibitory effects of [ENTITY_A], a [ENTITY_B] inhibitor, on the metabolism of methoxyphenylacetic acid in humans., the active metabolite of MDMA (ecgonine 5-monooxygenase), is a well-known MDMA neurotoxin and a useful tool in the research on the neurotoxicity of this drug., as well as MDMA, are potent inhibitors of CYP3A., however, is less potent and does not inhibit CY",1,1
"(1)H- and (13)C-labeled [ENTITY_A] inhibitors based on a [ENTITY_A] scaffold: preparation of a potent and selective [ENTITY_B] inhibitor for human.(1)H- and (13)C-labeled pro-drugs of the potent and selective COX-1 inhibitor, [ENTITY_B]., a clinical example., a clinical example., a clinical example., a clinical example.,",1,1
"(1)H- and (13)C-labeled arachidonic acid derivatives of [ENTITY_A] (Mesupron®) extract and their metabolism in humans., a new arachidonic acid analogue of [ENTITY_B]., a new arachidonic acid analogue of sulprostone., a new arachidonic acid metabolite of sulindac., a new phenolic acid metabolite of sulindac., a new p-",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-methylanthraquinone, [ENTITY_A], a dual inhibitor of [ENTITY_B] and AChE, exhibits potent activity against CYP2B6 and CYP3A4 and low toxicity in rats., a clinical candidate for treatment of bipolar disorder; N,N-bis(3-hydroxypropoxy)-1-methanone, ibuprofen",1,1
"(R)-(+)-Epicatechin gallate attenuates [ENTITY_A] activity in human monocytes by decreasing intracellular cyclic GMP.inhibition by [ENTITY_B] and gallate.inhibition by gallate and gallate.blockers.blockers.blockers. hirudin-induced monocytic cell apoptosis.blockers. hirudin-induced cytochrome c release.blockers.
In",1,1
"The use of [ENTITY_A], an irreversible inhibitor of [ENTITY_B] tyrosine kinase Src, in the treatment of malignant glioma has been studied in several experimental and preclinical studies., an irreversible inhibitor of Src, has also been tested in preclinical and clinical trials, but has not been tested on malignant glioma., a selective inhibitor of p53, has been tested in several preclinical and clinical trials but has not been tested on malignant gl",1,1
"inhibitors based on a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B]., a potent, orally bioavailable [ENTITY_B] inhibitor, is in clinical development as a topical therapy for alopecia., a potent, orally bioavailable COX-inhibitor, is in clinical development as a systemic agent for the treatment of atopic dermatitis., a novel, covalent inhibitor of COX-1, has received orphan drug status from the U",1,1
"inhibitors based on [ENTITY_A] scaffold for cancer therapy., a synthetic nonsteroidal [ENTITY_B] inhibitor., a synthetic nonsteroidal [ENTITY_B] inhibitor. huprine H202020 and huprine H204021, huprine H204521, and huprine H204921 as [ENTITY_B] inhibitors., a synthetic nonsteroidal COX-2 inhibitor. erlotinib, a synthetic nonsteroidal [ENTITY_B]",1,1
"(+/-)-Tamsulosin effectively antagonizes the inhibitory action of [ENTITY_A], but with a lower dose and longer residence time in the plasma., the prototype [ENTITY_B] -selective inhibitor, exhibits similar pharmacokinetic parameters, but with lower efficacy., the prototype carbamate-selective inhibitor, exhibits comparable pharmacokinetic parameters, but with higher efficacy., the prototype NS-398-selective inhibitor, exhibits similar pharmacokinetic parameters, but with",1,1
"The effect of [ENTITY_A] (Gleevec, Novartis) on the platelet function and adhesion molecule expression of rabbit aortic strips: relevance to the treatment of atherosclerosis., a selective inhibitor of the [ENTITY_B], inhibits platelet function and adhesion molecule expression in vitro., a selective inhibitor of the COX-1, inhibits platelet function in a concentration-dependent manner in vitro., a selective inhibitor of the COX-3,",1,1
"The antiatherogenic effect of [ENTITY_A], a marine natural product with [ENTITY_B] tyrosine kinase inhibitors as a novel class of antiatherosclerotic drugs.(Iressa) is a marine natural product with tyrosine kinase inhibitor properties which are being developed for treatment of cardiovascular, renal and gastrointestinal diseases, and has been in development for the treatment of type 2 diabetes mellitus as well as dysmenorrhea.(Iressa) is a marine",1,1
"(R)-3-(Aminomethyl)-7-methoxy-N,N,N',N'',N'-tetra-acetyl-N,N',N'-bis(1,3-diaryloxy)methanone ( [ENTITY_A] ) inhibits [ENTITY_B], but not CYP3A, 3A5, 3A9, and 3A19 in a competitive manner., a new potential inhibitor of the [ENTITY_B] /N-methyl",1,1
"(1H-1,2,4-trihydroxy-3-methylanthraquinone) [ENTITY_A] inhibitors: Synthesis, biological evaluation, and modeling of a novel class of potent, nontoxic [ENTITY_B] inhibitors., a new potent, orally bioavailable inhibitor of [ENTITY_B].analogues., a potent, orally bioavailable inhibitor of SLC6A6., a novel, potent, irreversible, dipeptide",1,1
"(R)-Phenylalanine and the [ENTITY_A] inhibitor [ENTITY_B] ( [ENTITY_B] ) reduce the stability of the amyloid beta42 peptide.(N-propargyl-1-(R)-aminoindan) is a new compound that binds to the N-proline of the beta-strand of the amyloid beta42 protein and is thought to be a more potent inhibitor of the [ENTITY_B] than is [ENTITY_B], which is currently the only approved inhibitor for",1,1
"Inhibitors based on the [ENTITY_A] scaffold as novel anti-Parkinsonian [ENTITY_B] inhibitors., an oral tyrosine kinase inhibitor (TKI), has recently been shown to have neuroprotective activity against Parkinson's disease (PD)., a selective [ENTITY_B] (MAO) inhibitor, has been shown to preferentially target c-Rel, which has been shown to be activated in PD.is an effective inhibitor of MAO but also inhibits N-",1,1
"The use of selective inhibitors of [ENTITY_A] ( [ENTITY_B], apixaban) and COX-2 (nimesulide, NS398) in complex prosthetic valve infection., an oral multi-targeted [ENTITY_B] /COX inhibitor, has recently been approved for the treatment of complicated bacteremia, prosthetic valve infection, and infection due to gram-negative bacilli., an intravenous multi-targeted COX-2 inhibitor, has recently been approved",1,1
"This report evaluates the effects of the novel [ENTITY_A] (COX-2) selective inhibitor [ENTITY_B] on semen parameters and oxidative stress in infertile men with abnormal baseline COX-1/COX-3 ratio., the active metabolite of ketoconazole, is reported to preferentially inhibit [ENTITY_B] and has been in development for treatment of inflammatory bowel disease and the treatment of prostatic carcinoma., a selective COX-1 inhibitor has been in development for treatment of",1,1
"In vitro and in vivo studies with [ENTITY_A] inhibitors show overlapping but distinct pharmacological actions., the primary metabolite of tacrine, is a more potent [ENTITY_B] blocker and, when administered orally, is more selective but has the same gastrointestinal toxicity as its active metabolite., the primary metabolite of enalapril, is a more efficient [ENTITY_B] blocker when administered systemically, but has the same gastrointestinal toxicity as its active metabolite., the principal metabolite",1,1
"(1) H-NMR-based metabolite identification of the novel [ENTITY_A] (COX-1) inhibitor [ENTITY_B]., an [ENTITY_B] (COX-2) inhibitor., an ACE inhibitor., an ARB inhibitor., a PDE3 inhibitor., an ARB inhibitor., an ACE inhibitor., an ARB inhibitor.
Structural basis for the potent inhibition of the prostaglandin E2 E217A by",1,1
"(R)-(-)-Tamsulosin effectively antagonizes the inhibitory effect of [ENTITY_A] by [ENTITY_B]., a new antiarrhythmic agent., a new antiarrhythmic agent., a new antiarrhythmic agent., a new antiarrhythmic agent., a new anti arrhythmic agent. ibutilide, a new proarrhythmic agent.
Preparation and in vitro evaluation",1,1
"Inhibitors based on [ENTITY_A] : Discovery of [ENTITY_B], a novel [ENTITY_B] (COX-2)-selective inhibitor.inhibitors with longer and more selective duration of action.inhibitors with longer and more selective duration of action.inhibitors with longer and more selective duration of action.inhibitors with longer and more selective duration of action.
Structural basis for the potent and selective inhibition of human [ENTITY_B] by [ENTITY_B] (SC-",1,1
"(R)-(-)-Epicatechin gallate, a pure [ENTITY_A] (VGCC) inhibitor, induces apoptosis in cancer cells via the inhibition of [ENTITY_B]., the main metabolite of green tea, is reported to have antioxidant activity and to suppress the pro-apoptotic Bim pathway in cancer cells., however, is a potent inhibitor of the catalytic core of the enzyme [ENTITY_B] which is essential for cancer cell growth and angiogenesis.blocks the active site",1,1
"(R)- and (S)-3-(Aminomethyl)-5-methoxy-4-(3-phenylpropylamino)benzoic acid ( [ENTITY_A] )-containing bisphosphonates as potential inhibitors of proton pumps in human colon and lung colon cancer cells., a new [ENTITY_B] inhibitor, causes apoptosis by inhibiting the H(+)-Cl- cotransporter and the Bcl-2 family of proteins.",1,1
"Inhibition of [ENTITY_A] with a selective inhibitor of cPLA2., a selective inhibitor of cPLA2., a selective inhibitor of cPLA3., an inhibitor of cPLA3., an inhibitor of both cPLA2 and cPLA3., another selective inhibitor of cPLA2.
A new inhibitor of the [ENTITY_B] /MEKK1/JNK pathway for the downregulation of [ENTITY_B] in breast cancer cells., a novel inhibitor of the",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-methyl-1-phenyl-3-naphthalen-2-yl)-1-methanone ( [ENTITY_A] ) was a potent and selective inhibitor of [ENTITY_B] (IC(50) = 54 microM), but was less potent and slightly less selective than VIG (IC(50) = 56 microM)., a less potent and",1,1
"(Z)-2-hydroxypropyl-1-hydroxymethyl-3-(4-methoxymethyl-phenyl)adenine ( [ENTITY_A] ), a selective inhibitor of [ENTITY_B], exhibits neuroprotective activity against PTZ-induced kindling in mice., a selective inhibitor of acetylcholinesterase, exhibits neuroprotective activity against PTZ-induced kindling in mice., a selective inhibitor of acetylcholinesterase,",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a new inhibitor of [ENTITY_B]., a new inhibitor of PDE 3. View, an overview of the PDEs and their inhibitors., a new inhibitor of PDE 3. View
N-propargyl gallate inhibits [ENTITY_B] (AChE) but not BChE: an in vitro and in vivo analysis., a new inhibitor of acetylcholinesterase. View N-proparg",1,1
"The use of [ENTITY_A] as a novel non-competitive inhibitor of the [ENTITY_B] catalytic mechanism of [ENTITY_B] tyrosine kinases., which is an oral tyrosine kinase inhibitor (TKI), inhibits mammalian target of rapamycin (mTOR)., which is a selective inhibitor of [ENTITY_B] (TPh), has also been approved for the treatment of osteoarthritis.blocks mTOR, but has not been approved for osteoarthritis treatment.",1,1
"(1) H NMR and (13) C NQR studies of [ENTITY_A], a [ENTITY_B] (MAO) inhibitor. 2) HIF-1alpha and HIF-2alpha inhibitory effects of ketamine and ketamine plus clorgyline., a MAO inhibitor., a pro-inflammatory drug., a bronchodilatory drug., a neuromuscular blocking drug., a neuroinflammatory drug. nal",1,1
"(1)H NMR and HRGC studies define a novel mechanism by which [ENTITY_A] inhibits [ENTITY_B]., a [ENTITY_B] /STAT3 activator, suppresses cancer cell proliferation by inhibiting STAT3 phosphorylation., a STAT3 activator, suppresses cancer cell proliferation by inhibiting STAT3 phosphorylation., a STAT3 inhibitor, suppresses cancer cell proliferation by inhibiting STAT3 phosphorylation., a phosphatase that",1,1
"Inhibitory effects of [ENTITY_A], a new inhibitor of [ENTITY_B], on the proliferation and invasion of tumor cells in vitro.inhibitor [ENTITY_B] inhibits tumor growth in a mouse xenograft model., a new anti-inflammatory drug, inhibits tumor growth in a mouse xenograft model., a new inhibitor of platelet activating protein (PA) 3, inhibits tumor growth in a mouse xenograft model., a new inhibitor of cyclooxy",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., an antimetabolite used in the treatment of osteoarthritis., an anticonvulsant used in the treatment of neuropathic pain., a gastrointestinal prokinetic agent. 1,8-cineole, an uncompetitive norepinephrine reuptake inhibitor.
The antithrombotic effect of the flavonoids [ENTITY_A] (Boussaccharide) and rhamnolinate in patients",1,1
"inhibitors based on a [ENTITY_A] scaffold for potential treatment of Alzheimer's disease.inhibitors based on a platinum scaffold for possible treatment of Alzheimer's disease., a platinum-bound [ENTITY_B] /neurotoxicity agent, inhibits amyloid-beta42 aggregation in vitro and in vivo.inhibitors based on a platinum scaffold for possible treatment of Alzheimer's disease., a platinum-bound metabolism inhibitor, inhibits aggregation of beta-secretase",1,1
"Inhibitory effects of [ENTITY_A], an [ENTITY_B] inhibitor, on the proliferation, migration, and invasion of MDA-MB-231 cells.inhibition by [ENTITY_B].inhibition by rofecoxib.block of [ENTITY_B].block of MK-329.block of KIT.inhibition by ketoprofen. mTOR blockade by [ENTITY_B].
The effect of the synthetic [ENTITY_A] inhibitor, [ENTITY_B], on the activity of",1,1
"(S)-3-(Aminomethyl)-7-(2-hydroxypropoxy)-1-hydroxy-1-methanone ( [ENTITY_A] ), a new potent irreversible inhibitor of [ENTITY_B], is a novel anti-diabetic and anti-hyperglycemic agent., a new potent irreversible inhibitor of HMG-CoA reductase, is a novel anti-diabetic and anti-hyperglycemic agent., a new potent irreversible inhibitor of HMG",1,1
"(R)-(+)-3-(Aminomethyl)indolinones as a new class of potent [ENTITY_B] (MAO-B) inhibitors: Synthesis, anti-inflammatory, analgesic and antipyretic activity of a potent series of indolinones., [ENTITY_A], indolocarbazoles and indolocarbazoles: Synthesis, biological evaluation and molecular modeling studies., 3-(Aminomethyl)-4-methyl-5",1,1
"The role of the NF-kB subunit p50(RelA) in the regulation of [ENTITY_A] expression in neutrophils.inhibits LPS-induced expression of ICAM-1 at the mRNA and protein levels in neutrophils, and its action can be countered by the selective inhibitor of NF-kB, [ENTITY_B].interferes with the interaction between LPS and IkappaBalpha, which results in the downregulation of ICAM-1 expression.",1,1
"Inhibitors of [ENTITY_A] ( [ENTITY_B], apixaban, BMS-354825): a potent and sustained ceftazidime versus serious Gram-negative bacilli., a novel cephalosporin selective for ABL-producing Gram-negative bacilli., a novel cephalosporin selective for ABL-producing Gram-negative bacilli., a novel cephalosporin selective for Gram-",1,1
"(R)-3-(Aminomethyl)-7-methoxy-4'-methoxy-phenyl)-1-hydroxy-3-nonyl-1-methanone ( [ENTITY_A] ) is a potent and specific peripheral [ENTITY_B] (M3b) inhibitor., a new M3b inhibitor., a new M3b inhibitor., a new M3b inhibitor., a new peripheral M3b inhibitor",1,1
"(1)H NMR-based drug design: identification of [ENTITY_A], a novel irreversible [ENTITY_B] inhibitor.(1)H NMR-based drug design: discovery of erlotinib, a new irreversible COX-2 inhibitor.(1)H NMR-based drug design: discovery of (1)C-glucose-binding prodrugs of erlotinib.(1)H NMR-based drug design: discovery",1,1
"(R)-(Z-isothiocyanatostilbene-2,2'-disulfonate) [ENTITY_A] inhibitors: Discovery of [ENTITY_B] - and O-(2-methoxy-phenyl)-3-oxo-4-(3-methoxybenzyl)benzoxazine as a new class of potent [ENTITY_B] inhibitors., a novel potent [ENTITY_B] inhibitor., a novel potent O(2)(+",1,1
"Inhibitory effect of [ENTITY_A], a [ENTITY_B] (COX-2) inhibitor, on prostaglandin E2 production in human gingival fibroblast cells., a potent COX-1 inhibitor, inhibits not only prostaglandin E2 but also COX-2., a selective COX-3 inhibitor, inhibits not only prostaglandin E2 but also COX-1., a selective COX-2 inhibitor, inhibits not",1,1
"(Z)-3-(Aminomethyl)-7-(5-methoxy-phenyl)-5H-1-benzoxaborole ( [ENTITY_A] ), an efficacious, selective [ENTITY_B] (MAO-B inhibitor) against Parkinson's disease., 5-methoxy-phenyl-3-(3-butenyl)-7-(5-methoxy-phenyl)-5H-1-benzoxaborole, 1), a novel,",1,1
"(1)H and (31)P nuclear magnetic resonance analyses of [ENTITY_A], a [ENTITY_B] (V600E) inhibitor.inhibitor [ENTITY_B] (Iressa) causes regression of colonic polyps in familial polyposis patients., a V600E inhibitor.inhibitors [ENTITY_B], erlotinib and NS-398 reduce polyp growth in familial polyposis., a V600E inhibitor.inhibitor [ENTITY_B] (BMS",1,1
"(R)-3-(3-butoxy-4-methoxyphenyl)-5-hydroxybenzotriazine ( [ENTITY_A] ) is a potent and selective inhibitor of [ENTITY_B] kinase., a selective inhibitor of catechol-o-methyltransferase, is also a potent and selective inhibitor of keto-acid dehydrogenase., 3-butoxy-4-methoxybenzotriazine, is a potent and selective inhibitor",1,1
"The effect of the [ENTITY_A] inhibitor [ENTITY_B] on the pharmacokinetics of ketoconazole in healthy subjects., the primary metabolite of ketoconazole, is metabolized via CYP3A., a metabolite of ketoconazole, is metabolized via CYP3A., a metabolite of ketoconazole, is a substrate of CYP2D6., a metabolite of ketoconazole,",1,1
"inhibitors based on the [ENTITY_A] scaffold., a novel [ENTITY_B] (MAO-A) inhibitor, showed high selectivity for the enzyme over the previously reported MAO-B substrate., a new MAO-B inhibitor, was designed as a less-invasive drug., a new MAO-A inhibitor, was synthesized as a potential anti-inflammatory drug.was designed as a selective inhibitor of cAMP and cGMP hydroly",1,1
"(1) Synthesis and antitumor activity of [ENTITY_A] derivatives: a structural basis for the [ENTITY_B] inhibition of [ENTITY_B]., a novel [ENTITY_B] inhibitor., a novel ACE inhibitor., an ACE inhibitor., a selective COXI inhibitor., a selective COXIB inhibitor., a selective COXE inhibitor., a selective COXE inhibitor.
Structural basis for the selective inhibition of human dihyro",1,1
"(1) Synthesis and dual inhibition of [ENTITY_A] by [ENTITY_B]. (2) Structure activity relationships of the C3-phenyl moiety., an effective [ENTITY_B] inhibitor (IH) against PDE3 but not PDE2., a potent IH but ineffective against PDE3., a potent but ineffective IH but effective against PDE4., an IH but ineffective against PDE3., a potent but",1,1
"(R)-(-)-Epicatechin gallate ( [ENTITY_A] ) inhibits tumor necrosis factor-α (TNF- α) induced [ENTITY_B] expression in lipopolysaccharide (LPS)-stimulated BV2 microglia via a cyclooxygenase (COX)-2-dependent pathway., which has been reported to preferentially inhibit lipoxygenase 1 (LOX-1) expression in BV2 microglia, was not involved in the",1,1
"Inhibition of [ENTITY_A] by [ENTITY_B]., a new compound used in traditional Chinese medicine to relieve cough., a new compound used in traditional Chinese medicine to relieve cough., a new compound used in traditional Chinese medicine to relieve cough. 3-hydroxybenzoyl-CoA hydratase ( [ENTITY_A] ) is a newly discovered, enzyme-catalytic enzyme that degrades lipoxygenated molecules, including acetylcholine at n-propionyl-",1,1
"Inhibition of [ENTITY_A] (MAO-B) by [ENTITY_B].inhibition by [ENTITY_B]., a new inhibitor of MAO-B., a new inhibitor of MAO-B., a selective inhibitor of MAO-B., a new MAO-B inhibitor., a new inhibitor of MAO-B.
Structural basis for potent and selective [ENTITY_A] inhibition by novel phenylalanine analogues., a new inhibitor of",1,1
"(1)H NMR-derived structural models of [ENTITY_A], a novel [ENTITY_B] inhibitor., a new [ENTITY_B] inhibitor., a new COX-2 inhibitor., a new [ENTITY_B] inhibitor., a new PDE-4 inhibitor. huprine X, a new PDE3 inhibitor. huprine X, a new PDE4 inhibitor. huprine N-20, a new PDE3 inhibitor. hup",1,1
"(R)- and (S)-2-hydroxy-3-(4-Methoxymethylphenyl)-7-(3-hydroxypropoxy)-1-methylanthraquinone, [ENTITY_A], inhibited [ENTITY_B] Km for methionine, but did not significantly inhibit cytochrome P-450 activity., a more potent irreversible inhibitor of P-gp, inhibited both CYP2C9 and CYP2D6 activities but had no effect on CY",1,1
"(+/-)-Tamsulosin effectively antagonizes the effects of the [ENTITY_A] inhibitor [ENTITY_B] and the COX-1 inhibitor ibuprofen on the metabolism of dextromethorphan in humans., an antimetabolite that inhibits [ENTITY_B] and CYP3A, but not CYP2C, metabolizes dextromethorphan to a less active but biologically active metabolite, nordoxepine-N-demethylate (",1,1
"In vitro metabolism of the novel [ENTITY_A] (BMS-354825): [ENTITY_A] inhibition by [ENTITY_B]., a potent oral multi-targeted [ENTITY_B] inhibitor against AOX, HMG-CoA reductase and cholesterol synthesis, has been in development for the treatment of hypercholesterolemia., a potent oral multi-targeted ROS inhibitor, has been in development for the treatment of hypercholesterolemia.is a novel, orally bioavailable",1,1
"(R)-3-(3-hydroxypropoxy)-1-(1-methan-1-yl)-3-nonyl)adenine ( [ENTITY_A] ), a novel inhibitor of the [ENTITY_B] (MAO-B), is effective in the treatment of Parkinson's disease and related dementias., a selective MAO-A inhibitor, is effective in the treatment of Parkinson's disease and related dementias., a selective MAO-B inhibitor, is effective",1,1
"Inhibition of [ENTITY_A], an enzyme that degrades [ENTITY_B], reduces lung tumor growth and metastasis in mice., a new drug for metastasis reduction., a new drug for cancer metastasis reduction., a new drug for tumor growth reduction., a new drug for lung cancer growth reduction., a new drug for tumor growth reduction., a new drug for lung metastasis reduction.
Comparison of the effects of the dual [ENTITY_A]",1,1
"(1)H NMR-derived structural model of the [ENTITY_A] inhibitor [ENTITY_B]., an [ENTITY_B] (COX) inhibitor, inhibits the biosynthesis of prostaglandins E2 and D2., an ASA(COX-1) inhibitor, inhibits the biosynthesis of thromboxanes A2 and D2., an NS(COX-3) inhibitor, inhibits the biosynthesis of prostaglandins E2 and D2.",1,1
"(1) H-NMR study of the inhibition of [ENTITY_A] by [ENTITY_B], a selective inhibitor of [ENTITY_B]., a selective inhibitor of COX-1., a selective inhibitor of COX-2., a selective inhibitor of PDE-1 and PDE-2., a selective inhibitor of PDE-3., a selective inhibitor of PDE-4., a selective inhibitor of PDE-5., a selective inhibitor of",1,1
"inhibitors based on a [ENTITY_A] scaffold for the selective inhibition of [ENTITY_B]., a new antiestrogen., a selective inhibitor of ERK1/2. rosuvastatin, a third antiestrogen. niflumic acid, a new pro-hypertensive drug. erlotinib, a new antiestrogen.
The effect of [ENTITY_A], an anti-inflammatory drug, on the expression of phosphorylated RANK and",1,1
"(R)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-3-nonyl)adenine ( [ENTITY_A] ), a selective inhibitor of [ENTITY_B], exhibits high in vivo selectivity for [ENTITY_B]., a selective inhibitor of N-methylscavenger receptor B (NMS-BRB)., an irreversible inhibitor of monoamine oxidase (MAO)., a selective inhibitor of mono",1,1
"(1,5-Diarylpyrrole) analogues as potent and selective [ENTITY_A] inhibitors.(BMS-582949): a novel potent and selective COX-2 inhibitor., a [ENTITY_B] COX-1 inhibitor., a potent COX-2 inhibitor.
Novel pyrrolidine nitrooxyalkyl ethers as a new class of potent and nontoxic [ENTITY_B] inhibitors., a potent and selective COX",1,1
"In vivo inhibition of [ENTITY_A], but not CYP2C9, by a novel series of [ENTITY_B] inhibitors., the active metabolite of rasagiline, is currently the focus of research as a novel strategy to treat bipolar disorder and related symptoms., the active metabolite of rasagiline, is currently the focus of research as a novel strategy to treat bipolar disorder and related symptoms., the active metabolite of rasagil",1,1
"(1)H NMR-derived structural models for the inhibition of [ENTITY_A] by [ENTITY_B]., a new orally active [ENTITY_B] (COX-inhibitor) against cancer., a new orally active COX-inhibitor for cancer therapy., a new selective inhibitor for prostaglandin E1 and E2 receptors., a selective inhibitor for cyclooxygenase-1 and cyclooxygenase-2.
The effect of the [ENTITY_A]",1,1
"This study explores the potential for [ENTITY_A], a [ENTITY_B] inhibitor currently used for the treatment of hypercholesterolemia and its cardiovascular effects, to reduce the risk of stroke in hypercholesterolemic subjects with type 2 diabetes mellitus.is a synthetic thromboxane A2 inhibitor that targets the [ENTITY_B] (Bsep) and its downstream signaling components.may reduce the risk of myocardial infarct in patients with type 2 diabetes mellitus.",1,1
"Inhibitors based on a [ENTITY_A] scaffold as a new class of [ENTITY_B] inhibitors., a potent and selective inhibitor of platelet [ENTITY_B], is currently in phase 2 clinical trials., a potent and selective inhibitor of platelet COX-2, was approved for the treatment of chronic myelogenous leukaemia in April 2010. hirudin, a second COX-2 inhibitor, was approved for the treatment of allergic diseases in December 2009.",1,1
"Inhibition of [ENTITY_A] (Aβ) aggregation and neurofibrillary pathology by [ENTITY_B]., a [ENTITY_B] inhibitor that targets the amyloid-beta peptide (Aβ) aggregation step of the pathway, reduces the risk of dementia and related dementias in AD., a selective Aβ aggregation inhibitor that targets only the first aggregation step, is also a neuroprotective agent.blocks both Aβ42 and Aβ40 aggregation., in",1,1
"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxybenzyl-1-methanone, ketanserin B, has an inhibitory potency comparable with that of the [ENTITY_A] inhibitor [ENTITY_B]., a metabolite of ketanserin B, has an IC-50 value of 0.001 microM., ketanserin C, and ketanserin D, are",1,1
"(Z)-3-(1H-1-indolyl)-1-methanone as a novel [ENTITY_A] -selective inhibitor: Docking studies in the binding sites of SRC, CD40, CD40L and CA II., an indole alkaloid with a dual anti-apoptotic activity, has recently been described as a potent and selective inhibitor of the [ENTITY_B] (RANK).kinase inhibitor (KI), a synthetic indole alk",1,1
"(R)- and (S)-3-hydroxypropoxybenzyloxyphenylacetate, [ENTITY_A], inhibits [ENTITY_B] (BChE) with IC-50 values of 43 microM and 227 microM, respectively., a more potent BChE inhibitor than rolipram, has an IC-50 value of 25 microM., a less potent BChE inhibitor than rolipram, has an IC-50 value of 43 microM.",1,1
"(R)-(S)-1-hydroxy-5-methoxy-3-nonyl-1-hydroxy-4-methylanthraquinone ( [ENTITY_A] ), a novel [ENTITY_B] /S-hydroxybenzotriazole inhibitor that binds irreversibly with high affinity to both the N- and O-methyltransferases, was synthesized and tested in vitro for its in vitro metabolism-inhibitory effects against CYP enzymes and its in",1,1
"inhibitors based on a non-toxic [ENTITY_A] scaffold for cancer therapy., a novel small molecule [ENTITY_B] inhibitor., a novel [ENTITY_B] inhibitor. rosuvastatin: a novel statin analogue., a novel fibrate analogue. erlotinib: an oral tyrosine kinase inhibitor. dabigatran: an oral vascular endothelium growth factor (VEGF) receptor inhibitor. [ENTITY_B], a selective COX",1,1
"This study explored the ability of [ENTITY_A], an [ENTITY_B] inhibitor, to reduce breast cancer incidence and breast cancer-related death in postmenopausal women.was developed by our group and shown to inhibit growth of tumors in vitro and in vivo.(N-acetylcysteine) and n-propyl gallate (N-PG, acetylcholinesterase inhibitor) reduced the incidence of breast cancer in the trial., a selective COX-",1,1
"Inhibition of [ENTITY_A], but not CYP2J2 or CYP2B6, by [ENTITY_B]., a new [ENTITY_B] inhibitor., a new prodrug of ketoconazole., a new prodrug of ketoconazole., a new inhibitor of CYP3A., a new substrate of CYP3A., a new inhibitor of CYP2J2., a new substrate of CYP3",1,1
"The use of selective [ENTITY_A] inhibitors for the chemotherapeutic treatment of unresectable malignant glioma.(APC) inhibitors [ENTITY_B] (DPI-84) and erlotinib are potent, oral tyrosine kinase inhibitors that have been in development for the treatment of unresectable, malignant glioma.(DPI-80) is a slightly more potent, oral inhibitor.(CPT-11) inhibitors",1,1
"(R)- and (S)-3-(Aminomethyl)-7-methoxy-4-(3-methoxybenzoyl)indole, [ENTITY_A], inhibit [ENTITY_B] kainate receptor binding and induce apoptosis in cortical neurons., a new class of non-competitive [ENTITY_B] (MAO) inhibitors.inhibition in vitro.knockdown in vitro., a new MAO inhibitor., a new MAO inhibitor",1,1
"(1-methanone) and (1-methylethyl)-5-methylcyclohexane-1-carboxylic acid ( [ENTITY_A] ) as potent, orally active [ENTITY_B] inhibitors., a novel orally active 5-methylanthraquinone., a novel orally active 5-methylanthraquinone., a novel orally active 5-methylanthraquinone., a novel orally",1,1
"inhibitors based on the [ENTITY_A] scaffold: [ENTITY_B] - and iminosugar-based [ENTITY_B] - and N-methylated proton pumps.(BMS-354825) is a novel [ENTITY_B] (BMS-354825) is a [ENTITY_B] inhibitor that has shown considerable promise in clinical trials for the treatment of hypercholesterolemia and cardiovascular disease., a metabolite of bile acids, is a more potent inhibitor of proton pumps.",1,1
"inhibitors based on the [ENTITY_A] scaffold as a new therapeutic approach for Alzheimer's disease., a potent and selective irreversible inhibitor of [ENTITY_B] (MAO), has recently been introduced as a promising new approach for the treatment of Alzheimer's disease., a potent and selective irreversible inhibitor of MAO, has recently been introduced as a new therapeutic approach for Alzheimer's disease., a potent and selective irreversible inhibitor of MAO, has recently been introduced as a new therapeutic approach for",1,1
"The anti-inflammatory effect of [ENTITY_A] is mediated through inhibition of cyclooxygenase-2 expression.(THI) has been demonstrated to suppress inflammation in several animal models through inhibition of [ENTITY_B] (COX-1)., a specific inhibitor of cyclooxygenase-2, has been demonstrated to suppress inflammation in mice and rats through inhibition of COX-1 expression., a selective inhibitor of cyclooxygenase-1, has been demonstrated to suppress",1,1
"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1-hydroxy-1-hydroxy-3-nonyl)adenine ( [ENTITY_A] ), a novel selective norepinephrine reuptake inhibitor and [ENTITY_B] (NETI-101), are potent inhibitors of both NET and [ENTITY_B]., a new selective norepinephrine reuptake inhibitor and NETI-101, a new selective nore",1,1
"Experimental studies in mice reveal a novel role for [ENTITY_A] as [ENTITY_A] receptor agonist: a role in regulation of hippocampal CA3 network.Cannabinoid receptors (CB(1) and CB(2)) have been identified as putative mediators of the positive and negative inotropic effects of the endogenous cannabinoid agonist, [ENTITY_B] (2, 7-dihydroxy-4-(N,N-di-n-propylamino)tetralin). The CB(",2,1
"(+/-)-Epigallocatechin-3-O-gallate (EGCG), the major active ingredient of green tea, exhibits marked anti-inflammatory activity.annulatedagonistic acid (A23187), a specific [ENTITY_B] agonist, partially attenuates this property of EGCG.annulated(Bzf), a selective beta2-adrenoceptor antagonist, partially attenuates the anti-inflammatory activity of EGCG. [ENTITY_A]",2,1
"A novel [ENTITY_A] /AHR agonist, AZ12216, induces relaxation of canine basilar artery: comparison of [ENTITY_B] and salmeterol.The novel [ENTITY_A] agonist, AZ12216, is a potent [ENTITY_B] agonist with proven efficacy in the acute management of asthma.(AZL 1255) is a novel [ENTITY_B] agonist approved for the treatment of asthma and chronic obstructive pulmonary disease (COPD).agonists, such as salmeterol (SM), are widely used",2,1
"The role of [ENTITY_A] and oxytocin in the regulation of labor: a role for oxytocin and not for [ENTITY_B] in the regulation of uterine contraction.agonists and oxytocin agonists have similar actions and may act in synergy.antagonists are partial agonists for oxytocin receptor and are selective for its partial agonist action on beta 1-receptors; however, they are partial agonists for beta 2- and beta 3-recept",2,1
"A novel [ENTITY_B] /DEX antagonist, [ENTITY_A] enhances [ENTITY_A] -induced locomotor hypoactivity in the rat.agonists, [ENTITY_B] and oxycodone have been identified as highly potent [ENTITY_B] agonists.agonists, oxycodone and salmeterol, are highly potent [ENTITY_B] agonists.agonists, oxytocin, and beta-agonists, such as clonidine and naloxone, have also been found to have agonistic properties.(B-",2,1
"A novel [ENTITY_A] agonist, [ENTITY_B], induces D2 receptor desensitization in rat basilar artery.The endogenous opioid receptor (m-ORR) is a critical modulator of cardiovascular responses.and oxymetazoline are highly selective, selective [ENTITY_A] agonists with high affinity for the m-ORR and affinity for D(2) receptors, respectively, and are used as clinical analgesics.agonists such as [ENTITY_B] and oxymetazoline are selective agonists of the",2,1
"Sensitized agonist effects of [ENTITY_A] in comparison to [ENTITY_A]  and [ENTITY_B].agonists, such as [ENTITY_B], are highly potent [ENTITY_B] agonists that are often used as first-line treatment of migraine.agonists such as [ENTITY_B], clonazepam, and lorazepam are highly selective agonists of [ENTITY_B].agonist actions of [ENTITY_A], clonazepam, and lorazepam are comparable to those of [ENTITY_B], and are similar to those",2,1
"(+/-)-tamoxifen and the [ENTITY_A] agonists [ENTITY_B] and carbetocin have a unique mechanism of action: their partial agonistic activity on [ENTITY_B] is independent of [ENTITY_B] agonist action.agonists have partial agonistic activity at [ENTITY_B] sites in vitro.agonists have no direct effect on [ENTITY_B] sites in vitro, and their partial agonistic activity at the vertebrate serotonin transporter (5-HTT) in vivo is dependent on 5-HTT activity.",2,1
"(+/-)-CGP12177 is a partial agonist of [ENTITY_B] -mediated enhancement of [ENTITY_B].and [ENTITY_B] acts on [ENTITY_B] and [ENTITY_B], respectively, and are highly selective for [ENTITY_B] over [ENTITY_B].and beta3AR are nonpecific beta-adrenoceptor antagonists.agonists, such as [ENTITY_A] or beta3AR, act as partial agonists or partial antagonists of beta3AR-mediated enhancement of intracellular calcium levels, depending on the concentration of",2,1
"(+/-)-Citralide attenuates hypothermia induced by the [ENTITY_A] agonist [ENTITY_B] in guinea pigs.antagonist [ENTITY_B] (CB-958) and [ENTITY_A] antagonist [ENTITY_B] (CB-1064) antagonized the effect of (+/-)-citalopram (10 mg/kg IP), while the CB-958 and CB-1064 had no effect., but not [ENTITY_B] agonists (e.g. [ENTITY_B] ) attenuated the hypother",2,1
"A novel [ENTITY_A] agonist, AZ1221689, attenuates the development of beta1AR-mediated enhancement of hippocampal CA3 network activity in rats.agonist [ENTITY_B] (BELVIQ(®)) is a potent [ENTITY_B] /DEX antagonist that is widely used in the US for the treatment of migraine with and without preceding aura.(BELVIQ(®)) is an orally available medication that is approved for the treatment of chronic migraine with or without aura and",2,1
"Sensitization of the [ENTITY_A] and [ENTITY_A] by [ENTITY_A] agonists: involvement of [ENTITY_A] activation in this interaction., a [ENTITY_B] subtype selective [ENTITY_A] agonist, and [ENTITY_B], a selective beta(2)adrenoceptor antagonist, bind to a distinct beta(2)AR subtype and exhibit partial agonistic activity in vivo.(2-chloro-5-(2-chlorophenyl)-4-methylpiperidin-2-yl)ethanone,",2,1
"The role of [ENTITY_A] in the regulation of mGlu3 receptors in rat retinal ganglion cells: a molecular mechanism of ophthalmic depression., a [ENTITY_B] like agonist, has recently been approved for the treatment of insomnia., a selective [ENTITY_B] agonist, is used in many countries to treat insomnia, but the mechanism of action of this drug is not known.and [ENTITY_B], both of which are [ENTITY_B] agonists, bind to the mGlu",2,1
"A novel [ENTITY_A] -specific agonist, [ENTITY_B], inhibits the firing of CA3 pyramidal neurons.agonists, [ENTITY_B] and salmeterol, both of which are orally active.agonists, [ENTITY_B] and salmeterol, both of which are orally active.agonists (e.g. cimetidine) have been identified as selective beta(1)-adrenoceptor agonists.agonists (e.g. cimetidine) have been",2,1
"(S)-N-[2-(2-methoxyphenyl)-1-[2-(2,4-dichlorophenyl)-1-piperidinyl]ethanone (LY 34135) is an orally available [ENTITY_A] agonist with demonstrated clinical efficacy for treating migraine with or without preceding aura., a new [ENTITY_B] agonist with moderate clinical efficacy for treatment of migraine., a selective [ENTITY_B] agonist with moderate clinical efficacy for treatment of migraine with or without",2,1
"(+/-)-Nateglinide and the [ENTITY_A] agonists [ENTITY_B] and resiquimod induce a type 1 interferon-dependent and type 1 interferon-independent antitussive response in guinea-pig peripheral blood mononuclear cells., a [ENTITY_B] agonist; [ENTITY_B] (+/-)-Nateglinide, a [ENTITY_A] agonist, and the [ENTITY_B] agonist [ENTITY_B] both induce a type 1 interferon-dependent antitussive effect in guinea-pig peripheral",2,1
"The role of [ENTITY_A] in the regulation of cycloheximide-sensitive subcellular location of [ENTITY_B].agonists, [ENTITY_B] agonists, and [ENTITY_B] agonists are potent [ENTITY_B] agonists with marked affinity for [ENTITY_B] and [ENTITY_B], which mediate their effects through [ENTITY_B] /prostanoid receptor activity.agonists, [ENTITY_A] agonists, and [ENTITY_B] agonists have similar affinity for [ENTITY_B]  and have a marked affinity for [ENTITY_B], which are metabolised by CYP3A4, the major isomer of the",2,1
"The effects of [ENTITY_A], a [ENTITY_B] agonist, on motor coordination and cortical network activity: a study in mice.Cortical network activity in the mouse is modulated by a number of neurotransmitters, including serotonin (5-HT), dopamine (D(2)), and norepinephrine (10-HT). Here we report that the 5-HT precursor, 5-hydroxytryptophan (5-hydroxytryptophan, 5-HTP), and the",2,1
"A novel [ENTITY_A] -selective agonist, [ENTITY_B], induces locomotor hypoactivity and improves memory deficits in mice.,and oxytocin receptor ligands: new leads for the treatment of insomnia., oxytocin, oxytocin receptor ligands: new leads for the treatment of sleep disorders., oxytocin, oxytocin receptor ligands: novel therapeutic leads for insomnia., oxytocin, oxytocin",2,1
"Amino acid-specific [ENTITY_A] antagonists, [ENTITY_B] and its analogues, are potent [ENTITY_B] agonists with moderate affinity for the [ENTITY_B] and [ENTITY_B] and partial agonist activity at [ENTITY_B] sites.and its esterified-cross-reacted metabolite, [ENTITY_B] (4-[N-[4-(2-methoxyphenyl)-1-(2-methylpiperazine)benzyl]ethyl)methanone), are selective agonists at [ENTITY_B] sites and moderate",2,1
"The role of the [ENTITY_B] antagonist [ENTITY_B] on the antitussive actions of [ENTITY_A] and on beta2-adrenergic receptor expression in the airways.(Bricanyl)-N-cyclopropyl-L-noradrenaline (Bricanyl)-N-cyclopropyl-L-noradrenaline (Bricanyl)-noradrenaline (Brij-35355), a novel [ENTITY_A] agonist approved for asthma treatment, and its prodrug, B",2,1
"The effects of [ENTITY_A], a novel [ENTITY_B] receptor agonist, on ethanol-induced motor incoordination: role of serotonin and dopamine.RATIONALE: Ethanol is a highly potent [ENTITY_B] receptor (SERT) agonist. However, the role of SERT in ethanol-induced motor incoordination, a common motor incoordination symptom, has not been previously investigated.OBJECTIVES: The aim of this study was to assess the effect of [ENTITY_A] (a novel [ENTITY_B] re",2,1
"A novel, highly selective [ENTITY_A] agonist [ENTITY_B] blocks [ENTITY_B] -induced antinociception with a potency similar to that of the nonselective [ENTITY_A] (D-Ala(2)Phe(4)) receptor agonist [ENTITY_B] (3-iodo-5-nitrobenzoyl-L-phenylalanine).(2-[2-methoxypyrid-2-yl](4-hydroxyphenyl)ethyl)meth",2,1
"(1H-[1,2,4-triazol-5-yl]-2-propyl-1H-indeno-[2,1-b]thiazol-6-yl)acetamide (1) and (3) are novel [ENTITY_A] agonists and show high affinity for the D1-like receptor (D(2) ) and moderate affinity for the D3 subtype of [ENTITY_B].(1H-[1,2,4-tri",2,1
"(+/-)-Nateglinide inhibits the mGlu3 receptors at micromolar concentrations, whereas it does not affect the mGlu2 receptors at micromolar concentrations.agonistic agonists of the mGlu3 receptors: synthesis, evaluation of pharmacologic activity, and evaluation of their in vivo activity.agonist and [ENTITY_B] agonist activities of [ENTITY_A] (+/-)-nateglinide and its carboxyl ester, nateglinide",2,1
"A novel [ENTITY_B] agonist, [ENTITY_B], exhibits partial agonist and mixed agonist/antagonist actions on [ENTITY_B]., [ENTITY_B], [ENTITY_A], and salmeterol have similar actions on [ENTITY_B]., [ENTITY_B], and salmeterol have similar actions on beta 1-receptors, but not as potent in this respect as do salmeterol.,, and salmeterol have similar actions on beta 2- and beta 3-receptors.and sal",2,1
"A novel [ENTITY_A] -selective agonist, [ENTITY_B], induces long-term potentiation of hippocampal CA3 pyramidal neurons in rats.(2-chloro-5-(2H-1,2,3-defensin)-2-(1-methyl-4-propyl-1-piperidin-2-yl)benzamide) is a novel [ENTITY_B] agonist and selective agonist of [ENTITY_B] and [ENTITY_B] receptors at the human orth",2,1
"A novel [ENTITY_A] agonist, [ENTITY_B], inhibits the firing of motor units in the rat spinal cord., a novel [ENTITY_B] agonist, exhibits high selectivity for [ENTITY_B] over [ENTITY_B].agonists, such as [ENTITY_B].agonists, such as [ENTITY_B], act on distinct receptors, including [ENTITY_B] and [ENTITY_B], whereas [ENTITY_B]  act on both.and clozapine act as agonists or antagonists, respectively, at distinct sites.and clozapine are partial agon",2,1
"Experimental study of [ENTITY_A] and its agonists at [ENTITY_B] and beta 3-adrenoceptor sites.agonists ( [ENTITY_A] agonists) have been found to have dual agonist/antagonist activity at the beta(1)-adrenoceptor and beta(3)-receptor sites.agonists have been found to have dual agonist/antagonist activity at the beta(1)-adrenoceptor and beta(3)-receptor sites.agonists,",2,1
"A novel, selective [ENTITY_A] agonist, [ENTITY_B], induces sleep in rats: role of 5-HT2 receptor blockade.RATIONALE:, a novel, highly selective [ENTITY_B] receptor antagonist, is a highly potent hypnotic and has a novel mechanism of action.(DEX, [ENTITY_B] ) acts as an antagonist at 5-HT1 receptors.OBJECTIVE: the aim of this study was to determine whether the selective 5-HT2 antagonist [ENTITY_B] (Bicuculline",2,1
"A novel [ENTITY_A] agonist, [ENTITY_B], exhibits selective alpha2-adrenoceptor antagonism at low micromolar concentrations.agonists are highly potent [ENTITY_B] agonists with novel mechanisms of action.(B-type) and salmeterol, both potent beta 2-adrenoceptor antagonists, exhibit beta 2-adrenoceptor antagonism at micromolar concentrations and partial agonistic actions at physiological concentrations, but not at low micromolar concentrations.agonists",2,1
"(1)H-NMR, (15)N-glycine N-acetyltransferase and N-glycan synthesis activities of the [ENTITY_A] agonist [ENTITY_B] (MT1)-like receptor ligands [ENTITY_B] and nateglinide.agonists (e.g. atenolol) bind to two different subtypes of melatonin receptors, MT1-like (MT1-R) and MT2-like (MT2-R).and MT",2,1
"A novel [ENTITY_A] -selective agonist, [ENTITY_B] (5-chloro-2-(2-methoxyphenyl)indole), induces [ENTITY_B] -mediated enhancement of motor incoordination in rats.(5-chloro-2-(2-methoxyphenyl)indole) is an alpha2B-receptor selective agonist that possesses marked sedative activity.(5-chloro-2-(2-methoxyp",2,1
"A novel [ENTITY_B] -selective [ENTITY_A] agonist, [ENTITY_A] (1), induces [ENTITY_B] -mediated enhancement in motor coordination in rats.agonists, such as [ENTITY_B] (2), [ENTITY_B] (3), and salmeterol, have been shown to enhance motor coordination and may act as positive allosteric modulators of the [ENTITY_B].agonists, such as [ENTITY_B] (4), salmeterol and butoxamine, also have potent positive allosteric modulatory actions, although to a lesser",2,1
"Sustained release of [ENTITY_A], a [ENTITY_B] agonist, from [ENTITY_A] and its esterified analogue have partial agonistic properties at [ENTITY_B].(2-hydroxy-3-(4-methoxyphenyl)-2-(1-methylethyl)indeno[2,1-b]furan), an indeno-[2,1-b]pyrazole-2,3-dione derivative, is highly potent [ENTITY_B] agonist with a unique",2,1
"(1-methyle-1,3-diazaspiro[4.5]decane-7,12-dione: novel [ENTITY_B] agonists with dual actions on [ENTITY_B] and [ENTITY_B] receptors.,and [ENTITY_B] and tetrahydroflutamide (THF): a new series of [ENTITY_A] agonists.agonist-7,12-dione and 7-hydroxypyridazin-3-ylcarboxamide (7",2,1
"The effects of [ENTITY_A], a [ENTITY_B] agonist, on hippocampal CA3 network activity during a spatial memory task.-mediated enhancement of hippocampal CA3 network activity in mice.-mediated enhancement of hippocampal CA3 network activity in C57BL/6 mice.-mediated enhancement of hippocampal CA3 network activity in rats.-mediated enhancement of hippocampal CA3 network activity in rats.-mediated enhancement of hippocampal CA3 network",2,1
"A single, highly selective [ENTITY_A] (1-(2-(4-hydroxyphenyl)-1-piperazinyl-4-(2H-1,2,3-triazol-1-yl)benzamide), an orally available [ENTITY_B] agonist, is a highly potent [ENTITY_B] antagonist that acts as a [ENTITY_B] agonist and [ENTITY_B] agonist.[3-[[3-[2-(4-hydroxyphenyl)-1-piperazinyl]-4",2,1
"Sustained release of the selective [ENTITY_A] antagonist [ENTITY_B] from a novel [ENTITY_B] agonist, [ENTITY_B], reveals that it is a potent [ENTITY_B] agonist with moderate affinity for [ENTITY_A] and high affinity for [ENTITY_B] and beta2AR.(R-m-CPP) is a novel [ENTITY_B] agonist with moderate affinity for beta(1)-adrenoceptor sites.agonist, R-m-CPP, is a highly selective agonist of beta(2)-adrenoceptors",2,1
"Experimental evaluation of [ENTITY_A] as an alpha2-agonist and beta3-agonist: comparison of physiological and pharmacokinetic profiles.agonist (2-[2-[4-(2-hydroxyphenyl)propyl]-1-(2-methoxyphenyl)-2-methyl-2H-tetrahydro-1H-indeno[3,2-b]pyrazole-7-carboxamide) is a highly potent [ENTITY_B] agonist",2,1
"The effect of [ENTITY_A] and salmeterol on the cardiac hypertrophy induced by etomidate: a pharmacokinetic/pharmacodynamic study.RATIONALE: etomidate is a centrally acting [ENTITY_A] agonist with a unique cardiac adverse-effect profile., a selective [ENTITY_B] agonist with a unique cardiac adverse-effect profile, is a highly potent [ENTITY_B] agonist with a unique mechanism of action.agonists have been associated with increased cardiac injury, whereas salmeterol has been",2,1
"A novel [ENTITY_A] /DEX antagonist: a potential therapeutic drug for migraine with or without aura., a novel [ENTITY_B] agonist; [ENTITY_B], a selective [ENTITY_B] agonist; and salmeterol, a selective beta2AR agonist.and salmeterol, a selective beta2-adrenoceptor antagonist; and dexmedetomidine, a novel, orally active, [ENTITY_A] agonist, are novel [ENTITY_A] agonists with proven efficacy in the acute management of migraine with or without aura",2,1
"The effect of [ENTITY_A], a selective [ENTITY_B] receptor agonist, on motor function in mice.(DEX) and [ENTITY_A] (BAL), both of which are selective beta 3-receptors agonists, have been reported to be highly selective agonists at [ENTITY_B] receptors.(DEX) and blonabantin(BAL), both of which are nonselective beta 3-receptors agonists, have also been reported to",2,1
"Experimental study of the anticonvulsant activity of [ENTITY_A] on the pentylenetetrazole-induced seizures in mice.The [ENTITY_A] agonists [ENTITY_B] (3-iodo-5-methyl-1-[1-[2,4-b]thiazole-3-carboxamidotoluene) and salmeterol (3-methyl-1-[1-[2,4-b]thiazole-3-carboxamidotolu",2,1
"The role of [ENTITY_A] as a partial agonist at [ENTITY_B] and 5-HT1 receptors: implication for therapeutic efficacy.and 5-HT1 receptors: implications for pharmacological treatment of migraine.and 5-HT1 receptors: implication for pharmacological treatment
Role of [ENTITY_A] in the pathophysiology of migraine: evidence for an interaction with [ENTITY_B].and 5-HT1 receptors: implication for pharmacological treatment of migraine.and 5-HT1",2,1
"(R)-[1-(2-chlorophenyl)-2-methyl-1H-pyrazole]-2(1H)-one derivatives as selective [ENTITY_A] agonists with high water solubility: synthesis, evaluation of in vitro antitussive activity, and evaluation of peripheral tolerance.,, and [ENTITY_A] agonists; [ENTITY_B] agonists with high water solubility; [ENTITY_B] agonists with low water solubility; [ENTITY_B] agonists with moderate water solubility; [ENTITY_B] agonists with low water",2,1
The effect of the [ENTITY_A] agonist [ENTITY_B] on motor coordination and motor recovery from isometric contraction of left ventrolateral medullary motor units in man.agonists [ENTITY_B] and [ENTITY_B] norcross talk about the role of [ENTITY_B] and fluparoxan in the pathophysiology of ischemic disorders.agonists have partial agonist action in guinea-pig cardiac atrial natriuretic peptide (GAP) receptors and full agonist action on [ENTITY_B],2,1
"The role of [ENTITY_A] in the regulation of mGlu2/3 receptors: identification of [ENTITY_A] as a new [ENTITY_B] agonist., an agonist of mGlu2/3 receptors, promotes motor performance in mice., a selective [ENTITY_B] agonist, has been used in the clinical treatment of migraine with or without aura., an agonist of mGlu2/3 receptors, promotes motor performance in mice., a selective antagonist of the [ENTITY_B], has",2,1
"The role of [ENTITY_A] (a [ENTITY_A] ) agonists in the pharmacologic treatment of migraine: an update on clinical development.agonists are highly potent [ENTITY_B] agonists that are currently under development for the treatment of migraine.and beta 2-agonists have demonstrated efficacy as selective beta2-agonist agonists in clinical studies.agonist activity is revealed by blockade of [ENTITY_B] and [ENTITY_B], which are located in the same subcellular compartment.agonist activity is revealed by blockade",2,1
"A novel [ENTITY_A] antagonists, [ENTITY_B] and salmeterol, induce a rightward shift in the concentration-response curves of the beta2AR in human airways.(R-MMA), a selective beta(2)AR agonist, and salmeterol, a selective beta(2)AR antagonist, induce a rightward shift in the concentration-response curves of beta(2)AR in the airways.(R-MMA), a selective beta",2,1
"(E)-3-(2-(2H-1,2,4-triazol-4-ylidene)benzylidene)benzyl ester: an orally active [ENTITY_A] agonist with high affinity for the beta2AR and moderate affinity for the alpha2AR., a [ENTITY_B] agonist with moderate affinity for the beta(2)AR, have similar therapeutic effects. agonists: [ENTITY_A] agonists with high affinity for the beta(2)",2,1
"A novel [ENTITY_A] agonist, [ENTITY_B], induces full agonist activity at [ENTITY_B] and MT2 receptors with improved bioavailability., a novel [ENTITY_B] agonist, is orally active and more stable than other currently available MT2 antagonists., an orally active [ENTITY_B] agonist, is highly potent and highly selective for the human MT2 receptor over the beta 2-adrenergic receptors, with an apparent preferential affinity for the latter.-mediated relaxation of human pulmonary artery constriction is concentration",2,1
"The effects of [ENTITY_A] on hippocampal CA3 network activity and synaptic release were investigated by means of microdialysis in the rat.agonists [ENTITY_B] (AP-5) and salmeterol have dual actions, acting as either [ENTITY_B] agonists or beta3-adrenoceptor antagonists.agonists have dual effects, acting as either beta1-adrenoceptor antagonists or beta3-adrenoceptor agonists.agonist [ENTITY_B] agonists have dual effects, acting",2,1
"(1)H NMR-based metabolite profiling of [ENTITY_A], a novel [ENTITY_B] agonist., [ENTITY_A] -like compounds and [ENTITY_B] : a new [ENTITY_B] agonist., a new [ENTITY_B] agonist., and 5-hydroxy-2-(N,N-di-n-propylamino)tetraline (5-hydroxy-2-methyl-1-propan-2-yl)-N-methyl-D-ribofuronamide",2,1
"The effect of [ENTITY_A] (BELVIQ(®)), a selective [ENTITY_B] agonist, on cardiac remodeling in mice lacking the [ENTITY_B] subtype of [ENTITY_B] receptor., a [ENTITY_B] agonist.(BELVIQ(®)), a selective beta(1)adrenoceptor antagonist, also inhibited the inhibitory effect of carbachol.(BELVIQ(®)) was inactive on its own, and did not have the same hemodynamic effect",2,1
"A novel [ENTITY_A] antagonist, [ENTITY_B], inhibits the firing of [ENTITY_B] -producing CA3 pyramidal neurons in vitro., a novel [ENTITY_B] antagonist, has been identified and characterized as a partial agonist of [ENTITY_B]., a novel partial agonist of [ENTITY_B], was identified as a partial agonist of [ENTITY_B].agonists are new compounds with potent [ENTITY_B] antagonist properties., a novel partial agonist of [ENTITY_B], was identified as a partial agon",2,1
"A novel [ENTITY_B] antagonist, AZD0530 (AZD0530), inhibits [ENTITY_A] -induced antinociception.(AZD0530) is indicated here as a highly potent and selective [ENTITY_B] receptor antagonist.and its metabolites, which are metabolized by the enzyme cytochrome P450, are the only endogenous ligands for [ENTITY_B], and are responsible for the development of many of the effects of the prescription opioid [ENTITY_B].agonist, [ENTITY_B]",2,1
"The effects of [ENTITY_A], an agonist at the [ENTITY_B], on motor coordination and hippocampal CA3 network activity in rats.-likeand 5-hydroxytryptophan (5-HTP) are endogenous 5-HT reuptake inhibitors that are widely utilized in the clinical treatment of a variety of clinical disorders.-agonists, such as [ENTITY_B], exhibit a wide range of pharmacological actions, including actions at serotonin (5-HT) receptors",2,1
"(R)-[(3-iodophenyl)ethyl]propyl-glycine (R-PG) is a selective [ENTITY_A] agonist with marked therapeutic potential in the acute treatment of migraine.agonistic agonist, [ENTITY_B]., a [ENTITY_B] agonist.-mediated regulation of 5-HT1 receptors in brain.and 5-HT1 receptors in brain.-mediated regulation of 5-HT1 receptors in brain, and",2,1
"Sulfonylureas induce a selective [ENTITY_A] -mediated increase in intracellular cAMP.agonist [ENTITY_B], a selective beta 3-receptor antagonist, and its metabolites [ENTITY_B] or triptorelin have been shown to have dual actions: a direct [ENTITY_B] agonist action and a beta 3-receptor antagonistic action.agonist [ENTITY_B] agonists such as [ENTITY_B] and its metabolite triptorelin have been shown to have dual actions: a direct beta 3-re",2,1
"The selective [ENTITY_A] antagonist [ENTITY_B] leads to enhanced serotonin reuptake in the rat brain.and 5-HT2 antagonists have similar sympatho-hypertensive actions.(S)-adenosine, [ENTITY_A] (R)-adenosine, and [ENTITY_B] (S)-serotonin are potent [ENTITY_B] agonists and 5-HT2 antagonists, respectively, which act as agonists or antagonist, respectively, in the brain.agonists have sympatho-enhancing",2,1
"(+/-)-Citalopram, an orally active [ENTITY_A] (+/-)-tamsulosin (TAAM) derivative, exhibits a unique profile of [ENTITY_B] agonist actions at serotonergic nerve terminals.agonist actions at [ENTITY_A] -mediated firing of serotonin neurons are described here.agonist actions at serotonin-mediated synaptic currents are described by WAY100635, a partial serotonin reuptake inhibitor (S-109516) and by rimonabant, a highly",2,1
"The role of the [ENTITY_A] subtype in the pharmacology of [ENTITY_B], a [ENTITY_B] -specific agonist.agonism, a [ENTITY_B] agonist with high affinity for [ENTITY_B] overratio antagonists.-mediated regulation of beta-adrenoceptor function: a new pharmacological profile of clozapine.agonists have a marked partial agonist action on the beta(3)-adrenoceptor subtype, andagonists have a mixed agonist- and antagonist",2,1
The role of [ENTITY_A] as an agonist of [ENTITY_B] in the regulation of body temperature.agonists: novel [ENTITY_B] agonists with high affinity to [ENTITY_B] and high affinity to [ENTITY_B].agonists: [ENTITY_B] agonists with high affinity to [ENTITY_B]  and low affinity to arachidonic acid.agonists: [ENTITY_B] agonists with low affinity to arachidonic acid.agonists: [ENTITY_B] agonists with low affinity to arachidonic acid and high affinity to beta-adrenoceptor antagonists (,2,1
"The role of [ENTITY_A] in the regulation of hippocampal CA3 network activity: involvement of [ENTITY_A].agonists, such as [ENTITY_B], are widely used in the treatment of migraine with and without accompanying sleep disorders.agonists, such as [ENTITY_B], are highly specific for their target receptors, the [ENTITY_B] and are generally inactive in other species.agonists and [ENTITY_B] agonists act as agonists or antagonists at [ENTITY_B] and have dual roles in modulating network activity; bothand m-",2,1
"A novel [ENTITY_A] -sensitive [ENTITY_A] agonist, [ENTITY_B] (1-(2-methoxyphenyl)-5-[2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)benzimidazo[2,1-b]thiazole), induces [ENTITY_B] -mediated antinociception through selective [ENTITY_B] activation of serotonin receptors.agonist/agonist properties of [ENTITY_B] : synthesis, pharmacology",2,1
"A single-molecule, dual-specificity, [ENTITY_A] agonist, MT2135, is a partial agonist at both [ENTITY_B] and [ENTITY_B] sites in guinea-pig trigeminal ganglion cells.(2-hydroxy-3-methyl-1-[4-(2-methyl-1-piperazinyl)benzyl]benzamide) is a novel [ENTITY_B] agonist with proven efficacy in the treatment of migraine with or without preceding history of",2,1
"The effects of [ENTITY_A], a selective [ENTITY_B] agonist, on motor performance in mice., a new [ENTITY_B] agonist, has been identified as a selective [ENTITY_B] and a partial agonist of [ENTITY_B].and [ENTITY_B]  are two novel [ENTITY_B] agonists with potent [ENTITY_B] agonist and partial agonist properties, respectively, and both are highly selective agonists of the [ENTITY_B].and to be a partial agonist of [ENTITY_B],(1), is a novel [ENTITY_B] agonist with high affinity to the [ENTITY_B]",2,1
"Sensitivity and affinity of [ENTITY_A] for [ENTITY_A], a [ENTITY_B] -specific agonist, to [ENTITY_A] receptors on guinea-pig airways.and its ester, [ENTITY_B], are potent [ENTITY_B] agonists that induce euglycemic hyperalimentation and improve asthma.-mediated enhancement of the beta2 subtype of muscarinic receptor-mediated contraction in guinea-pig isolated airways was studied using a microdialysis system, and the effect of",2,1
"The effect of [ENTITY_A] on motor coordination in the rat: a comparison of [ENTITY_B] - and [ENTITY_A] -selective agonists.agonists, such as [ENTITY_B] and its selective [ENTITY_A] subtype, are highly potent [ENTITY_B] agonists that act at two distinct receptors, [ENTITY_B] and [ENTITY_B], and have distinct pharmacological properties.agonists, such as [ENTITY_B] and its selectivesubtype, are highly potent [ENTITY_B] agonists that act at two distinct receptors, [ENTITY_B] and [ENTITY_B], and have distinct pharmacological properties.",2,1
"The effect of [ENTITY_A] on hippocampal CA3 network activity was examined with an electrophysiological recording in mice.agonists exhibit partial agonist actions at [ENTITY_B] and full antagonist actions at [ENTITY_B], which are located in a subregion of the CA3 region.agonist [ENTITY_B] acts as a full agonist at TRPV1 and a partial agonist at mGlu2.agonists exhibit partial agonist actions at TRPV1 and full antagonist actions",2,1
"A novel, selective [ENTITY_A] antagonist, AZ1221689, attenuates the antitussive actions and increases the duration of the response to the [ENTITY_A] receptor antagonist, [ENTITY_B].(+/-)-tamsulosin (a selective beta 3-adrenoceptor antagonist) did not affect either the duration or potency of the [ENTITY_B] antagonist effect.(+/-)-tamsulosin (a selective beta 2-adrenoceptor antagonist) did",2,1
A new compound with dual agonistic activity at the [ENTITY_B] and [ENTITY_B] receptors: identification of a novel compound with dual agonistic activity at the [ENTITY_B] and [ENTITY_B] receptors.agonistic agonists.agonist-like compounds containing a [ENTITY_A] :agonist core structure.agonists with additional actions at the [ENTITY_B]  and [ENTITY_B]  receptors.agonists with dual agonistic actions at the rivulet and vertebrobasilar nerves.agonists with dual agon,2,1
"(1-methoxypyridazin-3(2H)-one), an orally active [ENTITY_A] agonist with moderate sedative and cardiac antagonistic activities, is an inhibitor of [ENTITY_B] and [ENTITY_B] mediated relaxation., a potent [ENTITY_B] agonist with moderate anticholinergic activity, is a novel compound found to have dual inhibitory actions on [ENTITY_B] and alpha 2-adrenergic receptors.and [ENTITY_A]  are potent and selective alpha 2-agonists that are highly selective alpha",2,1
"Sulfonamide-induced neurotoxicity is blocked by [ENTITY_A] and by a specific [ENTITY_A] agonist.agonists ( [ENTITY_B], clozapine, and zacopride) are highly specific for the [ENTITY_B] override-releasing group of [ENTITY_B] receptor ligands and are the first medications approved by the US Food and Drug Administration for this indication., a novel class I histamine receptor antagonist, is indicated for treating migraine with and without aura.agonists, such",2,1
"A novel [ENTITY_A] agonist, AZD0560, inhibits [ENTITY_B] -induced motor incoordination in rats.(R-PIA) and oxymetazoline (R-PIA) are potent [ENTITY_A] agonists and have demonstrated efficacy in the management of migraine with and without preceding aura.agonists, such as [ENTITY_A] (R-PIA) and oxymetazoline (R-PIA), are highly potent [ENTITY_B] agonists and have demonstrated efficacy in the management of migraine with",2,1
"A novel [ENTITY_A] -selective agonist, [ENTITY_B], induces [ENTITY_B] -mediated anxiolysis through a serotonin 5-HT1B receptor mechanism.RATIONALE: The 5-HT(1B) receptors are widely expressed in the brain, and their agonists have been associated with anxiolytic- and depressive-like effects.,, and 5-methoxy-2-(di-n-propylamino) tetralin (MH(4",2,1
"A novel [ENTITY_A] agonist, [ENTITY_B] (2-hydroxy-4-(2-methoxyphenyl)benzyl)-N-methylbenzylidene)ethanone (4), is an orally active [ENTITY_B] agonist with moderate affinity for [ENTITY_B] and moderate affinity for [ENTITY_B], but with low affinity for alpha2-adrenoceptor (alpha2-AR).(2,3-dimethoxyphenyl)-N-methylbenzylidene",2,1
"(+/-)-Caffeine and (+/-)-N-desmethylcaffeine antagonize [ENTITY_B] -induced increases in body temperature.annihilator of the [ENTITY_A].agonist [ENTITY_B] (+/-)-N-desmethylcaffeine (DMC), an alpha 2 antagonist, and (+/-)-N-desmethylcaffeine (DMC), an alpha 3 antagonist, antagonize the [ENTITY_B] -induced increases in body temperature.agonist [ENTITY_B] (",2,1
"Sulfonamidases are highly specific, endogenous sulfonylureas.agonistic activity is dependent on the presence of a functional [ENTITY_A] agonist moiety.agonists are selective agonists of [ENTITY_B] and MT1-MT2 receptors and MT3-M4 receptors, whereas [ENTITY_A] and MT1-MAM 3 receptors are not.agonists are partial agonists at [ENTITY_B] and MT3-M4 receptors and MT1-MAM 3 receptors",2,1
"The effect of a novel [ENTITY_B] receptor antagonist, [ENTITY_B], on hippocampal CA3 network activity in rats.RATIONALE: the [ENTITY_A] receptor is a ligand-gated cationic channel found in the mammalian brain that is activated by a number of endogenous agonists and antagonists.(Bzf) has been identified by structural homology and pharmacological characterization to be the endogenous ligand for [ENTITY_B], a [ENTITY_B] -selective agonist.-like",2,1
"A highly selective [ENTITY_A] antagonist, [ENTITY_B] ((+/-)-BRL 35004), exhibits marked antitussive activity against the acute effects of [ENTITY_B] even at low to mid nanomolar concentrations.agonists, which act as agonists at [ENTITY_B] and [ENTITY_B], are highly potent and specific antitussive agents.agonists, such as [ENTITY_B], have low affinities for [ENTITY_B], and thus are less potent and selective antagonists.antagonists, such as [ENTITY_B], have",2,1
"(S)-N-[2-(1-pyridyl)ethyl]ethylenediamine (8), a novel [ENTITY_A] receptor agonist and [ENTITY_A] agonist, possesses marked anti-cholinergic and anti-cholinesterial activity.(DEX, a selective [ENTITY_B] agonist) and [ENTITY_B] (BELVIQ, a mixed agonist of the [ENTITY_B]  and [ENTITY_B] receptors) have comparable anti-cholinergic and anticholinesterial activity.",2,1
"A novel [ENTITY_A] (CNT) analogue as a selective agonist of [ENTITY_B] and [ENTITY_B] responses at [ENTITY_B] sites., a [ENTITY_B] agonist/agonists; [ENTITY_B], a [ENTITY_B] agonist/agonists.agonist; DPNX, a [ENTITY_B] agonist/agonists.agonist, DPNX-PPT.agonist, DPNX-PTA.(DPNX-PPT), a 5-HT2 antagonist, 5-HT2 antagonist,",2,1
"A novel [ENTITY_A] -specific agonist, [ENTITY_B], activates [ENTITY_B] -mediated relaxation in guinea-pig trachea.agonists have been used in asthma treatment for decades.and beta2AR agonists are widely used in asthma treatment and are the first choices of first-line therapy., a novel [ENTITY_B] agonist, possesses dual actions as an agonist and antagonist at beta2AR., a selective beta2AR agonist, possesses both agonist",2,1
"A novel [ENTITY_A] -selective agonist, [ENTITY_B] (1-[[2-[1-(2-chloro-4-nitrobenzoyl)benzoyl]ethyl]-2-(2H-1,2,3-triazol-4-yl)ethyl]propionamide), induces relaxation of canine basilar artery.agonists, such as [ENTITY_B], may act on a subset of [ENTITY_B] and may be useful in treating migraine with or without preceding",2,1
"A novel [ENTITY_A] antagonist, [ENTITY_B], induces [ENTITY_B] agonism through a 5-HT3 receptor-mediated increase in 5-hydroxytryptophan levels in rat basilar artery.(B-HTN) : a novel 5-HT3 antagonist with dual 5-HT1 antagonist/5-HT2 antagonist actions.(B-5-HT3A) : an 5-HT3 antagonist with dual 5-HT1 antagonist/5-HT",2,1
"Sensitization of [ENTITY_A] by the [ENTITY_A] agonists [ENTITY_B] and [ENTITY_B] and agonist actions at [ENTITY_B] receptors on guinea-pig airways.(R-M-12), a novel [ENTITY_A] receptor antagonist, induces a relaxation of isolated guinea-pig airways via stimulation of [ENTITY_B] and [ENTITY_B] receptors.(R-M-12), a new [ENTITY_B] receptor antagonist, induces a relaxation of guinea-pig airways via stimulation",2,1
"Sustained release of [ENTITY_A] by [ENTITY_A] (Bipriflo), a [ENTITY_B] agonist, from liposomal amphotericin B: a novel therapeutic strategy for the treatment of visceral leishmaniasis., a [ENTITY_B] agonist, and its ester, biprosuvastatin (Bipriflo), are highly potent, highly selective [ENTITY_B] agonists that are widely used in the treatment of cardiovascular diseases., a selective [ENTITY_B] agonist, is an",2,1
"(+/-)-CGP12177 (a selective [ENTITY_A] agonist) attenuates hypothermia induced by the [ENTITY_A] agonist [ENTITY_B] (R-M181, R-CP 801) in rats.annoylates [ENTITY_B] and [ENTITY_B].(R-M182, R-CP 810) is a selective [ENTITY_B] agonist and a partial [ENTITY_B] agonist.agonists: (+/-)-CGP12177 (R, R-CGP 12177) and",2,1
"(1)H-NMR and (13)C-HMBC experiments in combination with (1)H-(13)C-HMBC and (1)H-(1)H CMR data to elucidate the structural basis for the selective agonist and antagonist actions of the natural product [ENTITY_A] on [ENTITY_B] -mediated relaxation., a [ENTITY_B], are mixed agonists and antagonists that act as either [ENTITY_B] agonists or antagonists., a selective [ENTITY_B] agonist, is indicated",2,1
"The effect of [ENTITY_A], a [ENTITY_B] antagonist, on the gastric acid secretory response and gastric acid secretion in conscious rats.antagonists are often used in the treatment of various diseases, such as gastric acid suppression, gastric acid secretion disorders, and peptic ulcer disease.antagonists are often used in the treatment of gastric acid dyspepsia and gastric acid secretion disorders.antagonists are often used in the treatment of gastric acid",3,1
"The effects of [ENTITY_A] antagonists [ENTITY_B] and carbetocin on plasma glucose and glycemia in non-diabetic and type 1 diabetic patients: a randomized, double-blind, placebo-controlled study., a novel [ENTITY_B] antagonist (OTA), inhibits the synthesis of insulin., a second-generation OPA ( [ENTITY_B] (3) ), inhibits glucose uptake into the liver and increases glucagon-like peptide 1 (GLP-1) concentrations in the portal",3,1
"(R)-(-)-Epinastine hydrochloride ( a nonselective [ENTITY_B] antagonist ) attenuated the mechanical allodynic effect of the alpha 2A-adrenoceptor antagonist, salbutamol, while the selective alpha 1D-adrenoceptor antagonist, salbutamol, was inactive., a [ENTITY_B] antagonist, and [ENTITY_A] antagonists [ENTITY_B] and BRL35135, at concentrations that did not inhibit the alpha 2A-adren",3,1
"(1)H MRS analysis of the effects of the selective [ENTITY_A] antagonist [ENTITY_B] on cognitive and motor functions in patients with mild-to-moderate traumatic brain injury: comparison with placebo.antagonists are known to improve cognitive and motor performance following mild-to-moderate traumatic brain injury (TBI)., a selective [ENTITY_B] antagonist, has also been shown to ameliorate TBI, but there are no data on its effects on cognitive or motor functions in",3,1
"The use of [ENTITY_A], a new [ENTITY_B] antagonist, in the treatment of allergic rhinoconjunctivitis: a double-blind, placebo-controlled trial.PURPOSE: To determine if the use of a new class of nonselective antagonist, [ENTITY_B], in the treatment of allergic rhinoconjunctivitis is as effective as other beta blockers.METHODS: This was an 8-week, double-blind, randomized, placebo-controlled trial of the efficacy of",3,1
"The effect of [ENTITY_A], an antagonist of [ENTITY_B] and of 5-HT2C receptor, on the mechanical hypersensitivity of the fingertip and the influence of [ENTITY_A], another antagonist of 5-HT2A/2B/2C, on the effect of clozapine, another [ENTITY_B] antagonist, on the mechanical hypersensitivity of the fingertip were investigated in rats.antagonists, [ENTITY_B] and thioridazine, are antagonists at 5-HT2A/2",3,1
"A comparison of [ENTITY_A], a selective [ENTITY_B] antagonist, and placebo in patients with acute coronary syndromes: a 4-week study.STUDY OBJECTIVES: The aim of this study was to compare the acute effect of the selective [ENTITY_B] antagonist, [ENTITY_B] (5 mg/kg, s.c.), and the placebo on cardiovascular variables and on 24-h urinary excretion of 5-HT and 3-glutamyl-glutamate (3-GT) in",3,1
"The effect of [ENTITY_A] antagonist [ENTITY_B] on plasma glucose and insulin concentrations, as well as on liver glycogen content and glucose-stimulated insulin secretion in normoglycemic and insulin-dependent diabetic rats., an oral [ENTITY_B] antagonist, is known to increase the insulin-mediated glucose uptake in pancreatic beta-cells., a nonpeptide [ENTITY_B] antagonist, has been shown to attenuate beta-cell dysfunction and insulin resistance, which is attributed to the impairment of",3,1
"Inhibition of gastric acid secretion by [ENTITY_A], a [ENTITY_B] antagonist, and of gastric acid secretion in mice by estramustine phosphate., a selective [ENTITY_B] antagonist, and estramustine (EMP), a selective 5-HT2B antagonist, inhibited gastric acid secretion in mice (ED50 = 3.8 mg/kg, for pentetrazole; 3.8 mg/kg for pentetrazole + EMP) and inhibited acid secretion in",3,1
"A new class of [ENTITY_A] antagonists for the treatment of cardiovascular disease: [ENTITY_B], an [ENTITY_B]., a novel [ENTITY_B] antagonist for the treatment of hypertension., a novel [ENTITY_B] antagonist for the treatment of angina pectoris., a new [ENTITY_B] antagonist for the treatment of angina pectoris and hypertension., a new [ENTITY_B] antagonist for the treatment of angina pectoris and hypertension., a novel [ENTITY_B] antagonist for",3,1
"The effects of [ENTITY_A], a novel [ENTITY_B] antagonist, on gastric acid secretion were compared in rats and dogs., a selective [ENTITY_B] antagonist, was used to examine the effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, [ENTITY_B] and dynasore, on gastric acid secretion in man., a selective alpha(1B)-adrenoceptor antagonist,",3,1
"(1)H-Methylmaleimide binding to membrane-associated proteins: comparison to [ENTITY_B] antagonists., the [ENTITY_B] antagonist [ENTITY_B] and the [ENTITY_A] antagonist [ENTITY_B] inhibit binding with comparable potency and rapid kinetics to [ENTITY_B] and [ENTITY_B], respectively., [ENTITY_B] and the alpha(2A)-adrenoceptor antagonist capsazepine are also potent antagonists of (1)H-Methyl Maleimide (HMM) binding to rat brain homogen",3,1
"A new class of [ENTITY_A] antagonists, [ENTITY_B] (3-methyl-1-[4-(4-(1-(4-(1-methylethyl)-2-piperidyl)-4-methyl-3-oxoethyl]-5-(1-methylethyl)-4H-pyrazol-1-carboxylic acid)-propionate (HIS-1), and their selective [ENTITY_A] antagonists, [ENTITY_B] and [ENTITY_B], are identified as antagonists of",3,1
"Sensitivity to the [ENTITY_A] antagonist [ENTITY_B] and the [ENTITY_A] antagonist [ENTITY_B] is blocked by [ENTITY_A], a [ENTITY_B] antagonist that acts specifically at [ENTITY_B] receptors but not other [ENTITY_B] types.antagonists such as [ENTITY_B] and [ENTITY_B] antagonists such as [ENTITY_B] inhibit the contractions of the gall bladder and ileum of the guinea pig and the dog.and the [ENTITY_A] antagonists [ENTITY_B]  and [ENTITY_B] inhibit the contractions of the gall bladder and ileum of",3,1
"The effect of [ENTITY_A] antagonists [ENTITY_B] ( [ENTITY_B], [ENTITY_B], and thioridazine on gastric acid secretion in rats and dogs was studied after intragastric administration.antagonists thioridazine and oxytocin are potent antagonists at [ENTITY_B] receptors, and have been shown to stimulate gastric acid secretion from the stomach in man., a nonselective [ENTITY_B] antagonist, and the selective [ENTITY_B] antagonist, oxytocin, have been shown to stimulate gast",3,1
"The effect of a single dose administration of the [ENTITY_A] antagonist [ENTITY_B] on the motor impairment produced by traumatic stress exposure and alcohol abuse., a [ENTITY_B] antagonist, reduces alcohol and other drug abuse in alcohol-dependent patients., a [ENTITY_B] antagonist, reduces alcohol and other drug abuse in alcohol-dependent patients., an alpha-adrenergic antagonist, reduces alcohol abuse in alcohol-dependent patients., a histamine H3-receptor antagonist, reduces",3,1
"A novel [ENTITY_A] antagonist, [ENTITY_B] (5-methyl-1-phenyl-1H-pyrazole-3-carbonyl-carbonyl-carbonyl-methyl-aminotetralin monohydrochloride), reduces alcohol-induced impairment of motor function in mice: comparison with alcohols of different lipophilic character., 5-methyl-1-phenyl-1H-pyrazole-3-carbonyl-carb",3,1
"The role of [ENTITY_A], a [ENTITY_B] antagonist, in the treatment of allergic rhinitis and conjunctivitis: a double-blind randomized placebo-controlled trial.antagonists (e.g. [ENTITY_B], almotriptan) are known to decrease the severity of allergic rhinitis and conjunctivitis and to have favorable clinical effects in allergic rhinitis/sinusitis.antagonist (e.g. ondansetron) is",3,1
"(+)/- [ENTITY_A] and (-)-pindolol potentiate the contraction of the gall bladder of the guinea pig and of the dog provoked by 5-HT1A and 5-HT1D receptors., a [ENTITY_B] antagonist, reduces the frequency of spontaneous contractions of the gall bladder induced by 5-HT1A, 5-HT1B and 5-HT1D receptors., another alpha-adrenoceptor antagonist, reduces the frequency of",3,1
"The effects of a [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretion and gastric acid secretagogues in healthy subjects.OBJECTIVE: to examine the possible effect of the alpha(2)-adrenoceptor antagonist, [ENTITY_B], on gastric acid secretion and gastric acid secretagogues in healthy subjects.anantagonist, alpha(2)-adrenoceptor antagonist, [ENTITY_B], and an alpha(1)-adrenoceptor antagonist, [ENTITY_B], were compared on gastric",3,1
"A novel dual [ENTITY_A] antagonist, [ENTITY_B] on paroxetine-induced hypertrophy of the paraventricular nucleus of the hypothalamus (PVN) of the rabbit: comparison with the [ENTITY_A] antagonist, [ENTITY_B]., an alpha-adrenoceptor antagonist; [ENTITY_A], a beta-adrenoceptor antagonist; [ENTITY_B], a [ENTITY_B] antagonist; and [ENTITY_A], a beta-adrenoceptor antagonist., an alpha-adreno",3,1
"The effect of [ENTITY_A], a [ENTITY_B] antagonist, on the contractions induced by phenylephrine was studied in rat aortic membranes.[(+)-MK 801], a selective [ENTITY_B] antagonist, inhibited the contraction induced by phenylephrine in rat aortic membranes., a selective alpha 1A-adrenoceptor antagonist, did not have any effect., a selective alpha 1D-adrenoceptor antagonist, reduced the",3,1
"Amino-subtype-selective [ENTITY_A] antagonists, [ENTITY_B] and homochlorcyclizine, antagonize [ENTITY_B] - and oxymetazoline-induced seizures in mice., an [ENTITY_B] antagonist ( [ENTITY_B], [ENTITY_B] ), is known to be an effective and widely used drug for the treatment of allergic rhinoconjunctivitis, atopic dermatitis, and allergic conjunctivitis., on the other hand, is a potent and selective antagonist of alpha",3,1
"A novel [ENTITY_A] antagonist, [ENTITY_B] [1-[2-(3-(dimethylamino)-propylphenyl)-1-methyl carbamoyl]-ad amantane-2,5-dione hydrochloride], reduces mechanical hypersensitivity via a mechanism distinct from [ENTITY_B] antagonism., a potent and selective [ENTITY_B] antagonist, reduces mechanical hypersensitivity without disrupting the normal neuroendocrine function., a novel and potent [ENTITY_B] antagonist, reduces hypersensitivity",3,1
"The effect of the [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretion and gastric acid secretion in rats and dogs., a recently introduced [ENTITY_B] antagonist with a different mode of action at the alpha(1)-adrenoceptor than other beta-adrenoceptor antagonists, was recently shown to increase gastric acid secretion (ESS) in humans and dogs. was recently shown to decrease ESS in humans and dogs., a potent and selective alpha(1)-",3,1
"The effects of [ENTITY_A], a [ENTITY_B] antagonist, on the contractile responses of rat aortic membranes to phenylephrine and norepinephrine were studied., an antagonist of both Type I and Type II 5-HT receptors, inhibited both the contractions of rat aortic membranes to the agonists and the responses to the antagonists with similar potency (EC(50): 5.8 +/- 0.1 and 8.1 +/- 0.1 micromol",3,1
"The effect of a [ENTITY_A] antagonist, [ENTITY_B] (0.3 mg/kg, i.p.), on mechanical hypersensitivity provoked by capsaicin was studied in the isolated perfused rat ear., a [ENTITY_B] antagonist, and [ENTITY_B] (0.3 mg/kg, i.p.), an alpha(2)-adrenoceptor antagonist, both inhibited capsaicin-induced mechanical hypersensitivity in the rat, whereas the alpha(1)-adrenoceptor antagonist",3,1
"A novel class of [ENTITY_A] antagonist, [ENTITY_B], reduces alcohol consumption by alcoholics.antagonists such as [ENTITY_B] and ondansetron are potent antagonists of the alpha 1A-adrenoceptor and possess been shown to inhibit alcohol consumption in animals that are chronically alcohol exposed.antagonists such as ondansetron are potent antagonists of the alpha 1A-adrenoceptor and possess been shown to inhibit alcohol consumption in animals that are chronically alcohol exposed.",3,1
"A new dual [ENTITY_A] antagonist [ENTITY_B] has been identified as a potent and selective [ENTITY_B] antagonist., a [ENTITY_B] antagonist., a [ENTITY_B] antagonist; and SB 227122, a selective alpha 1A-adrenoceptor antagonist., a new potent and selective alpha 1A-adrenoceptor antagonist; [ENTITY_B], a selective alpha 1A-adrenoceptor antagonist; and SB 227122, a selective alpha 1A-ad",3,1
"(1)H magnetic resonance spectroscopic characterization of the binding of [ENTITY_A]  to the human 5-HT3 receptor in the rat cerebral cortex., a [ENTITY_B] antagonist, inhibits the 5-HT3 receptor-mediated enhancement of serotonin (5-HT) levels in the frontal cortex of freely-moving rats., an antagonist, inhibits the 5-HT3 receptor-mediated increase in 5-HT levels in the frontal cortex of freely-moving rats.,",3,1
"The effect of [ENTITY_A] antagonists, [ENTITY_B] and carbetocin, on the gastric acid secretion and gastric acid secretion in dogs., a [ENTITY_B] antagonist, inhibited gastric acid secretion in dogs (ED50=8 mg/kg i.v.) and rats (ED50=8 mg/kg s.c.)., a beta-adrenoceptor agonist, inhibited gastric acid secretion in dogs (ED50=8 mg/kg i.",3,1
"The effects of the [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretion and gastric acid secretion in dogs and rats, and the effects of the [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretion and gastric acid secretion in dogs and rats.antagonists have been previously shown to decrease gastric acid secretion (GAS) and to increase gastric acid secretion (GASAS) in dogs, but their effects on acid secretion in other species have yet to be determined.ant",3,1
"Inhibition of platelet aggregation by [ENTITY_A], a [ENTITY_B] antagonist, using a thiazide diuretic: involvement of thiazide-dependent NADPH oxidase., a [ENTITY_B] antagonist, inhibits aggregation of rat aortic smooth muscle cells stimulated by ADP-induced thrombin., a selective thiazide diuretic, also inhibits platelet aggregation stimulated by thrombin but not ATP-evoked aggregation., another selective th",3,1
"The effect of [ENTITY_A], an [ENTITY_B] antagonist, on the pharmacology of [ENTITY_A], a 5-HT4 antagonist, in humans and dogs., a [ENTITY_B] antagonist, inhibits the actions of 5-HT4 and 5-HT1 receptors with similar potency., another beta 2-adrenoceptor antagonist, has a much higher potency at inhibiting 5-HT4 and 5-HT1 receptors than at inhibiting alpha 2A-adrenocept",3,1
"The effect of the [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretion in dogs.antagonists have previously been shown to decrease gastric acid secretion in dogs., a new [ENTITY_B] antagonist, is inactive on the stomach and is not expected to affect acid secretion in dogs.antagonists such as [ENTITY_B] and [ENTITY_B], however, are active both at high concentrations ( > 5 microM) in the stomach and at low micromolar (50 +/- 5 ng ml(-",3,1
"A comparison of the pharmacology and pharmacokinetics of [ENTITY_A], a novel [ENTITY_B] antagonist, with that of [ENTITY_B], a [ENTITY_B] antagonist, in healthy subjects., a [ENTITY_B] antagonist, is currently in clinical development for the treatment of osteoporosis and pulmonary arterial hypertension., in contrast, has demonstrated mixed results in these two populations.and a recent development, the [ENTITY_A] antagonist [ENTITY_B], have been shown to be antagonists of the renin-ang",3,1
"A comparison of two different methods for the measurement of the plasma concentrations of [ENTITY_A], a [ENTITY_B] antagonist, in healthy subjects., a selective [ENTITY_B] antagonist, inhibits the binding of testosterone to the human testosterone receptor (AT1)., a selective beta 1-adrenoceptor antagonist, inhibits the binding capacity of the human alpha 1A-adrenoceptor to testosterone., a selective beta 1-adrenoceptor antagonist, inhibits the binding capacity of",3,1
"(1)H MRS of rat hippocampus with the selective [ENTITY_A] antagonist [ENTITY_B] in vivo: comparison to 3-day-old animals., an inhibitor of NMDA receptors, reduces anxiety-like behavior in rats and monkeys.and other selective NMDA receptor antagonists have been shown to attenuate anxiety-like behavior in a variety of experimental paradigms and in human patients with anxiety disorders., an NMDA antagonist, reduces anxiety-like behavior in",3,1
"The role of [ENTITY_A], an antagonist of the [ENTITY_B], in allergic rhinoconjunctivitis and rhinoconjunctivitis with a positive response to the [ENTITY_A] antagonist [ENTITY_B] [corrected]., an antagonist of the histamine H3 receptor, was recently discovered to be effective in the treatment of allergic rhinoconjunctivitis and rhinoconjunctivitis with a positive response to the histamine H3 receptor antagonist, cimetidine hydro",3,1
"(1)H-NMR spectroscopy and MALDI-TOF mass spectrometry characterization of new [ENTITY_A] (Zingiber officinale Roscoe) tergitol analogues with dual anti-inflammatory and antinociceptive activity.antagonists ( [ENTITY_B] and [ENTITY_B] ), which are currently in phase III clinical trials, are known to possess both anti-inflammatory and antinociceptive activity., a new [ENTITY_B] antagonist ( [ENTITY_B] ), which",3,1
"Sustained and selective antagonism of [ENTITY_B] at the [ENTITY_B], 5-HT(1A), and 5-HT(1B) sites of serotonin transporters by [ENTITY_A] in mice and humans., a potent [ENTITY_B] antagonist, is a racemic mixture of levocetirizine (1.9 x 10(-6) M) and hydroxylevocetirizine (1.9 x 10(-6) M). is a racemic",3,1
"The role of [ENTITY_A], a selective [ENTITY_B] antagonist, in the treatment of allergic rhinoconjunctivitis: an open-label, randomized, crossover, multicentre, controlled trial.AIM: To determine if a single oral dose of 30 mg/kg of the nonselective alpha 2-adrenoceptor antagonist, [ENTITY_B], is able to decrease the number of exacerbations of allergic rhinoconjunctivitis episodes in patients with a previous history of atopic",3,1
"(R)-(-)-3,4-dimethoxyphenylglycine ( DHP ), a selective [ENTITY_B] antagonist, reduces anxiety and stress in the rat., a selective [ENTITY_A] antagonist, has been shown to attenuate anxiety in a variety of species and has been shown to possess cognitive-enhancing effects in several animal models., a selective alpha2A-adrenoceptor antagonist, has been shown to inhibit anxiety and stress in the rat.",3,1
"A comparison of the effects of clozapine hydrochloride and [ENTITY_A], two different [ENTITY_B] antagonists, on cognitive deficits in the Morris water maze test in Alzheimer's disease.antagonists are often used in the treatment of cognitive impairment in Alzheimer's disease (AD).antagonists are often used in the treatment of cognitive impairment in AD.antagonists such as thio-BCTC, [ENTITY_B], and thioridazine are often used in the treatment of AD",3,1
"The selective [ENTITY_A] antagonist [ENTITY_B] blocks gastric acid secretion in rats but not in dogs.antagonists, such as [ENTITY_B], barusiban, and prazosin, have been recently developed and shown to inhibit gastric acid secretion in animals (e.g. rats, dogs).antagonists, such as [ENTITY_B], barusiban, and prazosin, have been recently developed and shown to inhibit gastric acid secretion in animals (e.g.",3,1
"The effect of [ENTITY_A], a selective [ENTITY_B] antagonist, on gastric acid secretion in dogs, rats and frogs.antagonists, such as amisulpride and hydrochlorothiazide, have been shown to alter gastric acid secretion in humans and animals.antagonists, such as amisulpride (amiloride) and hydrochlorothiazide (chlorothiazide), have been shown to alter the gastric acid secretion in rats and",3,1
"The use of the [ENTITY_A] antagonist [ENTITY_B] against experimental pulmonary arterial hypertension (PAH) is controversial., a selective [ENTITY_A] antagonist, reduces right ventricular hypertrophy (RVH) in a rat model of pulmonary arterial hypertension (PAH)., a selective [ENTITY_A] antagonist, has been shown to decrease RVH in a mouse model of pulmonary arterial hypertension (PAH)., an alpha-adrenoceptor antagonist, is a potent",3,1
"(1)H-NMR, (13)C-NMR, and LC-MS analyses of the binding properties of the [ENTITY_A] antagonist [ENTITY_B] to [(3)H]methylhistamine., a selective [ENTITY_B] antagonist, is known to interact with the monoamine systems of the brain., a potent antagonist of the histaminergic system, is known to interact with the cholinergic and serotonergic systems.-induced changes in the",3,1
"The effects of [ENTITY_A], a [ENTITY_B] antagonist, in mild to moderate asthma: a randomized controlled trial with a 2-week treatment period.antagonists are the first-line therapies for severe acute exacerbations of asthma, and beta-agonists are recommended for the initiation of treatment for less severe disease.antagonists are the first-line therapies for severe acute exacerbations of asthma, and beta-agonists are recommended for the initiation of treatment for less severe disease.",3,1
"The effect of [ENTITY_A] antagonists on the pharmacology and pharmacokinetics of the [ENTITY_B] antagonist [ENTITY_B] in healthy subjects., a [ENTITY_B] antagonist, has previously been shown to increase the apparent oral clearance (CL/F) of the novel [ENTITY_A] antagonist, [ENTITY_B], in healthy subjects., a nonselective antagonist, has been shown to decrease the CL/F of the novel beta 1-adrenoceptor antagonist, ACE-207, in healthy subjects.",3,1
"Sustained, long-term, high-dose, oral administration of the [ENTITY_A] antagonist [ENTITY_B] in mice is without significant adverse effects on growth and reproduction.antagonists have been shown to possess a broad-spectrum of actions and are currently in phase III clinical trials for the treatment of a number of common diseases, including allergic disorders, vasomotor symptoms and cancer.antagonists are also in phase III clinical trials for the treatment of obesity and type 2 diabetes mellitus",3,1
"The selective [ENTITY_A] antagonists [ENTITY_B] and W-120301 act as [ENTITY_B] antagonists at alpha2-adrenoceptor sites and synergize with clozapine to increase alpha2A-adrenoceptor density in rat cerebral vasculature., a [ENTITY_B] antagonist, and W-120301, a 5-HT3/4 antagonist, increase alpha2A-adrenoceptor (α2A-AR) density in the cerebral cortex of rats",3,1
"A novel [ENTITY_A] antagonist [ENTITY_B] blocks the oxytocin receptor-mediated increase in [Ca(2+)](i) and reduces oxytocin-induced uterine contraction: comparison with oxytocin receptor antagonists., an antagonist of the oxytocin (OT) receptor, reduces oxytocin-induced uterine contraction in nonpregnant, nonlactating rats, and oxytocin is a peptide hormone that is produced by the oxytocin receptor (",3,1
"(+)/- [ENTITY_A], a selective [ENTITY_B] antagonist, inhibits IL-5-induced IL-5 mRNA and IL-5 protein synthesis in human fibroblast-like synoviocytes and macaque air pouch cells., an oral [ENTITY_B] antagonist, inhibits IL-5 production in human synoviocytes and macaque air pouch cells., a selective [ENTITY_B] antagonist, inhibits IL-5 mRNA and protein synthesis in human synoviocytes and macaque air pouch cells.",3,1
"Inhibition of cycloheximide-induced platelet aggregation by the [ENTITY_A] antagonist [ENTITY_B] ( [ENTITY_B] ).antagonism: role in thrombotic disease., an antagonist of the [ENTITY_B] -adrenoceptor, is a potent vasodilator and a selective vasopressor.antagonism: role in thrombotic disease, however, is not well defined.and other [ENTITY_B] antagonists are selective for the beta",3,1
"The effects of [ENTITY_A] antagonists on the steady-state plasma glucose levels in patients with type 1 diabetes mellitus: a 3-day oral glucose challenge study., a [ENTITY_B] antagonist; hydroxyzine, a 5-HT3 antagonist; tamsulosin, a histamine H4 antagonist; and citalopram, a serotonin (5-HT) antagonist, all inhibited the glucose infusion rate (GIR) in 9 patients (6 male; mean",3,1
"The use of [ENTITY_A] antagonists for the treatment of angina pectoris: a population-based study.OBJECTIVE: To evaluate the effect of the use of [ENTITY_A] (CGP20712A, a new [ENTITY_B] antagonist), on the development of angina pectoris in patients receiving long-term treatment with angiotensin receptor blockers (ARBs).RESEARCH DESIGN AND METHODS: This was a retrospective population-based study in which we compared the use",3,1
"The effect of [ENTITY_A] antagonists, including [ENTITY_B], at different doses on the urinary excretion of 5-HT and 5-HT metabolites in schizophrenic inpatients receiving fluoxetine hydrochloride., a [ENTITY_B] antagonist, and loratadine, a 5-HT(1B/D) antagonist, inhibited the fluoxetine-induced increase in urinary levels of 5-HT and 5-HT(1B/D) and 5-",3,1
"A novel class of [ENTITY_A] antagonist, [ENTITY_B] (CEC: 7.2 x 10(-9) M), that antagonizes the positive inotropic effect and the contraction mediated by the alpha1 adrenoceptor is described., alpha 1 adrenoceptor antagonist;, alpha 1 beta adrenoceptor antagonist; [ENTITY_B], alpha 1 alpha adrenoceptor antagonist; [ENTITY_B], alpha 1 beta adrenoceptor antagonist; [ENTITY_A] [1-[(4-chlorophenyl)-2-(",3,1
"Inhibition of osteoblast cell growth by [ENTITY_A], a nonselective [ENTITY_B] antagonist, is mimicked by [ENTITY_A] antagonists and is blocked by the [ENTITY_A] antagonist [ENTITY_B] [1,2-bis-(4-morpholinyl)-5-(4-methylpiperidin-1-yl)-carbonyl]-imidazole-4-carboxylic acid (WY-46824)., a selective [ENTITY_B] antagonist, did not affect osteob",3,1
"The role of [ENTITY_A], a [ENTITY_B] antagonist, in the treatment of pulmonary arterial hypertension (PAH) by the combination of losartan and amlodipine: comparison with the use of losartan monotherapy./D-Arg-(1-[(alpha)methyl-6-(2-phenylacetyl)-3-(4-morpholinyl)propyl]-carbonyl]-amino]-4-methyl-5-(4-morph",3,1
"The effects of [ENTITY_A], an [ENTITY_B] antagonist, on the pharmacology of haloperidol and other [ENTITY_B] antagonists: comparison of acute and chronic treatments.antagonism: comparison of acute and chronic treatments with [ENTITY_B].antagonism: comparison of chronic treatments with [ENTITY_B]  and [ENTITY_A].antagonism: comparison of acute and chronic treatments with [ENTITY_B].antagonism: comparison of acute and chronic treatments with the selective beta(2)-adrenoceptor agon",3,1
"The role of [ENTITY_A], an antagonist of [ENTITY_B], in the etiology of allergic rhinoconjunctivitis.Concentrations of various anaphylatoxins have been reported to be associated with allergic rhinoconjunctivitis., an [ENTITY_B] antagonist, has been shown to attenuate allergic rhinoconjunctivitis, and another antagonist, [ENTITY_B], to aggravate it., a 5-HT3 receptor antagonist and 5-HT3",3,1
"Sensitivity of the alpha(2)-adrenoceptor to isoproterenol is reduced by [ENTITY_A], a selective [ENTITY_B] antagonist, but not by [ENTITY_B], a nonselective antagonist., a selective [ENTITY_B] antagonist, reduces heart rate variability (HRV) and increases heart rate variability (HRV time-resolved variability) in healthy subjects., a nonselective antagonist, reduces HRV in subjects with cardiovascular disease (CHD).,",3,1
"(1)H NMR and (13)C NFS data indicate that [ENTITY_A] is a nonselective [ENTITY_B] antagonist, with an IC50 value of 7.0+/-1.3 nmol/L.[1-(5-(4-chloro-phenyl)-1H-pyrazole-4-carbonyl)-amino]-ad amantane monohydrochloride (LY293558), a selective [ENTITY_B] antagonist, has",3,1
"Amino acid-derived [ENTITY_A] -receptors for [ENTITY_A] and oxymetazoline are expressed in the paraventricular nucleus of the hypothalamus (PVN) and the paraventricular nucleus of the thalamus (PVN/PVNx), and are oxymetazoline-receptor specific., an antagonist of oxymetazoline-receptors for both [ENTITY_B] and oxymetazoline-receptor specificantagonists were",3,1
"(+)/- and (-)-pindolol attenuated [(35)S]-GTPgammaS binding in the striatum and hippocampus of aged rats and in aged and young rats treated chronically with the [ENTITY_A] antagonist [ENTITY_B]., [ENTITY_A] [(+)-1-(4-chloro-phenyl)-2-(4-methylpiperidin-1-yl)-ethanol (HICPPE), a selective [ENTITY_B] antagonist, inhibited the spontaneous seizure activity",3,1
"A novel antagonist, [ENTITY_A] (1-[(Z)-3-(dimethylamino)-propylidene]-2-methyl-5-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-adamantane-2-carboxylic acid (HIS 5-31), antagonizes the positive allosteric modulation exerted by [ENTITY_B] in the rat paraventricular nucleus of the hypothalamus (PVN) and in an",3,1
"The effects of a [ENTITY_A] -selective [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretion in rats and humans., a new nonselective [ENTITY_B] antagonist, reduces acid secretion in animals., a new nonselective alpha 1A-adrenoceptor antagonist, reduces gastric acid secretion in rats and humans., a selective [ENTITY_B] antagonist, reduces gastric acid secretion in rats and humans., a selective alpha 1D-adrenoceptor antagonist,",3,1
"(+)-MK 801, a [ENTITY_B] antagonist, induces anxiety-like behavior in mice.antagonists, such as [ENTITY_B], have been shown to be effective in many animal models of anxiety., a [ENTITY_B] antagonist, is an effective treatment for major depressive disorder (MDD)., a [ENTITY_B] antagonist, was recently approved by the US Food and Drug Administration ( FDA) for the treatment of major depressive disorder., a selective [ENTITY_A] antagonist,",3,1
"A new class of [ENTITY_A] antagonists for the treatment of cardiovascular disease: [ENTITY_B]., a novel [ENTITY_B] antagonist for the treatment of angina pectoris, hypertensive crisis, angina pectoris with associated vasomotor symptoms, and hypertension., a new antihypertensive drug., a new vasodilator., a new antagonist of the renin-angiotensin-aldosterone system., a new",3,1
"The effects of [ENTITY_A] ( [ENTITY_B] ), a novel [ENTITY_B] antagonist, on gastric acid secretion in dogs and rats., a selective alpha 2-adrenoceptor antagonist, reduces gastric acid secretion in dogs and rats., another selective alpha 2-adrenoceptor antagonist, has been shown to inhibit gastric acid secretion in humans., another alpha 2-adrenoceptor antagonist, reduces gastric acid secretion in dogs and rats.,",3,1
"The effects of [ENTITY_A] antagonists on gastric acid secretion in dogs with gastric acidosis.[corrected].(10 mg/kg, i.p.), a selective [ENTITY_B] antagonist, inhibited gastric acid secretion in the absence (wild-type; W) and presence of (Tg; +/-) gastric acidosis, while it did not affect acid secretion in the presence of (Tg; +/-) gastric acidosis.[correct",3,1
"Inhibition of the 5-HT(1A) receptors by [ENTITY_A] is due to a specific interaction with the [ENTITY_A] antagonist [ENTITY_B]., but not by leflunomide., on the other hand, is a 5-HT(1A) antagonist.and leflunomide are chemically unrelated antagonists at the 5-HT(1A) and 5-HT(1D) receptors, but both drugs exhibit agonist effects at the 5",3,1
"A new class of [ENTITY_A] antagonist with potent anti-obesity activity: design, synthesis, characterization and pharmacology., a novel [ENTITY_B] antagonist, was designed, synthesized, and characterized., a new [ENTITY_B] antagonist, was designed, synthesized, characterized and evaluated., a novel [ENTITY_A] antagonist, was designed, synthesized, and evaluated.,antagonist, was identified as the first [ENTITY_B] antagonist with potent anti-obesity",3,1
(1)H-NMR and (13)C- and (15)N-NMR spectroscopic studies on the binding of the [ENTITY_A] antagonist [ENTITY_B] (1-methyl-4-(1-(4-(1-methoxyphenyl)-3-(4-(4-(trifluoromethylphenyl)-1H-pyrazole-3-carbonyl)-propyl)-4-methyl-amino)-ad amantane-3,3,1
"Inhibition of platelet aggregation by [ENTITY_B], a [ENTITY_B] antagonist, through selective [ENTITY_A] antagonism at peroxisome proliferator-activated receptor-γ., a [ENTITY_B] antagonist, inhibits platelet aggregation via a mechanism distinct from that mediated by thromboxane (PAT) and thrombin receptors., a [ENTITY_B] antagonist, also inhibits platelet aggregation via a mechanism distinct from that mediated by thromboxane (PAT) and th",3,1
"The selective [ENTITY_A] antagonist, [ENTITY_B], reduces alcohol consumption in alcohol-dependent individuals., a nonselective [ENTITY_B] antagonist, is known to have a range of other pharmacological actions including sedative, dopaminergic, and hypothermic effects., an [ENTITY_B] antagonist, is known to be associated with the abuse of various drugs, and to increase ethanol consumption., a selective beta-adrenoceptor antagonist, is known to decrease ethanol consumption.",3,1
"A novel [ENTITY_A] antagonist [ENTITY_B] (CGP20712A: [ENTITY_B] ), which inhibits the binding of the [ENTITY_B]  to the alpha1-adrenoceptor, has anti-hypertensive and anti-inflammatory effects in rats., a novel [ENTITY_B] antagonist, is currently in phase III clinical trials., a selective alpha 1A-adrenoceptor antagonist, inhibits angiotensin II-induced hypertension and inflammation in humans., a selective alpha 1A",3,1
"The effect of [ENTITY_A] antagonist [ENTITY_B] (0.5 mg/kg), an [ENTITY_B] antagonist, on the mechanical hypersensitivity induced by capsaicin was studied in the rat pylorus, using a pressure-overload model.antagonists such as [ENTITY_B]  and [ENTITY_B] also attenuated capsaicin-induced mechanical hypersensitivity in the pylorus, while the alpha(1A)-adrenoceptor antagonist [ENTITY_B] and the beta(2)-adrenoceptor antagonist RS-",3,1
"The effects of estramustine phosphate, an alpha(1)-adrenoceptor antagonist, on the heart rate variability and plasma renin activity in patients undergoing coronary artery bypass surgery.,, [ENTITY_B], [ENTITY_B], ARC239, and CGP20712A are nonpeptide alpha(1)-adrenoceptor antagonists., a [ENTITY_A] antagonist., a 5-HT2 antagonist., a 5-HT4 antagonist",3,1
"The role of the [ENTITY_A] islet amiloride-sensitive sodium channel in the pharmacology and neuropathology of the new [ENTITY_B] antagonists [ENTITY_B] and [ENTITY_B]., a [ENTITY_B] antagonist with a novel structure-activity relationship, is currently in clinical development for the treatment of cardiovascular and cerebrovascular disease; however, none of the currently available pharmacology and neuropathology studies have examined the role of this channel in the pharmacology or neuropathology of [ENTITY_B].",3,1
"(1)H-NMR studies of [ENTITY_A] - and homochlorcyclizine-induced changes in the membrane potential of Jurkat T cells.antagonists ( [ENTITY_B] and homochlorcyclizine) are two potent [ENTITY_B] antagonists (IC50 = 150 +/- 20 and 300 +/- 30 nM, respectively).antagonists ( [ENTITY_B] and homochlorcyclizine) are two potent [ENTITY_B] antagonists (IC50 = 150 +/- 20 and 300 +/- 30",3,1
"The effect of [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretion in dogs and man.The effects of the alpha(1)-adrenoceptors antagonist, [ENTITY_B] (0, 10, and 30 mg) on gastric acid secretion in dogs and man were studied., a nonselective alpha(1)-adrenoceptor antagonist, inhibited gastric acid secretion in dogs and man with similar potency (EC50 = 7.9 +/- 1.1 and 9.3 +/-",3,1
"A novel [ENTITY_A] antagonist, [ENTITY_B] (0.3 mg/kg), inhibits the contractions induced by isoproterenol, fenoterol, salbutamol and salbutamol hydrochloride in the rat vas deferens and the rabbit vas deferens., a [ENTITY_B] antagonist (5 mg/kg, IP), reduces the contractions of the isolated rabbit aorta induced by 5-HT, 5-HT2, 5-",3,1
"Sulfated-4-methylpiperazine-induced hyperthermia is blocked by the [ENTITY_A] antagonist [ENTITY_B] (S)-2-[[4-(1-methylpiperazine)-2-(4-methylpiperidin-1-yl)-ethyl]-1H-pyrazole-3-carbonyl]-ad amantane-2-carboxylic acid methyl ester (WY 55858, 55859)., an [ENTITY_B] ant",3,1
"(1)H-NMR and LC-MS studies of the interaction of the [ENTITY_A] (1-methoxycarbonyl)-4-(3-(dimethylamino)-propionic acid)-6-azaspiro[4.5]decane with the bovine aortic valve., a selective [ENTITY_B] antagonist, inhibits contraction of isolated aortic valves by decreasing valve function., a selective 5-HT2 antagonist, inhibits contraction",3,1
"Sensitivity and selectivity of the [ENTITY_A] receptor antagonist, [ENTITY_B], for the selective beta 2-adrenoceptor agonist oxymetazoline in comparison with oflertine and salbutamol are demonstrated in rabbit aorta.antagonists, [ENTITY_B] and oflertetrazole, have been developed as potent selective beta 2-adrenoceptor agonists.antagonists, oxymetazoline and salbutamol, are two",3,1
"The effects of [ENTITY_A] antagonists, [ENTITY_B] and homochlorcyclizine, both of which are inhibitors of CYP3A4, on the pharmacokinetics and pharmacodynamics of the [ENTITY_A] antagonist [ENTITY_B], as well as on the pharmacology of the [ENTITY_A] antagonist [ENTITY_B], when given concomitantly, have been studied in healthy subjects.(1) H-benzo[4,5]cyclohexanol (BCH) and homochlorcycliz",3,1
"(1)H NMR analysis of the effects of [ENTITY_A], a [ENTITY_B] antagonist, on the binding properties of the alpha 2-adrenoceptor in rat basilar artery., a selective alpha 2-adrenoceptor antagonist, inhibits cardiac hypertrophy by modulating cardiac contractile function.antagonists such as oxymetazoline and phenoxybenzamine, which are also selective alpha 2-adrenoceptors antagonists, have similar inhibitory",3,1
"Sensitivity and specificity of [ENTITY_A], WAY-100635, a selective [ENTITY_B] antagonist, for the differential diagnosis of allergic and nonallergic urticaria., a selective [ENTITY_B] antagonist, is approved by the US Food and Drug Administration (FDA) for the treatment of allergic rhinitis, conjunctivitis, and conjunctivitis associated with asthma and atopic dermatitis; however, the use of other selective aminopeptidase-deficient (",3,1
"(R)-(-)-pindolol attenuates mechanical stress-induced bronchoalveolar lavage fluid oxidative stress and inflammation: possible mechanism(s) related to [ENTITY_A] antagonist properties.antagonists have been used in the treatment of asthma and chronic obstructive pulmonary disease (COPD); however, their use is limited largely by their adverse effects on pulmonary function.antagonists, such as [ENTITY_B], are often used in the treatment of bronchial asthma and",3,1
"Inhibition of cyclic AMP production by [ENTITY_A] is due to the antagonistic interaction of [ENTITY_B] and [ENTITY_A] with [ENTITY_B]., an antagonist of the renin-angiotensin system, reduces blood pressure but does not alter heart rate variability., an antagonist of the renin-angiotensin systems, reduces blood pressure but has no effect on heart rate variability., an antagonist of both the renin-angiotensin systems, and [ENTITY_B]",3,1
"(1-[2-(1-methylpiperidin-1-yl)-propyl]-cyclohexanol (WY-46824), a selective [ENTITY_A] antagonist, attenuates inflammatory pain without disrupting cognition., a novel [ENTITY_B] antagonist, reduces mechanical hypersensitivity and inflammation without disrupting cognition., a selective alpha(2A)-adrenoceptor antagonist, attenuated inflammatory pain without disrupting cognition., a selective beta(2B)-adren",3,1
"(1-methoxy-4-methylpiperidin-3-yl)-propionitrile and (+/-)-pindolol are competitive antagonists at [ENTITY_B] types I and II of the [ENTITY_A] and [ENTITY_B], respectively., a [ENTITY_B] antagonist, inhibits binding of the alpha2-adrenoceptor to the plasma membrane with high affinity (K(b) = 7.1 +/- 0.1 x 10(-8) M; alpha(2B)-",3,1
"The effect of [ENTITY_A], an antagonist of [ENTITY_B], on gastric acid secretion was evaluated in rats., an antagonist of [ENTITY_B], was used as a positive control., a nonselective [ENTITY_B] antagonist, had no effect., a selective alpha(2A)-adrenoceptor antagonist, inhibited gastric acid secretion in rats administered the acidophilic peptide, pylorus-pumping inhibitor-4 (PPI-4) with an IC",3,1
"Inhibition of platelet aggregation by the [ENTITY_A] antagonist [ENTITY_B] in patients receiving clozapine-containing antipsychotic drugs: an observational study., an inhibitor of platelet aggregation, was recently identified as an antagonist of the [ENTITY_B] antagonist [ENTITY_B]., an oral [ENTITY_B] antagonist, is also an antagonist of the alpha 1-adrenoceptor., an oral delta-9-tetrahydrocannabinol (THC) receptor antagonist,",3,1
"Inhibition of cyclic AMP production by [ENTITY_A], a [ENTITY_B] antagonist, in human colon cancer cells via the [ENTITY_A] - and 5-HT2A/2C receptor systems., a 5-HT2 antagonist, inhibits colon cancer cell proliferation by inhibiting cyclic AMP (cAMP) production., a 5-HT2A antagonist, inhibited colon cancer cell growth both in vitro and in vivo via the 5-HT2A/2B/2",3,1
"The role of [ENTITY_A] (1-[2-(6-methylpiperazin-1-yl)-ethynyl]-1H-pyrazole-3-carboxyamide) in the pharmacology of [ENTITY_B] antagonists.(LY293558), a potent [ENTITY_B] antagonist, is currently in phase III clinical trials in treatment of cardiovascular disease., a [ENTITY_B] antagonist, is in phase II clinical trials in treatment of angina pectoris and hypertension.",3,1
"The selective [ENTITY_A] antagonist [ENTITY_B] blocked the antitussive effect of fluoxetine and dextromethorphan without affecting its acute oral antagonism., a selective serotonin and dopamine D2/D3 receptor antagonist, and the selective [ENTITY_A] antagonist [ENTITY_B] blocked the antitussive effect of fluoxetine and dextromethorphan without affecting its acute oral antagonism., a selective serotonin and dopamine D2/D3 receptor antagonist, and",3,1
"(1)H NMR spectra and (13)C NMR chemical shifts in prokinetic [ENTITY_A] and [ENTITY_B] antagonists.(1)H and 13C NMR studies in comparison to the reference antagonist [ENTITY_B]., hydroxychloroquine, and a number of other antagonists., hydroxychloroquine, and other selective beta-adrenoceptor antagonists have been synthesized, and their binding to the alpha(1)-ad",3,1
"The effect of [ENTITY_A], an antagonist of the [ENTITY_B] receptor, on the pharmacology of the alpha(1)-adrenoceptor antagonist salbutamol in humans.antagonists (e.g., salbutamol) are alpha(1)-adrenoceptor antagonists that are widely used to treat cardiovascular disease.antagonists are often used in combination with other cardiovascular drugs for the treatment of cardiovascular disease.antagonists are often used in combination with",3,1
"Amino acid substitution at position 3 of the [ENTITY_A] islet receptor antagonist, [ENTITY_B], inhibits the binding of the beta 2-adrenoceptor ligand, oxytocin, to the islets of Langerhans., a [ENTITY_B] antagonist, inhibits oxytocin-mediated uterine contractions., a beta 2-adrenoceptor antagonist/ [ENTITY_B] antagonist, inhibits uterine contractions mediated by oxytocin.,",3,1
"The use of the [ENTITY_A] /5-HT(1B/1D) antagonist [ENTITY_B] in patients with obsessive-compulsive disorder: a placebo-controlled study.antagonist (OTA), [ENTITY_B] antagonist (OTA), and 5-HT(1D) antagonist [ENTITY_B] also attenuated the abnormal behavior of obsessive-compulsive disorder (OCD) patients.and a 5-HT(1D) antagonist, yohimbine, also reduced the abnormal behavior",3,1
"The selective [ENTITY_A] antagonist [ENTITY_B] blocked the mechanical allodynic effects of capsaicin and capsaicin-sensitive nACh receptors, suggesting that capsaicin-sensitive nACh receptors contribute to the allodynia of neuropathic pain., a selective [ENTITY_B] antagonist, reduces mechanical hypersensitivity and mechanical allodynia produced by the nonselective [ENTITY_B] antagonist [ENTITY_B] (0.03 mg/kg, s.c.) in the isolated rat sciatic nerve",3,1
"The effects of [ENTITY_A], a selective [ENTITY_A] antagonist, on gastric acid secretion and gastric acid production in dogs and humans.[1,2-bis(4-(N-methylanthyl)-amino)-5-(N-methyl-amino)-2-phenylpiperazine], a selective [ENTITY_B] antagonist, has been developed as an effective therapeutic agent in the treatment of gastric acid secretion disorders.antagonists are under development as new",3,1
"(1)H-NMR spectroscopic characterization of the binding domains of the [ENTITY_A] antagonist [ENTITY_B] (0.01-1 mg/kg) to the alpha 1A-adrenoceptors., a selective beta 1-adrenoceptor antagonist, and hydroxyzine, a selective alpha 1A-adrenoceptor antagonist, are both known to inhibit the contraction of the gall bladder of dogs and to inhibit contractions in human subjects with alpha",3,1
"A novel [ENTITY_A] antagonist [ENTITY_B] (LY139033), a member of a new class of [ENTITY_B] antagonists that antagonizes alpha 1-adrenoceptor-mediated contractions., a potent and selective [ENTITY_B] antagonist, reduces arterial pressure in humans and in animals., a selective alpha 1A-adrenoceptor antagonist, has been shown to inhibit contraction in rabbit left atria and guinea-pig pulmonary artery., a selective alpha",3,1
"A novel [ENTITY_A] antagonist [ENTITY_B] (CGP20712A) reduces stress-induced hippocampal synaptic deficits in rats., a novel [ENTITY_B] antagonist, reduces stress-induced anxiety-like behavior in mice, and reduces cognitive deficits in the forced swim test in rats., a novel [ENTITY_B] antagonist, reduces stress-induced anxiety-like and cognitive deficits in the forced swim test in mice, and reduces cognitive deficits in the novel open field test in rats., a",3,1
"A single-dose, rapid-acting [ENTITY_A] antagonist [ENTITY_B] has no effect on ethanol-seeking behavior in alcohol-dependent subjects, and may be associated with alcohol withdrawal syndrome., a potent and selective [ENTITY_B] antagonist, reduces alcohol consumption by blocking ethanol-induced increases in ethanol concentration and alcohol consumption.antagonists are often used for the treatment of alcohol dependence, andat a low dose (30 mg/kg) is effective in reducing alcohol consumption and alcohol withdrawal symptoms in",3,1
"(R)-(-)-Epinastine hydrochloride ( [ENTITY_A] ) is an antagonist of [ENTITY_B], [ENTITY_B] -, and 5-HT(2A/2C) receptors., another [ENTITY_B] antagonist, also blocked the 5-HT(2A/2C) response to fluoxetine, but did not affect the 5-HT(1A) response., an [ENTITY_B] antagonist, also did not affect the 5-HT(2A/",3,1
"The effect of [ENTITY_A], a new [ENTITY_B] antagonist, on the pharmacology and pharmacokinetics of clozapine and the interaction of clozapine with the [ENTITY_B] antagonist [ENTITY_B]., a potent antagonist of [ENTITY_B] and [ENTITY_B] -sensitive ion channels, has been previously shown to decrease the clearance of clozapine and to increase plasma concentrations of clozapine in healthy subjects., a new [ENTITY_B] antagonist, was recently approved by the US Food and Drug",3,1
"The effect of a [ENTITY_A] antagonist, [ENTITY_B], on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol and on the plasma concentrations of haloperidol and haloperidol metabolites after administration of haloperidol in humans has been studied.antagonists have been developed as treatment options for attention deficit hyperactivity disorder (ADHD)., a [ENTITY_B] antagonist, has been developed as an anti-emetic agent",3,1
"Sulfation by CYP2D6, but not by CYP2B6, was blocked by the [ENTITY_A] antagonist [ENTITY_B].[1-[(2-Methoxy-5-(3-chlorophenyl)-1-methylpiperazine] (mifepristone) is a potent and selective estrogen antagonist that is often used in the treatment of breast and cervical cancer., a selective [ENTITY_B] antagonist, is also available.,",3,1
"The effects of [ENTITY_A] antagonist [ENTITY_B] on glucose and insulin levels and on liver glycogen content and oxidative stress in diabetes., a [ENTITY_B] antagonist, is known to decrease plasma glucose and insulin levels and to increase liver glycogen contents and antioxidant defense in diabetes mellitus.antagonists such as amlodipine and granisetron have also been shown to be able to decrease plasma glucose and insulin levels and to increase liver glycogen contents and antioxidant defense in type 1",3,1
"The effect of combined [ENTITY_A] and flumazenil on the cardiovascular system was evaluated in male rats., a [ENTITY_B] (CysL-aspartyl-L-glutamate synthetase inhibitor) and flumazenil, a [ENTITY_B] antagonist, inhibit the cardiovascular effects of amiloride, a vasodilator, at similar concentrations., a CysL-aspartyl-L-glutamate synthetase (",3,1
"A comparison of two different dosing regimens for the oral [ENTITY_A] antagonist [ENTITY_B] in healthy subjects., a potent and selective alpha 1A-adrenoceptor antagonist;, a selective alpha 1D-adrenoceptor antagonist; and [ENTITY_B], an antagonist of both the alpha 1A- and alpha 1D-adrenoceptor classes, have been previously developed and shown to be effective in the therapy of hypertension and hypertrophy associated with angina pector",3,1
"A novel class of [ENTITY_A] antagonists: [ENTITY_A]., a novel class of [ENTITY_B] antagonists that inhibit the binding of [ENTITY_B] to alpha(1)-adrenoceptors with high affinity., an [ENTITY_B] antagonist [ENTITY_B], and [ENTITY_B] (CEC 0.05-1 microg/mL), a selective alpha(1)-adrenoceptor antagonist, were compared for their ability to antagonize the alpha(1)-adrenoceptor- mediated contractions of",3,1
"The effects of [ENTITY_A], a [ENTITY_B] antagonist, on gastric acid secretion and gastric acid secretion in pylorus-ligated rats., a selective [ENTITY_A] antagonist, has previously been shown to inhibit gastric acid secretion in pylorus-ligated rats., a selective beta 1-adrenoceptor antagonist, has previously been shown to inhibit gastric acid secretion in pylorus-ligated rats., a selective beta 2-adren",3,1
"The use of a [ENTITY_A] antagonist [ENTITY_B] for the treatment of urinary incontinence in dogs and cats with castration-induced or stress-induced incontinence., a [ENTITY_B] antagonist with a broad spectrum of pharmacological actions, has been shown to inhibit the growth of various tumors and to inhibit the growth of many normal cells., a nonselective beta-adrenoceptor antagonist, has been shown to be an effective treatment for stress incontinence in humans",3,1
"A novel dual [ENTITY_A] antagonist, [ENTITY_B] (1-[1-(2-methoxyphenyl)-4-(4-morpholinyl)ethyl]-1H-pyrazole-3-carboxylic acid), reduces stress-induced cognitive deficit in the rat: involvement of the monoaminergic system., (1) a novel dual [ENTITY_B] antagonist/ [ENTITY_B] antagonist, (2) [ENTITY_B] antagonist, and (3) [ENTITY_B] antagonist, have been",3,1
"Sensitivity to the [ENTITY_A] antagonist [ENTITY_B] in patients with advanced cancer: a comparison with the positive control group for the [ENTITY_A] antagonist [ENTITY_B].,, and the [ENTITY_A] antagonist [ENTITY_B] against the growth of human colon cancer cells in vitro.antagonists have been used in the treatment of cancer for many years.antagonists are often used in clinical practice for the treatment of cancer.antagonists such as amitriptyline are also used in clinical practice for",3,1
"The effects of the [ENTITY_A] antagonist [ENTITY_B] on glucose metabolism were investigated in subjects with type 2 diabetes mellitus and non-obese diabetic mice.The effects of the [ENTITY_A] antagonist (1 μg/kg, iv) and the glucagon-like peptide-1 (GLP-1; 10 μg/kg, iv) on glucose uptake (i.e. glucose uptake rate [GRE]), insulin secretion (INS; i.e. insulin secretory capacity;",3,1
"The effects of the [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretagogues and gastric acid secretion in humans.antagonists are often used in the treatment of gastric acid dysmotility and peptic ulcers., a recently introduced oral anticopper, is a potent [ENTITY_B] antagonist that is also an effective inhibitor of gastric acid secretory responses in humans., a recently introduced oral relaxant, also has antisecretive and gastroprot",3,1
"The selective [ENTITY_A] antagonist [ENTITY_B] (3-[2-(4-(N-(4-morpholinyl)-1H-pyrazole-1-carbonyl)-ethyl]-amino]-adamantane-2,5-dione) is a potent and selective [ENTITY_B] antagonist for the renin-angiotensin system., an inhibitor of the renin-angiotensin system, has been recently introduced., an antagonist of the ren",3,1
"Inhibition of osteoblast cell growth by [ENTITY_A], a non-selective [ENTITY_B] antagonist, via the ER stress response pathway., a nonselective [ENTITY_B] antagonist, inhibits cell growth in a number of human tumor cell lines., a nonselective [ENTITY_B] antagonist, is a potent inhibitor of osteoblast cell growth in vitro and in mice., another nonselective antagonist, has been shown to inhibit osteoblast cell growth in a panel of",3,1
"The effect of [ENTITY_A] antagonists ( [ENTITY_B], alprenolol and salbutamol) on the alpha 1A-adrenoceptor density in human vas deferens from the dog and rabbit., an [ENTITY_B] antagonist, inhibits alpha 1A-adrenoceptor-mediated vasodilation in the rabbit vas deferens and in the dog aorta, but not the vas deferens of the dog with alpha 1A-adreno",3,1
"The selective [ENTITY_A] antagonist [ENTITY_B] (0.3 mg/kg, i.m.) did not alter motor or cognitive performance in the novel object recognition test in mice., another selective [ENTITY_B] antagonist, inhibited the learning and memory of the novel object recognition test in mice., a novel [ENTITY_B] antagonist, had no effect on learning and memory of the novel object recognition test in mice., another selective alpha 1-adrenoceptor antagonist (nor-BN",3,1
"Sustained activation of ERα by [ENTITY_A] in human colon cancer cells is associated with downregulation of Bcl-2, an anti-apoptotic protein., a [ENTITY_B] antagonist, reduces the proliferation and invasion of colon cancer cells, but its mechanism of action is unclear.antagonists are currently in clinical development for the treatment of various diseases., such as the [ENTITY_B] antagonists [ENTITY_B], [ENTITY_B], and ondansetron, are known to inhibit",3,1
(1)H-NMR spectroscopic characterization of the interaction of the [ENTITY_A] antagonist [ENTITY_B] with [(35)S]GTPgammaS and [(35)S]GTPgammaS binding to the rat alpha(2)-adrenoceptors: implications for the pharmacology of alpha(2A)-adrenoceptor antagonists.[(1)H]-N-methyl-(3-chloro-phenyl)-4-methyl-5,3,1
The effects of [ENTITY_A] antagonists [ENTITY_B] and carbetocin on gastric acid secretion in dogs and pigs.antagonists are the first-line treatment options for patients receiving gastric acid suppression medications.antagonists are the first-line treatment options for patients receiving gastric acid suppression medications.antagonists have been developed and evaluated in many laboratories worldwide for their capacity to inhibit gastric acid secretion.antagonists are available in some countries.antagonists have not been,3,1
"(+)-pindolol attenuates inflammatory pain through suppression of IL-1beta expression and prostanoid production in inflammatory pain-exposed animals., an oral [ENTITY_A] antagonist, has been recently shown to attenuate inflammatory pain through a similar mechanism as [ENTITY_B] antagonism at the level of protein kinases A and J., two potent [ENTITY_B] antagonists, both of which inhibit cyclic AMP production., another oral [ENTITY_B] antagonist, has",3,1
"The effects of [ENTITY_A] antagonists [ENTITY_B] ( [ENTITY_B] ), [ENTITY_B] ( [ENTITY_B] ), and homochlorcyclizine (a [ENTITY_B] antagonist) on the induction of hypokalemia in conscious dogs and man.[1-(2-methoxy-4-(N-(3-dimethylaminopropyl)-amino)-4-(N-(4-methoxyphenyl)-4-methylphenyl)-amino]-ad amantane-2-carb",3,1
"The role of [ENTITY_A], an endogenous ligand for the oxytocin receptor, in the regulation of uterine contractions: comparison with vasopressin and oxytocin.antagonists (e.g. [ENTITY_B] ) have previously been shown to decrease uterine contractions in nonhuman primates and in humans.antagonists (e.g. carbetocin) have been shown to inhibit uterine contractions in a number of species, but their roles in",3,1
"(1)H-NMR spectroscopy and molecular dynamics simulations of [ENTITY_A], a [ENTITY_B] antagonist.(1)H-NMR spectroscopy and molecular dynamics simulations of the [ENTITY_B] antagonist [ENTITY_B], [ENTITY_B], have revealed that both molecules bind to the central piperidine ring of the agonist with similar affinities, and that binding of the antagonist to the central piperidine ring is significantly enhanced by the presence of the antagonist's antagonist effect.,",3,1
"The effects of [ENTITY_A], a [ENTITY_B] antagonist, on gastric acid secretion and gastric acid secretion in rats with acute pancreatitis., an antagonist of [ENTITY_B], reduces gastric acid secretion and gastric acid secretion in rats with acute pancreatitis (AP)., a nonselective alpha(1)-adrenoceptor antagonist, reduces gastric acid secretion and gastric acid secretion in rats with AP and in rats with chronic pancreatitis induced by isoproterenol",3,1
"The effect of [ENTITY_A], a selective [ENTITY_B] antagonist, on the cardiovascular responses to a single hypoxia exposure in man., a selective alpha 1A-adrenoceptor antagonist, inhibits hypoxia-induced vasoconstriction in rat vas deferens and rat aorta, but not in rabbit aorta., a selective alpha 1D-adrenoceptor antagonist, inhibits hypoxia-induced vasoconstriction in rat vas def",3,1
"The effect of [ENTITY_A] antagonists [ENTITY_B] and carbetocin on gastric acid secretion and gastric acid secretion in dogs and man.PURPOSE: To determine whether the gastric acid secretagogue, 5-methylhistamine, and the gastric acid secretagogue, carbetocin, have any gastrokinetic properties.PATIENTS AND METHODS: Gastric acid secretion was evaluated in dogs (n = 8) and man (n = 8). Gastric acid",3,1
"The effect of [ENTITY_A] on anxiety, motor activity and neuroendocrine stress response in the dog., an [ENTITY_B] antagonist, reduces anxiety and motor activity in the dog and is an established drug of abuse., a selective [ENTITY_B] antagonist, has been shown to ameliorate some anxiety-related symptoms in the rat and to have antidepressant effects in some human subjects., as yet another selective alpha 1-adrenoceptor antagonist, has been shown to possess both [ENTITY_B]",3,1
"(R)-(-)-Epinastine hydrochloride ( [ENTITY_A], [ENTITY_B] ), another [ENTITY_B] antagonist, inhibited gastric acid secretion in pylorus-ligated rats with a potency of approximately 80% at a concentration of 300 nmol., (+/-)-2-methyl-3-propionic acid, (-)-4-methyl-5-methyl-7-phenyl piperidine, (+/-)-3-methyl-4-isoxazolylethy",3,1
"(+)-MK 807, a selective [ENTITY_B] antagonist, inhibits tumor growth in the nude mouse model of gastric cancer., an [ENTITY_B] antagonist, inhibits growth of several cancer cells in vitro and in vivo., a selective [ENTITY_B] antagonist, inhibits growth of several cancer cells in vitro and in vivo., a selective [ENTITY_B] antagonist, has been shown to exhibit anti-nocifensive and anti-emetic properties., a selective [ENTITY_A]",3,1
"The effect of [ENTITY_A] antagonist [ENTITY_B] on gastric acid secretory states and gastric acid secretory states in the dog., a new [ENTITY_B] antagonist [ENTITY_B], is currently in clinical development for the treatment of gastric acid secretion disorder (GES) associated with peptic ulcer disease, gastric dyspepsia and gastric acid secretion disorder in man.[corrected] is an oral non-peptic antagonist, which acts to decrease gastric acid secretion by",3,1
(+/-)-Modafinil blocks [ENTITY_A] uptake by inhibiting [ENTITY_B] uptake.(+/-) mice metabolize drugs rapidly and show a marked impairment in their drug uptake and metabolism compared with wild-type mice.(+/-) mice metabolize drugs slowly and show no apparent impairment in their drug uptake or metabolism when treated with the drug.(+/-) mice metabolize drugs slowly but show no apparent impairment in their drug uptake or metabolism when,4,1
The effects of acute administration of the [ENTITY_A] (DEX-P) on the metabolism of [ENTITY_B] (DXM) and the absorption of unbound DXM via the gastrointestinal tract in rats.(DEX-P) is a newly developed drug that inhibits the metabolism of the neuropeptide norepinephrine (NE) by inhibiting [ENTITY_B] (DEX-1).(DXM) is a selective inhibitor of the [ENTITY_A] (DXM)-transporter that,4,1
"The role of cytosolic [ENTITY_A] in the absorption of [ENTITY_B] and copper(II) ions., cytosolic [ENTITY_A] (CSE) and zinc transporter 1 (ZnT1) are transporters that mediate the uptake of a broad range of xenobiotics including copper(II), zinc, as well as metabolites of [ENTITY_A] and thioethers., cytosolicutyric acid (CVA) transporter (ABCC2) mediates the uptake",4,1
Tobramycin inhibits [ENTITY_A] -mediated [ENTITY_B] uptake by inhibiting [ENTITY_B] -mediated [ENTITY_B] uptake.hydrolysis inhibitors.(DGK) and difluoro-tobramycin(DFMT) are novel inhibitors of the enzyme [ENTITY_A] (DGK) with high potential for clinical use as anti-tuberculosis agents.-mediated metabolism of beta-lactose: insights from in vitro studies and in vivo,4,1
"(+)-Methionine synthases ( [ENTITY_A] ) and methionine synthases (MSS) catalyze the conversion of L-methionine to [ENTITY_B] and Mg(2+) ions, respectively.synthesis and methylarginine methyltransferase activities were evaluated in wild-type (WT) and three mutants (Lys9Gln/Val12Gln, Ala70Thr/Pro92Thr, and Ala119Thr/",4,1
"Protein kinase C (PKC) inhibitors, such as ketorolac, baicalin and telmisartan, can reduce [ENTITY_A] uptake by inhibiting [ENTITY_B] and thus have the potential to reduce cardiovascular morbidity and mortality.-mediated [ENTITY_B] uptake: role of [ENTITY_B] in the cardiovascular system.-mediated uptake of [ENTITY_B].metabolism: role of OATP1B3 and OATP3B1 in the",4,1
"Tetrabenazine inhibits [ENTITY_A] uptake into cerebrocortical granules: relevance to bipolar disorder.UNLABELLED: AIMS: We investigated the effect of trabenazine, a prototypical [ENTITY_A] uptake inhibitor, on the uptake of the prototypical BZ-drug, lithium chloride, in cerebrocortical granules of rats.(GDX)(DEX-PCE4A), a substrate of the [ENTITY_B], was",4,1
"Proteomic analysis of [ENTITY_A] - and OATP1B3-mediated [ENTITY_B] uptake in rat stomach and intestinal mucosa.(PEPT2) and OATP1B3 are involved in O-phosphorylation of [ENTITY_B], zinc, and thiols and are involved in the regulation of [ENTITY_B] transport through [ENTITY_B] metabolism.(PEPT1) is also involved in O-phosphorylation of thiols and",4,1
"Protein kinase C-dependent effects of [ENTITY_A] on Na(+) current: implications for the role of [ENTITY_B] in [ENTITY_B] -mediated currents.channel subfamily: channel proteins involved in transport, ion channel, or intracellular signaling.channel subfamily: channel proteins involved in intracellular transport, ion channel, or intracellular signaling. channel subfamily: channel proteins involved in transport, ion channel, or intracellular signaling.channel subfamily",4,1
"The role of [ENTITY_A] (CYP3A5) in drug metabolism and pharmacokinetics in rats.(CYP3A5) is responsible for metabolizing [ENTITY_B] as well as most of the non-selective CYP3A inhibitors (i.e., diphenhydramine, ketotifen, olanzapine, tamoxifen and ziconotide) used in clinical practice.(CYP3A7) is responsible",4,1
"Treatment-induced increase in [ENTITY_A] production by human granulosa cells is mediated by a novel mechanism: enhanced [ENTITY_A] uptake through activation of the [ENTITY_B] -PAK/PKB pathways./PAK-kinase signaling in granulosa cells mediates the effect of various growth factors, such as insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 2 (IGFBP2), and insulin-like growth factor binding protein 3",4,1
"The effects of acute administration of duloxetine, a selective serotonin reuptake inhibitor, on the levels of several monoamines and the activities of [ENTITY_A] and [ENTITY_B] in rat striatum: an in vitro study.The aim of the present study was to examine the effects of acute treatment with duloxetine, a selective serotonin reuptake inhibitor, on the levels of several monoamines and the activities of the enzyme [ENTITY_B] and the transporter of [ENTITY_B], vesicular monoamine transporter",4,1
"A comparison of the effects of different difluorothymidine analogues on the metabolism of [ENTITY_A] and its metabolites in rats.(dFdC, 2',2'-difluorodeoxyuridine; FDU), which is metabolized principally by [ENTITY_B], inhibits the formation of adenosine triphosphate and adenosine deaminase in vitro and in vivo.(dFdU), 3',3'-dif",4,1
The effect of the presence or absence of a functional [ENTITY_A] in the gastrointestinal tract on the absorption of unbound [ENTITY_B] and unbound [ENTITY_B] was evaluated.(DEX-P) and PEPT2 (cPEPT2)-transfected Chinese hamster ovary cells expressing human PEPT2 (hPEPT2) or PEPT2 with a mutated PEPT2 (mPEPT2)-transfected Chinese hamster ovary cell,4,1
"Tumor-growth-promoting [ENTITY_A] kinase, BCRP, and p-glycoprotein are essential for the proliferation and survival of human ovarian carcinoma cells.- and BCRP-deficient cancer cells exhibit a significant increase in apoptosis and are sensitive to the apoptotic effects of the anti-cancer drug doxorubicin.can also phosphorylate [ENTITY_A], which leads to increased levels of [ENTITY_B] in cancer cells.",4,1
The role of the [ENTITY_A] in acid-induced [ENTITY_B] production in human astrocytes.production in astrocytes.production in astrocytes.production by astrocytes.production by astrocytes.production by neuronal cells.production by astrocytes.production by astrocytes.production by neuronal cells.production by neuronal cells.production by,4,1
"The role of [ENTITY_A] in the absorption of unbound azo dyes in human conjunctival cells.PURPOSE: The purpose of the present study was to determine the role of OAT3, a rate-limiting enzyme in [ENTITY_B] hormone metabolism, in the absorption of unbound [ENTITY_B] and unbound conjugated azo dyes in human conjunctival cells. conjugated by [ENTITY_B] (D2) and D5
The role of the glucocortic",4,1
"The effects of selective serotonin reuptake inhibitor (SSRI) antidepressants on extracellular levels of [ENTITY_A] and norepinephrine in the brain.and norepinephrine are involved in the control of various functions in the brain, including learning and memory.and norepinephrine are involved in the control of various functions in the brain, including learning and memory.and its metabolites, such as [ENTITY_B] and norepinephrine, play important roles in",4,1
"(+)-Epigallocatechin 3-O-gallate (EGCG) inhibits [ENTITY_A] -mediated metabolism of [ENTITY_B] by inhibiting [ENTITY_A] -dependent [ENTITY_B] uptake.-mediated metabolism of [ENTITY_B].-mediated metabolism of [ENTITY_B].-mediated metabolism of silymarin, silybin A, and baicalin.-mediated metabolism of salicylic acid.-mediated metabolism of ketotif",4,1
"(+/-)-Modafinil increases circulating levels of [ENTITY_A] and [ENTITY_A] and suppresses the production of inflammatory prostaglandin E2 in humans, possibly by facilitating the elimination of [ENTITY_B].hydrolysis product:(PGE2), the product of the hydrolysis of [ENTITY_A] (PGE2).(PGE2), the product of hydrolysis of PGE2.(PGE2) mediates its vasopressor",4,1
The role of the [ENTITY_A] in the absorption of [ENTITY_B] and copper in RBL cells.channel subtype-selective channel activators: effects of chalcogenopyrylium chloride and diphenhydramine.channel subtype-selective channel activators: effects of diphenhydramine and pizotifen.channel subtype-selective channel activators: effects of ketotifen. channel sub,4,1
"The role of [ENTITY_A] in the absorption of unbound azo dyes in human whole blood.(ACHA) and bis(acenaphthene) (BAC) are the most important alkylphenols in human blood, and their accumulation in plasma and tissues is due to their affinity for the [ENTITY_B] (HNE) ion, which is present only as a dimeric form.(BAL) is an alkylphenol found in many foods",4,1
Phenotype-defined [ENTITY_A] -deficient mice exhibit altered plasma levels of [ENTITY_A] and are resistant to oxidative stress-induced cell death.-mediated [ENTITY_B] uptake in the brain./hNET./hNTS./hNTS.metabolism and detoxification in the brain./hNTS./hNTS./hNTS,4,1
"The effects of acute cocaine treatment on the levels of [ENTITY_A] and its metabolites in the brain: a study using multi-well plates.The purpose of this study was to examine the effects of acute administration of cocaine (1mg/kg, iv) on the levels of several of the main metabolites in the brain, [ENTITY_B], 3-methoxytryptamine (3-MT; also known as [ENTITY_B] ), norepinephrine and dopamine, and their metabolites in the same animal models.",4,1
A novel [ENTITY_A] inhibitor with high potential for use in the treatment of pulmonary hypertension: analysis of metabolism in rats and in healthy volunteers./N-acetylcysteine (NAC) is a key component of the cystolic acid-sensing mechanism of [ENTITY_B] and has been shown to inhibit the production of nitric oxide (NO) in vitro and to be useful for the treatment of pulmonary vascular disorders./L-cysteine (L-,4,1
"A new highly selective phosphorylation site for the [ENTITY_A] of [ENTITY_A] (COT) for new antiarrhythmics.(COT) is a zinc ion binding enzyme involved in the control of [ENTITY_B] (COT) activity.(COT) contains three amino acids (Arg(354), His(358), and Glu(361)) which are phosphorylated at different sites by members of the [ENTITY_B]  ( [ENTITY_B] ) family of enzymes.(",4,1
A new method to measure the stability of [ENTITY_A] in the presence of lipid-rich liposomes: a study on the transport of [ENTITY_B] (MPL) in human intestinal cells.and lipopolysaccharide(LPS) are lipophilic compounds with high affinity for the inner mitochondrial membrane.and lipopolysaccharide(LPS) are lipophilic compounds with high affinity for the inner mitochondrial membrane.and lipopolysaccharide(L,4,1
"Tumor necrosis factor-alpha enhances the apoptotic effect of baicalin via inhibiting [ENTITY_A] -mediated [ENTITY_B] release.(LTC4), a dual probe substrate of TCA, thymidylate synthase (TS, EC 2.6.1.20) and thymidylate synthase reductase (TSR, EC 2.1.3.1), inhibits apoptosis of tumor cells.(Baicalin), a",4,1
"(+/-)-Modafinil acts through an unusual mechanism, inhibiting the metabolism of [ENTITY_A] (+/-) mice at the expense of the CYP3A subfamily at the expense of the CYP2B1 and CYP2C9 classes of drugs.hydroxylation index(+)were evaluated in the brain and liver as indices of [ENTITY_B] -drug metabolism.hydroxylation index(+)were",4,1
"The effect of age and sex on the clearance of [ENTITY_A] from blood, hepatic, and intestinal mucosal compartments.The metabolism of [ENTITY_B] (DXM) is primarily mediated by [ENTITY_B] and cytochrome b5 (Cyt b5).(DXM-CYP2J2) is metabolized primarily by CYP2J2, although it also metabolizes by other means.(DXM) is metabolized primarily by CYP3A4",4,1
"Tetrabenazine blocks the formation of [ENTITY_A] (LTC4) in vitro and blocks the uptake of [ENTITY_B] into mouse liver microsomes and whole blood cells.(LTC4), 3,4-dihydroxyphenylamide; 4,4'-dihydroxyphenylamide of diphenhydramine; 3,4-dihydroxyphenylhydantoin; 2-ethynylphenylphenylamino",4,1
"The effects of acute cocaine treatment on the levels of [ENTITY_A] and CYP2D6 in the striatum and the effects of acute cocaine treatment on the levels of [ENTITY_A] in the cerebrocortical midbrain regions.hydroxylation is a critical detoxification process that reduces the formation of the neurotransmitter [ENTITY_B] in the brain.can be oxidized by [ENTITY_B], but the contributions of cocaine and other drugs of abuse to the levels of oxidative metabolite in",4,1
The role of [ENTITY_A] in the absorption and systemic absorption of [ENTITY_B] and its metabolites in rats.and its metabolites: a multi-critically assessed study.(BChE) and its glucuronides: a multi-critically assessed study.and bChE: a multi-critically assessed study.and chalcone: a multi-critically assessed study.and chalcone: a multi-critically assessed,4,1
"A new method for the determination of the [ENTITY_A] substrate specificity using the analysis of asymmetrically methylated [ENTITY_A] and 4-methoxytryptamine in rat plasma.substrate specificities were determined for four [ENTITY_B], four 4-methoxytryptamine, and three norepinephrine transporter (NET) substrates using rat whole blood.binding was determined by measuring the asymmetric dimethylation of [ENTITY_A] and 4-methoxytryptamine",4,1
"The impact of the [ENTITY_A] in the regulation of hepatic [ENTITY_A] synthesis in vivo and in vitro.synthesis in vivo: effects of the selective alpha-ketoglutaramate inhibitor, ketoglutaramate.metabolism in vitro: influence of the selective inhibitor of acetyl glucuronidation, ketoconazole, and the substrate, [ENTITY_B].metabolism in vivo and in vitro: effects of the selective alpha-",4,1
(+)-Epicatechin3-gallate inhibits the metabolism of [ENTITY_A] in rats.(+)- epigallocatechin 3-gallate inhibits the metabolism of BDP in rats.(+)- epigallocatechin 3-phosphate reduces the formation of [ENTITY_B] in rats.(+)- epigallocatechin 3-gallate reduces the formation of BDP in rats.(+)- epigallocatechin 3,4,1
(E)-Modafinil inhibits the formation of [ENTITY_A] -containing [ENTITY_B] in vitro and in vivo.and modafinil are selective serotonin reuptake inhibitors (SSRIs) that act on the 5-HT2A receptor and block the reuptake of [ENTITY_B] at the expense of other neurotransmitters.and modafinil are potent inhibitors of [ENTITY_A] uptake.can reverse the effects of drugs that block the 5-HT transporter,4,1
Phenolic compounds from the marine alga Chlorella epidermidis reduce [ENTITY_A] -mediated [ENTITY_B] hydroxylation in human astrocytes.-dependent: inhibition of vesicular [ENTITY_B] uptake in human astrocytes.biosynthetic: alanine serine transporter 1 and 2 are involved in the transport of alanine.hydrogenase: an enzyme involved in the metabolism of alanine and methion,4,1
"The role of [ENTITY_A] in the absorption of [ENTITY_B] and in the transport of [ENTITY_B] in rats.(CA) and ocular membrane (OM) transport of [ENTITY_B].and OATP-1B1: a study of transport of diphenhydramine and its metabolite, diphenhydramine N-oxide, by rat CA and OM.and transport of diphenhydramine and its metabolite, 3-ethynylphenoxyb",4,1
The effects of the selective serotonin reuptake inhibitor citalopram on the metabolism of [ENTITY_A] in healthy subjects.(CA) is the rate-limiting enzyme in the metabolism of [ENTITY_B] and norepinephrine.(BChE) is the rate-limiting enzyme in the metabolism of norepinephrine.(BChE) also catalyzes the metabolism of dopamine.(BChE) also catalyses the,4,1
"The role of the [ENTITY_A] in the inhibition of lipopolysaccharide (LPS)-induced prostaglandin E2 production in mouse lungs: a study using in utero electroporation.-mediated [ENTITY_B] uptake and its relevance to the pharmacotherapy of inflammatory disorders.(PAO) is an enzyme that catalyses the first committed step in the synthesis of [ENTITY_B] and mediates its action through the selective inhibition of PGH2, the enzyme that produces [ENTITY_B]",4,1
"Tumor-growth-promoting [ENTITY_A] (PGE2) is a receptor-bound enzyme that is capable of activating a broad range of signal transduction cascades, including [ENTITY_B] and its downstream effectors, prostaglandins and [ENTITY_B].production by tumor cells is mediated by [ENTITY_A].production by tumor cells is mediated by prostaglandins.production by tumor cells is mediated by prostaglandins.production is mediated by COX-",4,1
"A novel [ENTITY_A] inhibitor containing a 4-aminobiphenyl moiety as a new antiarrhythmic drug./N-acetyl-aspartyl-l-glutamate conjugate inhibits the action of [ENTITY_B], norketamine, and serotonin with similar potency and potency-dependent inhibitory effects on [ENTITY_A] uptake in the anterior pituitary./N-acetyl-aspartyl-l-glutamate conj",4,1
"(+/-)-Modafinil inhibits [ENTITY_A] uptake through inhibition of the [ENTITY_B] and [ENTITY_B] pathway.hydroxylation and deamination are involved in the metabolism of drugs and alcohols in mammals.can also metabolize cocaine and other drugs; however, it is unclear whether it is involved in cocaine metabolism.can also metabolize cocaine, ketamine, ketamine/naloxone and other drugs; however, it is unclear whether it is involved",4,1
A novel [ENTITY_A] substrate for the selective determination of N-demethylation: application to the analysis of human serum and urine./N-demethylation assays; human serum and urine./N-demethylation assays;-dependent enzymes;.metabolism./N-demethylation of [ENTITY_A] and CYP3A substrates./N-demethylation of [ENTITY_B],4,1
"(+)WIN 35428 (dFdC, 2,4-dihydroxyphenylamide; [ENTITY_B] ), a specific inhibitor of the [ENTITY_A] (WIN) enzyme, caused a marked reduction of the formation of [ENTITY_B] in [ENTITY_B] (+/+) mice (p < 0.01).(+/+) mice had approximately threefold higher plasma vesicular [ENTITY_B] than did wild-type mice.(+/+) mice had approximately threefold higher plasma [ENTITY_B] than",4,1
(+)-Epicatechin 3-O-gallate inhibited [ENTITY_A] -mediated [ENTITY_B] uptake by >50% with an IC50 value of 0.26 microM.hydroxylation is mediated through the epigallocatechin 3-O-gallate receptor and catalyzed by [ENTITY_B].(+)-epigallocatechin 3-O-gallate inhibits [ENTITY_B] uptake by >50% and taurine uptake by >50%.(,4,1
"Treatment with the selective [ENTITY_A] -selective inhibitor tacrine reversibly blocks the development of cocaine- and amphetamine-dependent responding in a dose-dependent manner, whereas selective dopamine D(2)-selective antagonists do not.preferably inhibit the synthesis of [ENTITY_B] and cocaine, whereas cocaine and amphetamine preferentially inhibit dopamine D(2)-mediated transport.(+/+) and D(2)-deficient mice (DAT(-/-",4,1
The role of the enzyme [ENTITY_A] (5-LO) in the metabolism of [ENTITY_B] in rats./lactulose/L-rhamnose absorption./lactulose/L-rhamnose absorption./lactulose/L-rhamnose elimination in WKY and SHR PTE rats./lactulose/L-rhamnose elimination in WKY and SH,4,1
"A novel highly specific, sensitive, and specific enzyme-linked immunosorbent assay (ELISA) for the quantification of [ENTITY_A] in whole blood.(b5) : a novel, highly specific, and sensitive enzyme-linked immunosorbent assay for the quantification of [ENTITY_B] in whole blood.(b5) : a novel, highly specific, and sensitive enzyme-linked immunosorbent assay for the quantitative determination of [ENTITY_B] in whole blood.",4,1
The role of [ENTITY_A] in the absorption of [ENTITY_B] from lipid-rich liposomes.(Lipozyme A(4)) is a lipid-associated enzyme that catalyses the oxidation of [ENTITY_B] to [ENTITY_B].(Lipozyme A(4)) oxidizes [ENTITY_B] to [ENTITY_B] and plays a role in absorption and distribution in the body.(Lipozyme A(1)) is an enzyme that also catalyzes the oxidation of other lipid-associated molecules.,4,1
"The role of [ENTITY_A] in the absorption of [ENTITY_B] and its metabolite 4-aminobiphenyl in rat lungs: an in vitro study.4-Amino-1-naphthylamide (ABP; 4-aminobiphenyl, 4-ABP) is a common oxidant found in cigarette smoke and is a major source of endothelial nitric oxide (iNO).and 4-aminobiphenyl metabolite 4-aminob",4,1
"The effects of simvastatin, telmisartan and sirtuins in the regulation of [ENTITY_A] -mediated [ENTITY_B] metabolism./sirtuin-dependent mechanisms in human atherosclerosis./sirtuins are key enzymes in the control of lipid metabolism and have a pivotal role in the development of atherosclerosis./sirtuins also have a pivotal role in the control of cholesterol metabolism./sirt",4,1
"The role of the [ENTITY_A] in the absorption of [ENTITY_B] and its metabolite 4-aminobiphenyl in rat lungs.(4-aminobiphenyl) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury and is conjugated by [ENTITY_B] and metabolized by 4-aminobiphenyl-N-oxygenase (4-ABNP).(4-ABNP) is a mutagenic alpha,",4,1
Protein levels of [ENTITY_A] (LTA4) and OATP1B3 influence the transport characteristics of [ENTITY_B] in rat cerebrocortical astrocytes.(LTA4) and OATP1B3 are two members of the high-density lipoproteins (HDLs) family that play pivotal roles in brain energy metabolism and metabolism.(LTA4) is also an HDL-associated protein that is expressed primarily in adipocytes,4,1
A novel mutation in the gene encoding [ENTITY_A] (DAT) that abolishes enzymatic activity in the absence of serotonin converts the enzyme from being a substrate of [ENTITY_A] to a product that blocks the entry of [ENTITY_A] into the brain.(DA) is responsible for most of the [ENTITY_B] deprivation in patients with attention-deficit/hyperactivity disorder and is thought to be a risk factor for the disorder.(DAT) is also involved in the pathogenesis of,4,1
"Tumor cell death triggered by [ENTITY_A] is mediated through the activation of the [ENTITY_B] pathway.Enzymes have the ability to degrade [ENTITY_B], glutamine, alanine, and threonine, and this enzyme activity is essential for various metabolic processes including synthesis and degradation of [ENTITY_B], glycine, and threonine.Enzymes also catalyze the deamination of glutamine to alanine and threonine.path",4,1
"The impact of the CYP2J2*6 allele on the metabolism of [ENTITY_B] in healthy subjects and patients with severe combined immunodeficiency.OBJECTIVES: The aim was to assess the impact of the polymorphism of the [ENTITY_A] (CYP2J2) gene on the metabolism of tacrolimus, mycophenolic acid, and cobicistat.SUBJECTS AND METHODS: In this study, CYP2J2*2/*",4,1
"(+)/-: effects of [ENTITY_A] -derived [ENTITY_B] on glucose uptake and lipolysis in human adipocytes.(+/+)
The effect of simvastatin and sildenafil on the [ENTITY_A] metabolising enzyme [ENTITY_B] (PGE2) in vitro and in vivo.(+/+) mice have a higher [ENTITY_B] production than PGE2(-/-) mice, which may be partly responsible for higher [ENTITY_B] levels in the atherosclerotic plaques",4,1
"The role of the [ENTITY_A] in the transport of [ENTITY_B] and its metabolites in mammalian tissues.(DEX-P) and p-hydroxybenzoic acid(BHBA) are the main metabolites of p-glycoprotein (PGP), the predominant enzyme responsible for the de novo synthesis of [ENTITY_B] and p-hydroxybenzoic acids (PHB).(DEX-P) and p-hydroxybenzoic acid(BHBA",4,1
"Phenylhydantoin inhibits the metabolism of [ENTITY_A], ketotifen, tamoxifen, pizotifen, ketoconazole and midazolam by [ENTITY_B], CYP3A4, CYP3A5 and CYP3A7.-drug metabolism studies in humans: an overview.-drug interactions and pharmacokinetics.metabolism studies in humans: an overview.-drug",4,1
The role of [ENTITY_A] in the absorption of copper and zinc from aqueous solutions.(MCTs) are membrane vesicles containing [ENTITY_B] and MCTs that are capable of taking up and releasing copper and zinc from a variety of aqueous substrates.(MCTs) are membrane vesicles containing nerve agents and are capable of taking up and releasing nerve agents from a variety of aqueous substrates.(MCTs),4,1
"A new method for the determination of [ENTITY_A] -drug conjugates using LC-MS.A convenient, sensitive, and selective analytical method has been developed for the determination of the [ENTITY_A] (dFdC) conjugates, which act as substrates for [ENTITY_B] and cocaine uptake by [ENTITY_B] cells.substrate conjugates: 1) an indirect competitive ELISA to measure the apparent affinity for the substrate; 2) an indirect competitive enzyme kinetic analysis to measure the apparent affinity for",4,1
"(E)-3-(hydroxyphenyl)-5-methoxytryptamine inhibits [ENTITY_A] -mediated [ENTITY_B] uptake by preventing the opening of [ENTITY_B] -mediated channel opening.hydrase inhibitors: effects on [ENTITY_B] and dopamine transmission in vivo.hydrase inhibitors: effects on uptake and metabolism of [ENTITY_B] in vivo.hydratase inhibitors: effect on metabolism, uptake, and toxicity in vitro.hydratase inhibitors: effect on metabolism, uptake",4,1
"Tumor-growth-promoting [ENTITY_A] [ENTITY_B] pathways: from tumor-associated macrophages to tumor-associated neutrophils.(PGE2) and prostaglandin E2 (PGE2) have been implicated in the pathogenesis of several malignancies.(PGE1) has also been implicated in the pathogenesis of malignancies, including breast cancer.(PGE2) also has been implicated in the etiology of",4,1
A new method for the determination of [ENTITY_A] -mediated metabolism of [ENTITY_A] in vitro and in vivo: application to the analysis of metabolism in healthy volunteers.hydroxylation assay.(BchlA) is a key enzyme of the [ENTITY_B] (BChE) enzyme family that transfers a cysteine residue from glutathione (GSH) to [ENTITY_B] in the presence of oxygen. This study describes a new method for the determination of BChE enzyme activity that,4,1
(+)- and Serine/threonine-dependent transmembrane transport of [ENTITY_A] (vitamin A2) through [ENTITY_B] (pyridoxamine) and pyridoxamine/pyridoxine-N-oxide transporter 1 (PNUT1).(vitamin A2) and PNUT2 mediate [ENTITY_B] uptake through a pyridoxine transporter mechanism.(vitamin A2) and PNUT1 med,4,1
"The role of the [ENTITY_A] in the absorption of [ENTITY_B] (BChE) in human red blood cells.(BChE) is a membrane-bound enzyme that mediates the oxidative deamination of choline, glycine, and threonine in the presence of Mn(2+) ion.(BChE) oxidized glutamine to [ENTITY_B], and it is also involved in the oxidation of L-cysteine and L-threonine.",4,1
"The role of the [ENTITY_A] in the transport of [ENTITY_B] and oxotremorine across rat cerebrocortical astrocytes.(ACTH) is a key regulator of the sympathetic nervous system (SN), with its activation required for the generation and transmission of sympathetic nerve impulses.(ACTH) is a ligand-dependent activator of the [ENTITY_A] (AC) receptor, which also mediates the contraction of smooth muscle cells.(G",4,1
Phenotypic expression of phosphodiesterases in mouse pancreatic acini: effects of [ENTITY_A] hydroxylation on [ENTITY_B] -mediated [ENTITY_B] hydroxylation./PGE2 are two enzyme families that play critical roles in the acid-base balance./PTGS2 are two enzyme families that play critical roles in the acid-base balance./PEDPS are two enzyme families that play key roles in the control of intracellular [ENTITY_B],4,1
"The role of [ENTITY_A] (PCC) in the uptake and toxicity of [ENTITY_B].(PCC) is a zinc transporter that is involved in the transport of [ENTITY_B] as well as [ENTITY_B] in mammalian tissue.(PCC) also has a role in zinc transport, but this does not appear to affect PCC function.(PCC) also has a role in zinc transport, but it is unclear how PCC and PCC functionally interact with zinc.",4,1
The role of [ENTITY_A] -NK-2R in [ENTITY_A] metabolism.production by [ENTITY_B] cells.secretion by microglia.-NK-2R expression by astrocytes.production by astrocytes.responses to different stimuli.-NK-2R expression and production are regulated in a tissue-specific manner in response to various stimuli.production by astrocytes.,4,1
"The role of [ENTITY_A] in the absorption of [ENTITY_B] was evaluated in vitro and in vivo.(DEX-PEG) and PEG-DEX copolymer (PEG-DEX-PL) were synthesized by condensation of DEX with poly(ethylene glycol) and PEG, respectively.(DEX-PEG) and PEG-DEX-PL were synthesized by condensation of DEX with poly(ethylene",4,1
"A novel [ENTITY_A] hydroxynonenal modification by [ENTITY_A] -mediated oxidation in mitochondria impairs [ENTITY_B] -catalyzed [ENTITY_B] hydration in rat cerebrocortical astrocytes./hydrogen peroxide mediate the efflux of [ENTITY_B] from cells to the medium and the toxicity of [ENTITY_B] in neuronal cells.(+/-) mice have a severe impairment in cerebrocortical energy metabolism, which is reversed by early administration of [ENTITY_A], the predominant [ENTITY_B]",4,1
"Protein kinase C-dependent, [ENTITY_A] uptake and cytosolic [ENTITY_A] uptake are selectively inhibited by resveratrol: relevance to cardiovascular and Alzheimer's diseases./ [ENTITY_B] /natriuretic peptides are two key signaling molecules in the control of cardiovascular function and are important in the etiology of various cardiovascular diseases./natriuretic peptides are two key signaling molecules in the control of cardiovascular function and are important in the etiology of various cardiovascular",4,1
A novel [ENTITY_A] -catalyzed sulfation of [ENTITY_B] (4-methoxytryptamine) and 4-methoxytryptamine sulfate.and sulfasalazine: Effect of disulfide bond formation. and sulfasalazine: Effect of disulfide bond formation.and sulfasalazine: Effect of disulfide bond formation.and sulfasalazine: Effect of disulfide bond formation.,4,1
"Tumor necrosis factor-alpha-/- mice exhibit increased hepatic [ENTITY_A] synthesis that is abolished by pretreatment with the [ENTITY_A] inhibitor, alpha-linolenic acid.-/- mice exhibit increased hepatic synthesis of [ENTITY_B] that is mediated via a mechanism other than enhanced hepatic [ENTITY_B] expression or metabolism.-/- mice exhibit increased hepatic synthesis of [ENTITY_B] that is mediated via a mechanism other than enhanced hepatic expression or metabolism./",4,1
Tumor-derived [ENTITY_A] is metabolized by [ENTITY_B] to inactive metabolites and inhibits angiotensin II-induced [ENTITY_B] production in 3T3-L1 adipocytes.(LXR) family members contain members that play critical role(s) in metabolism of xenobiotics.(GSTO1) and glutathione S-transferase P1 (GSTP1) are responsible for de novo detoxification of xenobiotics.,4,1
"The role of [ENTITY_A] in [ENTITY_B] -mediated [ENTITY_B] uptake into cerebrocortical astrocytes.(PGE2) is a potent inflammatory cytokine that is also taken up by astrocytes; this makes it an interesting candidate for a therapeutic target.(COX-2) is an endothelin type A (ET type A) receptor antagonist, but its role in neuropathic pain remains unclear.(PECs) are membrane",4,1
"(+/-)-Modafinil inhibits [ENTITY_A] -mediated [ENTITY_B] uptake by blocking the [ENTITY_B] uptake process.(+/-) mice metabolize cocaine more effectively than wild-type mice, but the reason for this difference is uncertain.hydramine and its metabolite, BDP, are potent inhibitors of cocaine and other drugs of abuse.(+/-) mice metabolize cocaine more effectively than wild-type mice, but the reason for this difference",4,1
The role of [ENTITY_A] in [ENTITY_B] metabolism and the inhibition of [ENTITY_B] uptake in rats.metabolism and uptake in WKY and SHR PTE cells were investigated.metabolism in WKY PTE cells was inhibited by the selective alpha-hydroxyphenylamide analog of phenytoin but not by the alpha-hydroxyphenylamide of ketotifen.uptake in WKY PTE cells was,4,1
The role of [ENTITY_A] in acid-induced [ENTITY_B] production by human gerbil DRG neurons.-mediated [ENTITY_B] production by human gerbil DRG neurons.-mediated acid-induced apoptosis are both important in the acid-induced stomach inflammation and acid-induced gastric carcinogenesis.producing by DRG neurons-mediated apoptosis are both important in the acid-induced stomach inflammation and acid-induced gastric carcinogenesis.-mediated,4,1
"Tumor-growth-promoting [ENTITY_A] kinase, TK-1, controls epithelial NaV1.5 transport through the [ENTITY_B] pathway./ [ENTITY_B] (EPCs) are membrane transporters that play critical roles in many processes related to epithelial ion transport, including epithelial Na(+) transport./hNAT1 are the major cytosolic enzymes that catalyze the phosphorolysis of [ENTITY_B], glycine, and alan",4,1
"The effect of simvastatin on [ENTITY_A] -mediated [ENTITY_B] uptake in healthy Japanese volunteers.We investigated the effect of simvastatin (40 mg) on the absorption of a prototypical [ENTITY_A] -drug, pravastatin, in a Japanese population. acan be rapidly metabolized by cytochrome P450 (CYP) 3A activities and by [ENTITY_B] (SMO), but not by [ENTITY_B] (PAT).uptake is mediated mainly by [ENTITY_B]",4,1
A novel high throughput assay to measure [ENTITY_B] -catalyzed sulfation of [ENTITY_A].-catalyzed sulfation of [ENTITY_B].-mediated metabolism of [ENTITY_B].metabolism of sulfasalazine..metabolism of sulfasalazine.metabolism of sulfasalazine.-mediated metabolism of sulfasalazine..,4,1
"(1S,2S,3S,4S,6S)-3-hydroxy-6,8,9-trimethylxanthine (MHX), a product of metabolism of [ENTITY_A], was evaluated for its inhibitory effects on the metabolism and binding properties of [ENTITY_B] in rats.(+/+) and PEPT2(-/-) mice.(+/+) mice.(+/+) were fed a 0.5%",4,1
(+)/- and (-)/-PATIENT: We investigated whether [ENTITY_A] -mediated [ENTITY_B] uptake is affected by age and sex. We also evaluated whether differences in [ENTITY_B] uptake among different brain regions contribute to sex differences in response.-mediated uptake of [ENTITY_B] was determined in young adult wild-type (WT) and mutant pups lacking [ENTITY_A]  (Pts) with the help of in vivo and in vitro imaging techniques.uptake in the young adult brain was,4,1
"(E)-7,8-dihydroxycoumarin inhibits [ENTITY_A] -mediated [ENTITY_B] uptake by inhibiting [ENTITY_B] uptake in rats.(PGE(2)) is a bioactive [ENTITY_A] with potent vasopressor activity that is synthesized from arachidonic acid (AA) by [ENTITY_B] (PGE(2)) and prostaglandin E synthases (PGES).(PGES(2)) also produces PGE(2) via",4,1
"The role of [ENTITY_A] in metabolic activation of [ENTITY_B] in rat lungs.(LTC4) is a novel enzyme that hydrolyzes [ENTITY_B] and l-carnitine into [ENTITY_B] and free LTC4.(LTC5) also contains a glutamate residue that may be important for catalysis.(LTC6) has a Cys residue that is important for substrate specificity.(LTC7), a novel enzyme containing a Gly residue that is",4,1
A novel mutation of the ATP6V1 gene (p.Gly547G) resulting in a substitution of argininosuccinate for glutamic acid in the enzyme-ketamine shuttle channel of rat stomach.synthesis: the contribution of the [ENTITY_A] pathway to the synthesis of [ENTITY_B] and oxazoline alkaloids in the gastrointestinal tract.metabolism: the contribution of the isozyme-ketamine shuttle to the metabolism of ketamine,4,1
"The role of [ENTITY_A] in the absorption of [ENTITY_B] (DXM) is disputed.channel variants with altered affinities for [ENTITY_B] and olanzapine.(DEX) is a transporter that mediates the efflux of several drugs from the synaptic vesicles to peripheral tissues, including the lungs.(DEX) variants with altered affinities for diphenhydramine and olanzapine.(DX",4,1
"A novel method for the determination of the [ENTITY_A] hydration ratio in whole blood with the use of a modified PFA-100 colorimetric assay.A new colorimetric assay for the simultaneous determination of the [ENTITY_B] and sodium phosphate in whole blood with the use of the modified PFA-100 colorimetric assay is described. The assay includes a reaction with the substrate, a second reaction with the product of the first reaction, and a third reaction with the phosphate.hydration",4,1
Tetrandrine blocks [ENTITY_A] uptake by blocking [ENTITY_B] -mediated [ENTITY_B] uptake.uptake in [ENTITY_B] -sensitive [ENTITY_B] -mediated absorption.uptake in vivo.uptake in vitro.metabolism in vitro.-mediated transport studies in vivo.transport studies in vitro.-mediated transport of drugs across intestinal epithelia in rats.transport studies in vivo.trans,4,1
"The role of [ENTITY_A] in the absorption of [ENTITY_B] and olanzapine in rats.(AMPS) catalyzes the formation of [ENTITY_B] from L-arginine and methionine, facilitating the absorption of drugs with high methionine contents.(BAY-K-8644) is a novel enzyme inhibitor of the AOX that also catalyses the conversion of argininosuccinate to oxazepine via a mechanism that is distinct from AOX",4,1
"Tumor-growth-promoting [ENTITY_A] pathway involves [ENTITY_A] -mediated activation of [ENTITY_B].pathwaypathway
Methylglyoxal inhibits [ENTITY_A] -mediated [ENTITY_B] uptake by blocking [ENTITY_B] -mediated [ENTITY_B] uptake./tRNA synthetase I and II are involved in the posttranscriptional regulation of specific mRNA targets./tRNA synthetase III also hydrolyzes tRNA(Ser) to generate [ENTITY_B].",4,1
The role of [ENTITY_A] in the absorption and transport of [ENTITY_B] and olanzapine: a comparison with diphenhydramine and ketotifen.and olanzapine: a comparison with diphenhydramine and ketotifen.and olanzapine: a comparison with diphenhydramine and ketotifen.and olanzapine: a comparison with diphenhydramine and,4,1
"The effects of the selective serotonin reuptake inhibitors, selective serotonin reuptake inhibitors, and the serotonin autoreceptor antagonist, citalopram, on synaptic vesicular levels of [ENTITY_B] and on vesicular [ENTITY_B] uptake at synapses of the rat striatum.synapseuptake at vesicular levels of [ENTITY_B].uptake.-mediated transmission at vesicular levels of [ENTITY_A].uptake.",4,1
The role of [ENTITY_A] in the absorption of [ENTITY_B] was clearly shown when [ENTITY_B] was used as the indicator of [ENTITY_B] activity.and oxaliplatin absorption and cytotoxicity assessed in vitro.channel subtype selectivity revealed by the in vitro selection of [ENTITY_B] -expressing HEK293 cells.-selective channel inhibitors as potential new anti-tumor agents.channel selective inhibitors as potential new anti-tumor drugs.,4,1
(+)/- [ENTITY_A] synthesis and transport by [ENTITY_B] and OATP2B1 are impaired in the liver of [ENTITY_B] -deficient mice./b7-2 knockout mice have an increased sensitivity to the toxic effects of alanine and glutamino compounds./b7-2 knockout mice have an increased sensitivity to the toxic effects of alanine and glutamino compounds./b7-2 wild-type mice are more susceptible,4,1
"(+)-Epigallocatechin 3-O-gallate inhibited [ENTITY_A] -mediated [ENTITY_B] uptake in rats.(+)-epigallocatechin 3-O-gallate inhibited the absorption of [ENTITY_B] in rats, but did not inhibit the absorption of [ENTITY_B] in mice.(+)- epigallocatechin 3-O-gallate inhibited [ENTITY_B] uptake in both types of rats, but inhibited it slightly more in the rats with the longest [ENTITY_B] uptake",4,1
(+/-)-Modafinil inhibits [ENTITY_A] uptake by blocking [ENTITY_B] uptake at the [ENTITY_B] uptake-inhibiting site.hydramine conjugates inhibit vesicular [ENTITY_A] uptake.hydramine conjugates inhibit vesicular [ENTITY_B] uptake in the presence of [ENTITY_B] and act as substrates for [ENTITY_B] and PDE4.hydramine conjugates inhibit vesicular [ENTITY_B] uptake in the presence of,4,1
A novel high throughput assay to measure [ENTITY_A] -mediated metabolism of [ENTITY_B] in human liver microsomes.and metabolites in human liver microsomes.and metabolite profiling by high-throughput liquid chromatography/tandem mass spectrometry.and metabolites in human liver microsomes. andmetabolite profiling by high-throughput liquid chromatography/electron-capture time-of-flight tandem mass,4,1
"Tumor-associated glycoprotein-1 inhibits [ENTITY_A] -mediated [ENTITY_B] uptake in tumor cells, but has little influence on tumor-associated macrophage migration.(PGE2) is an inflammatory glycoprotein that acts as both a receptor and a receptor-associated protein for the uptake of drugs and xenobiotics.(PGE1) is the most abundant isoform in the body and is primarily expressed in skeletal muscle.(PTGS",4,1
The impact of the [ENTITY_A] on the absorption of copper and lead in rat stomach: a spectroscopic study.and copper.(+/-) and PbT(2)-P cells display significantly higher absorption of copper than PbT(2)-P cells.and PbT(2)-P cells express significantly higher [ENTITY_B] uptake than PbT(2)-P cells.(+/-) cells exhibit significantly higher,4,1
"Proteins with high KM-1 activities, especially [ENTITY_A], are particularly susceptible to HNE modification.(MCTs) are ubiquitous proteins found in eukaryotic tissues and involved in a variety of metabolic processes.(MATs) are enzymes that catalyze the deamination of [ENTITY_B] and other nonprotein thiols and thioesters.(PTs) are ubiquitous proteins found in eukaryotic tissues and involved in a variety",4,1
"Tumor-growth-promoting [ENTITY_A] (BATP1) has been shown to catalyze [ENTITY_B] hydration and to play a major role in tumorigenesis.(BATP2) also catalyzes dehydration reactions., a member of the dimethylaminohydrolase family, has also been implicated in tumorigenesis.(BATP3) also catalyses dehydration reactions., a member of the thaumatin-like",4,1
A highly selective and potent [ENTITY_A] -catalyzed sulfation of 4-methoxytryptamine to [ENTITY_B].(SGLT2) has been identified as the main enzyme of the serotonin biosynthetic pathway.(SGLT4) is the first identified enzyme in the biosynthetic pathway of [ENTITY_B] and is also a major enzyme in the [ENTITY_B] reaction.(SGLT3) is a minor enzyme in the pathway that also,4,1
"Tumor cell-selective [ENTITY_A] uptake inhibitors targeting the [ENTITY_B] and OATP1B3 have distinct inhibitory effects on leukemic cells./Lipoxins are lipid-lowering drugs that inhibit lipopolysaccharide-induced release of [ENTITY_B] and OATP1B3, the rate-limiting enzyme for [ENTITY_B] synthesis./Lipoxin A(4) has the most potent lipoxin-binding and lipoxin",4,1
"(+)-Epigallocatechin 3-O-gallate (EGCG) inhibits [ENTITY_A] -mediated [ENTITY_B] uptake by inhibiting [ENTITY_B] uptake.(PGE2) has been found to play an important role in the absorption of [ENTITY_B] substrates in humans.(COX-2) is involved in the absorption of lipopolysaccharide (LPS), but the contribution of COX-2 to the absorption of [ENTITY_B] substrates is",4,1
"A novel mutation in the gene encoding [ENTITY_A] (DAT) alters the amino acid sequence of the protein and results in decreased levels of the active enzyme.-mediated metabolism of [ENTITY_B] In the presence of dopamine, the amino acid serine acts as an acceptor of [ENTITY_A] from [ENTITY_B], and this reaction is catalyzed by the terminal enzyme of the serine/threonine cascade, [ENTITY_B].biosynthetic enzymes [ENTITY_B] and dAT.-mediated",4,1
"Tumor-growth-promoting [ENTITY_A] kinase-1 (KTx1) is a novel, phosphorylated enzyme with two isoforms: a [ENTITY_A] and a phosphorylated [ENTITY_B].kinases ( [ENTITY_A] ) catalyze the first and second steps of the [ENTITY_B] synthesis from L-arginine and l-citrulline respectively.kinases (pks) are enzymes involved in arginase I and arginase II pathways",4,1
"The role of [ENTITY_A] in the absorption of [ENTITY_B] from aqueous humor and in [ENTITY_B] -mediated drug uptake in tumor and endothelial cells.(CA) and bicuculline (BCH) are two alkaloids of the family of [ENTITY_A], which are metabolized by cytochromes P450 (CYP) 3A and/or 3A4.(BA) and bicuculline (BCH) are both competitive inhibitors",4,1
"A highly sensitive electrochemical immunoaffinity assay to assess the [ENTITY_A] activity of recombinant [ENTITY_A] and of its natural substrate, [ENTITY_B].(ROSA) is an enzyme that catalyses the [ENTITY_B] hydration reaction, removing the toxic hydroperoxide from oxidized proteins.(BChE) catalyzes the oxidation of the neurotransmitter, GABA, to form GABA and is expressed in the brain.(BChE) also catalyses the",4,1
"(+)-Methionine synthase reductase ( [ENTITY_A] ) is responsible for the conversion of the [ENTITY_B] enzyme methionine synthase to the active form of Hcy, and also plays a role in the detoxification of [ENTITY_B] -containing compounds.synthetic enzymesand Hcy catalyzes the conversion of Hcy to [ENTITY_B] and ammonia.factors involved in methylation of [ENTITY_B] and Hcy.factors that are",4,1
Aminoglycosides and thiazolidinediones induce [ENTITY_A] uptake through competitive inhibition of [ENTITY_B] uptake through [ENTITY_B].channeling: a new mechanism of action for drugs affecting [ENTITY_B] transport./ [ENTITY_B] channels: new insights into the molecular basis of drug action.channeling: a mechanism of action study for the thiazolidine analogues of aspirin.channeling: a new mechanism of action study for the thiazolid,4,1
"(+/-)-Modafinil inhibits the [ENTITY_A] -mediated metabolism of [ENTITY_B] in rats.hydroxylation catalyzed by [ENTITY_B] and [ENTITY_B] can be inhibited by drugs with different affinities for the enzyme.can also catalyze the metabolism of [ENTITY_B], cocaine, and amphetamine.can also catalyze the metabolism of amphetamine, cocaine, and its metabolites, but it is less likely to be involved in the metabolism of cocaine.can also",4,1
"A novel mutation in the gene encoding [ENTITY_A] (TPH) associated with severe combined immunodeficiency impairs the formation of [ENTITY_A] -dependent [ENTITY_B].-mediated [ENTITY_B] production is defective in severe combined immunodeficiency (SCID); however, the molecular basis of this defect remains unclear./tetrahydrofolate reductase (THF-RT) catalyzes the de novo formation of [ENTITY_B] and thioethers from L-gl",4,1
"Aminoacids inhibit [ENTITY_A] uptake in the choroid plexus by blocking the [ENTITY_B] pathway.(PGE2) and prostaglandin E2 (PGE2) are important inflammatory mediators that enter brain parenchyma via the [ENTITY_B] and prostaglandin E synthases pathways.(PGE1) also enters the choroid plexus via the PGE1 pathway, but it does not produce P",4,1
"(11-14)C-methylguanosine inhibits [ENTITY_A] uptake in rat cerebrocortical astrocytes.It has been known for some time that the N-methylated form of [ENTITY_A], that is, methylguanine (MG) and its methyltransferase (MAT) product, 5-methoxytryptamine (5-MT), are transported into cells by the [ENTITY_B] subfamily of transporter proteins called [ENTITY_B].uptake in rat cere",4,1
"The impact of the [ENTITY_A] on [ENTITY_B] metabolism in rats.metabolism in rats.metabolism in ratsmetabolism in rats.metabolism in the liver.metabolism in the kidneys.metabolism in the liver.metabolism in the lungs.
The impact of the 5-fluorouracil/LV dose on [ENTITY_B] -mediated",4,1
"The role of the [ENTITY_A] in the absorption and toxicity of [ENTITY_B] in rat.(BChE), a [ENTITY_B], mediates the absorption of xenobiotics.(BChE), a double-barreled enzyme complex that catalyses the reversible oxidative deamination of [ENTITY_B] and bile acids, is expressed primarily in the liver.(BChE) contains two enzymes, BChE1 and BChE2, that differ in",4,1
"The role of the [ENTITY_A] in [ENTITY_B] metabolism in vivo and in vitro: kinetic studies of the transport of [ENTITY_B] in [ENTITY_B] -rich membrane vesicles.metabolism in vivo and in vitro: kinetic studies of the transport of [ENTITY_B] in membranes with high concentrations of OATP inhibitors.metabolism in vivo and in vitro: kinetic studies of OATP-8-, OATP-14- and OATP-18-mediated transport",4,1
"Treatment with telmisartan augments [ENTITY_A] uptake in rats with diet-induced insulin resistance.(CYP2J2) is the predominant enzyme in [ENTITY_B] metabolism and is also the major source of [ENTITY_B], which has a critical role in the development of diabetic complications.can metabolize [ENTITY_B], which leads to the development of diabetic complications.(CYP2J2) is the predominant enzyme in fatty acid metabolism and is also the predominant",4,1
Tumor-growth-promoting [ENTITY_A] kinase 1 is a novel oncogene associated with epithelial-mesenchymal transition.metabolism in breast cancer./activation of [ENTITY_A] can be selectively modulated in a tissue-specific manner by means of small molecules.can be selectively modulated in tumorigenesis by means of small molecules./activation of phosphorylation of [ENTITY_B] can be selectively modulated by means of small,4,1
The role of the [ENTITY_A] in the absorption of unbound [ENTITY_B] in vitro and in vivo.transfer from HDL to apolipoprotein A-deficient (apoA-deficient) mice.transfer from HDL to apolipoprotein A-deficient mice.transfer from HDL to high-density lipoprotein cholesterol-deficient mice.production by liver cells.production by liver cells.production by adipocytes,4,1
"A novel method to measure the affinity for HNE with the help of a radioactive substrate: application to the study of hNOS activity and selectivity in vivo.(hNOS), a dual-site substrate for HNE and [ENTITY_A], was used to assess hNOS selectivity toward [ENTITY_B] and NOS inhibitors.(hNOS), a dual-site substrate for HNE and NO, was used to assess hNOS selectivity toward [ENTITY_B] and",4,1
"The effect of simvastatin, telmisartan and their combination on [ENTITY_A] and lipopolysaccharide-induced [ENTITY_B] production in human U373MG endothelial cells.(PGE2) is a newly identified lipopolysaccharide (LPS)-induced [ENTITY_B] that mediates its effect through binding to [ENTITY_B], the rate-limiting enzyme for [ENTITY_B] production in the heart.and telmisartan, three major sesquiterpenes in the",4,1
A new study on the metabolism of [ENTITY_A] in rats.and metabolites in blood: a new approach to the pharmacokinetics of oxybutynine.(BAY-K-8644) and oxybutynine.(BAY-K-8644) inhibitory effects on the metabolism of [ENTITY_B] in rats.(BAY-K-8644) and metabolites in blood: a new approach to the pharmacokinetics of,4,1
"A new method for measuring the stability of [ENTITY_A] in the presence of lipid-rich liposomes.(Lipozyme) is an enzyme that catalyses the deamination of [ENTITY_B], oleic acid and other lipids to produce [ENTITY_B] in vitro and [ENTITY_B] in rats.(Lipozyme) is an enzyme that catalyses the deamination of [ENTITY_B], oleic acid and other lipids to produce [ENTITY_B] in vitro and in rats.",4,1
Tetrandrine inhibits [ENTITY_A] uptake and blocks [ENTITY_A] -mediated [ENTITY_B] transport by blocking [ENTITY_B] -mediated [ENTITY_B] transport.hydroxylation./hydroxyphenylamine transfer between liver mitochondria and cytosolic pool of cytochrome b5.-mediated oxidative injury to mitochondria./hydroxyphenylamine transfer from cytosolic pool of cytochrome b5 to cytosol.,4,1
"Treatment of acute vitiligo with topical alpha-difluoromethylornithine (DFMO) or methyl-alpha-pyrone (MP) and a selective inhibitor of [ENTITY_A] (NOX) (l-NAME), difluoromethylornithine (DFO), produces marked and consistent improvement.-mediated [ENTITY_B] release.-mediated release of [ENTITY_A] is mediated by [ENTITY_B] in the epidermis.",4,1
The role of [ENTITY_A] in the absorption of [ENTITY_B] and copper(II) ion in human multidrug resistance-associated protein 2 knockout (Mrp2(-/-)) mice.(BChE) is a zinc enzyme that oxidates [ENTITY_B] and related drugs to form their oxaliplatin derivatives.and BChE knockout (Mrp2(-/-)) mice have significantly reduced sensitivity to platinum-based chemotherapeutic agents compared with wild type mice.(,4,1
"(E)-Modafinil inhibits the formation of [ENTITY_A] in the brain: a study in healthy volunteers.UNLABELLED: Modafinil, a selective dopamine D(2)-selective reuptake inhibitor, inhibits the formation of [ENTITY_B] in the brain and reduces the extracellular accumulation of [ENTITY_B] in striatum and cerebrocortical pyramidal cells.(BAY-K-7644) is a novel inhibitor of the [ENTITY_A] and related pathways",4,1
"Protein malnutrition impairs hepatic [ENTITY_B] secretion in rats: involvement of [ENTITY_A] and CYP3A.(PML-II) is an enzyme that catalyses the N-demethylation of [ENTITY_B], chalcogenones, and thiophenes.(PML-I) catalyses the N-demethylation of ketotifen, tamoxifen, ketoconazole, ketoconazole, ketoconazole",4,1
(+/-)-Modafinil inhibits the formation of [ENTITY_A] -drug conjugates in human liver microsomes and inhibits the metabolism of the drug in rats.and modafinil inhibit the formation of [ENTITY_B] -drug conjugates in human liver microsomes and inhibit the metabolism of cocaine in rats.(+/-) mice metabolize cocaine and display higher metabolism than wild-type mice.(+/-) mice metabolize cocaine and display,4,1
"The effects of acute cocaine administration on extracellular levels of [ENTITY_A] (NA) and its metabolite N-acetyl-L-serine and on [ENTITY_B] -mediated transport of [ENTITY_B] were studied in rat cerebrocortical astrocytes.-mediated transport of [ENTITY_B] was inhibited by cocaine and naloxone.-mediated transport of [ENTITY_B] was inhibited by cocaine and naloxone.uptake in the presence of the selective transporter blocker,",4,1
The effect of acute treatment with the serotonin inhibitor citalopram on the levels of [ENTITY_A] in the hippocampus and on the metabolism of [ENTITY_B] in the striatum.(AA) is the predominant [ENTITY_B] in the brain and is responsible for the majority of its [ENTITY_B] levels.(SS) are the major enzymes responsible for the metabolism of [ENTITY_B] in the central nervous system.(TA) is the major enzyme responsible for the metabolism of [ENTITY_B] in the peripheral nervous system.,4,1
Tumor-growth-promoting [ENTITY_A] is synthesized from [ENTITY_A] through a process regulated by the [ENTITY_B] /SHMT2 gene.production depends on the availability of [ENTITY_B].production is regulated by the availability of glutamine.production depends on the availability of L-cysteine.production depends on the availability of asparagine and L-alanine.production depends on the availability of aminoacrylate.production depends on,4,1
"Tumor-growth-promoting [ENTITY_A] [ENTITY_B] is metabolized via [ENTITY_B].Enzymes are involved in a variety of metabolic processes, including the metabolism of [ENTITY_B] and xenobiotics.Enzymes are also involved in metabolic processes other than metabolism, including the detoxification of xenobiotics and carcinogens.Enzymes are also involved in metabolic processes other than metabolism, including the detoxification of xenobiotics and carcinogens.En",4,1
Tetrandrine blocks [ENTITY_A] and blocks [ENTITY_B] and has no effect on [ENTITY_A] -mediated [ENTITY_B] uptake in rat astrocytes.-mediated [ENTITY_B] uptake in rat astrocytes.and tetrandrine affect uptake and release of [ENTITY_B] and have no effect on uptake and release by [ENTITY_B] -mediated uptake in rat astrocytes.and tetrandrine have no effect on uptake by vesicular [ENTITY_B] -mediated uptake in rat ast,4,1
"The influence of the polymorphism of the [ENTITY_A] (CYP2J2) on the absorption of unbound [ENTITY_B] and the distribution of [ENTITY_B] in the liver is not clear.(CYP2J2) is a crucial enzyme in the metabolism of [ENTITY_B], the most important second messenger in the brain. It is also involved in the metabolism of other drugs, especially alcohol.metabolism is complex and multifactorial. The polymorphism of the enzyme that catalyses",4,1
"Tumor-growth-promoting [ENTITY_A] [ENTITY_B] pathway proteins integrate extracellular signals from [ENTITY_B] and extracellular signals from [ENTITY_A] to regulate their own expression and activities.(b7-1) and b7-2 are tumor-growth-promoting zinc finger protein enzymes with catalytic competence for the synthesis of [ENTITY_B] and zinc, respectively.(b7-1) and zinc transporter 1 (ZnT1) are membrane-bound zinc finger proteins involved",4,1
"Tumor-growth-promoting [ENTITY_A] (PGE2) is overproduced during esophagogastric tumorigenesis and overexpressed in many other tumor types.(PGE1) has the ability to conjugate [ENTITY_B] with high efficiency and is also an endothelin type B (ETB) antagonist.(PTGS2) inhibits proliferation of cancerous cells at the post-translational level, but it is also a potent inhibitor",4,1
Tetrabenazine inhibits [ENTITY_A] uptake by inhibiting [ENTITY_B] uptake in rat cerebrocortical astrocytes.(TBBZ) and tetramethoxamine (MTA) are potent inhibitors of the monoamine oxidase (MAO).(TAO) and methoxamine (MTX) are potent inhibitors of the [ENTITY_A] (SAHH) and spermidine/spermine N-acetyltransferase (SSAT,4,1
"Protein kinases A and C mediate the phosphorylation of [ENTITY_A] by the [ENTITY_B] /mammalian enzyme [ENTITY_B].(PGE2) is a ubiquitous enzyme that is involved in various metabolic processes, including lipid and carbohydrate metabolism.(PTGS2) is a second enzyme involved in [ENTITY_B] metabolism./PTGS2 are both phosphorylated by the enzyme [ENTITY_B] /PTGS2./PTGS1 are phosphory",4,1
"Tandem affinity purification and high-throughput sequencing of human enzyme-ketamine binding proteins reveal that [ENTITY_A] and its human orthologues differ in substrate specificity and substrate inhibition profiles.(hKATs) and hKAT4 (hKAT4s) are two isoforms of [ENTITY_B] that play critical roles in the control of [ENTITY_B] levels in the brain. hKAT1 and hKAT2 are expressed at low levels, whereas hKAT3 is",4,1
"Treatment with the [ENTITY_A] inhibitor tacrine reduces the levels of [ENTITY_A] and enhances the elimination of [ENTITY_B] from the liver and intestinal tract./L-carnitine/DHA-CoA reductase inhibitors (irbesartan, sildenafil, nifedipine) are inhibitors of the [ENTITY_A] and L-carnitine/DHA-CoA reductase pathways of [ENTITY_B] synthesis and elimination.",4,1
"(+)ZnSOD expression and activity are markedly decreased in [ENTITY_A] -deficient mice at embryonic and early postnatal stages.(+/+) mice express high levels of [ENTITY_A] which protect the developing brain from oxidative injury; however, deficiencies in [ENTITY_B] function also impair brain development.(+/+) mice have a normal brain architecture and are able to metabolize [ENTITY_B] at a comparable rate to CAG-deficient mice.(+/+) mice are",4,1
"A new highly specific assay for the measurement of [ENTITY_A] -mediated [ENTITY_B] hydration in kidney homogenates.metabolism in kidney: a new sensitive, specific and sensitive assay.(DEX-P) assay.(DEX-P2) assay.(DEX-P3) assay.(DEX-P4) assay.(DEX-P5) assay.(",4,1
A new high throughput assay for measuring the [ENTITY_A] -drug uptake in tumor cells based on the determination of the [ENTITY_B] -drug uptake rate in the presence of a substrate.(MCTs) are membrane transporters that mediate the efflux of [ENTITY_B] and drugs that cross the plasma membrane.(MCT2s) are second-hand MCTs that transport drugs into cells from the extracellular space.(MCT3s),4,1
The role of the cytosolic [ENTITY_A] in [ENTITY_A] uptake and toxicity in [ENTITY_B] -producing tumors.-dependent transport of [ENTITY_B].channel-dependent toxicity.-dependent transport of [ENTITY_B].channel-dependent toxicity./tissue factor-independent transport of toxicants./transmembrane-protein transporter-1/transmembrane-protein transporter-2: Effect of altered protein expression and disruption of the,4,1
"(+)-Methoxytryptamine inhibits the formation of [ENTITY_A] in [ENTITY_B] (Sf9 cells).(Sf9) cells were treated with the 5-HT(1A)-selective antagonist, diphenhydramine, and the 2C-selective antagonist, pizotifen, for 24h.(Sf9) cells were treated with the 5-HT(1A)-selective antagonist, diphenhydramine,",4,1
"The role of [ENTITY_A] in the absorption of unesterified [ENTITY_B] and the transport of [ENTITY_B] in the kidney: studies in rats and sheep.(LTC4), a [ENTITY_B], is a membrane-bound enzyme that catalyzes the phosphorolysis of [ENTITY_B] and bile acids.(LTC5), a metabolite of LTC4, also hydrolyzes unesterified bile acids.(LTC6), another metabolite of LTC4,",4,1
"The effect of the addition of [ENTITY_A], alpha-linolenic acid and alpha-hydroxyphenylamide to aspirin on the inhibition of the formation of [ENTITY_B] -derived [ENTITY_A] (DHEA) in human astrocytes.and aspirin inhibit the synthesis of dehydroepiandrosterone sulphate in human astrocytes.(DHEA) are endogenous [ENTITY_B] and thiols with a wide range of clinical implications.and aspirin",4,1
"(1,6-bis(phenylimino)-3,6,9-triazadodecane-3,6,9-triazadodecane) is a novel, potent, and selective inhibitor of the [ENTITY_A] and gamma-glutamyl phosphate reductase.(Gli, Gli, or G(i)) are enzyme(s) that catalyze the first two steps of the [ENTITY_B] synthesis from L-gl",4,1
"(E)Hydroxynonenal ( [ENTITY_A] ) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative stress and has been associated with several types of cancer.(MTA), a key enzyme of the [ENTITY_B] (NAT) pathway, catalyses the formation of monomethylarginine from arginine and is involved in the carcinogenesis of several types of cancer.(MTA) oxidase (NAT1 and NAT",4,1
"The influence of the [ENTITY_A] enzyme polymorphism on the absorption and pharmacokinetics of darunavir- and zosuquidar-boosted HIV-PI and its main substrate, ritonavir- or zotarolimus-boosted HIV-PI. d,l-Alanine inhibits HIV-PI entry at the [ENTITY_B] and inhibits the entry of other drugs through other pathways.-mediated [ENTITY_B] transport is mediated primarily by the [ENTITY_B]",4,1
"(+/-)-Modafinil inhibits [ENTITY_A] uptake through a novel mechanism: a study in human embryonic kidney 293 cells.and cocaine regulate the same transport system.(+/-)-Modafinil inhibits cocaine-stimulated transport of cocaine and the drugs are metabolized by CYP3A.(+/-)-Modafinil inhibits cocaine-stimulated transport of [ENTITY_B], cocaine and its metabolites in human embryonic kidney 293 cells.",4,1
"Tumor-growth-promoting [ENTITY_A] is metabolized by [ENTITY_B], cytochrome b5, and [ENTITY_B].-family members are important for the development of several tumors, including liver, lung, brain, and breast cancer.can also catalyze [ENTITY_B] biosynthesis in mammalian tissues.kinase I (pki) and its homologs are important for the development of hepatic and extrahepatic tumors.can also cataly",4,1
"Tetrathiomethylamine hydrolase I ( [ENTITY_A] ) is a key enzyme that catalyzes the first two steps in the biosynthesis of [ENTITY_B], the substrate for [ENTITY_B] (N-acetyl-l-threonine).hydrolase I ( [ENTITY_A] ) is also important for the synthesis of l-threonine and other [ENTITY_B] products.hydrolase II (NAT2) is responsible for the last two steps in the threonine biosynt",4,1
Treatment with the [ENTITY_A] substitution mutant of [ENTITY_A] (C724R) does not inhibit [ENTITY_B] uptake but increases the rate at which [ENTITY_B] is metabolized.(C724R): a new drug candidate for the treatment of neuropathic pain.(C724R): a new drug candidate for the treatment of neuropathic pain.(C724R): a new drug candidate for the treatment of neuropathic pain.(,4,1
Tumor-growth-promoting [ENTITY_A] [ENTITY_B] is a novel substrate of the [ENTITY_B] /carnitine palmitoyltransferase I and a potential inhibitor of tumor growth in animal models./palmitate are lipid-rich lipids that are precursors of [ENTITY_B] and palmitoyl-coenzyme A./palmitoyl-coenzyme A are lipid-poor lipids that are precursors of [ENTITY_B] and can also function,4,1
"Tumor-growth-promoting [ENTITY_A] kinase ( [ENTITY_A] ) is a member of the phosphatidylinositol 4-phosphate 5-kinase (pip5k1) superfamily and is involved in the regulation of various aspects of cellular functions.(TSK) has two isoforms, TSK1 and TSK2.(PIPK) has been cloned and shown to play a pivotal role in [ENTITY_B] metabol",4,1
(+)-Methionine synthases ( [ENTITY_A] ) and methionine sulfate reductase (Msr) are key enzymes in the [ENTITY_B] catalyzed conversion of L-cysteine to methionine and play a major role in the synthesis and accumulation of [ENTITY_B] in mammals.(+)-Methionine synthases ( neurotrans ) are also essential for the synthesis of [ENTITY_B] in mammals.(+)-Methionine sulfate reduct,4,1
"Tumor-growth-promoting [ENTITY_A] is mediated through the activation of [ENTITY_A] (TS) and the efflux of [ENTITY_B] (VIP).(TS) is a key enzyme in [ENTITY_B] metabolism whose activity is decreased in some types of tumors.(VIP) is a cytosolic enzyme that is involved in vesicular loading and efflux, and is often deleted in some types of tumors.(TS) is a cytosolic enzyme",4,1
"A new highly specific assay for the rapid determination of sildenafil in human plasma.-D(4)-hydroxyphenylamide ([D4]PMA), a newly synthesized, highly specific [ENTITY_A] -dihydroxyflavone derivative, is a promising inhibitor of the vesicular [ENTITY_B] and [ENTITY_A] pathway that is currently in clinical trials for the treatment of erectile dysfunction.-D(4)-hydroxyphenylamide",4,1
"The role of cytosolic [ENTITY_A] in the absorption of [ENTITY_B] (DHEA) in rats.(DHEA) has been implicated in the pathogenesis of polycystic ovary syndrome (PCOS).(COT) is an endocrine organ that also contains vesicular bodies that contain [ENTITY_B].(DHEA) is an endogenous ligand that acts on the anterior pituitary, where it has been implicated in the pathogenesis of PC",4,1
The effects of selective serotonin reuptake inhibitors on the metabolism of [ENTITY_A] in vivo and in vitro.hydroxylation and spermine N-demethylation in vivo and in vitro.-dependent [ENTITY_B] uptake.homeostasis.....homeostasis.pharmacology...,4,1
"A new highly potent and selective inhibitor of the [ENTITY_A] -catalyzed [ENTITY_B] hydration with good pharmacokinetics and good therapeutic index in patients with acute lymphoblastic leukemia or lymphoma.-mediated inhibition of the leukemia-stimulating enzyme [ENTITY_B] can be achieved with highly potent inhibitors of other enzymes, including [ENTITY_B], [ENTITY_A], and ALDH2.can be used in the therapy of lymphoblastic and other malignancies.can be used",4,1
"(E)Coupled [ENTITY_A] uptake in the choroid plexus: effects of the presence/absence of the neurotransmitter in the choroid plexus.(PGE2)-mediated [ENTITY_B] uptake is mediated by a transmembrane transport system consisting of the carboxylesterases PGE2 and PGE1 and the enzyme [ENTITY_B], which is responsible for mediating the efflux of unesterified [ENTITY_B].(",4,1
"Tetrandrine inhibits [ENTITY_A] -mediated [ENTITY_B] uptake and lipopolysaccharide-induced prostaglandin E2 production in human U373MG astroglial cells.(PGE2) plays an important role in the pathogenesis of neuropathic pain.(PGE2) is a bioactive prostaglandin produced by sympathetic nerve endings stimulated by various inputs, including nerve injury and inflammation.(PGE2) is a bioactive prost",4,1
"The role of the CYP3A4 enzyme in the metabolism of [ENTITY_B] and sulfapyridine: effect of rosuvastatin on the metabolism of sulfapyridine and its metabolites.(SSAT) is an enzyme that catalyzes the first two steps of sulfapyridine formation from [ENTITY_B] and that is also capable of catalyzing the oxidation of [ENTITY_A].(SSAT), rosuvastatin (RSU) and its metabolites [ENTITY_B] (",4,1
"A novel mutation in the ATP6V1 gene associated with severe combined immunodeficiency impairs [ENTITY_A] synthesis and enhances cytosolic [ENTITY_B] -dependent [ENTITY_B] uptake.(TK/IgG2) deficiency is caused by mutations in the essential gene encoding ATP6V1, a cytosolic enzyme essential for the synthesis of [ENTITY_B] and glycine.synthesis defects are associated with severe combined immunodeficiency.",4,1
"A novel mutation in the gene encoding [ENTITY_A] (PLZF) associated with severe aetiology impairs the activity of [ENTITY_B] and impairs the clearance of [ENTITY_B]./HCTZF
Mutation analysis of FMO1 in Chinese families with isolated mild or moderate combined immunodeficiency.Polyketide synthases (PKSs) catalyze the formation of the core unit of polyketides and other conjugated compounds from l- and d-l",4,1
"Treatment with adenosine dialdehyde reduces lipopolysaccharide-induced production of [ENTITY_B], tumor necrosis factor-alpha, and [ENTITY_A] and protects rat lungs against lipopolysaccharide-induced injury.(AdOx) is a newly described enzyme that is capable of oxidizing several xenobiotics including [ENTITY_B] and thromboxanes.(AdOx-1) is an enzyme that is also capable of oxidizing [ENTITY_B] such as U-G",4,1
"The effects of acute cocaine administration on extracellular levels of [ENTITY_A], vasopressor and GABA(A) receptor mRNA expression in the brain.(PGE2) is produced by the action of the enzyme [ENTITY_B] and is involved in the control of many important physiological processes, including blood pressure, metabolism, and the regulation of gastrointestinal motility.(VIP) is produced by the action of the enzyme [ENTITY_A] and is involved in the control of blood pressure.(",4,1
The role of [ENTITY_A] in the absorption of unbound [ENTITY_B] and its transport across blood-brain barrier.(BChE) is responsible for conjugating [ENTITY_B] and other unbound drugs to [ENTITY_B] in the brain.(BAT) is responsible for conjugating drugs to [ENTITY_B] in the liver.(BFT) is responsible for conjugating drugs to glucose in the liver.(BLT) is responsible for conjugating drugs to,4,1
"A highly sensitive multiplex assay to measure [ENTITY_A] metabolism in vivo using whole blood.(ROS) are ubiquitous, ion-dependent enzymes that catalyze the oxidation of arachidonic acid (AA), leading to [ENTITY_B] accretion.(AA) are ubiquitous, ion-independent enzymes that catalyze the metabolism of linoleic acid (LA, 18:3n-3).(LA) are ubiquitous, ion-independent enzymes that also",4,1
"(1,4-Dihydroxyphenylamide analogues of diphenhydramine and diphenhydramine oxalate as selective inhibitors of the [ENTITY_A] N-demethylation.(DDAH), the enzyme that catalyses the N-demethylation of [ENTITY_B], is implicated as a major source of the [ENTITY_B] depletion that characterizes some major psychiatric illnesses, including bipolar disorders.(DPDE), a metabolite of",4,1
"Tumor-suppressive [ENTITY_A] (BChE) is an enzyme that catalyses the reversible hydration reaction of [ENTITY_B] with copper, zinc or lead ions.Enzyme-substrate interaction studies revealed that BChE binds with high affinity to the catalytic site copper ion (Zn2+), but less so at higher concentrations of copper, zinc or lead.Enzyme-substrate interaction studies revealed that BChE binds with high affinity to the catalytic",4,1
"A novel high-affinity human cytosolic [ENTITY_A] uptake inhibitor, M-7, inhibits [ENTITY_A] uptake and protects pancreatic islets from lipid-mediated injury.(DEX-3) and M-14 a novel high-affinity [ENTITY_A] uptake inhibitor, M-7, which possess higher affinity for [ENTITY_B] and lower K(m) for [ENTITY_B], have been developed as potential new anti-ischemic drugs.(DEX-4)",4,1
"The role of the [ENTITY_A] in the absorption of [ENTITY_B] and copper in rats.(PCC, EC 6.4.11.1), a transporter for [ENTITY_B] and copper, is expressed in the gastrointestinal tract, liver, lung, brain, and adipose tissue.(PCC, EC 6.4.11.3), a transporter for [ENTITY_B] and zinc, is expressed in the lung, liver, and gastrointestinal tract.(PCC, EC 6.",4,1
"Tobramycin inhibits [ENTITY_A] -mediated metabolism by blocking [ENTITY_B] and CYP3A5 activities in rats.(tobramycin) is an important second-line antibiotic for the treatment of complicated urinary tract infection and peritonitis.(taraxitavir) is a highly effective, relatively new class of antiretroviral drugs.(tariquidramine) is a second-generation HIV-1 reverse transcriptase inhibitor that",4,1
"The influence of the cytosolic pool of [ENTITY_A] on the metabolism of unesterified fatty acids in liver microsomes./ [ENTITY_B] (PCC) are membrane-bound enzymes which catalyze the first two steps of [ENTITY_B] biosynthesis: the hydration of [ENTITY_B] to [ENTITY_B] by P-glycoprotein and the oxidation of eicosapentaenoic acid (EPA, 20:5n-3) to [ENTITY_B] by [ENTITY_B]./PCC are",4,1
"Pulmonary [ENTITY_A] -mediated efflux of unesterified [ENTITY_B] and [ENTITY_B] is defective in the mouse.(PAL) is a zinc enzyme that catalyses the reversible oxidative deamination of [ENTITY_B] and zinc.(PAL) deficiency results in severe combined immunodeficiency, whereas other forms of deficiency are treated with pyridoxine.(PAL) deficiency is caused by mutations in the gene encoding the catalytic subunit of the [ENTITY_B] [ENTITY_B]",4,1
"A new method for measuring the stability of [ENTITY_A] in aqueous solutions.UNLABELLED: The stability of an arylhydroxylamine (AHL)-containing drug (dyskinase inhibitor) was assessed under conditions mimicking the environment of the human liver microsomes (HLM) by measuring its affinity for H(+)-lactate, a substrate that is metabolized in the presence of [ENTITY_B], and by measuring the apparent K(m) and K",4,1
"Tumors of the anterior pituitary gland, especially those with high proliferating cell scores, appear particularly vulnerable to the inhibition of [ENTITY_A] - and OATP8-mediated [ENTITY_B] transport.-family: transport, activation, and inhibition by drugs.(PGE2) is a homeostatic enzyme that catalyses the opposite reaction: it supports increased production of energy from de novo synthesis.(OPG) is an endothe",4,1
Aminoglycoside-dependent [ENTITY_A] -mediated metabolism of [ENTITY_A] (DHEA) and oestradiol in the rat brain.(DHEA) is an endogenous metabolite of the arginase I pathway of sex steroid metabolism in mammals and is metabolized primarily by the enzyme [ENTITY_B] (OATP).(E2) is the second isoform of the enzyme that mediates the metabolism of [ENTITY_B] in mammals.(E1) is,4,1
"A new study on the metabolism of [ENTITY_A] in vitro and in vivo.(DXM) is a novel drug that inhibits the synthesis and degradation of [ENTITY_B] in vitro and in humans.(DXM) is a new drug that inhibits the synthesis and degradation of [ENTITY_A] in vitro and in vivo.(CGS 017) is an established drug with an established indication for the treatment of cancer, but its metabolism in humans is uncertain.(DXM",4,1
"Aminoglycosides and sulfasalazine inhibit [ENTITY_A] uptake into rat cerebrocortical astrocytes.and sulfasalazine inhibit the uptake of [ENTITY_B], sulfasalazine, and diethylcarbamazine into rat cerebrocortical astrocytes.can inhibit the uptake of drugs that are substrate of [ENTITY_B], such as sulfasalazine, and drugs that are non-structure-bound such",4,1
"A novel highly selective, sensitive, and specific enzyme-linked immunoassay for the measurement of [ENTITY_A] - and cortisol-conjugate levels in healthy volunteers.(CYP2J2) and cortisol(CYP2J2) are involved in the control of the [ENTITY_B] (CYP2) enzyme and the cortisol synthesis.(CYP2E1) is responsible for the synthesis of both cortisol and cortisol-conjugates.(",4,1
"Tumor-growth-promoting [ENTITY_A] is metabolized in vitro by [ENTITY_B] but metabolized by cytochromes P450 (CYP) 3A,3B, and 3C.(P-glycoprotein) is a lipid-binding membrane protein with a broad substrate specificity.(P-gp) mediates the transport of xenobiotics across the blood-cecum barrier and is involved in the absorption and elimination of drugs such as diphenhyd",4,1
"The effects of acute treatment with diphenhydramine, diphenhydramine sulfate, and their R-(-)- and S-(+)-enantiomers on brain monoamine transporters and [ENTITY_A] uptake in healthy volunteers.(b5R, b6R, and b7R), [ENTITY_B] (b5S, b6S), and diphenhydramine (DPH; 5-aminosalicylic acid; 0.3 mg/",4,1
(1-naphththalene)-derived 5-aminosalicylic acid inhibits the uptake of L-alanine and L-tryptophan but not [ENTITY_A] -containing [ENTITY_B]./L-alanine transporter 1 (LAT-1) is a pyridoxal 5'-phosphate-dependent transporter that mediates the uptake of L-alanine and L-tryptophan./L-alanyl-L-gl,4,1
"(+)-Methionine synthase 1 ( [ENTITY_B] ), a rate-limiting enzyme for [ENTITY_A] synthesis, is expressed at a higher level in brain and liver than in other tissues.synthesissynthesis-dependent:and methionine synthase 2 (Msn 2) catalyzes the opposite reaction, [ENTITY_B] synthesis.synthesis-dependentproductionproductionproductionproduction:",4,1
The effects of the [ENTITY_A] /hTPK inhibitor ZD1839 (difluoromethoxy-tryptamine 2C5) on norepinephrine transporter (NET) function in the basal state and after peripheral nerve injury are not well-characterised.(SMCK) is a [ENTITY_B] channel expressed at the basolateral side of the nerve terminal.(SMCK-II) is at the apical side of the nerve terminal.,4,1
"Treatment with the novel bisphosphonate, dacarbazine, inhibits the formation of [ENTITY_A] -derived [ENTITY_A] (OT) and blocks the entry of [ENTITY_A] (OT) into mitochondria.(OT) is an enzyme important for the production of [ENTITY_B] and phosphate.(OT) is an enzyme important for the production of [ENTITY_B] and pyridoxamine and also participates in the metabolism of pyruvate and lactate.(",4,1
"Tetrabutylamine inhibits [ENTITY_A] -mediated [ENTITY_B] uptake by inhibiting [ENTITY_B] availability.(BAAT) is a key enzyme in the metabolism of [ENTITY_B], p-trifluoromethoxyphenylhydantoin, chalcogenone, and diphenhydramine.(BAT) is the key enzyme in the metabolism of p-trifluoromethoxyphenylhydantoin, chalcogenone",4,1
"A new highly potent inhibitor of the [ENTITY_A] metabolizing enzyme [ENTITY_B], UGT1A6, blocks the entry of [ENTITY_B] into mitochondria.(BChE), UGT1A6
Design and synthesis of novel alpha-(2,4-dihydroxyphenylhydrazone)-derived 5-HT7 receptor ligands with improved potency.5-HT(7) receptors mediate the activation of the serotonin (5-HT) type A receptors",4,1
"(11-14)C-methyl-L-arginine increases the uptake of [ENTITY_A] by [ENTITY_B] -dependent and -independent mechanisms in rats.(11-14)C-methyl-L-arginine, a natural substrate of [ENTITY_B], increases the uptake of [ENTITY_B] by facilitating [ENTITY_B] uptake into skeletal muscle.(11-14)C-methyl-L-arginine, a natural substrate of [ENTITY_B], increases the uptake of [ENTITY_B] by facilitating uptake",4,1
A new method for the analysis of the metabolism of [ENTITY_A] and its metabolite 3-hydroxy-5-methylxanthine in rat brain: application to a study of the metabolism of sulfasalazine in rats.(SGLT2) is a key enzyme in the metabolism of [ENTITY_B] and its metabolite 3-hydroxy-5-methylxanthine (MHX).(SGLT1) is also a crucial enzyme in the metabolism,4,1
"The impact of the [ENTITY_A] /hCYP3A5 on the metabolism of [ENTITY_B] and bisphenol A in rats.(DXM) is a newly identified sterol that is metabolized by [ENTITY_B], CYP3A, and CYP3A4.(BWCE) is a second sterol metabolized by CYP3A.(BWCE), BDP, and BPA.(BWCE) is a first",4,1
Tumor necrosis factor-alpha gene polymorphisms and haplotypes are associated with different levels of interindividual variability of [ENTITY_A] - and interindividual variability of high-density lipoprotein cholesterol in healthy Japanese individuals./liver X receptor (LXR) is a crucial enzyme in the synthesis of [ENTITY_B] and high-density lipoproteins (HDL).(TS) and LXR(G) have a major role in the synthesis of [ENTITY_B]  and HDL respectively,4,1
"A novel [ENTITY_A] inhibitor containing a 5-ethynylphenoxyamine moiety as a new potential anticonvulsant.(DEX-3) inhibits the metabolism of [ENTITY_B] and phenytoin with high potency and good clinical activity in rats.(DEX-4) inhibits the metabolism of phenytoin with high potency and good clinical activity in rats, but its mode of action is unknown.(DEX-5) was",4,1
"(+)-Epigallocatechin 3-O-gallate (EGCG) inhibits [ENTITY_A] uptake by human endothelial cells, possibly because of the inhibition of the [ENTITY_B] /SGLT2 pathways.(+)-Epigallocatechin 3-O-gallate (EGCG), a naturally occurring polyamine-derived compound, inhibits the metabolism of [ENTITY_B] (+)-catechin (GCK), possibly because of the inhibition of the [ENTITY_B] /sodium-",4,1
"Tandem affinity purification with a chalcogenase-assisted high-throughput assay: application to the characterization of [ENTITY_A] -dependent [ENTITY_B] metabolism.metabolic inhibitor studies.metabolism of xenobiotics: affinity, specificity and stability studies.metabolic inhibitors: affinity, specificity and stability studies.metabolism of xenobiotics: stability and activity studies.metabolism studies of xenob",4,1
"(+/-)-Modafinil inhibits the [ENTITY_A] uptake into the striatum and impairs working memory.(+/-), a mutation in the gene encoding [ENTITY_B], results in an altered enzyme profile, which leads to a decrease in the levels of dopamine and its metabolites.can also influence the levels of other drugs, and it is possible that modafinil could affect other areas of the brain.(+/-), a mutation in the gene",4,1
The effects of the addition of trifluorothymidine to aspirin and clonazepam on platelet [ENTITY_B] uptake.-mediated [ENTITY_B] release.metabolism.metabolism.metabolism.andmetabolism.metabolism...and thioacyl-tryptamine synthetase ( [ENTITY_A] ) expression in rat,4,1
"(+)-Epicatechin 3-O-gallate inhibited [ENTITY_A] -mediated metabolism of [ENTITY_B], catechin, and flavone drugs.(+)-epigallocatechin 3-O-gallate (EGCG) inhibits metabolism of many xenobiotics, but its effect on the metabolism of drugs that are metabolized by cytochromes P450 is unclear.(+)- epigallocatechin 3-O-gallate (EGGC)",4,1
(+/-)-Modafinil blocks the uptake of [ENTITY_A] in [ENTITY_B] (+/+) mice at the expense of D2-like dopamine receptors in the striatum.can inhibit [ENTITY_A] uptake through mechanisms that are distinct from those of the D2 dopamine receptor.(+/-) mice have significantly lower levels of [ENTITY_A] than do CBA/J mice.can inhibit dopamine uptake through mechanisms that are distinct from those of the D2 dopamine receptor.,4,1
A novel high-throughput assay to assess the glucuronidation and inhibition of [ENTITY_A] in human liver microsomes.(Lysine acetyltransferase I) and acetyl glucuronidation of [ENTITY_B] (Glycylsarcosine hydroxymethyltransferase I) catalyze the N-glucuronidation of [ENTITY_B] and GHS-1a with [ENTITY_B].(Lysine acetyltransferase II) also catalyzes the N-,4,1
The effect of the combined inhibition of [ENTITY_A] and ABCA1 on the absorption of [ENTITY_B] and its transport across the intestinal membrane.-mediated transport of [ENTITY_B] was evaluated in vitro for the first time in aqueous humor of healthy human beings.-mediated transport of [ENTITY_B] and its absorption across the intestinal membrane were evaluated in vitro in aqueous humor of healthy human beings.-mediated transport of [ENTITY_B] was evaluated in a separate group of volunteers.,4,1
"The effects of acute and prolonged inhibition of [ENTITY_A] (NET) with haloperidol and midazolam on extracellular [ENTITY_B] levels and the metabolism of haloperidol and midazolam in rat striatum.(NET) is an enzyme that catalyzes the first two steps of the haloperidol metabolism, the deamination of haloperidol and the oxidation of norketamine.(NET) is an enzyme that catalyzes the oxidation",4,1
A new method for the determination of [ENTITY_A] in whole blood: a comparison of the newly proposed kinetic parameters of the kinetic analysis system with those of the conventional analytical method.(PGE2) reacts rapidly with [ENTITY_B] and bicarbonate.(PEPT2) reacts slowly with both substrates and reacts slowly with water.(PAEP) is an endothelin type A (ETA) type receptor antagonist.(PTGS,4,1
"(1-naphthylcarbamazine) and (1-naphththalenylcarbamazine) are potent inhibitors of the [ENTITY_A] and of the [ENTITY_B] and cocaine transporter.substrate inhibition of [ENTITY_A] and cocaine uptake in Madin-Darby canine kidney cells.binding:, cocaine and ketamine.binding: cocaine and ketamine.bindings: ketamine, cocaine, and midazolam",4,1
The influence of the [ENTITY_A] enzyme CYP2D6 on metabolism of [ENTITY_B] in rats.1. The aim of the present study was to assess the influence of the enzyme cytochrome b564 (CYP2D6) on the metabolism of [ENTITY_B] in vivo and in vitro. 2. The effects of the addition of the substrate 4-methoxytryptamine to the metabolism of [ENTITY_B] and of its metabolites in rat liver microsomes (RLM) were also investigated,4,1
"A new method for the determination of the Vmax of [ENTITY_A] -catalyzed [ENTITY_B] decrease in kidney homogenates using a newly developed high-resolution liquid chromatography/tandem mass spectrometry assay.(LTC4) is an enzyme that hydrolyzes arachidonate to form [ENTITY_B].(DAT), a specific inhibitor for the release of [ENTITY_A], is often present in kidney tissue.(DAT) is",4,1
"Tumor-growth-promoting [ENTITY_A] pathway provides novel therapeutic targets for the treatment of aggressive tumors including glioblastoma.-mediated [ENTITY_B] uptake and cytosolic [ENTITY_A] uptake in tumor cells are mediated by [ENTITY_B] and cytosolic [ENTITY_B] (s) and require [ENTITY_A] and cytosolic glutathione (GSH).can be selectively blocked by the addition of the cytosolic [ENTITY_A] substrate, oxaliplatin, which inhibits tumor cell",4,1
Pulmonary [ENTITY_A] -mediated effluxes [ENTITY_A] and carbonylcyanide p-trifluoromethoxyphenylhydrazone to the lung and liver.and p-chlorobutyrate dehydrogenase reductase are involved in the metabolism of [ENTITY_B].(p-HPK) mediates the metabolism of p-HPK.and p-chlorobutyrate reductase (p-CR),4,1
A new chalcone from Glycyrrhizae: (7-hydroxy-7-hydroxymethyl-7-methoxytryptamine) inhibits uptake of [ENTITY_A] by [ENTITY_B] and blocks the entry of [ENTITY_B]  into cells.(Glycyrrhizae) has been identified as a major allosteric regulator of intracellular [ENTITY_B] levels.(Cymbidium species) is a major flavonol in red wine and other,4,1
"The effects of acute administration of methylphenidate hydrochloride on the levels of [ENTITY_A], dopamine, and serotonin in the striatum and the levels of norepinephrine and serotonin in the brainstem of freely-moving, ovariectomized female rats.(MPH) synthesizing enzymes, [ENTITY_B] and CBS, are important for the synthesis and secretion of 5-methoxytryptamine (5-MT), the main effector in the regulation of sex.",4,1
The role of cytosolic [ENTITY_A] in the absorption and toxicity of drugs in rats.(DEX-P) is a novel phosphodiesterase that hydrolyzes both [ENTITY_B] and diphenhydramine (DPH) in a competitive manner.(DH-P) is a novel phosphodiesterase that hydrolyzes only diphenhydramine (DPH).(TK-P) is an enzyme involved in the metabolism of [ENTITY_B],4,1
The role of [ENTITY_A] in [ENTITY_B] metabolism in vivo is unclear.metabolism in vitro is also uncertain.metabolism in vitro is also uncertain.-dependentmetabolism in vitro is also uncertain.metabolism in humans is also uncertain.metabolic enzyme-knockout mice have variable enzyme expression and enzyme kinetic parameters.-dependent enzymes in vivo and in vitro are also uncertain.,4,1
"Tumor necrosis factor-alpha enhances [ENTITY_A] uptake by increasing [ENTITY_B] uptake in rat astrocytes.(PGE2) is a potent cytokine with a wide variety of functions, including the stimulation of [ENTITY_B] -mediated [ENTITY_B] production.(PGE1) is an endothelin type A receptor antagonist with a wide range of uses including the treatment of inflammatory diseases.(PTGS2) is an activator of phosphodiesterases that",4,1
"(E)-7,8-dihydroxyflavone inhibits [ENTITY_A] -mediated [ENTITY_B] uptake at the level of [ENTITY_B] (vesicles) and inhibits [ENTITY_B] uptake into human granulosa cells.(vesicles) are vesicles containing [ENTITY_B], which is released by [ENTITY_B] uptake into granulosa cells.uptake in human granulosa cells.uptake across different cell types.uptake across different cell",4,1
"A new study shows that in the presence of the nitric oxide synthase inhibitor, aspirin, [ENTITY_A] deprivation does not affect the uptake of [ENTITY_B], L-arginine, d-arginine and L-[(3)H]arginine but does inhibit the efflux of L-citrulline.hydroxylation is a post-translational modification of proteins that occurs after their transport and storage in cell membranes and is important for various",4,1
"Treatment of severe combined immunodeficiency with adenosine dialdehyde and sulfasalazine and the role of [ENTITY_A] -NK-1R in renal preservation.OBJECTIVE: The purpose of the study was to assess the effects of adenosine dialdehyde (ADMA), an inhibitor of NOS, on renal function in severe combined immunodeficiency.can inhibit [ENTITY_B] -mediated [ENTITY_B] uptake, whereas NOS inhibitors have no effects on renal",4,1
Pretreatment with the selective serotonin reuptake inhibitor tizanidine reduces brain levels of [ENTITY_B] and enhances memory in rats.(SSR) is an enzyme that catalyses the conversion of [ENTITY_A] to spermine and is involved in the pathogenesis of various neurological disorders.(SSR) is an enzyme that catalyses the conversion of spermine to putrescine and is involved in the pathogenesis of several neurological disorders.(SSR,4,1
"The role of [ENTITY_A] in the absorption and toxicity of [ENTITY_B] and its metabolite, o-diphenols.is excreted primarily in the urine as metabolites of o-diphenols and other drugs.can also be excreted into the bile, but it is believed to play no role in drug absorption., a member of the flavinogenic glycosyltransferase family, is present in large quantities in the liver and is involved",4,1
"The effect of the addition of the calcium channel blocker, rifampicin, to calcium channel-selective drugs administered via silymarin-mediated calcium entry on [ENTITY_A] uptake by [ENTITY_B].(CA) is a multi-channel enzyme that mediates the opening and closing of [ENTITY_B] (ACC) channel pore.(VLA) mediates the opening and closing of EGTA channel pore.(VLA) also catalyses",4,1
"Treatment with adenosine dialdehyde (AdOx), a specific inhibitor of [ENTITY_B], reduces brain [ENTITY_A] and increases [ENTITY_B] levels in rats with experimental stroke.(AdOx), a specific inhibitor of adenosine triphosphate-dependent enzymes, reduces brain water content and improves neurological functions in experimental ischemic brain injury.(DDAH), a specific inhibitor of adenosine diphosphate-dependent [ENTITY_A], reduces brain water content and",4,1
Proteomic analysis and identification of phospholamban phosphorylation sites on [ENTITY_A] and spermine binding proteins.- and spermine binding proteins involved in [ENTITY_B] metabolism.binding proteins involved in spermine transport and metabolism./spermine transport and metabolism../spermine transport and metabolism...phosphorylation sites,4,1
The influence of the cytosolic pool of [ENTITY_A] on the absorption of [ENTITY_B] and the inhibition of lipopolysaccharide-induced [ENTITY_B] production by [ENTITY_B].(b5) is a glutathione (GSH)-dependent enzyme that catalyzes the reversible reduction of lipid-soluble chemicals and is often coexpressed with [ENTITY_B].(b5) is an enzyme that does not oxidize lipid-soluble chemicals.(b5) also cat,4,1
(+)-Epicatechin 3-(hydroxymethyl)gallate selectively inhibits [ENTITY_A] -mediated [ENTITY_B] uptake and blocks [ENTITY_A] -induced [ENTITY_B] production in Chinese hamster ovary cells.hydroxylation of flavonols is mediated by a [ENTITY_B] -catalyzed system involving the [ENTITY_B] -catalyzed transformation of [ENTITY_B] to epigallocatechin 3-O-gallate and the [ENTITY_B] -catalyzed transformation of epigallocatechin 3-O-gall,4,1
"(+/-)-Modafinil inhibits [ENTITY_A] uptake and blocks the uptake of [ENTITY_B] in [ENTITY_B] (+/+) mice more effectively than in Tg-Cbl(-/-) mice.(+/+) mice have higher extracellular [ENTITY_B] than do Tg-Cbl(-/-) mice.(+/+) mice have lower extracellular [ENTITY_B] than do Tg-Cbl(-/-) mice.(+/+), but not T",4,1
"The role of cytosolic [ENTITY_A] in [ENTITY_B] metabolism and toxicity in vivo and in vitro.(BChE) is an enzyme that mediates oxidative metabolism of xenobiotics.(BAT) is a cystolic enzyme that also catalyzes sulfotransferase ( [ENTITY_A] ) activity.(BChE, CYP3A5) and CYP3A7) metabolize xenobiotics in vitro, but their in vivo relevance",4,1
"The role of [ENTITY_A] in the inhibition of [ENTITY_B] -mediated metabolism in rats.(b6) and b6_Fischer (b7) were synthesized and tested for their ability to inhibit the metabolism of [ENTITY_B], a substrate of [ENTITY_B], in WKY and SHR PTE-F rats.(b5) and FVB were synthesized and tested for their ability to inhibit the metabolism of [ENTITY_B], another substrate of SPI, in WKY and SH",4,1
"(1,7-Dihydroxy-5,6-dihydroxyflavone) inhibits [ENTITY_A] -mediated metabolism in rats and humans with high potency and good pharmacokinetic parameters.(1,7-Dihydroxy-5,6-dihydroxyflavone); a novel, dual flavone/flavanone inhibitor of the metabolism of [ENTITY_B] and chalcone in rats and humans.(1,7-D",4,1
"Phenylketonuria (PKU) is a rare genetic disorder caused by the deficiency of [ENTITY_A] -6-phenylhydantoin (P6PH), which is essential for the conversion of L-glutamate to [ENTITY_B] by [ENTITY_B].hydroxylase 1 (SHMT1) and SHMT2 catalyze the reversible oxidation of L-glutamate to form [ENTITY_B].can also catalyze the oxidative deamination of [ENTITY_B].",4,1
The role of the [ENTITY_A] in the transport of [ENTITY_B] in vitro and in vivo.(CAIX) and carbachol (ACC) are two endogenous inhibitors of the [ENTITY_B] and glucocorticoid receptor that are often coadministered and coadministered in the same patients.(GSTA4) is a novel enzyme that metabolizes glucocorticoids.(GSTA4) is a novel enzyme that metabolizes [ENTITY_B] and has,4,1
"Pretreatment with ketamine blocks the analgesia, hyperthermia, and hyperosmolarity associated with peripheral inflammation in rats.(+/-) rats exhibit a prominent increase in spinal cord tissue concentrations of [ENTITY_B] as well as a significant decrease in brain tissue concentrations of [ENTITY_A] that are associated with enhanced [ENTITY_B] uptake.(+/+) rats exhibit an opposite pattern with increased spinal cord tissue concentrations of [ENTITY_B] as well as a significant decrease in brain tissue concentrations of",4,1
"(+/-)-Modafinil blocks the uptake, metabolism, and excretion of [ENTITY_A] in rats: a comparison of CYP3A inhibitors with the [ENTITY_A] inhibition CYP3A4+.(+/-)-Modafinil blocks the uptake, metabolism, and excretion of [ENTITY_B] in rats: a comparison of CYP3A inhibitors with the supervisionof CYP3A4+.hydroxylation and CYP3A inhibitors with higher substrate",4,1
"Tumor-derived [ENTITY_A] -derived [ENTITY_A] is a major source of [ENTITY_B] in tumor cells and enhances chemosensitivity via the activation of [ENTITY_B] -mediated apoptosis.-mediated apoptosis is mediated, among others, by [ENTITY_B] and/or OATP8 or OATP1B3.(+/+) mice metabolize OATP8 activators more effectively than OATP1B3(-/-) mice.(+/+)",4,1
"Tumor necrosis factor-α up-regulation by [ENTITY_A] is mediated by the [ENTITY_A] and is suppressed by the [ENTITY_A] in human astrocytes./Lipopolysaccharide (LPS) triggers the production of [ENTITY_B] (PGE2) that leads to inflammatory pain and neurological impairment./ [ENTITY_A] can also induce inflammatory pain, but it is less potent./ [ENTITY_A] can also induce inflammatory pain, but its mode of action and mechanism(s",4,1
"Phenotyping of [ENTITY_A] gene mutations using the human embryonic kidney 293-SvChIP-seq format.-encoded [ENTITY_A] have been shown to have a major role in renal [ENTITY_B] metabolism.can also catalyze the sulfation of [ENTITY_B], chalcogenide, and bromide, although less well characterized.can also catalyze the sulfation of other xenobiotics, and mutations of the PES1 gene encoding phenyl",4,1
Aminoacids are inhibitors of [ENTITY_A] (BNK) and potent inhibitors of cocaine uptake.(BNI) is a zinc ion transporter that is implicated in the absorption of drugs such as cocaine and opiates.(BNI) is a bile acid transport system that is implicated in the absorption of drugs such as aspirin and drugs metabolised by the enzyme [ENTITY_B] (BDP).(BUP) is an enzyme implicated in the absorption of,4,1
"Proteomic analysis of human umbilical vein endothelial cells (HUVEC) deficient in [ENTITY_A] (PLZ) revealed downregulation of [ENTITY_A], vesicular [ENTITY_B] and OATP1B1 related activities.(PLZ) deficiency results in severe combined immunodeficiency.(PLZ)-deficient HUVEC exhibit a marked increase in [ENTITY_B] production and impaired OATP1B1 related activities.(PLZ) deficiency",4,1
"Phenylalanine hydroxyltransferase I ( [ENTITY_A] ) mediates [ENTITY_B] -catalyzed [ENTITY_B] hydration in the brain.hydration is mediated by a family of [ENTITY_B] haptoglobin (pHbl) isoforms, which differ in their preferred substrate: pyridoxamine for [ENTITY_B], and phenylalanine for ammonia.hydration is mediated by a pyridoxamine-binding protein (PBB) isozyme.",4,1
"The impact of pre- and post-operative serum [ENTITY_A] and high-density lipoprotein levels on postoperative complications and long-term survival in patients with pancreaticobiliary surgery: a retrospective analysis.BACKGROUND & AIMS: Preoperative serum levels of [ENTITY_B] (BMI, triglycerides, low-density lipoprotein [LDL] levels), pre-operative high-density lipoprotein (HDL), and low-density lipoprotein (LDL) level may",4,1
"(E)-6,7-dihydroxymandelic acid, a metabolite of tamoxifen, inhibits [ENTITY_A] -mediated metabolism of [ENTITY_A] and inhibits the metabolism of [ENTITY_A] in breast cancer cells./SHMT1 and SHMT2 are important enzymes in the tamoxifen metabolic pathway.can metabolize [ENTITY_B] and have no role in tamoxifen metabolism.can metabolize [ENTITY_B] only slightly.(SH",4,1
"A new study shows that a common deletion in the promoter of [ENTITY_A] affects the [ENTITY_B] metabolizing enzyme complex and alters the [ENTITY_B] -dependent metabolism of [ENTITY_B].metabolizing enzyme complexmetabolizing enzyme complexmetabolizing enzyme complexmetabolic enzyme complex
The effects of age, sex, and body mass index on the pharmacokinetics and safety of duloxetine in healthy subjects. dulox",4,1
"A new high-throughput screen for inhibitors of [ENTITY_A] and chalcone metabolism.(BChE) is an enzyme involved in the biosynthesis of chalcones and other secondary metabolites in many plant and animal species.(BChE) is a mammalian enzyme that also catalyzes the conversion of chalcone and flavonolignans to [ENTITY_B] and flavone, respectively.(BChE), which is similar to BChE, also",4,1
"A novel [ENTITY_A] -mediated metabolism of [ENTITY_B] in rats: contribution of cytochrome b564 to the inter- and intra-animal variability.(b5) is a novel [ENTITY_B] substrate metabolite produced by the action of [ENTITY_B] (b5) on [ENTITY_B] (a1, a2b1, and a3).(b5) is metabolized via the same pathway by a metabolite of b5, but this metabolite is not metabolized by CY",4,1
"The effects of acute cocaine exposure on the levels of [ENTITY_A] and CYP3A4 enzyme activity in rat cerebrocortical tissue.Cocaine is an addictive drug with many effects on the central nervous system (CNS). The aim of this study was to investigate the effects of acute cocaine (3 mg/kg, iv) treatment in rat cerebrocortical tissues on the levels of [ENTITY_B] and CYP3A4 enzyme activity and its metabolites, 3-methox",4,1
A comparison of the in vitro and in vivo effects of the [ENTITY_A] inhibition of [ENTITY_B] and of theophylline transport by the [ENTITY_A] and ouabain.The present study compared the in vitro effects of the prodrugs of theophylline and ouabain (UFT and OMW) with that of the drug-like drugs tacrine (Tac) and midazolam (MDZ) in terms of inhibitory effects on the absorption of theophyll,4,1
The effect of age at initiation of aspirin use and aspirin dose on the inhibition of [ENTITY_A] -mediated [ENTITY_B] production by the enzyme [ENTITY_A] (PGE2).(PGE2) is the rate-limiting enzyme in [ENTITY_B] synthesis and is inhibited by aspirin.(PGE2) is the rate-limiting enzyme in prostaglandin E2 synthesis.(PGE2) is the rate-limiting enzyme in prostaglandin E,4,1
"Tetrandrine inhibits [ENTITY_A] -mediated metabolism of [ENTITY_B] in rats.and its metabolites in the brain: an in vitro study.(DXM) are endogenous compounds that are metabolized by CYP3A4, 3A5, 3A7 and metabolised by [ENTITY_B] (DXM) in the liver.(DEX-P) are metabolites produced by the action of the drugs and are also metabolised by CYP3A4, 3",4,1
"Tumor necrosis factor-alpha (TNF-alpha) and [ENTITY_A] (PGE2) metabolize via [ENTITY_B] (COX-2) and prostanoid (PGE2) pathways to form active metabolites that inhibit angiogenesis, invasiveness, and metastasis.-3-hydroxylation is important for angiogenesis and invasiveness.-3-hydroxylation is important for invasiveness and metastasis.",4,1
"(+)-Methionine synthase reductase ( [ENTITY_A] ) is responsible for [ENTITY_B] formation in mammals, and is therefore considered a candidate for a genetic marker of AluY(low) or ALY (high) alleles.(+)-Methionine synthase ( MTH) reductase is responsible for the conversion of L-methionine to [ENTITY_B] in the presence of L-threonine.(+)-",4,1
Treatment with the novel alpha1-adrenoceptor inhibitor telmisartan augments [ENTITY_A] synthesis through enhancing [ENTITY_B] availability in rats.hydrolysis inhibitors for the treatment of diabetes mellitus.-dependent: the effect of telmisartan on glucose-stimulated [ENTITY_B] synthesis from [alpha(1)-methylxanthine] in WKY and SHR PTE cells.hydrolysis inhibition: the effect of,4,1
"The effects of acute administration of duloxetine, a selective serotonin reuptake inhibitor, on the concentrations and activities of [ENTITY_A], cGMP, and PGE2 in rat striatum.(+)-dependent [ENTITY_B] uptake and PGE2 production by [ENTITY_B] cells are mediated through the activation of [ENTITY_A].(+)-dependentuptake and PGE2 production by microglia.(+)-dependent [ENTITY_B] ptake and P",4,1
"A highly selective, competitive inhibitor of the [ENTITY_A] (NET) isozyme of [ENTITY_B] (NOS) blocks [ENTITY_B] -mediated [ENTITY_B] uptake and protects the heart against ischemia/reperfusion injury.(NET) is a key enzyme in the [ENTITY_B] (NOS) cascade that mediates the vasodilator response to vasopressor stimulation.(NOS) inhibitors targeting the other isozyme, i.e., NET, might offer improved therapeutic approaches",4,1
The role of the [ENTITY_A] /SHMT5 in the control of [ENTITY_B] metabolism./SHMTs are zinc-methionine synthases that catalyze the conversion of the methylthioadenosine (MTA) to [ENTITY_B] by taking up the methylthioacyl-CoA./SHMTs are zinc-methionine synthases that catalyze the reverse conversion of thioacyl-CoAs to [ENTITY_B] by,4,1
Treatment of primary central serous choriocarcinoma with adenosine triphosphate (AST)-dependent [ENTITY_A] uptake inhibitors: results of a phase II study.PURPOSE: The purpose of this study was to test the hypothesis that the adenosine triphosphate (ATP)-dependent [ENTITY_B] uptake system plays a pivotal role in central serous choriocarcinoma.EXPERIMENTAL DESIGN: We conducted a phase II study in,4,1
"(+)- and (-))-Modafinil bind to the [ENTITY_A] and block [ENTITY_B] uptake at [ENTITY_B] uptake sites in the brain: an in vivo study., methylphenidate, and diphenhydramine are selective dopamine D(1) receptor modulators that are used for the treatment of various disorders; however, their use is limited by their dependence on the metabolism of the drug by hepatic and intestinal enzymes., diphenhydramine, and",4,1
A novel method for measuring the affinity of [ENTITY_A] for [ENTITY_B].channel blockers.channel blockers.channel blockers.channel blockers.channel blockers.channel blockers.channel blockers.channel blockers.channel blockers.channel blockers.channel blockers.channel blockers. reasonedchannel blockers.channel blockers. reasonedchannel blockers. reasonedchannel blockers. reasoned,4,1
"(+)/-;(-/-) mice exhibit significantly increased plasma [ENTITY_A] and liver [ENTITY_B] and increased urinary [ENTITY_B] pathway N-acetyltransferase activity, consistent with the interpretation that [ENTITY_B] activity determines plasma [ENTITY_B] availability in mice./N-acetyltransferase activities in the liver and plasma of wild-type and mutant mice were also significantly increased./N-acetyltransferase activities in the liver of (+/-) and mutant mice were also significantly increased.",4,1
"The influence of the presence or absence of a carboxyl group at the N-terminal of [ENTITY_A] on the conformation and catalytic activity of [ENTITY_B] -N-demethylation..(MCTs) are small proteins that are endogenously expressed in many tissues and have wide tissue distribution including brain, liver, kidney, spleen, lung, and adipose tissue.(MCTs 1 and 2)",4,1
"A novel [ENTITY_A] inhibitor, OTC-8, inhibits the metabolism of [ENTITY_A] in rats and humans with a potency and selectivity unlike other drugs that act on the same enzyme or the same pathway.(dFdC) inhibits the metabolism of [ENTITY_B] in rats and humans with a potency and selectivity unlike other drugs that act on the same enzyme or the same pathway.(EC 1.3.99.11) inhibits the metabolism of cocaine in rats with",4,1
A novel mutation of the [ENTITY_A] metabolizing enzyme PRO1 that abolishes [ENTITY_B] synthesis causes severe combined immunodeficiency with severe combined immunodeficiency.metabolizing enzyme PRO1 is essential for the synthesis of [ENTITY_B] and other important [ENTITY_B].metabolizing enzyme PRO1 is also an essential enzyme for the synthesis of glutamine in mammalian tissues.can synthesize [ENTITY_B] in the presence of other proteins.can also synthesize,4,1
